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Abstract 
Tuberculosis (TB), caused by infection with the bacterium Mycobacterium 
tuberculosis, has re-emerged as a global health risk with a significant proportion of 
new TB cases classified as multi-drug resistant (MDR) or extensively drug resistant 
(XDR). As such, there is a desperate need for the development of TB therapies which 
operate via novel modes of action. 
This thesis outlines the development of new drug leads for tuberculosis employing a 
target-based approach and by synthesis and derivatization of natural product 
scaffolds. Specifically, the first and second section of the thesis describes the  
target-based approach towards the development of inhibitors against enzymes in the 
shikimate and peptidoglycan biosynthetic pathways such as type II dehydroquinase 
(type II DHQase) and N-acetylglucosamine-1-phosphate (GlmU) uridyltransferase. 
These enzymes have been demonstrated to be essential for the survival and virulence 
of M. tuberculosis in vitro. The third section of the thesis describes the development 
of synthetic derivatives of sansanmycins, uridylpeptide antibiotics isolated from 
Streptomyces spp. SS.  
Inhibition of M. tuberculosis type II DHQase is the subject of chapter 3 of this thesis. 
Initial synthetic efforts were directed at the preparation of inhibitors possessing an 
anhydroquinate core which served as a mimic for the enol intermediate of the type II 
DHQase catalyzed reaction. A library of inhibitors with triazole and alkyne linkers 
designed to bridge the anhydroquinate core with various aryl and heteroaryl groups 
were synthesized from a common ene-yne intermediate employing Cu(I) azide-alkyne 
cycloaddition and palladium catalyzed Sonogashira cross-coupling. The majority of 
compounds exhibited potent inhibition of M. tuberculosis type II DHQase  
(Ki = 0.039-3.2 µM). Despite the potent inhibition against M. tuberculosis type II 
DHQase, anhydroquinate-based compounds exhibited poor inhibition of  
M. tuberculosis (H37Rv) in vitro. The lack of antitubercular activity was mainly 
attributed to the hydrophilicity of the anhydroquinate core which makes it difficult for 
these compounds to traverse the waxy, hydrophobic M. tuberculosis cell wall. This 
problem was addressed by substituting this core with functionally simpler, more 
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hydrophobic fragments. A fragment elaboration approach was subsequently employed 
to devise novel type II DHQase inhibitors. This fragment elaboration study led to the 
identification and development of catechol and acetonide-based compounds which 
exhibited low micromolar inhibition against M. tuberculosis type II DHQase  
(Ki = 5-86 µM) and markedly improved antitubercular activity relative to 
anhydroquinate-based inhibitors (MIC50 = 10-850 µM against the avirulent H37Ra 
strain of M. tuberculosis). 
Chapter 5 of this thesis outlines the successful development of a continuous enzyme 
kinetic assay for M. tuberculosis GlmU uridyltransferase. It also features the design of 
inhibitors based on the substrates and putative transition-state of the GlmU 
uridyltranferase reaction. Three classes of substrate-based inhibitors based on 
aminothiazole, sulfonamide and chromone scaffolds were synthesized along with 
transition-state mimics. Unfortunately, these compounds only demonstrated weak to 
moderate inhibition of M. tuberculosis GlmU uridyltransferase. This chapter also 
outlines the successful synthesis of the first inhibitors of M. tuberculosis GlmU 
uridylransferase based on an aminoquinazoline scaffold which exhibited micromolar 
inhibitory activity. The structure-activity relationships (SARs) elucidated from this 
series of compounds will aid the design of more potent compounds in the future. 
Chapter 6 of this thesis focuses on the development of a low-epimerization fragment 
condensation strategy to assemble analogues of sansanmycins with high optical 
purity. A total of nine sansanmycin analogues were synthesized and evaluated for  
in vitro growth inhibition of M. tuberculosis H37Rv. Most compounds exhibited 
excellent antitubercular activity with MIC50 values in the high nanomolar to low 
micromolar range (0.3-2.2 µM). Preliminary data indicated that these compounds 
demonstrated intracellular killing of M. tuberculosis in infected human THP-1 
macrophages. The SARs elucidated for the first-generation sansanmycin analogues 
now form the foundation for the design and synthesis of more potent second-
generation compounds. The activity of these compounds in macrophage killing assays 
holds promise for the in vivo evaluation of these analogues.  
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1.1 Global distribution of tuberculosis cases and current treatment 
Tuberculosis (TB) is caused by infection with the bacterium Mycobacterium 
tuberculosis.[1] In 2012, the World Health Organization (WHO) reported 8.6 million 
new cases and approximately 1 million deaths as a result of TB. Sub-Saharan Africa 
has the highest number of TB cases per capita which arises from the existence of a 
large degree of co-infection with the human immunodeficiency virus (HIV) endemic 
in this area (Figure 1).[1] However, the majority of the world’s TB cases (about 60%) 
are found in India, China and the Russian Federation (Figure 1).[1]  
 
Figure 1. Estimates of global TB incidence rates in 2011, image courtesy of the WHO. 
Tuberculosis is transmitted via inhalation of aerosol M. tuberculosis (droplet nuclei 
with diameters ranging from 2-5 µm) from patients with active TB infection.[2] 
Although pulmonary TB is found in the majority of cases, this disease can also affect 
other sites (extrapulmonary TB).[2-3] It is important to realize that only a small 
proportion of individuals (approximately 10%) infected with M. tuberculosis develop 
active TB in their lifetime, while the rest asymptomatically carry a latent form of the 
bacterium.[2] In the cases of pulmonary TB, inhaled M. tuberculosis bacteria are first 
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taken up by macrophages and subsequently transported across the alveolar epithelium 
into the lung. These infected macrophages start to aggregate and ultimately form an 
organized structure called a granuloma.[4] Granuloma is an aggregate of epithelioid 
cells which evolve from macrophages and have a similar appearance to epithelial 
cells.[4] Other cells derived from granuloma macrophages include giant cells and foam 
cells which contain only a few bacteria.[4] The majority of the bacterial population 
resides within the central caseous, necrotic region infiltrated with dead and dying 
macrophages.[4] The granuloma is also populated with other cell types such as 
neutrophils, dendritic cells, B and T cells, natural killer cells and fibroblasts.[4] 
During active infection (or reactivation of latent M. tuberculosis infection), the 
granuloma can weaken resulting in the extracellular release of M. tuberculosis which 
leads to recruitment of macrophages and initiation of granuloma formation as 
described above.[4] Recent findings indicate that this dissemination stage also involves 
the movement of some infected macrophages from the primary granuloma to other 
sites to participate in the establishment of secondary granulomas.[4] 
 
Figure 2. Stages of TB infection: latent TB and active infection. Latent TB infection is 
commonly activated in immune-compromised individuals. 
It is estimated that two billion people (one third of the world’s population) are living 
with latent TB infection (LTBI) and are susceptible to disease re-activation.[2] In 
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particular, individuals with compromised immune systems such as those infected with 
HIV, diabetes and patients receiving anti-tumour necrosis factor therapy are at 
increased risk of developing ative TB.[2] The sizable pool of latent TB infection stems 
from the ability of M. tuberculosis to remain in a non-replicative state in macrophages 
in very low numbers for long periods of time making complete eradication difficult.[5] 
This characteristic of M. tuberculosis, known as persistency has resulted in the need 
for long and complicated TB regimens.[5] Specifically, treatment of TB usually 
requires a minimum of 6 months treatment of four first-line antibiotics each of which 
was introduced for TB therapy over 40 years ago.[3] This treatment regimen is 
separated into two phases: the intensive phase which involves the two month 
administration of four drugs (isoniazid, rifampicin, ethambutol and pyrazinamide, 
Figure 3), followed by a continuation phase which features a four month course of 
isoniazid and rifampicin.[3] For drug susceptible TB, this quadruple drug therapy 
achieves a cure rate >95% when given under directly observed treatment, short course 
(DOTS) conditions.[3] The molecular targets for these agents and their individual role 
in the treatment regimen have been reviewed.[6] Briefly, isoniazid, after initial 
activation by catalase peroxidase enzyme KatG, inhibits enoyl-ACP reductase, one of 
the key enzymes in type II fatty acid synthesis pathway that is responsible for 
biosynthesis of mycolic acids (the key component of the mycobacterial cell wall, 
Figure 3A and Figure 3C).[7] Isoniazid has early bactericidal activity and is highly 
effective in irradicating replicating M. tuberculosis populations with a reduction in 
95% of bacterial load after the first two days of treatment.[3] Similar to isoniazid 
which disrupts the biosynthesis of a key cell wall component (mycolic acids), 
ethambutol interferes with the biosynthesis of the mycobacterial cell wall, this time by 
disrupting the incorporation of arabinan (Figure 3A and Figure 3C).[8] While isoniazid 
and ethambutol target actively growing M. tuberculosis population, rifampicin plays a 
key role in preventing relapse due to its bactericidal activity against sporadically 
active TB bacilli.[3] Rifampicin disrupts transcription by binding to the β-subunit of 
DNA-dependent RNA polymerase (Figure 3A and Figure 3C).[9] The non-replicating  
M. tuberculosis population which has low metabolism in an acidic environment is 
preferentially killed by pyrazinamide, a prodrug that upon activation, is thought to 
inhibit trans-translation, a process that is required for stress survival and pathogenesis 
in M. tuberculosis.[10] The remarkable in vivo sterilizing activity of pyrazinamide was 
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instrumental in the shortening of TB treatment regimen to 6 months from an initial  
9-12 months period.[3] 
Poor adherence to current TB regimens combined with poor public health 
management in many developing countries have resulted in the emergence of  
multi-drug resistant (MDR) and extensively drug resistant (XDR) strains of  
M. tuberculosis.[11] There is an alarming increase in the reported incidence rates of 
MDR-and XDR-TB globally. In 2012, 450000 cases of MDR-TB were estimated and, 
alarmingly approximately 10% of these MDR-TB cases were classified as XDR-
TB.[1] Despite the existence of a number of effective antibiotics against sensitive  
M. tuberculosis strains, the prognosis is poor with regard to patients infected with 
resistant strains.[12] MDR strains are defined as being resistant to isoniazid and 
rifampicin, the two first-line antibiotics of choice and, as such, treatment of these 
infections requires second line antibiotics including fluoroquinolones (ofloxacin and 
levofloxacin) and injectable aminoglycosides (kanamycin and amikacin) which 
interfere with transcription and translation processes, respectively within  
M. tuberculosis (Figure 3B and Figure 3C).[13] Fluoroquinolones inhibit transcription 
and repair by interacting with DNA gyrase giving rise to stabilization of DNA breaks 
and the eventual degradation of DNA (Figure 3B and Figure 3C).[9] Aminoglycosides 
bind to the 30S subunit of the ribosome, giving rise to misincorporation of amino 
acids to the growing peptide chains, forming misfolded proteins.[9] These misfolded 
proteins are incorporated into the cell membrane, increasing uptake of 
aminoglycosides, causing further protein mistranslation which ultimately results in 
cell death (Figure 3B and Figure 3C).[9]  
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Figure 3. First and Second-Line TB drugs and mechanisms of action. 3A: First-Line TB 
drugs; 3B: Second-Line TB drugs; 3C: Mechanisms of action. 
Second line drugs need to be administered for at least 20 months as they are less 
effective than their first-line counterparts.[12b] Unfortunately, the use of second line 
antibiotics has widened the exposure of M. tuberculosis to a larger range of 
antibacterials which has led to the emergence and greater incidence of XDR  
M. tuberculosis strains.[11] These strains are defined as being resistant to both first and 
second line antibiotics, in particular fluoroquinolones and one of the injectable 
agents.[14] The treatment of XDR-TB therefore relies on the utilization of a small 
number of antibiotics that are not in frequent use due to their high toxicity and low 
efficacy.[14] The ineffectiveness of such treatments is reflected in the high mortality 
rate of individuals infected with XDR-TB. Indeed, in many countries, XDR-TB is 
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virtually untreatable as highlighted by a 98% mortality rate from this strain in a recent 
outbreak in South Africa.[15] 
The other problem with current TB therapies is the lack of effectiveness against latent 
M. tuberculosis populations which are characterized by hypoxia, a feature that is also 
observed in active infection. Among the first and second-line TB drugs, only 
rifampicin exhibits some efficacy under lower-oxygen conditions.[16] Given the 
lifelong risk of disease reactivation, developing agents that can target bacterial 
populations in hypoxic environments is key to shortening TB treatment.  
1.2 Current TB drug pipeline 
In order to effectively combat the alarming rise in the number of MDR and XDR-TB 
cases, new agents against validated and novel drug targets are needed. Apart from 
possessing a satisfactory safety profile, new TB drugs need to fulfill a number of 
other criteria. These include higher potency than existing therapies to reduce the 
duration of treatment and inhibition of novel drug targets in order to be effective 
against MDR-and XDR-TB.[3] Furthermore, new drug candidates must not show any 
antagonism to existing TB therapies in order to allow for use in combination 
treatment comprising of at least three active drugs.[3] Importantly, given the  
co-existence of HIV and TB, new treatments should preferentially be compatible with 
standard antiretroviral therapy (ART).[3] Furthermore, as mentioned previously, new 
clinical candidates should demonstrate effectiveness towards LTBI. The past 5 years 
have seen an explosion of new chemical entities and repurposed drugs with promising 
antitubercular activity, giving rise to a relatively healthy pipeline with four 
repurposed and 7 new drugs currently under investigation (as of June 2013, Figure 4).  
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Figure 4. Current global TB drug pipeline. Image courtesy of the 'Working Group on new TB  
Drugs'. 
1.2.1 Repurposed drugs 
Compounds that fall under this category include well-characterised drugs that were 
originally developed and used for other indications but were later found to possess 
bactericidal or sterilizing activity through observational studies or large multicenter, 
randomized clinical trials.[3] The main classes of repurposed compounds currently 
under evaluation include fluoroquinolones (gatifloxacins and moxifloxacin), 
rifamycins (rifapentine), riminophenazines (clofazimine), oxazolidinones and  
β-lactams.[3] As previously mentioned, fluoroquinolones and rifamycins inhibit DNA 
gyrase and DNA-dependent RNA polymerase respectively, thereby disrupting 
transcription. Riminophenazines such as clofazimine, originally developed as a 
leprosy drug, was recently shown to possess promising activity in a mouse model of 
actute TB infection.[17] 
Oxazolidinones inhibit protein synthesis by binding the 50S ribosomal unit of 
bacteria. Linezolid, a first-generation oxazolidinone, was approved in 2000 for the 
treatment of gram-positive bacterial infections prior to discovery that this drug was 
effective against both MDR-TB and XDR-TB.[18] Despite its efficacy, clinically 
significant adverse events including myelosuppression and peripheral neuropathy 
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were reported.[3] Second-generation fluoroquinolones such as AZD5847 and sutezolid 
are currently in phase II clinical trials.  
Another class of compounds recently repurposed were the β-lactam antibiotics such as 
meropenem. Despite the effectiveness of β-lactams in the treatment of gram-positive 
and gram-negative infections, the presence of BlaC, an efficient β-lactamase in  
M. tuberculosis has made this bacterium naturally resistance to this class of 
compounds.[19] However, it was recently demonstrated that when used in conjunction 
with clavulanate, a BlaC inhibitor, M. tuberculosis became susceptible to 
meropenem.[20] In fact, this combination has been used with moderate success to treat 
patients with MDR-and XDR-TB.[20] These studies have successfully rekindled 
interest in the development of novel β-lactams for TB treatment. 
1.2.2 New chemical entities 
Apart from repurposed drugs, there are 7 new chemical entities/regimens currently in 
phase II and phase III clinical trials for TB with a handful of compounds in early 
preclinical stages. These new chemical entities belong to chemical classes that are 
distinct to the existing TB drugs and operate via novel modes of action. The most 
promising compounds belong to diarylquinoline, nitroimidazole, 1,2-ethylenediamine 
and benzothiazinone chemical classes. 
1.2.3 Bedaquiline (Sirturo™) 
Bedaquiline (Sirturo™, Figure 5) has recently been approved for use in combination 
therapy against MDR-TB where alternative treatment regimens are not available and 
represents the first TB drug to be approved in over 40 years. Bedaquiline belongs to 
the diarylquinoline chemical class and is an inhibitor of M. tuberculosis ATP synthase 
(Figure 5). The drug facilitates killing of M. tuberculosis by binding to the c subunit 
of ATP synthase, preventing oligomerization of the c proteins to form the c-ring, a 
component of the F0 unit of ATP synthase.[21] Ultimately, this leads to the disruption 
of proton translocation which is necessary for ATP production.[21] Bedaquiline was 
identified by whole cell screening against multiple-cycle growth of Mycobacterium 
smegmatis, a non-infectious homologue of M. tuberculosis and its mechanism of 
action was elucidated from whole-genome sequencing of spontaneously generated  
M. tuberculosis mutants that are resistant to bedaquiline. Bedaquiline exhibits 
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remarkable selectivity for the mycobacterial ATP synthase as the compound is 20000-
fold less sensitive against the human counterpart.[21] This compound also displays 
equipotent bactericidal activity against replicating and dormant M. tuberculosis 
populations, a feature that is not shared by any existing TB drug. This arises from the 
need for de novo ATP synthesis in non-replicating M. tuberculosis.[22]  
The accelerated approval of bedaquiline was due to the bactericidal activity of this 
compound against both drug-sensitive and MDR M. tuberculosis strains with minimal 
inhibitory concentrations equal or lower than that of isoniazid and rifampicin.[3] The 
clinical success of bedaquiline has truly validated ATP synthase as a vulnerable target 
for M. tuberculosis.[3] 
 
Figure 5. Tuberculosis drug candidates and sites of action.[3] 
1.2.4 Nitroimidazoles 
Nitroimidazole compounds (Figure 5) are well known for their activity against 
anaerobic microorganisms and, as such, hold potential for the treatment of LTBI.[3] 
Two newer nitroimidazoles, PA-824 and delamanid (previously known as 
OPC67683) are currently in phase II and III clinical trials respectively for the 
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treatment of MDR-TB. Similar to many other TB drugs, both of these compounds are 
pro-drugs, being activated intracellularly by an F420-deazaflavin-dependent 
nitroreductase (Ddn) present in M. tuberculosis.[23] This activation generates  
des-nitroimidazole which triggers the synthesis of reactive nitrogen species such as 
nitric oxide that is responsible for bactericidal activity under anaerobic conditions.[24] 
Gene expression profiling studies indicate that PA-824 and delamanid also disrupt 
mycolic acid biosynthesis (Figure 5), currently believed to be the main aerobic killing 
mechanism of M. tuberculosis by these nitroimidazoles.[25]  
1.2.5 SQ109 and other MmpL3 inhibitors 
SQ109 (Figure 5) was identified through a combinatorial medicinal chemistry effort 
to generate more potent analogues of ethambutol.[26] It was later shown that this 
compound possessed a distinct mechanism of action to that of ethambutol, inhibiting 
mycolic acid biosynthesis instead of arabinogalactan mediated by the inhibition of an 
essential membrane protein called MmpL3, responsible for the transport of trehalose 
monomycolate.[27] SQ109 and bedaquiline are synergistic in vitro, decreasing the 
minimal inhibitory concentration of bedaquiline against the virulent M. tuberculosis 
strain (H37Rv) by four to eightfold.[3] This is probably due to the ability of SQ109 to 
weaken the cell wall, increasing membrane permeability of bedaquiline. SQ109 is 
currently in a phase II clinical trial and, given the observed synergism with 
bedaquiline, it is likely that these two agents will be tested as a novel regimen in the 
near future. Apart from SQ109, adamantyl urea AU1235 and pyrrole BM212 were 
also found to inhibit MmpL3 (Figure 5).[3] The structural diversity of MmpL3 
inhibitors suggests that this membrane protein may have other roles and functions that 
warrant further investigation. 
1.2.6 Benzothiazinones 
Benzothiazinones display low nanomolar inhibition of M. tuberculosis growth in vitro 
and ex vivo models.[28]Furthermore, benzothiazinone BTZ043 is not only active 
against drug susceptible but also effective against MDR and XDR M. tuberculosis 
clinical isolates.[28] BTZ043 does not show antagonism to current TB drugs or other 
clinical candidates. The compound also exhibits synergistic effects when used in 
conjunction with bedaquiline.[29] 
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BTZ043 is a first in class inhibitor of decaprenylphosphoryl-beta-D-ribose 2’-
epimerase (DprE1) which catalyzes the conversion of decaprenyl-phosphoryl-D-
ribose to decaprenyl-phosphoryl-D-arabinose, the sole arabinose precursor for the 
biosynthesis of arabinogalactan and lipoarabinomanan (Figure 5). BTZ043 is 
currently in preclinical development. Apart from BTZ-043, three other classes of 
nitroaromatic compounds were recently shown to be DprE1 inhibitors.[3]  
The promising biological activity of BTZ043 implies the vulnerable nature of DprE1, 
making it an exciting new target for the development of inhibitors for the treatment of 
TB.  
1.3 New drug targets 
Given the high attrition rate in the late stage of drug development, it is imperative that 
agents targeting new drug targets continue to be developed and progressed through 
the TB pipeline. Historically, new medicines have been discovered based on three 
approaches: phenotypic screening, synthetic derivatives of natural products and 
target-based approaches. Each of these methods offers distinct advantages and 
disadvantages. 
1.3.1 Phenotypic screening 
The phenotypic screening strategy is based on assays that measure a specific 
physiological phenomenon without prior knowledge of the molecular mechanism of 
action (MMOA).[30] Specifically, in the context of TB drug discovery, the end point of 
this approach is usually the in vitro growth inhibition of the laboratory virulent strain 
of M. tuberculosis (H37Rv). This approach has led to the discovery of 
benzothiazinone BTZ043 and adamantyl urea AU1235.  
The main advantage of this approach is that it produces hits that already possess  
cell-permeating properties, a property that is difficult to engineer into existing 
compounds due to the low permeability of M. tuberculosis cell wall.[30] The main 
drawback of this method is the challenge associated with optimizing molecular 
properties without knowledge of the MMOA.[30] Furthermore, identification of the 
molecular targets of hits from phenotypic screens can be daunting despite recent 
advances in genome sequencing and chemical proteomics.[31] 
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1.3.2 Target-based Approach 
The complete sequencing of the M. tuberculosis genome in 1998[32] and the parallel 
development of proteomics has resulted in an explosion of novel TB drug targets with 
high resolution X-ray structures enabling structure-based drug discovery (SBDD) as a 
complimentary approach to the more traditional phenotypic screening.[33] The strength 
of this approach lies in the ability to utilize structural information and mechanistic 
insights to drive the discovery or optimization of an initial high-throughput screening 
(HTS) hit. The main disadvantage of target-based approaches, especially in the 
context of TB drug discovery, is that it is difficult to build in properties such as cell 
permeability into existing enzyme inhibitors or protein modulators. As such, even for 
a validated target, the translation from target inhibition to antitubercular activity is not 
an easy task. Despite the above drawbacks, the target-based approach still presents an 
exciting opportunity for the discovery of compounds with novel MMOA especially 
with judicious choice of target. 
1.3.3 Synthetic derivatives of natural products 
Historically, natural products have provided excellent starting points for the discovery 
and development of novel drug candidates. In an analysis by Swinney and 
Anthony[30], 36% of first-in-class small molecule new chemical entities approved by 
the Food and Drug Administration (FDA) originated from natural products which is 
in agreement with a previous report by Newman and Cragg.[34] Modification of 
natural products usually represents a fruitful strategy as these molecules have been 
selected by evolution with optimized biology and MMOA. Indeed, rifampicin which 
significantly reduced standard TB therapies to 6 months (from the initial 18-24 
months) in the 1970s, is a semi-synthetic derivative of rifamycin which is produced 
by cultures of Amycolatopsis mediterranei.[35] Other natural products or their 
synthetic derivatives used in the treatment of TB include second line injectable agents 
(i.e. amikacin, kanamycin and capreomycin) and the orally available  
D-cycloserine.[35a] 
1.4 Thesis overview 
 In this thesis, efforts towards the development of inhibitors against enzymes in the 
shikimate and peptidoglycan biosynthetic pathways using a target-based approach are 
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described. Enzymes in both the shikimate pathway and peptidoglycan biosynthesis 
have been demonstrated to be essential for the survival and virulence of  
M. tuberculosis. Specifically, inhibition studies against type II dehydroquinase (type 
II DHQase), the third enzyme in the shikimate pathway is described in chapter 3, 
while the development of novel inhibitors against N-acetylglucosamine-1-phosphate 
uridyltransferase (GlmU) is presented in chapter 5.  
Furthermore, this thesis also describes the development of synthetic derivatives of 
sansanmycins as potential TB drug leads. The sansanmycins are members of the 
uridylpeptide antibiotic family which were previously shown to possess activity 
against Pseudomonas aeruginosa and M. tuberculosis. Specifically, the development 
of an efficient synthetic route towards sansanmycin analogues will be discussed along 
with biological evaluation against M. tuberculosis in vitro. 
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2.1 Overview of the shikimate pathway 
The complete sequencing of the M. tuberculosis genome in 1998[32] and the parallel 
development of proteomics have resulted in an explosion of novel TB targets with 
high resolution X-ray structures, enabling SBDD as a complimentary approach to the 
more traditional whole cell empirical screening.[33] Among the promising targets 
identified by the genome project and subsequently validated against M. tuberculosis 
in vitro are the enzymes that constitute the shikimate pathway.[36] This pathway 
operates in plants, bacteria, fungi and apicomplexan parasites. Inhibitors of the 
shikimate pathway enzymes therefore have the potential to serve as broad-spectrum 
antimicrobials, herbicides, fungicides or antimalarials. In fact, the potential of 
inhibitors of the shikimate pathway acting as broad spectrum herbicides has been 
realized by glyphosate (Roundup®), an extremely successful post emergence 
herbicide. Importantly, the absence of the shikimate pathway in mammals removes 
the complication of selective targeting or delivery of inhibitor drug leads. 
The shikimate pathway in M. tuberculosis involves seven enzyme-catalyzed steps 
which facilitate the conversion of erythrose-4-phosphate (1) and phosphoenolpyruvate 
(2) to chorismate (3) (Scheme 1).[37] Chorismate (3) is known to be a branching point 
for the biosynthesis of a host of essential secondary metabolites such as folate, the 
aromatic amino acids and the ubiquinones.[37] Given the essential nature of these 
secondary metabolites to the survival of M. tuberculosis, inhibitors of any enzyme on 
the shikimate pathway have the potential to serve as new TB therapeutics. 
Chapter 2. The shikimate pathway 
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Scheme 1. The shikimate pathway 
2.2 Dehydroquinases 
M. tuberculosis dehydroquinase  (DHQase, EC 4.2.1.10) is encoded by Rv2537c, 
identified as the aroD gene. This enzyme catalyzes the third step of the shikimate 
pathway which involves the reversible dehydration of 3-dehydroquinate (4) to give  
3-dehydroshikimate (5). There are two types of DHQase enzymes that exhibit no 
sequence or structural similarity and are believed to arise from convergent evolution, 
catalyzing the same dehydration reaction via completely different reaction 
mechanisms which involve the abstraction of different protons.[38] Type I DHQase 
enzymes are heat labile dimeric proteins containing 27 kDa subunits with exclusive 
participation in the biosynthetic shikimate pathway. This class of enzyme catalyzes a 
syn-dehydration of 3-dehydroquinate (4), as a result of pro-R hydrogen loss (Scheme 
2).[38] Type II DHQase enzymes are heat stable, dodecameric proteins with 16.5 kDa 
subunits with participation in both biosynthetic and catabolic pathways.[38] Type II 
DHQase catalyzes a trans-dehydration of the substrate with the loss of pro-S 
hydrogen (Scheme 2).[38] 
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Scheme 2. Dehydration reaction catalyzed by type I and type II DHQase enzymes. 
In M. tuberculosis, there is only one type of DHQase, namely type II DHQase and 
this enzyme participates exclusively in the biosynthetic shikimate pathway and does 
not play any role in the catabolic cycle of quinic acid to form succinyl CoA.[39] This is 
reflected in its low KM value (KM = 24 µM and kcat = 4.6 s-1) relative to type II 
DHQase from other species such as Aspergillus nidulans in which the enzyme is 
implicated in both biosynthetic and catabolic pathways.[39]  
M. tuberculosis type II DHQase is a homododecameric enzyme consisting of four 
trimers (Figure 6A).[40] Each subunit consists of a five-stranded parallel β-core 
flanked by four α-helices, an arrangement that is similar to the overall fold topology 
of flavodoxin (Figure 6B).[40] The trimeric assembly is held in place by strong 
electrostatic interactions, with each monomer interacting with the other three-fold 
symmetry-related subunit via five salt bridges.[40] The two-fold interactions (between 
trimers) involve backbone hydrogen bonding between two C-terminal β-strands. 
Consistent with these structural observations, treatment of the dodecameric enzyme 
with guanidine hydrochloride produced a trimeric species as a minimum active 
unit.[40] The active site region is located near the C-terminus of the β-strands 3, 4 and 
5 (Figure 6B). Early site-directed mutagenesis studies indicated the essential nature of 
two residues, R19 and Y24, located on a flexible loop that closes on the active site of 
the enzyme following substrate binding.[40]  
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Figure 6. A: Structure of the homododecamer of M. tuberculosis type II DHQase (PDB code: 
3N76)[41]; B: Ribbon representation of one monomer of type II DHQase; α-helices (red) are 
labeled α1-α4 and β-strands (cyan) are labeled β1-β5. 
2.3 Mechanisms 
As discussed previously, the dehydration reaction catalyzed by type I and type II 
DHQases proceeds via vastly different mechanisms.[38b, 42] Type I DHQase catalyzes 
the syn elimination of water via the formation of an imine intermediate (Schiff base) 
between a conserved lysine residue in the enzyme active site and the carbonyl group 
of 4 (Scheme 3).[38b] This imine then acts as an electron sink, increasing the reactivity 
of the pro-R hydrogen at C2 by distorting the cyclohexyl ring into a boat 
conformation.[38b] The presence of the imine intermediate was confirmed by Shneier 
and co-workers[43] who utilized electrospray mass spectrometry to provide evidence 
for the covalent adduct formed between the enzyme and the product,  
3-dehydroshikimate (5). The detection of this species instead of the covalent imine 
intermediate between the enzyme and the substrate was consistent with a large 
equilibrium constant of dehydration (Keq = 15).[38b] The importance of the conserved 
lysine residue was also demonstrated by irreversible inactivation of type I DHQase 
upon sodium borohydride treatment of an equilibrium mixture of enzyme, substrate 
and product. Inactivation of type II DHQase did not occur under these conditions, 
again highlighting the different catalytic mechanisms utilized by these two classes of 
enzymes.[38b] 
B. A. 
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Scheme 3. The reaction mechanism of type I DHQase-catalyzed dehydration of  
3-dehydroquinate 4.[38b] 
In contrast to the type I enzyme, type II DHQase catalyzes the dehydration of 4 via an 
E1CB mechanism. In this case, the more acidic pro-S hydrogen is abstracted by a 
conserved tyrosine residue (Y24) to form the enol intermediate (Scheme 3).[42] Y24 is 
located on a flexible loop that closes onto the active site upon substrate binding.[42] 
Also present on this loop is R19, which along with R108, significantly lower the pKa 
of the phenol moiety on the side chain of tyrosine, allowing for deprotonation to the 
corresponding phenolate at physiological pH (pH = 7.0). Following the formation of 
the enol intermediate, anti-elimination of water then occurs, facilitated by a water 
molecule and conserved asparagine (N12) and histidine (H101) residues.[42]  
 
Scheme 4. The reaction mechanism of type II DHQase-catalyzed dehydration of  
3-dehydroquinate (4). 
2.4 Previous type II DHQase inhibitors 
2.4.1 The first selective and competitive inhibitors of type II DHQases 
The presence of type II DHQase in M. tuberculosis and Helicobacter pylori makes 
this enzyme an attractive target for the development of new TB and peptic ulcer 
therapies, respectively. The mechanistic insights into the catalysis of the dehydration 
reaction performed by type II DHQase has therefore been exploited in the design and 
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synthesis of several reversible competitive inhibitors against this enzyme. The first 
selective and competitive inhibitors of type II DHQase were reported by Frederickson 
et al.[44] in 1999. The most potent inhibitor, 2,3-dehydroquinic acid 6 was designed to 
mimic the flattened enol intermediate (Table 1). This study established that 
incorporation of a double bond between C-2 and C-3 was crucial for potent inhibition 
of type II DHQases. The importance of unsaturation between C-2 and C-3 was well 
illustrated with 6 (Ki = 200 µM) being 6 times more potent than its saturated 
counterpart 7 (Ki = 1200 µM) against M. tuberculosis type II DHQase (Table 1). 
Isosteric replacement of a hydrogen in inhibitor 6 with fluorine gave rise to a 20-fold 
improvement in potency (8: Ki = 10 µM) as this analogue effectively mimicked the 
electron density and distribution of the enol intermediate.[45] 
Table 1. Inhibition constants for compounds 6-8 against M. tuberculosis type II DHQase. 
Assay condition: 50 mM Tris.HCl, pH = 7.0, 25 oC.[44-45] 
 
 
 
 
 
 
 
 
 
In 2002, the first co-crystal structure with inhibitor 6 bound to  
Streptomyces coelicolor type II DHQase was unveiled, establishing both the binding 
mode of inhibitor 6 as well as revealing a subsidiary binding pocket adjacent to the 
active site which was occupied by a glycerol molecule that was an artifact from the 
crystallization process.[46] This discovery sparked the development of the next 
generation inhibitors with extension at C-3 designed to occupy the subsidiary binding 
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pocket.[46] It was also discovered that, unlike the active sites of type II DHQase 
enzymes which contain highly conserved amino acid residues, subtle differences exist 
within the subsidiary binding pockets. As such, the development of selective 
inhibitors against type II DHQase from different bacterial species is possible.[46] 
2.4.2 Bifunctional inhibitors of type II DHQases 
The first type II DHQase inhibitors (9-11, Figure 7) designed to extend into the 
glycerol-binding pocket incorporated features from both inhibitor 7 and glycerol.[47] 
The best inhibitor in this series was compound 11, bearing a hydroxypropyl side chain 
at C-3 (11: Ki = 180 µM against S. coelicolor type II DHQase).[47] This compound 
was three-fold more potent than the saturated analogue without the C-3 extension (7 
and 11, Figure 7 and Table 1) suggesting favourable interactions with the residues 
present in the glycerol binding pocket.[47]  
 
Figure 7. First type II DHQase bifunctional inhibitors. 
Subsequent inhibition studies by Sánchez-Sixto and co-workers[48], incorporated 
aryl/heteroaryl moieties at C-3. Given the importance of C2-C3 planarity for correct 
mimicry of the enol intermediate, the researchers decided to append these moieties 
directly on to the anhydroquinate core.[48] The rationale behind the adoption of 
aryl/heteroaryl terminal rings was to facilitate a π-stacking interaction with the 
catalytic tyrosine residue (Y24) that is located on the flexible loop.[48] The majority of 
inhibitors in this study showed potent inhibition against M. tuberculosis type II 
DHQase with the best inhibitor exhibiting a Ki of 54 nM (12, Figure 8).[48] The 
inhibition of type II DHQase was sensitive to both the electronic and steric nature of 
the terminal aryl rings. For example, when the 3-nitrophenyl in 12 was replaced by  
3-hydroxyphenyl (13, Figure 8) and 3-carboxyphenyl moieties (14, Figure 8), a three 
order of magnitude drop in potency was observed. The incorporation of more 
sterically demanding groups such as 3-and 4-trifluoromethylphenyl at C-3 and C-4 
was also not well tolerated with a 10-fold decrease in potency (15 and 16, Figure 
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8).[48] The improvement in potency observed in this study relative to inhibitor 6 was 
attributed to a cation-π interaction between aryl/heteroaryl rings with R19.[48] 
 
Figure 8. Anhydroquinate-based M. tuberculosis type II DHQase inhibitors. 
In order to gain a better understanding of the M. tuberculosis type II DHQase 
subsidiary binding pocket, Prazeres and co-workers[49] designed inhibitors with more 
bulky, bicyclic moieties directly attached to C-3 of the anhydroquinate core 
(representative compounds 17-19, Figure 9). Although these larger heterocycles were 
not as well tolerated by M. tuberculosis type II DHQase compared with the  
S. coelicolor counterpart, these compounds still exhibited low micromolar inhibition 
of the enzyme (Figure 9).[49] These results also lend support to the hypothesis that the 
subsidiary binding pocket in M. tuberculosis is more compact than that in  
S. coelicolor type II DHQase.[49]  
 
Figure 9. Anhydroquinate-based M. tuberculosis type II DHQase inhibitors incorporating 
bicyclic heterocycles. 
While the above inhibition studies featured inhibitors with aryl/heteroaryl moieties 
directly attached to the anhydroquinate core, Payne et al.[50] took a different approach. 
Initially, an aromatic ring directly attached to C-3 of the anhydroquinate core was 
incorporated to serve as a rigid linker to bridge terminal aromatic moieties that could 
interact with residues within the subsidiary binding pocket.[50] Analogues with ether, 
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thioether, sulfone and carbonyl functionalities between the two aryl rings were 
synthesized and evaluated against type II DHQase enzymes from S. coelicolor,  
M. tuberculosis and H. pylori.[50] Two of these inhibitors, containing diphenylsulfide 
and diphenylether moieties at C-3, exhibited nanomolar inhibition against  
M. tuberculosis type II DHQase (20 and 21, Figure 10).[50]  
 
Figure 10. Biaryl inhibitors of M. tuberculosis type II DHQase. 
In order to elucidate the role of the rigid linker on inhibition of M. tuberculosis type II 
DHQase, subsequent studies by Payne et al.[51] utilized olefin and amide linkers of 
different length and rigidity to append aryl/heteroaryl groups to the anhydroquinate 
core. It was discovered that the olefin linker was superior to the more rigid amide 
linker (22 and 23, Figure 10).[51] When the co-crystal structures of inhibitor 22 and 23 
with M. tuberculosis type II DHQase were superimposed, it became apparent that the 
side chain of 22 was 0.7 Å closer to the phenol side chain of Y24, hence giving rise to 
a stronger edge on π-stacking interaction with this residue (Figure 11). In addition, the 
phenyl ring in 22 was optimally positioned within a hydrophobic patch that consisted 
of L13, L16 and Y24. These differences gave rise to a 16-fold improvement in Ki for 
inhibitor 22 over 23 (22: Ki = 140 ± 10 nM and 23: Ki = 2300 ± 200 nM).[41]  
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Figure 11. Overlay of M. tuberculosis type II DHQase/inhibitor 22 complex (PDB code: 
3N76 with protein backbones are shown in brown ribbons) with type II DHQase/inhibitor 23 
complex (PDB code: 3N76 with protein backbones are shown in cyan ribbons). Inhibitors 22 
and 23 are shown in cyan and green respectively.[41]  
The co-crystal structure of inhibitor 22 bound to the active site of M. tuberculosis type 
II DHQase provided insights into the molecular interactions necessary for potent 
enzyme inhibition. Specifically, the anhydroquinate core was seen to form a hydrogen 
bonding network with active site residues including H101, I102 and S103 while the 
terminal phenyl moiety was poised for π-stacking interaction with the essential Y24 
residue (Figure 12).[41] 
 
 
Figure 12. Crystal structure of M. tuberculosis type II DHQase (PDB code: 3N76) with 
inhibitor 22 bound.[41] 
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The important role of rigid linkers was also observed by Blanco et al.[52] in a study 
which utilized anhydroquinate-based inhibitors with flexible alkyl linkers bridging the 
anhydroquinate core and terminal aryl groups (Figure 13). It was found that 
replacement of the oxygen atom in the methyleneoxy linker in 24 with a carbon atom 
as in 25 resulted in a 10-fold decrease in potency, emphasizing the importance of the 
hydrogen bonding interaction between the oxygen atom in the linker of 24 with a 
catalytically essential water molecule.[52] 
 
Figure 13. 3-alkyl enol mimics as type II DHQase inhibitors. 
2.5 Research aims 
Given the essentiality of type II DHQase to the survival of M. tuberculosis and the 
existence of a robust enzyme kinetic assay, this enzyme represents a viable drug 
target. Previous inhibition studies against type II DHQase served as a foundation for 
the design and synthesis of novel inhibitors in this research project. To this end, the 
use of affordable and reliable chemistry to assemble a small library of inhibitors in a 
fast and efficient manner was envisioned in this study. Specifically, the synthesis of 
two novel inhibitor libraries was planned possessing triazole or alkyne functionalities 
as rigid linkers between the anhydroquinate core and the terminal aryl or heteroaryl 
moieties at C-3 (Figure 14). It was anticipated that these new inhibitors would exhibit 
potent inhibition of type II DHQase in vitro and serve as lead compounds for the 
development of new TB drugs. 
 
Figure 14. Proposed triazole-and alkynyl-based inhibitor libraries.
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3.1 Retrosynthesis of triazole-and alkynyl-based inhibitor libraries 
The synthesis of triazole-and alkyne-based inhibitors was proposed from a common 
ene-yne intermediate 26 which in turn could be prepared from vinyl triflate 27 via a 
palladium-catalyzed Sonogashira cross-coupling reaction (Scheme 5). Introduction of 
the aryltriazole moieties was proposed via a Cu(I)-catalyzed alkyne-azide 
cycloaddition (CuAAC) of 26 by reacting with a variety of aromatic azides. Entry into 
the alkyne-based inhibitor series was proposed via palladium-catalyzed Sonogashira 
cross-coupling reaction with a range of aromatic halides or triflates.  
 
Scheme 5. Retrosynthesis of triazole-and alkynyl-based inhibitor libraries. 
3.2 Design of triazole-based inhibitors 
In order to maximise diversity in the inhibitor library, terminal aryl and heteroaryl 
moieties with a variety of electronic properties were incorporated. Electron rich and 
electron deficient rings were selected to probe the effect of electron density on 
inhibition of type II DHQases (Figure 15). Heteroaryl moieties such as furan and 
thiophene, connected to the triazole linker via a methylene unit were also incorporated 
to evaluate the effect of conformational flexibility on inhibition of type II DHQases 
(Figure 15).  
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Figure 15. Design of triazole-based inhibitor library. 
In 2010, when the work described in this chapter began, two co-crystal structures of 
inhibitors in complex with M. tuberculosis type II DHQase were available (PDB 
codes: 1H0R and 1H0S). However, these structural studies did not capture the flexible 
catalytic loop which contains highly conserved and essential Arg and Tyr residues 
(R19 and Y24 in M. tuberculosis type II DHQase and R23 and Y28 in S. coelicolor 
type II DHQase). As such, the proposed inhibitor libraries were docked into the active 
site of S. coelicolor and H. pylori type II DHQase enzymes where full loop structures 
were resolved in the presence of various ligands. This study enabled evaluation of the 
potential binding modes of the compounds in the active site and subsidiary binding 
pocket and hence allowed a qualitative assessment of the suitability of these 
compounds as inhibitors of type II DHQase. This assessment was highly relevant as 
these potential inhibitors would also be evaluated for inhibition of S. coelicolor and 
H. pylori type II DHQases. While the former is a non-pathogenic soil microorganism 
responsible for the production of many natural antibiotics, the latter is the etiological 
agent of peptic ulcer and gastric cancer[53] and thus represents an important 
therapeutic target. 
The use of docking studies to predict the binding mode of type II DHQase inhibitors 
was recently validated by Payne et al.[50] In this study, the docking software GOLD 
was used for the rational design of nanomolar type II DHQase inhibitors. The 
accuracy and validity of the docking studies was reflected in the small RMSD value 
between the co-crystal structure of 20 with S. coelicolor type II DHQase and the 
docked structure (RMSD = 0.46 Å).[50] The predictive power of the docking software 
Glide[54] has not yet been established for type II DHQase. However, Glide (available 
at the University of Sydney) appeared to provide a good approximation of the actual 
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binding modes of proposed inhibitors. This was validated by conducting a control 
pilot experiment whereby inhibitor 6 was docked into the active site of S. coelicolor 
type II DHQase. The inhibitor docked in a similar binding mode to that observed in 
the co-crystal structure of 6 with type II DHQase (PDB code: 1GU1).[46] This 
provided the confidence that Glide would be a useful tool for studying the putative 
binding modes of triazole-based inhibitor series 28-35. 
Prior to the docking studies, the proposed inhibitors (28-35) were built using Maestro 
(version 9.0) and an energy minimization was performed so that the ligands were in 
their minimum energy conformations prior to docking. The protein files containing 
the crystal structures of type II DHQase enzymes from S. coelicolor and H. pylori 
were downloaded from the Research Collaboratory for Structural Bioinformatics 
(RCSB) Protein DataBank (PDB code: 1GU1 for S. coelicolor type II DHQase[46] and 
2WKS for H. pylori isozyme[55]). The protein was then prepared using the ‘Protein 
Preparation Wizard’ in Maestro (version 9.1) which re-orients protein side chains, 
relieves steric clashes and assigns bond orders as well as ionization states of amino 
acid residues and the co-crystallized inhibitor.[54] Following protein preparation, 
compounds 28-35 were docked flexibly into a specified receptor grid which 
encompassed the active site and the subsidiary binding pocket. Almost all docking 
runs returned two binding poses which were ranked. These two binding modes did not 
differ substantially in terms of the position of key functional groups such as those that 
interact with active site amino acid residues via hydrogen bonding.  
3.3 Docking of triazole-based inhibitors 
Triazole-based inhibitors 28-35 showed very similar binding modes when docked into 
the active site of S. coelicolor type II DHQase using Glide with the exception of 
inhibitor 30 and 31 bearing 3-nitrophenyl and 3-carboxyphenyl moieties, respectively 
in which the proposed binding modes were oriented 180o from the normal pose with 
the anhydroquinate core predicted to interact with residues lining the subsidiary 
glycerol binding pocket. A representative docking of inhibitor 28 bearing a terminal 
phenyl substituent is shown in Figure 16.[54] As mentioned above, two binding poses 
with relatively small energy differences were returned. The main difference in these 
two binding poses was the orientation of the C-1 carboxylate group, with the positions 
of the anhydroquinate core and the terminal aromatic moieties remaining unchanged. 
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A number of key binding interactions were predicted by Glide. Specifically, the C-1 
hydroxyl group of inhibitor 28 formed a hydrogen bond with H106 while the carbonyl 
group of the C-1 carboxyl group was shown to hydrogen bond with the peptide 
backbone of H106 and I107 (Figure 16). A weaker hydrogen bonding interaction 
between the C-5 hydroxyl and H85 was also predicted (Figure 16). As expected, the 
triazole linker served as a rigid scaffold for the presentation of the terminal phenyl 
ring to form a π-stacking interaction with the essential Y28 residue (Figure 16). In 
addition, a cation-π interaction was also predicted between the terminal aromatic ring 
and the guanidinium side chain of R23 (Figure 16).  
 
Figure 16. Glide-predicted lowest energy binding mode of triazole-based inhibitor 28 with  
S. coelicolor type II DHQase (PDB code: 1GU1)[46]. 
Similar hydrogen bonding interactions with active site amino acid residues were also 
predicted for triazole-based inhibitors 28-35 when docked into the binding site of  
H. pylori type II DHQase. The main difference was in the positioning of the terminal 
aryl/heteroaryl rings which were no longer able to form a π-stacking interaction with 
the essential Y22 residue (Figure 17). Instead, there appears to be edge-to-face  
π-stacking interaction between Y22 and the triazole linker. 
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Figure 17. Glide-predicted lowest energy binding mode of triazole-based inhibitor 28 with  
H. pylori type II DHQase (PDB code: 2 WKS)[55]. 
3.4 Synthesis of key ene-yne intermediate 26 
Having established the suitability of triazole-based inhibitors 28-35 as type II 
DHQase inhibitors, attention turned to the synthesis of key ene-yne intermediate 26. 
The synthesis of ene-yne 26 began from commercially available (-)-quinic acid 36 
(Scheme 6). Acid-catalyzed lactonization of (-)-quinic acid 36 served as a convenient 
mean to protect both the C-1 carboxylic acid and the C-3 hydroxyl groups. Treatment 
of (-)-quinic acid with p-toluenesulfonic acid (PTSA) in benzene at reflux in the 
presence of a Dean-Stark trap gave the desired lactone 37 in 75% yield.[56] Selective  
C-3 silylation of lactone 37 was achieved using tert-butyldimethylsilyl chloride and 
imidazole in dimethylformamide at 0 oC. The reaction was stirred for 2 h at  
0 oC followed by 5 h at ambient temperature to afford the 3-silylated lactone 38 in 
60% yield (Scheme 6).[56] With the C-3 protected lactone 38 in hand, the next step 
involved protection of the tertiary C-1 and secondary C-4 hydroxyl groups with 
methoxymethyl ether (MOM) groups. Treatment of 38 with excess 
dimethoxymethane and phosphorus pentoxide at room temperature for 3 h gave the 
fully protected lactone 39 in 78% yield (Scheme 6).  
Deprotection of the C-3 silyl group in 39 was achieved using tetrabutylammonium 
fluoride (TBAF) in tetrahydrofuran (THF) at 0 oC to afford 40 in 72% yield (Scheme 
6). Alcohol 40 was then oxidised by treatment with Dess-Martin Periodinane (DMP) 
in dichloromethane at ambient temperature to afford the corresponding ketone 41 in 
62% yield (Scheme 6). 
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Scheme 6. Synthesis of vinyl triflate 27 from quinic acid 36. Reagents and conditions:  
a) cat. PTSA, benzene, 90 oC, 19 h, 75%; b) TBS-Cl, imidazole, DMAP, DMF, 0 oC to rt, 7 h, 
60%; c) (OCH3)2CH2, P2O5, CH2Cl2, rt, 3 h, 78%; d) TBAF, THF, 0 oC, 3.5 h, 70%; e) Dess-
Martin Periodinane, CH2Cl2, rt, 1.5 h, 62%; f) (i) KHMDS, DMF, PhCH3, -78 oC, 1 h,   
(ii) Comin’s reagent, -78 oC to rt, 1.5 h, 49%. 
Ketone 41 was converted to vinyl triflate 27 via low temperature deprotonation with 
potassium hexamethyldisilazane and subsequent reaction of the potassium enolate 
with Comin’s triflating reagent to afford the desired enol triflate intermediate 27 in 
49% yield (Scheme 6). The vinyl triflate was next subjected to palladium-catalyzed 
Sonogashira cross-coupling conditions in order to append the desired alkyne moiety 
(Scheme 7). Treatment of 27 with TMS-acetylene using palladium 
tetrakis(triphenylphosphine)palladium(0) and copper iodide as a co-catalyst in the 
presence of piperidine as a base at 40 oC facilitated the smooth sp2-sp coupling to 
afford TMS-protected ene-yne 43 in 69% yield (Scheme 7). Facile deprotection of 
TMS ether using catalytic TBAF in THF proceeded smoothly in quantitative yield to 
afford 44 which was subsequently treated with 90 vol.% trifluoroacetic acid (TFA) to 
give the key ene-yne intermediate 26 in 64% yield (Scheme 7).[57] 
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Scheme 7. Synthesis of ene-yne intermediate 26 via vinyl triflate 27. Reagents and 
conditions: a) TMS-acetylene, [Pd(PPh3)4] (15 mol%), CuI (20 mol%), piperidine, THF,  
40 oC, 3.5 h, 69%; b) cat. TBAF, THF, rt, 15 min, quant.; c) TFA: H2O (9:1 v/v), 0 oC,  
30 min, rt, 3 h, 64%.  
3.5 Synthesis of triazole-based inhibitor library 
 
Scheme 8. Synthesis of triazole-based inhibitors. Reagents and conditions: a) sodium 
ascorbate (1 eq.), CuSO4.5H2O (0.1 eq.), R-N3, tert-butanol/water (1:1 v/v), rt, 24 h;  
b) (i) LiOH, THF, rt, 1-2 h, (ii) Amberlite IR-120 (H+ form), 27-69% over two steps. 
With the key ene-yne intermediate 26 in hand, attention next turned to the preparation 
of the proposed triazole-based inhibitors. To this end, ene-yne 26 was reacted with a 
library of aryl and heteroaryl-azides using previously reported CuAAC reaction 
conditions (0.1 eq. CuSO4, 1 eq. sodium ascorbate, 1:1 v/v water/tert-butanol) to 
furnish the corresponding triazole lactones (Scheme 8).[58] Saponification of the 
resulting lactones followed by acidification afforded the desired triazole-based 
inhibitors 28-35 in moderate to good yields (27-69%) over the two steps (Scheme 8). 
3.6 Inhibition studies against type II DHQases 
The inhibitory activity of triazole-based inhibitors 28-35 against  
S. coelicolor, H. pylori and M. tuberculosis type II DHQase enzymes were 
determined using a UV spectrophotometric assay. This entailed measuring the initial 
rate of product (3-dehydroshikimate, 5, Scheme 9) formation from 3-dehydroquinate 
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4 by detection of the enone-carboxylate chromophore at λ = 234 nm (Scheme 9).[44] 
The assays were conducted in the presence of a range of inhibitor and  
3-dehydroquinate concentrations and the initial rate of 3-dehydroshikimate formation 
was monitored at 234 nm (section 7.2.1). Inhibition constants (Ki) were calculated 
using non-linear regression fitting to a competitive enzyme inhibition model by 
GraphPad Prism (version 5.0.3 for Windows).[59] Compounds 28-35 exhibited 
reverisible and competitive inhibition of type II DHQase enzymes as indicated by the 
same Vmax values in the absence and presence of these inhibitors, suggesting the 
restoration of enzymatic activity at high concentration of substrate. 
 
Scheme 9. Enzymatic transformation by type II DHQase. 
The most potent inhibition was observed against S. coelicolor type II DHQase for all 
analogues. This is perhaps not surprising given the larger subsidiary binding pocket in  
S. coelicolor type II DHQase relative to those in H. pylori or M. tuberculosis 
isozymes. Inhibitors 28 and 33 bearing phenyl and 3-pyridyl terminal groups were the 
most potent compounds against S. coelicolor type II DHQase, a trend that was also 
observed for the M. tuberculosis isozyme (inhibitors 28 and 33, Table 2). Substitution 
of the terminal phenyl ring with electron-donating and electron-withdrawing groups 
resulted in most cases a drop in potency. This is particularly true for compound 31 
bearing a 3-carboxyphenyl terminal group which exhibited high nanomolar inhibition 
against S. coelicolor type II DHQase (31: Ki = 1720 ± 120 nM, Table 2). 
Interestingly, compound 30 bearing a 3-nitrophenyl terminal moiety that was 
predicted to possess similar binding mode to 31, displayed potent inhibition of  
S. coelicolor type II DHQase (30: Ki = 78 ± 8 nM, Table 2). The only example in 
which substitution of the terminal phenyl ring gave rise to superior inhibition was  
compound 32 bearing a 2-hydroxyphenyl terminal group. This compound exhibited 
more potent inhibition of  H. pylori type II DHQase relative to inhibitor 28 bearing an 
unsubstituted phenyl ring (32: Ki = 157 ± 14 nM and 28: Ki = 225 ± 51 nM, Table 2).  
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Table 2. Inhibition constants of triazole-based inhibitors 28-35 against S. coelicolor,  
H. pylori and M. tuberculosis type II DHQase enzymes.a 
Inhibitor S. coelicolor  
Type II DHQase 
Ki (nM) 
H. pylori 
Type II DHQase 
Ki (nM) 
M. tuberculosis  
Type II DHQase 
Ki (nM) 
28 5.7 ± 0.9 225 ± 51 39 ± 5 
29 29 ± 3 561 ± 75 154 ± 16 
30 78 ± 8 538 ± 83 230 ± 20 
31 1720 ± 120 5780 ± 540 3126 ± 315 
32 48 ± 4 157 ± 14 330 ± 24 
33 5.7 ± 0.8 375 ± 53 136 ± 12 
34 217 ± 17 2200 ± 300 2122 ± 193 
35 73 ± 10 925 ± 120 1579 ± 149 
aKinetic parameters of the type II DHQase enzymes: S. coelicolor: KM = 679 ± 68 µM,  
kcat = 84 s-1, 50 mM Tris.HCl, pH 7.0, 25 oC; H. pylori: KM = 228 ± 33 µM, kcat = 1.4 s-1,  
50 mM Tris.HOAc, pH 7.0, 25 oC; M. tuberculosis: KM = 52 ± 8 µM, kcat = 6.3 s-1, 50 mM 
Tris.HCl, pH 7.0, 25 oC. 
 
It is important to note that the above triazole-based inhibitors were less potent against  
H. pylori type II DHQase. Upon close inspection of the proposed binding modes of 
triazole-based inhibitors to H. pylori and S. coelicolor type II DHQase enzymes in 
docking experiments, it was revealed that the terminal aryl/heteroaryl moieties could 
not participate in a π-stacking interaction with Y22 in H. pylori type II DHQase while 
it was evident that such interactions were possible in the S. coelicolor isozyme (the 
relevant residue is Y28). Instead, there appears to be an edge-to-face π-stacking 
interaction between the Y22 and the triazole linker. In the case of inhibitor 32, the 
triazole linker was 0.6 Å closer to the phenol side chain of Y22, potentially giving rise 
to a stronger edge-to-face interaction which may explain the observed potency of 
inhibitor 32. 
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Inhibition of type II DHQase enzymes was sensitive not only to the electronic 
properties of terminal aryl/heteroaryl groups but also to conformational flexibility of 
these groups. Inhibitors 34 and 35 incorporating flexible methylene linked furan and 
thiophene groups, respectively exhibited significantly weaker inhibition of type II 
DHQase enzymes (Table 2). Whilst these compounds still exhibited nanomolar 
inhibition against S. coelicolor type II DHQase, they were significantly less potent 
against H. pylori and M. tuberculosis isozymes. These results suggest that rigid 
positioning of the terminal aromatic moieties and triazole linker may be an important 
feature for favourable parallel-displaced or edge-to-face π-stacking interactions with 
the essential Tyr residue. 
3.7 Design of alkynyl-based inhibitors 
For the alkynyl-based inhibitor series, terminal groups such as phenyl,  
4-fluorophenyl, 3-nitrophenyl and 3-pyridyl were incorporated as common groups 
that were previously included in the triazole-based inhibitor library. This enabled 
evaluation of the role of the linear sp-hybridized rigid linker in the inhibition of type 
II DHQase (Figure 18). To maximise molecular diversity, heterocylic moieties such 
as thiophene, quinoline and benzothiazole were also incorporated (Figure 18). It was 
envisaged that the proposed alkynyl-based inhibitors 45-52 could be prepared from a 
palladium-catalyzed Sonogashira cross-coupling from key ene-yne intermediate 26 
with a range of aryl/heteroaryl halides and triflates (Figure 18, Scheme 5). 
 
Figure 18. Design of alkynyl-based inhibitors. 
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Figure 19. Glide-predicted lowest energy binding mode of inhibitor 48 into the active site of  
A) S. coelicolor type II DHQase (PDB code: 1GU1)[46] and B) H. pylori type II DHQase 
(PDB code: 2 WKS)[55]. 
To support our inhibitor design, the proposed alkynyl-based inhibitors 45-52 were 
initially docked into the active site of type II DHQase from S. coelicolor (PDB code: 
1GU1)[46] and H. pylori (PDB code: 2WKS)[55] using Glide (Schrödinger Inc.)[54]. 
Most inhibitors possessed a common predicted binding mode whereby the 
anhydroquinate core formed a number of favourable hydrogen bonding interactions 
with the active site residues as has been observed with previous crystal structures of 
anhydroquinate-containing inhibitors (Figure 19A and Figure 19B). In addition, the 
rigid alkyne linker positioned the terminal aryl and heteroaryl moieties so as to 
achieve a favourable π-stacking interaction with the essential Tyr residue (Y28 in  
S. coelicolor and Y22 in H. pylori). These aryl and heteroaryl moieties were also 
predicted to engage in favourable lipophilic interactions with hydrophobic residues 
such as methionine and leucine (L17 and L19 in S. coelicolor type II DHQase and 
A 
B 
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L11, L14 and M13 in H. pylori type II DHQase). Representative dockings of 48, 
bearing a terminal 3-trifluoromethylphenyl substituent, depicting this common 
binding mode are shown in Figure 19. 
Compounds 51 and 52, containing terminal benzothiazole and quinoline groups, 
appeared to dock in a modified mode into the active site of S. coelicolor type II 
DHQase whereby the anhydroquinate core was oriented 180 degrees from the normal 
pose. It is assumed that this is due to the steric nature of these groups, which in order 
to establish a favourable π-stacking interaction with the essential Tyr residue, must 
present the anhydroquinate core in a different orientation.  
3.8 Synthesis of alkynyl-based inhibitors 
Having established that the proposed inhibitors provided favourable binding modes in 
silico, attention turned to the synthesis of inhibitors 45-52 from key ene-yne 
intermediate 26. Subjecting 26 to palladium-catalyzed Sonogashira cross-coupling 
reaction conditions with a variety of halides and triflates using 
tetrakis(triphenylphosphine)palladium(0) as the catalyst and copper iodide as the  
co-catalyst and piperidine as a base afforded the desired precursor lactones. Following 
saponification, the desired inhibitors 45-52 were afforded in moderate to good yields 
over the two steps (30-85%, Scheme 10). 
 
Scheme 10. Synthesis of alkynyl-based inhibitors 45-52 from ene-yne intermediate 26. 
Reagents and conditions : a) R-X (X= Br, I, or OTf), Pd(PPh3)4, CuI, piperidine, THF, 40 oC, 
2-3 h ; b) LiOH, THF/H2O, rt, 1-1.5 h, 30-85% over two steps. NB: * denotes compounds 
synthesized by Dr. Katie Cergol. 
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3.9 Inhibition of type II DHQase enzymes by alkynyl-based inhibitors 
Compounds 45-52 were next screened against type II DHQase enzymes from three 
organisms, namely S. coelicolor, H. pylori and M. tuberculosis. The inhibitors were 
tested using the UV spectrophotometric assay described in section 3.6. Gratifyingly, 
the majority of the compounds prepared in this study proved to be potent inhibitors of 
all three of the type II DHQase enzymes studied, with inhibition constants in the 
nanomolar range (Table 3). 
As previously mentioned, inhibitors 45-52 were designed and synthesized to evaluate 
the role of triazole and alkyne linkers on the inhibition of type II DHQase enzymes. It 
was therefore interesting to note that the triazole linker was favoured for inhibition of  
M. tuberculosis type II DHQase (28: 39 ± 5 nM to 45: 356 ± 23 nM; 29: 154 ± 16 nM 
to 46: 548 ± 64 nM and 33: 136 ± 12 nM to 49: 2194 ± 404 nM, Table 2 and Table 3) 
while the alkyne linker gave rise to more potent inhibition of the H. pylori isozyme 
(46: 106 ± 18 nM to 29: 561 ± 75 nM ; 47: 98 ± 16 nM to 30: 538 ± 83 nM, Table 2 
and Table 3). This phenomenon has been reported for previously prepared 
anhydroquinate inhibitors, suggesting subtle differences in the active site structures of 
these two enzymes.[60]  
Compounds 47, 48 and 51 bearing 3-nitrophenyl, 3-trifluoromethylphenyl and 
benzothiazole substituents, respectively, exhibited the most potent inhibition against 
all three enzymes and were among the most potent inhibitors prepared to date against 
M. tuberculosis and particularly H. pylori type II DHQase enzymes (Table 3). 
Examination of molecular docking results revealed additional favourable interactions 
between inhibitors 48 and 51 to the binding site of H. pylori type II DHQase.  
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Table 3. Inhibition constants of alkynyl-based inhibitors 45-52 against S. coelicolor,  
H. pylori and M. tuberculosis type II DHQase enzymes.a 
Inhibitor S. coelicolor  
Type II DHQase 
Ki (nM) 
H. pylori 
Type II DHQase 
Ki (nM) 
M. tuberculosis  
Type II DHQase 
Ki (nM) 
45 28 ± 3 253 ± 33 356 ± 23 
46 12 ± 1 106 ± 18 548 ± 64 
47 2.2 ± 0.4 98 ± 16 133 ± 15 
48 6.9 ± 0.9 103 ± 13 108 ± 10 
49 171 ± 23 712 ± 137 2194 ± 404 
50 7.1 ± 0.8 316 ± 44 187 ± 18 
51 7.5 ± 0.7 94 ± 11 126 ± 9 
52 168 ± 20 1203 ± 134 885 ± 67 
aKinetic parameters of the type II DHQase enzymes: S. coelicolor: KM = 210 ± 32 µM,  
kcat = 61 s-1, 50 mM Tris.HCl, pH 7.0, 25 oC; H. pylori: KM = 75 ± 10 µM, kcat = 0.34 s-1,  
50 mM Tris.HOAc, pH 7.0, 25 oC; M. tuberculosis: KM = 36 ± 4 µM, kcat = 4.6 s-1, 50 mM 
Tris.HCl, pH 7.0, 25 oC. 
Apart from the hydrogen bonding network with active site residues and a π-stacking 
interaction with the conserved Tyr residue, inhibitor 48 bearing a terminal  
3-trifluoromethylphenyl substituent engaged in favourable lipophilic interactions with 
M13 and L14. Furthermore, there appeared to be an interaction between the fluorine 
atom of the CF3 group with the amide carbonyl carbon of N10 in H. pylori type II 
DHQase (Figure 19B).[61] In a similar manner to inhibitor 48, compound 51 also 
engaged in an additional favourable interaction. In this case, the divalent sulfur atom 
of the benzothiazole moiety appeared to interact with the π system of Y22 (Figure 
20). This interaction is similar to close contacts (3.7-4.2 Å) made between the sulfur 
of methionine side chains and π systems which occur at a frequency of about 22% in 
25000 PDB structures in Relibase.[62] These additional favourable interactions may be 
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responsible for the superior inhibition of all three enzymes by compounds 48 and 
51.[61-62] 
 
Figure 20. Glide-predicted lowest energy binding mode of inhibitor 51 into the active site of  
H. pylori type II DHQase (PDB code: 2WKS).[50] 
From the results of the inhibition studies above, it was clear that pyridine and  
quinoline terminal groups were not tolerated by type II DHQase (inhibitors 49 and 52, 
Table 3). Upon close inspection of the proposed binding mode of inhibitor 52 to  
H. pylori type II DHQase, it was revealed that the quinoline nitrogen was in close 
proximity to L11 and L13. The positively charged nitrogen (at physiological pH) 
represented a poor match for the hydrophobic leucine residues which potentially 
resulted in the observed loss of potency. With respect to inhibitor 49, bearing the  
3-pyridyl substituent, the positively charged nitrogen was located in a more polar 
region of the glycerol binding pocket. However, the nitrogen lone pair was in close 
proximity to the amide carbonyl lone pair (4 Å) of N10 resulting in lone pair 
repulsion that could account for the moderate inhibition against all three enzymes. 
Recently, a co-crystal structure of S. coelicolor type II DHQase with inhibitor 50 
bound to the active site was obtained. This enzyme-inhibitor complex provides 
significant insights into the binding modes of alkynyl-based inhibitors. As predicted 
by Glide, the anhydroquinate core of inhibitor 50 forms a hydrogen bonding network 
with the active site residues (H85, H106, I107 and S108) while the terminal thiophene 
ring participates in π-stacking interaction with the essential Y28 (Figure 21). Other 
favourable interactions include lipophilic interactions between the thiophene moiety 
with L17 and L19 (Figure 21). It is important to note that, in this co-crystal structure, 
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R23 is displaced from the active site (Figure 21). This prevents this residue from 
interacting with R28 via hydrogen bonding and electrostatic interactions. Without 
these interactions, the electron density of the phenol ring would be higher, potentially 
giving rise to a stronger π-stacking interaction with the terminal thiophene moiety. 
 
Figure 21. Crystal structure of S. coelicolor type II DHQase (courtesy of Dr. Marcio Dias, 
unpublished) with inhibitor 50 bound. 
The displacement of the conserved, essential Arg residue was first observed by Peón  
et al.[63] in a co-crystal structure of M. tuberculosis type II DHQase with substrate 
mimic 53. Expulsion of R19 from the active site of M. tuberculosis type II DHQase 
was evident when this co-crystal structure was superimposed on an earlier co-crystal 
structure of this enzyme bound to oxime-based inhibitor 54 (Figure 22). This 
compound was part of a series of 2-alkyl and 2-aryl substituted dehydroquinic acids 
(representative compounds 53, 55-57, Figure 23) and were designed based on the 
postulation that by replacing the pro-S hydrogen at C-2 with alkyl, allyl and aryl 
substituents, proton abstraction by Y24 would no longer be possible and would lead 
to enzyme inhibition.[60a] Furthermore, these substituents could interact with Y24 via 
lipophilic or π-stacking interactions. Docking studies of the proposed inhibitors have 
indicated that the other diastereomers with equatorial C-2 substituents would 
potentially be good inhibitors of type II DHQase.[60a] Most compounds in this study 
exhibited potent inhibition of type II DHQase with inhibition constants between 
0.026-1.85 µM.[60a]  
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Figure 22. Overlay of type II DHQase/inhibitor 53 complex (PDB code: 2XB8[63] with 
protein backbones are shown as brown ribbons) with type II DHQase/inhibitor 54 complex 
(PDB code: 1H0S with protein backbones are shown as cyan ribbons). Inhibitors 53 and 54 
are shown in green and blue respectively. 
Interestingly, it was found that in the majority of cases, inhibitors with equatorial C-2 
substituents exhibited more potent inhibition of type II DHQase than their 
corresponding epimers (Figure 23).[60a] It was later revealed by crystallographic 
studies that the axial 4-methoxybenzyl group in inhibitor 55 causes the flexible loop 
to move up 4.5 Å giving rise to a more open conformation.[63] This open conformation 
allows the side chain of R19 to move into active site which is in stark contrast to the 
epimer 53 where it is displaced from the active site region. In addition, in contrast to 
inhibitor 53, a π-stacking interaction between Y24 and 4-methoxybenzyl group is not 
present in inhibitor 55.[63] 
 
Figure 23. 2-substituted-3-dehydroquinic acids as M. tuberculosis type II DHQase inhibitors. 
O
HO CO2H
OH
OH
53
MeO
Ki = 26 ± 2 nM
O
HO CO2H
OH
OH
55
MeO
Ki = 100 ± 10 nM
O
HO CO2H
OH
OH
S
57
Ki = 56 ± 6 nM
O
HO CO2H
OH
OH
S
56
Ki = 28 ± 3 nM
N
HO
HO CO2H
OH
OH
54
Chapter 3-Inhibition Studies on Type II DHQases 
 
 42 
The superior potency of inhibitor 53 bearing an equatorial 4-methoxybenzyl 
substituent was attributed to the displacement from R19 from the active site.[63] Since 
R19 is among the two residues that flank Y24 (the other being R108) and lowers the 
pKa of Y24 side chain through electrostatic and hydrogen bonding interactions, the 
displacement of this residue decreases the basicity of Y24.[63] Subsequent molecular 
dynamics simulation studies have revealed that the 4-methoxybenzyl moiety in 53 
causes a conformational change in the flexible loop, thereby preventing Y24 from 
adopting a suitable orientation for abstraction of pro-S hydrogen. A combination of 
the above factors was responsible for the observed potency of inhibitor 53 and other 
dehydroquinic acid-based inhibitors with aryl substituents at  
C-2.[63] 
3.10 Inhibition of M. tuberculosis (H37Rv) in vitro by alkynyl-based 
inhibitors 45-52 (conducted by Ms. Elizabeth Randall, Centenary 
Institute, Sydney) 
As the ultimate aim of this research project was to develop novel lead compounds 
active against M. tuberculosis, the next step involved assessing the antibacterial 
activity of the above alkynyl-based inhibitors. Specifically, the activity of 45-52 
against virulent, replicating M. tuberculosis (strain H37Rv) was evaluated using the 
well-established microplate-based assay with Alamar blue (resazurin) readout 
(MABA)[64] for determination of bacterial growth (for assay protocols, see 
Appendices). This assay is based on the ability of metabolically active cells to oxidise 
NADH to NAD+. The oxidation of NADH is coupled to the reduction of the cell-
permeable redox indicator resazurin (λmax = 605 nm) to resorufin (λmax = 573 nm).[64] 
This transformation is associated with a blue shift that can be monitored by UV 
spectrophotometry or via fluorescence methods (Scheme 11). Therefore, a decrease in 
UV absorbance or fluorescence corresponds to a reduced population of viable  
M. tuberculosis.[64] 
 
Scheme 11. Molecular basis of MABA (resazurin) assay. 
O
N
O
O
NADH NAD
O
N
O
Emits fluorescence at 590 nm
Resazurin Resorufin
Chapter 3-Inhibition Studies on Type II DHQases 
 
 43 
Although the alkynyl-based inhibitors demonstrated activity, the majority of 
compounds exhibited low millimolar IC50 values against the growth of  
M. tuberculosis, which was significantly less potent than the in vitro activity against 
type II DHQase. The most potent inhibitor of M. tuberculosis growth was compound 
47 bearing a 3-nitrophenyl moiety, which exhibited a minimal inhibitory 
concentration of 1.2 mM. As in vitro inhibition of M. tuberculosis growth was only 
observed for 47, it is likely that the observed activity is unrelated to inhibition of type 
II DHQase. It is possible that 47 acts as a nitric oxide donor in an analogous manner 
to the nitroimidazole, PA-824 (section 1.2.4).[24]  
The reduced activity of alkynyl-based inhibitors against M. tuberculosis may be due 
to the non-rate limiting nature of type II DHQase in the shikimate pathway of  
M. tuberculosis. As such, high levels of enzyme inhibition would be required to show 
significant inhibition of bacterial growth. An alternative rationale for the poor activity 
of these compounds is correlated with their hydrophilic nature, which may make it 
difficult for the compounds to traverse the waxy mycobacterial cell wall.  
3.11 Identification of alternative scaffolds for the anhydroquinate core 
The lack of antibacterial activity of alkynyl-based compounds, despite potent 
inhibition of type II DHQase, was mainly attributed to the hydrophilicity of the 
carboxylate triol motif in the anhydroquinate core of these inhibitors. Since the 
mycobacterial cell wall is highly hydrophobic with the major constituent being 
mycolic acid (C70-C90 long chain α-alkyl and β-hydroxylated fatty acids), alkynyl-
based inhibitors with the hydrophilic anhydroquinate core are likely to exhibit low 
permeability, resulting in a small proportion reaching the intracellular type II 
DHQase. Recently, Tizón et al.[65] reported an improvement in in vitro antibacterial 
activity of a similar class of anhydroquinate-based inhibitors through the synthesis of 
n-propyl ester prodrugs. However the research presented in this thesis aimed to 
explore alternative strategies for increasing the antibacterial activity of type II 
DHQase inhibitors.  
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Table 4. Glide XP scores and cLogP of fragments 6 and 58-70. 
 Fragment Glide XP 
score 
cLogP 
6 
 
-10 -2.7 
58 
 
-8.2 2.3 
59 
 
-7.7 
 
 
1.0 
 
 
60 
 
-7.3 1.2 
61 
 
-7.3 -0.7 
62 
  
-7.2 2.4 
63 
 
-7.0 
 
0.7 
64 
 
-6.8 
 
-0.8 
 65 
 
-6.6 0.6 
66 
 
-6.5 
 
-0.01 
 67 
 
-6.5 
 
-2.9 
 68 
 
-6.4 1.6 
69 
 
-6.3 -1.5 
70 
 
-6.0 1.0 
 
Identification of alternative, simplified scaffolds to replace the hydrophilic 
anhydroquinate core represents an unexplored avenue. These alternative scaffolds 
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were identified by employing an in silico screening approach. Specifically, a total of 
13 putative active site binding fragments were selected from a 42-compound library 
of proposed type II DHQase inhibitors recently reported by Kumar et al.[66] in a 
virtual screening campaign. The 13 aryl-based fragments with clogP values ranging 
from -2.9 to 2.4 were docked into the active site of M. tuberculosis type II DHQase 
using Glide (Schrödinger Inc.)[54] to evaluate the suitability of these compounds as 
more hydrophobic replacements of the anhydroquinate core (Table 4). Two 
fragments, namely 3,4-dihydroxyacetophenone 59 and the corresponding acetonide 
analogue 62, were subsequently selected for synthetic elaboration. These two 
fragments were chosen based on favourable clogP values and Glide XP scores, and 
because these scaffolds were amenable to synthetic elaboration to generate inhibitor 
libraries. 
The results of molecular docking studies of the two fragments are shown in Figure 24 
along with the predicted binding mode of 2,3-dehydroquinate 6. The carbonyl moiety 
of 3,4-dihydroxyacetophenone 59 was predicted to make hydrogen bonding 
interactions with the amide backbone between H101 and I102 as well as the side 
chain of N75 in a similar manner to the C-1 carboxylate and C-1 hydroxyl group of 
2,3-anhydroquinate 6. Importantly, 2,3-anhydroquinic acid was predicted to form 
other hydrogen bonding interactions that are absent in the molecular docking of 59. 
These include hydrogen bonding interactions between the C-1 carboxylate of 6 with 
the amide backbone between I102 and S103 and the hydroxyl side chain of S103. 
Furthermore, the C-1 hydroxyl group of 6 was predicted to form a hydrogen bond 
with the side chain of H101. Acetonide-derived acetophenone 62 was predicted to 
bind to M. tuberculosis type II DHQase in exclusively one binding mode, different 
from that predicted for 59. Specifically, only the carbonyl group of the acetophenone 
moiety was predicted to form a hydrogen bonding interaction with the amide 
backbone between H101 and I102, whereas the acetonide moiety was oriented into a 
subsidiary binding pocket. Extra binding affinity in this pose can be attributed to a  
π-stacking interaction with Y24. Inhibitors based on 62 were pursued irrespective of 
this altered binding mode, as incorporation of aryl groups onto the acetophenone 
moiety of 62 was predicted to reorient the acetonide core and provide a similar 
binding pose to 59. In addition, inhibitors based on this acetonide core would be 
synthetic intermediates en route to inhibitors based on 59. 
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Figure 24. Molecular docking of A: 2,3-anhydroquinic acid 6; B: 3,4-dihydroxyacetophenone 
59 and C: acetonide analogue 62 into the active site of M. tuberculosis type II DHQase (PDB 
code: 2XB8).[63] 
The suitability of 3,4-dihydroxyacetophenone 59 and acetonide analogue 62 as 
mimics of the anhydroquinate core and as inhibitors of type II DHQase could be 
subsequently verified by screening for inhibitory activity against M. tuberculosis type 
II DHQase using the previously developed continuous kinetic UV spectrophotometric 
assay (section 3.6). Prior to evaluation of their inhibitory activity, the synthesis of 
these two fragments was undertaken. 
The synthesis of fragments 59 and 62 began with commercially available catechol. 
Friedel-Crafts acylation using acetyl chloride in the presence of excess aluminium 
chloride provided 3,4-dihydroxyacetophenone 59 in 95% yield (Scheme 12). 
Subsequent protection of the diol of 59 proved problematic. Initially, acetophenone 59 
was reacted with acetone in the presence of phosphorus trichloride as a Lewis acid 
B C 
A 
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catalyst for 72 h at room temperature. A significant amount of starting material still 
remained after this time period, giving rise to a poor isolated yield (<20% yield). 
However, when a modified method was employed in which acetone was added 
dropwise over 3 h to a mixture of acetophenone 59 and excess phosphorus pentoxide 
in toluene at 75 oC, the reaction proceeded to give acetonide 62 in 40% yield (Scheme 
12). It was discovered that slow addition of acetone was critical to the success of this 
reaction. The slow addition of acetone was to ensure that it would be effectively 
activated by excess phosphorus pentoxide, thus being immediately primed for 
nucleophilic attack by one of the hydroxyl groups on 3,4-dihydroxyacetophenone 59 
as well as minimizing the self-condensation of acetone under the employed acidic 
conditions.  Subsequent attempts to improve the yield of this reaction by changing to 
a relatively more polar solvent or employing a more reactive reagent such as  
2,2-dimethoxypropane were not successful.  
 
Scheme 12. Synthesis of fragments 59 and 62. Reagents and conditions: a) 1. AcCl, DCE, 
AlCl3, 10 oC → rt, 2. HCl (aq.), 10 oC, 95%; b) (CH3)2CO, P2O5, PhCH3, 75 oC, 40%. 
3.12 Inhibition of type II DHQase by fragments 59 and 62 
With fragments 59 and 62 in hand, the evaluation of their inhibitory activity against  
M. tuberculosis type II DHQase was next carried out to determine their suitability as 
anhydroquinate mimics. Gratifyingly, compounds 59 and 62 exhibited micromolar 
inhibition against the enzyme (Ki: 173 and 120 µM respectively, Table 5). 
Importantly, these small molecules showed inhibition constants similar to that of 2,3-
dehydroquinate 6 (Ki = 200 µM), yet possessed significantly more favorable ClogP 
values (Table 5). Both fragments were also tested against replicating M. tuberculosis 
(H37Ra strain) using an Alamar blue (resazurin)[64] bacterial growth assay. Both 59 
and 62 exhibited moderate antibacterial activity (MIC50: 275 and 330 µM, 
respectively) and, as such, were further confirmed as suitable fragments for chemical 
elaboration to generate a novel library of type II DHQase inhibitors with 
antitubercular activity. 
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Table 5. cLogP values and activity of compounds 6, 59 and 62 against  
M. tuberculosis type II DHQase (Ki) and M. tuberculosis strain H37Ra (MIC50). 
 Compound Ki (µM) MIC50 (µM)c cLogP 
6   
200 ± 20a 
 
> 1000 
 
-2.7 
59   
173 ± 34b 
 
275 ± 49  
 
1.0 
62   
120 ± 23b 
 
330 ± 14 
 
           2.4 
 aInhibition constant for 6 was determined by Frederickson et al.[44] Kinetic constants 
for this study: KM = 64 ± 6 µM; 50 mM Tris·HCl, pH 7.0, 25 oC. bKinetic constants: 
KM = 25 ± 3 µM, kcat = 4.5 s-1; 50 mM Tris·HCl, pH 7.0, 25 oC. cIsoniazid MIC50 = 176 
± 14 nM; rifampicin, MIC50 = 1.7 ± 0.4 nM; Glide XP scores: 6: -10, 59: -7.7,  
62: -7.2. Data represent the mean ± SD from two replicate assays for M. tuberculosis 
type II DHQase and three replicate assays for M. tuberculosis H37Ra. 
 
3.13 Fragment elaboration 
Having demonstrated the suitability of 59 and 62 as small scaffolds with considerable 
inhibitory activity against M. tuberculosis type II DHQase, attention turned to the 
elaboration these fragments to provide more potent inhibitors. Specifically, the 
investigation focused on conjugates of 59 and 62 in which a range of aryl and 
heteroaryl moieties were appended. These groups were designed to occupy the 
subsidiary binding pocket to form a favorable π-stacking interaction with the 
conserved Tyr residue (Y24) present on the flexible loop, which was predicted to 
enhance potency. Ether and thioether linkages to 59 and 62 were proposed by 
implementing a broad range of aryl and heteroaryl alcohols and thiols to provide a 
series of inhibitors with variation in the steric and electronic nature of the terminal 
aryl and heteroaryl moieties (e.g., generic structures 72 and 73, Figure 25). 
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Figure 25. Generalized inhibitor structures bearing an acetonide (compound 72) or catechol 
(compound 73) core linked to aryl or heteroaryl rings. X = O or S; R = variety of aryl and 
heteroaryl groups. 
A number of proposed inhibitors were assessed for suitability by the use of in silico 
molecular docking into the active site of M. tuberculosis type II DHQase using Glide 
(Schrödinger Inc.)[54]. These docking studies suggested that the majority of the 
inhibitors are capable of binding with the catechol and aryl acetonide moieties that 
occupy the active site of the enzyme, thus enabling the formation of hydrogen 
bonding interactions with key active site residues. Notably, the elaborated inhibitors 
of the aryl acetonide core led to a reorientation in binding mode relative to that 
predicted for fragment 62 alone, such that the pose was similar to that observed for 59 
and the elaborated inhibitors of this fragment. The docking studies also suggested that 
the terminal aromatic moieties of all inhibitors are capable of occupying the 
subsidiary binding site to interact with Y24 (located on the flexible loop) via an offset 
face-to-face or edge-to-face π-stacking interaction.  
3.14 Synthesis of catechol-and acetonide-based inhibitor libraries 
The synthesis of catechol- and acetonide-based inhibitor libraries began with 
acetonide-protected intermediate 62 (Scheme 13). Heterogenous bromination using 
copper(II) bromide in a mixture of dichloromethane and ethyl acetate afforded the 
acetonide protected α-bromoketone 74 in 57% yield which served as a key 
intermediate for the preparation of the proposed inhibitor libraries.[67] Reaction of 74 
with a range of aryl- and heteroaryl-derived alcohols and thiols facilitated 
nucleophilic substitution of the bromide and provided acetonide-based O-and S-linked 
inhibitors 75-88 in moderate to excellent yields (59-91% yield, Scheme 13). These 
compounds were subsequently deprotected using 90 vol.% aqueous TFA to afford 
catechol-based O-and S-linked inhibitors 89-102 (57-100% yield, Scheme 13). 
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Scheme 13. Synthesis of O- and S-linked inhibitors 75–88 and 89–102. Reagents and 
conditions: a) CuBr2, EtOAc/CH2Cl2 (1:1 v/v), reflux, 57%; b) Ar-OH or Ar-SH, K2CO3, 
acetone, reflux, 4–5 h, 59–91%; c) TFA: H2O (9:1, v/v), rt, 1.5 h, 57–100%. 
3.15 Inhibition of type II DHQase by acetonide and catechol-based inhibitors 
Having successfully prepared the library of acetonide-and catechol-based inhibitors, 
evaluation of these compounds for their enzyme inhibitory activity was undertaken. 
To this end, target compounds 75-88 and 89-102 were screened against  
M. tuberculosis type II DHQase in vitro using the previously described kinetic assay 
(section 3.6). Gratifyingly, most compounds exhibited competitive, reversible 
inhibition of M. tuberculosis type II DHQase with inhibition constants in the low 
micromolar range (Ki = 5-86 µM, Table 6 and Table 7) with catechol-based 
compounds 89-102 exhibiting more potent inhibition than the corresponding 
acetonide-based analogues 75-88. Close inspection of the predicted binding modes for 
these acetonide-based inhibitors showed that these compounds exhibited fewer 
hydrogen bonding interactions with active site residues. Furthermore, an analysis of 
the hydrophobic/hydrophilic surfaces of type II DHQase revealed that the geminal 
methyl groups of the acetonide-based inhibitors were unfavourably exposed to 
solvent. The associated entropic cost and the lack of hydrogen bonding interactions 
with the active site residues may therefore be responsible for the poorer inhibition of 
type II DHQase by these compounds. 
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It should be noted that although fragments 59 and 62 were capable of inhibiting type 
II DHQase with similar effectiveness to 2,3-anhydroquinic acid 6 (Table 5), the 
incorporation of aryl and heteroaryl groups to the acetophenone moiety resulted in, on 
average, a ten-fold increase in potency compared with three orders of magnitude 
increase observed when these groups were attached to C-3 of the anhydroquinate 
core. Close inspection of docking results suggests that the modest increase in potency 
upon conjugation of terminal aryl and heteroaryl groups may be due to weaker 
hydrogen bonds between the carbonyl moiety of the acetophenone core and the amide 
backbone of I102 and S103 as well as the side chain of N75 relative to the same  
H-bonding interactions displayed by the carboxylate group of anhydroquinate-based 
inhibitors (average H-bond distance: for 3,4-dihydroxyacetophenone-based inhibitors 
= 2.1 Å, for anhydroquinate-based inhibitors = 1.8 Å). Another possible contributing 
factor to the modest improvement in potency is the different presentation of terminal 
aromatic moieties by the planar acetophenone cores relative to the non-planar and 
chiral anhydroquinate core. Consequently, the intermolecular π-stacking distance 
between the terminal aryl and heteroaryl moieties and the conserved Tyr residue 
(Y24) in acetonide and catechol-based inhibitor library is larger than the 
corresponding distance observed for the anhydroquinate-based inhibitors (3.3 Å for 
anhydroquinate-based inhibitors and 3.8 Å for acetophenone-based inhibitors), giving 
rise to weaker π-stacking interactions. 
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Table 6. Activity of acetonide-based inhibitors 75-88 against M. tuberculosis type II 
DHQasea and H37Rab 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
O
O
X
R
Compound R X Ki (µM) MIC50 (µM) 
75 
 
O 29 ± 5 115 ± 28 
77 
 
O 22 ± 5 690 ± 56 
78 
 
O 41 ± 5 140 ± 1 
79 
 
O 15 ± 2 690 ± 14 
83 
 
O 13 ± 3 40 ± 7 
84 
 
O 18 ± 3 55 ± 7 
85 
   
O 28 ± 3 835 ± 35 
76 
 
S 42 ± 16 90 ± 7 
80 
 
S 27 ± 10 >1000 
81 
 
S 35 ± 7 73 ± 18 
82 
 
S 19 ± 2 70 ± 7 
86 
 
S 12 ± 5 33 ± 4 
87 
 
S 18 ± 2 10 ± 1 
88 
 
S 19 ± 2 850 ± 14 
aKinetic constants: KM = 25 ± 3 µM, kcat = 4.5 s-1; 50 mM Tris·HCl, pH 7.0, 
25 oC. bIsoniazid MIC50 =176 ± 14 nM; rifampicin, MIC50 = 1.7 ± 0.4 nM. 
Data represent the mean ± SD from two replicate assays for M. tuberculosis 
type II DHQase and three replicate assays for M. tuberculosis H37Ra.  
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Table 7. Activity of acetophenone-based inhibitors 89-102 against M. tuberculosis type II 
DHQasea and H37Rab 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound R X Ki (µM) MIC50 (µM) 
89 
 
O 18 ± 2 330 ± 14 
91 
 
O 20 ± 3 505 ± 134 
92 
 
O 14 ± 2 375 ± 35 
93 
 
O 13 ± 3 360 ± 14 
97 
 
O 5 ± 1 370 ± 14 
98 
 
O 8 ± 2 455 ± 7 
99 
   
O 12 ± 2 570 ± 42 
90 
 
S 12 ± 2 370 ± 84 
94 
 
S 36 ± 5 >1000 
95 
 
S 14 ± 3 485 ± 134 
96 
 
S 6 ± 1 295 ± 106 
100 
 
S 14 ± 2 270 ± 1 
101 
 
S 17 ± 2 >1000 
102 
 
S 13 ± 2 690 ± 70 
aKinetic constants: KM = 25 ± 3 µM, kcat = 4.5 s-1; 50 mM Tris·HCl, pH 7.0, 
25 oC. bIsoniazid MIC50 =176 ± 14 nM; rifampicin, MIC50 = 1.7 ± 0.4 nM. 
Data represent the mean ± SD from two replicate assays for M. tuberculosis 
type II DHQase and three replicate assays for M. tuberculosis H37Ra.  
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Interestingly, altering the electronic or steric properties of the aromatic moieties 
(appended to the 3,4-dihydroxyacetophenone and acetonide cores) did not result in 
dramatic differences in the inhibition of the enzyme. This suggests that the subsidiary 
binding pocket of the M. tuberculosis enzyme is capable of accommodating a diverse 
range of aryl and heteroaryl rings and that these can all form π-stacking interactions, 
consistent with previous inhibition studies with compounds based on the 
anhydroquinate core.[50, 60b] This is probably due to the flexible nature of the 
methylene linker which may re-orient more sterically demanding terminal aromatic 
moieties to facilitate a favourable face to face or edge to face π-stacking interaction 
with the conserved Tyr residue (Y24). In addition, the presence of a thioether in place 
of the ether linkage did not appear to contribute significantly to the inhibition of type 
II DHQase with similar inhibition constants observed for O-and S-linked 
acetophenone and acetonide-based inhibitors possessing the same terminal aromatic 
moieties (Table 6 and Table 7). However, the ether and thioether linkers played a 
major role in the orientation of the acetonide cores. Specifically, the acetonide 
fragment in the O-linked inhibitors was predicted to bind to a similar region of the 
active site as 3,4-dihydroxyacetophenone 59 and 2,3-anhydroquinic acid 6 while in 
most S-linked inhibitors, this core was predicted to bind a slightly different region of 
the active site. 
While the results from the inhibition studies indicate that the enzyme can tolerate a 
diverse set of terminal aromatic moieties, it is noteworthy to point out that 
acetophenone-based inhibitors 96, 97 and 98, bearing 4-chlorophenyl, 2-naphthyl and 
1-naphthyl moieties, exhibited the most potent inhibition of type II DHQase with 
inhibition constants of 6, 5, and 8 µM respectively. Given these results, more 
sterically demanding moieties such as phenylnaphthalene and diphenyloxazole (103-
108, Figure 26) were incorporated in order to probe the tolerance of the subsidiary 
binding pocket.  
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Figure 26. Catechol-and acetonide-based inhibitors 103-108 incorporating sterically 
demanding substituents. 
Prior to the synthesis of these targeted inhibitors, it was necessary to synthesize the 
precursor alcohols and thiols 109-111. The synthesis of desired phenols 109 and 110 
began with Kumada coupling of 2-bromonaphthalene with organomagnesium 
reagents 112 or 113 to afford 2-(4-methoxyphenyl)naphthalene 114 and 2-(3-
methoxyphenyl)naphthalene 115 respectively (Scheme 14).[68] Methyl ether 
deprotection was effected by treatment with pyridinium hydrochloride at 190 oC or 
boron tribromide at 0 oC to afford phenols 109 and 110 respectively in moderate 
yields over two steps (Scheme 14).  
 
Scheme 14. Synthesis of phenols 109 and 110 and thiol 111. Reagents and conditions: A: a) 
112 (1 eq.), Pd(PPh3)4 (5 mol%), THF, reflux, 16 h, 25%; b) 113 (1 eq.), Pd(PPh3)4 (5 mol%), 
THF, reflux, 16 h, 29%; c) Py.HCl, 190 oC, 2 h, 76%; d) BBr3 (1.1 eq.), CH2Cl2, 0 oC for 1 h 
and rt for 2 h, 81%; B: e) Aq. HCl (32%), KSCN, absolute ethanol, reflux, 24 h, 46%.   
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Thiol 111 was synthesized via condensation of benzoin with potassium thiocyanate 
under acidic conditions (Scheme 14). With phenols 109 and 110 and thiol 111 in 
hand, reactions with acetonide protected α-bromoketone 74 using the conditions 
developed previously afforded acetonide- and catechol-based inhibitors 103-108 in 
excellent yields (Scheme 15).  
 
Scheme 15. Synthesis of acetonide-and catechol-based inhibitors incorporating sterically 
demanding substituents. Reagents and conditions: a) 109-111, K2CO3, acetone, reflux, 4–5 h, 
58-65%; b) 9:1 v/v TFA: H2O, rt, 1.5 h, 83-84%. 
These compounds were tested for inhibitory activity against M. tuberculosis type II 
DHQase (Table 8). It appeared that these bulky terminal aromatic moieties were 
tolerated, albeit to different extents by the enzyme. Specifically, for both acetonide-
and catechol-based inhibitors, replacement of phenyl moiety in 76 and 90 with a 
diphenyloxazole group resulted in an increase in potency against the enzyme (105: Ki 
= 19 ± 4 µM to 76: Ki = 42 ± 6 µM and 108: Ki = 10 ± 2 µM to 90: Ki = 12 ± 2 µM, 
Table 8) while incorporation of phenylnaphthalene in place of the phenyl moiety gave 
mixed results. It is interesting to note that inhibitors bearing these bulky aromatic 
moieties (98 and 106-108) were better fitted to a mixed model of inhibition tending 
towards a competitive mode of inhibition (alpha = 1.3-2.2, GraphPad Prism, version 
5.03 for Windows). It is possible that sterically demanding moieties exhibited bias 
towards the subsidiary binding pocket and, as such, enable substrate binding to the 
active site.  
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Table 8. Activity of catechol-and acetonide-based inhibitors 103-108 against  
M. tuberculosis type II DHQasea and H37Rab 
 
3.16 Inhibition of M. tuberculosis (H37Ra) in vitro by acetonide- and 
catechol-based type II DHQase inhibitors (conducted by Ms Angel Pang, 
Centenary Institute, Sydney) 
Having demonstrated that the fragment-derived inhibitors were capable of exhibiting 
low-micromolar inhibition of M. tuberculosis type II DHQase in vitro, attention 
turned to the evaluation of growth inhibition of M. tuberculosis to assess the potential 
of these compounds to serve as new TB drug leads. Gratifyingly, most inhibitors 
exhibited significant inhibition of M. tuberculosis growth in vitro  
(MIC50: 10–835µM). Although there was no clear correlation between the inhibition 
of M. tuberculosis type II DHQase and the MIC50 values against M. tuberculosis 
growth, some interesting SAR trends emerged. Firstly, the majority of acetonide-
 
  
 
 
R X Compound Ki 
(µM) 
MIC50 
(µM) 
Compound Ki (µM) MIC50 
(µM) 
 
O 106 39 ± 9 195 ± 49 103 48 ± 16 > 1000 
 
O 107 8 ± 3 350 ± 14 104 30 ± 6 363 ± 10 
 
S 108 10 ± 2 350 ± 28 105 19 ± 4 575 ± 120 
aKinetic constants: KM = 25 ± 3 µM, kcat = 4.5 s-1; 50 mM Tris·HCl, pH 7.0, 25 oC. bIsoniazid 
MIC50 =176 ± 14 nM; rifampicin, MIC50 = 1.7 ± 0.4 nM. Data represent the mean ± SD from 
two replicate assays for M. tuberculosis type II DHQase and three replicate assays for  
M. tuberculosis H37Ra.  
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based compounds were at least two-fold more potent than the corresponding catechol-
based inhibitors against M. tuberculosis growth in vitro. This finding may reflect the 
increased hydrophobicity of the acetonide-based compounds, a factor that has been 
shown to be important in the penetration of the waxy cell wall of M. tuberculosis. It is 
feasible that the acetonide moiety of these compounds is hydrolyzed after entry into 
the mycobacterial cell. However, it is entirely possible, given the variation in activity 
against M. tuberculosis, that the compounds prepared in this study inhibit alternate or 
multiple pathways. Nonetheless, the incorporation of bicyclic moieties such as  
2-naphthalene and benzothiazole groups in 86 and 87 resulted in the most potent 
inhibitors of M. tuberculosis growth, with MIC50 values of 33 and 10 µM, 
respectively. Compound 87 was also shown to possess significant activity against the 
virulent H37Rv strain of M. tuberculosis (MIC50 = 33 µM) and, although significantly 
less potent than the frontline TB drugs isoniazid and rifampicin, now serves as a lead 
for further investigation. 
3.17 Conclusions  
In summary, this chapter described the successful synthesis of triazole-and alkynyl-
based inhibitors of type II DHQases from a common ene-yne intermediate using  
Cu(I) azide-alkyne cycloaddition and palladium-catalyzed Sonogashira  
cross-coupling chemistry. The majority of triazole-and alkynyl-based compounds 
exhibited potent inhibition against type II DHQase from S. coelicolor, H. pylori and 
M. tuberculosis. In particular, triazole-based inhibitors 28 and 33 bearing terminal 
phenyl and 3-pyridyl moieties as well as alkynyl-based inhibitor 48 and 51 with 
trifluoromethylphenyl and benzothiazole substituents are among the most potent 
inhibitors of M. tuberculosis type II DHQase ever prepared (Figure 27). Additionally, 
compounds 48 and 51 represent the most potent inhibitors of H. pylori isozyme 
identified to date (Figure 27). 
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Figure 27. Potent inhibitors of M. tuberculosis and H. pylori type II DHQase. 
Despite the potent inhibition against M. tuberculosis type II DHQase, alkynyl-based 
compounds exhibited poor inhibition of M. tuberculosis in vitro. The lack of  
antitubercular activity was mainly attributed to the hydrophilicity of the 
anhydroquinate core which makes it difficult for these compounds to traverse the 
waxy, hydrophobic M. tuberculosis cell wall. This problem was addressed by finding 
functionally simpler, more hydrophobic fragments to replace the hydrophilic 
anhydroquinate core and a fragment elaboration approach was subsequently employed 
to devise novel type II DHQase inhibitors. 
In the fragment elaboration study, 3,4-dihydroxyacetophenone and acetonide cores 
were identified as replacements for the anhydroquinate core previously employed. 
Elaboration of these fragments to incorporate a range of aryl and heteroaryl moieties 
led to a library of inhibitors that possessed low-micromolar inhibition of type II 
DHQase (Ki = 5-86 µM). Despite decreased potency against M. tuberculosis type II 
DHQase relative to the triazole-and alkynyl-based inhibitors, these compounds 
exhibited markedly improved anti-tubercular activity (MIC50 = 10-850 µM against  
M. tuberculosis H37Ra). In particular, acetonide-based inhibitor 87 with a terminal 
benzothiazole moiety exhibited significant activity (MIC50 = 33 ± 5 µM, Figure 28) 
against M. tuberculosis H37Rv and although significantly less potent than rifampicin 
and isoniazid, now serves as a lead for further investigation. Specifically,  
co-crystallization of 87 with M. tuberculosis type II DHQase will provide valuable 
information regarding the compound’s binding mode(s) which will aid the rational 
design of more potent inhibitors in the future. 
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Figure 28. Acetonide-based inhibitor 87 generated via fragment-elaboration approach. 
3.18 Future work 
The fragment elaboration approach, although successful, had highlighted the 
limitation of replacing the chiral anhydroquinate core with planar scaffolds in term of 
potency against type II DHQase. Initially, this strategy was utilized instead of ester 
derivatization of anhydroquinate-based inhibitors to generate pro-drugs. It was 
envisaged that the former strategy was advantageous over the latter strategy since 
many straight chain alkyl esters can either be unmasked by enzyme independent 
hydrolysis or by broad-substrate esterases prior to delivery to the alveolar macrophage 
where M. tuberculosis resides. As such, while simple alkyl ester prodrugs of 
anhydroquinate-based inhibitors may give promising growth inhibition of M. 
tuberculosis culture in vitro, the susceptibility to hydrolysis mentioned above limits 
the utilization of such esters in vivo.  
Cyclopropanecarboxylic esters have demonstrated improved stability to hydrolysis 
under acidic and basic conditions owning to the hyperconjugative stabilization of the 
cyclopropyl group.[69] This phenomenon was initially reported by Bodor et al.[69a] and 
was investigated in detail by Bender and co-workers[69b]. Briefly, when a range of 
straight chain, branched alkyl as well as benzyl esters were evaluated for their 
stability in acidic (0.1 M HCl) and basic (pH 10) conditions, it was found that  
1-methylcyclopropanecarboxylic ester was 8 times more stable under 0.1 M HCl at  
40 oC and 5 times more stable under basic condition  (pH 10) than the open chain 
isopropyl analogue.[69b] As such, derivatization of inhibitors as 
cyclopropanecarboxylic esters represents a promising approach for developing more 
stable pro-drugs with improved cellular permeability. Indeed, Tian et al.[70] recently 
demonstrated that fluorescein di(1-methylcyclopropanecarboxy methyl ether), an α-
cyclopropyl ester of the fluorophore fluorescein, was resistant to hydrolysis by 
endogenous esterases in numerous cell types from different species (i.e. human 
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S
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embryonic kidney cells, human uterus carcinoma cells, mouse fibroblast cells and 
mouse cortical brain slice).  
Given the population of 250 esterases present in M. tuberculosis with a wide range of 
substrate specificities, there is the potential that cyclopropanecarboxylic esters could 
be unmasked by the action of one of these esterases.[32] As such, it is envisaged that 
cyclopropanecarboxylic esters of anhydroquinate-based type II DHQase inhibitors 
will possess improved permeability across the mycobacterial cell wall in a manner 
similar to the n-propyl ester pro-drugs synthesized by Tizón et al.[65] but will exhibit 
higher stability to endogenous esterases, which are found in vivo.  
Cyclopropanecarboxylic esters of triazole-and alkynyl-based inhibitors could be 
readily synthesized from reacting the final unprotected inhibitors with chloromethyl  
1-methylcyclopropane-1-carboxylate using a hindered, non-nucleophilic base such as 
N,N-diisopropylethylamine (Scheme 16). The proposed synthesis of  
1-methylcyclopropanecarboxylic esters should be amenable to the generation of a 
number of novel anhydroquinate-based inhibitors. 
 
Scheme 16. Proposed synthesis of cyclopropanecarboxylic esters of triazole-and alkynyl-
based inhibitors. 
Conformationally restricted anhydroquinate-based compounds have not been 
extensively investigated as type II DHQase inhibitors, and as such, represent an 
exciting unexplored avenue. Given the potency of C-2 substituted dehydroquinic 
acids, pyridine-fused enol mimics (general structure shown in Scheme 17) may 
effectively interact with the conserved Tyr residue through a π-stacking interaction 
while also presenting the aryl/heteroaryl moieties in the subsidiary binding pocket. 
From a retrosynthetic viewpoint, this class of inhibitors could be obtained from 
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inverse electron demand Diels-Alder reactions of various C-5 substituted 1,2,3-
triazines with an enamine generated in situ from the reaction of a suitably protected 
ketone with catalytic pyrrolidine (Scheme 17).[71] C-5 substituted 1,2,3-triazines could 
then be synthesized from oxidative rearrangement of C-4 substituted  
N-aminopyrazoles which could be derived from 4-bromopyrazole.[71] Upon successful 
synthesis of pyridine-fused enol mimics, these compounds would be evaluated for 
inhibition of M. tuberculosis type II DHQase to establish SARs while the 
corresponding 1-methylcyclopropanecarboxylic acid esters, synthesized using the 
method described above, would be investigated for antitubercular activity.  
 
Scheme 17. Proposed synthesis of pyridine-fused enol mimics as potential inhibitors of type 
II DHQase. 
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4.1 An overview of the mycolyl arabinogalactan-peptidoglycan complex 
The cell wall of M. tuberculosis consists of three major components; the plasma 
membrane, the mycolyl arabinogalactan-peptidoglycan complex (mAGP) and the 
extractable non-covalently linked lipids, proteins and glycans (Figure 29).[72] The 
insoluble mAGP is essential to the survival of M. tuberculosis by maintaining shape, 
withstanding internal osmotic pressure and regulating the penetration of nutrients and 
xenobiotics.[72] Solubilized components such as phosphatidylinositol mannosides, 
lipoarabinomannan, trehalose dimycolate and trehalose monomycolate act as 
signaling molecules or effectors in disease pathogenesis.[72]  
4.1.1 Mycolic acids 
Mycolic acids constitute 40% of mycobacterial cell wall dry weight. Structurally, they 
are α-branched, β-hydroxylated fatty acids (C70-C90) which interact via hydrophobic 
packing to generate a highly impermeable lipid shell.[72] Mycolic acids are 
synthesized by two fatty acid synthase systems, namely the multifunctional FasI and 
the dissociated FasII systems with the former responsible for saturated, shorter α-
branch (up to C26) and the latter involved in the synthesis of the meromycolate 
branch (C26-C56).[72] Both of these systems contain four enzymatic activities 
including condensation via β-ketoacyl synthase (KAS), keto reduction via β-ketoacyl 
reductase, dehydration via β-hydroxyacyl dehydrase and carbon-carbon double bond 
reduction via enoyl reductase.[72] Subsequent condensation of C26 straight chain fatty 
acids and meromycolates takes place, followed by the transfer of the product onto a 
carrier enzyme (possibly coenzyme A) for covalent attachment to the arabinogalactan 
layer via ester linkages resulting from esterification of arabinan chains with mycolic 
acids.[72]  
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Figure 29. Schematic representation of M. tuberculosis cell wall adapted from the work of 
Daffé and Draper[73], image courtesy of Dr. Alexandra Manos-Turvey[74].  
4.1.2 Arabinogalactan core 
The assembly of the arabinogalactan core, a network of covalently linked 
homogalactan and homoarabinan polymers, occurs on a polyprenyl phosphate carrier 
lipid and begins with the construction of the disaccharide unit which bridges the 
arabinogalactan core and peptidoglycan layer.[72] As this intermediate is transported 
through the cytoplasmic membrane, sequential elongation with galactan and arabinan 
units then takes place to ultimately form the arabinogalactan core.[72] As discussed 
above, galactans of arabinogalactan are covalently attached to the peptidoglycan via a 
phosphoryl N-acetylglucosaminosyl-rhamnopyranosyl linker. Specifically, the C-6 
position of some muramic acid residues in the peptidoglycan form phosphodiester 
bonds with C-1 of α-N-acetyl-D-glucosamine (α-D-GlcNAc) which are linked via C-3 
to the C-1 of α-L-rhamnopyranose (α-L-Rhap) (Figure 30).[72]  
 
Figure 30. The disaccharide linker bridging arabinogalactan and peptidoglycan layers. AG: 
arabinogalactan, PG: peptidoglycan. 
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4.1.3 Peptidoglycan layer 
The peptidoglycan layer in M. tuberculosis is a highly cross-linked, polymeric 
structure made up of alternating units of N-acetyl-D-glucosamine and modified 
muramic acids via a β-1→4 linkage.[72] Unlike most other bacteria, in which N-acetyl-
D-muramic acid is the sole modified muramic acid, M. tuberculosis also possesses  
N-glycolylmuramic acid. N-glycolylmuramic acid arises from the oxidation of  
N-acetyl-D-glucosamine by an enzyme called NamH.[72] Other unique structural 
features include amidation of the free carboxylic acid groups of meso-diaminopimelic 
acid and γ-D-glutamic acid. Despite the above structural differences, the biochemistry 
of peptidoglycan assembly is similar to the process found in other bacteria which 
involves concerted enzyme-catalyzed reactions taking place in both the cytoplasm and 
the outer side of cytoplasmic membrane.[72]  
4.2 Biosynthesis of the peptidoglycan layer 
4.2.1 Intracellular steps of peptidoglycan biosynthesis 
4.2.1.1 MurA: structure and function 
The biosynthesis of the peptidoglycan layer begins with the assembly of UDP-N-
acetylmuramyl (UDP-MurNAc) pentapeptide, a process catalyzed by MurA-F 
enzymes that are present in the cytosol (Scheme 18).[75] UDP-MurNAc pentapeptide 
subsequently enters the first membrane-associated step catalyzed by MraY which 
transfers this moiety onto the undecaprenyl phosphate carrier generating lipid I 
(Scheme 18).[75] This reaction is followed by a glycosyl transfer of UDP-GlcNAc by 
MurG to form lipid II which is transported across the cytoplasmic membrane by a 
putative ‘flippase’ (Scheme 18).[75] Following the export of lipid II, polymerization of 
this intermediate is achieved by transglycosylases forming nascent peptidoglycan 
strands (Scheme 18). Subsequent transpeptidation of adjacent strands result in the 
formation of mature peptidoglycan with peptide cross-links (Scheme 18).[75]  
The first committed cytoplasmic step of the peptidoglycan biosynthesis is catalyzed 
by MurA which transfers an enolpyruvyl moiety from phosphoenolpyruvate (PEP) to 
UDP-N-acetyl-D-glucosamine (UDP-GlcNAc) to form enolpyruvyl-UDP-GlcNAc.[75] 
This enzyme possesses two globular domains with each domain featuring a three-fold 
repetition of one folding unit comprised of four β-sheets and two parallel α-helices.[75] 
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MurA is the molecular target for fosfomycin, a broad-spectrum antibiotic used to treat 
uncomplicated urinary tract infections.[75] Fosfomycin effectively binds to MurA by 
mimicking PEP and, as a virtue of the epoxide moiety in the drug, is susceptible to 
nucleophic attack by the active site Cys115 (Escherichia coli amino acid numbering) 
resulting in complete inactivation of the enzyme.[76] Fosfomycin is ineffective against 
M. tuberculosis MurA due to the replacement of the active site cysteine present in  
E. coli MurA with an aspartic acid residue.[77] 
 
Scheme 18. Biosynthesis of peptidoglycan layer and clinically approved or investigational 
drugs against enzymes in the peptidoglycan biosynthetic pathway. 
4.2.1.2 MurB-F: structure and function 
The conversion of enolpyruvyl-UDP-GlcNAc to UDP-MurNAc is catalyzed by 
MurB. Although several crystal structures of MurB from E. coli[78] and 
Staphylococcus aureus[79] are available, crystallographic information is currently 
lacking for the M. tuberculosis counterpart. Although MurB represents a promising 
drug target, inhibitors against M. tuberculosis MurB have not been developed to date. 
Following the formation of UDP-MurNAc, stepwise installation of the pentapeptide 
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side chain onto the lactate moiety occurs. These non-ribosomal peptide bond forming 
reactions are catalyzed by a family of ATP-dependent amino acid ligases (MurC-F) 
that are highly conserved across various bacterial species.[75] MurC-F each possess 
three structural domains: an N-terminal domain possessing a Rossmann-type α/β fold 
to accommodate the activated UDP-sugar substrate, a central ATPase domain 
responsible for ATP binding and hydrolysis, and a C-terminal domain to bind the 
amino acid substrate.[80]  
M. tuberculosis MurC-F ligases in active and appropriately folded forms were 
recently expressed and purified by Munshi et al.[81] The authors demonstrated that a 
divalent metal ion is essential for catalytic activity of MurC-F ligases and that activity 
was regulated by concentrations of ATP and the UDP-sugar substrate. Specifically, 
higher concentrations of the above substrates had inhibitory effects on the activity of 
MurC-F enzymes. The study conducted by Munshi et al.[81] also revealed interactions 
established between MurC-F ligases and serine/threonine kinases PknA and PknB. 
These interactions suggested that MurC-F ligases are potential substrates of the above 
kinases. As PknA and PknB are involved in the regulation of cell wall synthesis and 
division, it is possible that the activity of MurC-F is under stringent control by the 
above kinases.  
MurC catalyzes the first addition of L-Ala onto UDP-MurNAc. This is subsequently 
followed by the addition of γ-D-Glu to UDP-MurNAc-L-Ala. In the above reactions,  
L-Ala and γ-D-Glu are delivered to the acyl phosphate of UDP-MurNAc and UDP-
MurNAc-L-Ala, respectively (Scheme 19).[75] These reactive intermediates are 
generated from the activation of the carboxyl-terminal of the above substrates by 
ATP-dependent phosphorylation.[82]  
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Scheme 19. Reactions catalyzed by MurC and MurD ligases via acyl phosphate intermediates 
(a common reaction mechanism is shared by MurC-F ligases).   
Currently, there are no inhibitors against MurC ligase while a number of inhibitors 
designed to mimic the tetrahedral intermediate of MurD catalyzed reaction, exist in 
the literature (a similar tetrahedral intermediate is also proposed for reactions 
catalyzed by MurC, E and F). MurD inhibitors were initially designed against E. coli 
MurD and were recently screened for inhibitory activity against MurD from S. 
aureus, Streptococus pneumoniae, Borrelia burgdorferi and M. tuberculosis by 
Barraeteau et al.[83] Generally speaking, all compounds in this study were 
significantly more potent against E. coli MurD than the other four orthologs (Figure 
31). Unfortunately, these compounds exhibited poor in vitro antibacterial activity with 
minimal inhibitory concentrations (MICs) against S. aureus, S. pneumoniae and E. 
coli being greater than 128 µg/mL.[83] 
 
Figure 31. Sulfonamide and thiazolidin-4-one based MurD inhibitors. 
Similar to the MurC and MurD enzymes, MurE catalyzed ligation of meso-
diaminopimelic acid to the γ-carboxyl group of glutamic acid in UDP-MurNAc-L-
Ala-γ-D-Glu proceeds via an acyl phosphate intermediate which is corroborated by a 
recent M. tuberculosis MurE crystal structure.[84] Recently identified M. tuberculosis 
MurE inhibitors were originally isolated from the fruits of the Chinese medicine tree 
Evodia rutaecarpa and belong to N-methyl-2-alkenyl-4-quinolone structural class.[85] 
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These compounds demonstrated modest activity against  
M. tuberculosis H37Rv (MIC50 = 10-25 µM, Figure 32).[85] They were later found to 
be inhibitors of MurE with IC50 in the micromolar range (36-72 µM, Figure 32). It 
was suggested by molecular docking studies into the active site of M. tuberculosis 
MurE that these quinolones bind to a hydrophobic pocket adjacent to the uridine 
recognition site. The aliphatic, lipophilic side chains of these molecules were 
proposed to interact with buried hydrophobic residues, potentially inducing a 
conformational change that prevented the binding of the UDP-MurNAc dipeptide 
substrate.[85]  
 
 
 
Figure 32. Quinolone-based MurE inhibitors. 
The last step in the assembly of UDP-MurNAc pentapeptide is catalyzed by MurF 
ligase with the addition of D-Ala-D-Ala to the UDP-MurNAc tripeptide product of 
MurE. D-Ala-D-Ala dipeptide is synthesized via epimerization of L-Ala by L-Alanine 
racemase and subsequent dipeptide formation is mediated by dipeptidyl synthase. 
These two enzymes are targeted by the second-line TB drug cycloserine used in the 
treatment of MDR-TB (Scheme 18).  
Unlike MurC-E ligases, the N-terminal domain of MurF does not adopt a Rossmann 
fold. As such, this domain is not involved in the binding of UDP-MurNAc tripeptide, 
a task that is instead carried out by the central ATPase domain. Currently, inhibitors 
against M. tuberculosis MurF have not been identified despite the existence of 
structurally diverse MurF inhibitors (non-hydrolyzable ATP mimics[86], phosphinate 
transition state analogues[87], sulfonamides[88], thiazolylaminopyrimidines[89],  
8-hydroquinolines[90]) against E. coli and S. pneumonia orthologs. However, these 
inhibition studies have consistently demonstrated that despite potent inhibition of 
MurF, these compounds did not exhibit antibacterial activity when evaluated against 
E. coli, S. aureus or S. pneumoniae. In 2009, Baum et al.[91] reported for the first time, 
that MurF inhibitors belonging to the diarylquinoline structural class showed activity 
against lipopolysaccharide (LPS)-defective E. coli OC2530 (116, MIC = 8 µg/mL, 
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Figure 33) despite being devoid of activity against wild-type E. coli and S. aureus. 
Muropeptide quantitation experiments in which an accumulation in MurF substrate 
UDP-MurNAc-tripeptide and a simultaneous decrease in the amount of UDP-
MurNAc-pentapeptide upon treatment with diarylquinoline 116 were observed, 
suggesting that MurF was indeed the molecular target being inhibited in the bacterial 
cells.[91] However, these studies did not prove the connection between MurF 
inhibition and observed antibacterial activity as overexpression of MurF did not give 
rise to an increase in the MIC value of compound 116.[91]  
 
Figure 33. Diarylquinoline 116 as inhibitor of E. coli MurF. 
4.2.2 Membrane-associated steps of the peptidoglycan biosynthesis 
4.2.2.1 MraY: structure and function 
UDP-MurNAc-pentapeptide serves as the substrate for the first membrane-associated 
step in the biosynthesis of the peptidoglycan, which is catalyzed by MraY (MurX in 
M. tuberculosis).[75] This enzyme is responsible for the transfer of UDP-MurNAc-
pentapeptide from the cytoplasm onto undecaprenyl phosphate  
(C55-P, also known as bactoprenol phosphate), giving rise to the formation of 
undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide (Lipid I).[75] According to 
sequence analysis and topology studies on S. aureus and E. coli orthologs, MraY 
possesses 10 trans-membrane domains with the N-and C-termini both located on the 
periplasmic side.[92] These structural predictions were confirmed in a recent crystal 
structure of MraY from Aquifex aeolicus.[92] MraY is believed to be the target for 
naturally derived nucleoside antibiotics such as liposidomycins, caprazamycins, 
capuramycins, muraymycins and uridylpeptides.[93] 
4.2.2.2  ‘Flippase’: structure and function 
MurG converts lipid I, the product of MraY-catalyzed reaction into lipid II via 
glycosyl transfer from a UDP-activated N-acetyl-D-glucosamine donor.[75] MurG 
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consists of two domains adopting an α/β open sheet structure that are separated by a 
deep active site cleft.[94] This cleft is lined by hydrophobic residues that potentially 
interact with the phospholipid bilayer.[94] Similar to other glycosyltransferases, MurG 
exhibits ordered bi-bi kinetics in which the UDP-GlcNAc donor first binds to the 
enzyme, followed by the acceptor (Lipid I) to generate lipid II via a proposed 
oxocarbenium ion-like transition state.[95] Currently, there are no inhibitors against  
M. tuberculosis MurG, however, transition-state analogues incorporating a neutral 
linker have been prepared and shown to be weak inhibitors of E. coli MurG exhibiting 
IC50 values in the high micromolar range.[96]  
The lipid II building block is subsequently transported across the cytoplasmic 
membrane to the outer membrane region by a putative ‘flippase’ enzyme.[75] The 
identity of enzyme that performs this function is still under active investigation. In  
E. coli, it was suggested that MurJ was the flippase as MurJ deletion was lethal to the 
microorganism and MurJ depleted strains showed a 70% decrease in  
3H-diaminopimelic acid incorporation into the mature peptidoglycan.[97] As the 
membrane of E. coli lacks a proton motive force, the alternative energy source or 
coupling factor that drives the translocation of lipid II remains to be determined in 
this organism.[75]   
MurJ is unlikely to be the potential flippase for gram-positive bacteria as the gene 
encoding this enzyme is absent in 21 genomes representative of the gram-positive 
bacteria.[75] Recently, Van Dam et al.[98] demonstrated the translocation of a 
fluorescent-labelled lipid II analogue in Bacillus subtilis membranes mediated by 
FtsW. This study provided the first biochemical evidence for the direct involvement 
of FtsW in lipid II transport and established the link between lipid II transport and 
subsequent transglycosylation activity.[98] Currently, the identity of the potential 
flippase in M. tuberculosis is not known.  
4.2.3 Periplasmic peptidoglycan biosynthetic steps 
4.2.3.1  Transglycosylation 
The export of lipid II to the outer surface of the cytoplasmic membrane sets the scene 
for the subsequent transglycosylation step that can either be catalyzed by a 
monofunctional glycosyltransferase peptidoglycan polymerization enzyme (mGTPGP) 
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or bifunctional enzymes also known as penicillin-binding proteins (PBP).[75] The 
reaction is proposed to proceed via deprotonation of the  
C-4 hydroxyl of N-acetyl-D-glucosamine of lipid II followed by the nucleophilic 
attack onto C-1 of N-acetylmuramic acid of a donor unit.[99] This reaction is repeated 
over many cycles to generate nascent polymeric peptidoglycan strands.  
 
Scheme 20. Proposed mechanism for lipid II polymerization by S. aureus 
transglycosylase.[99a] 
Adjacent strands are then cross-linked by transpeptidase enzymes forming mature 
peptidoglycan with different degrees of cross-linking found in different bacterial 
species. The transglycosylation step is targeted by glycopeptides such as vancomycin 
and teicoplanin which bind to the acyl D-Ala-D-Ala termini of lipid II pentapeptide 
side chains, preventing peptidoglycan polymerization (Scheme 18).[100] These 
glycopeptides were used extensively to treat methicillin-resistant S. aureus (MRSA) 
in the 1980s which resulted in the development of vancomycin resistance in 
pathogenic enterococci in 1988.[101] Over the years, vancomycin resistance has 
become more prevalent as it is now extended to the virulent staphylococci.[102] 
Despite the emergence of vancomycin resistance, transglycosylase enzymatic activity 
is still a key antibacterial target.[99, 103]  
PBPs are separated into two main categories including high-molecular-mass (HMM) 
PBPs and low-molecular-mass (LMM) PBPs.[104] HMM PBPs are membrane-
associated, multi-modular proteins that are involved in peptidoglycan polymerization 
and incorporation of the newly formed layer into pre-existing cell wall structure.[104] 
This family of PBPs are further sub-divided into two main classes namely class A and 
B.[105] Class A PBPs are bifunctional enzymes possessing an N-terminal domain with 
glycosyltransferase activity and a C-terminal domain exhibiting transpeptidase 
activity.[105] Class B PBPs feature a complex N-terminal domain coupled to a  
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C-terminal transpeptidase region.[105] The N-terminal domain is associated with non-
penicillin binding functions and was hypothesized to be devoid of catalytic activity in 
S. aureus.[104] LMM PBPs are mostly soluble enzymes with carboxypeptidase activity 
responsible for cleaving the peptide bond between two penultimate D-Ala residues in 
muramyl pentapeptide.[105]  
4.2.3.2 Transpeptidation by PBPs and L,D-transpeptidases 
4.2.3.2.1 PBPs: structure and mechanism 
The catalytic domains of HMM and LMM PBPs are structurally similar and consist of 
two subdomains including a five stranded β-sheet surrounded by three α-helices and 
an all helical region with the active site located at the interface.[104] The active site 
features three conserved sequences: SXXK (catalytic serine and general base lysine), 
(S/Y)X(N/C), and (K/H)(S/T)G. Transpeptidation and carboxypeptidation reactions 
begin with non-covalent association of donor strand muramyl peptide with the 
transpeptidase domain of PBPs (Scheme 21). The active site serine residue then 
attacks the carboxyl-terminus of the D-Ala-D-Ala peptide bond generating an acyl 
intermediate with the terminal D-Ala as the leaving group (Scheme 21).[106] This acyl-
enzyme intermediate is susceptible to nucleophilic attack either by water in 
carboxypeptidation or the amino terminus of the acceptor strand to form a new 
peptide bond in transpeptidation with the release of the free enzyme. The amino acid 
bearing the reactive amino group is different across bacterial species (i.e. glycine in  
S. aureus, meso-diaminopimelic acid in E. coli and M. tuberculosis). Unlike other 
bacterial species, 80% of peptidoglycan cross-links in M. tuberculosis are of the 3→3 
type formed by L,D-transpeptidases (structurally unrelated to PBPs) with only 20% 
featuring the 4→3 cross-links catalyzed by classical PBPs (D,D-transpeptidases).[107] 
As such, classical D,D-transpeptidases only play a small role in peptidoglycan  
cross-linking in M. tuberculosis.[107] 
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Scheme 21. Mechanism of 4→3 transpeptidation by PBP (D,D-transpeptidase). 
4.2.3.2.2 L,D-transpeptidases: structures and mechanisms 
In 2010, Gupta et al.[108] characterized LdtMt2, a L,D-transpeptidase from  
M. tuberculosis. It was demonstrated that a M. tuberculosis strain lacking LdtMt2 lost 
virulence and exhibited attenuated growth during the chronic phase of infection.[108] 
Furthermore, this strain was more susceptible to treatment with carbapenem (a  
β-lactam antibiotic) and clavulanic acid (β-lactamase inhibitor) suggesting the 
important contribution of the 3→3 peptidoglycan cross-links towards β-lactam 
resistance.[108] Another vital contributor to high β-lactam resistance in  
M. tuberculosis is BlaC, a highly efficient and broad spectrum β-lactamase natively 
present in both drug sensitive and resistant strains of the bacterium.[19]  
 
Figure 34. Cartoon representation of the structure of extramembrane LdtMt2 with features of 
secondary structure labeled. N-term: N-terminus, C-term: C-terminus, CTSD: C-terminal sub-
domain, IgD: immunoglobulin domain, CD: catalytic domain.  
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The important roles of LdtMt2 in M. tuberculosis growth and virulence had stimulated 
significant research activity in this area. In 2012, the structure of the extramembrane 
region of LdtMt2 was determined which provided insights into the catalytic mechanism 
and inhibition by carbapenems (Figure 34).[109] Extramembrane LdtMt2 existed as a 
dimer with each monomer comprised of two globular domains. The N-terminal 
domain exhibited an anti-parallel β-barrel fold resembling an immunoglobulin 
domain (Figure 34). The catalytic domain located at the C-terminus consisted of a  
β-sandwich with two mixed β-sheets characteristic of the Erfk/YbiS/YhnG fold. 
 
 
Scheme 22. Mechanism of 3→3 L,D-transpeptidation by LdtMt2. NB: * denotes residues on 
the acceptor strand. R1 represents the carbohydrate backbone of the peptidoglycan, and R2 
represents the L-Ala-γ-D-Glu dipeptide attached to the carbohydrate backbone (acceptor 
strand) respectively. 
The LdtMt2 enzyme features a cysteine as the nucleophilic active site residue (serine in 
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moiety of S337 to deprotonate the side chain of C354 forming the corresponding 
cysteine thiolate (Scheme 22).[109] This thiolate subsequently attacks the amide bond 
between the meso-diaminopimelic acid and D-Ala residues to form a tetrahedral 
intermediate that is stabilized by an ‘oxyanion hole’ and the protonated H336 residue 
(Scheme 22).[109] Subsequent thioester formation is concomitant to the release of the 
terminal D-Ala residue. From here, the amino terminus of the meso-diaminopimelic 
acid in the acceptor stem, which has been deprotonated by H336, attacks the thioester-
enzyme intermediate creating a new amide bond (Scheme 22).[109] This creates cross-
links between two adjacent peptidoglycan strands with the concomitant release of the 
active site cysteine and deprotonation of the imidazolium side chain of H336.[109]  
It was previously demonstrated by Triboulet et al.[110] that LdtMt2 is inactivated by 
carbapenems via a two-step mechanism. The first step was reversible and involved the 
nucleophilic attack of the active site cysteine of LdtMt2 onto the lactam ring of 
carbepenems (carbepenems mimic the meso-diaminopimelic acid-D-Ala moiety in the 
donor stem tetrapeptide) forming the oxyanion tetrahedral intermediate. The second 
step was irreversible and involved the cleavage of the lactam ring resulting in the 
formation an acyl enzyme intermediate. Recently, Cordillot et al.[107] have also 
purified other L,D-transpeptidase paralogues (LdtMt1, LdtMt3, LdtMt4 and LdtMt5) that 
were functional in vitro. Fluorescence kinetics and mass spectrometry analyses had 
indicated that carbapenems inactivated most of the L,D-transpeptidase paralogues 
(LdtMt1-LdtMt4) with the exception of LdtMt5.[107]  
The clinical success of β-lactam antibiotics had played a part in directing significant 
research efforts and resources towards the later stages of peptidoglycan biosynthesis 
(i.e. transpeptidation). Extensive research in this area has shed light on the innate 
resistance of M. tuberculosis towards β-lactam antibiotics through the interplay of the 
highly effective β-lactamase (BlaC)[19] and the dominant presence of 3→3 cross-links 
that are not targeted by traditional β-lactams such as the penicillins.[108] These studies 
have unraveled new targets and strategies to tailor β-lactams to  
M. tuberculosis killing. Hugonnet et al.[20] recently demonstrated the potent in vitro 
inhibition of M. tuberculosis XDR strains (<1 µg/mL) when meropenem (an inhibitor 
L,D-transpeptidases) was used in a combination a BlaC inhibitor, clavulanic acid. 
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Peptidoglycan biosynthesis, which is facilitated through a multitude of enzyme-
catalyzed steps, offers many opportunities for therapeutic intervention for the 
development of novel TB therapies. This is particularly true for the early cytoplasmic 
and membrane-associated steps of the peptidoglycan biosynthetic pathway. In  
chapter 5, efforts towards the development of the first inhibitors of  
M. tuberculosis N-acetylglucosamine-1-phosphate uridyltransferase (GlmU) which is 
responsible for the synthesis of UDP-GlcNAc, the substrate for the first committed 
cytoplasmic step of the peptidoglycan biosynthesis will be presented. In chapter 6 the 
development of analogues of sansanmycins, naturally occurring uridylpeptides as 
potential inhibitors of the MraY/MurX step of the peptidoglycan biosynthesis will be 
described together with their potential as novel TB drugs.   
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5.1 N-acetylglucosamine-1-phosphate uridyltransferase (GlmU): a 
bifunctional enzyme 
The concept that the enzymes responsible for peptidoglycan biosynthesis are 
underexploited drug targets is particularly true for M. tuberculosis. This is in part due 
to the well-established, broad spectrum β-lactamase (BlaC) activity of M. tuberculosis 
that is capable of inactivating traditional β-lactams, one of the main classes of 
antibiotics that operate through the disruption of peptidoglycan biosynthesis. 
Nonetheless, efficacy of the β-lactam meropenem in combination with clavulanic acid 
(a BlaC inhibitor) in chronically infected mice was recently demonstrated by  
England et al.[111] This study highlighted the potential of inhibitors of peptidoglycan 
biosynthetic enzymes as promising antitubercular agents.  
Biosynthesis of the peptidoglycan is catalyzed by a multitude of enzymes and while 
the extracellular enzymes involved in peptidoglycan biosynthesis have been well 
studied (i.e. transglycosylases and transpeptidases), in general, the enzymes involved 
in the cytoplasmic and membrane-associated steps of peptidoglycan assembly have 
not been extensively investigated as drug targets. One such target is  
N-acetylglucosamine-1-phosphate uridyltransferase (GlmU). This bi-functional 
enzyme, found exclusively in bacteria, is responsible for catalyzing the formation of 
UDP-GlcNAc which serves as the substrate for MurA, the first enzyme in the 
cytoplasmic stage of peptidoglycan biosynthesis (see Chapter 4).  
The bifunctional role of GlmU arises from two independent domains of the enzyme 
which possess acetyltransferase and uridyltransferase activities.[112] The 
acetyltransferase domain found in the C-terminal domain of the protein is responsible 
for the first step of the reaction in which an acetyl group is transferred from acetyl-
CoA (AcCoA) to D-glucosamine-1-phosphate (GlcN-1-P) forming N-acetyl-D-
glucosamine-1-phosphate (GlcNAc-1-P).[112] GlcNAc-1-P then serves as a substrate 
for the uridyltransferase active site in the N-terminal domain of the enzyme which 
forms UDP-GlcNAc (Scheme 23).[112] Structurally, the C-terminus domain of the 
Chapter 5. Inhibition Studies on Mycobacterium tuberculosis 
N-acetylglucosamine-1-phosphate uridyltransferase (GlmU) 
Chapter 5-Inhibition Studies on M. tuberculosis N-acetylglucosamine-1-phosphate 
uridyltransferase (GlmU) 
 
 79 
protein adopts a regular left-hand β-helix while the N-terminus exhibits a Rossmann 
fold topology (Scheme 23B).[112] It has been proposed that the mechanism of  
M. tuberculosis GlmU catalysis first involves UTP and Mg2+ binding to the 
uridyltransferase active site prior to GlcNAc-1-P binding in the adjacent pocket.[112-
113] Upon GlcNAc-1-P binding, the enzyme is thought to undergo major 
conformational changes to facilitate uridylation which begins with nucleophilic attack 
by the phosphate group of GlcNAc-1-P at the α-phosphate of UTP thus forming a 
pentacoordinate intermediate stabilized by the Mg2+ cation (Scheme 23A).[112-113] The 
final steps involve inversion of stereochemistry at the α-phosphate and the release of 
pyrophosphate (Scheme 23A).[112-113] 
 
 
 
 
 
 
 
 
 
 
Scheme 23. A: Mechanism of uridylation by GlmU. B: Structure of M. tuberculosis GlmU 
showing the C- and N-terminal catalytic domains. 
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5.2 Synthesis of GlcNAc-1-P 
An efficient route to GlcNAc-1-P was necessary prior to the development of  
a kinetic assay for M. tuberculosis GlmU uridyltransferase. The synthesis of  
GlcNAc-1-P began with N-acetyl-D-glucosamine 117 which was first acetylated by 
treatment with acetic anhydride in pyridine to afford the peracetylated sugar 118 in 
86% yield (Scheme 24). Anomeric acetate deprotection was effected by benzylamine 
to give the hemiacetal 119 (56% yield) which was subsequently reacted with  
N,N-diisopropylphosphoramidite in dichloromethane in the presence of 1,2,4-tetrazole 
as a nucleophilic catalyst to provide glycosyl phosphite 120 in 30% yield (Scheme 
24). Oxidation of glycosyl benzylphosphite 120 to the corresponding benzyl 
phosphate 121 was achieved using 30% aqueous hydrogen peroxide in 79% yield 
(Scheme 24). Debenzylation proceeded smoothly under an atmosphere of hydrogen 
using 10% palladium on carbon as the catalyst to give the glycosyl phosphate 122 in 
quantitative yield (Scheme 24). It is important to note that due to the inherent 
instability of the free phosphate moiety to acidic conditions, it was necessary to 
deactivate Celite® prior to use by a saturated solution of ammonium hydrogen 
carbonate in ethanol. Glycosyl phosphate 122 was subsequently subjected to a 
deacetylation procedure using aqueous sodium hydroxide at room temperature. Under 
these conditions, the reaction was sluggish with starting material still present after 2 h 
at which point, decomposition of starting material had also occurred. To alleviate the 
formation of by-products, an alternative method was sought. To this end, treatment of 
glycosyl phosphate with 10 vol.% triethylamine in aqueous methanol for 16 h gave 
the GlcNAc-1-P 123 in 54% yield with excellent purity (>95%) following column 
chromatography (Scheme 24). 
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Scheme 24. Synthesis of GlcNAc-1-P 123 from N-acetylglucosamine 117. Reagents and 
conditions: a) DMAP (cat.), Ac2O, pyridine, 0 oC to rt, 16 h, 86%; b) BnNH2, THF, 0 oC,  
30 min, 56%; c) Dibenzyl N,N-diisopropylphosphoramidite, 1,2,4-triazole, CH2Cl2, 0 oC to rt, 
16 h, 30%; d) 30% H2O2, THF, -78 oC to rt, 3 h, 79%; e) 10% Pd/C, H2 (1 atm), EtOH, rt,  
16 h, quant.; f) 10 vol.% Et3N, MeOH: H2O (1:1 v/v), rt, 16 h, 54%.  
5.3 Development of M. tuberculosis GlmU uridyltransferase kinetic assay 
Prior to the design and synthesis of M. tuberculosis GlmU uridyltransferase inhibitors, 
it was necessary to develop a continuous kinetic assay. To this end, a double coupled 
enzyme assay was developed based on an assay previously reported by Webb and  
co-workers which monitors the formation of inorganic pyrophosphate.[114] 
Specifically, this assay used excess amounts of two coupling enzymes, namely 
inorganic pyrophosphatase (IPP) (EC 3.6.1.1) and purine nucleoside phosphorylase 
(PNPase) (EC 2.4.2.1) in the presence of 2-amino-6-mercapto-7-methylpurine 
ribonucleoside (MESG).[114] In this double coupled enzyme assay, the pyrophosphate 
produced by GlmU uridyltransferase is subsequently hydrolyzed to inorganic 
phosphate by inorganic pyrophosphatase (Scheme 25). The inorganic phosphate then 
serves as a substrate for purine nucleoside phosphorylase which catalyzes the 
phosphorolytic cleavage of the glycosidic bond in MESG (λmax = 330 nm), resulting 
in the formation of 2-amino-6-mercapto-7-methylpurine (λmax = 360 nm) that can be 
detected spectroscopically (Scheme 25).  
 
aOHO
HO OH
b c
d e f
117 118 119 120
121 123122
AcHN
OH
O
AcO
AcO OAc
AcHN
OAc
O
AcO
AcO
AcHN
OAc
OH
O
AcO
AcO
AcHN
OAc
OP(OBn)2
O
AcO
AcO
AcHN
OAc
O P
O
OBn
OBn
O
AcO
AcO
AcHN
OAc
O P
O
OH
OH
O
HO
HO
AcHN
OH
O P
O
OH
OH
Chapter 5-Inhibition Studies on M. tuberculosis N-acetylglucosamine-1-phosphate 
uridyltransferase (GlmU) 
 
 82 
 
Scheme 25. Double-enzyme coupled M. tuberculosis GlmU uridyltransferase assay. 
During the development of the GlmU uridyltransferase kinetic assay, a number of 
variables including the concentrations of M. tuberculosis GlmU and MESG as well as 
the assay temperature were modified to identify the optimal assay conditions for 
screening inhibitors. In addition, experiments to confirm that the coupling enzymes, 
IPP and PNPase, were not rate-limiting and that the assay was directly measuring the 
activity of GlmU uridyltransferase were performed. Specifically, initial rates were 
measured at various concentrations of two coupling enzymes, IPP and PNPase (0.96-
4.8 U/mL IPP and 0.4-2 U/mL PNPase). The data obtained was fitted to a  
Michaelis-Menten model by non-linear regression using GraphPad Prism (version 
5.03 for Windows, Figure 35).[59] The results from these initial studies indicated that 
the rate of reaction was not dependent on the concentrations of the coupling enzymes 
as no appreciable change in kinetic parameters such as apparent KM and Vmax for UTP 
was detected (Figure 35). As such, these experiments demonstrated that IPP and 
PNPase were not rate limiting in the assay and that the kinetics of GlmU was being 
monitored directly. 
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Figure 35. Least square fitted curve to the Michaelis-Menten model for M. tuberculosis 
GlmU uridylransferase with varying concentrations of PNPase and IPP. 
To confirm the dependence of reaction rate on GlmU concentration, initial velocities 
were measured in the presence of varying concentrations of GlmU uridyltransferase 
(23-188 nM) and 53 µM GlcNAc-1-P and 1 mM UTP. It was found that there was a 
linear increase in initial rates as the concentration of GlmU uridyltransferase 
increased (Figure 36). The result from this study provided confidence that the kinetics 
of GlmU was being monitored.  
 
Figure 36. Dependence of initial rates on GlmU concentration. 
The optimized assay was subsequently used for the determination of kinetic 
parameters for both UTP and GlcNAc-1-P as substrates for GlmU activity, whereby 
the apparent KM and Vmax values for one substrate were determined at a saturating 
0 50 100 150 200
0.00
0.02
0.04
0.06
1 U/mL PNPase & 2.4 U/mL IPP
2 U/mL PNPase & 4.8 U/mL
IPP
0.4 U/mL PNPase & 1 U/mL IPP
[UTP] µM
R
at
e 
(µ
M
/s
)
Chapter 5-Inhibition Studies on M. tuberculosis N-acetylglucosamine-1-phosphate 
uridyltransferase (GlmU) 
 
 84 
concentration (1 mM) of the other substrate (Figure 37 and Figure 38). The apparent 
KM values for UTP and GlcNAc-1-P were determined to be 34 µM and 22 µM 
respectively while the Vmax values were ascertained to be 0.082 µM/s and 0.076 µM/s 
for UTP and GlcNAc-1-P respectively. 
 
Figure 37. Least square fitted curve to the Michaelis-Menten model for M. tuberculosis 
GlmU uridyltransferase (KM UTP = 34 ± 3 µM, Vmax = 0.082 ± 0.002 µM s-1, [GlcNAc-1-P] = 1 
mM).  
 
Figure 38. Least square fitted curve to the Michaelis-Menten model for M. tuberculosis 
GlmU uridyltransferase (KM GlcNAc-1-P = 22 ± 1 µM, Vmax = 0.076 ± 0.001 µM s-1, [UTP] = 1 
mM).  
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5.4 Design of bi-substrate inhibitors of M. tuberculosis GlmU 
5.4.1 Design of aminothiazole-based inhibitors 
Having successfully developed a continuous kinetic assay for the uridyltransferase 
activity of M. tuberculosis GlmU uridyltransferase, the next step was the development 
of the first inhibitor against this enzyme. The substrates and putative transition state 
of the GlmU uridyltransferase reaction were used as starting points for inhibitor 
design. To begin with, bi-substrate inhibitors containing structural features of both 
UTP and GlcNAc-1-P were designed. Specifically, compounds 124 and 125 
containing a uridine moiety and GlcNAc mimicking catechol or adamantyl units were 
designed (Scheme 26). The incorporation of both catechol and adamantyl moieties 
was to assess the contribution of hydrogen bonding interactions in the GlcNAc-1-P 
binding site towards GlmU inhibitory activity. Compounds 124 and 125 also featured 
an aminothiazole bridge (Scheme 26). This moiety was successfully employed by 
Kiessling et al.[115] as a pyrophosphate shape mimic in the development of UDP-
galactopyranose mutase inhibitors. It was envisaged that aminothiazole containing 
inhibitors 124 and 125 could be obtained from Hantzsch thiazole-based synthesis of a 
suitably protected thiourea intermediate with various α-bromoketones. It was 
envisaged that the thiourea intermediate could arise from suitably protected uridine. 
 
Scheme 26. Design of bisubstrate inhibitors of M. tuberculosis GlmU. 
5.4.2 Synthesis of aminothiazole-based inhibitors 124 and 125 
The synthesis of aminothiazole-based inhibitors 124 and 125 began with 
commercially available uridine 126. Simultaneous protection of the C-2’ and C-3’  
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cis-hydroxyl groups with an isopropylidene group was achieved by treatment with  
2,2-dimethoxypropane in acetone in the presence of a catalytic amount of  
PTSA and proceeded in 82% yield to afford protected uridine 127 (Scheme 27). 
Subsequent activation of the C-5’ primary alcohol with p-toluenesulfonyl chloride in 
pyridine afforded the corresponding tosylate 128 in 50% yield. From here, 
nucleophilic displacement of the tosylate with sodium azide in dimethylformamide 
gave the protected azidouridine 129 in 77% yield. 
 
Scheme 27. Synthesis of azido-uridine 129. Reagents and conditions: a) 1. Cat. PTSA, 
acetone, 2,2-dimethoxypropane, 0 oC → reflux, 4 h, 2. NaHCO3, rt, 30 min, 82%; b) Tosyl 
chloride, pyridine, rt, 16 h, 50%; c) NaN3, DMF, 45 oC, 16 h, 77%.  
Subsequent reduction of the azide in 129 proved problematic with catalytic 
hydrogenation over palladium on carbon in either methanol or ethanol providing 
starting material or trace amounts of amine 130 (Table 9, entries 1 and 2). The 
employment of Staudinger reduction conditions (Table 9, entries 3 and 4) resulted in 
only trace formation of amine 130 while reduction using cobalt boride, generated  
in situ from cobalt chloride hexahydrate and sodium borohydride, also failed to 
deliver the desired amine in appreciable yield (Table 9, entry 5). Interestingly, 
Bertozzi and Winans[116] also observed the remarkable resistance of azidouridine 129 
to catalytic hydrogenation conditions (using palladium on carbon) which prompted 
them to remove the isopropylidine group before the reduction step. Upon removal of 
this group, azide reduction proceeded smoothly under standard catalytic 
hydrogenation conditions.[116] 
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Table 9. Conditions used for reduction of azido-uridine 129. 
 
Entry                Conditions Outcome 
1 10% Pd/C, H2 (1 atm), MeOH, rt, 3 h Starting material 
2    10% Pd/C, H2 (1 atm), EtOH, rt, 32 h Starting material + product (trace) 
 
3 PPh3, pyridine/H2O 
(2.5:1 v/v), 0 oC, 1 h 
Starting material 
4 PPh3, THF, cat. H2O, 16 h Starting material + product (trace) 
5     CoCl2.6H2O, NaBH4, H2O, rt, 36 h Starting material + product (trace) 
 
To circumvent the problematic reduction of isopropylidene-protected azidouridine 
129, a different protecting group was employed. To this end, a tert-butyl dimethylsilyl 
ether was selected due to the stability of this group under a wide range of reaction 
conditions (except in the presence of fluoride anion or acidic conditions). The 
synthesis began with the formation of 5’-azidouridine 131 via an Appel reaction of 
uridine 126 by treatment with carbon tetrabromide, triphenylphosphine and sodium 
azide in dimethylformamide (Scheme 28). It is important to note that azidouridine 
131, obtained in 52% yield, could arise either directly from the activated phosphorus 
derivative of alcohol 126 or via 5’-bromouridine formed under the Appel reaction 
conditions (Scheme 28). Subsequent silyl protection of the C-2’ and C-3’ hydroxyl 
groups proceeded in 60% yield to give silyl protected 5’-azidouridine 132 (Scheme 
28). 
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Scheme 28. Synthesis of silyl-protected azidouridine 132. Reagents and conditions: a) PPh3, 
CBr4, NaN3, DMF, rt, 16 h, 52%; b) TBS-Cl, imidazole, DMF, rt, 16 h, 60%.  
5’-azidouridine 132, unlike isopropylidene-protected azidouridine 129, was not 
resistant to reduction by catalytic hydrogenation over palladium on charcoal. Instead, 
over reduction of 132 was observed after 16 h at room temperature. Specifically, 
desired amine 133 was formed along with 134 in which the double bond of the uridine 
base had been reduced (Scheme 29). In order to avoid this over-reduction, an 
alternative method was sought. To this end, azidouridine 132 was reduced by 
treatment with 1,3-propanedithiol and triethylamine which enabled chemoselective 
reduction of the azide moiety to afford the desired amine 133 in 57% yield after 
column chromatography on deactivated silica gel (Scheme 29). 
 
Scheme 29. Synthesis of silyl-protected uridylamine 133. Reagents and conditions: a) 10% 
Pd/C, MeOH, H2 (1 atm), rt, 16 h, quant. (133:134 in 1:1 ratio); b) 1,3-propanedithiol, Et3N, 
EtOH, 18 h, rt, 57%.  
Silyl-protected uridylamine 133 was subsequently reacted with  
1,1’-thiocarbonyldiimidazole to generate activated intermediate 135 which was 
subsequently reacted with aqueous ammonia in one pot to afford thiourea 
intermediate 136 in 70% yield over the two steps (Scheme 30). Subsequent 
condensation of intermediate 136 with α-bromoketones 137 and 138 then afforded the 
desired aminothiazole-based inhibitors 124 and 125 following TFA mediated silyl 
group removal in 25% and 36% yield, respectively over the two steps (Scheme 30). 
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Scheme 30. Synthesis of aminothiazole-based inhibitors 124 and 125. Reagents and 
conditions: a) 1. 1,1’-thiocarbonyldiimidazole, DMF: THF (1:1 v/v), rt, 15 h, 2. NH4OH (25 
vol.% in H2O), rt, 3 h, 70% over two steps; b) 137 or 138, DMF, rt, 16 h; c) TFA: CH2Cl2 
(9:1 v/v), rt, 5 h, 25% and 36% over two steps.  
5.4.3 Design and synthesis of sulfonamide-based inhibitor 139 
In addition to the aminothiazole-based inhibitors 124 and 125, a further bi-substrate 
inhibitor employing a sulfonamide moiety as a phosphate bioisostere was also 
designed. Specifically, compound 139 was proposed which featured a uridine motif 
and an α-GlcNAc moiety linked via a sulfonamide bridge. This compound was 
synthesized via amide coupling of sulfamoyluridine 140 with acid 141[117] using N,N’-
dicyclohexylcarbodiimide (DCC) as the coupling reagent to yield the fully protected 
sulfonamide-based compound 142 (Scheme 31). Deprotection of the isopropylidene 
moiety followed by global deacetylation afforded sulfonamide-based inhibitor 139 in 
20% yield over two steps (Scheme 31). The modest yield of compound 139 was 
mostly due to difficulties encountered during reverse-phase HPLC purification. 
Specifically, as a result of poor retention of this compound on C18 column, 
significant optimization of HPLC gradients was necessary, ultimately resulting in 
poor recovery of compound 139.  
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Scheme 31. Synthesis of sulfonamide-based inhibitor 139. Reagents and conditions: a) 141, 
DCC, DMAP, CH2Cl2, rt, 16 h, 48%; b) TFA: H2O (3:1 v/v), rt, 16 h; c) 10 vol.% Et3N, 
MeOH: H2O (1:1 v/v), rt, 16 h, 20% over two steps. 
5.5 Biological evaluation of bi-substrate inhibitors 
 
Figure 39. Inhibitory activity of putative bi-substrate inhibitors of M. tuberculosis GlmU 
uridyltransferase activity.  
Aminothiazole and sulfonamide-based inhibitors 124, 125 and 139 were next 
evaluated for inhibitory activity against M. tuberculosis GlmU using the coupled 
continuous kinetic assay described above (section 5.3 and 7.2.2). Unfortunately, these 
compounds demonstrated weak inhibition of GlmU uridyltransferase activity (124: 
55% inhibition at 2 mM, 125: no inhibition at 200 µM and 139: 37% inhibition at  
2 mM, Figure 39). The lack of potency of these bi-substrate inhibitors prompted a 
change in design strategy with the emphasis being shifted towards incorporation of 
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characteristic features of the putative transition state of the GlmU uridyltransferase 
reaction. 
5.6 Design, synthesis and evaluation of transition state mimics 
Transition-state mimics incorporating either a metal ion chelation motif such as a 
catechol moiety or negatively charged functionalities (at physiological pH) such as 
carboxylate groups were next designed. Specifically, compound 143 possessing a  
2,3-dihydroxybenzamide moiety was designed to serve as a surrogate for the leaving 
pyrophosphate group (Scheme 32). In contrast, compound 144 featured a  
di-carboxylate moiety capable of co-ordinating to the catalytic Mg2+ in a similar 
manner to the phosphate motif in the transition state (Scheme 33).  
The synthesis of compound 143 took advantage of the Ugi multi-component 
condensation[118] which allowed for rapid generation of molecular complexity from 
simple building blocks such as uridylamine 133, benzoic acid 145, formaldehyde and 
cyclohexyl isonitrile. This multi-component condensation proceeded at room 
temperature, in methanol to give 146 after 72 h. Global deprotection mediated by 
TFA then provided transition state mimic 143 in 39% yield over two steps (Scheme 
32).  
 
Scheme 32. Synthesis of compound 143 via Ugi multicomponent condensation. Reagents and 
conditions: a) cyclohexyl isonitrile, formaldehyde, MeOH, rt, 72 h; b) TFA: H2O (9:1 v/v), rt, 
4.5 h, 39% over two steps.  
The synthesis of compound 144 began with uridylamine intermediate 133 (Scheme 
33). Amide coupling with Fmoc-L-Asp(OtBu)-OH in the presence of (benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) as the coupling 
reagent and 1-hydroxybenzotriazole (HOBt) as an additive proceeded to give amine 
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147 in 57% yield following Fmoc-deprotection (Scheme 33). Compound 147 was 
then subjected to an amide coupling/deprotection sequence in a similar manner to the 
previous step to afford amine 148 in 67% yield over two steps. Amine 148 was 
coupled to acid 141 employing the uronium-based coupling reagent O-(7-
azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HATU), a 
more reactive coupling reagent than PyBOP) in combination with 1-hydroxy-7-
azabenzotriazole (HOAt) as an additive to give the fully protected transition state 
mimic 149 (Scheme 33). Global deprotection was carried out in two stages with the 
removal of acetate groups preceding the unmasking of tert-butyl esters and silyl 
ethers giving transition state mimic 144 in 10% yield over 3 steps (Scheme 33). It is 
important to note that the modest yield obtained for compound 144 was due to the 
sluggish amide coupling between amine 148 and acid 141 even in the presence of 
HATU and HOAt (70% of amine 148 was recovered at the end of the reaction).  
 
Scheme 33. Synthesis of compound 144 from uridylamine 133. Reagents and conditions: a) 
1. Fmoc-L-Asp(OtBu)-OH, PyBOP, HOBt, iPr2NEt, DMF, 0 oC to rt, 1.5 h, 2. 20 vol.% 
piperidine in CH2Cl2: MeOH (1:1 v/v), rt, 3.5 h, 57% over two steps; b) 1. Fmoc-L-
Asp(OtBu)-OH, PyBOP, HOBt, iPr2NEt, DMF, 0 oC to rt, 1.5 h, 2. 20 vol.% piperidine in 
CH2Cl2: MeOH (1:1 v/v), rt, 3.5 h, 67% over two steps; c) 141, HATU, HOAt, iPr2NEt, 
DMF, rt, 1 h; d) 1. 10 vol.% Et3N, MeOH: H2O (1:1 v/v), rt, 16 h, 2. TFA: H2O (9:1 v/v), rt, 
16 h, 10% over 3 steps.  
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The coupled continuous kinetic assay described in section 5.3 was used to ascertain 
the inhibitory activity of transition-state mimics 143 and 144. Unfortunately, despite 
the incorporation of transition state features of the proposed GlmU uridyltransferase 
reaction, these compounds only exhibited weak inhibition against the enzyme (10% 
and 60% inhibition at 2 mM for 143 and 144, respectively, Figure 40). 
 
Figure 40. Transition-state mimics of M. tuberculosis GlmU uridyltransferase. 
5.7 Inhibitors targeting GlcNAc-1-P binding site 
5.7.1 Design and synthesis of a GlcNAc-1-P mimic 
As discussed in section 5.1, M. tuberculosis GlmU uridyltransferase catalysis 
proceeds through a sequential, ordered bi-bi mechanism. UTP first binds to the apo 
conformation of GlmU uridyltransferase, followed by GlcNAc-1-P. The binding of 
GlcNAc-1-P triggers the conformational change necessary for the uridylation reaction 
catalyzed by the enzyme. As such, it was envisaged that compounds that interacted 
with the GlcNAc-1-P binding site would potentially intercept the conformational 
change required for catalysis, leading to inhibition of the uridyltransferase activity of 
GlmU. 
At the time this work was in progress, Min et al.[119] identified luteolin as a  
sub-micromolar inhibitor of GlmU uridyltransferase from Xanthomonas oryzae 
through a virtual screening campaign. Analysis of enzyme inhibition kinetics revealed 
that luteolin exhibited competitive inhibition with regard to GlcNAc-1-P.[119] 
Encouraged by the competitive binding mode of luteolin, this compound was 
purchased from Sigma-Aldrich and was subsequently screened against  
M. tuberculosis GlmU uridyltransferase. Although luteolin only reduced the 
uridyltransferase activity of GlmU by 40% at 200 µM (Figure 41), it provided a 
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starting point for the design of compounds that potentially targeted the GlcNAc-1-P 
binding site.  
 
Figure 41. Luteolin and analogues. NB : reduction of GlmU uridyltransferase activity is 
expressed as percentage inhibition. 
The importance of hydrogen bond donors and acceptors in the left and right-hand 
rings of luteolin were sequentially evaluated in compounds 150 and 151. The 
synthesis of 150 and 151 began with 2’-hydroxyl-4’,6’-dimethoxyacetophenone 152 
and 2-hydroxyacetophenone 153, respectively (Scheme 34). An aldol condensation 
with benzaldehyde and 3,4-dimethoxybenzaldehyde, followed by elimination by 
treatment with potassium hydroxide afforded enones 154 and 155 in 60% and 66% 
yield, respectively (Scheme 34). Oxidative cyclization of 154 and 155 at 150 oC in the 
presence of catalytic iodine then gave chromones 156 and 157 in 38% yield in both 
cases. Demethylation by boron tribromide resulted in the formation of 150 and 151 in 
80% and 74% yield, respectively (Scheme 34).  
 
Scheme 34. Synthesis of luteolin analogues 150 and 151. Reagents and conditions: a) 154: 
benzaldehyde, 50% KOH, MeOH, 30 oC, 15 h, 60%, 155: 3,4-dimethoxybenzaldehyde, 70% 
KOH, EtOH, rt, 20 h, 66%; b) 156: I2, DMSO, 150 oC, 1 h, 38%, 157: I2, DMSO, 150 oC, 3 h, 
38%; c) 150: BBr3, CH2Cl2, 0 oC to rt, 3 h, 80%, 151: BBr3, CH2Cl2, 0 oC to rt, 3 h, 74%. 
Luteolin analogues 150 and 151 were subsequently screened against M. tuberculosis 
GlmU uridyltransferase. Interestingly, it appeared that the hydrogen bond donor and 
acceptor groups on the left hand ring did not contribute to inhibitory activity as 
removal of the hydroxyl groups (as in 151) resulted in a modest improvement in 
potency (151: 43% inhibition at 100 µM, Figure 42). In contrast, replacement of the 
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3,4-dihydroxyphenyl moiety in luteolin with a phenyl group in 150 abolished activity 
(150: 7% inhibition at 100 µM, Figure 42).  
 
Figure 42. Inhibitory activity of luteolin analogues 150 and 151. NB : reduction of GlmU 
uridyltransferase activity is expressed as percentage inhibition. 
Having established the lack of importance of hydroxyl groups on the left-hand ring of 
luteolin, further functionalization was carried out at this site to probe the tolerability 
of the GlmU uridyltransferase binding site to additional substitution. Initially, 
functionalization at C-5 was carried out due to availability of the starting aryl 
bromide. Morpholine and phenyl moieties were selected to gauge tolerability of the 
GlmU uridyltransferase binding site to polar and hydrophobic groups (158 and 159, 
Figure 43).  
 
Figure 43. Luteolin analogues with C-5 functionalization. 
The synthesis of 158 began with 5’-bromo-2’-hydroxyacetophenone 160. In a similar 
manner to 156 and 157, an aldol condensation followed by elimination afforded enone 
161 which was cyclized using catalytic iodine to give bromoflavone 162 (Scheme 35). 
Unfortunately, the coupling of bromoflavone 162 with morpholine under Buchwald-
Hartwig conditions was sluggish with starting material still observed after heating at 
100 oC for 16 h. The formation of a complex mixture of products was a major factor 
leading to the poor yield (15%) of 163 (Scheme 35). Nonetheless, with compound 163 
in hand, subsequent demethylation with boron tribromide was carried out in order to 
obtain inhibitor 158. Unfortunately, this deprotection proved unsuccessful with 
compound 163 decomposing under the reaction conditions leading to the isolation of 
only trace amounts of the desired product (Scheme 35). 
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Scheme 35. Synthesis of compound 158. Reagents and conditions: a) 3,4-
dimethoxybenzaldehyde, 70% KOH, EtOH, rt, 20 h, 66%; b) I2, DMSO, 150 oC,  
1 h, quant.; c) Morpholine, Pd2(dba)3 (10 mol%), BINAP (15 mol%), Cs2CO3, toluene,  
100 oC, 16 h, 15%; d) BBr3, CH2Cl2, 0 oC to rt, 1 h.  
Due to the difficulties encountered with the deprotection of the methyl ether 
protecting groups in 163, benzyl ether was selected as an alternative protecting group 
for the hydroxyl moieties of 159 as it was envisaged that this group could be removed 
under mild catalytic hydrogenation conditions. To this end, benzyl protected 
bromoflavone 164 was synthesized via enone 165 in a similar manner to 162, starting 
with 5’-bromo-2’-hydroxyacetophenone 160 and 3,4-bis(benzyloxy)benzaldehyde 
166 (Scheme 36). A palladium-catalyzed Suzuki-Miyaura coupling between 
bromoflavone 164 and phenylboronic acid using tetrakistriphenylphosphine 
palladium(0) in dioxane and DMSO gave 167 in 93% yield. Unfortunately, 
subsequent debenzylation was unsuccessful as the starting material decomposed under 
the catalytic hydrogenation conditions.  
 
Scheme 36. Synthesis of compound 159. Reagents and conditions: a) 3,4-
bis(benzyloxy)benzaldehyde 166, 70% KOH, EtOH, 30 oC, 20 h, quant.; b) I2, DMSO,  
150 oC, 1 h, quant.; c) [Pd(PPh3)4] (10 mol%), phenylboronic acid, Cs2CO3, dioxane/DMSO 
(2:1 v/v), 85 oC, 22 h, 93%; d) 10% Pd/C, H2 (1 atm), EtOH, rt, 7 h.   
Whilst the presence of the hydroxyl groups on the right hand aryl ring were shown to 
be essential for GlmU inhibition, the synthesis of analogues necessitated the use of 
protecting groups prior to chemical manipulation in other regions of the lead 
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compound 151. Unfortunately, attempts to identify protecting groups that were 
compatible to the reaction conditions employed in the synthesis of analogues were 
unsuccessful. In light of the synthetic difficulties encountered and due to time 
constraints, further investigation of luteolin analogues as potential inhibitors of GlmU 
uridyltransferase was not carried out. However, luteolin and 151 have been sent to the 
laboratory of Prof. Ted Baker at the University of Auckland for co-crystallization 
studies with GlmU uridyltransferase. The structural information should aid in the 
development of second generation inhibitors in the future.  
5.8 Aminoquinazoline-based compounds 
5.8.1 Synthesis and evaluation of lead compounds 
In parallel with the above transition-state and bisubstrate inhibitor design strategy, 
aminoquinazoline-based inhibitors 168 and 169 which were identified in a recent 
high-throughput screen against Haemophilus influenzae GlmU uridyltransferase by 
Larsen and co-workers from AstraZeneca were also synthesized (Scheme 37).[120] The 
synthesis of targeted aminoquinazoline-based compounds 168 and 169 began with 2-
amino-4,5-dimethoxybenzoic acid (170) and 2-amino-4-(benzyloxy)-5-
methoxybenzoic acid (171) respectively. Condensation with trimethyl orthoformate 
and ammonium acetate in methanol afforded quinazolones 172 and 173 in 85% and 
86% yield, respectively. Subsequent chlorination using phosphorus(V) oxychloride 
then provided the corresponding chloroquinazolines 174 and 175 in good yields. 
Chloroquinazolines 174 and 175 were next subjected to SNAr reactions with  
N-(4-aminophenyl)benzamide 176 followed by debenzylation under catalytic 
hydrogenation conditions to afford the targeted aminoquinazoline-based compounds 
168 and 169 in 75% and 50% yield over two steps, respectively.  
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Scheme 37. Synthesis of aminoquinazoline-based compounds 168 and 169. Reagents and 
conditions: a) CH(OMe)3, NH4OAc, MeOH, 141 oC, 172: 3 h, 85%, 173: 16 h, 86%; b) 
POCl3, 110 oC, 5 h, 174: 70%, 175: 77%; c) Benzamide 176, 2-propanol, 110 oC, 3 h, 75%; d) 
Benzamide 176, 2-propanol, 110 oC, 3 h, 110 oC; e) 10% Pd/C, H2 (1 atm), MeOH, rt, 1.25 h, 
50% over two steps. 
Gratifyingly, aminoquinazoline-based compounds 168 and 169 exhibited promising 
activity when screened against M. tuberculosis GlmU uridyltransferase. Specifically, 
compound 168 exhibited 44% inhibition of the uridytransferase activity at 50 µM 
while compound 169 was slightly less potent with 36% inhibition at the same 
concentration (Figure 44). It should be noted that while this represents a significant 
drop in activity compared to that observed against H. influenzae GlmU 
uridyltransferase (168 and 169 were shown to be sub-micromolar inhibitors of  
H. influenzae GlmU uridyltransferase), the M. tuberculosis GlmU N-terminal domain 
only possesses 41% sequence identity to the H. influenzae isozyme. It is also 
important to note that strong absorption of the aminoquinazoline compounds at  
λ = 360 nm meant that the assays could not be conducted with inhibitor 
concentrations above 50 µM and therefore IC50 values could not be calculated for 
these compounds as the UV spectrophotometer reached maximum absorption values 
at higher inhibitor concentrations.  
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Figure 44. Aminoquinazoline-based inhibitors of M. tuberculosis GlmU uridyltransferase. 
5.8.2 First-generation aminoquinazoline-based inhibitors 
5.8.2.1 Design and synthesis 
Encouraged by the activity of analogues 168 and 169, an aminoquinazoline-based 
inhibitor library using the more potent 6,7-dimethoxyquinazoline inhibitor 168 as a 
starting point was designed to explore SAR against M. tuberculosis GlmU 
uridyltransferase.[121] The general strategy for structural modifications of compound 
168 is summarized in Figure 45. SAR exploration was focused on the sequential 
evaluation of the role and relative importance of the central 1,4-phenylenediamine 
linker, the terminal phenyl group and the bicyclic dimethoxyquinazoline scaffold.  
 
Figure 45. Proposed structural modifications of inhibitor 168. 
Initial investigations focused on the evaluation of the importance of the terminal 
phenyl group and the central 1,4-phenylenediamine linker in 168. To this end, the 
phenyl moiety of aminoquinazoline-based inhibitor 168 was replaced with 
cyclohexane, pyrrolidine and 4-hydroxypyrrolidine, while piperazine and 1,2-
diaminocyclohexane linkers were employed to substitute the 1,4-phenylenediamine 
moiety in 168. These groups were introduced to evaluate the effect of incorporating 
hydrogen bond donors and acceptors as well as conformational flexibility into the 
terminal group and the central linker on GlmU uridyltransferase inhibitory activity. 
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Compounds lacking the terminal phenyl group were also synthesized to assess the 
contribution of this functionality on inhibitory activity. 
The synthesis of the proposed aminoquinazoline-based inhibitors began with SNAr 
reactions between chloroquinazoline 174 and piperazine, racemic trans-1,2-
diaminocyclohexane and 1,4-phenylenediamine to afford amines 177-179 in good 
yields (Scheme 38). Amines 177-179 were subsequently coupled with a variety of 
carboxylic acids using either N,N’-diisopropylcarbodiimide (DIC) or HATU as 
coupling reagents to afford inhibitors 180-184 in 31-50% yield (Scheme 39A-C). 
Finally, the tert-butyl carbamate of 185 was removed by treatment with 4 M HCl in 
dioxane to provide inhibitor 186 (Scheme 39D).   
 
Scheme 38. Synthesis of amines 177-179. Reagents and conditions: a) piperazine 
hydrochloride hydrate, 2-propanol, 110 oC, 3 h, 70%; b) (±)-trans-1,2-diaminocyclohexane, 
2-propanol, 110 oC, 3 h, 60%; c) 1,4-phenylenediamine, 2-propanol, 110 oC, 3 h, 85%.  
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Scheme 39. Synthesis of inhibitors 180-184, 186 and 187. Reagents and conditions: A. a) 
181: Benzoic acid, HATU, iPr2NEt, DMF, rt, 4 h, 47%; 182: Cyclohexane carboxylic acid, 
HATU, iPr2NEt, DMF, rt, 20 h, 50%; B. b) 183: Benzoic acid, HATU, iPr2NEt, DMF, rt, 4 h, 
30%; 184: Cyclohexane carboxylic acid, HATU, iPr2NEt, DMF, rt, 24 h, 31%; C. c) 180: 
cyclohexane carboxylic acid, DIC, DMAP, DMF, rt, 20 h, 56%; D. d) 185: Boc-L-Hyp-OH, 
HATU, iPr2NEt, DMF, rt, 20 h; e) 186: 4 M HCl in dioxane, rt, 16 h, 30% over two steps.  
E. f) 188: Fmoc-L-Pro-OH, HATU, iPr2NEt, CH2Cl2, rt, 1 h, 57%; g) 189: 174, 2-propanol, 
110 oC, 3 h; h) 187: 25% piperidine, CH2Cl2: MeOH (1:1, v/v), rt, 30 min, 25% over 2 steps. 
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As a result of solubility problems in the coupling reaction, a modified procedure was 
required for the preparation of the proposed inhibitor bearing an unsubstituted 
pyrrolidine terminal group (187). An SNAr reaction between  
(S)-N-(4-aminophenyl)pyrrolidine-2-carboxamide fragment 188 and 
chloroquinazoline 174 was proposed. Precursor carboxamide fragment 188 was 
obtained from an amide coupling between Fmoc-L-proline-OH and  
1,4-phenylenediamine using HATU as the coupling reagent in dichloromethane 
(Scheme 39E). Chloroquinazoline 174 was subjected to an SNAr reaction with 
carboxamide 188 to initially provide Fmoc-protected aminoquinazoline 189. 
Deprotection of the Fmoc-carbamate of 189 using 25 vol.% piperidine in a mixture of 
dichloromethane and methanol (1:1 v/v) afforded inhibitor 187 in moderate yield over 
two steps (Scheme 39E).   
5.8.2.2 Evaluation of first-generation aminoquinazoline-based inhibitors 
The first series of 11 inhibitors were next screened for inhibitory activity against  
M. tuberculosis GlmU uridyltransferase using the double coupled continuous kinetic 
assay described above (section 5.3 and 7.2.2). The inhibition assays were carried out 
at fixed concentrations of UTP and GlcNAc-1-P ([UTP] = 35 µM and [GlcNAc-1-P] 
= 35 µM) in the presence of the inhibitors at 50 µM. Unfortunately, as with parent 
compounds, IC50 values could not be obtained for the majority of compounds owing 
to the combination of low solubility at high concentrations (>200 µM) and high 
absorbance (at λ = 360 nm) at concentrations that were required for determining 
accurate IC50 values.  
After screening the 1,4-phenylenediamine-linked series of inhibitors (168, 179, 180, 
186 and 187), it was clear that the terminal phenyl group was essential for inhibition 
of GlmU uridyltransferase activity. The importance of the phenyl group was 
emphasized by the substitution of the phenyl group in 168 with a cyclohexane moiety 
in 180 which resulted in a two-fold decrease in inhibition (168: 44% inhibition at  
50 µM vs 180: 22% inhibition at 50 µM, Table 10). Similarly, removal of this group 
led to a three-fold drop in potency (179: 14% inhibition at 50 µM, Table 10). 
Replacement of the terminal phenyl group in 168 with pyrrolidine and 
hydroxypyrrolidine moieties in 187 and 186 respectively, also resulted in reduced 
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inhibition of GlmU uridyltransferase activity (8% inhibition at 50 µM for 186 and 
187, Table 10).  
Table 10. Inhibition of uridyltransferase activity of M. tuberculosis GlmU by 
aminoquinazoline inhibitors with variation in linker and terminal groups. 
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Replacement of the rigid 1,4-phenylenediamine linker in 168 and 180 with piperazine 
(181 and 182) and 1,2-diaminocyclohexane linkers (183 and 184) also resulted in a 
substantial decrease in inhibitory activity, suggesting that precise positioning of the 
terminal group is necessary for optimal interactions with GlmU uridyltransferase 
active site residues. Piperazine-linked inhibitor 181 bearing a terminal phenyl ring 
only exhibited 14% inhibition at 50 µM compared to 44% inhibition at 50 µM for 168 
(Table 10). Similar to the observation in the 1,4-phenylenediamine series, 
replacement of the phenyl moiety in 181 with cyclohexane in 182 led to a further 
decrease in enzyme inhibition. This decrease was even more pronounced in the  
1,2-diaminocyclohexane-linked compounds 183 and 184 in which no inhibition of 
GlmU uridyltransferase activity was observed at 50 µM (Table 10). This result 
suggests that 1,4-substitution of the linker unit is important for optimal activity. 
5.8.3 Second-generation aminoquinazoline-based inhibitors 
5.8.3.1 Design and synthesis 
Given the superiority of the rigid 1,4-phenylenediamine linker over more flexible 
linkers, this feature was retained in a second-generation series of GlmU 
uridyltransferase inhibitors. In order to identify the optimal terminal group for the  
1,4-phenylenediamine linked inhibitors, a large range of aryl moieties with varied 
electronic and steric properties were incorporated via the SNAr route previously used 
for the synthesis of compound 187 with an unsubstituted pyrrolidine terminal group.  
The synthesis of second-generation aminoquinazoline inhibitors via the SNAr route 
required the preparation of a range of 4-amino-carboxamide fragments. While  
HATU-mediated amide coupling between 1,4-phenylenediamine and a range of 
carboxylic acids worked well in the majority of cases (190-195, Scheme 40A), this 
procedure failed to deliver fragments 196-198 (Scheme 40B). In these cases, the 
desired products were not formed and the nature of by-products varied with the 
substitution of hydroxyl group on the terminal phenyl ring. Specifically, amide 
coupling between 1,4-phenylenediamine and 4-hydroxybenzoic acid gave unreacted 
starting materials after 3 h at room temperature (Scheme 40B), while under the 
similar reaction conditions, with 2-hydroxybenzoic acid, a mixture of the starting acid 
and a by-product with a molecular weight of 349 g mol-1 was found. This molecular 
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weight either corresponded to a di-substituted carboxamide (199, Scheme 40B) or  
4-amino-carboxamide with a phenyl 2-hydroxybenzoate terminal group appended 
(200, Scheme 40B). For 3-hydroxybenzoic acid, a guanylated carboxamide (201, 
Scheme 40B) was identified by liquid chromatography-mass spectrometry (LC-MS). 
Although there was no literature precedent at the time for amide coupling of  
4-hydroxybenzoic acid with any anilines, successful amide couplings with various 
anilines via acid chloride formation of silyl protected 3,4,5-trihydroxybenzoic acid 
existed.[122] As such, the hydroxyl group of 4-hydroxybenzoic acid was protected as a 
TBS ether using a two step literature procedure to afford acid 202.[122b] Treatment of 
202 with oxalyl chloride in dichloromethane in the presence of catalytic DMF 
afforded the corresponding acid chloride 203, which was subsequently reacted with 
1,4-phenylenediamine to obtain carboxamide fragment 204 in 63% yield (Scheme 
41A). In the case of 2-hydroxybenzoic acid, previous examples in the literature for 
amide couplings have been reported via the corresponding acid chloride.[123] Different 
reagents to effect acid chloride formation such as thionyl chloride and Ghosez’s 
reagent[124] were explored. Gratifyingly, by using Ghosez’s reagent[124], the desired 
acid chloride of 2-hydroxybenzoic acid (205) was successfully synthesized and 
coupled to 1,4-phenylenediamine to give the corresponding carboxamide fragment 
196 in 20% yield after HPLC purification (Scheme 41B). 
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Scheme 40. A: Synthesis of carboxamide fragments 190-195. Reagents and conditions: a) 
RCO2H, HATU, iPr2NEt, CH2Cl2, rt, 1 h, 29-98%; B: Attempted synthesis of carboxamide 
fragments 196-198 and by-products formation. Reagents and conditions: b) R1CO2H, HATU, 
iPr2NEt, CH2Cl2, rt, 1-3 h.  
Although carboxamide fragments 196 and 204 were successfully obtained by 
activation of the relevant hydroxybenzoic acids as the acid chlorides, amide coupling 
using coupling reagents appeared more appealing as acid activation and amide bond 
formation could occur in one pot. As such, amide coupling using HATU was  
re-visited for 3-hydroxybenzoic acid. As previously mentioned, in the first attempt of 
this reaction, a guanylated carboxamide formed instead of the desired product. 
Guanylation of a free amino group in amide coupling reactions with HATU indicates 
slow activation of the carboxylic acid, allowing the free amine to effectively compete 
and react with the coupling reagent. To circumvent this problem,  
3-hydroxybenzoic acid was preactivated with HATU and  
N,N-diisopropylethylamine for 10 minutes, allowing sufficient time for the formation 
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of the active ester to reach completion. The 1,4-phenylenediamine was subsequently 
added and gratifyingly, on this occasion, the desired carboxamide 197 was formed as 
the sole product in 65% yield (Scheme 41C).  
 
Scheme 41. Synthesis of carboxamide fragments 196, 197 and 204. Reagents and conditions: 
a) (COCl)2, CH2Cl2, cat. DMF, 0 oC to rt, 2 h; b) 1,4-phenylenediamine, Et3N, THF, 0 oC to 
rt, 16 h, 63%; c) Ghosez’s reagent, MeCN, rt, 2.5 h; d) 1,4-phenylenediamine, Et3N, THF,  
0 oC to rt, 16 h, 20% over two steps; e) 1. HATU, iPr2NEt, CH2Cl2, rt, 10 min,  
2. 1,4-phenylenediamine, rt, 1 h, 65%.  
With the required 4-aminocarboxamide fragments in hand, aminoquinazoline-based 
inhibitors were subsequently prepared using the established SNAr route (Scheme 
42A). It is important to note that compounds 210 and 216 were obtained from the 
reduction of 209 and 215 by catalytic hydrogenation (Scheme 42B) while 
deprotection of the silyl group in 211P using TBAF afforded  compound 211 in 51% 
yield (Scheme 42C).  
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Scheme 42. Synthesis of aminoquinazoline-based inhibitors 206-216. Reagents and 
conditions: a) 190-197 or 204, 2-propanol, 120 oC, 5 h, 29-98%; b) 210: 10% Pd/C, H2  
(1 atm), EtOAc, rt, 16 h, 29%, 216: 10% Pd/C, H2 (1 atm), MeOH, rt, 24 h, 30%; c) TBAF, 
THF, rt, 1 h, 51%. 
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5.8.3.2 Evaluation of second-generation aminoquinazoline inhibitors 
Firstly, the effect of the terminal group on inhibition of GlmU uridyltransferase 
activity was investigated via screening inhibitors against the enzyme in the assay 
developed previously (section 5.3 and 7.2.2). In a co-crystal structure of H. influenzae 
GlmU, the terminal benzamide group of 169 clearly occupies a lipophilic pocket 
adjacent to the GlcNAc binding subsite. However, the homologous residues in the 
predicted lipophilic pocket of the M. tuberculosis enzyme (V229-V235, V139-T143 
and V180-A182) do not exhibit high sequence homology to those in H. influenzae 
GlmU (A217-V223, L143-147 and V168-T170). As such, the interactions made with 
the lipophilic pocket of M. tuberculosis GlmU were probed by incorporating a range 
of substituents of varied steric bulk and electronics as the terminal moiety. 
Initial studies incorporating hydrophobic aryl/heteroaryl moieties resulted in 
compounds with low solubility under the enzyme assay conditions (compounds not 
presented here). However, 4-fluorophenylisoxazole-based inhibitor 206 could be 
solubilized to a concentration of 50 µM and this modification resulted in a two-fold 
decrease in potency compared to 168. This suggests that sterically bulky terminal aryl 
moiety is not well accommodated in the lipophilic pocket of M. tuberculosis GlmU. 
Substitution of the terminal phenyl ring in 168 with pyrazine in 207 resulted in 
reduced potency against GlmU uridyltransferase (207: 19% at 50 µM vs 168: 44% at 
50 µM) as did the introduction of a range of both electron-donating and electron-
withdrawing ortho and para substituents into the terminal phenyl ring in 208-212  
(13-21% at 50 µM). However, substitution at the meta position of the terminal phenyl 
ring was well tolerated with inhibitors bearing m-hydroxyphenyl 213 and  
m-methoxyphenyl 214 moieties showing similar potency to to lead compound 168 
with 38% and 35% inhibition at 50 µM, respectively. In contrast to the vast majority 
of inhibitors synthesized in this study, for compound 213, the solubility at high 
concentrations in the assay conditions allowed for the determination of IC50 value 
(1% DMSO in water, IC50 = 74 ± 1 µM). Introduction of other meta substituents such 
as nitro and amino groups (compounds 215 and 216 respectively) into the terminal 
phenyl ring of 168 led to diminished inhibitory activity. 
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Table 11. Inhibition of uridyltransferase activity of M. tuberculosis GlmU by 
aminoquinazoline inhibitors with varied terminal aryl groups. 
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5.8.3.3 Derivatization of compound 213 
Given that compound 213 bearing the m-hydroxylphenyl moiety was equipotent to 
lead compound 168, the tolerance of the GlmU binding site to larger substituents was 
next probed. To this end, cyanomethyl and carboxymethyl groups were appended to 
the m-hydroxyl of 213, to investigate the possibility of hydrogen bonding and ionic 
interactions in this region. Both 217 and 218 were synthesized from 213. Specifically, 
treatment of 213 with bromoacetonitrile in the presence of cesium carbonate as the 
base in acetonitrile at 80 oC afforded 217 in 55% yield (Scheme 43). Reaction of 213 
with tert-butyl bromoacetate in the presence of cesium carbonate at 50 oC gave 
compound 219 (Scheme 43). The lower temperature used in this case (50 oC) was 
necessary to suppress the formation of a side product which arose from further 
reaction of the secondary amine of 219 with tert-butyl bromoacetate to form the  
N-carboxymethylated product. Deprotection of the tert-butyl ester was achieved using 
TFA (TFA: CH2Cl2, 1:1 v/v) to obtain compound 218 in 14% yield over two steps 
(Scheme 43). 
With compounds 217 and 218 in hand, the inhibitory activity against GlmU 
uridyltransferase was evaluated using the enzyme assay developed previously (section 
5.3 and 7.2.2). Surprising, compound 217 bearing a cyanomethyl group exhibited no 
inhibition at 50 µM while 218 possessing a carboxymethyl group was equipotent to 
unfunctionalized inhibitor 213. In the absence of an enzyme-inhibitor, it is difficult to 
rationalize the differing activity of these two compounds. 
 
Scheme 43. Synthesis of cyanomethyl and carboxymethyl compounds 217 and 218. Reagents 
and conditions: a) 217: Bromoacetonitrile (1.1 eq.), Cs2CO3 (2.5 eq.), MeCN,  
80 oC, 1 h, 55%; 218: tert-butyl bromoacetate (1.3 eq.), Cs2CO3 (2.6 eq.), MeCN, 50 oC, 3 h; 
b) TFA: CH2Cl2 (1:1 v/v), 16 h, rt, 14% over two steps. 
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5.8.3.4 Importance of the 6,7-dimethoxyquinazoline moiety 
Having established m-hydroxylphenyl as a suitable terminal group (on the basis of the 
potency and solubility profile), attention turned to modification of the two methoxy 
substituents on the quinazoline ring. To this end, inhibitors 220 and 221, in which the  
6,7-dimethoxyquinazoline moiety in 213 was replaced by thienopyrimidine (220) and 
5,6,7,8-tetrahydroquinazoline (221) moieties, were synthesized via SNAr reactions 
with chloroquinazolines 222 and 223 (Scheme 44B). Compound 223 was in turn 
synthesized from ethyl 2-cyclohexanone carboxylate 224. Condensation with 
trimethyl orthoformate and ammonium acetate gave the corresponding quinazolone 
225 which was chlorinated using phosphorus(V) oxychloride to afford 
chloroquinazoline 223 (Scheme 44A). Compound 220 exhibited comparable 
inhibitory activity against GlmU uridyltransferase activity as 213 (220: 38% 
compared to 213: 35% inhibition at 50 µM, Table 11 and Table 12). Inhibitor 221, 
bearing a cyclohexyl ring was slightly less potent (221: 29% inhibition at 50 µM, 
Table 11 and Table 12). While preliminary, the above results indicate that although 
the methoxy groups were not essential for inhibition of GlmU uridyltransferase, the 
planarity of the quinazoline ring may contribute to the binding of inhibitors to the 
active site of the uridyltransferase domain of GlmU. These results are in stark contrast 
with those obtained for the H. influenzae enzyme by Larsen et al.[120] Specifically, the 
co-crystal structure of the aminoquinazoline-based inhibitor 169 bound to  
H. influenzae GlmU uridyltransferase revealed an important hydrogen bonding 
interaction between the C-7 hydroxyl of the quinazoline ring with the amide backbone 
of an alanine residue (A13 in H. influenzae GlmU uridyltransferase). It was proposed 
that this hydrogen bonding interaction mimics the interaction made by the C-2 
carbonyl of the uridine moiety in the substrate (UTP). In light of the above results, it 
is therefore possible that the aminoquinazoline inhibitors synthesized here exhibit 
different binding modes to M. tuberculosis GlmU compared to the H. influenzae 
GlmU homologue. These results also offer the possibility of further structural 
modifications in future inhibition studies. 
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Scheme 44. Synthesis of 220, 221 and 226. Reagents and conditions: A. a) CH(OMe)3, 
NH4OAc, MeOH, 141 oC, 3 h; b) POCl3, 110 oC, 4 h, 74% over two steps. B. c) 220: 197, 
222, 2-propanol, 141 oC, 5 h, 28%, 221: 197, 223, 2-propanol, 141 oC, 5 h, 70%. C.  
d) 4-aminobenzoic acid, 2-propanol, 141 oC, 5 h, 50%; e) 3-aminophenol, HATU, iPr2NEt, 
DMF, rt, 16 h, 50%.  
At this point, the arrangement of hydrogen bond donor and acceptor moieties in the 
amide linker that bridges the central motif with the terminal groups was investigated. 
This therefore prompted the preparation of compound 226 with a reverse amide 
linker. It was envisaged that 226 could be obtained in a similar manner to 220 and 
221. However, the synthesis of corresponding carboxamide fragment was 
problematic. As such, 226 was synthesized in a similar manner to the first-generation 
aminoquinazoline inhibitors via an amide coupling between intermediate 227 and  
3-aminophenol (Scheme 44C). Surprisingly, compound 226 showed a remarkable 
decrease in inhibition of GlmU (226: 7% at 50 µM, 213: 35% at 50 µM, Table 11 and 
Table 12), suggesting that the alignment of hydrogen bond donors and acceptors in 
the amide linker region may be important for inhibition of the enzyme. 
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Table 12. Inhibition of uridyltransferase activity of M. tuberculosis GlmU by inhibitors with 
variation in the aminoquinazoline core or central amide linker. 
 
Compound R L % Inhibition  
at 50 µM 
220 
  
38% 
221 
  
30% 
226 
 
 
7% 
 
5.8.4 Inhibition of M. tuberculosis (H37Rv) in vitro by aminoquinazoline-based 
inhibitors (conducted by Ms. Angel Pang, Centenary Institute, Sydney). 
The aminoquinazoline-based inhibitor library was also screened for activity against 
the virulent H37Rv strain of M. tuberculosis to assess the antitubercular activity of 
these compounds. These compounds were screened using the MABA readout 
discussed earlier (section 3.10).[64, 125] Unfortunately, most compounds did not possess 
significant anti-tubercular activity (MIC50s > 250 µM) with the exception of 
compounds 169 and 184 which exhibited MIC50 values of 200 µM.  
5.9 Conclusions and future work 
In summary, this chapter described the successful development of a continuous 
enzyme kinetic assay for M. tuberculosis GlmU uridyltransferase. The chapter also 
featured the design of inhibitors based on the substrates and putative transition state of 
the GlmU uridyltransferase reaction. Two classes of bi-substrate inhibitors based on 
aminothiazole and sulfonamide scaffolds were synthesized along with transition-state 
mimics. Unfortunately, these compounds proved to be poor inhibitors of  
M. tuberculosis GlmU uridyltransferase activity (Figure 46A). 
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Compounds based on luteolin that were designed to interact with the GlcNAc-1-P 
binding site were also targeted. Synthesis of structurally related analogues revealed 
the importance of hydrogen bond donor and acceptor groups in the right hand ring 
(Figure 46B). Further structural modifications were attempted, however, problems 
with protecting group removal meant that the synthesis of the desired compounds 
remained elusive and will therefore be subjected to modified synthetic efforts in the 
future. 
 
Figure 46. A: Bi-substrate and transition-state mimics as M. tuberculosis GlmU 
uridyltransferase inhibitors. B: Features of luteolin-based compounds necessary for inhibition 
of M. tuberculosis GlmU uridyltransferase. 
This chapter also outlined the successful synthesis of the first micromolar inhibitors 
of the uridyltransferase activity of M. tuberculosis GlmU based on an 
aminoquinazoline scaffold. Sequential evaluation of the role of the central linker, 
tolerability of GlmU uridyltransferase binding site towards different terminal groups 
and the importance of the 6,7-dimethoxyquinazoline moiety were carried out. These 
studies have led to the establishment of 1,4-phenylenediamine and m-hydroxyphenyl 
as the optimal linker and terminal group, respectively (Figure 47). It was also 
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demonstrated that the 6,7-dimethoxyquinazoline moiety of 213 could be replaced with 
a thiophene ring without adverse impact on inhibitory activity (Figure 47).  
 
Figure 47. Best inhibitors of M. tuberculosis GlmU uridyltransferase identified in this study. 
The aminoquinazoline-based inhibitors will serve as useful tools for enzyme  
co-crystallization studies that will provide important information on the interactions 
necessary for potent inhibition of M. tuberculosis GlmU uridyltransferase. The 
information obtained could then be used to guide the development of more potent 
GlmU uridyltransferase inhibitors. Apart from the aminoquinazoline scaffold, 
Urbaniak et al.[126] recently identified a micromolar oxindole-based inhibitor of 
Trypanosoma brucei GlmU uridyltransferase (Figure 48). Evaluation of the inhibitory 
activity of this compound against M. tuberculosis GlmU uridyltransferase, followed 
by co-crystallization studies will therefore also provide directions for the design and 
synthesis of more potent inhibitors in the future. 
 
Figure 48. Oxindole-based inhibitor of T. brucei GlmU uridyltransferase. 
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6.1 MraY: Structure and Mechanisms 
MraY (MurX in M. tuberculosis) is an integral membrane protein that catalyzes the 
first membrane-associated step in peptidoglycan biosynthesis. Specifically, MraY is 
responsible for the transfer of MurNAc pentapeptide from the cytoplasm onto 
undecaprenyl phosphate (C55-P, also known as bactoprenol phosphate), giving rise to 
the formation of undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide (Lipid I) 
(Scheme 45A).[93] MraY belongs to the polyprenyl-phosphate N-acetyl hexosamine-1-
phosphate transferase (PNPT) superfamily.  
 
 
 
 
 
 
Scheme 45. A: Reaction catalyzed by MraY. Ala: alanine, Glu: glutamate, A2pm: meso-
diaminopimelate; B: Topology of MraY- transmembrane loops are given numbers. Catalytic 
aspartate and histidine residues are shown in red and blue spheres respectively (numbering of 
residues in A. aeolicus); IH: interfacial helix; PB: periplasmic β hairpin and PH: periplasmic 
helix. 
According to sequence analysis and topology studies on S. aureus and E. coli 
orthologs, MraY possesses 10 transmembrane domains with the N and C-termini both 
located on the periplasmic side.[127] These observations are in agreement with a recent 
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crystal structure of MraY from A. aeolicus which also showed the presence of an 
interfacial helix (IH), a periplasmic β hairpin (PB), a periplasmic helix (PH) and five 
cytoplasmic loops (loop A to loop E) (Scheme 45B).[92] Mutagenesis experiments in 
Bacillus subtilis demonstrated that there are 19 invariant polar/charged amino acid 
residues that are essential to the activity of MraY.[127] It was also established that 
MraY is an Mg2+-dependent enzyme.[127] Subsequent mutagenesis studies in  
A. aeolicus found that at least three aspartate residues and one histidine residue in the 
active site are necessary for catalysis.[92] The reaction catalyzed by MraY is proposed 
to go via either a two-step catalytic mechanism, whereby an aspartate residue acts as 
the nucleophile (Scheme 46A) or via a one step direct attack of phosphate anion of  
C55-P (generated from deprotonation of C55-P with the side chain of an aspartate 
residue) onto the β-phosphate of UDP-MurNAc-pentapeptide (Scheme 46B).[127]  
 
Scheme 46. A: Hypothetical two-step catalytic mechanism of MraY. B: Hypothetical one step 
catalytic mechanism of MraY. 
As MraY exhibits sequence similarity to the Mg2+-binding motif (DDXXD/N) present 
in prenyl transferases, it was assumed that the Mg2+ in MraY is co-ordinated by two 
essential, consecutive aspartate residues (D117 and D118 in A. aeolicus MraY, 
Scheme 45B).[128] Recent studies have challenged this assumption and particularly, as 
observed in the crystal structure of MraY from A. aeolicus, Mg2+ appeared to interact 
directly with the other aspartate residue in the aspartate triad (D265 in A. aeolicus 
MraY, Scheme 45B).[92, 127]  
Given the importance of the peptidoglycan layer to the survival of M. tuberculosis, 
disruption of its formation via inhibition of MraY, a key enzyme in the peptidoglycan 
biosynthetic pathway, represents an exciting avenue for the development of new 
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antibacterial agents that operate by a novel mode of action. Although MraY has not 
been targeted clinically, there has been considerable interest in the development of 
MraY inhibitors as novel antibacterial agents. Indeed, SQ641, a semi-synthetic 
analogue of capuramycin, that is proposed to target MraY is currently in pre-clinical 
development.[129] 
6.2 Nucleoside antibiotics: liposidomycins, caprazamycins, capuramycins 
and muraymycins 
6.2.1  Liposidomycins and caprazamycins 
Liposidomycins were identified as peptidoglycan biosynthetic inhibitors of E. coli by 
Isono et al.[130] in 1985. Liposidomycins contain a diazepanone moiety, an 
aminoribose unit and significant lipid substitution (Figure 49A).[131] Caprazamycins 
were isolated from the fermentation broth of Streptomyces sp. MK730-62F2 and 
possess similar structure to the liposidomycins (Figure 49B). These natural products 
derive their complex structures from 5’-(β-O-aminoribosyl)-glycyluridine and possess 
a unique N-methyldiazepanone ring.[93] Although many caprazamycins are active 
against both gram-positive bacteria and mycobacteria, only caprazamycin B exhibits 
bactericidal activity against mycobacteria (MIC: 3-50 µg/mL).[132] Caprazamycins can 
be hydrolyzed under acidic conditions to yield caprazene which has a more narrow 
spectrum of antibacterial activity (confined to mycobacteria).[133] An analogue of 
caprazene, caprazene-4-butylanilide (CPZEN-45) is currently in pre-clinical 
development (Figure 49B) and has demonstrated efficacy against both drug sensitive 
and extensively drug resistant mouse models of acute TB.[133] The compound 
possesses higher water solubility and metabolic stability compared to the 
caprazamycins and exhibits no cytotoxicity observed to date.[133] 
Caprazamycins are known to target MraY and therefore disrupt the biosynthesis of 
peptidoglycan, a key component in bacterial cell wall.[132] As such, inhibitors of MraY 
are usually expected to be broad-spectrum antibiotics. The more narrow spectrum 
activity of CPZEN-45 suggests that this compound may act via a different mode of 
action.[133] Indeed, it was recently demonstrated through the generation of 
spontaneous drug resistant mutants followed by whole genome sequencing that 
CPZEN-45 targeted WecA, a polyprenyl-phosphate-GlcNAc-1-phosphate transferase, 
which is involved in the biosynthesis of mycolylarabinogalactan.[133] Unlike MraY 
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which is a strictly bacterial enzyme, the reaction catalyzed by WecA is conserved in 
eukaryotes.[134] 
 
Figure 49. Structures of liposidomycins, caprazamycin B and CPZEN-45. 
6.2.2 Capuramycin 
Capuramycin is produced by Streptomyces griseus 446-S3 and was first identified in 
the 1980s.[135] Capuramycin contains a uracil nucleoside and a caprolactam and 
exhibits antibacterial activity against Streptococcus pneumoniae (MIC 12.5 µg/mL) 
and M. smegmatis (MIC 3.1µg/mL).[136] This natural product was isolated again in 
2003 by investigators at Sankyo (now Daiichi Sankyo, Japan) along with a number of 
new derivatives including the methylated derivative of capuramycin (SQ997, Figure 
50) and this time it was demonstrated that the molecular target of capuramycin is 
MraY (IC50 = 18 nM).[137]  
The isolation of new capuramycin derivatives allowed for evaluation of the 
importance of caprolactam for activity (both against MraY and whole-cell bacteria). 
This had prompted the generation of capuramycin analogues via a semi-synthesis 
approach. More than 7000 analogues of capuramycin and SQ997 were synthesized by 
Sankyo and through these studies, compounds such as SQ922 and SQ641 with better 
antimycobacterial properties were identified (Figure 50).[138] Sequella has licensed the 
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above compound library from Daiichi Sankyo and is now involved in the 
development and commercialization of SQ641, the most potent semi-synthetic 
analogue of capuramycin. SQ641 exhibited excellent in vitro activity against  
M. tuberculosis (1 µg/mL) and Mycobacterium avium complex (0.016-16 µg/mL).[139] 
This compound killed M. tuberculosis at a faster rate than any existing TB drug and 
was shown to possess post-antibiotic effects up to 55 h.[139] SQ641 is active against 
MDR M. tuberculosis strains and is efficacious in preventing the development of drug 
resistant mutants in M. tuberculosis.[139] SQ641 is currently in preclinical 
development with ongoing efforts by Sequella investigators aimed at improving in 
vivo activity as well as intracellular activity against M. tuberculosis by engineering 
novel delivery vehicles such as micellar and phospholipid-based nanoemulsion 
formulations.[140] 
 
Figure 50. Capuramycin and analogues. 
6.2.3 Muraymycins 
Muraymycins, which were isolated from the culture broth of Streptomyces sp. in 2002 
are peptide conjugates of glycosylated uronic acid (Figure 51A).[141] Muraymycins 
were shown to inhibit MraY and demonstrated good antibacterial activity against  
Gram-positive organisms such as S. aureus and Enterococci.[141] The best compound, 
muraymycin A1 protected mice against S. aureus infection at ED50 of 1.1 mg/kg.[141] 
Important SARs were obtained through the synthesis of simplified synthetic 
analogues. Firstly, a free amino group at the C-5” position of the aminoribose was 
necessary for MraY activity.[142] It was later proposed by Tanino et al.[134] that this 
amino group (protonated at physiological pH) interacts via salt-bridge interactions 
with highly conserved aspartate residues located on a cytoplasmic loop. Secondly, the 
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epi-capreomycidine-urea-valine moiety was an important structural element for MraY 
inhibition as the removal of this moiety led to less active compounds.[134] Finally, 
muraymycin analogues containing the leucine moiety in the L-configuration were 
more active against MraY than the corresponding epimer.[134]  
 
Figure 51. A: General structure of muraymycins with various R groups. B: Simplified 
muraymycin analogue via Ugi multicomponent condensation. 
Tanino et al.[134] assembled a library of muraymycin analogues using the Ugi 
multicomponent condensation to introduce lipophilic substituents in the place of the 
leucine residue in muraymycin. The authors demonstrated that these lipophilic 
moieties did not contribute to binding to MraY as synthetic lipophilic muraymycin 
analogues exhibited less potent inhibition of MraY. Instead, owing to increased 
lipophilicity, the incorporation of these moieties resulted in improved antibacterial 
activity.[134] Also in the same study, Tanino et al.[134] discovered that simplification of 
the core structure of muraymycin could be carried out without negative impact on 
antibacterial activity. For example, muraymycin analogue 228 (Figure 50B) exhibited 
good activity against methicillin-resistant S. aureus (MIC = 8 µg/mL) and 
vancomycin-resistant Enterococcus (MIC = 4 µg/mL).[134] Another possible  
contributing factor to the improved antibacterial activity of lipophilic muraymycin 
analogues was non-specific membrane disruption resulting from detergent-like 
properties of these compounds. 
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6.2.4 Uridylpeptide antibiotics 
Table 13. Structures of mureidomycins, pacidamycins, napsamycins and sansanmycins. NB: 
AA3 and AA4 denote side chains of respective amino acids and R2 represents amino acid 
residues. 
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N
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NMe
R2
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N
AA4
HO2C
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OH
NH
O
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Bicyclic 1
Bicyclic 2
NH
O
HO
Bicyclic 3
R2 =
R2 =
NH
O
HO
Bicyclic 4
R2 =
Name R1 R2 AA3 AA4 Other 
Mureidomycin A/ 
Sansanmycin D 
 
  H m-Tyr Met m-Tyr  
Mureidomycin B   H m-Tyr Met m-Tyr Dihydrouracil 
Mureidomycin C Gly m-Tyr Met m-Tyr  
Mureidomycin D Gly m-Tyr Met m-Tyr Dihydrouracil 
Pacidamycin 1 Ala Trp Ala Trp  
Pacidamycin 2 Ala m-Tyr Ala Phe  
Pacidamycin 3 Ala m-Tyr Ala Trp  
Pacidamycin 4 H m-Tyr Ala Trp  
Pacidamycin 4N H Bicyclic 1 Ala Trp  
Pacidamycin 5 H m-Tyr Ala Phe  
Pacidamycin 5T H m-Tyr Ala Trp  
Pacidamycin 6 Gly m-Tyr Ala Trp  
Pacidamycin 7 Gly m-Tyr Ala Phe  
Pacidamycin D H Ala Ala Trp  
Napsamycin A H Bicyclic 2 Met m-Tyr  
Napsamycin B H Bicyclic 
3 
Met m-Tyr  
Napsamycin C H Bicyclic 
2 
Met m-Tyr Dihydrouracil 
Napsamycin D H Bicyclic 
3 
Met m-Tyr Dihydrouracil 
Sansanmycin A H m-Tyr Met Trp  
Sansanmycin B H m-Tyr Leu Trp  
Sansanmycin C H m-Tyr MetSO Trp  
Sansanmycin E H m-Tyr MetSO m-Tyr  
Sansanmycin F H Bicyclic 
4 
Met Trp  
Sansanmycin G H Bicyclic 
4 
Leu Trp  
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MraY has been proposed as the enzymatic target for nucleoside natural products such 
as caprazamycins as well as uridylpeptide antibiotics such as pacidamycins, 
muraymycins and mureidomycins.[93] Uridylpeptide antibiotics encompass a class of 
structurally related compounds which possess a 3’-deoxyuridine attached to  
N-methyl-2,3-diaminobutyric acid (DABA) via a 4’,5’-enamide linkage.[93] The next 
amino acid connected to the α-nitrogen of DABA is either a methionine (as in the 
mureidomycins and sansanmycins) or alanine (the pacidamycins). Methionine or 
alanine are connected via a urea linkage to a C-terminal aromatic acid such as meta-
tyrosine (in mureidomycins and napsamycins) and tryptophan (pacidamycins and 
sansanmycins).[93]  
6.2.4.1 Pacidamycins 
The pacidamycins 1-7 (Table 13) were isolated in 1989 from Streptomyces 
coeruleorubidus AB 1183F-64.[143] These natural products exhibited antibacterial 
activity against P. aeruginosa (MICs: 4-16 µg/mL) in vitro but failed to protect mice 
against P. aeruginosa infection.[143b] Additional pacidamycins (D, 4N and 5T) were 
later isolated from S. coeruleorubidus NRRL 18730 exhibiting similar antibacterial 
profile as pacidamycins 1-7.[144] The absolute stereochemistry for all amino acids in 
pacidamycin D was determined to be L (or S) for all natural amino acids and (S,S) for 
the DABA fragment.[145] This formed the basis for assignment of configuration of 
amino acids in other uridylpeptide antibiotics.  
6.2.4.2 Mureidomycins 
Mureidomycins A-D were isolated from Streptomyces flavidoviridens SANK 60486 
in 1989.[146] These uridylpeptide antibiotics showed potent antibacterial activity 
against P. aeruginosa (MICs: 1.5-12.5 µg/mL) and protected mice against  
P. aeruginosa infection (ED50 for Mrd A-D: 69, 75, 50 and > 100 mg/kg).[146] 
Mureidomycins were shown to be selective inhibitors of bacterial MraY.[147]  
6.2.4.3 Napsamycins 
Napsamycins A-D were isolated from Streptomyces spp. HIL Y-82 in 1994. They 
possess similar structures to the mureidomycins with the exception of bicyclic amino 
acids in place of meta-tyrosine in mureidomycins (Table 13).[148] They exhibited 
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similar anti-pseudomonal activity to the mureidomycins and pacidamycins (MICs: 
6.2-50 µg/mL).[148]  
6.2.4.4 Sansanmycins 
Sansanmycins A-C and E-G (Table 13) were isolated in the period between 2007 and 
2010 by Xie et al. from Streptomyces sp. SS.[149] Similar to previously isolated 
uridylpeptide antibiotics, sansanmycins showed anti-pseudomonal activity  
(MICs: 4-16 µg/mL) while sansanmycins A and B were reported to show promising 
activity against a range of M. tuberculosis strains (including MDR M. tuberculosis 
strains).[149b] Sansanmycin D was also isolated but was subsequently revealed to be 
identical to mureidomycin A.  
6.2.4.5 Mechanisms of inhibition of uridylpeptide antibiotics 
The antibacterial activity of uridylpeptide antibiotics has been attributed to the 
inhibition of MraY by this class of compounds. It was previously demonstrated in 
inhibition studies against solubilized E. coli MraY that mureidomycin A exhibited 
time-dependent, slow-binding and competitive inhibition (Ki = 35 nM) with respect to 
UDP-MurNAc pentapeptide and C55-phosphate.[150]  
It was proposed that the primary amino group of mureidomycin A (protonated at 
physiological pH) might displace the catalytically essential Mg2+ from the active site 
of MraY and may engage in salt-bridge interactions with two highly conserved 
aspartate residues (Figure 52).[151] Given the structural similarity of mureidomycin A 
with the other uridylpeptide antibiotics, it is possible that the potential binding modes 
for the other uridylpeptides are similar.  
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Figure 52. A: Proposed binding of UDP-MurNAc pentapeptide to the active site of MraY 
(amino acid numbering in E. coli); B: Proposed binding mode of mureidomycin A to the 
active site of MraY (amino acid numbering in E. coli).  
6.2.4.6 Dihydrosansanmycin analogues: preliminary results against  
M. tuberculosis H37Rv in vitro 
Given the therapeutic potential of uridylpeptide antibiotics and in particular the 
inhibition of M. tuberculosis by the sansanmycins, our research group has recently 
become interested in this class of compounds, initially from a total synthesis 
viewpoint. During the studies towards the total synthesis of sansanmycins, promising 
antitubercular activity by a number of dihydrosansanmycin analogues (in which the 
cis-4’,5’-enamide linkage in sansanmycins is replaced by an amide moiety) was 
discovered (Table 14).[152]   
Preliminary SARs had been obtained through the synthesis of a focused library of 
dihydrosansanmycin analogues. Firstly, the stereochemistry at the C-4’ position of 
uridine played a critical role in inhibition of M. tuberculosis growth  
(233-R stereoisomer: MIC50 = 8 µM to 234-S stereochemistry: MIC50 > 250 µM, 
Table 14) with R-stereochemistry significantly favoured over the corresponding  
S-stereochemistry. This phenomenon was also observed in a series of 
dihydropacidamycin analogues in which a dihydropacidamycin analogue with  
C-4’(R) stereoisomer (P. aeruginosa MIC = 32 µg/mL) was 16 times more potent 
than the corresponding 4’S-epimer (P. aeruginosa MIC = 512 µg/mL).[93]  
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Table 14. Inhibition of synthetic dihydrosansanmycin analogues 229-235 against  
M. tuberculosis H37Rv 
 
Compound R1 R2 R3 R4 C4’ 
(R/S) 
MIC50 
(µM) 
229 CH2-3-
indolyl 
(CH2)2-SMe CH2-3-
hydroxyphenyl 
H R 3.3 
230 CH2-3-
indolyl 
CH2-CH(CH3)2 CH2-3-
hydroxyphenyl 
H R 0.3 
231 CH2-3-
indolyl 
(CH2)2-S(O)Me CH2-3-
hydroxyphenyl 
H R 9.0 
232 CH2-3-
indolyl 
CH2-CH(CH3)2 CH2-4-
hydroxyphenyl 
H R 8.0 
233 Ph CH2-CH(CH3)2 CH2-4-
hydroxyphenyl 
H R 32 
234 Ph CH2-CH(CH3)2 CH2-4-
hydroxyphenyl 
H S > 250 
235 Ph CH2-CH(CH3)2 CH2-4-
hydroxyphenyl 
OH R > 250 
 
Secondly, replacement of the m-Tyr residue with the proteinogenic Tyr resulted in a 
significant reduction in antitubercular activity (230: MIC50 = 0.3 µM compared to  
232: MIC50 = 8 µM, Table 14). Thirdly, analogue 231 with an oxidized methionine 
side chain at R2 (231: MIC50 = 9 µM) was 4-fold less potent than 229 with a 
methionine side chain (229: MIC50 = 3.3 µM). Finally, replacement of the Trp (232: 
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MIC50 = 8 µM) side chain at R1 for that of Phe (233: MIC50 = 32 µM vs 232: MIC50 = 
8 µM) resulted in a 4-fold reduction in activity against M. tuberculosis. 
6.3 Design and synthetic strategy for dihydrosansanmycin analogues 
Given the promising anti-tubercular activity of the above dihydrosansanmycin 
analogues, further SAR exploration was undertaken with a view to define the features 
necessary for antibacterial, in particular, antitubercular activity. Although the 
molecular target of dihydrosansanmycin analogues is currently unknown, it is likely 
that these compounds target MraY in a similar manner as structurally similar 
mureidomycins. As such, it was hypothesized that the primary amino group of 
dihydrosansanmycin analogues displaces the Mg2+ co-factor and forms salt-bridge 
interactions with two catalytically important aspartate residues. Although other 
interactions also exist and contribute to the overall binding energetics to MraY, the 
above salt-bridge interactions may be the most important. In order to probe the 
importance of these interactions in dihydrosansanmycins, m-Tyr was substituted with 
various amino acids (Figure 53). Specifically, L-glycine was incorporated to 
determine the contribution of the 3-hydroxyphenyl moiety to MraY binding and 
antibacterial activity. Incorporation of L-threonine was to assess tolerance to the polar 
aliphatic side chain. Amino acids with acidic/basic side chains (i.e. L-aspartic acid,  
L-ornithine and L-lysine) were incorporated to gauge the importance of the proposed 
salt bridge interactions with the conserved aspartate residues on the cytoplasmic loop 
of MraY. The above modifications were proposed to be introduced on compound 230 
which possessed the best antitubercular activity (MIC50 = 0.3 µM) in the previous 
inhibition study within the Payne research group. As such, leucine and tryptophan 
side chains were retained as well as the stereochemistry at C-4’ of the uridine moiety. 
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Figure 53. Design of novel dihydrosansanmycin analogues. 
It was envisaged that a solid-phase approach would streamline the synthesis of the 
dihydrosansanmycin analogues proposed above. Specifically, it was envisioned that, 
starting from an acid-labile resin-bound uridylamine, Fmoc-solid phase synthesis 
(SPPS) could be employed to assemble fully protected dihydrosansanmycin analogues 
(Scheme 47). Global deprotection would also cleave the dihydrosansanmycin 
analogues from the resin to give the crude uridylpeptides that upon HPLC 
purification, would afford pure dihydrosansanmycin analogues in a rapid manner for 
biological evaluation (Scheme 47). 
 
Scheme 47. Proposed synthesis of dihydrosansanmycin analogues. 
 
 
N
H
H
N
O
N
O
H2N
OH
N
O
OH
N
NH
O
O
O
H
N
O
HO
R
HN
R = H
NH2
NH2
CO2H HO
O
O
N NH
O
O
FmocHN SPPS
H
N
Global 
acidic cleavageR, R2:  H
R2:
R:
N
H
H
N
O
N
O
BocHN
OH
N
R1
O
O
N
NH
O
O
O
H
N
O
O
R
BocN
N
H
H
N
O
N
O
H2N
OH
N
R1
O
OH
N
NH
O
O
O
H
N
O
R2
HN
HO
HO
HN
NH2
CO2H
NH2
PG
PG
O
O
PG
R1: various amino acid side chains
Chapter 6-Sansanmycin Analogues as TB Drug Leads 
 
 130 
6.4 Synthesis of uridylamine intermediate 236 
The synthesis of uridylamine 236 began with isopropylidene-protected uridine 
127[116]. Oxidation of the primary alcohol in 127 with Collins reagent (formed in situ 
from the reaction between chromium trioxide and pyridine) in the presence of excess  
tert-butanol and acetic anhydride gave tert-butyl ester 237 in 52% yield (Scheme 
48).[152] This reaction is likely to proceed via a hemiacetal 238 formed between the 
intermediate aldehyde 239 and tert-butanol (Scheme 48). This hemiacetal can 
subsequently be oxidized (at a faster rate than the intermediate aldehyde) to the 
corresponding tert-butyl ester 237 by Collins reagent.[153]  
 
Scheme 48. Proposed oxidative transformation of alcohol 127 to tert-butyl ester 237. 
De-oxygenation at C-3’ was achieved via an E1CB elimination of the tert-butyl ester 
237 by tert-butoxide in tert-butanol to give ester 240 in 70% yield, (Scheme 49).[145b] 
Subsequent protection of the free C-2’ alcohol with a triisopropylsilyl (TIPS) group 
by treatment of intermediate 240 with TIPS-triflate proceeded in 82% yield (Scheme 
49).[152] Installation of the desired R-stereochemistry at C-4’ was achieved by 
hydrogenation of intermediate 241. The sterically hindered TIPS group favoured 
hydrogen delivery to the β-face, potentially via a lower energy transition state in 
which pseudo-1,3-diaxial interaction between the tert-butyl ester and triisopropylsilyl 
group is minimized, giving rise to tert-butyl ester 242 with R-stereochemistry at C-4’ 
as a single diastereoisomer (Scheme 49). Selective removal of the tert-butyl group in 
the presence of the TIPS group was achieved by short treatment with 90% TFA in 
dichloromethane. The resulting carboxylic acid was activated as a mixed anhydride 
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upon treatment with isobutylchloroformate and N,N-diisopropylethylamine and the 
resulting anhydride was readily reduced by treatment with sodium borohydride in 
water to afford desired alcohol 243 in 69% yield.[145b] 
The desired alcohol 243 was subsequently activated as tosylate 244 which was 
displaced by sodium azide to install the nitrogen functionality at C-5’.[145b] Reduction 
of the azide moiety in 245 was achieved using catalytic hydrogenation to give amine 
246 in quantitative yield. Subsequent protection of the amine 246 as an Fmoc-
carbamate proceeded smoothly using Fmoc-chloride and sodium hydrogen carbonate 
in a mixture of dioxane and water to afford 247 in 93% yield. Efficient desilylation 
ensued under strongly acidic conditions (TFA: H2O, 9:1 v/v) to give uridylamine 236 
in 75% yield. 
 
Scheme 49. Synthesis of Fmoc-protected uridylamine 236. Reagents and conditions: a) (i) 
tert-butoxide, t-BuOH, rt, 15 min; (ii) Glacial AcOH, pH 7, 70%; b) TIPSOTf, iPr2NEt, 
DMF, rt, 2.5 h, 82%; c) 10% Pd/C, H2 (1 atm), MeOH, rt, 30 min, 80%; d) (i) TFA: CH2Cl2, 
(9:1 v/v), rt, 15 min; (ii) Isobutylchloroformate, iPr2NEt, THF, 0 oC to rt, 1.5 h; (iii) NaBH4, 
H2O (dropwise), 0 oC, 1 h, 69%; e) Tosyl chloride, pyridine, rt, 18 h, 82%; f) NaN3, DMF,  
75 oC, 4 h, 82%; g) 10% Pd/C, H2 (1 atm), MeOH, rt, 1.5 h, quant; h) Fmoc-Cl, 10% aq. 
Na2CO3, dioxane, 2 h, 0 oC and 1 h, rt, 93%; (i) TFA: H2O (9:1 v/v), rt, 6 h, 75%.  
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6.5 Solid phase synthesis of dihydrosansanmycin analogues 
6.5.1 Optimization of loading of uridylamine 236 onto PS-DES resin 
Selection of a suitable linker-functionalized resin was crucial to the successful  
solid-phase synthesis of the proposed dihydrosansanmycin analogues. Resins were 
evaluated according to stability to the basic conditions employed in Fmoc-SPPS and 
ease of cleavage under acidic conditions to ensure that the N-glycosidic linkage 
present in the dihydrosansanmycin analogues remained intact. After surveying a large 
range of commercially available linker-functionalized resins, PS-DES resin, a shelf-
stable, polymer-supported trialkylsilane, originally developed by Hu et al.[154] was 
selected. This resin was previously used in the Fmoc-solid phase synthesis of a 
thymidine dipeptide urea library by Sun et al.[155] The authors demonstrated that this 
resin could be cleaved under mild acidic conditions (15-20% TFA in CH2Cl2 at room 
temperature) in which the N-glycosidic linkage was stable.[155]  
 
Scheme 50. PS-DES resin activation and loading of Fmoc-protected uridylamine 236 onto the 
activated resin. Reagents and conditions: a) (i): PS-DES resin, CH2Cl2, 30 min, (ii) 1,3-
dichloro-5,5-dimethylhydantoin, CH2Cl2, 2 h, rt, b) Fmoc-protected uridylamine 236, 
imidazole, DMF, 4 h. 
Prior to the loading of uridylamine 236, it was necessary to activate PS-DES resin to 
the corresponding trialkylsilyl chloride. To this end, pre-swollen PS-DES resin was 
reacted with a chlorinating reagent, 1,3-dichloro-5,5-dimethyl hydantoin for 2 h at 
room temperature in dichloromethane to generate the moisture-sensitive, highly 
reactive silyl chloride derivative 248 (Scheme 50Error! Reference source not 
found.). The silyl chloride resin was immediately reacted with Fmoc-protected 
uridylamine 236 using imidazole as a base and nucleophilic catalyst in 
dimethylformamide for 4 h to give solid-anchored uridylamine 249 (Scheme 
50Error! Reference source not found.). The loading yield was subsequently 
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determined by measuring the UV absorbance of the dibenzofulvene-piperidine adduct 
formed during Fmoc-deprotection (with 10 vol.% piperidine in DMF) at λ = 301 nm. 
Using the optimized loading conditions reported by Sun et al.[155] which employed 3 
equivalents of Fmoc-protected uridylamine 236 and 3.5 equivalents of imidazole, 
only a moderate loading yield (40%) was obtained. Neither an increase in reaction 
time (up to 16 h) nor an increase in the amount of imidazole (4 equivalents) led to an 
improvement in loading efficiency and the synthesis was therefore continued.  
With the successful loading of Fmoc-protected uridylamine 236 onto activated  
PS-DES resin, the next stage of the project focused on developing an efficient 
coupling protocol for the assembly of dihydrosansanmycin analogues. It was 
envisaged that these analogues could be constructed via sequential coupling of 
commercially available as well as synthetic building blocks to the solid phase 
anchored uridylamine 249 (Scheme 51). In order to evaluate the robustness of various 
coupling protocols, 232, a derivative of dihydrosansanmycin B in which L-m-Tyr was 
replaced by the proteinogenic L-Tyr, was chosen as the target molecule as the latter is 
commercially available and amenable to large scale synthesis required for 
optimization studies. 
As indicated in Scheme 51, the assembly of proposed dihydrosansanmycin analogues 
229-232 and 250-254 required the synthesis of building blocks 255 and 256-263. It 
was envisaged that 255 could be obtained from the reaction between 4-nitrophenyl 
chloroformate (Scheme 51) and the amino terminus of a suitably protected tryptophan 
moiety. Dipeptide 256-262 could arise from amide coupling between Fmoc-protected 
diaminobutyric acid (DABA) 263 and various Boc-protected amino acids (Scheme 
51). Finally, it was proposed that diamino acid 263 could be synthesized from 
threonine-derived hydroxamic acid 264 via an intramolecular Mitsunobu reaction. 
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Scheme 51. Retrosynthetic analysis of dihydrosansanmycin analogues. 
6.5.2 Synthesis of tryptophan 4-nitrophenyl carbamate 255 
The synthesis of carbamate 255 began with commercially available  
Fmoc-L-Trp(Boc)-OH 265. Protection of the C-terminal carboxylic acid as a  
tert-butyl ester was achieved using tert-butanol, DIC as the coupling reagent and 
catalytic copper(I) chloride to afford 266 in 47% yield (Scheme 52).[156] Subsequent 
Fmoc deprotection using 20 vol.% piperidine in MeCN revealed the free amino group 
in 267 which was captured by 4-nitrophenyl chloroformate to afford tryptophan 4-
nitrophenyl carbamate 255 in 70% yield (Scheme 52).[152]  
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Scheme 52. Synthesis of tryptophan 4-nitrophenyl carbamate 255. Reagents and conditions: 
a) (i) CuCl, t-BuOH, DIC, 40 oC, 48 h; (ii) Fmoc-L-Trp(Boc)-OH, CH2Cl2, rt, 18 h, 47%; b) 
20 vol.% piperidine in MeCN, rt, 30 min, 85%; c) 4-nitrophenyl chloroformate, CH2Cl2, rt, 18 
h, 70%. 
6.5.3 Synthesis of diaminobutyric acid 263 
 
Scheme 53. Synthesis of diaminobutyric acid 263. Reagents and conditions: a) i. HBTU,  
O-benzyl hydroxylamine, MeCN, rt, 5 min, ii. iPr2NEt (added over 2 min), rt, 2 h, 70% ; b) 
DIAD, PPh3, THF, 0 oC to rt, 24 h, 67%; c) 1 M NaOH (added over 1 h), THF: H2O (1:1 v/v), 
rt, 1 h, 85%; d) i. NaBH3CN, MeOH, 0 oC, ii. Formaldehyde (added over 1 h), rt, 16 h, 97%; 
e) i. TFA: CH2Cl2 (1:1 v/v), rt, 30 min, ii. Fmoc-OSu, TFA: H2O (1.2:1 v/v), NaHCO3, 70% 
over two steps; f) Nanoparticle Zn, 2 M HCl, MeOH, rt, 16 h, 78%.  
Starting from commercially available Boc-L-Thr-OH 268, HBTU mediated coupling 
with O-benzyl-hydroxylamine afforded hydroxamic acid 264 in 70% yield  
(Scheme 53).[152] The subsequent intramolecular Mitsunobu reaction proceeded 
smoothly in the presence of diisopropyl azodicarboxylate (DIAD) and 
triphenylphosphine at room temperature to give lactam 269 in 78% yield (Scheme 
53).[157] Subsequent hydrolysis of lactam 269 by sodium hydroxide gave intermediate 
270 in 87% yield (Scheme 53). N-methylation was achieved by subjecting 270 to 
reductive amination conditions with formaldehyde and sodium cyanoborohydride as 
the reducing agent to afford 271 in 95% yield (Scheme 53).[152] This intermediate was 
then subjected to a two-step protecting group switch to install the Fmoc group, which 
is necessary for subsequent Fmoc-SPPS strategy. Specifically, deprotection of the 
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Boc group under acidic condition gave the free amine which was immediately reacted 
with Fmoc-succinimide to afford intermediate 272 in 70% yield (Scheme 53). 
Reduction of the O-benzyl-hydroxylamine moiety in 272 was achieved using 
nanoparticle zinc in aqueous hydrochloric acid (2 M) giving diaminobutyric acid 263 
in 78% yield (Scheme 53).[152] 
6.5.4 Synthesis of L-Boc-m-Tyr(OTBS)-OH 
L-m-Tyr-OH 273 was synthesized by Dr. Katie Cergol via enzymatic resolution of 
racemic m-Tyr.[158] Treatment of L-m-Tyr-OH 273 with di-tert-butyl dicarbonate in 
the presence of sodium hydrogen carbonate afforded tert-butyl carbamate 274 in 97% 
yield (Scheme 54). Subsequent silyl protection of the phenol side chain of 274 using 
tert-butyl dimethylsilyl chloride with triethylamine as a base at 45 oC proceeded in 
50% yield to furnish Boc-L-m-Tyr(OTBS)-OH 275 which was ready for amide 
coupling with diaminobutyric acid 263.  
 
Scheme 54. Synthesis of Boc-L-m-Tyr(OTBS)-OH  275. Reagents and conditions: a) (i)  
L-m-Tyr-OH 273, THF, saturated aq. NaHCO3 solution, (ii) Boc2O, rt, 16 h, 97%; b) TBS-Cl, 
Et3N, CH2Cl2, 45 oC, 16 h, 50%.  
6.5.5 Synthesis of dipeptide fragments 256-262 
With diaminobutyric acid 263 in hand, dipeptide fragments 256-262 were next 
targeted. To this end, a variety of Boc-protected amino acids 275-281 were allowed to 
stir with the coupling reagent HATU for 10 min at room temperature prior to the 
addition of diaminobutyric acid 263 and N-methylmorpholine (NMM) or  
N,N-diisopropylethylamine at 0 oC. The reactions were then allowed to stir at room 
temperature (2-6 h) to obtain dipeptides 256-261 in moderate yields (23%-61%, 
Scheme 55). While this coupling protocol was adequate for most amino acids, it was 
not effective for Boc-L-Thr-OH 281 as initial attempts to couple this amino acid to 
diaminobutyric acid 263 resulted in the recovery of both starting materials. It was 
hypothesized that the sterically hindered side chain of threonine slowed down the rate 
of the amide coupling. As such, addition of HOAt (10 eq. relative to HATU), an 
H2N CO2H
OH a
BocHN CO2H
OH b
BocHN CO2H
OTBS
273 274 275
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additive that is known to enhance the rate of amide coupling process (through a 
hydrogen bonding interaction between the ‘pyridine’ nitrogen of the HOAt active 
ester and the incoming amine[159]) resulted in the successful formation of dipeptide 
262 in 40% yield (Scheme 55). 
 
Scheme 55. Synthesis of dipeptide fragments 256-262. Reagents and conditions:  
a) (i) 275-280, HATU, DMF, 0 oC, 10 min; (ii) Diaminobutyric acid 263, NMM or iPr2NEt, 
DMF, 0 oC to rt, 3-6 h, 23-61%; b) (i) Boc-L-Thr-OH 281, HATU, HOAt, iPr2NEt, DMF,  
0 oC, 10 min; (ii) Diaminobutyric acid 263, iPr2NEt, DMF, 0 oC to rt, 3 h, 37%.  
6.5.6 Solid phase synthesis of dihydrosansanmycin analogues 
With dipeptides 256-262 in hand, attention was turned to the coupling of these 
dipeptide fragments to solid-phase anchored uridylamine 249. As discussed in section 
6.5.1, compound 232, a derivative of dihydrosansanmycin B in which the m-Tyr was 
replaced with the proteinogenic Tyr was selected as the targeted molecule for the 
evaluation of various amide coupling protocols. To this end, Fmoc-deprotection of 
uridylamine 249 revealed the free amine that was subsequently coupled to dipeptide 
257 employing PyBOP as the coupling reagent and NMM as base. After 1 h, LC-MS 
analysis revealed negligible product formation and primarily the presence of starting 
materials. In order to increase the efficiency of this amide coupling, a more reactive 
coupling reagent HATU was used along with HOAt as an additive. Although the 
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desired product was observed after 16 h, an unidentified by-product was also formed 
in significant amount. Eventually, it was discovered that pre-activation of dipeptide 
257 with PyBOP and NMM for 3 minutes prior to the addition of  
solid-phase anchored uridylamine led to clean product formation (282) after 16 h at 
room temperature (Scheme 56).  
 
Scheme 56. Solid phase synthesis of dihydrosansanmycin analogue 232. 
Having successfully coupled the first amino acid to the solid-phase anchored 
uridylamine 249, coupling of the next amino acid (Leu) following Fmoc-deprotection 
of 282 proved to be more straight forward. In this case, the coupling was finished 
after 1 h at room temperature to afford 283 (Scheme 56). Subsequent deprotection of 
the Fmoc-group of 283 was followed by reaction with tryptophan  
4-nitrophenyl carbamate 255 to give 284. At this stage, an acidic cocktail (90:5:5 
v/v/v TFA: H2O: iPr3SiH) was employed to facilitate both global deprotection and 
cleavage from the resin. Unfortunately, these conditions led to product decomposition 
(Entry 1, Table 15). It was found that decreasing the acidity of the cleavage solutions 
could suppress product decomposition (Entry 2, Table 15). In particular, in 10 vol.% 
TFA in CH2Cl2 over 16 h, conditions previously employed by Sun et al.[155] in their 
solid-phase synthesis of a thymidine-based library, complete global deprotection and 
resin cleavage was observed without discernible product decomposition (Entry 3, 
Table 15). However, these conditions also led to the formation of hydantoin  
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by-product (Figure 54) in appreciable amounts (the estimated ratio of desired product 
relative to hydantoin product was 3:1 ratio as judged by integrating the area under the 
LC-MS peak). The formation of a hydantoin by-product during acid cleavage was 
previously observed by Boeijen et al.[160] during their solid phase synthesis of 
oligourea peptidomimetics. Although the by-product could be separated from the 
desired dihydrosansanmycin analogue 232 by HPLC purification, by the virtue of its 
formation significantly hampered the yield of the final product.  
Table 15. Optimization of global deprotection and resin cleavage conditions. 
Entry Conditions Outcome 
1 90:5:5 (v/v/v)  
TFA: H2O: iPr3SiH 
rt, 2 h 
Decomposition 
2 50% TFA in CH2Cl2,  
2.5% iPr3SiH, rt, 0.5 h 
Product (232) + partly deprotected 
products 
3 10% TFA in CH2Cl2,  
2.5% iPr3SiH, rt, 16 h 
Product (232) + Hydantoin (285) 
(3:1) 
 
 
Figure 54. Structure of dihydrosansanmycin analogue 232 and hydantoin by-product 285. 
6.5.7 Synthesis of dihydrosansanmycin analogues via fragment condensation 
approach 
Given the problems encountered in the global deprotection and resin cleavage, focus 
was shifted to the assembly of dihydrosansanmycin analogues via a fragment 
condensation approach. This involved a late stage amide coupling between a range of 
fully protected depsipeptides 286-293 and uridylamine 294 in solution phase (Scheme 
57). The depsipeptides 286-293 could be synthesized via Fmoc-SPPS strategy from  
2-chlorotrityl chloride resin-bound dipeptides 256-262.  
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Scheme 57. Retrosynthesis of dihydrosansanmycin analogues via fragment condensation 
approach. 
6.5.7.1 Synthesis of depsipeptides 286-293 via Fmoc-SPPS strategy 
The synthesis of depsipeptides 286-293 began with loading of dipeptides 256-262 
onto 2-chlorotrityl chloride resin using N,N-diisopropylethylamine in 
dichloromethane (Scheme 58). Fmoc-deprotection with piperidine revealed the free 
amine that was poised for amide coupling with Fmoc-L-Leu-OH using PyBOP as the 
coupling reagent and NMM as the base. The resulting peptide was again subjected to 
treatment with piperidine in DMF to remove the N-terminal Fmoc group. The free 
amino group was captured with Trp nitrophenyl carbamate in the presence of  
N,N-diisopropylethylamine to furnish the desired urea linkage. Finally, acidolytic 
cleavage of the peptide from resin using hexafluoroisopropanol (HFIP) afforded 
desired depsipeptides 286-293 in 17-41% yield over the whole synthetic sequence 
(Scheme 58). 
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Compound R R1 Yield (%) 
286 CH2-3-(OTBS)-Ph (CH2)2-S(O)Me 26% 
287 CH2-3-(OTBS)-Ph CH2-CH(CH3)2 35% 
288 CH2-4-(OtBu)-Ph CH2-CH(CH3)2 41% 
289 H CH2-CH(CH3)2 27% 
290 (CH2)3-NHBoc CH2-CH(CH3)2 17% 
291 (CH2)4-NHBoc CH2-CH(CH3)2 22% 
292 CH2-CO2tBu CH2-CH(CH3)2 28% 
293 CH(CH3)-OH CH2-CH(CH3)2 21% 
Scheme 58. Synthesis of depsipeptides 286-293 via Fmoc-SPPS strategy. 
6.5.7.2 Optimization of solution phase amide coupling 
In order to obtain the uridylamine 294, required for late stage solution-phase amide 
coupling with depsipeptides 286-293, Fmoc-protected uridylamine 236 was subjected 
to treatment with piperidine in DMF to remove the Fmoc group (Scheme 59). The 
polar nature of uridylamine 294 allowed the extraction of this compound into the 
aqueous phase and simultaneous separation from the dibenzofulvene-piperidine 
adduct. This procedure gave the desired uridylamine 294 in quantitative yield 
(Scheme 59). 
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Scheme 59. Synthesis of uridylamine 294. 
While the fragment condensation approach allows for a more convergent synthesis of 
dihydrosansanmycin analogues, it is more prone to epimerization due to a high 
tendency for the peptide to form a chiral labile oxazolone species upon amino acid 
activation by a coupling reagent.[161] This problem would need to be addressed if a 
robust protocol for late stage solution-phase amide coupling were to be developed. 
To this end, a number of coupling conditions with variation in coupling agents, 
additives, bases and solvents were trialed in the synthesis of model 
dihydrosansanmycin analogue 295  (Table 16). It was anticipated that using PyBOP 
as a coupling reagent in the absence of any additive would lead to epimerization. 
Indeed, this appeared to be the case with 35% epimerization (determined by LC-MS 
analysis via integration of areas under the peak) (Entry 1, Table 16). Subsequently, 
conditions 2-4 were trialed. It is important to note that these three conditions were 
similar to the best conditions identified by Zhang et al.[162] for suppressing 
epimerization occurred during solid-phase peptide coupling with glycosylated amino 
acids. It was discovered that both conditions 2 and 4 gave rise to low degree of 
epimerization while conditions 3 with DCC and HOBt resulted in considerable 
epimerization for the model uridylpeptide 295 (Table 16).  Eventually, conditions 4 
were chosen using 2,4,6-trimethylpyridine (TMP) as a hindered, weaker base than 
N,N-diisopropylethylamine. TMP has been shown to be a superior base in 
epimerization-prone peptide couplings.[162-163] 
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Table 16. Coupling conditions trialed for the synthesis of dihydrosansanmycin analogue 295. 
NB: preactivation was not carried out for depsipeptide 288 in all conditions tested. * denotes 
the stereogenic centre undergoing epimerization. 
 
 
Conditions 4 were subsequently applied to the synthesis of dihydrosansanmycin 
analogues 296-298 (glycine, m-Tyr and aspartic acid). However, unlike the model 
system, considerably higher degrees of epimerization (8-23%, Scheme 60) were 
observed. As a result of this epimerization, it was necessary to purify the fully 
protected dihydrosansanmycin 297 via HPLC prior to global deprotection. This 
contributed to a low isolation yield (20%) for 230. 
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Entry Coupling Conditions % epimerization 
1 PyBOP (1 eq.), depsipeptide 288 (1 eq.), 
uridylamine 294 (2 eq.), NMM (5 eq.),  
0 oC, 1 h in DMF.  
35% 
2 HATU (1.2 eq.), depsipeptide 288 (1.1 
eq.), uridylamine 294 (1 eq.), iPr2NEt (2.4 
eq.), 25 oC, 1 h in DMF. 
< 5% 
3 DCC (6.6 eq.), depsipeptide 288 (1.1 eq.), 
uridylamine 294 (2 eq.), HOBt (7.0 eq.),  
25 oC, 1 h in NMP. 
30% 
4 HATU (2.2 eq.), HOAt (2.2 eq.) 
depsipeptide 288 (1.1 eq.), uridylamine 
294 (1 eq.), 2,4,6-trimethylpyridine (2 
eq.), 25 oC, 1 h in DMF. 
< 5% 
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Scheme 60. Coupling of depsipeptides 287, 289 and 292 with uridylamine 294 using 
HATU/HOAt/TMP (condition 2, Table 16) and observed epimerization. Reagents and 
conditions: a) TFA: CH2Cl2 (1:1 v/v), 2.5 vol.% iPr3SiH, 6 h, rt, 20% over two steps (NB: 
only compound 297 was purified and subjected to global deprotection).   
In order to avoid HPLC purification of the fully protected dihydrosansanmycin 
analogues, it was necessary to identify coupling conditions that would give rise to low 
or no epimerization. On this occassion, uridylpeptide 298 was chosen as the model 
system as the highest rate of epimerization was observed for this system. Different 
classes of coupling reagents were selected. These include (1-cyano-2-ethoxy-2-
oxoethylideaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate 
(COMU), a uronium salt derived from 2-cyano-2-(hydroxyimino) acetate 
(Oxyma)[164], DIC in combination with HOAt[165]  and n-propanephosphonic acid 
anhydride (T3P) in conjunction with pyridine as a base[166]. These coupling reagents 
have been demonstrated to induce low epimerization in epimerization-prone amide 
couplings.[164-166]  
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Figure 55. Coupling reagents used in the optimization of amide coupling between 
uridylamine 294 and depsipeptide 292. 
Specifically, COMU was shown to exhibit comparable reactivity to the current gold 
standard coupling reagent HATU by El-Faham et al.[164] while capable of suppressing 
epimerization, which is a base-mediated process via the oxazolone intermediate. Also, 
the morpholine group present in COMU can serve as an internal base which allowed 
for the use of only one equivalent of external base.[164] Alternative amide coupling 
conditions such as HOAt accelerated DIC coupling (DIC can also act as a base)[165] 
and T3P in the presence pyridine as a base [166] were also explored. It was envisaged 
that these conditions would give rise to low epimerization as an external base was not 
utilized in the former while the latter featured the use of a weak base (pyridine,  
pKa = 5.2). 
As observed in Table 17, COMU/TMP (entry 1, Table 17) resulted in a similar rate of 
epimerization as HATU/HOAt/TMP mediated coupling (18% to 23%, Table 17 and 
Scheme 60). The T3P/pyridine protocol (entry 2, Table 17) did not give rise to any 
product formation with both starting materials observed after reacting for 5 h. This 
was probably due to the limited solubility of uridylamine 294 in ethyl acetate, 
especially at 0 oC which required the use of a substantially large volume of solvent 
compared to the amount employed by Dunetz et al.[166] (2 volumes of ethyl acetate 
relative to the volume of pyridine used). It is likely that the substantial reduction in 
concentrations of reactants severely reduced the rate of activation of depsipeptide 292 
and sequential coupling with uridylamine 294 so that product formation was not 
observed after 5 h.  
It was clear from the optimization study above that DIC/HOAt provided the fully 
protected dihydrosansanmycin analogue 298 with the greatest retention of 
configuration (5% epimerization, entry 3, Table 17). As such, these conditions were 
selected for the fragment condensation of uridylamine 294 with other depsipeptides 
(286, 289-291 and 293) to assemble a library of dihydrosansanmycin analogues. 
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Gratifyingly, all the amide couplings proceeded with low epimerization (≤ 5%) to 
afford the dihydrosansanmycin precursors 296 and 298-302. Following acidolytic 
cleavage with a 1:1 (v/v) mixture of TFA and CH2Cl2 for 1.5 h, dihydrosansanmycin 
analogues 231 and 250-254 were obtained, after HPLC purification, in moderate to 
good yields over the two steps (40-69%, Scheme 61).  
Table 17. Coupling conditions trialed for the synthesis of 298. NB: preactivation was not 
carried out for depsipeptide 292 in all conditions tested. 
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Entry Coupling Conditions % epimerization 
1 COMU (1.05 eq.), depsipeptide 292  
(1 eq.), uridylamine 294 (1.2 eq.), TMP (1 
eq.), 0 oC, 2 h in DMF. 
 
18% 
2 T3P (2 eq.), depsipeptide 292 (1 eq.), 
uridylamine 294 (1.1 eq.), pyridine (2.8 
eq.), -15 oC to 0 oC, 5 h in EtOAc. 
No reaction 
3 DIC (1 eq.), depsipeptide 292 (1 eq.),  
uridylamine 294 (1.2 eq.), HOAt (5 eq.), 
25 oC, 1.5 h in CH2Cl2 : DMF (1:1 v/v).  
5% 
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Scheme 61. Synthesis of dihydrosansanmycin analogues 231, 250-254 using DIC/HOAt.  
NB: yields over two steps were given. 
Dihydrosansanmycin analogue 299 bearing a methionine sulfoxide sidechain was 
subjected to ammonium iodide and 90% TFA (9:1 v/v TFA: H2O) with dimethyl 
sulfide as a co-reductant (Scheme 62). This cocktail enabled the global deprotection 
and the in situ reduction of methionine sulfoxide to the corresponding sulfide (229) 
with dimethyl sulfoxide produced as the by-product.[167]  
 
Scheme 62. Synthesis of dihydrosansanmycin analogue 229. 
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6.6 Evaluation of antitubercular activity of dihydrosansanmycin analogues 
229-232 and 250-254 (conducted by Angel Pang, Centenary Institute) 
With dihydrosansanmycin analogues 229-232 and 250-254 in hand, attention was 
shifted to the evaluation of the antibacterial activity of these compounds against  
M. tuberculosis in vitro. The in vitro growth inhibition of a virulent M. tuberculosis 
strain (H37Rv) was determined by the MABA assay discussed previously (Chapter 3, 
section 3.10). It was pleasing to see that most compounds exhibited potent inhibition 
against M. tuberculosis with MIC50 in the high nanomolar to low micromolar range. 
Also, it is noteworthy to point out that compounds 229-232 which were previously 
synthesized in the Payne research group and screened for antitubercular activity, 
exhibited similar activity trends to those observed here (Table 18). Specifically, 
dihydrosansanmycin B (230) was the most potent compound with an MIC50 of 0.3 
µM while dihydrosansanmycin A (229) was slightly less potent (MIC50 = 0.5 µM, 
Table 18). Changing the methionine side chain in dihydrosansanmycin A to 
methionine sulfoxide in 231 led to a significant drop in potency (231: MIC50 = 18.5 
µM compared to 230: MIC50 = 0.5 µM, Table 18). Furthermore, replacement of m-Tyr 
with proteinogenic Tyr residue resulted in a 7-fold decrease in antitubercular activity 
(232: MIC50 = 2.15 µM compared to 229: MIC50 = 0.3 µM, Table 18).   
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Table 18. In vitro growth inhibition of M. tuberculosis H37Rv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is interesting to observe that replacement of the m-Tyr moiety in 
dihydrosansanmycin B 230 with glycine (250) only led to a slight decrease in potency 
(250: MIC50 = 0.65 µM compared to 230: MIC50 = 0.3 µM, Table 18) suggesting the 
modest contribution of 3-hydroxyphenyl moiety to antibacterial activity. Substitution 
N
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H
N
O
R2
HN
HO
Compound R1 R2 MIC50 (µM) 
M. tuberculosis 
H37Rv 
230 CH2-CH(CH3)2 CH2-3-
hydroxyphenyl 
0.3 
232 CH2-CH(CH3)2 CH2-4-
hydroxyphenyl 
2.15 ± 0.07 
250 CH2-CH(CH3)2 H 0.65 ± 0.07 
254 CH2-CH(CH3)2 CH(CH3)OH 1.35 ± 0.07 
229 (CH2)2-SMe CH2-3-
hydroxyphenyl 
0.5 
231 (CH2)2-S(O)Me CH2-3-
hydroxyphenyl 
18.5 ± 0.70 
251 CH2-CH(CH3)2 (CH2)3-NH2 0.95 ± 0.07 
252 CH2-CH(CH3)2 (CH2)4-NH2 1.35 ± 0.07 
253 CH2-CH(CH3)2 CH2-CO2H 9.8 ± 1.1 
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of the m-Tyr in 230 with an aliphatic polar Thr residue (254) and positively charged 
ornithine (251) and Lys (252) residues was also tolerated (Table 18), albeit not as well 
as the above replacement of m-Tyr with glycine. However, it was clear from this 
dataset that the presence of a negatively charged residue such as aspartate (253) in 
place of m-Tyr was detrimental to activity with a 33-fold increase in MIC50 value 
(Table 18). 
6.7 Conclusions 
In summary, this chapter describes an efficient route to uridylamine 294 from 
commercially available uridine and a divergent solid-phase synthesis of depsipeptide 
fragments. A fragment condensation strategy was utilized to unify the uridylamine 
and depsipeptide portions of dihydrosansanmycin analogues. After extensive 
investigation of a range of amide coupling conditions, it was discovered that by using 
a DIC/HOAt coupling system in the absence of base, the fragment condensation 
reactions proceeded with low epimerization to give dihydrosansanmycin analogues 
with high optical purity. 
A total of nine dihydrosansanmycin analogues were synthesized and evaluated for in 
vitro growth inhibition of M. tuberculosis H37Rv. Most compounds exhibited 
excellent antitubercular activity with MIC50 in the high nanomolar to low micromolar 
range (0.3-2.2 µM). Dihydrosansanmycin A (229) and B (230) possessed the best  
antitubercular activity with MIC50 values of 0.5 µM and 0.3 µM respectively (Figure 
56). Preliminary data indicated that dihydrosansanmycin A (229) and B (230) 
demonstrated intracellular killing of M. tuberculosis in infected human THP-1 
macrophages. It was pleasing to observe that compound 250 still retained significant 
activity despite replacement of m-Tyr with commercially available glycine (250: 
MIC50 = 0.65 ± 0.07 µM, Figure 56) which has implications for the synthesis of 
further simplified analogues in the future. The SARs for the first-generation 
dihydrosansanmycin analogues will now form the foundation for the design and 
synthesis of more potent second-generation compounds. The activity of these 
compounds in macrophage killing assays holds promise for the in vivo evaluation of 
these analogues.  
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Figure 56. Dihydrosansanmycin analogues exhibiting the most potent anti-tubercular activity. 
6.8 Future work 
6.8.1 Molecular mechanism of dihydrosansanmycin analogues 
As the first-generation dihydrosansanmycin analogues exhibited excellent  
anti-tubercular activity, it is anticipated that these compounds can now be progressed 
further into lead optimization and pre-clinical development stages. Progression into 
the later stages of drug development will require knowledge of the molecular targets 
responsible for anti-tubercular activity of the dihydrosansanmycin analogues. As 
previously mentioned, sansanmycins belong to the family of uridylpeptide antibiotics 
(i.e. pacidamycins, mureidomycins and muraymycins) that has been shown to inhibit 
MraY in other organisms, with detailed investigation into the mechanism of inhibition 
already carried out for mureidomycins and muraymycins. Specifically, 
mureidomycins were shown to be slow-binding inhibitors of solubilized E. coli MraY 
and exhibited competitive inhibition with respect to UDP-MurNAc pentapeptide and 
the polyprenyl phosphate lipid substrate.[147b] Muraymycins were demonstrated to be 
competitive inhibitors of B. subtilis MraY with respect to UDP-MurNAc pentapeptide 
while showing non-competitive inhibition against the lipid substrate.[134]  
Given the structural similarities between sansanmycins and mureidomycins, it is 
likely that sansanmycin, as well as the dihydrosansanmycin analogues described 
herein target MraY (MurX in M. tuberculosis). To unequivocally demonstrate the 
molecular target(s) of dihydrosansanmycin analogues, the generation of spontaneous 
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drug-resistant mutants followed by whole genome sequencing will be carried out.[168] 
Knowledge of the molecular mechanisms of dihdrosansanmycin analogues in this 
early stage of the project is critical as it will establish that these compounds exhibit 
their anti-tubercular activity via specific inhibition of molecular targets and not via 
non-specific killing. 
If the target of dihydrosansanmycin analogues is demonstrated to be MurX, 
subsequent cloning, expression, purification and crystallization of this enzyme will 
follow. While the crystallographic studies of this enzyme will provide invaluable 
structural information that can be used for future inhibitor design, the existence of a 
purified solubilized MurX enzyme will allow for inhibition studies to be conducted on 
current and future dihydrosansanmycin analogues in parallel with in vitro inhibition 
of M. tuberculosis in cell cuture and in macrophage infection models. Ultimately, 
these studies will allow the determination of structural features that are important in 
potent enzyme inhibition and antibacterial activity that will guide the development of 
novel dihydrosansanmycin analogues. 
6.8.2 Second-generation dihydrosansanmycin analogues 
 
 
 
 
6.8.2.1 Modification in region 1 
In the first generation dihydrosansanmycin analogues, modification to region 1 was 
introduced by incorporation of different amino acids (mostly amino acids with acidic 
and basic side chains) in place of m-Tyr. As the antibacterial activity was sensitive to 
changes in this region, further modification might provide valuable information 
regarding structural features necessary for antibacterial activity. Firstly, incorporation 
of aromatic acids such as phenylalanine and histidine in place of m-Tyr would 
facilitate a more comprehensive evaluation of the role of amino acid side chains. 
Incorporation of phenylalanine in place of m-Tyr in dihydrosansanmycin B would 
allow the assessment of the importance of 3-hydroxy group towards antibacterial 
N
H
H
N
O
N
O
H2N
OH
N
R2
O
OH
N
NH
O
O
O
H
N
R3
O
HO
R1
Region 1
Region 2Region 3
Chapter 6-Sansanmycin Analogues as TB Drug Leads 
 
 153 
activity while modification with histidine would give an indication of the tolerance 
towards heterocycles in this region. 
Perhaps the most interesting result obtained from the first-generation 
dihydrosansanmycin series was that in the absence of any side chain, as in case of 
analogue 250 (glycine incorporation in place of m-Tyr), the compound still displayed 
excellent antibacterial activity. In light of this result, it is hypothesized that the amino 
group of glycine significantly contributes to antibacterial activity. In order to test this 
hypothesis, the amino group would be removed i.e. compound 303 (Figure 57). This 
compound could be readily synthesized incorporating the dipeptide fragment formed 
from the amide coupling of DABA 263 with acetic acid. Comparison of the 
antibacterial activity obtained for this compound with that of 250 would give an 
indication of the importance of the amino group. 
 
Figure 57. Dihydrosansanmycin analogue 303 designed to evaluate the importance of the 
amino group of glycine in 250. 
Another means to assess the contribution of the amino group in region 1 to 
antibacterial activity will be to insert a guanidinium group in its place. The rationale 
behind this replacement is that regardless of the molecular target of 
dihydrosansanmycin analogues, the amino group which is positively charged at 
physiological pH is likely to engage in important salt bridge interactions. It is 
hypothesized that replacement of this moiety with a guanidinium group will 
strengthen this interaction, resulting in stronger inhibition of the target and better 
antibacterial activity (the antibacterial activity may be confounded by a corresponding 
change in polarity as a result of guanidinium group incorporation). The guanidinium 
group can be introduced by reacting the free amino group of amino acid methyl esters 
with di-Boc thiourea in the presence of Mukaiyama’s reagent or N-iodo-succinimide 
as promoters (Scheme 63).[169] This reaction would afford Boc-protected guanidine 
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amino acid methyl esters and upon deprotection, could be reacted with the DABA 
building block 256 to form a range of dipeptides that could serve as candidates for the 
solid-phase synthesis of depsipeptides (Scheme 63). 
 
Scheme 63. Proposed synthesis of Boc-protected guanidine dipeptides. 
6.8.2.2 Modification in region 2 and evaluation of dihydrosansanmycin fragments 
In the first-generation dihydrosansanmycin analogues, only leucine, methionine and 
methionine sulfoxide were incorporated in region 2. Examination of the tolerability to 
changes in this region would require incorporation of a broader range of amino acids 
with different steric and electronic properties such as phenylalanine, tyrosine, valine 
as well as acidic/basic residues. This array of analogues would allow one to determine 
the amino acid side chains that gave rise to good antibacterial activity. 
In a similar manner to other nucleoside antibiotics such as caprazamycins and 
capuramycins, uridylpeptides are poorly absorbed owning to high molecular weights. 
As such, identification of the minimal structural unit that retains antibacterial activity 
and inhibition of the molecular target will ultimately allow for the development of 
smaller dihydrosansanmycin analogues with greater bioavailability. The easiest way 
to approach this task is to sequentially remove region 3 and region 2 from the 
elaborated dihydrosansanmycin analogues and evaluate the antibacterial activity of 
these simplified analogues. 
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Figure 58. Simplified dihydrosansanmycin analogues. 
6.8.2.3 Modification in region 3 
As discussed in section 6.2.4.6, small changes in region 3 had a significant impact on 
antibacterial activity. Specifically, replacement of the terminal tryptophan with 
phenylalanine resulted in a 4-fold decrease in antibacterial activity (Table 14). To 
further explore SARs in this region, it would be important to introduce small 
structural changes on the indole ring of tryptophan such as fluorination and 
trifluoromethylation and assess the effects of such changes. However, these 
transformations cannot be readily achieved with current synthetic methodologies. If 
the indole ring of tryptophan could be substituted with pyridine without a negative 
impact on antibacterial activity, an array of reactions are available from the chemist’s 
toolbox that would enable the introduction of small structural changes for SARs 
exploration. 
The installation of pyridine (and in fact a range of aryl and heteroaryl moieties) in 
place of indole could be achieved by the Erlenmeyer-Plöchl azalactone synthesis from  
4-pyridinecarboxaldehyde 304 and N-acetylglycine (Scheme 64A).[158] Opening of the 
azalactone intermediate with sodium acetate and methanol would afford the  
Z-configured enamide 305 that could be subjected to asymmetric hydrogenation to 
give ester 306 bearing the pyridine side chain.[158] Ester 306 would then serve as a 
branch point for a range of C-H functionalization at C-2 and/or C-6 using the zinc 
sulfinate methodology (Scheme 64B).[170] Furthermore, C-2 fluorination of the 
pyridine moiety of ester 306 could be achieved using silver(II) fluoride at ambient 
temperature.[171] Straight-forward protecting group manipulations could then afford 
suitably protected amino acid building blocks ready for incorporation into 
depsipeptides via Fmoc-SPPS. 
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Scheme 64. A: Proposed synthesis of amino acid ester 306 bearing pyridine side chain.  
B: C-H functionalization of amino acid ester 306 using zinc(II) sulfinate salts and silver(II) 
fluoride. 
6.8.2.4 Evaluation of the importance of the free carboxylate group in the 
dihydrosansanmycin analogues 
Another structural feature of the dihydrosansanmycin analogues that warrants further 
investigation is the terminal carboxylate group. The replacement of the carboxylate 
group with lipophilic amides, inspired by the presence of long alkyl chains in the 
potent antitubercular natural products caprazamycins, will allow an assessment of the 
importance of such groups to antibacterial activity (Figure 59). 
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Figure 59. General structure of dihydrosansanmycin analogue designed to evaluate the 
importance of the terminal carboxylate group.  
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7.1 Molecular modeling experimental 
7.1.1 Protein Preparation 
The crystal structures of S. coelicolor, H. pylori and M. tuberculosis type II DHQases were 
downloaded from the Research Collaboratory for Structural Bioinformatics (RCSB) 
Protein DataBank (PDB code: 2XB8).[63] The structures were subjected to further 
modification to ensure suitability for molecular docking using Glide (version 5.0).[54] The 
ligand/protein co-crystal structures were imported into Accelrys DS visualiser 2.0 
(Accelrys Software Inc.) where the dodecamers were simplified into a dimer (Subunits A 
and B). The co-crystallized inhibitors were kept in subunit A. Structural waters were also 
removed. The simplified type II DHQase protein structures were then imported into 
Maestro (version 9.1) and prepared using the Protein Preparation Wizard tool in which 
bond orders were assigned to the ligands. Hydrogens were added to both ligands and the 
proteins in a manner consistent with physiological pH (pH = 7.0) using an all atom force 
field. Restrained minimization of the protein structures was then conducted using impref 
using an OPLS-AA force field until the root mean square deviation (RMSD) of non-
hydrogen atoms reached 0.3.  
7.1.2 Ligand Preparation 
Ligands were built in Maestro (version 9.1) and used as maegz files. The ligands were then 
subjected to treatment with Ligprep (version 2.3) which generates low-energy 3D 
structures with tautomers and possible states at pH 7.  
7.1.3 Glide docking 
Receptor grid files were generated using the Receptor Grid Generation utility in Glide 
(version 5.0). The co-crystallized ligands were chosen as the centre for receptor grid 
generation. Van der Waal radius scaling and partial charge cut off default values were 
used. Per atom scale factors which soften receptor potential were not used. After the 
receptor grids were generated, ligands were docked into the active site using extra 
precision (XP) mode. 
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7.2 Biological Experimental 
7.2.1 Type II DHQases assays 
Enzyme assays for type II DHQases from S. coelicolor, H. pylori and  
M. tuberculosis were carried out using a Shimadzu UV Vis1800 spectrophotometer with a 
6×6 peltier cell holder using 1 cm path length quartz cuvettes at a wavelength of 234 nm to 
monitor the formation of the product, 3-dehydroshikimate. Specifically, the initial reaction 
rates were measured by the increase in absorbance at 234 nm, due to the formation of the 
enone-carboxylate chromophore of 3-dehydroshikimate (ε = 1.2 × 104 M-1 cm-1). The 
assays for S. coelicolor, H. pylori and M. tuberculosis type II DHQases contained 0.62, 
2.41 and 3.80 nM of the enzyme, and were performed in duplicate. The assay mixtures 
were prepared in 1 mL quartz cuvettes, and the assays were initiated by the addition of the 
substrate (3-dehydroquinate) to the mixture after incubating the buffer, inhibitor (dissolved 
in water or DMSO and water mixture with a final concentration of 0.5% DMSO in the 
assay mixture) and enzyme at 25 oC for three minutes.  
The kinetic data for inhibition studies were obtained by measuring the initial rates of 
reaction over a range of inhibitor concentrations (3-4 different concentrations) at 5 
different substrate concentrations (0.9 KM - 4 KM). The inhibition constants (Ki) and the 
standard deviations were determined using non-linear regression fitting to the competitive 
model by GraphPad Prism (version 5.03 for Windows).  
7.2.2 M. tuberculosis GlmU uridyltransferase assays 
In 96-well plate format, the standard inhibition assay of 200 µL contained the following  
50 mM Tris.HCl (pH 7.6), 5 mM MgCl2, 1 mM DTT, 0.2 mM 7-methyl-6-thioguanosine 
(MESG), 1 U/mL purine nucleoside phosphorylase (PNPase), 2.4 U/mL inorganic 
pyrophosphatase, 94 nM M. tuberculosis GlmU uridyltransferase, 35 µM GlcNAc-1-P and 
50 µM of a given inhibitor (dissolved in DMSO and water mixture with a final 
concentration of 1% DMSO in the assay mixture) with the exception of inhibitor 213 for 
which a range of concentrations were used (0-400 µM). The assay mix was incubated, in 
duplicate at 25 oC for 10 minutes prior to initiation by the addition of 35 µM UTP and 
monitored for 6 minutes at 360 nm on a Polarstar-Omega (BMG LabTech) microplate 
reader. The IC50 value for 213 was determined by non-linear regression fitting to the 
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sigmoidal Hill equation (below) using GraphPad Prism (version 5.03 for Windows) where 
vi/vo is the initial fractional velocity, A and B represent top and bottom of curve, l is the 
logarithm of inhibitor concentration and h is Hill slope. 
 
7.3 General Synthetic Experimental 
1H NMR spectra were recorded at 300K unless otherwise specified using a Bruker Avance 
DPX 300, DPX 400 and DPX 500 NMR spectrometer at a frequency of 300.2, 400.2 and 
500.2 MHz respectively. 1H NMR chemical shifts are reported in parts per million (ppm) 
and are referenced to solvent residual signals: CDCl3 δ 7.26, MeOD δ 3.31, acetone-d6 δ 
2.05, CD3CN δ 1.94, DMSO-d6 δ 2.50 and D2O δ 4.79. 1H NMR data is reported as 
chemical shift (δH), relative integral, multiplicity (s = singlet, d = doublet, t = triplet,  
q = quartet, dd = doublet of doublets, ddd = doublet of doublet of doublets, dt = doublet of 
triplets, td = triplet of doublets, tt = triplet of triplets, qd = quartet of doublets), coupling 
constant (J Hz) and assignment where possible. Low resolution mass spectra were 
recorded on a Finnigan LCQ Deca ion trap mass spectrometer (ESI). High resolution mass 
spectra were recorded on a Bruker 7T Fourier Transform Ion Cyclotron Resonance Mass 
Spectrometer (FTICR). 
Melting points were recorded using a Stanford Research Systems OptiMelt Automated 
Melting Point System. Infrared (IR) absorption spectra were recorded on a Bruker ALPHA 
Spectrometer with Attenuated Total Reflection (ATR) capability, using OPUS 6.5 
software. Optical rotations were measured using a Perkin Elmer Model 341 polarimeter 
and [!]!!" values are reported in 10-1 deg cm2 g-1. 
Preparative reverse phase HPLC was performed using a Waters 600 Multisolvent Delivery 
System and Waters 500 pump with a Waters 2996 photodiode array detector or Waters 
490E programmable wavelength detector operating at 254 and 280 nm using  Sunfire Prep 
C18 OBD, 19 x 50 mm column, operating at a flow rate of  
7 mL min-1. Compounds were eluted with 0.1% TFA or formic acid in water (solvent A), 
vi
vo
= B+ A−B1+10(log IC50−l )×h
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and 0.1% TFA or formic acid in CH3CN (solvent B) using a linear gradient of 0-50% B 
over 40 min or 0-100% B over 40 min or 50-100% B over 40 min. 
LC-MS was performed on a Shimadzu LC-MS 2020 instrument consisting of a LC-M20A 
pump and a SPD-20A UV/Vis detector coupled to a Shimadzu 2020 mass spectrometer 
(ESI) operating in positive mode. Separations were performed on a Waters Sunfire 5 µm, 
2.1 x 150 mm column (C18), operating at a flow rate of 0.2 mL min-1. Separations were 
performed using a mobile phase of 0.1% formic acid in water (Solvent A) and 0.1% formic 
acid in MeCN (Solvent B) and a linear gradient of 0-100% B over 30 min or 0-50% B over 
30 min. 
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7.4 Synthesis for compounds in chapter 3 
(1S,3R,4R,5R)-1,3,4-trihydroxy-6-oxabicyclo[3.2.1]octan-7-one (37) 
 
A mixture of (-)-quinic acid 36 (11 g, 58 mmol) and p-toluenesulfonic acid 
monohydrate (1.2 g, 6.2 mmol) in benzene (100 mL) was heated at reflux for 20 h. 
The reaction mixture was cooled to 20 oC before solid NaHCO3 was added until the 
reaction mixture became neutral. The solvent was removed in vacuo and the residue 
was re-dissolved in acetone (450 mL). The solution was filtered and the filtrate 
removed in vacuo to afford lactone 37 as a white solid which was used without further 
purification (5.1 g, 50%).  
m.p. 176-177 oC. IR (ATR): ν = 3446, 3327, 3234, 1788 cm-1. 1H NMR (400 MHz,  
DMSO-d6): δ 4.61 (1H, dd, J  5.2, 5.6 Hz, H-3), 3.82 (1H, t, J  4.4 Hz, H-4), 3.48 (1H, 
td, J  4.8, 11.6 Hz, H-5), 2.25 (1H, d, J  11.6 Hz, H-2ax), 2.11 (1H, ddd,  J  2.8, 5.2, 
11.6 Hz, H-2eq), 1.88 (1H, ddd, J  2.4, 6.4, 11.6 Hz, H-6eq), 1.72 (1H, t, J 11.6 Hz,  
H-6ax). [!]!!"= -40o (c = 1.0 in CH3OH). These data are in agreement with those 
previously reported by Huang et al.[172]  
 (1S,3R,4R,5R)-4-(tert-butyldimethylsilyloxy)-1,4-dihydroxy-6-
oxabicyclo[3.2.1]octan-7-one (38) 
 
TBS-Cl (3.9 g, 26 mmol) was added to a solution of lactone 37 (3.3 g, 19 mmol), 
imidazole (1.8 g, 26 mmol) and DMAP (0.50 g, 4.0 mmol) in anhydrous DMF (30 
mL) at 0 oC. The reaction was stirred at 0 oC for 2 h followed by stirring for 5 h at 
room temperature. Ethyl acetate (250 mL) was then added, the resulting solution 
filtered and the filtrate washed with water (4 × 100 mL). The organic layer was 
OH
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HO
O
OH
TBSO O
HO
O
Chapter 7-Experimental 
 
163 
 
 
 
 
concentrated in vacuo to yield a crude yellow oil that was purified by column 
chromatography (1:1 v/v diethyl ether/hexane → 4:1 v/v diethyl ether/hexane) to 
afford 3-silylated lactone 38 as a white, crystalline solid (3.3 g, 60%). 
IR (ATR): ν = 3324, 2929, 2856, 1774 cm-1. 1H NMR (400 MHz, CDCl3): δ 4.88 (1H, 
dd, J  5.6, 5.6 Hz, H-5), 3.98 (1H, dd, J  4.4, 4.4 Hz, H-4), 3.90 (1H, ddd, J  4.8, 7.6, 
10.4 Hz, H-3), 2.94 (1H, s, OH), 2.63 (1H, d,  J  11.6 Hz, H-6ax), 2.30 (1H, ddd, J  
2.4, 6.0, 11.2 Hz, H-2eq), 2.02-1.96 (2H, m, H-6eq + H-2ax), 0.90 (9H, s, (CH3)3CSi), 
0.10 (6H, s, 2× CH3Si). [!]!!"= -28o (c = 0.80 in CHCl3). These data are in agreement 
with those previously reported by Sanchez-Abella et al. [56] 
(1R, 3R, 4S, 5R)-3-(tert-butyldimethylsilyloxy)-1,4-bis(methoxymethoxy)-6-
oxabicyclo[3.2.1]octan-7-one (39) 
 
Phosphorus pentoxide (6.5 g, 23 mmol) was added every h to a stirred mixture of 3-
silylated lactone 38 (2.5 g, 8.3 mmol) and dimethoxymethane (100 mL, 1.1 mol) in 
dichloromethane (100 mL). The suspension was stirred vigorously for 2 h.  Another 
portion of dimethoxymethane (40 mL, 0.4 mol) was then added and the reaction was 
stirred at room temperature for 1 h. The reaction mixture was then diluted with 
dichloromethane (125 mL) and washed with saturated aqueous NaHCO3 solution (150 
mL). The aqueous layer was further extracted with diethyl ether (3 × 100 mL) and the 
combined organic layers were dried over anhydrous Na2SO4 and the solvent was 
removed in vacuo. The crude residue was purified by flash column chromatography 
(1:1 v/v diethyl ether/hexane) to afford lactone 39 as a pale yellow oil (4.6 g, 78%). 
IR (ATR): ν = 2954, 2931, 2896, 1789 cm-1. 1H NMR (400 MHz, CDCl3): δ 4.84-
4.67 (5H, m, 2× OCH2CH3 + H-5), 3.95-3.91 (2H, m, H-3 + H-4), 3.40 (3H, s, 
OCH2CH3), 3.32 (3H, s, OCH2CH3), 2.59-2.46 (2H, m, H-2eq + H-6ax), 2.08-2.06 (2H, 
m, H-2ax + H-6eq), 0.87 (9H, s, (CH3)3CSi), 0.06 (6H, s, 2× CH3Si). 13C NMR (100 
MHz, CDCl3): δ 175.5 (C=O), 97.9, 92.9, 75.2, 72.5, 67.7, 56.0, 55.8, 38.3, 35.3, 
OMOM
O
MOMO
O
TBSO
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26.1, 18.4, -4.3, -4.5. HRMS cald. for C17H32O7SiNa [M+Na+] 399.1810; found 
399.1812. [!]!!"= -44o (c =1.25 in CH2Cl2). 
(1S,3R,4R,5R)-3-hydroxy-1,4-bis(methoxymethoxy)-6-oxabicyclo[3.2.1]octan-7-
one (40) 
 
TBAF (8.20 mL of a 1 M solution in THF, 8.20 mmol) was added dropwise to a 
solution of lactone 39 (2.6 g, 6.9 mmol) in THF (54 mL) at 0 oC. The reaction was 
stirred at room temperature for 2.5 h. The reaction mixture was then diluted with ethyl 
acetate (75 mL) and washed with saturated aqueous NH4Cl solution (75 mL), brine 
(75 mL) and dried over anhydrous Na2SO4. The solvent was removed in vacuo and 
the crude residue was purified by flash column chromatography (5:1 v/v diethyl 
ether/hexane) to afford alcohol 40 as a pale yellow oil (1.6 g, 87%). 
IR (ATR): ν = 3464, 2924, 2854, 1789 cm-1. 1H NMR (300 MHz, CDCl3): δ 4.83-
4.72 (5H, m, 2× OCH2CH3+ H-5), 3.98 (1H, dd, J 4.8, 4.8 Hz, H-4), 3.90 (1H, ddd, J 
4.4, 6.4, 11.2 Hz, H-3), 3.42 (3H, s, OCH2CH3), 3.40 (3H, s, OCH2CH3), 2.49 (1H, d, 
J 11.4 Hz, H-6ax), 2.57 (1H, ddd, J 2.7, 6.0, 11.4 Hz, H-6eq), 2.32 (1H, ddd, J 2.7, 6.3, 
11.4 Hz , H-2eq), 1.88 (1H, t, J 11.4 Hz, H-2ax). 13C NMR (100 MHz, CDCl3): δ 174.0 
(C=O), 96.0, 93.0, 76.4, 75.8, 72.4, 65.2, 56.1, 56.0, 35.5, 34.2. [!]!!"= -32o (c = 1.5 
in CHCl3). 
(1R, 4S, 5R)-1,4-bis(methoxymethoxy)-6-oxabicyclo[3.2.1]octane-3,7-dione (41) 
 
To a suspension of Dess-Martin Periodinane (440 mg, 1.1 mmol) in anhydrous 
dichloromethane (2.5 mL) was added alcohol 40 in dichloromethane (2.5 mL). The 
reaction was allowed to stir at room temperature for 1.5 h. Diethyl ether (10 mL) was 
then added followed by a 1:1 (v/v) mixture of saturated aqueous NaHCO3 and 
OMOM
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Na2S2O3 until all solid material had dissolved. The aqueous layer was extracted with 
diethyl ether (2 × 20 mL), the organic layer was dried over anhydrous Na2SO4 and the 
solvent removed in vacuo to afford ketone 41 as a pale yellow oil which was used 
without further purification (170 mg, 62%).  
IR (ATR): ν = 2918, 1798, 1729 cm-1. 1H NMR (400 MHz, CDCl3): δ 4.90-4.78 (4H, 
m, OCH2CH3 + OCHHCH3 + H-5), 4.64 (1H, d, J 6.6 Hz, OCHHCH3), 3.97 (1H, d, J 
3.6 Hz, H-4), 3.41 (3H, s, OCH3), 3.36 (3H, s, OCH3), 3.05 (1H, d, J 17.4 Hz, H-2ax), 
2.92 (1H, ddd, J 3.2, 6.4, 12.0, H-6eq), 2.84 (1H, dd, J 2.8, 17.2 Hz, H-2eq), 2.68 (1H, 
d, J 12.0 Hz, H-6ax). 13C NMR (100 MHz, CDCl3): δ 201.9 (C=O), 173.8 (C=O), 
96.4, 93.2, 75.4, 73.9, 73.1, 56.1, 56.1, 48.6, 33.9. [!]!!"= -56o (c = 7.3 in CHCl3). 
(1R, 4S, 5R)-1,4-bis(methoxymethoxy)-7-oxo-6-oxabicyclo[3.2.1]oct-2-en-3-
ylttrifluoromethanesulfonate (27) 
 
To a solution of KHMDS (3.9 mL of a 0.5 M solution in toluene, 1.93 mmol) in 
anhydrous DMF (2 mL) at -78 oC was added dropwise a solution of ketone 41 (390 
mg, 1.5 mmol) in dry DMF (3.2 mL) and toluene (2.2 mL). The mixture was stirred 
for 1 h at -78 oC before a solution of 2-[N,N-bistrifluoromethylsulfonyl)amino]-5-
chloropyridine (1.10 g, 2.71 mmol) in anhydrous DMF (2.6 mL) was added dropwise. 
The resulting mixture was stirred at room temperature for 15 h at which point the 
reaction was diluted with ethyl acetate (100 mL) and washed with water (5 × 20 mL). 
The organic layers were dried over anhydrous Na2SO4 and solvent was removed in 
vacuo. The crude residue was then purified by flash column chromatography (2:1 v/v 
diethyl ether/hexane) to afford vinyl triflate 27 as a pale yellow oil (290 mg, 49%). 
IR (ATR): ν = 2958, 2904, 1807, 1664 cm-1. 1H NMR (400 MHz, CDCl3): δ 6.30 (1H, 
d, J 1.3 Hz, H-2), 4.91 (1H, d, J 7.6 Hz, OCHHCH3), 4.86 (1H, dd, J 3.7, 5.8 Hz, H-
5), 4.80 (1H, d, J 7.0 Hz, OCHHCH3), 4.78 (1H, d, J 8.6 Hz, OCHHCH3), 4.76 (1H, 
d, J 7.0 Hz, OCHHCH3), 4.27 (1H, d,  J 3.4 Hz, H-4), 3.45 (3H, s, OCH3), 3.43 (3H, 
MOMO
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s, OCH3), 2.68 (1H, ddd, J  1.2, 6.0, 11.5 Hz, H-6eq), 2.46 (1H, d, J 11.5 Hz, H-6ax); 
13C NMR (100 MHz, CDCl3): δ 172.3 (C=O), 145.0, 125.3, 119.8 (m, JC-F, CF3), 
97.8, 93.9, 76.0, 73.4, 72.3, 56.4, 56.4, 34.4. HRMS (APCI) m/z: cald for 
C12H16F3O9S [M+H]+: 393.0467, found 393.0462.  [!]!!"= -83o (c = 1.0 in CH2Cl2). 
(1R,4R,5R)-1,4-bis(methoxymethoxy)-3-((trimethylsilyl)ethynyl)-6-
oxabicyclo[3.2.1]oct-2-en-7-one (43)  
 
Ethynyltrimethylsilane (0.24 mL, 1.7 mmol) and piperidine (0.49 mL, 4.9 mmol) 
were added to a suspension of vinyl triflate 27 (128 mg, 0.33 mmol),  
tetrakis(triphenylphosphine)palladium (0) (68 mg, 57 µmol) and copper iodide (13 
mg, 65 µmol) in anhydrous THF (19 mL). The resulting solution was heated at 40 oC 
for 3.5 h before cooling to room temperature. Saturated aqueous NaHCO3 (20 mL) 
was added and the organic layer was separated. The aqueous phase was extracted with 
diethyl ether (3 × 30 mL) and the combined organic extracts were dried over 
anhydrous Na2SO4 and the solvent was removed in vacuo. The crude residue was 
purified by flash column chromatography (1:1 v/v diethyl ether/hexane) to afford  
ene-yne 43 as a dark orange oil (76 mg, 69%). 
IR (ATR): ν = 2958, 2899, 1801 cm-1. 1H NMR (400 MHz, CDCl3): δ 6.44 (1H, d, J 
1.7 Hz, H-2), 4.87 (1H, d, J 7.5 Hz, OCHHCH3), 4.85 (1H, d, J 7.0 Hz, OCHHCH3), 
4.79 (1H, d, J 7.6 Hz, OCHHCH3), 4.74 (1H, d, J 6.8 Hz, OCHHCH3), 4.72 (1H, dd, 
J 2.9, 6.1 Hz, H-5), 4.12 (1H, d, J 3.1 Hz, H-4), 3.42 (3H, s, OCH3), 3.40 (3H, s 
OCH3), 2.61 (1H, ddd, J  1.8, 6.1, 11.2 Hz, H-6eq), 2.42 (1H, d, J 11.2 Hz, H-6ax). 
13C NMR (100 MHz, CDCl3): δ 173.2 (C=O), 139.8, 122.0, 101.5, 97.5, 97.0, 93.5, 
77.5, 74.2, 72.0, 56.9, 56.2, 34.4, -0.3. HRMS (APCI) m/z: cald for C16H25O6Si 
[M+H]+: 341.1420, found 341.1415. [!]!!"= -134o (c = 2.3 in CHCl3). 
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(1R,4R,5R)-3-ethynyl-1,4-dihydroxy-6-oxabicyclo[3.2.1]oct-2-en-7-one (26) 
 
Ene-yne 43 (76 mg, 0.22 mmol) in THF (9 mL) was treated with a solution of TBAF 
(74 µL of a 1.0 M in THF, 0.074 mmol) and the reaction mixture was stirred for 15 
min at room temperature. The reaction mixture was diluted with ethyl acetate (50 
mL), washed with saturated aqueous NH4Cl (20 mL), brine (20 mL) and dried over 
anhydrous Na2SO4. The solvent was removed in vacuo to yield the intermediate 
protected ene-yne 44 which was used in the next step without purification. Treatment 
of this protected ene-yne 44 with TFA (11 mL of a 90% aqueous solution) for 30 min 
at 0 oC follow by stirring for a further 3 h at room temperature. The solvent was 
removed in vacuo to yield the crude residue which was purified by flash column 
chromatography (3:1 v/v diethyl ether/hexane) to afford the ene-yne 26 as a yellow oil 
(25 mg, 64%). 
IR (ATR):  ν = 3293, 3283, 3270, 2356, 1785 cm-1. 1H NMR (400 MHz, CD3OD): δ 
6.35 (s, 1H, H-2), 4.66 (dd, 1H, J 5.6, 3.2 Hz, H-5), 4.09 (d, 1H, J 3.2 Hz, H-4), 3.48 
(s, 1H, CH), 2.39 (ddd, 1H, J 11.2, 5.6, 1.6 Hz, H-6eq), 2.34 (d, 1H, J 11.0 Hz, H-6ax). [!]!!"= -234o (c = 1.0 in MeOH). These data are in agreement with those reported by 
C. González-Bello et al.[173] 
(1R,4R,5R)-1,4,5-trihydroxy-3-(phenylethynyl)cyclohex-2-enecarboxylic acid (45) 
 
Iodobenzene (40 µL, 0.36 mmol) and piperidine (110 µL, 1.07 mmol) were added to a 
suspension of 26 (15 mg, 0.083 mmol), tetrakis(triphenylphosphine)palladium(0) 
(14.2 mg, 0.012 mmol) and copper iodide (2.6 mg, 0.013 mmol) in dry THF (4 mL). 
The resulting solution was heated to 40 ºC for 3 h before cooling to room temperature. 
Saturated aqueous NaHCO3 (15 mL) was added and the organic layer was separated. 
HO
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The aqueous phase was extracted with ethyl acetate (3 × 15 mL). The combined 
organic extracts were dried over anhydrous Na2SO4 and solvent was removed in 
vacuo. The crude residue was purified by flash column chromatography (2:98 v/v 
MeOH/CH2Cl2 → 4:96 v/v MeOH/CH2Cl2) to yield the alkynyl-lactone. Lithium 
hydroxide (0.5 M, 170 µL) was then added to a solution of the alkynyl-lactone (8.9 
mg, 0.035 mmol) in THF (370 µL) and the reaction was stirred at room temperature 
for 1.5 h. The solvent was removed in vacuo and the reaction mixture was diluted 
with water (2 mL). The solution was then treated with Amberlite IR-120 (H+ form) 
until pH 6 was reached. The resin was filtered and washed with milli-Q water. The 
aqueous fractions were lyophilised to afford the desired acid 45 as an off white solid 
(7.9 mg, 37% over two steps).  
m.p. 117–118 ºC (decomp.). IR (ATR): ν = 3394, 3341, 3310, 1607 cm-1. 1H NMR 
(400 MHz, D2O): δ 7.44-7.32 (5H, m, Ar-H), 6.01 (1H, s, H-2), 4.00 (1H, d, J 7.6 Hz, 
H-4), 3.78 (1H, ddd, J 3.0, 7.6, 11.1 Hz, H-5), 2.11-1.96 (2H, m, H-6ax + H-6eq).  
13C NMR (100 MHz, D2O): δ 179.4 (C=O), 135.0, 131.7, 131.0,129.1, 128.7, 126.5, 
122.0, 91.5, 86.3, 72.5, 69.0, 39.1. LRMS [M-H+]–  273.0. HRMS (ESI) m/z: cald for 
C15H14O5Na [M+Na+]: 297.0733, found 297.0731. [!]!!"= –17º (c = 0.6 in MeOH).  
(1R,4R,5R)-3-((4-fluorophenyl)ethynyl)-1,4,5-trihydroxycyclohex-2-
enecarboxylic acid (46) 
 
4-Fluoroiodobenzene (34 µL, 0.29 mmol) and piperidine (85 µL, 0.86 mmol) were 
added to a suspension of 26 (12 mg, 0.067 mmol),  
tetrakis(triphenylphosphine)palladium(0) (11 mg, 0.010 mmol) and copper iodide (2.0 
mg, 0.010 mmol) in dry THF (3.2 mL). The resulting solution was heated to 40 ºC for 
3 h before cooling to room temperature. Saturated aqueous NaHCO3 (15 mL) was 
added and the organic layer was separated. The aqueous phase was extracted with 
ethyl acetate (3 × 15 mL). The combined organic extracts were dried over anhydrous 
Na2SO4 and solvent was removed in vacuo. The crude residue was purified by flash 
column chromatography (1:9 v/v MeOH/CH2Cl2) to yield the alkynyl-lactone. 
HO CO2H
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Lithium hydroxide (0.5 M, 120 µL) was then added to a solution of the alkynyl-
lactone (6.6 mg, 0.024 mmol) in THF (260 µL) and the reaction was stirred at room 
temperature for 1.5 h. The solvent was removed in vacuo and the reaction mixture 
was diluted with water (2 mL). The solution was then treated with Amberlite IR-120 
(H+ form) until pH 6 was reached. The resin was filtered and washed with milli-Q 
water. The aqueous fractions were lyophilised to afford the desired acid 46 as a light 
yellow oil (6.9 mg, 36% over two steps).  
IR (ATR): ν = 3324, 2945, 1656 cm-1. 1H NMR (400 MHz, D2O): δ 7.48–7.45 (2H, 
m, Ar-H), 7.08–7.03 (2H, m, Ar-H), 6.04 (1H, s, H-2), 4.01 (1H, d, J 8.1 Hz, H-4), 
3.82 (1H, ddd, J 3.6, 9.0, 11.6 Hz, H-5), 2.08-1.98 (2H, m, H-6eq + H-6ax). 13C NMR 
(100.6 MHz, D2O): δ 178.7 (C=O), 162.5 (d, JC-F 286 Hz, ipso-Ar-C), 134.3, 133.9, 
126.9, 118.9, 115.7 (d, JC-F 23 Hz, ortho-Ar-C), 90.8, 85.9, 73.7, 72.5, 68.8, 39.0. 
LRMS [M-H+]– 290.9. HRMS (ESI) m/z: cald for C15H13FO5Na [M+Na+]: 315.0639, 
found 315.0637. [!]!!"= –17º (c = 0.50 in MeOH). 
(1R,4R,5R)-1,4,5-trihydroxy-3-((3-nitrophenyl)ethynyl)cyclohex-2-enecarboxylic  
acid (47) 
 
3-Nitrophenyl trifluoromethanesulfonate (81 mg, 0.30 mmol) and piperidine (88 µL, 
0.89 mmol) were added to a suspension of ene-yne 26 (11 mg, 0.059 mmol), 
tetrakis(triphenylphosphine)palladium(0) (10 mg, 0.0089 mmol) and copper iodide 
(2.0 mg, 0.0095 mmol) in dry THF (2 mL). The resulting solution was heated to 40 ºC 
for 2 h before cooling to room temperature. Saturated aqueous NH4Cl (15 mL) and 
dichloromethane (15 mL) were added and the organic layer was separated. The 
aqueous phase was extracted with dichloromethane (2 × 15 mL). The combined 
organic extracts were dried over anhydrous Na2SO4 and solvent was removed in 
vacuo. The crude residue was purified by flash column chromatography (3:97 v/v 
MeOH/CH2Cl2 → 5:95 v/v MeOH/CH2Cl2) to afford the alkynyl-lactone. Lithium 
hydroxide (0.50 M, 220 µL, 0.11 mmol) was then added to the alkynyl-lactone (14 
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mg, 0.045 mmol) in THF (500 µL) and the reaction was stirred at room temperature 
for 1.5 h. The solvent was removed in vacuo and the reaction mixture was diluted 
with water (4 mL). The solution was then treated with Amberlite IR-120 (H+ form) 
until pH 6 was reached. The resin was filtered and washed with milli-Q water. The 
aqueous fraction was lyophilised to afford the desired acid 47 as an off white solid  
(12 mg, 65% over two steps).  
m.p. 195–196 ºC (decomp.). IR (ATR): ν = 3332, 2948, 1648, 1451 cm-1.   
1H NMR (400 MHz, D2O): δ 8.40 (1H, s, Ar-H, C-2), 8.24 (1H, d, J 8.4 Hz, Ar-H, C-
4), 7.90 (1H, d, J 8.0 Hz, Ar-H, C-6), 7.63 (1H, t, J 8.0 Hz, Ar-H, C-5), 6.18 (1H, s, 
H-2), 4.14 (1H, d, J 8.4 Hz, H-4), 3.91 (1H, ddd, J 11.6, 8.0, 4.4 Hz, H-5), 2.16-2.07 
(2H, m, H-6ax + H-6eq). 13C NMR (100 MHz, D2O): δ 179.9 (C=O), 147.6, 138.1, 
136.2, 129.8, 126.1, 125.4, 123.8, 123.6, 88.9, 88.3, 74.0, 72.4, 60.0, 39.1.  
LRMS [M-H+]– 318.0. HRMS (ESI) m/z: cald for C15H12NO7 [M-H+]–: 318.0612, 
found 318.0621. [!]!!"= –29º (c = 1.0 in MeOH). 
(1R,4R,5R)-3-((3-trifluoromethylphenyl)ethynyl)-1,4,5-trihydroxycyclohex-2-
enecarboxylic acid (48) 
 
3-Trifluoromethylphenyl trifluoromethanesulfonate (95 µL, 0.52 mmol) and 
piperidine (150 µL, 1.5 mmol) were added to a suspension of 26 (19 mg, 0.10 mmol), 
tetrakis(triphenylphosphine)palladium(0) (18 mg, 0.015 mmol) and copper iodide (3.1 
mg, 0.016 mmol) in dry THF (2.7 mL). The resulting solution was heated to 40 ºC for 
2 h before cooling to room temperature.  Saturated aqueous NH4Cl (20 mL), and 
dichloromethane (20 mL) were added and the organic layer was separated. The 
aqueous phase was extracted with dichloromethane  (2 × 20 mL). The combined 
organic extracts were dried over anhydrous Na2SO4 and solvent was removed in 
vacuo. The crude residue was purified by flash column chromatography (2:98 v/v 
HO CO2H
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MeOH/CH2Cl2 → 1:9 v/v MeOH/CH2Cl2) to yield the alkynyl-lactone. Lithium 
hydroxide (0.5 M, 220 µL) was then added to a solution of the alkynyl-lactone (15 
mg, 0.047 mmol) in THF (500 µL) and the reaction was stirred at room temperature 
for 1.5 h. The solvent was removed in vacuo and the reaction mixture was diluted 
with water (4 mL). The solution was then treated with Amberlite IR-120 (H+ form) 
until pH 6 was reached. The resin was filtered and washed with milli-Q water. The 
aqueous fractions were lyophilised to afford the desired acid 48 as an off white foam 
(17 mg, 45% over two steps).  
IR (ATR): ν = 3360, 1607 cm-1. 1H NMR (400 MHz, D2O): δ 7.89 (1H, br s, Ar-H), 
7.79–7.73 (2H, m, Ar–H), 7.62–7.60 (1H, m, Ar–H), 6.21 (1H, s, H-2), 4.17 (1H, app. 
d, J 6.4 Hz, H-4), 3.98–3.96 (1H, m, H-5), 2.22–2.10 (2H, m, H-6ax + H-6eq).  
13C NMR (100.6 MHz, D2O): δ 179.4 (C=O), 130.6, 129.9, 125.1 (q, JC-F 129 Hz, 
CF3), 124.1, 123.2 (q, JC-F16 Hz, C–CF3), 121.1, 120.3 (m, C–C–CF3), 120.0, 117.9, 
90.0, 87.6, 73.9, 72.5, 69.1, 39.0. LRMS [M+H+] 343.0. HRMS (ESI) m/z: cald for 
C16H12F3O5 [M–H+]–: 341.0642, found 341.0639. [!]!!"= –43º (c = 0.10 in MeOH). 
(1R,4R,5R)-1,4,5-trihydroxy-3-(pyridin-3-ylethynyl)cyclohex-2-enecarboxylic 
acid (49) 
 
3-Iodopyridine (105 mg, 0.51 mmol) and piperidine (150 µL, 1.5 mmol) were added 
to a suspension of 26 (19 mg, 0.10 mmol), tetrakis(triphenylphosphine)palladium(0) 
(18 mg, 0.015 mmol) and copper iodide (3.1 mg, 0.016 mmol) in dry THF (2.7 mL). 
The resulting solution was heated to 40 ºC for 2 h before cooling to room temperature.  
Saturated aqueous NH4Cl (20 mL), and dichloromethane (20 mL) were added and the 
organic layer was separated. The aqueous phase was extracted with dichloromethane 
(2 × 20 mL). The combined organic extracts were dried over anhydrous Na2SO4 and 
solvent was removed in vacuo. The crude residue was purified by flash column 
chromatography (3:97 v/v MeOH/CH2Cl2→ 1:9 v/v MeOH/CH2Cl2) to yield the 
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alkynyl-lactone. Lithium hydroxide (0.5 M, 370 µL) was then added to a solution of 
the alkynyl-lactone (20 mg, 0.079 mmol) in THF (850 µL) and the reaction was 
stirred at room temperature for 1.5 h. The solvent was removed in vacuo and the 
reaction mixture was diluted with water (6 mL). The solution was then treated with 
Amberlite IR-120 (H+ form) until pH 6 was reached. The resin was filtered and 
washed with milli-Q water. The aqueous fractions were lyophilised to afford the 
desired acid 49 as an off white solid (10 mg, 36% over two steps).  
m.p. 197–198 ºC (decomp.). IR (ATR): ν = 3272, 1601 cm-1. 1H NMR (400 MHz, 
D2O): δ 8.61 (1H, br s, Ar-H), 8.46 (1H, br s, Ar-H), 7.96 (1H, d, J 8.0 Hz, Ar-H), 
7.45 (1H, dd, J 4.8, 8.0 Hz, Ar-H), 6.11 (1H, s, H-2), 4.07 (1H, dd, J 2.0, 8.0 Hz, H-
4), 3.85 (1H, ddd, J 5.2, 8.4, 10.8 Hz, H-5), 2.09–1.99 (2H, m, H-6ax + H-6eq).  
13C NMR (100.6 MHz, D2O): δ 174.7 (C=O), 145.1, 142.0, 135.4, 131.3, 120.5, 
118.9, 115.0, 84.7, 82.0, 68.7, 67.1, 63.8, 33.9. LRMS [M-H+]– 274.0. HRMS (ESI) 
m/z: cald for C14H12NO5 [M–H+]–: 274.0721, found 274.0723. [!]!!"= –39º (c = 0.10 
in MeOH). 
1-(3,4-dihydroxyphenyl)ethanone (59)  
 
Anhydrous aluminium chloride (0.98 g, 7.4 mmol) was dissolved in 1,2-
dichloroethane and the reaction cooled to 10 oC for 30 min. Catechol 71 (0.32 g, 2.9 
mmol) was added in three portions over 5 min and the reaction stirred at 10 oC for a 
further 30 min. Acetyl chloride (0.26 mL, 3.2 mmol) was added dropwise to the 
reaction mixture which was allowed to warm to room temperature and stirred for  
20 h. The reaction was subsequently cooled to 10 oC before quenching with 1 M HCl 
solution (10 mL) and the reaction mixture was allowed to stir for a further 2 h. The 
reaction mixture was diluted with CH2Cl2 (30 mL) and the organic layer was 
separated. The aqueous layer was extracted with ethyl acetate (2 × 30 mL) and the 
combined organic layers were washed with brine (40 mL) and dried over anhydrous 
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Na2SO4. The solvent was removed in vacuo to afford acetophenone 59 as a red solid 
which was used without further purification (0.43 g, 95%).  
m.p. 120-121 oC. IR (ATR): ν = 3000, 1796 cm-1. 1H NMR (400 MHz, CDCl3):  
δ 7.47 (1H, dd, J 4.0, 8.0 Hz, Ar-H, C-6), 7.42 (1H, d, J 4.0 Hz, Ar-H, C-2), 6.88 (1H, 
d, J 8.0 Hz, Ar-H, C-5). 13C NMR (100 MHz, Acetone-d6): δ 195.9, 150.2, 145.3, 
130.1, 122.2, 115.6, 114.8, 25.5. These data are in agreement with those previously 
reported by Xiao et al.[174] 
1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)ethanone (62).  
 
A mixture of 3,4-dihydroxyacetophenone 59 (3.87 g, 25 mmol) and phosphorus 
pentoxide (220 mg) in toluene (13 mL) was heated to 75 oC. Acetone (7.4 mL, 100 
mmol) was added dropwise to the suspension over 3 h. After the addition, four 
portions of phosphorus pentoxide (4 × 220 mg) were added to the reaction mixture 
every 30 min. The reaction was allowed to stir at 75 oC for 5 h. The reaction was 
quenched with 25% aqueous sodium hydroxide solution (15 mL) and the solvent 
removed in vacuo to yield a crude residue that was purified by column 
chromatography (2:1 v/v CH2Cl2: hexane) to afford acetonide 62 as a pale yellow oil 
(1.96 g, 40%).  
IR (ATR): ν = 1675 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.53 (1H, dd, J 1.6, 8.0 Hz, 
Ar-H, H-6), 7.35 (1H, s, Ar-H, H-2), 6.75 (1H, d, J 8.0 Hz, Ar-H, H-5), 2.52 (3H, s, 
CH3), 1.69 (6H, s, 2 × CH3).13C NMR (100 MHz, CDCl3):  δ 196.5, 151.7, 147.9, 
131.6, 124.4, 119.4, 107.9, 107.7, 26.5, 25.9. LRMS [M+H]+ 193.0.  
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2-bromo-1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)ethanone (74).  
 
A solution of acetonide 62 (380 mg, 1.9 mmol) was added to a solution of CuBr2 (830 
mg, 3.7 mmol) in ethyl acetate (2.5 mL) and CH2Cl2 (2.5 mL). The reaction mixture 
was refluxed with vigorous stirring for 9 h. The reaction mixture was then filtered, the 
solvent removed in vacuo and the crude residue purified by column chromatography 
(1:1 v/v CH2Cl2: hexane → 2:1 v/v CH2Cl2: hexane) to afford α-bromoketone 74 as a 
pale yellow oil (290 mg, 57%).  
IR (ATR): ν = 1668 cm-1. 1H NMR (300 MHz, CDCl3): δ 7.55 (1H, dd, J 1.8, 8.4 Hz, 
Ar-H, H-6), 7.36 (1H, d, J 1.8 Hz, Ar-H, H-2), 6.77 (1H, d, J 8.4 Hz, Ar-H, H-5), 4.36 
(2H, s, CH2), 1.70 (6H, s, 2 × CH3). 13C NMR (75 MHz, CDCl3): δ 190.0, 152.9, 
148.6, 128.5, 125.6, 120.2, 108.8, 108.3, 30.9, 26.3.  
General procedure A: synthesis of acetonide-based inhibitors 75-88.  
To a suspension of K2CO3 (0.18-0.23 mmol) in acetone (0.4 mL) was added a suitable 
aryl or heteroaryl alcohol or thiol (0.22-0.32 mmol), and the reaction mixture was 
stirred at room temperature for 15 min. α-Bromoketone 74 (0.16-0.21mmol) in 
acetone (0.4 mL) was added dropwise, and the reaction was stirred at reflux for 4-5 h. 
The reaction was diluted with diethyl ether (10 mL), and washed with water (2× 10 
mL). The organic layer was dried over anhydrous MgSO4 and the solvent removed in 
vacuo to yield a crude residue that was purified by column chromatography to afford 
the corresponding ether or thioether.  
1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-phenoxyethanone (75)  
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Phenol (21 mg, 0.22 mmol) was reacted with α-bromoketone 74  (57 mg, 0.21 mmol) 
using general procedure A and purified by column chromatography (3:2 v/v CH2Cl2: 
hexane) to afford 75 as a pale yellow oil (40 mg, 67%).  
IR (ATR): ν = 1693 cm-1.  1H NMR (300 MHz, CDCl3): δ 7.58 (1H, dd, J 1.5, 8.1 Hz, 
Ar-H), 7.40 (1H, d, J 1.5 Hz, Ar-H), 7.27 (2H, t, J 8.4 Hz, 2 x Ar-H), 6.97-6.92 (3H, 
m, 3 x Ar-H), 6.78 (1H, d, J 8.1 Hz, Ar-H), 5.17 (2H, s, CH2), 1.64 (6H, s, 2 × CH3). 
13C NMR (100 MHz, CDCl3): δ 192.7, 158.4, 152.9, 148.2, 129.8, 129.1, 124.4, 
121.8, 120.1, 115.0, 108.4, 108.2, 70.6, 26.1. HRMS cald. for C17H16O4Na [M+Na+] 
307.0941, found 307.0944. 
1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-(phenylthio)ethanone (76) 
 
Thiophenol (33 µL, 0.32 mmol) was reacted with α-bromoketone 74 (57 mg, 0.21 
mmol) in acetone (0.4 mL) using general procedure A and purified by column 
chromatography (3:1 v/v hexane: CH2Cl2 → 3: 2 v/v CH2Cl2: hexane) to afford 76 as 
a pale yellow oil (28 mg, 45%).  
IR (ATR): ν = 1671 cm-1.  1H NMR (400 MHz, CDCl3): δ 7.50 (1H, dd, J 1.5, 8.0 Hz, 
Ar-H), 7.39 (2H, dd, J 1.4, 7.7 Hz, 2 x Ar-H), 7.34 (1H, d, J 1.5 Hz, Ar-H), 7.28 (2H, 
t, J 7.7 Hz, 2 x Ar-H), 7.23-7.20 (1H, m, Ar-H), 6.74 (1H, d, J 8.0 Hz, Ar-H), 4.20 
(2H, s, CH2), 1.70 (6H, s, 2 × CH3). 13C NMR (100 MHz, CDCl3): δ 192.5, 152.1, 
148.3, 135.1, 131.7, 129.6, 129.1, 127.0, 124.8, 119.7, 108.3, 107.9, 41.9, 22.8. 
HRMS cald. for C17H16O3SNa [M+Na+]  323.0712, found 323.0708. 
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1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-(3-(trifluoromethyl)phenoxy)ethanone 
(77)  
 
3-(Trifluoromethyl)phenol (39 µL, 0.32 mmol) was reacted with α-bromoketone 74  
(57 mg, 0.21 mmol) using general procedure A and purified by column 
chromatography (3:2 v/v CH2Cl2: hexane) to afford 77 as a white solid (67 mg, 90%).  
IR (ATR): ν = 1694 cm-1. 1H NMR (300 MHz, CDCl3): δ 7.54 (1H, dd, J 1.8, 8.1 Hz, 
Ar-H), 7.42-7.33 (2H, m, 2 x Ar-H), 7.26-7.20 (1H, m, Ar-H), 7.19-7.14 (1H, m, Ar-
H), 7.13-7.04 (1H, m, Ar-H), 6.79 (1H, d, J 8.1 Hz, Ar-H), 5.23 (2H, s, CH2), 1.71 
(6H, s, 2 × CH3). 13C NMR (100 MHz, CDCl3): δ 191.9, 158.2, 152.7, 148.3, 131.9 
(q, J 33 Hz), 130.2, 128.4, 125.3 (q, J 270 Hz, CF3), 124.2, 119.9, 118.3 (q, J 3.1 Hz), 
118.1, 111.9 (q, J 3.2 Hz), 108.1, 107.8, 70.4, 26.0. HRMS cald. for C18H15F3O4Na 
[M+Na+] 375.0815, found 375.0813. 
1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-(2-fluorophenoxy)ethanone (78)  
 
2-Fluorophenol (28 µL, 0.32 mmol) was reacted with α-bromoketone 74 (57 mg, 0.21 
mmol) using general procedure A and purified by column chromatography (2:1 v/v 
CH2Cl2: hexane) to afford 78 as a white solid (62 mg, 97%).  
m.p. 113-114 oC. IR (ATR): ν = 1692 cm-1. 1H NMR (300 MHz, CDCl3): δ 7.57 (1H, 
dd, J 1.8, 8.4 Hz, Ar-H), 7.38 (1H, d, J 1.8 Hz, Ar-H), 7.08 (1H, dt, J 1.8, 8.1 Hz, Ar-
H), 7.00 (1H, dd, J 1.8, 8.1 Hz, Ar-H), 6.95-6.89 (2H, m, 2 x Ar-H), 6.78 (1H, d, J 8.4 
Hz, Ar-H), 5.25 (2H, s, CH2), 1.70 (6H, s, 2 × CH3). 13C NMR (100 MHz, CDCl3): δ 
192.2, 153.3 (d, J 258 Hz, ipso-C), 152.5, 148.2, 146.1 (d, J 9.5Hz, ortho-C), 128.5, 
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124.3 (d, J 4.8 Hz, para-C), 124.2, 122.2 (d, J 7.9 Hz, meta-C), 119.8, 116.6 (d, J 19 
Hz, ortho-C), 116.0, 108.1, 107.8, 71.9, 26.0. HRMS cald. for C17H15FO4Na  
[M+Na+] 325.0845, found 325.0842. 
1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-(3-nitrophenoxy)ethanone (79)  
 
3-Nitrophenol (32 mg, 0.23 mmol) was reacted with α-bromoketone 74 (57 mg, 0.21 
mmol) using general procedure A and purified by column chromatography (3:1 v/v 
CH2Cl2: hexane) to afford 79 as an off-white solid (41 mg, 59%).  
m.p. 171-172 oC. IR (ATR): ν = 1653 cm-1. 1H NMR (300 MHz, 1:1 v/v CDCl3: 
Acetone-d6): δ 7.87 (1H, dd, J 1.6, 8.1 Hz, Ar-H), 7.79 (1H, d, J 1.6 Hz, Ar-H), 7.64 
(1H, dd, J 1.6, 8.1 Hz, Ar-H), 7.50 (1H, t, J 8.1 Hz, Ar-H), 7.36-7.33 (2H, m, 2 x Ar-
H), 6.85 (1H, d, J 8.1 Hz, Ar-H), 5.46 (2H, s, CH2), 1.74 (6H, s, 2 × CH3). 13C NMR 
(100 MHz, 1:1 v/v CDCl3: Acetone-d6): δ 196.5, 164.0, 157.7, 154.3, 153.4, 135.4, 
133.5, 129.2, 127.0, 125.0, 121.4, 114.5, 113.3, 112.7, 75.6, 30.9. HRMS cald. for 
C17H15NO6Na  [M+Na+] 352.0792, found 352.0793. 
1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-(2-(trifluoromethyl) phenylthio) 
ethanone (80) 
 
2-Trifluoromethyl benzenethiol (43 µL, 0.32 mmol) was reacted with α-bromoketone 
74 (57 mg, 0.21 mmol) using general procedure A and purified by column 
chromatography (3:2 v/v CH2Cl2: hexane) to afford 80 as a pale yellow oil (38 mg, 
49%).  
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IR (ATR): ν = 1672 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.65 (1H, m, Ar-H), 7.59-
7.50 (2H, m, 2 x Ar-H), 7.46 (1H, t, J 7.6 Hz, Ar-H), 7.35-7.31 (2H, m, 2 x Ar-H), 
6.76 (1H, d, J 8.0 Hz, Ar-H), 4.24 (2H, s, CH2), 1.07 (6H, s, 2 × CH3). 13C NMR (100 
MHz, CDCl3): δ 192.2, 152.6, 148.4, 134.7, 133.4, 132.6, 130.8 (q, J 30 Hz), 129.8, 
127.4, 127.2 (q, J 5.5 Hz), 125.4 (q, J 272 Hz, CF3), 125.2, 120.0, 108.6, 108.2, 41.4, 
26.0. HRMS cald. for C18H15F3O3SNa  [M+Na+] 391.0586, found 391.0588. 
1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-((4-fluorophenyl)thio)ethanone (81)  
 
4-Fluorothiophenol (34 µL, 0.32 mmol) was reacted with α-bromoketone 74 (57 mg, 
0.21 mmol) using general procedure A and purified by column chromatography (3: 2 
v/v CH2Cl2: hexane) to afford 81 as a pale yellow oil (42 mg, 63%).  
IR (ATR): ν = 1649 cm-1. 1H NMR (300 MHz, CDCl3): δ 7.47 (1H, dd, J 1.8, 8.1 Hz, 
Ar-H), 7.45-7.36 (2H, m, 2 x Ar-H), 7.31 (1H, d, J 1.8 Hz, Ar-H), 7.00-6.94 (2H, m, 2 
x Ar-H), 6.75 (1H, d, J 8.1 Hz, Ar-H), 4.08 (2H, s, CH2), 1.72 (6H, s, 2 × CH3).  
13C NMR (100 MHz, CDCl3): δ 192.6, 162.0 (d, J 210 Hz, ipso-C), 152.4, 148.6, 
134.1 (d, J 8.1 Hz, meta-C), 130.0 (d, J 3.1 Hz, para-C), 129.8, 125.1, 120.0, 116.5 
(d, J 22 Hz, ortho-C), 108.6, 108.2, 42.0, 26.0. HRMS cald. for C17H15FO3SNa 
[M+Na+] 341.0618, found 341.0615. 
2-((4-chlorophenyl)thio)-1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)ethanone (82).  
 
4-Chlorothiophenol (45 mg, 0.32 mmol) was reacted with α-bromoketone 74  (57 mg, 
0.21 mmol) using general procedure A and purified by column chromatography (3:2 
v/v CH2Cl2: hexane) to afford 82 as a pale yellow oil (31 mg, 44%).  
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IR (ATR): ν = 1672 cm-1. 1H NMR (300 MHz, CDCl3): δ 7.50 (1H, dd, J 1.5, 8.1 Hz, 
Ar-H), 7.33 (2H, d, J 8.8 Hz, 2 x Ar-H), 7.26-7.23 (3H, m, 3 x Ar-H), 6.75 (1H, d, J 
8.1 Hz, Ar-H), 4.17 (2H, s, CH2), 1.70 (6H, s, 2 × CH3). 13C NMR (100 MHz, 
CDCl3): δ 192.4, 152.6, 148.5, 133.9, 133.5, 132.2, 129.9, 129.6, 125.1, 120.0, 108.6, 
108.2, 41.4, 26.3. HRMS cald. for C17H16ClO3S [M+H+] 335.0503, found 335.0502. 
1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-(naphthalen-2-yloxy)ethanone (83)  
 
2-Naphthol (31 mg, 0.22 mmol) was reacted with α-bromoketone 74 (57 mg, 0.21 
mmol) using general procedure A and purified by column chromatography (3:2 v/v 
CH2Cl2: hexane) to afford 83 as a white solid (70 mg, 91%).  
m.p. 129-130 oC (decomp.). IR (ATR): ν = 1689 cm-1. 1H NMR (300 MHz, CDCl3): δ 
7.77-7.75 (2H, m, 2 x Ar-H), 7.71 (1H, d, J 8.4 Hz, Ar-H), 7.63 (1H, dd, J 1.6, 8.0 
Hz, Ar-H), 7.45-7.43 (2H, m, 2 x Ar-H), 7.34 (1H, t, J 7.2 Hz, Ar-H), 7.26 (1H, dd, J 
2.4, 8.8 Hz, Ar-H), 7.11 (1H, d, J 2.4 Hz, Ar-H), 6.80 (1H, d, J 8.0 Hz, Ar-H), 5.30 
(2H, s, CH2), 1.72 (6H, s, 2 × CH3). 13C NMR (75 MHz, CDCl3): δ 192.9, 156.5, 
152.8, 148.6, 134.7, 130.1, 129.8, 129.3, 128.1, 127.3, 126.9, 124.6, 124.4, 120.0, 
119.1, 108.4, 108.3, 107.7, 71.1, 26.3. HRMS cald. for C21H18O4Na [M+Na+] 
357.1097, found 357.1091. 
1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-(naphthalen-1-yloxy)ethanone (84)  
 
1-Naphthol (31 mg, 0.22 mmol) was reacted with α-bromoketone 74 (57 mg, 0.21 
mmol) using general procedure A and purified by column chromatography (3:2 v/v 
CH2Cl2: hexane) to afford 84 as a colourless oil (54 mg, 77%).  
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IR (ATR): ν = 1698 cm-1. 1H NMR (300 MHz, CDCl3): δ 8.40-8.37 (1H, m, Ar-H), 
7.83-7.79 (1H, m, Ar-H), 7.65 (1H, dd, J 1.5, 8.1 Hz, Ar-H), 7.52-7.46 (4H, m, 4 x 
Ar-H), 7.32 (1H, t, J 8.1 Hz, Ar-H), 6.80-6.75 (2H, m, 2 x Ar-H), 5.33 (2H, s, CH2), 
1.71 (6H, s, 2 × CH3). 13C NMR (75 MHz, CDCl3): δ 193.1, 154.3, 152.7, 148.6, 
135.0, 129.3, 127.8, 126.9, 126.1, 126.0, 125.9, 124.8, 122.6, 121.6, 120.0, 108.3, 
105.7, 71.6, 26.3. HRMS cald. for C21H19O4  [M+H+] 335.1278, found 335.1280. 
1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-(2-(isoxazol-5-yl)phenoxy)ethanone 
(85)  
 
2-(5-Isoxazolyl)phenol (38 mg, 0.23 mmol) was reacted with α-bromoketone 74  (57 
mg, 0.21 mmol) using general procedure A and purified by column chromatography 
(4:1 v/v CH2Cl2: hexane) to afford 85 as an off-white solid (38 mg, 52%).  
m.p. 138-139 oC (decomp.). IR (ATR): ν = 1697 cm-1. 1H NMR (300 MHz, 1:1 v/v 
CDCl3: Acetone-d6): δ 8.38 (1H, s, Ar-H), 7.98 (1H, d, J 8.0 Hz, Ar-H), 7.68-7.65 
(1H, m, Ar-H), 7.48 (1H, s, Ar-H), 7.42-7.38 (2H, m, 2 x Ar-H), 7.15 (1H, d, J 8.0 
Hz, Ar-H), 7.10 (1H, t, J 8.0 Hz, Ar-H), 6.82 (1H, d, J 8.0 Hz, Ar-H), 5.52 (2H, s, 
CH2), 1.71 (6H, s, 2 × CH3). 13C NMR (100 MHz, 1:1 v/v CDCl3: Acetone-d6): δ 
192.0, 154.6, 152.3, 151.2, 148.2, 131.1, 128.6, 127.4, 123.9, 121.4, 119.7, 116.7, 
112.6, 108.0, 107.3, 103.9, 70.4, 25.6. HRMS cald. for C20H17NO5Na [M+Na+] 
374.0998, found 374.1002. 
1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-(naphthalen-2-ylthio)ethanone (86)  
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2-Naphthalenethiol (51 mg, 0.31 mmol) was reacted with α-bromoketone 74  (57 mg, 
0.21 mmol) using general procedure A and purified by column chromatography (3: 2 
v/v CH2Cl2: hexane) to afford 86 as a pale yellow oil (39 mg, 53%).  
IR (ATR): ν = 1668 cm-1. 1H NMR (300 MHz, CDCl3): δ 7.83-7.73 (4H, m, 4 x Ar-
H), 7.55 (1H, dd, J 1.8, 8.1 Hz, Ar-H), 7.48 (1H, d, J 1.8 Hz, Ar-H), 7.47-7.43 (2H, 
m, 2 x Ar-H), 7.36 (1H, d, J 1.5 Hz, Ar-H), 6.75 (1H, d, J 8.1 Hz, Ar-H), 4.30 (2H, s, 
CH2), 1.69 (6H, s, 2 × CH3). 13C NMR (75 MHz, CDCl3): δ 192.7, 152.5, 148.5, 
134.1, 132.9, 132.6, 130.1, 129.0, 128.3, 128.1, 127.7, 126.9, 126.4, 125.1, 119.9, 
108.7, 108.2, 41.3, 26.3. HRMS cald. for C21H18O3SNa  [M+Na+] 373.0869, found 
373.0863. 
2-(benzo[d]thiazol-2-ylthio)-1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)ethanone 
(87).  
 
2-Mercaptobenzothiazole (66 mg, 0.36 mmol) was reacted with α-bromoketone 74   
(50 mg, 0.18 mmol) using general procedure A and purified by column 
chromatography (49: 1 v/v CH2Cl2: Acetone) to afford 87 as a pale yellow oil (39 mg, 
61%).  
IR (ATR): ν = 1673 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.83 (1H, app. d, J 8.0 Hz, 
Ar-H), 7.74 (1H, app. d, J 7.8 Hz, Ar-H), 7.67 (1H, app. d, J 7.5 Hz, Ar-H), 7.44-7.38 
(2H, m, 2 x Ar-H), 7.31-7.26 (1H, m, Ar-H), 6.80 (1H, d, J 8.0 Hz, Ar-H), 4.87 (2H, 
s, CH2), 1.71 (6H, s, 2 × CH3). 13C NMR (100 MHz, CDCl3): δ 190.7, 164.8, 152.5, 
151.9, 147.4, 135.0, 129.2, 125.6, 124.8, 123.8, 121.1, 120.8, 119.2, 107.7, 107.4, 
40.3, 25.5. HRMS cald. for C18H16NO3S2  [M+H+] 358.0566, found 358.0569. 
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2-((2-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-oxoethyl)thio)quinazolin-4(3H)-
one (88) 
 
2-Mercaptoquinazolin-4(3H)-one (56 mg, 0.31 mmol) was reacted with  
α-bromoketone 74   (57 mg, 0.21 mmol) using general procedure A to yield 88 as a 
white solid which was used without further purification (55 mg, 71%).  
m.p. 219-220 oC (decomp.). IR (ATR): ν = 1661 cm-1. 1H NMR (400 MHz, DMSO-
d6): δ 8.04 (1H, dd, J 1.2, 7.9 Hz, Ar-H), 7.76 (1H, dd, J 1.7, 8.2 Hz, Ar-H), 7.72 (1H, 
dt, J 1.5, 8.5 Hz, Ar-H), 7.50 (1H, d, J 1.7 Hz, Ar-H), 7.42 (1H, dt, J 1.2, 7.9 Hz), 
7.27 (1H, app. d, J 8.5 Hz, Ar-H), 7.05 (1H, d, J 8.2 Hz, Ar-H), 4.82 (2H, s, CH2), 
1.73 (6H, s, 2 × CH3). 13C NMR (100 MHz, DMSO-d6): δ 192.0, 161.6, 155.6, 151.9, 
148.4, 147.4, 134.9, 130.7, 126.6, 126.1, 125.0, 120.3, 120.1, 108.5, 108.1, 37.8, 26.0. 
HRMS cald. for C19H17N2O4S  [M+H+] 369.0904, found 369.0903. 
General procedure B: synthesis of catechol-based inhibitors 89-102 
90% Aqueous TFA (0.3-0.4 mL) was added dropwise to acetonide-based inhibitor 75-
88 (0.017-0.12 mmol) and the reaction was stirred at room temperature or at 50 oC for 
1.5-5 h. At this point, the solvent was removed in vacuo to yield a crude residue that 
was purified by column chromatography. 
1-(3,4-dihydroxyphenyl)-2-phenoxyethanone (89).  
 
Acetonide-based inhibitor 75 (27 mg, 0.095 mmol) was deprotected using general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(95:5 v/v CH2Cl2: CH3OH) to afford inhibitor 89 as an off-white solid (20 mg, 87%).  
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m.p. 157-158 oC (decomp.). IR (ATR): ν = 3404, 3367, 1676 cm-1. 1H NMR (400 
MHz, Acetone-d6): δ 7.55-7.57 (2H, m, 2 x Ar-H), 7.25-7.29 (2H, m, 2 x Ar-H), 6.91-
6.96 (4H, m, 4 x Ar-H), 5.38 (2H, s, CH2). 13C NMR (100 MHz, Acetone-d6): 
δ 192.7, 159.0, 150.9, 145.5, 129.7, 128.0, 122.0, 121.2, 115.3, 115.1, 115.0, 70.4. 
HRMS cald. for C14H12O4Na  [M+Na+] 267.0628, found 267.0624. 
1-(3,4-dihydroxyphenyl)-2-(phenylthio)ethanone (90) 
 
Acetonide-based inhibitor 76 (25 mg, 0.083 mmol) was deprotected using the general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(98:2 v/v CH2Cl2: CH3OH) to afford inhibitor 90 as a pale yellow oil (23 mg, 93%).  
IR (ATR): ν = 3474, 3270, 1657 cm-1. 1H NMR (300 MHz, acetone-d6): δ 7.53-7.50 
(2H, m, 2 x Ar-H), 7.41-7.39 (2H, dd, J 1.2, 7.5 Hz, 2 x Ar-H), 7.29 (2H, t, J 7.5 Hz, 
2 x Ar-H), 7.19 (1H, t, J 7.5 Hz, Ar-H), 6.92 (1H, d, J 8.4 Hz, Ar-H), 4.41 (2H, s, 
CH2). 13C NMR (100 MHz, acetone-d6): δ 192.5, 150.9, 145.4, 136.6, 129.4, 129.3, 
128.7, 126.5, 122.8, 115.7, 115.2, 40.3. HRMS cald. for C14H12SO3Na [M+Na+] 
283.0399, found 283.0395. 
1-(3,4-dihydroxyphenyl)-2-(3-(trifluoromethyl)phenoxy)ethanone (91)  
 
Acetonide-based inhibitor 77 (20 mg, 0.057 mmol) was deprotected using general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(95:5 v/v CH2Cl2: CH3OH) to afford inhibitor 91 as a white solid (14 mg, 78%).  
m.p. 192-193 oC (decomp.). IR (ATR): ν = 3508, 3349, 1678 cm-1. 1H NMR (300 
MHz, Acetone-d6): δ 7.56-7.49 (3H, m, Ar-H), 7.29-7.24 (3H, m, Ar-H), 6.95 (2H, d, 
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J 8.0 Hz, 2 x Ar-H), 5.56 (2H, s, CH2). 13C NMR (100 MHz, Acetone-d6): δ 191.1, 
158.6, 150.4, 144.6, 130.6 (q, J 32 Hz), 129.9, 126.9, 122.4 (q, J 262 Hz, CF3), 121.1, 
118.1, 117.5 (app. d, J 3.7 Hz), 114.5, 114.2, 111.0 (app. d, J 3.4 Hz), 69.6. HRMS 
cald. for C15H11F3O4Na  [M+Na+] 335.0502, found 335.0501. 
1-(3,4-dihydroxyphenyl)-2-(2-fluorophenoxy)ethanone (92)  
 
Acetonide-based inhibitor 78 (17 mg, 0.056 mmol) was deprotected using general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(98:2 v/v CH2Cl2: CH3OH) to afford inhibitor 92 as a white solid (14 mg, 98%).  
m.p. 190-191 oC (decomp.). IR (ATR): ν = 3320, 1691 cm-1. 1H NMR (300 MHz, 
Acetone-d6): δ 7.54-7.51 (2H, m, Ar-H), 7.13 (1H, app. t, J 7.8 Hz, Ar-H), 7.06-7.03 
(2H, m, 2 x Ar-H), 6.94-6.92 (2H, m, 2 x Ar-H), 5.46 (2H, s, CH2). 13C NMR (75 Hz, 
Acetone-d6): δ 193.1, 153.7 (d, J 244 Hz, ipso-C), 152.1, 147.9 (d, J 11 Hz, ortho-C), 
146.4, 128.6, 125.6 (d, J 3.8 Hz, para-C), 122.9, 122.6 (d, J 6.8 Hz, meta-C), 117.2 
(d, J 18 Hz, ortho-C), 116.5, 116.2, 115.7, 71.9. HRMS cald. for C14H11FO4Na  
[M+Na+] 285.0534, found 285.0537. 
1-(3,4-dihydroxyphenyl)-2-(3-nitrophenoxy)ethanone (93) 
 
Acetonide-based inhibitor 79 (22 mg, 0.067 mmol) was deprotected using general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(95:5 v/v CH2Cl2: CH3OH) to afford inhibitor 93 as an off-white solid (16 mg, 85%).  
m.p. 206-207 oC (decomp.). IR (ATR): ν = 3491, 3398, 1679 cm-1. 1H NMR (300 
MHz, Acetone-d6): δ 7.83 (1H, dd, J 1.2, 8.1 Hz, Ar-H), 7.81 (1H, d, J 2.7 Hz, Ar-H), 
7.60-7.54 (3H, m, 3 x Ar-H), 7.41 (1H, dd, J 1.6, 8.0 Hz, Ar-H), 6.95 (1H, d, J 8.0 
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Hz, Ar-H), 5.62 (2H, s, CH2). 13C NMR (75 MHz, Acetone-d6): δ 192.6, 160.6, 152.2, 
150.5, 146.5, 131.6, 128.5, 123.0, 122.9, 116.9, 116.3, 115.9, 110.5, 71.6. HRMS 
cald. for C14H11NO6Na  [M+Na+] 312.0479, found 312.0476. 
1-(3,4-dihydroxyphenyl)-2-((2-(trifluoromethyl)phenyl)thio)ethanone (94)  
 
Acetonide-based inhibitor 80 (18 mg, 0.049 mmol) was deprotected using general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(98:2 v/v CH2Cl2: CH3OH) to afford inhibitor 94 as an off-white solid (13 mg, 86%).  
m.p. 169-170 oC (decomp.). IR (ATR): ν = 3485, 3367, 1657 cm-1. 1H NMR (300 
MHz, CD3OD): δ 7.68 (1H, dd, J 1.2, 7.8 Hz, Ar-H), 7.62 (1H, dd, J 1.2, 7.8 Hz, Ar-
H), 7.53 (1H, dt, J 1.5, 7.8 Hz, Ar-H), 7.48-7.43 (2H, m, 2 x Ar-H), 7.35 (1H, dt, J 
1.2, 7.5 Hz, Ar-H), 6.82 (1H, d, J 8.5 Hz, Ar-H), 4.87 (2H, s, CH2). 13C NMR (100 
MHz, Acetone-d6): δ 191.9, 151.1, 145.4, 136.4, 132.9, 131.2, 128.9, 128.6, 127.0 (q, 
J 28 Hz), 126.3,125.9 (q, J 271 Hz, CF3), 122.9, 115.6, 115.3, 40.7. HRMS cald. for 
C15H12F3O3S  [M+H+] 329.0454, found 329.0454. 
1-(3,4-dihydroxyphenyl)-2-((4-fluorophenyl)thio)ethanone (95)  
 
Acetonide-based inhibitor 81 (29 mg, 0.091 mmol) was deprotected using general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(98:2 v/v CH2Cl2: CH3OH) to afford inhibitor 95 as a pale yellow oil (18 mg, 73%).  
IR (ATR): ν = 3527, 3329, 1654 cm-1. 1H NMR (300 MHz, Acetone-d6): δ 7.58-7.42 
(4H, m, 4 x Ar-H), 7.09-7.04 (2H, m, 2 x Ar-H), 6.78 (1H, d, J 7.8 Hz, Ar-H), 4.35 
(2H, s, CH2). 13C NMR (100 MHz, Acetone-d6): δ 192.1, 162.0 (d, J 240 Hz, ipso-C), 
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150.6, 145.0, 132.4 (d, J 8.0 Hz, meta-C), 131.3 (d, J 3.1 Hz, para-C), 128.2, 122.5, 
116.0 (d, J 20 Hz, ortho-C), 115.3, 114.7, 40.9. HRMS cald. for C14H11FO3SNa  
[M+Na+] 301.0305, found 301.0301. 
2-((4-chlorophenyl)thio)-1-(3,4-dihydroxyphenyl)ethanone (96)  
 
Acetonide-based inhibitor 82 (20 mg, 0.060 mmol) was deprotected using general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(98:2 v/v CH2Cl2: CH3OH) to afford inhibitor 96 as a pale yellow oil (17 mg, 98%).  
IR (ATR): ν = 3545, 3442, 1709 cm-1. 1H NMR (300 MHz, Acetone-d6): δ 7.52-7.49 
(2H, m, 2 x Ar-H), 7.38 (2H, d, J 8.7 Hz, 2 x Ar-H), 7.30 (2H, d, J 8.7 Hz, 2 x Ar-H), 
6.92 (1H, d, J 8.8 Hz, Ar-H), 4.45 (2H, s, CH2). 13C NMR (75 MHz, Acetone-d6): δ 
193.1, 151.9, 146.3, 136.5, 132.8, 131.9, 130.1, 129.5, 123.8, 116.6, 116.1, 41.2. 
HRMS cald. for C14H11ClO3SNa  [M+Na+] 317.0010, found 317.0015. 
1-(3,4-dihydroxyphenyl)-2-(naphthalen-2-yloxy)ethanone (97).  
 
Acetonide-based inhibitor 83 (39 mg, 0.12 mmol) was deprotected using general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(95:5 v/v CH2Cl2: CH3OH) to afford inhibitor 97 as an off-white solid (31 mg, 88%).  
m.p. 174-175 oC (decomp). IR (ATR): ν = 3423, 3283, 1682 cm-1. 1H NMR (300 
MHz, Acetone-d6): δ 7.86-7.84 (2H, m, 2 x Ar-H), 7.75 (1H, app. d, Ar-H, J 8.1 Hz), 
7.62-7.60 (2H, m, 2 x Ar-H), 7.43 (1H, dt, J 1.5, 8.1 Hz, Ar-H), 7.36-7.32 (2H, m, 2 x 
Ar-H), 7.25 (1H, dd, J 2.4, 9.0 Hz, Ar-H), 6.98 (1H, d, J 8.7 Hz, Ar-H), 5.51 (2H, s, 
CH2). 13C NMR (100 MHz, Acetone-d6): δ 191.6, 156.1, 150.2, 144.6, 134.2, 128.9, 
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128.8, 127.2, 127.1, 126.3, 125.8, 123.2, 121.2, 118.2, 114.5, 114.4, 106.8, 69.7. 
HRMS cald. for C18H14O4Na  [M+Na+] 317.0784, found 317.0787. 
1-(3,4-dihydroxyphenyl)-2-(naphthalen-1-yloxy)ethanone (98)  
 
Acetonide-based inhibitor 84 (39 mg, 0.12 mmol) was deprotected using general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(98:2 v/v CH2Cl2: CH3OH) to afford inhibitor 98 as a colourless oil (31 mg, 88%).  
IR (ATR): ν = 3518, 3430, 1705 cm-1. 1H NMR (300 MHz, Acetone-d6): δ 8.40-8.37 
(1H, m, Ar-H), 7.88-7.85 (1H, m, Ar-H), 7.63-7.61 (2H, m, 2 x Ar-H), 7.55-7.47 (3H, 
m, 3 x Ar-H), 7.38 (1H, app. t, J 7.8 Hz, Ar-H), 6.99-6.94 (2H, m, 2 x Ar-H), 5.57 
(2H, s, CH2). 13C NMR (75 MHz, Acetone-d6): δ 192.4, 154.5, 151.2, 145.6, 135.1, 
127.9, 127.8, 126.7, 126.2, 126.1, 125.5, 122.6, 122.5, 120.8, 115.5, 115.3, 105.8, 
70.8. HRMS cald. for C18H14O4Na [M+Na+] 317.0784, found 317.0787. 
1-(3,4-dihydroxyphenyl)-2-(2-(isoxazol-5-yl)phenoxy)ethanone (99)  
 
Acetonide-based inhibitor 85 (29 mg, 0.082 mmol) was deprotected using general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(9:1 v/v CH2Cl2: CH3OH) to afford inhibitor 99 as an off-white solid (23 mg, 92%). 
m.p. 198-199 oC (decomp.).  
IR (ATR): ν = 3352, 3234, 1683 cm-1. 1H NMR (300 MHz, Acetone-d6): δ 8.53 (1H, 
m, Ar-H), 8.03 (1H, dd, J 1.5, 7.8 Hz, Ar-H), 7.66-7.64 (2H, m, 2 x Ar-H), 7.56 (1H, 
m, Ar-H), 7.50 (1H, app. t, J 8.4 Hz, Ar-H), 7.33 (1H, d, J 8.4 Hz, Ar-H), 7.19 (1H, 
app. t, J 7.8 Hz), 7.00 (1H, d, J 8.7 Hz, Ar-H), 5.69 (2H, s, CH2). 13C NMR (100 
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MHz, Acetone-d6): δ 191.3, 164.8, 154.9, 151.2, 150.9, 145.3, 131.2, 127.2, 127.1, 
121.6, 121.2, 116.5, 115.1, 114.6, 112.9, 104.3, 70.4. HRMS cald. for C17H13NO5Na  
[M+Na+] 334.0686, found 334.0689. 
1-(3,4-dihydroxyphenyl)-2-(naphthalen-2-ylthio)ethanone (100)  
 
Acetonide-based inhibitor 86 (30 mg, 0.086 mmol) was deprotected using general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(98:2 v/v CH2Cl2: CH3OH) to afford inhibitor 100 as a white solid (20 mg, 75%).  
m.p. 125-126 oC (decomp.). IR (ATR): ν = 3470, 3384, 1667 cm-1. 1H NMR (400 
MHz, Acetone-d6): δ 7.95-7.84 (4H, m, 4 x Ar-H), 7.63-7.60 (2H, m, 2 x Ar-H), 7.57-
7.48 (3H, m, 3 x Ar-H), 6.98 (1H, app. d, J 8.0 Hz, Ar-H), 4.62 (2H, s, CH2). 13C 
NMR (100 MHz, Acetone-d6): δ 192.1, 150.7, 145.1, 134.0, 133.9, 131.9, 128.4, 
128.3, 127.7, 127.1, 127.0, 126.7, 126.5, 125.8, 122.6, 115.3, 114.9, 39.8. HRMS 
calcd. for C18H14O3SNa  [M+Na+] 333.0556, found 333.0554. 
2-(benzo[d]thiazol-2-ylthio)-1-(3,4-dihydroxyphenyl)ethanone (101)  
 
Acetonide-based inhibitor 87 (6 mg, 0.017 mmol) was deprotected using general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(98:2 v/v CH2Cl2: CH3OH) to afford inhibitor 101 as a yellow oil (4.4 mg, 83%).  
IR (ATR): ν = 3287, 1671 cm-1. 1H NMR (400 MHz, Acetone-d6): δ 7.95 (1H, d, J 8.0 
Hz, Ar-H), 7.81 (1H, d, J 8.0 Hz, Ar-H), 7.63 (1H, dd, J 1.8, 8.0 Hz, Ar-H), 7.60 (1H, 
app. d, J 1.8 Hz, Ar-H), 7.46 (1H, app. t, J 8.0 Hz, Ar-H), 7.36 (1H, app. t, J 8.0 Hz, 
Ar-H), 6.99 (1H, app. d, J 8.0 Hz, Ar-H), 5.03 (2H, s, CH2). 13C NMR (100 MHz, 
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Acetone-d6): δ 190.5, 167.0, 153.2, 151.0, 145.2, 135.3, 128.2, 126.2, 124.4, 122.4, 
121.4, 121.3, 115.2, 115.0, 40.3. LRMS [M+H]+ 318.0. These data are in agreement 
with those previously reported by Madsen et al.[175] 
2-((2-(3,4-dihydroxyphenyl)-2-oxoethyl)thio)quinazolin-4(3H)-one (102) 
 
Acetonide-based inhibitor 88 (18 mg, 0.049 mmol) was deprotected using general 
procedure B at 50 oC for 5 h and purified by column chromatography  
(9:1 v/v CH2Cl2: CH3OH) to afford inhibitor 102 as a white solid (16 mg, 83%).  
m.p. 214-215 oC. IR (ATR): ν = 3164, 1667 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 
9.99 (1H, s, OH), 9.43 (1H, s, OH), 8.01 (1H, app. d, J 8.2 Hz, Ar-H), 7.70 (1H, dt, J 
1.1, 8.0 Hz, Ar-H), 7.53 (1H, dd, J 1.7, 8.5 Hz, Ar-H), 7.43 (1H, app. d, J 1.7 Hz, Ar-
H), 7.39 (1H, app. t, J 8.0 Hz, Ar-H), 7.27 (1H, app. d, J 8.2 Hz, Ar-H), 6.88 (1H, 
app. d, J 8.2 Hz, Ar-H), 4.76 (2H, s, CH2). 13C NMR (100 MHz, DMSO-d6): δ 191.7, 
161.5, 155.5, 151.5, 148.7, 145.6, 135.1, 128.2, 126.5, 126.2, 126.1, 122.3, 120.3, 
115.6 (×2), 37.5. HRMS cald. for C16H13N2O4S  [M+H+] 329.0591, found 329.0590. 
4-(naphthalen-2-yl)phenol (109) 
 
To a solution of isopropylmagnesium chloride (1.8 mL, 2.0 M in THF, 3.6 mmol) in 
THF (6 mL) was added n-butyllithium (3.1 mL, 2.3 M in hexane, 7.2 mmol) at 0 oC 
and the mixture was stirred at this temperature for 10 min. The resulting yellow 
solution was cooled to -78 oC and a solution of 4-bromoanisole (560 mg, 3.0 mmol) in 
THF (6 mL) was added dropwise. The reaction was stirred at -78 oC for 1 h to afford 
112 which was immediately used in the next step. 
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112 in THF (6.8 mL, 1.2 mmol) was added to a solution of 2-bromonaphthalene (746 
mg, 3.60 mmol) and tetrakis(triphenylphosphine)palladium (210 mg, 0.18 mmol) in 
THF (4.5 mL). The reaction was allowed to heat at reflux for 16 h. The reaction 
mixture was cooled to room temperature and poured into 1 M HCl (40 mL). The 
mixture was extracted with CH2Cl2 (2× 100 mL) and the solvent was removed in 
vacuo to give a crude residue that was purified by column chromatography to afford 
methyl ether 114 (3:1 v/v CH2Cl2: Hexane → 2:1 v/v CH2Cl2: Hexane) as a white 
solid (70 mg, 25%).  
Methyl ether 114 (70 mg, 0.30 mmol) and pyridinium hydrochloride (0.50 g, 4.3 
mmol) was heated at 190 oC for 2 h. The reaction mixture was allowed to cool to 
room temperature and was stirred with 1 M HCl (10 mL). The resulting suspension 
was filtered and dissolved in ethyl acetate (30 mL) and washed with water (10 mL), 
dried over anhydrous Na2SO4. The solvent was removed in vacuo to give a crude 
residue that was purified by column chromatography (3:2 v/v Hexane: EtOAc) to 
afford 109 as a white solid (50 mg, 76%).  
m.p. 163-164 oC (decomp.). IR (ATR): 3322, 1610, 1590 cm-1. 1H NMR (400 MHz, 
CDCl3): δ 8.00-7.95 (1H, m, Ar-H), 7.93-7.81 (3H, m, Ar-H), 7.70 (1H, dd, J 8.5, 1.9 
Hz, Ar-H), 7.62 (2H, d, J 8.6 Hz, Ar-H), 7.54-7.40 (2H, m, Ar-H), 6.95 (2H, d, J 8.6 
Hz, Ar-H). These data are in agreement with those previously reported by Bolliger et 
al.[176] 
3-(naphthalen-2-yl)phenol (110) 
 
 
To a solution of isopropylmagnesium chloride (1.8 mL, 2.0 M in THF, 3.6 mmol) in 
THF (6 mL) was added n-butyllithium (3.1 mL, 2.3 M in hexane, 7.2 mmol) at 0 oC 
and the mixture was stirred at this temperature for 10 min. The resulting yellow 
solution was cooled to -78 oC and a solution of 4-bromoanisole (560 mg, 3.0 mmol) in 
THF (6 mL) was added dropwise. The reaction was stirred at -78 oC for 1 h to afford 
113 which was immediately used in the next step. 
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113 in THF (6.8 mL, 1.2 mmol) was added to a solution of 2-bromonaphthalene (746 
mg, 3.60 mmol) and tetrakis(triphenylphosphine)palladium (210 mg, 0.18 mmol) in 
THF (4.5 mL). The reaction was allowed to heat at reflux for 16 h. The reaction 
mixture was cooled to room temperature and poured into 1 M HCl (40 mL). The 
mixture was extracted with CH2Cl2 (2× 100 mL) and the solvent was removed in 
vacuo to give a crude residue that was purified by column chromatography to afford 
methyl ether 115 (3:1 v/v CH2Cl2: Hexane → 2:1 v/v CH2Cl2: Hexane) to afford 115 
as a white solid (82 mg, 29%).  
Methyl ether 115 (82 mg, 0.35 mmol) in CH2Cl2 (2 mL) was treated with boron 
tribromide solution (385 µL of a 1 mM solution in CH2Cl2) at 0 oC. The reaction was 
stirred at 0 oC for 1 h and warmed to room temperature over 2 h. The reaction mixture 
was poured onto ice (10 mL) and allowed to stir for 15 min. The reaction mixture was 
extracted with EtOAc (30 mL) and the combined organic extract was washed with 
brine, dried over anhydrous Na2SO4, filtered and the solvent was removed in vacuo to 
give a crude residue that was purified by column chromatography (3:2 v/v CH2Cl2: 
Hexane → 5:1 v/v CH2Cl2: Hexane) to afford 110 as a white solid (63 mg, 81%).  
m.p. 110-112 oC (decomp.). IR (ATR): 3276, 1600, 1583 cm-1. 1H NMR (400 MHz, 
CDCl3): δ 8.09-8.00 (1H, m, Ar-H), 7.97-7.81 (3H, m, Ar-H), 7.72 (1H, dd, J 8.6, 1.8 
Hz, Ar-H), 7.58-7.41 (2H, m, Ar-H), 7.36 (1H, t, J 7.8 Hz, Ar-H), 7.33-7.28 (1H, m, 
Ar-H), 7.20 (1H, t, J 2.1 Hz, Ar-H), 6.95-6.77 (1H, m, Ar-H). 13C NMR (101 MHz, 
CDCl3): δ 155.9, 142.9, 138.0, 133.6, 132.7, 130.1, 128.4, 128.2, 127.6, 126.3, 126.0, 
125.8, 125.5, 120.1, 114.3 (× 2). These data are in agreement with those previously 
reported by Frotscher et al.[177]  
4,5-diphenyloxazole-2-thiol (111) 
 
32% HCl solution (1.5 mL) was added to a solution of potassium thiocyanate (1.37 g, 
14 mmol) in absolute ethanol (20 mL) and the precipitate (potassium chloride) was 
filtered. Benzoin (2.0 g, 9.3 mmol) was added to the filtrate and the reaction mixture 
N
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was stirred at reflux for 24 h. The reaction mixture was allowed to cool, precipitate 
filtered and dissolved in 1 M NaOH (15 mL). Unreacted benzoin was subsequently 
filtered and the filtrate was acidified with glacial acetic acid. The precipitate formed 
was filtered, washed with water and dried to afford thiol 111 as an off-white 
crystalline solid (1.08 g, 46%) which was used without further purification.  
m.p. 252-254 oC. IR (ATR):  3067, 2929, 1511, 1496 cm-1. 1H NMR (400 MHz, 
DMSO-d6): δ 7.63-7.46 (5H, m, Ar-H), 7.44-7.33 (5H, m, Ar-H). These data are in 
agreement with those previously reported in AIST and BIORAD databases.[178]  
1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-(4-(naphthalen-2-
yl)phenoxy)ethanone (103).  
 
4-(Naphthalen-2-yl)phenol 109 (40 mg, 0.18 mmol) was reacted with α-bromoketone 
74 (45 mg, 0.16 mmol) using general procedure A and purified by column 
chromatography (3:2 v/v CH2Cl2: hexane) to afford 103 as a white solid (40 mg, 
62%).  
m.p. 119-120 oC (decomp.). IR (ATR): ν = 1691 cm-1. 1H NMR (400 MHz, CDCl3): δ 
7.99 (1H, s, Ar-H), 7.90-7.84 (3H, m, 3 x Ar-H), 7.70 (1H, d, J 8.3 Hz, Ar-H), 7.66-
7.61 (3H, m, 3 x Ar-H), 7.51-7.44 (3H, m, 3 x Ar-H), 7.05 (2H, d, J 8.4 Hz, 2 x Ar-
H), 6.81 (1H, d, J 8.1 Hz, Ar-H), 5.24 (2H, s, CH2), 1.72 (6H, s, 2 × CH3). 13C NMR 
(100 MHz, CDCl3): δ 192.5, 157.8, 152.3, 148.2, 138.0, 134.4, 132.5, 128.8, 128.5, 
128.4, 128.0, 127.6, 126.2, 125.7, 125.4, 125.1, 124.2, 119.7, 115.2, 108.0, 107.9, 
70.6, 25.7. HRMS cald. for C27H23O4  [M+H+] 411.1596, found 411.1591. 
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1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-(3-(naphthalen-2-yl)phenoxy)ethan-1-
one (104) 
 
3-(Naphthalen-2-yl)phenol 110 (40 mg, 0.18 mmol) was reacted with α-bromoketone 
74 (45 mg, 0.16 mmol) using general procedure A and purified by column 
chromatography (3:2 v/v CH2Cl2: hexane) to afford 104 as an amorphous solid (38 
mg, 58%).  
IR (ATR): ν = 1706 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.02 (1H, d, J 1.4 Hz, Ar-
H), 7.92-7.85 (3H, m, 3 x Ar-H), 7.72 (1H, dd, J 1.8, 8.5 Hz, Ar-H), 7.62 (1H, dd, J 
1.8, 8.2 Hz, Ar-H), 7.51-7.48 (2H, m, 2 x Ar-H), 7.44 (1H, d, J 1.8 Hz, Ar-H), 7.40 
(1H, app. t, J 7.8 Hz, Ar-H), 7.36 (1H, app. t, J 1.4 Hz, Ar-H), 7.34-7.32 (1H, m, Ar-
H), 6.94 (1H, ddd, J 1.4, 2.6, 7.8 Hz, Ar-H), 6.80 (1H, app. d, J 8.2 Hz, Ar-H), 5.26 
(2H, s, CH2), 1.73 (6H, s, 2 × CH3). 13C NMR (100 MHz, CDCl3): δ 192.6, 158.9, 
152.2, 147.9, 142.7, 137.9, 133.6, 132.7, 129.9, 128.8, 128.4, 128.2, 127.6, 126.3, 
126.0, 125.9, 125.6, 124.7, 120.8, 119.7, 114.3, 113.3, 108.0, 107.9, 70.7, 26.3. 
HRMS cald. for C27H23O4  [M+H+] 411.1596, found 411.1591. 
1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-((4,5-diphenyloxazol-2-
yl)thio)ethanone (105).  
 
4,5-Diphenyloxazole-2-thiol 111 (61 mg, 0.24 mmol) was reacted with  
α-bromoketone 74 (50 mg, 0.18 mmol) using general procedure A and purified by 
column chromatography (2:1 v/v CH2Cl2: hexane) to afford 105 as a colourless oil (52 
mg, 65%).  
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IR (ATR): ν = 1675 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.65 (1H, dd, J 1.6, 8.0 Hz, 
Ar-H), 7.62 (2H, dd, J 1.6, 8.0 Hz, 2 x Ar-H), 7.54 (2H, dd, J 1.6, 8.0 Hz, 2 x Ar-H), 
7.44 (1H, app. d, J 1.6 Hz, Ar-H), 7.39-7.31 (6H, m, Ar-H), 6.79 (1H, app. d, J 8.0 
Hz, Ar-H), 4.77 (2H, s, CH2), 1.71 (6H, s, 2 × CH3). 13C NMR (100 MHz, CDCl3): δ 
191.1, 158.3, 152.5, 148.2, 147.4, 136.4, 129.6, 128.7, 128.6, 128.5, 126.4, 124.8, 
119.7, 108.1, 107.8, 40.6, 25.6. HRMS cald. for C26H22NO4S [M+H+] 444.1264, 
found 444.1264. 
1-(3,4-dihydroxyphenyl)-2-(4-(naphthalen-2-yl)phenoxy)ethanone (106)  
 
Acetonide-based inhibitor 103 (10 mg, 0.024 mmol) was deprotected using general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(9:1 v/v CH2Cl2: CH3OH) to afford inhibitor 106 as an amorphous solid (7.5 mg, 
84%).  
IR (ATR): ν = 3300, 1726 cm-1. 1H NMR (400 MHz, Acetone-d6): δ 8.13 (1H, s, Ar-
H), 7.98-7.96 (2H, m, 2 x Ar-H), 7.91 (1H, d, J 8.4 Hz, Ar-H), 7.81 (1H, dd, J 1.8, 8.6 
Hz, Ar-H), 7.75 (2H, d, J 8.8 Hz, 2 x Ar-H), 7.60-7.58 (2H, m, 2 x Ar-H), 7.54-7.47 
(2H, m, 2 x Ar-H), 7.11 (2H, d, J 8.8 Hz, 2 x Ar-H), 6.97 (1H, d, J 8.0 Hz, Ar-H), 
5.46 (2H, s, CH2). 13C NMR (100 MHz, Acetone-d6): δ 192.2, 158.3, 150.9, 145.2, 
137.9, 133.9, 133.4, 132.4, 128.3, 128.1, 128.0, 127.5, 126.2, 125.6, 125.1, 124.7, 
121.6, 115.1, 114.9, 114.7, 70.0. HRMS cald. for C24H19O4 [M+H+] 371.1278, found 
371.1278. 
1-(3,4-dihydroxyphenyl)-2-(3-(naphthalen-2-yl)phenoxy)ethan-1-one (107) 
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Acetonide-based inhibitor 104 (21 mg, 0.051 mmol) was deprotected using general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(9:1 v/v CH2Cl2: CH3OH) to afford inhibitor 107 as an amorphous solid (16 mg, 
84%). 
IR (ATR):  ν = 3339, 1689 cm-1. 1H NMR (400 MHz, Acetone-d6): δ 8.17 (1H, s, Ar-
H), 7.99-7.96 (2H, m, 2 x Ar-H), 7.92 (1H, dd, J 2.1 Hz, 8.8 Hz, Ar-H), 7.81 (1H, dd, 
J 1.8, 8.5 Hz, Ar-H), 7.66-7.56 (2H, m, 2 x Ar-H), 7.54-7.50 (2H, m, 2 x Ar-H), 7.41-
7.39 (3H, m, 3 x Ar-H), 7.00 (1H, ddd, J 1.7, 2.4, 7.6 Hz, Ar-H), 6.95 (1H, app. d, J 
8.2 Hz), 5.49 (2H, s, 2 × CH2). 13C NMR (100 MHz, Acetone-d6): δ 192.0, 159.2, 
150.9, 145.1, 142.1, 138.0, 133.7, 132.9, 129.9, 128.4, 128.2, 127.5 (×2) 126.2, 126.0, 
125.6, 125.2, 121.7, 119.9, 114.9, 114.7, 113.7, 113.5, 69.8. HRMS cald. for 
C24H19O4 [M+H+] 371.1278, found 371.1273. 
1-(3,4-dihydroxyphenyl)-2-((4,5-diphenyloxazol-2-yl)thio)ethanone (108)  
 
Acetonide-based inhibitor 105 (40 mg, 0.090 mmol) was deprotected using general 
procedure B at room temperature for 1.5 h and purified by column chromatography 
(9:1 v/v CH2Cl2: CH3OH) to afford inhibitor 108 as a white solid (30 mg, 83%).  
m.p. 190-191 oC (decomp.). IR (ATR): ν = 3257, 1659 cm-1. 1H NMR (400 MHz, 
DMSO-d6): δ 7.51-7.38 (12H, m, 12 x Ar-H), 6.85 (1H, d, J 8.5 Hz, Ar-H), 4.96 (2H, 
s, CH2). 13C NMR (100 MHz, DMSO-d6): δ 191.4, 158.8, 151.5, 146.7, 145.8, 136.2, 
132.1, 129.4, 129.2, 127.9, 126.6, 122.6, 115.7, 115.6, 40.2. HRMS cald. for 
C23H18NO4S [M+H+]  404.0951, found 404.0951. 
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7.5 Synthesis for compounds in chapter 5 
 (3R,4R,5S,6R)-3-acetamido-6-(acetoxymethyl)tetrahydro-2H-pyran-2,4,5-triyl 
triacetate (118) 
 
N-acetyl-D-glucosamine 117 (10 g, 45 mmol) was dissolved in pyridine (54 mL) and 
the reaction mixture was stirred at 0 oC. 4-dimethylaminopyridine (109 mg, 0.9 
mmol) was added followed by the dropwise addition of acetic anhydride (27 mL, 280 
mmol) and the reaction was warmed up to room temperature and stirred for a further 
16 h. The reaction was subsequently dissolved in ethyl acetate (200 mL), washed with 
1 M HCl (2× 50 mL), water (4× 50 mL), brine (50 mL) and the organic layer was 
dried over anhydrous MgSO4 to give a crude residue that was purified by column 
chromatography (9:1 v/v EtOAc: CH2Cl2) to afford peracetylated sugar 118 as a white 
foam (15 g, 86%).  
IR (ATR): ν = 1749, 1663 cm-1. 1H NMR (400 MHz, CD3OD): δ 6.09 (1H, d, J 3.6 
Hz, H-1), 5.30 (1H, dd, J 11.0, 9.3 Hz, H-3), 5.10 (1H, dd, J 10.2, 9.3 Hz, H-4), 4.40 
(1H, dd, J 11.0, 3.6 Hz, H-2), 4.29 (1H, dd, J 12.4, 4.1 Hz, H-6), 4.14 (1H, ddd, J 
10.2, 4.1, 2.4 Hz, H-5), 4.06 (1H, dd, J 12.4, 2.4 Hz, H-6), 2.19 (3H, s, OAc), 2.05 
(3H, s, OAc), 2.02 (3H, s, OAc), 2.00 (3H, s, NHAc). [!]!!" = +91o (c = 0.39 in 
CH2Cl2). These data are in agreement with those previously reported by Knapp et 
al.[179]  
(2R,3S,4R,5R,6S)-5-acetamido-2-(acetoxymethyl)-6-hydroxytetrahydro-2H-
pyran-3,4-diyl diacetate (119) 
 
A solution of peracetylated sugar 118 (5.0 g, 13 mmol) and benzylamine (2.1 mL, 19 
mmol) in THF (30 mL) was stirred at 0 oC for 30 min and slowly warmed to room 
temperature and was stirred for a further 16 h. The mixture was then diluted with cold 
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water (50 mL) and extracted with CH2Cl2 (3× 80 mL). The combined organic layers 
were washed with cold 1 M HCl (50 mL), saturated aqueous NaHCO3 solution (50 
mL), water (50 mL), brine (50 mL) and dried over anhydrous Na2SO4 to afford a 
crude residue that was purified by column chromatography (9:1 v/v EtOAc: CH2Cl2) 
to afford hemiacetal 119 as a white foam (2.5 g, 56%, α-anomer only).  
IR (ATR): ν = 1738, 1657 cm-1. 1H NMR (400 MHz, Acetone-d6): δ 5.31-5.24 (1H, 
m, H-4), 5.18-5.13 (1H, m, H-1), 5.00 (1H, t, J 9.7 Hz, H-3), 4.24-4.16 (3H, m, H-2 + 
H-6), 4.09-3.98 (1H, m, H-5), 2.09 (3H, s, OAc), 2.00 (3H, s, OAc), 1.98 (3H, s, 
OAc), 1.90 (3H, s, NHAc). [!]!!" = +44o (c = 0.38 in MeOH). These data are in 
agreement with those previously reported by Sim et al.[180]   
(3S,4R,5S,6R)-5-acetamido-2-(acetoxymethyl)-6-
((bis(benzyloxy)phosphanyl)oxy)tetrahydro-2H-pyran-3,4-diyl diacetate (120) 
 
Dibenzyl N,N-diisopropylphosphoramidite (470 µL, 1.44 mmol) was added to a 
solution of hemiacetal 119 (200 mg, 0.57 mmol) and 1,2,4-triazole (156 mg, 2.3 
mmol) in anhydrous CH2Cl2 (4 mL) at 0 oC. The mixture was then allowed to warm to 
room temperature and stirred for a further 16 h. The mixture was then diluted with 
diethyl ether (20 mL), washed with ice cold saturated aqueous NaHCO3 solution (20 
mL), brine (20 mL) and dried over anhydrous MgSO4 to give a crude residue that was 
purified by column chromatography (4:1 v/v Hexane: EtOAc) to afford phosphite 120 
as a colourless oil (101 mg, 30%, β-anomer only).  
IR (ATR): ν = 3320, 1750, 1654 cm-1. 1H NMR (400 MHz, CDCl3): δ 5.56 (1H, dd, J 
7.9, 3.4 Hz, H-1), 5.48 (1H, d, J 9.3 Hz, NH), 5.24-5.16 (1H, m, H-4), 5.16-5.09 (1H, 
m, H-3), 4.35 (1H, app. td, J 9.9, 3.5 Hz, H-2), 4.16-4.04 (1H, m, H-6), 4.05-3.97 
(1H, m, H-6), 3.92 (1H, dd, J 12.4, 2.3 Hz, H-5), 2.03 (3H, s, OAc), 2.02 (3H, OAc), 
2.01 (3H, OAc), 1.63 (3H, s, NHAc). [!]!!" = +0.5o (c = 0.94 in CH2Cl2). These data 
are in agreement with those previously reported by Sim et al.[180]   
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(2R,3S,4R,5R,6R)-5-acetamido-2-(acetoxymethyl)-6-
((bis(benzyloxy)phosphoryl)oxy)tetrahydro-2H-pyran-3,4-diyl diacetate (121) 
 
To a solution of phosphite 120 (101 mg, 0.17 mmol) in THF (4 mL) cooled to -78 oC 
was added dropwise 30% (w/v) aqueous hydrogen peroxide (770 µL, 6.8 mmol). The 
mixture was allowed to warm up to room temperature and was stirred for a further  
3 h. The mixture was diluted with diethyl ether (20 mL) and washed with ice cold 
saturated aqueous NaHCO3 solution (20 mL), brine (20 mL) and dried over anhydrous 
MgSO4 to give a crude residue that was purified by column chromatography (2:1 v/v 
EtOAc: CH2Cl2 → 4:1 v/v EtOAc: CH2Cl2) to afford phosphate 121 as a colourless 
oil (80 mg, 79%, β-anomer only).  
IR (ATR): ν = 3319, 2972, 1714, 1649 cm-1. 1H NMR (400 MHz, CD3OD): δ 5.70 
(1H, dd, J 6.2, 3.4 Hz, H-1), 5.24 (1H, dd, J 11.0, 9.3 Hz, H-3), 5.08-5.00 (1H, m,  
H-4), 4.32 (1H, app. ddt, J 10.9, 8.6, 3.4 Hz, H-2), 4.16 (1H, dd, J 12.1, 4.1 Hz, H-6), 
4.04-3.93 (2H, m, H-5 + H-6), 2.01 (3H, s, OAc), 1.98 (3H, s, OAc), 1.95 (3H, s, 
OAc), 1.82 (3H, s, NHAc). [!]!!" = +0.1o (c = 0.58 in CH2Cl2). These data are in 
agreement with those previously reported by Sim et al.[180]   
(2R,3S,4R,5R,6R)-5-acetamido-2-(acetoxymethyl)-6-(phosphonooxy)tetrahydro-
2H-pyran-3,4-diyl diacetate (122) 
 
Phosphate 121 (420 mg, 0.70 mmol) was hydrogenated (1 atm) over 10% Pd/C (110 
mg) in absolute ethanol (27 mL). The reaction was allowed to stir at room 
temperature for 16 h. The reaction mixture was subsequently filtered over deactivated 
Celite® (deactivation was achieved by passing a saturated solution of NH4HCO3 in 
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ethanol through Celite®) and the filter cake was thoroughly washed with ethanol (100 
mL). The solvent was removed in vacuo to afford phosphate 122 as a colourless oil 
(298 mg, quant., β-anomer only).  
IR (ATR): ν = 2989, 1738, 1658 cm-1. 1H NMR (400 MHz, CD3OD): δ 5.48 (1H, dd, 
J 6.4, 3.4 Hz, H-1), 5.31 (1H, app. t, J 10.0 Hz, H-3), 5.09 (1H, app. t, J 10.0 Hz, H-
4), 4.42-4.22 (3H, m, H-2 + H-5 + H-6), 4.17 (1H, dd, J 12.3, 2.1 Hz, H-6), 2.05 (3H, 
s, OAc), 2.01 (3H, s, OAc), 1.96 (3H, s, OAc), 1.94 (3H, s, NHAc). [!]!!" = +71o  
(c = 0.12 in MeOH). These data are in agreement with those previously reported by 
Sim et al.[180] 
(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-
pyran-2-yl dihydrogen phosphate (diammonium salt, 123) 
 
Phosphate 122 (106 mg, 0.25 mmol) was treated with 10 vol.% triethylamine in a 
mixture of methanol and water (1:1 v/v, 1.4 mL) for 16 h at room temperature. The 
solvent was removed in vacuo to give a crude residue that was purified by column 
chromatography (CH2Cl2 → 7:3 v/v CH2Cl2: 5 mM NH4HCO3 in MeOH → 1:1 v/v 
CH2Cl2: 5 mM NH4HCO3 in MeOH → 3:7 v/v CH2Cl2: 5 mM NH4HCO3 in MeOH 
→ 5 mM NH4HCO3) to afford 123 as a white solid (diammonium salt) following in 
vacuo removal of solvents and lyophilization (40 mg, 54%).  
Rf (2:1:1 v/v/v t-BuOH: AcOH: H2O) = 0.26. IR (ATR): ν = 3243, 1635 cm-1.  
1H NMR (500 MHz, D2O): δ 5.41 (1H, dd, J 7.5, 3.3 Hz, H-1), 3.96 (2H, m, H-2 + H-
5), 3.91 (1H, dd, J 12.4, 2.3 Hz, H-6), 3.87-3.74 (2H, m, H-3 + H-6), 3.52 (1H, app. t, 
J 9.5 Hz, H-4), 2.08 (3H, s, NHAc). 13C NMR (125 MHz, D2O): δ 174.7 (C=O), 93.0 
(d, J 5.5 Hz), 72.3, 71.2, 69.9, 60.6, 54.0 (d, J 7.6 Hz), 22.1. These data are in 
agreement with those previously reported by Sim et al.[180]   
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1-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)pyrimidine-2,4(1H,3H)-dione (127) 
 
To a mixture of uridine (2.0 g, 8.1 mmol) and p-toluenesulfonic acid (161 mg, 2 
mmol) in acetone (49 mL) at 0 oC was added 2,2-dimethoxypropane (1.1 mL, 8.9 
mmol). The reaction mixture was heated at reflux for 4 h. At this point, the solution 
was cooled to room temperature, solid NaHCO3 (341 mg, 3.96 mmol) was added and 
the solution was allowed to stir at this temperature for 30 min. The solid was filtered, 
the solvent was removed in vacuo to give a crude residue that was purified by column 
chromatography (95:5 v/v CH2Cl2: MeOH → 9:1 v/v CH2Cl2: MeOH) to afford 
alcohol 127 as a white foam (1.92 g, 82%). 
IR (ATR): ν = 2931, 1688 cm-1. 1H NMR (300 MHz, CD3OD): δ 7.83 (1H, d, J 8.1 
Hz, H-6), 5.87 (1H, d, J 2.8 Hz, H-1’), 5.68 (1H, d, J 7.9 Hz, H-5), 4.91 (1H, dd, J 
6.3, 2.8 Hz, H-2’), 4.84-4.80 (1H, m, H-3’), 4.21 (1H, app. q, J 3.8 Hz, H-4’), 3.78 
(1H, dd, J 11.9, 3.7 Hz, H-5’), 3.71 (1H, dd, J 11.9, 4.5 Hz, H-5’), 1.55 (3H, s, CH3), 
1.35 (3H, s, CH3). LRMS [M+Na+] 306.9. [α]!!" = -20o (c = 0.30 in CH2Cl2). 
1-((3aR,4R,6R,6aR)-6-(azidomethyl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)pyrimidine-2,4(1H,3H)-dione (129) 
 
To a solution of uridine 127 (1.0 g, 3.5 mmol) in pyridine (30 mL) was added  
p-toluenesulfonyl chloride (810 mg, 4.25 mmol). The mixture was stirred at room 
temperature for 16 h. The reaction was diluted with ethyl acetate (100 mL), washed 
with 1 M HCl (40 mL), saturated aqueous NaHCO3 solution (40 mL), brine (40 mL) 
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and dried over anhydrous Na2SO4. The solvent was removed in vacuo to give a crude 
residue that was purified by column chromatography (95:5 v/v CH2Cl2: MeOH) to 
afford tosylate 128 as a colourless oil (0.92 g).  
Tosylate 128 (0.92 g, 2.1 mmol) was dissolved in DMF (5.8 mL). Sodium azide (683 
mg, 11 mmol) was added and the reaction was heated at 45 oC for 16 h. The reaction 
mixture was diluted with ethyl acetate (100 mL), washed with water (5× 20 mL), 
brine (20 mL) and dried over anhydrous Na2SO4. The solvent was removed in vacuo 
to give a crude residue that was purified by column chromatography (95:5 v/v 
CH2Cl2: MeOH → 9:1 v/v CH2Cl2: MeOH) to afford azide 129 as a colourless oil 
(500 mg, 46% over two steps).  
IR (ATR): ν = 2931, 1688 cm-1. 1H NMR (400 MHz, CDCl3): δ 9.16 (1H, s, NH), 
7.30 (1H, d, J 8.1 Hz, H-6), 5.77 (1H, d, J 8.1 Hz, H-5), 5.67 (1H, d, J 2.1 Hz, H-1’), 
5.00 (1H, app. dt, J 6.4, 2.1 Hz, H-2’), 4.82 (1H, dd, J 6.4, 4.1 Hz, H-3’), 4.28-4.22 
(1H, m, H-4’), 3.70-3.55 (2H, m, H-5’), 1.57 (3H, s, CH3), 1.36 (3H, s, CH3). 
 [!]!!" = -20o (c = 0.30 in CH2Cl2). These data are in agreement with Winans et al.[116]  
1-((2R,3R,4S,5R)-5-(azidomethyl)-3,4-dihydroxytetrahydrofuran-2-
yl)pyrimidine-2,4(1H,3H)-dione (131) 
 
To a mixture of uridine 126 (2.0 g, 8.2 mmol), triphenylphosphine (3.1 g, 12 mmol) 
and sodium azide (1.2 g, 25 mmol) in DMF (41 mL) was added carbon tetrabromide 
(4.1 g, 12 mmol). The reaction mixture was stirred at room temperature for 16 h and 
was subsequently diluted with ethyl acetate (250 mL), washed with water (5× 50 mL), 
brine (2× 50 mL) and dried over anhydrous MgSO4. The solvent was removed in 
vacuo to give a crude residue that was purified by column chromatography (9:1 v/v 
CH2Cl2: MeOH) to afford azide 131 as a colourless oil (1.1 g, 50%).  
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IR (ATR): ν = 2105, 1692 cm-1. 1H NMR (400 MHz, CD3OD): δ 7.64 (1H, d, J 8.1 
Hz, H-6), 5.80 (1H, d, J 3.9 Hz, H-1’), 5.73 (1H, d, J 8.1 Hz, H-5), 4.29-4.14 (1H, m, 
H-2’), 4.14-4.01 (2H, m, H-3’ + H-4’), 3.73 (1H, dd, J 13.4, 2.8 Hz, H-5’), 3.59 (1H, 
dd, J 13.4, 3.9 Hz, H-5’). [!]!!" = +50o (c = 0.34 in MeOH). These data are in 
agreement with Winans et al.[116]  
1-((2R,3R,4R,5R)-5-(azidomethyl)-3,4-bis((tert-
butyldimethylsilyl)oxy)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (132) 
 
To a stirred solution of azide 131 (1.1 g, 4.1 mmol) in DMF (16 mL) was added 
imidazole (1.93 g, 28 mmol) and tert-butyldimethylsilyl chloride (3.06 g, 20 mmol). 
The reaction was allowed to stir at room temperature for 16 h and was subsequently 
diluted with ethyl acetate (250 mL), washed with water (5× 50 mL), brine (2× 50 mL) 
and dried over anhydrous MgSO4. The solvent was removed in vacuo to give a crude 
residue that was purified by column chromatography (95:5 v/v CH2Cl2: MeOH) to 
afford azide 132 as a colourless oil (3.68 g, 90%).  
IR (ATR): ν = 2929, 2857, 2103, 1687 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.45 (1H, 
s, NH), 7.68 (1H, d, J 8.2 Hz, H-6), 5.76 (1H, d, J 8.2 Hz, H-5), 5.68 (1H, d, J 3.2 Hz, 
H-1’), 4.20 (1H, dd, J 4.3, 3.2 Hz, H-2’), 4.14 (1H, dt, J 6.3, 3.3 Hz, H-4’), 3.97 (1H, 
dd, J 6.0, 4.3 Hz, H-3’), 3.82 (1H, dd, J 13.4, 3.3 Hz, H-5’), 3.61 (1H, dd, J 13.4, 3.3 
Hz, H-5’), 0.96-0.83 (18H, m, 2× (CH3)3CSi), 0.15-0.06 (12H, 4× CH3Si). [!]!!" = +31o (c = 0.48 in CH2Cl2). These data are in agreement with those previously 
reported by Peterson et al.[181]  
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1-((2R,3R,4R,5R)-5-(aminomethyl)-3,4-bis((tert-
butyldimethylsilyl)oxy)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (133) 
 
To a solution of azide 132 (1.71 g, 3.42 mmol) in degassed absolute ethanol (128 mL) 
was added triethylamine (2.1 mL, 15 mmol) and 1,3-propanedithiol (2.1 mL, 20 
mmol) and the reaction was allowed to stir at room temperature for 16 h. The solvent 
was removed in vacuo to give a crude residue that was purified by column 
chromatography (9:1 v/v CH2Cl2: MeOH) using deactivated silica (deactivation was 
achieved by passing through 400 mL of CH2Cl2 containing 2 vol.% Et3N prior to 
loading of the above crude residue onto the column) to afford amine 133 as a white 
amorphous solid (0.98 g, 61%).  
IR (ATR): ν = 2924, 2853, 1692 cm-1. 1H NMR (400 MHz, CD3OD): δ 7.73 (1H, d, J 
8.1 Hz, H-6), 5.80 (1H, d, J 5.9 Hz, H-1’), 5.73 (1H, d, J 8.0 Hz, H-5), 4.42 (1H, dd, J 
5.9, 4.5 Hz, H-2’), 4.08-4.03 (1H, m, H-3’), 4.03-3.99 (1H, m, H-4’), 2.93-2.89 (2H, 
m, H-5’), 0.95 (9H, s, (CH3)3CSi), 0.90 (9H, s, (CH3)3CSi), 0.14 (3H, s, CH3Si), 0.13 
(3H, s, CH3Si), 0.10 (3H, s, CH3Si), 0.04 (3H, s, CH3Si). LRMS [M+H+] 472.0. [!]!!"  = -3o (c = 0.15 in 2:1 v/v CH2Cl2: MeOH). These data are in agreement with 
those previously reported by Peterson et al.[181]  
1-(((2R,3R,4R,5R)-3,4-bis((tert-butyldimethylsilyl)oxy)-5-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl)thiourea (136) 
 
Amine 133 (0.26 g, 0.55 mmol) was dissolved in 1:1 (v/v) mixture of THF and DMF 
(5 mL). 1,1’-Thiocarbonyldiimidazole (110 mg, 0.61 mmol) was added and the 
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reaction was stirred for 16 h at room temperature. At this point, aqueous ammonia 
solution (0.61 mL, 25% in water) was added and the reaction mixture was allowed to 
stir at room temperature for a further 3 h. The reaction mixture was diluted with water 
(10 mL) and extracted with ethyl acetate (30 mL). The organic layer was washed with 
water (5 × 5 mL) and the aqueous phase was back extracted with ethyl acetate (2 × 25 
mL). The combined organic layers were dried over anhydrous MgSO4 and the solvent 
was removed in vacuo to give a crude residue that was purified by column 
chromatography (95:5 v/v CH2Cl2: MeOH) to afford thiourea 136 as an off-white 
foam (200 mg, 70%). 
IR (ATR): ν = 3325, 3197, 2887, 2857, 1687 cm-1. 1H NMR (400 MHz, CD3OD): δ 
7.70 (1H, d, J 8.0 Hz, H-6), 5.87 (1H, d, J 6.8 Hz, H-1’), 5.77 (1H, d, J 8.0 Hz, H-5), 
4.45-4.42 (1H, m, H-2’), 4.12-4.06 (2H, m, H-3’ + H-4’), 3.97 (1H, dd, J 5.2, 13.2 
Hz, H-5’), 3.74 (1H, dd, J 5.2, 13.2 Hz, H-5’), 0.95 (9H, s, (CH3)3CSi), 0.88 (9H, s, 
(CH3)3CSi), 0.18-0.09 (12H, m, CH3Si).13C NMR (101 MHz, CD3OD): δ 163.4, 
151.0, 142.2, 102.0, 89.3, 85.1, 73.4, 72.9, 25.0, 25.0, 17.5, 17.4, -5.5, -5.6, -5.6, -6.1. 
LRMS [M+H+] 531.0. HRMS (ESI) m/z cald for C22H43N4O5SSi2 [M+H+]: 531.2487, 
found 531.2490. [!]!!" = -137o (c = 0.40 in CH3OH). 
General procedure C: synthesis of aminothiazole-based compounds 124 and 125 
To a solution of thiourea 136 (1 eq.) in DMF (1 mL) was added α-bromoketone 137 
or 138 (2 eq.) and the reaction was allowed to stir at room temperature for 16 h. The 
reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (100 
mL). The organic layer was washed with water (5 × 20 mL) and the aqueous phase 
was extracted with ethyl acetate (2 × 50 mL). The combined organic layers were dried 
over anhydrous MgSO4. The solvent was removed in vacuo to give a crude residue 
that was purified by column chromatography (100:1 v/v CH2Cl2: MeOH → 95:5 v/v 
CH2Cl2: MeOH) to afford protected aminothiazole-based compounds.  
Protected aminothiazole-based compounds (1 eq.) were dissolved in a mixture of TFA 
and dichloromethane (TFA: CH2Cl2, 9:1 v/v, 61 mL/mmol) and the reaction was 
allowed to stir at room temperature for 5 h. The solvent was removed in vacuo to give 
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crude residues that were purified by column chromatography (9:1 v/v CH2Cl2: 
MeOH) to afford aminothiazole-based compounds 124 and 125.  
1-((2R,3R,4S,5R)-5-(((4-(3,4-dihydroxyphenyl)thiazol-2-yl)amino)methyl)-3,4-
dihydroxytetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (124) 
 
 
Thiourea 136 (164 mg, 0.31 mmol) was reacted with α-bromoketone 137 (84 mg, 
0.55 mmol) in DMF (1 mL) according to general procedure C to obtain protected 
aminothiazole-based compound (173 mg, 0.25 mmol) which was subsequently 
deprotected (general procedure C) using a mixture of TFA in CH2Cl2 (TFA: CH2Cl2, 
9:1 v/v, 7.2 mL) and purified by column chromatography (9:1 v/v CH2Cl2: MeOH) to 
afford 124 as a white solid (34 mg, 25% over two steps).  
IR (ATR): ν = 3322, 1675 cm-1. 1H NMR (400 MHz, CD3OD): δ 7.63 (1H, d, J 8.1 
Hz, H-6), 7.13 (1H, d, J 2.1 Hz, Ar-H, H-2”), 7.04 (2H, dd, J 2.1, 8.2 Hz, Ar-H, H-
6”), 6.80 (1H, d, J 8.2 Hz, Ar-H, H-5”), 5.75 (1H, d, J 4.2 Hz, H-1’), 5.62 (1H, d, J 
8.1 Hz, H-5), 4.30 (1H, dd, J 4.2, 5.8 Hz, H-2’), 4.12-4.06 (2H, m, H-3’ + H-4’), 3.97 
(1H, dd, J 3.6, 13.2 Hz, H-5’), 3.74 (1H, dd, J 3.6, 13.2 Hz, H-5’). 13C NMR (100 
MHz, CD3OD): δ 170.4, 164.6, 150.8, 146.1, 145.5, 145.2, 142.1, 123.5, 117.8 (× 2), 
115.1, 113.0, 101.6, 91.7, 82.3, 73.0, 70.6, 46.8. LRMS [M+H+] 435.3. HRMS (ESI) 
m/z cald for C18H18N4O7SNa [M+Na+]: 457.0788, found 457.0790. [!]!!" = +33o (c = 
0.40 in CH3OH). 
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1-((2R,3R,4S,5R)-5-(((4-((3R,5R,7R)-adamantan-1-yl)thiazol-2-yl)amino)methyl)-
3,4-dihydroxytetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (125) 
 
Thiourea 136 (164 mg, 0.31 mmol) was reacted with α-bromoketone 138 (150 mg, 
0.58 mmol) in DMF (1 mL) according to general procedure C to obtain protected 
aminothiazole-based compound (173 mg, 0.25 mmol) which was subsequently 
deprotected (general procedure C) using a mixture of TFA in CH2Cl2 (TFA: CH2Cl2, 
9:1 v/v, 15.4 mL) and purified by column chromatography (98:2 v/v CH2Cl2: MeOH 
→ 9:1 v/v CH2Cl2: MeOH) to afford 125 as a white solid (50 mg, 36% over two 
steps).  
IR (ATR): ν = 2902, 2847, 1680 cm-1. 1H NMR (400 MHz, CD3OD): δ 7.62 (1H, d, J 
8.1 Hz, H-6), 6.09 (1H, s, aminothiazole-CH), 5.80 (1H, d, J 4.5 Hz, H-1’), 5.66 (1H, 
d, J 8.1 Hz, H-5), 4.33-4.16 (1H, m, H-2’), 4.20-3.93 (2H, m, H-3’ + H-4’), 3.79-3.50 
(2H, m, H-5’), 2.08-1.70 (13H, m). 13C NMR (101 MHz, CD3OD): δ 170.1, 164.6, 
162.2, 150.9, 141.4, 101.4, 97.6, 90.4, 82.8, 73.4, 70.8, 46.4, 41.6, 36.6, 36.2, 28.6. 
LRMS [M+H+] 461.0. HRMS (ESI) m/z cald for C22H29N4O5S [M+H+]: 461.1853, 
found 461.1850. [!]!!" = -6.3o (c = 0.22 in CH2Cl2). 
((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl (2-(((2S,3R,4R,5S,6R)-3-acetamido-4,5-
dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)acetyl)sulfamate 
(139) 
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To a solution of 2’,3’-O-Isopropylidene-5’-O’-sulfamoyluridine 140[117] (130 mg, 
0.35 mmol) in dichloromethane (31 mL) was added acid 141 (160 mg, 0.39 mmol), 
DIC (116 mg, 0.56 mmol) and DMAP (71 mg, 0.56 mmol). The reaction was allowed 
to stir at room temperature for 16 h. The solvent was concentrated to 5 mL before the 
resulting precipitate was filtered off and washed with a minimal amount of 
dichoromethane. The solvent was removed in vacuo and the crude residue was 
purified by column chromatography (10:1 v/v CH2Cl2: MeOH → 7:1 v/v CH2Cl2: 
MeOH) to afford sulfonamide 142 as a colourless oil (130 mg, 48%). 
Sulfonamide 142 (100 mg, 0.13 mmol) was dissolved in a mixture of TFA and water 
(3:1 v/v TFA: H2O, 10 mL) and the reaction was allowed to stir at room temperature 
for 16 h. The solvent was removed in vacuo and azeotroped with toluene to a crude 
residue that was dissolved in 10 vol.% triethylamine in 1:1 (v/v) MeOH and water 
(1.4 mL). The reaction was stirred at room temperature for 16 h. The solvent was 
removed in vacuo to give a residue that was purified by reverse phase HPLC (0 to 
50% MeCN over 50 min) to afford sulfonamide 139 as a white solid (15 mg, 20% 
over 2 steps). 
IR (ATR): ν = 3355, 1683 cm-1. 1H NMR (500 MHz, CD3OD): δ 7.72 (1H, d, J 8.2 
Hz, H-6), 5.87 (1H, d, J 4.3 Hz, H-1’), 5.76 (1H, d, J 8.1 Hz, H-5), 4.89-4.81 (1H, m, 
H-1”, overlapping with HDO signal in CD3OD as determined by HSQC experiment), 
4.59 (1H, dd, J 11.3, 2.6 Hz, H-5’), 4.52 (1H, dd, J 11.2, 3.7 Hz, H-5), 4.29-4.12 (5H, 
m, CH2 + H-2’ + H-3’ + H-4’), 3.96 (1H, dd, J 10.7, 3.6 Hz, H-2”), 3.83 (1H, dd, J 
11.9, 2.3 Hz, H-6”), 3.72-3.63 (2H, m, H-6” + H-3”), 3.60 (1H, ddd, J 9.9, 5.7, 2.2 
Hz, H-5”), 3.37 (1H, dd, J 10.0, 8.9 Hz, H-4”), 2.03 (3H, s, NHAc). 13C NMR (126 
MHz, CD3OD): δ 172.6, 169.0, 164.8, 151.0, 141.2, 101.8, 97.9, 90.1, 81.4, 73.7, 
73.3, 71.4, 71.2, 70.8, 69.8, 65.4, 61.3, 53.7, 21.5. LRMS [M+H+] 585.2. HRMS 
(ESI) m/z cald for C19H29N4O15S [M+H+]: 585.1345, found 585.1345. [!]!!" = +92o  
(c = 0.20 in CH3OH). 
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N-(2-(cyclohexylamino)-2-oxoethyl)-N-(((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)-2,3-
dihydroxybenzamide (143) 
 
To a solution of TBS-protected uridylamine 133 (70 mg, 0.14 mmol) in methanol (1.8 
mL) was added paraformaldehyde (4.2 mg, 1.4 mmol). The solution was allowed to 
stir at room temperature for 30 min. 2,2-Dimethylbenzo[d][1,3]dioxole-4-carboxylic 
acid 145 (27 mg, 0.14 mmol) in methanol (180 µL) was added to the above solution, 
followed by cyclohexyl isonitrile (17 µL, 0.15 mmol). The reaction was allowed to 
stir at room temperature for 72 h at which point, the solvent was removed in vacuo to 
give a crude a residue that was purified by column chromatography (95:5 v/v CH2Cl2: 
MeOH) to give amide 146 as a colourless oil (84 mg). 
Amide 146 (84 mg, 0.11 mmol) was dissolved in a mixture of TFA and water  
(TFA: H2O, 9:1 v/v, 4 mL) and the reaction was allowed to stir at room temperature 
for 4.5 h. The solvent was removed in vacuo to give a crude residue that was purified 
by column chromatography (95:5 v/v CH2Cl2: CH3OH → 85:15 v/v CH2Cl2: CH3OH) 
to afford amide 143 as an off-white solid.  
m.p. 150-154 oC (decomp.). IR (ATR): ν = 3253, 2937, 2860, 1688 cm-1. 1H NMR 
(400 MHz, CD3CN, 330 K): δ 7.28 (1H, app. s, H-6), 6.91 (1H, dd, J 8.0, 1.7 Hz, Ar-
H, H-6”), 6.80 (1H, t, J 7.8 Hz, Ar-H, H-5”), 6.72 (1H, dd, J 7.6, 1.7 Hz, Ar-H, H-4”), 
5.71-5.67 (1H, m, H-1’), 5.63 (1H, d, J 8.2 Hz, H-5), 4.20-3.89 (5H, m), 3.84-3.58 
(3H, m), 1.87-1.79 (2H, m, CH2), 1.70-1.68 (2H, m, CH2), 1.65-1.57 (1H, m, CH2), 
1.41-1.31 (2H, m, CH2), 1.28-1.17 (3H, m, CH2). LRMS [M+H+] 519.3. HRMS (ESI) 
m/z cald for C24H30N4O9Na [M+Na+]: 541.1905, found 541.1904. [!]!!"  = +28o  
(c = 0.20 in CH3OH). 
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(S)-tert-butyl-3-amino-4-((((2R,3R,4R,5R)-3,4-bis((tert-butyldimethylsilyl)oxy)-5-
(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl)amino)-
4-oxobutanoate (147) 
 
To a solution of Fmoc-L-Asp(OtBu)-OH (105 mg, 0.25 mmol), HOBt (34 mg, 0.25 
mmol) and PyBOP (130 mg, 0.25 mmol) in DMF (1.7 mL) was added  
N,N-diisopropylethylamine (45 µL, 0.25 mmol) at 0 oC. Amine 133 (60 mg, 0.13 
mmol) was added and the reaction was allowed to warm to room temperature and was 
stirred for 1.5 h. The reaction was diluted with ethyl acetate (40 mL) and washed 
successively with 1 M HCl (2× 40 mL), saturated aqueous NaHCO3 solution (5× 50 
mL) and brine (2× 40 mL). The organic layer was dried over anhydrous MgSO4 and 
the solvent was removed in vacuo to give a crude residue that was purified by column 
chromatography (98: 2 v/v CH2Cl2: MeOH → 95: 5 v/v CH2Cl2: MeOH) to afford the 
Fmoc-protected amide as a white foam. 
Fmoc-protected amide (99 mg, 0.11 mmol) was treated with 20 vol.% piperidine in a 
mixture of dichloromethane and methanol (1:1 v/v CH2Cl2: MeOH, 1.4 mL). The 
reaction was allowed to stir at room temperature for 3.5 h. The solvent was removed 
in vacuo to afford a crude residue that was purified by column chromatography (95: 5 
v/v CH2Cl2: MeOH → 9: 1 v/v CH2Cl2: MeOH) to afford amine 147 as a white foam 
(46 mg, 67% over 2 steps).  
IR (ATR): ν = 3281, 2950, 1662, 1591 cm-1. 1H NMR (400 MHz, CD3OD): δ 7.73 
(1H, d, J 8.1 Hz, H-6), 5.84 (1H, d, J 6.4 Hz, H-1’), 5.76 (1H, d, J 8.1 Hz, H-5), 4.40 
(1H, dd, J 6.5, 4.5 Hz, H-2’), 4.14-3.99 (2H, m, H-3’ + α-CH), 3.67-3.58 (1H, m,  
H-4’), 3.51 (2H, app. d, J 6.1 Hz, β-CH2), 2.67 (1H, dd, J 16.4, 5.4 Hz, H-5’), 2.57 
(dd, J 16.3, 6.9 Hz, H-5’), 1.45 (9H, s, CO2tBu), 0.94 (9H, s, (CH3)3CSi), 0.89 (9H, s, 
(CH3)3CSi), 0.146 (3H, s, CH3Si), 0.132 (3H, s, CH3Si), 0.090 (3H, s, CH3Si), 0.028 
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(3H, s, CH3Si). 13C NMR (101 MHz, CD3OD): δ 175.1 (C=O), 170.8 (C=O), 164.5 
(C=O), 151.0 (C=O), 142.1, 101.8, 89.7, 84.1, 80.8, 73.8, 73.0, 51.6, 41.1, 39.9, 27.0, 
25.0, 24.9, 17.5, 17.4, -5.6, -5.6, -5.8, -6.0. LRMS [M+H+] 643.4.  
(S)-tert-butyl-3-amino-4-(((S)-1-((((2R,3R,4R,5R)-3,4-bis((tert-
butyldimethylsilyl)oxy)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)methyl)amino)-4-(tert-butoxy)-1,4-dioxobutan-2-
yl)amino)-4-oxobutanoate (148) 
 
To a solution of Fmoc-L-Asp(OtBu)-OH (60 mg, 0.14 mmol), HOBt (20 mg, 0.14 
mmol) and PyBOP (76 mg, 0.14 mmol) in DMF (1.7 mL) was added  
N,N-diisopropylethylamine (27 µL, 0.14 mmol) at 0 oC. Amine 133 (46 mg, 0.072 
mmol) was added and the reaction was allowed to warm to room temperature and was 
stirred for 1.5 h. The reaction was diluted with ethyl acetate (40 mL) and washed 
successively with 1 M HCl (2× 40 mL), saturated aqueous NaHCO3 solution (5× 50 
mL) and brine (2× 40 mL). The organic layer was dried over anhydrous MgSO4 and 
the solvent removed in vacuo to give a crude residue that was purified by column 
chromatography (98 CH2Cl2: 2 MeOH → 95 CH2Cl2: 5 MeOH) to afford Fmoc-
protected amide as a white foam. 
Fmoc-protected amine (67 mg, 0.065 mmol) was treated with 20 vol.% piperidine in a 
mixture of dichloromethane and methanol (1:1 v/v CH2Cl2: MeOH, 1.4 mL). The 
reaction was allowed to stir at room temperature for 3.5 h. The solvent was removed 
in vacuo to afford a crude residue that was purified by column chromatography (95: 5 
v/v CH2Cl2: MeOH → 9: 1 v/v CH2Cl2: MeOH) to afford amine 148 as a white foam 
(40 mg, 67% over 2 steps).  
IR (ATR): ν = 3279, 2955, 1659, 1588 cm-1. 1H NMR (400 MHz, CD3OD):  δ 7.70 
(1H, d, J 8.1 Hz, H-6), 5.86 (1H, d, J 6.8 Hz, H-1’), 5.80 (1H, d, J 8.0 Hz, H-5), 4.75 
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(1H, t, J 6.0 Hz, α-CH), 4.30 (1H, dd, J 6.8, 4.6 Hz, H-2’), 4.14 (1H, dd, J 4.7, 2.3 
Hz, H-3’), 4.05 (1H, ddd, J 6.7, 4.8, 2.3 Hz, H-4’), 3.67 (1H, t, J 6.5 Hz, α-CH), 3.57 
(1H, dd, J 14.2, 6.4 Hz, β-CH2), 3.43 (1H, dd, J 14.2, 4.8 Hz, β-CH2), 2.75 (3H, m,  
β-CH2 + H-5’), 2.61 (1H, dd, J 16.8, 6.4 Hz, H-5’), 1.46 (9H, s, CO2tBu), 1.45 (9H, s, 
CO2tBu), 0.93 (9H, s, (CH3)3CSi), 0.88 (9H, s, (CH3)3CSi), 0.15 (3H, s, CH3Si), 0.13 
(3H, s, CH3Si), 0.09 (3H, s, CH3Si), 0.03 (3H, s, CH3Si). 13C NMR (101 MHz, 
CD3OD): δ 174.5 (C=O), 171.9 (C=O), 171.2 (C=O), 170.1 (C=O), 164.5, 151.0, 
142.1, 101.9, 88.8, 84.5, 81.2, 81.1, 73.8, 72.9, 51.4, 49.7, 41.3, 39.5, 36.6, 27.0, 27.0, 
25.0, 25.0, 17.5, 17.4, -5.5, -5.6, -5.7, -6.0. LRMS [M+H+] 814.5.  
 (S)-3-(2-(((2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)acetamido)-4-(((S)-3-carboxy-1-
((((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)amino)-1-oxopropan-2-yl)amino)-4-
oxobutanoic acid (144) 
 
To a solution of acid 141 (6.2 mg, 15 µmol) in DMF (150 µL) was added amine 133 
(19 mg, 23 µmol), HATU (6.4 mg, 16 µmol) followed by 1-hydroxy-7-
azabenzotriazole (2.3 mg, 16 µmol) and N,N-diisopropylethylamine (6.4 µL, 36 
µmol). The reaction was allowed to stir at room temperature for 1 h. The reaction was 
subsequently diluted with ethyl acetate (30 mL), washed with water (5 × 10 mL), 
brine (10 mL). The organic layer was dried over anhydrous MgSO4 and the solvent 
was removed in vacuo to give a crude residue that was purified by reverse phase 
HPLC (0-100% MeCN over 40 min) to afford fully protected uridylpeptide 149 as a 
white solid. 
Fully protected uridylpeptide 149 (10 mg, 8.3 µmol) was dissolved in a 1:1 (v/v) 
mixture of methanol and water (90 µL). Triethylamine (10 µL, 140 µmol) was added 
and the reaction was allowed to stir at room temperature for 16 h. The solvent was 
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removed in vacuo to give a residue that was immediately suspended in 90: 5: 5 (v/v/v) 
TFA: iPr3SiH: H2O (200 µL). The reaction mixture was allowed to stir at room 
temperature for 16 h. The solvent was removed in vacuo to give a crude residue that 
was purified by reverse phase HPLC (0-50% MeCN over 40 min) to afford compound 
144 as a white solid (1.1 mg, 10% over 3 steps). 
1H NMR (500 MHz, CD3OD):  δ 7.68 (1H, d, J 8.0 Hz, H-6), 5.83-5.80 (1H, m), 
5.76-5.74 (1H, m), 4.88-4.85 (1H, m), 4.29-4.19 (2H, m), 4.07-3.94 (4H, m), 3.88-
3.75 (2H, m), 3.75-3.68 (1H, m), 3.65-3.57 (2H, m), 3.57-3.43 (2H, m), 3.46-3.38 
(2H, m), 2.93-2.72 (4H, m), 2.03 (3H, s, NHAc). LRMS [M+H+] 735.3. HRMS (ESI) 
m/z cald for C27H38N6O18Na [M+Na+]: 757.2135, found 757.2137. 
(E)-3-(3,4-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (155) 
 
To a solution of 2’-hydroxyacetophenone 153 (120 mg, 1.0 mmol) in ethanol (1.25 
mL), was added 3,4-dimethoxybenzaldehyde (182 mg, 1.10 mmol) and 70% 
potassium hydroxide solution (250 µL, 3.12 mmol). The mixture was heated at 30 oC 
for 18 h. The reaction mixture was poured onto water and 1 M HCl was added to 
acidify the mixture to pH 2 and extracted with ethyl acetate (2× 20 mL), dried over 
anhydrous MgSO4 and concentrated in vacuo to afford 155 as a yellow solid that was 
used without further purification (189 mg, 66%). 
IR (ATR): ν = 2935, 2837, 1634, 1582 cm-1. 1H NMR (300 MHz, CDCl3): δ 7.92-7.72 
(2H, m, Ar-H), 7.49-7.28 (2H, m, Ar-H), 7.15 (1H, dd, J 8.3, 2.0 Hz, Ar-H, H-2), 7.06 
(1H, d, J 2.0 Hz, Ar-H, H-6), 6.98-6.87 (1H, m, Ar-H), 6.87-6.75 (2H, m, Ar-H), 3.85 
(3H, s, OCH3), 3.82 (3H, s, OCH3). LRMS [M+H+] 283.3. These data are in 
agreement with those previously reported by Mewett et al.[182] 
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5,7-dimethoxy-2-phenyl-4H-chromen-4-one (156) 
 
To a solution of 2’-hydroxyl-4’,6’-dimethoxyacetophenone 152 (200 mg, 1.0 mmol) 
in methanol (4 mL) was added benzaldehyde (111 µl, 1.1 mmol) and 70% potassium 
hydroxide solution (392 µL, 3.4 mmol). The mixture was heated at 30 oC for 16 h. 
The reaction mixture was poured onto water and 1 M HCl was added to acidify the 
mixture to pH 2 and extracted with ethyl acetate (2 × 20 mL), dried over anhydrous 
MgSO4 and concentrated in vacuo to afford 154 as a yellow solid that was used 
without further purification (169 mg, 60%). 
α,β-unsaturated ketone 154 (169 mg, 0.60 mmol) was dissolved in DMSO (1.5 mL) 
and iodine (7.0 mg, 0.026 mmol) was added. The reaction was heated to 150 oC for  
3 h. The reaction was diluted with ethyl acetate (30 mL) and washed with water (3× 
20 mL) and brine (20 mL). The organic layer was dried over anhydrous MgSO4 and 
the solvent was removed in vacuo to afford 156 as a yellow solid (65 mg, 38%) which 
was used without further purification.  
mp 116-117 oC (decomp.). IR (ATR): ν = 1642, 1606 cm-1. 1H NMR (400 MHz, 
CD3OD): δ 7.92-7.90 (2H, m, Ar-H, H-2’ + H-6’), 7.52-7.50 (3H, m, Ar-H, H-3’ +  
H-4’ + H-5’), 6.68 (1H, d, J 2.0 Hz, Ar-H, H-8), 6.62 (1H, s, H-3), 6.42 (1H, d, J 2.0 
Hz, Ar-H, H-6), 3.90 (3H, s, OCH3), 3.86 (3H, s, OCH3). 13C NMR (100 MHz, 
CD3OD): δ 178.4 (C=O), 165.0, 161.2, 160.8, 160.0, 131.3, 130.9, 128.7 (×2), 125.8 
(×2), 107.9, 107.4, 96.1, 92.8, 55.1 (×2). LRMS [M+H+] 283.3. These data are in 
agreement with those previously reported by Compton et al.[183] 
5,7-dihydroxy-2-phenyl-4H-chromen-4-one (150) 
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To a cooled solution of 156 (60 mg, 0.21 mmol) in dichloromethane (1 mL) was 
added boron tribromide (0.84 mL, 0.84 mmol) dropwise. The mixture was allowed to 
warm up to room temperature and stirred at room temperature for 3 h. The reaction 
was quenched with 5% Na2HPO4 (10 mL) solution and extracted with 
dichloromethane (2× 30 mL). The combined organic extracts were washed with 
saturated aqueous NaHCO3 solution, brine and dried over anhydrous MgSO4. The 
solvent was removed in vacuo to afford a crude residue that was purified by column 
chromatography (2:1 v/v Hexane: EtOAc) to give 150 as a yellow solid (43 mg, 
80%). 
IR (ATR): ν = 3075, 1650, 1611 cm-1. 1H NMR (500 MHz, DMSO-d6): δ 8.03 (1H, 
dd, J 8.0, 1.5 Hz, Ar-H), 7.80 (1H, m, Ar-H), 7.72 (1H, d, J 8.0 Hz, Ar-H), 7.48 (1H, 
d, J 7.5 Hz, Ar-H), 7.46-7.45 (1H, m, Ar-H), 7.44 (1H, s, Ar-H), 6.89 (1H, d, J 7.5 
Hz, Ar-H), 6.75 (1H, s, H-3). LRMS [M+H+] 255.3. These data are in agreement with 
those previously reported by Advanced Chemistry Development, Inc.[184] 
2-(3,4-dihydroxyphenyl)-4H-chromen-4-one (151) 
 
α,β-Unsaturated ketone 155 (189 mg, 0.66 mmol) was dissolved in DMSO (1.5 mL) 
and iodine (7.0 mg, 0.026 mmol) was added. The reaction was heated to 150 oC for  
3 h. The reaction was diluted with ethyl acetate (30 mL) and washed with water  
(3 ×20 mL) and brine (20 mL). The organic layer was dried over anhydrous MgSO4 to 
afford 157 as a yellow solid (65 mg, 38%) which was used without further 
purification.  
To a cooled solution of chromone 157 (77 mg, 0.27 mmol) in dichloromethane (1.4 
mL) was added boron tribromide (1.1 mL, 1.1 mmol) dropwise. The mixture was 
allowed to warm up to room temperature and stirred at this temperature for 3 h. The 
reaction was quenched with 5% Na2HPO4 solution (10 mL) and extracted with 
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dichloromethane (2× 30 mL). The combined organic extracts were washed with 
saturated aqueous NaHCO3 solution, brine and dried over anhydrous MgSO4. The 
solvent was removed in vacuo to afford a crude residue that was purified by column 
chromatography (2:1 v/v Hexane: EtOAc) to give 151 as a yellow solid (50 mg, 
74%). 
IR (ATR): ν = 3200, 1620 cm-1. 1H NMR (500 MHz, MeOD): δ 7.93-7.92 (1H, m, 
Ar-H), 7.58-7.52 (4H, m, Ar-H), 6.69-6.67 (1H, m, Ar-H), 6.57 (1H, s, H-3), 6.36 
(1H, d, J 2.0 Hz, Ar-H, H-2’). LRMS [M+H+] 255.3. These data are in agreement 
with those previously reported by Moon et al.[185] 
6-bromo-2-(3,4-dimethoxyphenyl)-4H-chromen-4-one (162) 
 
To a solution of 5’-bromo-2’-hydroxyacetophenone 160 (215 mg, 1.0 mmol) in 
ethanol (1.3 mL) was added 3,4-dimethoxybenzaldehyde (182 mg, 1.1 mmol) and 
70% potassium hydroxide solution (250 µL, 2.2 mmol). The mixture was heated at  
30 oC for 16 h. The reaction mixture was poured onto water and 1 M HCl was added 
to acidify the mixture to pH 2 and extracted with ethyl acetate (2× 20 mL), dried over 
anhydrous MgSO4 and concentrated in vacuo to afford 161 as a yellow solid that was 
used without further purification (341 mg, 94%). 
α,β-unsaturated ketone 161 (341 mg, 0.94 mmol) was dissolved in DMSO (2.1 mL) 
and iodine (9.5 mg, 0.038 mmol) was added. The reaction was heated to 150 oC for  
3 h. The reaction was diluted with ethyl acetate (30 mL) and washed with water  
(3× 20 mL) and brine (20 mL). The organic layer was dried over MgSO4 and the 
solvent was removed in vacuo to give a crude residue that was purified by column 
chromatography (2:1 v/v Hexane: EtOAc) to afford 162 as a yellow solid (256 mg, 
70%).  
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 m.p. 197-198 oC (decomp.). IR (ATR): ν = 1655, 1600 cm-1. 1H NMR (400 MHz, 
CDCl3): δ 8.17 (1H, d, J 2.4 Hz, Ar-H, H-5), 7.66 (1H, dd, J 8.9, 2.4 Hz, Ar-H, H-7), 
7.44 (1H, dd, J 8.5, 2.2 Hz, Ar-H, H-6’), 7.37 (1H, d, J 8.9 Hz, Ar-H, H-8), 7.26 (1H, 
d, J 2.2 Hz, Ar-H, H-2’), 6.87 (1H, d, J 8.5 Hz, Ar-H, H-5’), 6.64 (1H, s, Ar-H, H-3), 
3.85 (3H, s, OCH3), 3.83 (3H, s, OCH3). LRMS [M+H+] 363.3. These data are in 
agreement with those previously reported by Yang et al.[186] 
2-(3,4-dimethoxyphenyl)-6-morpholino-4H-chromen-4-one (163) 
 
A mixture containing cesium carbonate (106 mg, 0.32 mmol), Pd2(dba)3 (7.2 mg, 6.9 
µmol) and BINAP (6.6 mg, 10 µmol) were purged with argon for 10 min. A solution 
of bromide 162 (84 mg, 0.23 mmol) and morpholine (24 µL, 0.27 mmol) in toluene  
(1 mL) was added to the above reaction mixture and the reaction was subsequently 
purged with argon for another 10 min. The reaction was allowed to stir at 110 oC for 
16 h. The solvent was removed in vacuo to give a crude residue that was purified by 
column chromatography (95:5 v/v CH2Cl2: MeOH) to afford 163 as a yellow oil (13 
mg, 15%).  
IR (ATR): ν = 2955, 2837, 1614 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.59 (1H, d, J 
3.0 Hz, Ar-H, H-5), 7.55 (1H, dd, J 8.5, 2.1 Hz, Ar-H, H-6’), 7.51 (1H, d, J 9.1 Hz, 
Ar-H, H-8), 7.39 (1H, d, J 2.1 Hz, Ar-H, H-2’), 7.33 (1H, dd, J 9.1, 3.0 Hz, Ar-H, H-
7), 6.98 (1H, d, J 8.5 Hz, Ar-H, H-5’), 6.74 (1H, s, Ar-H, H-3), 3.98 (3H, s, OCH3), 
3.96 (3H, s, OCH3), 3.92-3.84 (4H, m, 2× CH2), 3.34-3.18 (4H, 2× CH2). LRMS 
[M+H+] 368.0. HRMS (ESI) m/z cald for C21H22NO5 [M+H+]: 368.1492, found 
368.1492. 
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2-(3,4-bis(benzyloxy)phenyl)-6-bromo-4H-chromen-4-one (164) 
 
To a solution of 5’-bromo-2’-hydroxyacetophenone 160 (355 mg, 1.55 mmol) in 
ethanol (5.8 mL) was added 3,4-bis(benzyloxy)benzaldehyde (450 mg, 1.40 mmol) 
and 70% potassium hydroxide solution (350 µL, 3.0 mmol). The mixture was heated 
at 30 oC for 16 h. The reaction mixture was poured onto water and 1 M HCl was 
added to acidify the mixture to pH 2 and extracted with ethyl acetate (2 × 20 mL), 
dried over anhydrous MgSO4 and concentrated in vacuo to afford 165 as a yellow 
solid that was used without further purification (726 mg, quant.). 
α,β-unsaturated ketone 165 (726 mg, 1.40 mmol) was dissolved in DMSO (3.3 mL) 
and iodine (16 mg, 0.064 mmol) was added. The reaction was heated to 150 oC for  
3 h. The reaction was diluted with ethyl acetate (30 mL) and washed with water (3 
×20 mL) and brine (20 mL). The organic layer was dried over MgSO4 and the solvent 
was removed in vacuo to give a crude residue that was purified by column 
chromatography (2:1 v/v Hexane: EtOAc) to afford 164 as a yellow solid (503 mg, 
70%).  
m.p. 148-150 oC (decomp.). IR (ATR): ν = 1654, 1598 cm-1. 1H NMR (300 MHz, 
DMSO-d6): δ 8.10 (1H, d, J 2.5 Hz, Ar-H, H-5), 8.00 (1H, dd, J 8.9, 2.5 Hz, Ar-H, H-
7), 7.85-7.76 (1H, m, Ar-H, H-8), 7.72 (1H, dd, J 8.5, 2.1 Hz, Ar-H, H-6’), 7.53-7.30 
(11H, m, Ar-H), 7.25 (1H, d, J 8.6 Hz, Ar-H, H-5’), 7.08 (1H, s, Ar-H, H-3), 5.29 
(2H, s, CH2Ph), 5.26 (2H, s, CH2Ph). 13C NMR (75 MHz, DMSO-d6): δ 176.4, 163.6, 
155.1, 152.0, 148.8, 137.5, 137.2, 128.9, 128.4, 128.1, 128.0, 127.3, 125.3, 123.8, 
121.7, 120.9, 118.2, 114.5, 112.6, 106.2, 70.8, 70.4. LRMS [M+H+] 512.9. HRMS 
(ESI) m/z cald for C29H22BrO4 [M+H+]: 513.0696, found 513.0702. 
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2-(3,4-Dimethoxyphenyl)-6-morpholino-4H-chromen-4-one (172).  
 
To a solution of 4,5-dimethoxyanthranilic acid 170 (1.0 g, 5.1 mmol) in methanol  
(4 mL) was added trimethyl orthoformate (2.20 mL, 20.3 mmol) and ammonium 
acetate (1.56 g, 20.3 mmol). The reaction was heated at 120 oC for 3 h. The reaction 
was allowed to cool to room temperature, water (40 mL) was added and the 
suspension was stirred for an additional 1 h. The solution was subsequently filtered to 
afford 172 as a white solid (900 mg, 86%).  
m.p. 283-284 oC (decomp.). IR (ATR): ν = 2837, 1645, 1606 cm-1. 1H NMR (400 
MHz, DMSO-d6): δ 7.96 (1H, s, Ar-H, H-2), 7.43 (1H, s, Ar-H, H-5), 7.08 (1H, s, Ar-
H, H-8), 3.90 (3H, s, OCH3), 3.85 (3H, s, OCH3). 13C NMR (75 MHz, DMSO-d6):  
δ 160.3, 154.4, 148.5, 144.8, 143.8, 115.6, 107.9, 104.9, 55.9, 55.7. LRMS [M+H+] 
207.0. These data are in agreement with those previously reported by VanBrocklin et 
al.[187] 
4-Chloro-6,7-dimethoxyquinazoline (174) 
 
A mixture of quinazoline 172 (0.44 g, 2.0 mmol) and phosphorus(V) oxychloride (4.4 
mL, 43 mmol) was refluxed for 5 h. The solvent was removed in vacuo and the 
residue was dissolved in dichloromethane (200 mL) and washed with saturated 
aqueous NaHCO3 solution (3 × 50 mL) and brine (50 mL). The organic layer was 
dried over anhydrous MgSO4 and the solvent was removed in vacuo to afford a crude 
residue that was purified by column chromatography (95:5 v/v CH2Cl2: MeOH) to 
afford 174 as a white solid (310 mg, 70%).  
m.p. 186-188 oC. IR (ATR): ν = 1683 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.87 (1H, 
s, Ar-H, H-2), 7.39 (1H, s, Ar-H, H-5), 7.33 (1H, s, Ar-H, H-8), 4.07 (6H, s, 2 × 
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OCH3). 13C NMR (101 MHz, CDCl3): δ 159.1, 156.8, 152.5, 151.5, 149.1, 119.6, 
106.9, 102.7, 56.6, 56.4. LRMS [M+H+] 225.0. These data are in agreement with 
those previously reported by VanBrocklin et al.[187]  
General procedure D: synthesis of aminoquinazoline-based inhibitors 168, 169, 
177-179, 187 and 206-216 
To a solution of 4-chloro-6,7-dimethoxyquinazoline 174 or 175 (0.07-1.33 mmol) in 
isopropanol (11.2-25.7 mL/mmol) was added 1,2-diaminocyclohexane, piperazine 
hydrochloride hydrate, 1,4-phenylenediamine or the corresponding  
4-aminocarboxamides 190-197 and 204 (0.07-5.63 mmol, 1-12 eq.) and the reaction 
mixture was heated at 120 oC for 3-5 h. The reaction was subsequently filtered and 
washed with diethyl ether (2 × 10 mL) to obtain compounds 168, 169, 177-179, 187 
and 206-216 which were purified by column chromatography, reverse phase HPLC or 
used without further purification as specified. 
General procedure E: Synthesis of aminoquinazoline-based inhibitors 181-185.  
To a stirring solution of amine 177-179 (0.26-0.31 mmol) in DMF (58 mL/mmol) was 
added benzoic acid, cyclohexanecarboxylic acid or Boc-L-hydroxyproline-OH (1.1 
eq.), N,N-diisopropylethylamine (1-1.6 eq.) and HATU (1.6 eq.). The reaction 
mixture was allowed to stir at room temperature for 4-20 h at which point it was 
diluted with ethyl acetate (30 mL), washed with water (4 × 10 mL), brine (10 mL) and 
dried over anhydrous MgSO4. The solvent was removed in vacuo to give a crude 
residue that was purified by column chromatography or reverse phase HPLC to afford 
compound 181-185. 
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N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)benzamide (168) 
 
4-Chloro-6,7-dimethoxyquinazoline 174 (126 mg, 0.56 mmol) was reacted with  
N-(4-aminophenyl)benzamide 176 (119 mg, 0.56 mmol) in isopropanol (8 mL) for 5 h 
according to general procedure D to obtain 168 as a yellow solid (168 mg, 75%).  
m.p. = 258-259 oC (decomp.). IR (ATR): ν = 2921, 1627 cm-1. 1H NMR (300 MHz, 
DMSO-d6): δ 11.22 (1H, s, NH), 10.42 (1H, s, NH), 8.80 (1H, s, Ar-H, H-2), 8.23 
(1H, s, Ar-H, H-8), 7.99 (2H, d, J 7.4 Hz, Ar-H, H-2’ + H-6’), 7.90 (2H, d, J 8.6 Hz, 
Ar-H, H-2” + H-6”), 7.66 (2H, d, J = 8.7 Hz, Ar-H, H-3” + H-5”), 7.62-7.53 (5H, m, 
Ar-H), 7.31 (1H, s, Ar-H, H-5), 4.01 (3H, s, OCH3), 3.99 (3H, s, OCH3). LRMS 
[M+H+] 401.1. HRMS (ESI) m/z cald for C23H21N4O3 [M+H+]: 401.1608, found 
401.1609. 
N-(4-((7-hydroxy-6-methoxyquinazolin-4-yl)amino)phenyl)benzamide (169) 
 
 
 
7-(Benzyloxy)-4-chloro-6-methoxyquinazoline 175[188] (15 mg, 0.050 mmol) was 
reacted with N-(4-aminophenyl)benzamide 176 (12 mg, 0.055 mmol) in isopropanol 
(1 mL) according to general procedure D for 5 h to obtain benzyl ether intermediate 
as a yellow solid which was used in the next step without purification. 
A mixture of the benzyl ether intermediate (21 mg, 0.044 mmol) in methanol (10 mL) 
was hydrogenated (1 atm) over 10% Pd/C (10 mg) for 1.25 h. The reaction mixture 
was subsequently filtered over Celite® and the filtrate concentrated in vacuo to give a 
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crude solid that was purified by column chromatography (95: 5 v/v CH2Cl2: MeOH 
→ 9:1 v/v CH2Cl2: MeOH) to afford 169 as a yellow solid (10 mg, 50% over 2 steps). 
m.p. 148-152 oC (decomp.). IR (ATR): ν = 3000, 1701 cm-1.1H NMR (400 MHz, 
CD3OD): δ 8.34 (1H, s, Ar-H, H-2), 7.97-7.94 (2H, m, Ar-H, H-2’ + H-6’), 7.76-7.69 
(5H, m, Ar-H), 7.59-7.50 (3H, m, Ar-H), 7.06 (1H, s, H-5), 4.05 (6H, s, 2× OCH3). 
13C NMR (100 MHz, CD3OD): δ 167.4 (C=O), 157.3, 154.4, 152.0, 149.5, 145.7, 
135.4, 135.0, 134.9, 131.4, 128.2, 127.2, 123.2, 121.2, 108.6, 108.2, 101.1, 55.4. 
LRMS [M+H+] 387.3. HRMS (ESI) m/z cald for C22H19N4O3 [M+H+]: 387.1452, 
found 387.1450.  
6,7-dimethoxy-4-(piperazin-1-yl)quinazoline (177).  
 
4-Chloro-6,7-dimethoxyquinazoline 174 (300 mg, 1.33 mmol) was added to a 
solution of piperazine hexahydrate (1.03 g, 5.32 mmol) in isopropanol (15 mL) 
according to general procedure D for 3 h. The reaction was subsequently diluted with 
dichloromethane (100 mL), washed with brine (2 × 40 mL) and dried over anhydrous 
Na2SO4. The solvent was removed in vacuo to give a residue that was purified by 
column chromatography (9:1 v/v CH2Cl2: CH3OH → 4:1 v/v CH2Cl2: CH3OH) to 
afford compound 177 as a white solid (255 mg, 70%).  
m.p. 153-154 oC. IR (ATR): ν = 3235, 2827, 1616 cm-1. 1H NMR (500 MHz, 
CD3OD): δ 8.48 (1H, s, Ar-H, H-2), 7.13 (2H, s, Ar-H, H-5 + H-8), 3.97 (3H, s, 
OCH3), 3.95 (3H, s, OCH3), 3.66 (4H, t, J = 5 Hz, H-2’+ H-6’), 3.04 (4H, t, J = 5 Hz, 
H-3’ + H-5’). 13C NMR (125 MHz, CD3OD): δ 163.8, 155.2, 152.0, 148.9, 148.1, 
110.9, 105.7, 103.2, 55.2, 55.1, 50.1, 44.9. LRMS [M+H+] 275.1. HRMS (ESI) m/z 
cald for C14H19N4O2 [M+H+]: 275.1503, found 275.1502.  
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N1-(6,7-dimethoxyquinazolin-4-yl)cyclohexane-1,2-diamine (178).  
 
4-Chloro-6,7-dimethoxyquinazoline 174 (300 mg, 1.33 mmol) was added to a 
solution of 1,2-diaminocyclohexane (0.65 mL, 5.33 mmol) in isopropanol (15 mL) 
according to general procedure D. Following column chromatography (9:1 v/v 
CH2Cl2: MeOH) compound 178 was obtained as a yellow solid (234 mg, 60%).  
m.p. 123-126 oC. 1H NMR (400 MHz, DMSO-d6): δ 9.37 (1H, d, J 8.2 Hz, NH), 8.75 
(1H, s, Ar-H, H-2), 8.07 (2H, br. s, NH2), 7.88 (1H, s, Ar-H, H-8), 7.35 (1H, s, Ar-H, 
H-5), 4.59-4.54 (1H, m, H-1’), 3.98 (6H, s, OCH3), 3.40 (1H, t, J 11.4 Hz, H-2’), 2.16 
(1H, app. dd, J 13.3, 4.1 Hz, H-3’), 2.01 (1H, app. d, J 12.8 Hz, H-6’), 1.83-1.79 (2H, 
m, H-5’), 1.65-1.54 (2H, m, H-3’ + H-6’), 1.38-1.32 (2H, m, H-4’). 13C NMR (101 
MHz, DMSO-d6): δ 158.8, 154.3, 153.5, 148.6, 146.3, 109.4, 107.1, 103.9, 57.0, 56.1, 
52.9, 52.5, 31.5, 30.3, 24.7, 24.3. LRMS [M+H+] 303.2. HRMS (ESI) m/z cald for 
C16H23N4O2 [M+H+]: 303.1816, found 303.1817. 
N1-(6,7-dimethoxyquinazolin-4-yl)benzene-1,4-diamine (179).  
 
4-Chloro-6,7-dimethoxyquinazoline 174 (103 mg, 0.46 mmol) was added to a 
solution of 1,4-phenylenediamine (609 mg, 5.63 mmol) in isopropanol (7.5 mL) 
according to general procedure D to obtain 179 as a yellow solid (120 mg, 89%) 
which was used without further purification.   
m.p. 137-140 oC (decomp.). IR (ATR): ν = 3333, 1631 cm-1. 1H NMR (400 MHz, 
DMSO-d6): δ 8.32 (1H, s, Ar-H, H-2), 7.81 (1H, s, Ar-H, H-8), 7.29 (2H, d, J 8.8 Hz, 
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Ar-H, H-2’ + H-6’), 7.13 (1H, s, Ar-H, H-5), 6.60 (2H, d, J 8.8 Hz, Ar-H, H-3’ + H-
5’), 3.94 (3H, s, OCH3), 3.93 (3H, s, OCH3). 13C NMR (75 MHz, DMSO-d6): δ 157.0, 
154.2, 152.2, 148.8, 145.6, 127.4, 124.9, 118.3, 113.7, 108.3, 105.6, 102.4, 56.2, 55.8. 
LRMS [M+H+] 297.1. These data are in agreement with those previously reported by 
Garske et al.[189] 
N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)cyclohexane carboxamide 
(180).  
 
To a mixture of cyclohexane carboxylic acid (29 mg, 0.22 mmol) in DMF (1.6 mL) 
was added DIC (55 µL, 0.35 mmol) and DMAP (43 mg, 0.35 mmol). The solution 
was allowed to stir at room temperature for 15 min. Amine 179 (60 mg, 0.20 mmol) 
was then added to the above reaction mixture which was allowed to stir at room 
temperature for 20 h. The reaction mixture was diluted with ethyl acetate (50 mL), 
washed with water (5 × 15 mL), brine (15 mL) and dried over anhydrous MgSO4. The 
solvent was removed in vacuo to give a crude residue that was purified by reverse 
phase HPLC (0 to 100% MeCN over 40 min) to afford compound 180 as a yellow 
solid (50 mg, 56%).  
m.p. 222-225 oC (decomp.). IR (ATR): ν = 2937, 1676 cm-1. 1H NMR (400 MHz, 
DMSO-d6): δ 10.85 (1H, s, NH), 9.97 (1H, s, NH), 8.76 (1H, s, Ar-H, H-2), 8.05 (1H, 
s, Ar-H, H-8), 7.72 (2H, d, J 8.9 Hz, Ar-H, H-2’ + H-6’), 7.56 (2H, d, J 8.9 Hz, Ar-H, 
H-3’ + H-5’), 7.28 (1H, s, Ar-H, H-5), 4.00 (3H, s, OCH3), 3.99 (3H, s, OCH3), 2.35 
(1H, tt, J 11.6, 3.5 Hz, H-1”), 1.86-1.73 (4H, m), 1.67 (1H, d, J 11.7 Hz), 1.43 (2H, 
qd, J 11.4, 9.9, 2.0 Hz), 1.35-1.17 (3H, m). 13C NMR (101 MHz, DMSO-d6): δ 174.8 
(C=O), 158.6, 158.3, 156.5, 150.5, 149.9, 138.0, 132.2, 125.3, 119.6, 107.7, 103.6, 
101.4, 57.0, 56.9, 45.3, 29.6, 25.9, 25.7. LRMS [M+H+] 407.2. HRMS (ESI) m/z cald 
for C23H27N4O3 [M+H+]: 407.2077, found 407.2078.  
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(4-(6,7-dimethoxyquinazolin-4-yl)piperazin-1-yl)(phenyl)methanone (181).  
 
Amine 177 (71 mg, 0.26 mmol) was reacted with benzoic acid (35 mg, 0.29 mmol) in 
DMF (15 mL) in the presence of N,N-diisopropylethylamine (70 µL, 0.26 mmol) and 
HATU (156 mg, 0.40 mmol) for 4 h according to general procedure E. Purification by 
column chromatography (9:1 v/v CH2Cl2: CH3OH) provided compound 181 as a 
white solid (45 mg, 47%).   
m.p. 221-223 oC (decomp.). IR (ATR): ν = 2800, 1641 cm-1. 1H NMR (400 MHz, 
DMSO-d6): δ 8.57 (1H, s, Ar-H, H-2), 7.49-7.44 (4H, m, Ar-H), 7.24 (1H, s, Ar-H, H-
8), 7.16 (1H, s, Ar-H, H-5), 3.94 (3H, s, OCH3), 3.92 (3H, s, OCH3), 3.75-3.56 (8H, 
m, 4 × CH2). 13C NMR (101 MHz, DMSO-d6): δ 169.9 (C=O), 163.3, 155.0, 152.8, 
149.2, 148.9, 136.4, 130.0, 128.9, 127.4, 111.1, 107.9, 104.1, 56.4, 56.3, 49.5 (×2). 
LRMS [M+H+] 379.4. HRMS (ESI) m/z cald for C21H23N4O3 [M+H+]: 379.1765, 
found 379.1764.  
Cyclohexyl(4-(6,7-dimethoxyquinazolin-4-yl)piperazin-1-yl)methan-one (182).  
 
Amine 177 (71 mg, 0.26 mmol) was reacted with cyclohexane carboxylic acid (38 
mg, 0.29 mmol) in DMF (15 mL) in the presence of N,N-diisopropylethylamine (70 
µL, 0.26 mmol) and HATU (156 mg, 0.40 mmol) for 20 h according to general 
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procedure E. Purification by reverse phase HPLC (0 to 100% MeCN over 40 min) 
provided compound 182  as a white solid (50 mg, 50%).   
m.p. 165-166 oC (decomp.). IR (ATR): ν = 2936, 2855, 1792, 1772, 1678 cm-1. 1H 
NMR (400 MHz, CD3OD): δ 8.66 (1H, s, Ar-H, H-2), 7.47 (1H, s, Ar-H, H-8), 7.24 
(1H, s, Ar-H, H-5), 4.35 (4H, dt, J = 10.4, 5.2 Hz, H-3’ + H-5’), 4.08 (3H, s, OCH3), 
4.03 (3H, s, OCH3), 3.88-3.84 (4H, m, H-2’+ H-6’), 2.72 (1H, ddd, J 11.3, 8.1, 3.2 
Hz, H-1”), 1.86-1.77 (5H, m), 1.56-1.27 (5H, m). 1H NMR (100 MHz, CD3OD): δ 
176.1 (C=O), 161.9, 157.3, 149.6, 146.2, 137.4, 106.6, 105.8, 98.8, 55.9, 55.6, 44.0, 
40.9, 40.2, 29.0, 25.6, 25.3. LRMS [M+H+] 385.1. HRMS (ESI) m/z cald for 
C21H29N4O3 [M+H+]: 385.2234, found 385.2232.  
N-(2-((6,7-dimethoxyquinazolin-4-yl)amino)cyclohexyl)benzamide (183).  
 
Amine 178 (65 mg, 0.21 mmol) was reacted with benzoic acid (28 mg, 0.23 mmol) in 
DMF (12 mL) in the presence of N,N-diisopropylethylamine (58 µL, 0.20 mmol) and 
HATU (126 mg, 0.32 mmol) for 4 h according to general procedure E. Purification by 
column chromatography (95:5 v/v CH2Cl2: CH3OH) provided compound 183 as a 
pale yellow oil (41 mg, 48%).   
IR (ATR): ν = 2923, 1707 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 8.40 (1H, d, J 
11.0 Hz, NH), 8.38 (1H, s, Ar-H, H-2), 7.76 (1H, s, NH), 7.59 (2H, dd, J 7.3, 1.4 Hz, 
Ar-H, H-2” + H-6”), 7.48 (1H, s, Ar-H, H-8), 7.45-7.38 (1H, m, Ar-H, H-4”), 7.37-
7.28 (2H, m, Ar-H, H-3” + H-5”), 7.01 (1H, s, Ar-H, H-5), 4.30 (1H, app. dd, J 13.6, 
7.9 Hz, H-2’), 4.04 (1H, app. dd, J 12.1, 9.8 Hz, H-1’), 3.89 (3H, s, OCH3), 3.87 (3H, 
s, OCH3), 2.11 (1H, t, J 11.4 Hz), 2.02 (1H, app. d, J 12.7 Hz), 1.78 (2H, app. d, J 8.7 
Hz, CH2), 1.70-1.42 (2H, m, CH2), 1.36 (2H, app. t, J 10.3 Hz, CH2). 13C NMR (101 
MHz, DMSO-d6): δ 167.1 (C=O), 158.8, 154.3, 153.6, 148.8, 145.8, 134.9, 131.5, 
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128.6, 127.4, 108.5, 107.1, 102.4, 56.5, 56.1, 54.8, 54.1, 32.2 (×2), 25.2, 25.1. LRMS 
[M+H+] 407.2. HRMS (ESI) m/z cald for C23H27N4O3 [M+H+]: 407.2078, found 
407.2076. 
N-(2-((6,7-dimethoxyquinazolin-4-yl)amino)cyclohexyl)cyclohexane carboxamide 
(184).  
 
Amine 178 (93 mg, 0.31 mmol) was reacted with cyclohexane carboxylic acid (84 µL, 
0.48 mmol) in DMF (18 mL) in the presence of N,N-diisopropylethylamine (58 µL, 
0.20 mmol) and HATU (181 mg, 0.48 mmol) for 24 h according to general procedure 
E. Purification by column chromatography (98:2 v/v CH2Cl2: CH3OH → 95:5 v/v 
CH2Cl2: CH3OH) provided compound 184 as a white solid (40 mg, 31%).  
m.p. 98-100 oC (decomp.). IR (ATR): ν = 3266, 2934, 2859, 1675, 1636 cm-1. 1H 
NMR (400 MHz, CD3OD): δ 8.60 (1H, s, Ar-H, H-2), 7.86 (1H, d, J 6.0 Hz, NH), 
7.67 (1H, s, Ar-H, H-8), 7.12 (1H, s, Ar-H, H-5), 4.43 (1H, dt, J 11.6, 4.8 Hz, H-2’), 
4.05 (3H, s, OCH3), 4.02 (3H, s, OCH3), 4.01-3.93 (1H, m, H-1’), 2.20-2.12 (1H, m, 
H-3’), 2.02-1.93 (2H, m), 1.92-1.83 (2H, m), 1.70-1.40 (8H, m), 1.33-1.15 (2H, m), 
1.11-1.01 (3H, m), 0.95 (1H, app. dt, J 12.0, 3.6 Hz, H-5’). 13C NMR (101 MHz, 
CD3OD): δ 178.0 (C=O), 159.5, 157.2, 151.0, 148.3, 134.3, 106.5, 102.7, 98.8, 57.1, 
55.8, 55.8, 51.8, 44.8, 31.3, 30.7, 29.2, 28.9, 25.3, 25.2, 25.1, 24.6, 24.3. LRMS 
[M+H+] 413.2. HRMS (ESI) m/z cald for C23H33N4O3 [M+H+]: 413.2547, found 
413.2546.  
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(2S,4R)-N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)-4-
hydroxypyrrolidine-2-carboxamide (186).  
 
Amine 179 (74 mg, 0.26 mmol) was reacted with Boc-L-hydroxyproline (97 mg, 0.29 
mmol) in DMF (15 mL) in the presence of N,N-diisopropylethylamine (70 µL, 0.26 
mmol) and HATU (156 mg, 0.40 mmol) for 20 h according to general procedure E to 
obtain Boc-carbamate 185 which was used without further purification. To a solution 
of Boc-carbamate 185 (52 mg, 0.10 mmol) in THF (3 mL) was added 4 M HCl in 
dioxane (408 µL). The reaction was stirred at room temperature for 16 h at which 
point the reaction was quenched with saturated aqueous NaHCO3 (10 mL). The 
mixture was then extracted into ethyl acetate (3 × 50 mL), washed with water, brine 
and dried over anhydrous MgSO4. The solvent was removed in vacuo to give a crude 
residue that was purified by reverse phase HPLC (0 to 100% MeCN over 40 min) to 
afford compound 186 (32 mg, 30%) as a yellow amorphous solid.  
IR (ATR): ν = 3581, 1739, 1724 cm-1. 1H NMR (400 MHz, CD3OD):  δ 8.67 (1H, s, 
Ar-H, H-2), 7.98 (1H, s, Ar-H, H-8), 7.77-7.72 (4H, m, Ar-H, H-2’ + H-6’ + H-3’ + 
H-5’), 7.25 (1H, s, Ar-H, H-5), 4.74-4.57 (2H, m, H-2” + H-4”), 4.09 (3H, s, OCH3), 
4.08 (3H, s, OCH3), 3.51 (1H, dd, J 12.1, 3.5 Hz, H-5”ax), 3.39 (1H, dd, J 12.5, 1.8 
Hz, H-5”eq), 2.61 (1H, dd, J 13.6, 7.5 Hz, H-3”eq), 2.22 (1H, ddd, J 14.0, 10.3, 4.0 Hz, 
H-3”ax). 13C NMR (101 MHz, CD3OD):  δ 166.5 (C=O), 158.5, 157.5, 151.4, 148.3, 
136.1, 136.0, 133.3, 124.7, 120.0, 107.5, 102.4, 99.4, 69.9, 59.3, 55.9, 55.8, 53.9, 
38.7. LRMS [M+H+] 410.0. HRMS (ESI) m/z cald for C21H24N5O4 [M+H+]: 
410.1820, found 410.1823. [!]!!"= +28o (c = 0.10 in CH3OH).  
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(S)-N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)pyrrolidine-2-
carboxamide (187).  
 
4-Chloro-6,7-dimethoxyquinazoline 174 (100 mg, 0.44 mmol) was reacted with 
amine 188 (191 mg, 0.44 mmol) in isopropanol (9.6 mL) according to general 
procedure D to obtain Fmoc-carbamate 189 as a yellow solid which was submitted to 
the next step without purification. A solution of Fmoc-carbamate 189 was treated with 
25 vol.% piperidine in a mixture of dichloromethane and methanol (1:1, v/v, 5 mL) 
for 1 h. The solvent was removed in vacuo to afford a crude residue that was purified 
by column chromatography (95:4:1 v/v/v CH2Cl2: MeOH: Et3N → 90:9:1 v/v/v 
CH2Cl2: MeOH : Et3N) to afford compound 187 as an amorphous solid (59 mg, 34% 
over 2 steps).  
IR (ATR): ν = 3066, 2986, 1673, 1639 cm-1. 1H NMR (400 MHz, DMSO-d6, 330 K):  
δ 10.59 (1H, s, NH), 8.67 (1H, s, Ar-H, H-2), 8.01 (1H, s, Ar-H, H-8), 7.74-7.66 (4H, 
m, Ar-H, H-2’ + H-6’ + H-3’ + H-5’), 7.30 (1H, s, Ar-H, H-5), 4.40 (1H, m, H-2”), 
3.99 (6H, s, 2× OCH3), 3.33 (2H, m, H-5”), 2.43 (1H, m, H-3”eq), 2.03 (3H, m, H-3”ax 
+ H-4”). 13C NMR (100 MHz, DMSO-d6, 330 K): δ 167.2 (C=O), 158.7, 156.3, 
150.7, 150.4, 140.0, 135.8, 134.4, 124.9, 120.4, 108.3, 103.7, 103.2, 60.4, 57.1, 56.8, 
46.4, 30.0, 24.0. LRMS [M+H+] 394.0. HRMS (ESI) m/z cald for C21H24N5O3 
[M+H+]: 394.1874, found 394.1872. [!]!!"= -26o (c = 0.15 in CH3OH).  
General procedure F: Synthesis of 4-aminocarboxamides 188 and 190-195 
To a solution of carboxylic acid (1.19-1.48 mmol) in dichloromethane (27-34 
mL/mmol) was added HATU (1.19-1.48 mmol, 1 eq.), followed by 1,4-
phenylenediamine (1.19-1.48 mmol, 1 eq.) and N,N-diisopropylethylamine (1.19-1.48 
mmol, 1 eq.). The reaction was allowed to stir at room temperature for 1-1.5 h. The 
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reaction mixture was diluted with dichloromethane (30 mL) and washed with brine  
(2 × 20 mL). The organic layer was dried over anhydrous MgSO4. The solvent was 
removed in vacuo to give 4-aminocarboxamides 188 and 190-195 following column 
chromatography or reverse phase HPLC purification. 
(S)-(9H-fluoren-9-yl)methyl 2-((4-aminophenyl)carbamoyl)pyrrolidine-1-
carboxylate (188) 
 
 
Fmoc-L-proline (402 mg, 1.2 mmol) was reacted with 1,4-phenylenediamine (130 mg, 
1.2 mmol) in dichloromethane (40 mL) in the presence of HATU (450 mg, 1.5 mmol) 
and N,N-diisopropylethylamine (200 µL) for 1 h according to general procedure F to 
afford 4-aminocarboxamide 188 as a yellow oil (290 mg, 57%) after column 
chromatography (98:2 v/v CH2Cl2: CH3OH → 95:5 v/v CH2Cl2: CH3OH). 
IR (ATR): ν = 3309, 2937, 1666, 1641 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 8.73 
(1H, s, NH), 7.92 (1H, d, J 7.3 Hz, Ar-H), 7.89-7.85 (2H, m, Ar-J), 7.61 (1H, d, J 7.4 
Hz, Ar-H), 7.51-7.42 (1H, m, Ar-H), 7.42-7.33 (1H, m, Ar-H), 7.31 (1H, t, J 7.4 Hz, 
Ar-H), 6.77 (d, J 8.3 Hz, Ar-H, H-2 + H-6), 6.38 (2H, d, J 8.3 Hz, Ar-H, H-3 + H-5), 
4.17 (1H, dd, J 10.8, 5.0 Hz, CH), 3.49-3.43 (1H, m, H-5’), 3.18 (2H, dd, J 11.8, 5.2 
Hz, CH2), 3.11 (1H, dd, J 9.6, 4.9 Hz, H-2’), 2.62 (1H, q, J 8.3 Hz, H-5’), 2.22-2.10 
(1H, m, H-3’), 1.94-1.79 (3H, m, H-3’ + H-4’ax + H-4’eq). 13C NMR (101 MHz, 
DMSO-d6): δ 171.1, 146.4, 145.8, 145.3, 141.1, 140.7, 127.8, 127.8, 127.6, 127.5, 
127.5, 126.2, 125.0, 120.9, 120.8, 120.5, 114.0, 68.7, 59.2, 53.7, 46.6, 30.1, 24.1. 
LRMS [M-CO2] 384.0. HRMS (ESI) m/z cald for C26H26N3O3 [M+H+]: 428.2332, 
found 428.2333. [!]!!! = -100o (c = 0.20 in CH2Cl2).  
N-(4-aminophenyl)-3-(4-fluorophenyl)-5-methylisoxazole-4-carboxamide (190) 
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3-(4-Fluorophenyl)-5-methylisoxazole-4-carboxylic acid (328 mg, 1.48 mmol) was 
reacted with 1,4-phenylenediamine (160 mg, 1.48 mmol) in dichloromethane (40 mL) 
in the presence of HATU (563 mg, 1.48 mmol) and N,N-diisopropylethylamine (260 
µL) for 1 h according to general procedure F to afford 4-aminocarboxamide 190  
(TFA salt) as an off-white solid (219 mg, 47%) which was used without further 
purification. 
m.p. 179-182 oC (decomp.). IR (ATR): ν = 3262, 2967, 2922, 1670, 1609 cm-1.1H 
NMR (400 MHz, DMSO-d6): δ 10.41 (1H, s, NH), 7.80-7.70 (2H, m, Ar-H, H-2’ + H-
6’), 7.56 (2H, d, J 8.3 Hz, 1H, Ar-H, H-2 + H-6), 7.38-7.28 (2H, m, Ar-H, H-3’ + H-
5’), 7.05 (2H, d, J 8.3 Hz, Ar-H, H-3 + H-4), 2.58 (3H, s, CH3). 13C NMR (101 MHz, 
DMSO-d6): δ 170.5, 164.8 (C=O), 161.2 (d, J 221 Hz, ipso-C), 160.3, 159.8, 134.8, 
130.5 (d, J 8.7 Hz, meta-C), 125.0 (d, J 3.2 Hz, para-C), 121.6, 120.4, 116.4 (d, J 22 
Hz, ortho-C), 113.6, 12.4. LRMS [M+H+] 312.1. HRMS (ESI) m/z cald for 
C17H15FN3O2 [M+H+]: 312.1143, found 312.1143.  
N-(4-aminophenyl)pyrazine-2-carboxamide (191) 
 
2-Pyrazinecarboxylic acid (184 mg, 1.48 mmol) was reacted with  
1,4-phenylenediamine (160 mg, 1.48 mmol) in dichloromethane (40 mL) in the 
presence of HATU (563 mg, 1.48 mmol) and N,N-diisopropylethylamine (260 µL) for 
1.5 h according to general procedure F to afford 4-aminocarboxamide 191 as an off-
white solid (109 mg, 34%) after reverse phase HPLC purification (0 to 100% MeCN 
over 40 min). 
m.p. 167-171 oC (decomp.). IR (ATR): ν = 3348, 2639, 1685 cm-1. 1H NMR (400 
MHz, DMSO-d6): δ 10.72 (1H, s, NH), 9.30-9.27 (1H, m, Ar-H, H-2’), 8.93 (1H, dd, 
J 2.5, 1.0 Hz, Ar-H, H-4’), 8.81-8.80 (1H, m, Ar-H, H-5’), 7.84 (2H, d, J 8.7 Hz, Ar-
H, H-2 + H-6), 7.09 (2H, d, J 8.4 Hz, H-3 + H-5). 13C NMR (101 MHz, DMSO-d6): δ 
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161.9 (C=O), 148.1, 145.5, 144.5, 143.7, 134.6, 122.2, 120.5, 120.5. LRMS [M+H+] 
215.0. HRMS (ESI) m/z cald for C11H11N4O [M+H+]: 215.0927, found 215.0928.  
N-(4-aminophenyl)-2-nitrobenzamide (192) 
 
2-Nitrobenzoic acid (247 mg, 1.48 mmol) was reacted with 1,4-phenylenediamine 
(160 mg, 1.48 mmol) in dichloromethane (40 mL) in the presence of HATU (563 mg, 
1.48 mmol) and N,N-diisopropylethylamine (260 µL) for 1 h according to general 
procedure F to afford 4-aminocarboxamide 192  as a white solid (228 mg, 60%) after 
reverse phase HPLC purification (0 to 100% MeCN over 40 min). 
m.p. 98-99 oC (decomp.). IR (ATR): ν = 3288, 1678 cm-1. 1H NMR (400 MHz, 
DMSO-d6): δ 8.23-8.07 (1H, m, Ar-H, H-3’), 7.87 (1H, t, J 7.5 Hz, 1H, Ar-H), 7.79-
7.71 (2H, m, Ar-H), 7.66 (2H, d, J 8.4 Hz, H-2 + H-6), 7.16 (2H, d, J 8.4 Hz, H-3 + 
H-5). 13C NMR (101 MHz, DMSO-d6): δ 164.5 (C=O), 146.9, 136.3, 134.5, 133.0, 
132.4, 131.5, 129.7, 124.7, 121.6, 121.3. LRMS [M+H+] 258.0. HRMS (ESI) m/z cald 
for C13H12N3O3 [M+H+]: 258.0873, found 258.0874.  
N-(4-aminophenyl)-4-fluorobenzamide (193) 
 
4-Fluorobenzoic acid (207 mg, 1.48 mmol) was reacted with 1,4-phenylenediamine 
(160 mg, 1.48 mmol) in dichloromethane (40 mL) in the presence of HATU (563 mg, 
1.48 mmol) and N,N-diisopropylethylamine (260 µL) for 1 h according to general 
procedure F to afford 4-aminocarboxamide 193 as a white solid (170 mg, 50%) after 
reverse phase HPLC purification (0 to 100% MeCN over 40 min). 
m.p. 179-181 oC (decomp.). IR (ATR): ν = 3350, 3339, 1675, 1643 cm-1. 1H NMR 
(500 MHz, DMSO-d6): δ 9.86 (1H, s, NH), 7.98-7.96 (2H, m, Ar-H, H-2’ + H-6’), 
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7.34-7.29 (4H, m, Ar-H, H-2 + H-6 + H-3’ + H-5’), 6.52 (2H, d, J 8.7 Hz, Ar-H, H-3 
+ H-5). 13C NMR (126 MHz, DMSO-d6): δ 164.8 (d, J 156 Hz, ipso-C), 163.4 (C=O), 
145.9, 132.3 (d, J 2.9 Hz, para-C), 130.6 (d, J 9.0 Hz, meta-C), 128.6, 122.9, 115.8 
(d, J 22 Hz, ortho-C), 114.3. LRMS [M+H+] 231.0. HRMS (ESI) m/z cald for 
C13H12FN2O [M+H+]: 231.0928, found 231.0928.  
N-(4-aminophenyl)-3-methoxybenzamide (194) 
 
3-Methoxybenzoic acid (225 mg, 1.48 mmol) was reacted with 1,4-phenylenediamine 
(160 mg, 1.48 mmol) in dichloromethane (40 mL) in the presence of HATU (563 mg, 
1.48 mmol) and N,N-diisopropylethylamine (260 µL) for 1 h according to general 
procedure F to afford 4-aminocarboxamide 194 as a yellow oil (178 mg, 50%) after 
column chromatography (95:5 v/v CH2Cl2: CH3OH).  
IR (ATR): ν = 3350, 3341, 2955, 2942, 1631 cm-1. 1H NMR (400 MHz, DMSO-d6):  
δ 9.82 (1H, s, NH), 7.54-7.47 (1H, m, Ar-H, H-6’), 7.47-7.43 (1H, m, Ar-H, H-2’), 
7.40 (1H, t, J 7.9 Hz, Ar-H, H-5’), 7.36 (2H, d, J 8.4 Hz, Ar-H, H-2 + H-6), 7.11 (1H, 
ddd, J 8.2, 2.4, 1.1 Hz, Ar-H, H-4’), 6.54 (2H, d, J 8.5 Hz, Ar-H, H-3 + H-5), 3.82 
(3H, s, OCH3). 13C NMR (101 MHz, DMSO-d6): δ 164.8 (C=O), 159.6, 145.7, 137.2, 
129.9, 128.5, 122.8, 120.1, 117.3, 114.1, 113.1, 55.7. LRMS [M+H+] 243.1. HRMS 
(ESI) m/z cald for C14H15N2O2 [M+H+]: 243.1128, found 243.1130. 
N-(4-aminophenyl)-3-nitrobenzamide (195) 
 
3-Nitrobenzoic acid (250 mg, 1.5 mmol) was reacted with 1,4-phenylenediamine (160 
mg, 1.5 mmol) in dichloromethane (40 mL) in the presence of HATU (560 mg, 1.5 
mmol) and N,N-diisopropylethylamine (260 µL) for 1 h according to general 
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procedure F to afford 4-aminocarboxamide 195 as an off-white solid (190 mg, 50%) 
after reverse phase HPLC purification (0 to 100% MeCN over 40 min). 
m.p. 170-173 oC (decomp.). IR (ATR): ν = 3080, 2932, 2637, 1667 cm-1. 1H NMR 
(400 MHz, CD3CN): δ 8.73 (1H, s, Ar-H, H-2’), 8.39 (1H, ddd, J 8.3, 2.2, 1.0 Hz, Ar-
H, H-6’), 8.28 (1H, dt, J 8.1, 1.3 Hz, Ar-H, H-4’), 7.75 (1H, t, J 8.0 Hz, Ar-H, H-5’), 
7.58 (2H, d, J 8.8 Hz, Ar-H, H-2 + H-6), 6.95 (2H, d, J 8.7 Hz, H-3 + H-5). 13C NMR 
(101 MHz, CD3CN):  δ 163.4 (C=O), 148.3, 138.0, 136.7, 133.5, 132.3, 129.9, 126.0, 
122.3, 122.2, 117.9. LRMS [M+H+] 258.0. HRMS (ESI) m/z cald for C13H12N3O3 
[M+H+]: 258.0873, found 258.0874.  
N-(4-aminophenyl)-2-hydroxybenzamide  (196) 
 
To a stirred solution of salicylic acid (135 mg, 0.97 mmol) in acetonitrile (2.9 mL) at 
room temperature was added 1-chloro-N,N-2-trimethyl-1-propenylamine (258 µL, 
1.95 mmol). The reaction was allowed to stir at room temperature for 2.5 h. The 
solvent was removed in vacuo to give a residue that was suspended in 
dichloromethane (2.2 mL) and the solution was allowed to cool to 0 oC. A solution of 
1,4-phenylenediamine (106 mg, 1 mmol) in dichloromethane (14.7 mL) was added 
dropwise, followed by triethylamine (280 µL, 1.94 mmol). The reaction was allowed 
to stir at 10 oC for 16 h. The solvent was subsequently removed in vacuo and the 
resulting residue was diluted with ethyl acetate (70 mL), washed with water (30 mL) 
and brine (30 mL) to give a crude residue that was purified by reverse phase HPLC (0 
to 100% MeCN over 40 min) to afford 4-aminocarboxamide 196 (TFA salt) as a 
white solid (45 mg, 20%). 
m.p. 169-171 oC (decomp.). IR (ATR): ν = 3427, 1679, 1625 cm-1. 1H NMR (500 
MHz, DMSO-d6): δ 11.88 (1H, OH), 10.36 (1H, s, NH), 7.95 (1H, dd, J 8.0, 1.7 Hz, 
Ar-H, H-6’), 7.63 (2H, d, J 8.7 Hz, Ar-H, H-3 + H-5), 7.44 (1H, ddd, J 8.5, 7.2, 1.7 
Hz, Ar-H, H-4’), 7.07 (2H, d, J 8.8 Hz, Ar-H, H-2 + H-6), 6.99-6.93 (2H, m, Ar-H, 
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H-3’ + H-5’). 13C NMR (126 MHz, DMSO-d6): δ 167.2 (C=O), 159.2, 134.2 (×2), 
129.5 (×2), 122.9, 120.4, 119.6, 117.9, 117.8. LRMS [M+H+] 229.0. HRMS (ESI) 
m/z cald for C13H13N2O2 [M+H+]: 229.0972, found 229.0971.  
N-(4-aminophenyl)-3-hydroxybenzamide (197) 
 
To a solution of 3-hydroxybenzoic acid (205 mg, 1.48 mmol) in dichloromethane (50 
mL) was added HATU (563 mg, 1.48 mmol) followed by N,N-diisopropylethylamine 
(260 µL, 1.48 mmol) and the reaction mixture was allowed to stir at room temperature 
for 10 min. At this point, 1,4-phenylenediamine (160 mg, 1.48 mmol) was added and 
the reaction was allowed to stir at room temperature for 1 h. The reaction mixture was 
diluted with dichloromethane (30 mL) and washed with brine (2 × 20 mL). The 
organic layer was dried over anhydrous MgSO4. The solvent was removed in vacuo to 
give a crude residue that was purified by column chromatography (95:5 v/v CH2Cl2: 
CH3OH → 9:1 v/v CH2Cl2: CH3OH) to afford 4-aminocarboxamide 197 as a white 
solid (220 mg, 65%). 
m.p. 178-181 oC (decomp.). IR (ATR): ν = 3288, 2923, 1672 cm-1. 1H NMR (500 
MHz, DMSO-d6):  δ 7.76 (2H, d, J 8.8 Hz, Ar-H, H-2 + H-6), 7.37 (1H, dt, J 8.0, 1.3 
Hz, Ar-H, H-6’), 7.34-7.26 (2H, m, Ar-H, H-4’ + H-5’), 7.15 (2H, d, J 8.8 Hz, Ar-H, 
H-3 + H-5), 6.97 (1H, ddd, J 8.0, 2.4, 1.1 Hz, Ar-H, H-4’). 13C NMR (126 MHz, 
DMSO-d6): δ 166.1 (C=O), 158.0, 137.0, 136.8, 130.0, 130.0, 122.1, 121.7, 119.1, 
118.7, 115.1. LRMS [M+H+] 229.0. HRMS (ESI) m/z cald for C13H13N2O2 [M+H+]: 
229.0972, found 229.0973.  
N-(4-aminophenyl)-4-((tert-butyldimethylsilyl)oxy)benzamide (204) 
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A stirring solution of 4-((tert-butyldimethylsilyl)oxy)benzoic acid 202 (500 mg, 3.62 
mmol) in dichloromethane (15 mL) was allowed cooled to 0 oC for 10 min. Oxalyl 
chloride (735 µL, 8.69 mmol) was added dropwise to this solution, followed by DMF 
(10 µL). The mixture was allowed to warm up to room temperature over 2 h. The 
solvent was removed in vacuo, and the residue was immediately suspended in THF 
(15 mL) and cooled to 0 oC. A solution of 1,4-phenylenediamine in THF (0.25 M, 392 
mg in 15 mL of THF) was added dropwise, followed by triethylamine (555 µL). The 
reaction was warmed to room temperature and allowed to stir at this temperature for 
16 h. The solvent was subsequently removed in vacuo and the resulting residue was 
diluted with ethyl acetate (70 mL), washed with water (30 mL) and brine (30 mL) to 
give a crude residue that was purified by column chromatography (100:1 v/v CH2Cl2: 
CH3OH → 98:2 v/v CH2Cl2: CH3OH) to afford 4-aminocarboxamide 204 as a pale 
yellow oil (779 mg, 63%). 
IR (ATR): ν = 3337, 3037, 2955, 1638, 1604 cm-1. 1H NMR (400 MHz, CDCl3): δ 
7.75 (2H, d, J 8.2 Hz, Ar-H, H-2’ + H-6’), 7.60 (1H, s, NH), 7.37 (2H, d, J 8.2 Hz, 
Ar-H, H-2 + H-6), 6.89 (2H, d, J 8.2 Hz, Ar-H, H-3’ + H-5’), 6.69 (2H, d, J 8.2 Hz, 
Ar-H, H-3 + H-5), 3.60 (2H, s, NH2), 0.996 (9H, s, (CH3)3CSi), 0.23 (6H, s,  
2× CH3Si); 13C NMR (101 MHz, CDCl3): δ 165.2 (C=O), 158.8, 143.4, 129.5, 128.7, 
128.1, 122.3, 120.1, 115.5, 38.6, 25.6, -4.4. LRMS [M+H+] 343.3. HRMS (ESI) m/z 
cald for C19H27N2O2Si [M+H+]: 343.1836, found 343.1837. 
N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)-3-(4-fluoro-phenyl)-5-
methylisoxazole-4-carboxamide (206).  
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4-Chloro-6,7-dimethoxyquinazoline 174 (90 mg, 0.39 mmol) was reacted with  
4-aminocarboxamide 190 (124 mg, 0.39 mmol) in isopropanol (8.8 mL) according to 
general procedure D to obtain compound 206 as an off-white solid (140 mg, 72%).   
m.p. 253-256 oC (decomp.). IR (ATR): ν = 1659, 1631 cm-1. 1H NMR (400 MHz, 
DMSO-d6): δ 11.45 (1H, s, NH), 10.64 (1H, s, NH), 8.76 (1H, s, Ar-H, H-2), 8.34 
(1H, s, Ar-H, H-8), 7.81-7.72 (4H, m, Ar-H, H-2’ + H-6’ + H-2” + H-6”), 7.66 (2H, d, 
J 8.5 Hz, Ar-H, H-3’ + H-5’), 7.42-7.30 (3H, m, Ar-H, H-5, H-3” + H-5”), 4.02 (3H, 
s, CH3), 3.99 (3H, s, OCH3), 2.62 (3H, s, OCH3). 13C NMR (100 MHz, DMSO-d6):  
δ 170.7, 164.8 (C=O), 161.4 (d, J 199 Hz, ipso-C), 159.9, 158.5, 156.7, 150.6, 149.1, 
137.1, 135.9, 133.2, 130.5 (d, J 8.7 Hz, meta-C), 125.8, 125.0 (d, J 3.1 Hz, para-C), 
120.4, 116.4 (d, J 21.8 Hz, ortho-C), 113.6, 107.7, 104.5, 100.3, 57.4, 56.9, 12.5. 
LRMS [M+H+] 500.3. HRMS (ESI) m/z cald for C27H23FN5O4 [M+H+]: 500.1729, 
found 500.1728.  
N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)pyrazine-2-carboxamide 
(207).  
 
4-Chloro-6,7-dimethoxyquinazoline 174 (50 mg, 0.22 mmol) was reacted with  
4-aminocarboxamide 191 (109 mg, 0.22 mmol) in isopropanol (3.1 mL) according to 
general procedure D to obtain a crude solid that was purified by reverse-phase HPLC 
(gradient: 0-100% MeCN over 40 min) to afford compound 207 (TFA salt) as a 
yellow solid (80 mg, 90%).  
m.p. 220-224 oC (decomp.). IR (ATR): ν = 3340, 1686 cm-1. 1H NMR (500 MHz, 
DMSO-d6):  δ 10.89 (1H, s, NH), 10.86 (1H, s, NH), 9.30 (1H. d, J 1.5 Hz, Ar-H, H-
3”), 8.94 (1H, d, J 2.5 Hz, Ar-H, H-5”), 8.89-8.82 (1H, m, Ar-H, H-6”), 8.77 (1H, s, 
Ar-H, H-2), 8.04 (1H, s, Ar-H, H-8), 8.00 (2H, d, J 8.9 Hz, Ar-H, H-2’ + H-6’), 7.65 
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(2H, d, J 8.9 Hz, Ar-H, H-3’ + H-5’), 7.27 (1H, s, Ar-H, H-5), 3.99 (6H, s, 2 × 
OCH3). 13C NMR (100 MHz, DMSO-d6): δ 162.3 (C=O), 158.5, 156.7, 150.7, 150.0, 
148.4, 145.6, 144.7, 143.9, 137.4, 136.8, 133.6, 125.5, 121.4, 107.9, 103.8, 101.4, 
57.2, 57.1. LRMS [M+H+] 403.3. HRMS (ESI) m/z cald for C21H19N6O3 [M+H+]: 
403.1513, found 403.1514.  
N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)-2-hydroxy benzamide (208).  
 
4-Chloro-6,7-dimethoxyquinazoline 174 (16 mg, 0.072 mmol) was reacted with  
4-aminocarboxamide 196 (16 mg, 0.072 mmol) in isopropanol (1.6 mL) according to 
general procedure D to obtain a crude solid that was purified by reverse-phase HPLC 
(gradient: 0-100% MeCN over 40 min) to afford compound 208 as a yellow solid (9 
mg, 30%).  
m.p. = 213-214 oC. IR (ATR): ν = 3385, 1703 cm-1. 1H NMR (400 MHz, Acetone-d6):  
δ 9.94 (1H, s, NH), 8.71 (1H, s, Ar-H, H-2), 8.04 (1H, dd, J = 8.0, 1.6 Hz, Ar-H, H-
6”), 7.96 (1H, s, Ar-H, H-8), 7.87-7.75 (4H, m, Ar-H, H-2’ + H-3’ + H-5’+ H-6’), 
7.68 (1H, s, Ar-H, H-5), 7.47 (1H, ddd, J = 8.6, 7.1, 1.6 Hz, Ar-H, H-4”), 7.00 (1H, 
app. d, J 8.6 Hz, Ar-H, H-3”), 6.93 (1H, dd, J 7.6, 7.1 Hz, Ar-H, H-5”), 4.01 (3H, s, 
OCH3), 3.96 (3H, s, OCH3). 13C NMR (100 MHz, DMSO-d6): δ 166.9 (C=O), 158.8, 
158.5, 158.1, 156.4, 150.4, 150.3, 136.3, 134.1, 133.7, 129.5, 125.1, 121.6, 119.5, 
118.1, 117.7, 107.9, 103.6, 102.0, 57.0, 56.8. LRMS [M+H+] 417.3. HRMS (ESI) m/z 
cald for C23H21N4O4 [M+H+]: 417.1557, found 417.1560.  
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N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)-2-nitro-benzamide (209).  
 
4-Chloro-6,7-dimethoxyquinazoline 174 (200 mg, 0.86 mmol) was reacted with  
4-aminocarboxamide 192 (221 mg, 0.86 mmol) in isopropanol (20 mL) according to 
general procedure D to obtain compound 209 as a yellow solid (200 mg, 52%) after 
filtration and washing with diethyl ether (2 × 10 mL).  
m.p. 263-265 oC (decomp.). IR (ATR): ν = 2756, 1679, 1530 cm-1. 1H NMR (500 
MHz, DMSO-d6):  δ 11.37 (1H, s, NH), 10.85 (1H, s, NH), 8.80 (1H, s, Ar-H, H-2), 
8.30 (1H, s, Ar-H, H-8), 8.17 (1H, app. d, J 8.0 Hz, Ar-H, H-3”), 7.90 (1H, dd, J 8.0, 
7.5 Hz, Ar-H, H-5”), 7.82-7.77 (4H, m, Ar-H, H-2’ + H-6’ + H-3’ + H-5’), 7.68 (2H, 
m, Ar-H, H-4” + H-6”), 7.36 (1H, s, Ar-H, H-5), 4.02 (3H, s, OCH3), 3.99 (3H, s, 
OCH3). 13C NMR (125 MHz, DMSO-d6): δ 164.6 (C=O), 158.6, 156.7, 150.6, 149.2, 
146.9, 137.4, 136.0, 134.6, 133.0 (×2), 131.5, 129.8, 125.8, 124.8, 120.2, 107.7, 
104.3, 100.4, 57.4, 56.9. LRMS [M+H+] 446.2. HRMS (ESI) m/z cald for C23H20N5O5 
[M+H+]: 446.1459, found 446.1459.  
2-amino-N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl) benzamide (210).  
 
Compound 209 (45 mg, 0.10 mmol) in ethyl acetate (1.5 mL) was hydrogenated  
(1 atm) over 10% Pd/C (15 mg) for 16 h. The reaction mixture was subsequently 
filtered over Celite® and the filtrate concentrated in vacuo. Purification by reverse 
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phase HPLC (gradient: 0-100% MeCN over 40 min) provided compound 210 as a 
yellow solid (12 mg, 29%).  
m.p. 127-128 oC (decomp.). IR (ATR): ν = 3452, 1677, 1639 cm-1. 1H NMR (400 
MHz, CD3OD):  δ 8.67 (1H, s, Ar-H, H-2), 7.99 (1H, s, Ar-H, H-8), 7.88-7.77 (2H, 
m, Ar-H, H-2’ + H-6’), 7.71 (2H, d, J 8.9 Hz, Ar-H, H-3’ + H-5’), 7.67 (1H, dd, J = 
7.9, 1.5 Hz, Ar-H, H-6”), 7.30 (1H, ddd, J 8.5, 7.5, 1.5 Hz, Ar-H, H-4”), 7.22 (1H, s, 
Ar-H, H-5), 6.93-6.84 (1H, m, Ar-H, H-3”), 6.80 (1H, app. t, J = 7.5 Hz, Ar-H, H-5”), 
4.08 (6H, s, 2 × OCH3). 13C NMR (101 MHz, CD3OD): δ 168.7 (C=O), 158.5, 157.6, 
151.4, 148.0, 147.8, 137.4, 135.3, 132.5, 132.2, 128.0, 124.5, 121.0, 117.5, 117.2, 
117.0, 107.3, 102.5, 99.0, 55.9, 55.8. LRMS [M+H+] 416.0. HRMS (ESI) m/z cald for 
C23H22N5O3 [M+H+]: 416.1717, found 416.1714.  
N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)-4-hydroxy benzamide (211).  
 
4-Chloro-6,7-dimethoxyquinazoline 174 (21 mg, 0.09 mmol) was reacted with  
4-aminocarboxamide 204 (32 mg, 0.094 mmol) in isopropanol (2.0 mL) according to 
general procedure D to obtain TBS-protected intermediate 211P as a yellow solid 
which was used in the next step without purification (50 mg, quant.).  
To a solution of the TBS-protected intermediate 211P (50 mg, 0.094 mmol) in 
anhydrous tetrahydrofuran (1 mL) was added tetrabutylammonium fluoride (1 M 
solution in THF, 0.11 mL, 0.11 mmol) and the reaction was allowed to stir at room 
temperature for 1 h. The reaction mixture was then diluted with ethyl acetate (60 mL) 
and washed with saturated aqueous NH4Cl solution (2 × 30 mL) and brine (30 mL). 
The organic layer was then dried over anhydrous MgSO4. The solvent was removed 
in vacuo to give a crude residue that purified by reverse-phase HPLC (gradient: 0-
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100% MeCN over 40 min) to afford compound 211 (TFA salt) as a yellow solid (20 
mg, 51% over 2 steps).  
m.p. 164-165 oC. IR (ATR): ν = 3009, 1709 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 
10.91 (1H, s, NH), 10.13 (1H, s, NH), 8.77 (1H, s, Ar-H, H-2), 8.08 (1H, s, Ar-H, H-
8), 7.93-7.83 (4H, m, Ar-H), 7.62 (2H, d, J 8.5 Hz, Ar-H, H-3’ + H-5’), 7.30 (1H, s, 
Ar-H, H-5), 6.88 (2H, d, J 8.2 Hz, Ar-H, H-4” + H-5”), 3.99 (6H, s, 2 × OCH3).  
13C NMR (100 MHz, DMSO-d6): δ 165.6 (C=O), 161.1, 158.3, 156.5, 150.5, 149.9, 
138.0, 137.3, 132.6, 130.2, 125.7, 125.2, 120.8, 115.4, 107.7, 103.7, 101.3, 57.1, 56.9. 
LRMS [M+H+] 417.1. HRMS (ESI) m/z cald for C23H21N4O4 [M+H+]: 417.1557, 
found 417.1557. 
N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)-4-fluoro-benzamide (212).  
 
4-Chloro-6,7-dimethoxyquinazoline 174 (100 mg, 0.44 mmol) was reacted with  
4-aminocarboxamide 193 (102 mg, 0.44 mmol) in isopropanol (9.6 mL) according to 
general procedure D. Purification by reverse phase HPLC (gradient: 0-100% MeCN 
over 40 min) provided compound  212 as a yellow solid (12 mg, 29%).   
m.p. 257-260 oC (decomp.). IR (ATR): ν = 1636 cm-1. 1H NMR (400 MHz, DMSO-
d6):  δ 10.89 (1H, s, NH), 10.41 (1H, s, NH), 8.77 (1H, s, Ar-H, H-2), 8.09-8.03 (3H, 
m, Ar-H, H-8, H-2” + H-6”), 7.87 (2H, d, J 8.6 Hz, Ar-H, H-2’ + H-6’), 7.65 (2H, d, J 
8.6 Hz, Ar-H, H-3’ + H-5’), 7.39 (2H, app. t, J 8.6 Hz, Ar-H, H-3” + H-5”), 7.27 (1H, 
s, Ar-H, H-2), 3.99 (6H, s, 2× OCH3). 13C NMR (100 MHz, DMSO-d6): δ 165.8 
(C=O), 165.0 (d, J 161 Hz, ipso-C), 158.7, 158.3, 156.5, 150.5, 149.9, 137.5, 133.0, 
131.7 (d, J 3.4 Hz, para-C), 130.8 (d, J 9.2 Hz, meta-C), 125.3, 121.1, 115.8 (d, J 22 
Hz, ortho-C), 107.7, 103.6, 101.3, 57.0, 56.9. LRMS [M+H+] 419.4. HRMS (ESI) m/z 
cald for C23H20FN4O3 [M+H+]: 419.1514, found 419.1513. 
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N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)-3-hydroxy benzamide (213).  
 
4-Chloro-6,7-dimethoxyquinazoline 174 (54 mg, 0.24 mmol) was reacted with  
4-aminocarboxamide 197 (54 mg, 0.24 mmol) in isopropanol (5.6 mL) according to 
general procedure D. Purification by reverse phase HPLC (gradient: 0-100% MeCN 
over 40 min) provided compound 213 as a yellow solid (39 mg, 39%).  
m.p. 181-182 oC (decomp.). IR (ATR): ν = 3474, 1675 cm-1. 1H NMR (500 MHz, 
DMSO-d6): δ 10.71 (1H, br. s), 10.28 (1H, s, NH), 9.78 (1H, br. s), 8.74 (1H, s, Ar-H, 
H-2), 8.04 (1H, s, Ar-H, H-8), 7.87 (2H, d, J 8.7 Hz, Ar-H, H-2’ + H-6’), 7.64 (2H, d, 
J 8.7 Hz, Ar-H, H-3’ + H-5’), 7.40 (1H, d, J 7.7 Hz, Ar-H, H-6”), 7.35-7.33 (2H, m, 
Ar-H, H-2” + H-5”), 7.26 (1H, s, Ar-H, H-5), 6.99 (1H, dd, J = 8.0, 2.5 Hz, Ar-H, H-
4”), 3.99 (6H, s, 2 × OCH3). 13C NMR (125 MHz, DMSO-d6): δ 166.0 (C=O), 158.5, 
158.2, 157.8, 156.3, 150.4, 150.3, 137.4, 136.8, 133.2, 129.9, 125.0, 120.9, 119.0, 
118.6, 115.0, 107.9, 103.5, 102.1, 57.0, 56.8. LRMS [M+H+] 417.3. HRMS (ESI) m/z 
cald for C23H21N4O4 [M+H+]: 417.1557, found 417.1558.  
N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)-3-methoxy benzamide (214).  
 
4-Chloro-6,7-dimethoxyquinazoline 174 (72 mg, 0.32 mmol) was reacted with  
4-aminocarboxamide 194 (78 mg, 0.32 mmol) in isopropanol (7.4 mL) according to 
general procedure D to obtain compound 214 (90 mg, 65%) as a yellow solid after 
filtration and washing with diethyl ether (2 × 10 mL).  
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m.p. 187-190 oC (decomp.). IR (ATR): ν = 2952, 1674 cm-1. 1H NMR (400 MHz, 
DMSO-d6): δ 11.11 (1H, s, NH), 10.36 (1H, s, NH), 8.78 (1H, s, Ar-H, H-2), 8.24 
(1H, s, Ar-H, H-8), 7.89 (2H, d, J 8.4 Hz, Ar-H, H-2’ + H-6’), 7.67 (2H, d, J 8.4 Hz, 
Ar-H, H-3’ + H-5’), 7.57 (1H, app. d, J 7.7 Hz, 1H, Ar-H, H-6”), 7.52 (1H, s, Ar-H, 
H-2”), 7.46 (1H, app. t, J 7.9 Hz, Ar-H, H-5”), 7.32 (1H, s, Ar-H, H-5), 7.17 (1H, dd, 
J 8.0, 2.5 Hz, Ar-H, H-4”), 4.01 (3H, s, OCH3), 3.99 (3H, s, OCH3), 3.85 (3H, s, 
OCH3). 13C NMR (101 MHz, DMSO-d6): δ 165.7 (C=O), 159.7, 158.4 (×2), 156.6, 
150.6, 149.5, 137.6, 136.7, 133.0, 130.1, 125.4, 121.0, 120.4, 117.8, 113.5, 107.8, 
104.2, 100.9, 57.3, 56.9, 55.9. LRMS [M+H+] 417.3. HRMS (ESI) m/z cald for 
C23H21N4O4 [M+H+]: 417.1557, found 417.1560 
N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)-3-nitro-benzamide (215).  
 
4-Chloro-6,7-dimethoxyquinazoline 174 (160 mg, 0.69 mmol) was reacted with 4-
aminocarboxamide 195 (177 mg, 0.69 mmol) in isopropanol (16 mL) according to 
general procedure D to obtain compound 215 (TFA salt) as a yellow solid (300 mg, 
98%)  after filtration and washing with diethyl ether (2 × 10 mL).  
m.p. 140-144 oC (decomp.). IR (ATR): ν =1673, 1640 cm-1. 1H NMR (500 MHz, 
DMSO-d6): δ 10.69 (1H, s, NH), 8.79 (1H, t, J 2.0 Hz, Ar-H, H-2”), 8.71 (1H, s, Ar-
H, H-2), 8.44 (1H, dd, J 8.2, 2.0 Hz, Ar-H, H-4”), 8.43 (1H, dd, J 8.0, 1.5 Hz, Ar-H, 
H-6”), 8.04 (1H, s, Ar-H, H-8), 7.88-7.84 (3H, m, Ar-H, H-2’ + H-6’ + H-5”), 7.68 
(2H, d, J 9.0 Hz, Ar-H, H-3’ + H-5’), 7.25 (1H, s, Ar-H, H-5), 3.98 (3H, s, OCH3), 
3.97 (3H, s, OCH3). 13C NMR (126 MHz, DMSO-d6): δ 164.1 (C=O), 158.4, 156.6, 
150.6, 150.3, 148.4, 138.0, 136.9, 136.7, 134.7, 133.8, 130.9, 126.9, 125.3, 122.9, 
121.5, 108.0, 103.6, 101.9, 57.1, 57.0. LRMS [M+H+] 446.2. HRMS (ESI) m/z cald 
for C23H20N5O5 [M+H+]: 446.1459, found 446.1459. 
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3-amino-N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl) benzamide (216).  
 
Compound 215 (61 mg, 0.13 mmol) in methanol (10 mL) was hydrogenated (1 atm) 
over 10% Pd/C (13 mg) for 24 h. The reaction mixture was subsequently filtered over 
Celite® and the filtrate concentrated in vacuo to afford a crude solid that was purified 
by reverse phase HPLC (gradient: 0-100% MeCN over 40 min) to afford compound 
216 as a yellow solid (16 mg, 30%).  
m.p. 121-123 oC (decomp.). IR (ATR): ν = 1735, 1697  cm-1. 1H NMR (400 MHz, 
DMSO-d6): δ 11.06 (1H, s, NH), 10.24 (1H, s, NH), 8.80 (1H, s, Ar-H, H-2), 8.08 
(1H, s, Ar-H, H-8), 7.87 (2H, d, J 8.5 Hz, Ar-H, H-2’ + H-6’), 7.61 (2H, d, J 8.5 Hz, 
Ar-H, H-3’ + H-5’), 7.28 (1H, s, Ar-H, H-5), 7.20-7.15 (3H, m, Ar-H), 6.81 (1H, app. 
d, J 8.0 Hz, Ar-H, H-4”), 4.00 (6H, s, 2 × OCH3). 13C NMR (101 MHz, DMSO-d6): δ 
166.8 (C=O), 158.5, 156.7, 150.6, 149.6, 148.3, 138.1, 136.3, 132.5, 129.3, 125.5, 
120.8, 118.0, 116.0, 115.7, 114.0, 107.6, 103.8, 100.8, 57.1, 57.0. LRMS [M+H+] 
416.3. HRMS (ESI) m/z cald for C23H22N5O3 [M+H+]: 416.1717, found 416.1717.  
3-(cyanomethoxy)-N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)benzamide 
(217).  
 
Compound 213 (20 mg, 0.048 mmol), bromoacetonitrile (3.7 µL, 0.053 mmol) and 
cesium carbonate (39 mg, 0.12 mmol) in anhydrous acetonitrile (1 mL) was heated at 
80 oC for 1 h. The reaction was subsequently filtered and the solvent was removed in 
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vacuo to afford a crude residue that was purified by reverse phase HPLC (0 to 100% 
MeCN over 40 min) to afford compound 217 (TFA salt) as a yellow solid (12 mg, 
55%).   
m.p. 141-144 oC. IR (ATR): ν = 2954, 2365, 1672 cm-1. 1H NMR (500 MHz, DMSO-
d6): δ 10.39 (1H, s, NH), 8.76 (1H, s, Ar-H, H-2), 8.04 (1H, s, Ar-H, H-8), 7.89-7.87 
(2H, m, Ar-H, H-2’ + H-6’), 7.71-7.63 (4H, m, Ar-H, H-3’ + H-5’, H-2” + H-6”), 
7.56 (1H, t, J 8.0 Hz, Ar-H, H-5”), 7.33 (1H, dd, J 8.2, 2.7 Hz, Ar-H, H-4”), 7.27 (1H, 
s, Ar-H, H-5), 5.28 (2H, s, CH2), 3.99 (6H, 2 × OCH3). 13C NMR (126 MHz, DMSO-
d6): δ 165.2 (C=O), 158.5, 158.2, 156.8, 156.4, 150.4, 150.2, 137.3, 137.0, 133.3, 
130.4, 125.1, 122.2, 121.0, 118.45, 116.9, 114.7, 107.9, 103.6, 101.8, 57.0, 56.8, 54.2. 
LRMS [M+H+] 456.3. HRMS (ESI) m/z cald for C25H22N5O4 [M+H+]: 456.1666, 
found 456.1666.  
2-(3-((4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl) 
carbamoyl)phenoxy)acetic acid (218).  
 
Compound 213 (60 mg, 0.14 mmol), tert-butyl bromoacetate (28 µL, 0.19 mmol) and 
cesium carbonate (118 mg, 0.36 mmol) in anhydrous acetonitrile (3 mL) was heated 
at 50 oC for 3 h. The reaction was subsequently filtered and the solvent was removed 
in vacuo to afford 219 as a crude residue that was dissolved in a mixture of TFA in 
dichloromethane (300 µL, 1:1 v/v). The reaction was stirred at room temperature for 
16 h. The solvent was removed in vacuo to give a crude residue that was purified by 
reverse phase HPLC (0 to 100% MeCN over 40 min) to afford compound 218 as a 
yellow solid (10 mg, 14% over 2 steps).  
m.p. 236-239 oC (decomp.). IR (ATR): ν = 3365, 1679, 1631 cm-1. 1H NMR (500 
MHz, DMSO-d6): δ 10.32 (1H, s, NH), 8.61 (1H, s, Ar-H, H-2), 7.98 (1H, s, Ar-H, H-
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8). 7.83 (1H, d, J 8.5 Hz, Ar-H, H-3’ + H-5’), 7.70 (2H, d, J 8.5 Hz, H-2’ + H-6’), 
7.59 (1H, app. d, J 8.0 Hz, Ar-H, H-6”), 7.51-7.50 (1H, m, Ar-H, H-2”), 7.46-7.43 
(1H, m, Ar-H, H-5”), 7.27 (1H, s, Ar-H, H-5), 7.14 (1H, dd, J 8.5, 2.5 Hz, Ar-H, H-
4”), 4.78 (2H, s, CH2), 3.97 (3H, s, OCH3), 3.95 (3H, s, OCH3). 13C NMR (126 MHz, 
DMSO-d6): δ 170.5 (C=O), 165.4 (C=O), 158.8, 158.2, 157.7, 155.6, 151.4, 149.9, 
136.6, 136.4, 134.3, 130.0, 124.3, 121.1, 120.8, 118.2, 114.1, 108.5, 104.2, 103.1, 
65.1, 56.8, 56.6. LRMS [M+Na+] 496.9. HRMS (ESI) m/z cald for C25H23N4O6 
[M+H+]: 475.1612, found 475.1612.  
3-hydroxy-N-(4-(thieno[3,2-d]pyrimidin-4-ylamino)phenyl)benzamide (220) 
 
4-chlorothieno[3,2-d]pyrimidine 222 (59 mg, 0.35 mmol) was reacted with the 
corresponding 4-aminocarboxamide 197 (78 mg, 0.35 mmol) in isopropanol (8.6 mL) 
according to general procedure D to obtain compound 220 (as TFA salt), after reverse 
phase HPLC purification (0 to 100% MeCN over 40 min), as an off-white solid (47 
mg, 28%).  
m.p.125-126 oC (decomp.). IR (ATR): ν = 3248, 1672 cm-1. 1H NMR (400 MHz, 
DMSO-d6): δ 10.55 (1H, s, NH), 10.27 (1H, s, NH), 8.75 (1H, s, Ar-H. H-2), 8.35 
(1H, d, J 5.5 Hz, Ar-H, H-6), 7.84 (2H, d, J 8.9 Hz, Ar-H, H-2’ + H-6’), 7.74-7.59 
(2H, m, Ar-H, H-3’ + H-5’), 7.50 (1H, d, J 5.5 Hz, Ar-H, H-7), 7.39 (1H, dt, J 7.6, 1.3 
Hz, Ar-H, H-6”), 7.35-7.33 (2H, m, Ar-H, H-2” + H-5”), 6.98 (1H, ddd, J 7.9, 2.5, 1.1 
Hz, Ar-H, H-4”). 13C NMR (101 MHz, DMSO- d6): δ 166.0 (C=O), 157.8, 156.7, 
154.5, 152.0, 137.7, 137.3, 136.8, 133.4, 129.9, 124.8, 121.8, 121.0, 119.0, 118.6, 
115.7, 115.0. LRMS [M+H+] 363.2. HRMS (ESI) m/z cald for C19H15N4O2S [M+H+]: 
363.0910, found 363.0910.  
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4-chloro-5,6,7,8-tetrahydroquinazoline (223) 
 
To a solution of ethyl 2-cyclohexanone carboxylate 224 (810 µL, 5.1 mmol) in 
methanol (4 mL) was added trimethyl orthoformate (2.20 mL, 20.3 mmol) and 
ammonium acetate (1.56 g, 20.3 mmol). The reaction was heated at 120 oC for 3 h. 
The reaction was allowed to cool to room temperature, water (40 mL) was added and 
the suspension was stirred for an additional 1 h. The solution was subsequently 
filtered to afford 225 as a white solid (800 mg).  
A mixture of quinazolinone 225 (0.44 g, 2 mmol) and phosphorus(V) oxychloride 
(4.4 mL, 43 mmol) was refluxed for 4 h. The solvent was removed in vacuo and the 
residue was dissolved in dichloromethane (200 mL) and washed with saturated 
aqueous NaHCO3 solution (3 × 50 mL) and brine (50 mL). The organic layer was 
dried over anhydrous MgSO4 and the solvent was removed in vacuo to afford a crude 
residue that was purified by column chromatography (95:5 v/v CH2Cl2: MeOH) to 
afford 223 as a yellow solid (630 mg, 74% over 2 steps). 
m.p. 86-87 oC (decomp.); IR (ATR): ν = 2939, 2869, 1530 cm-1. 1H NMR (300 MHz, 
CDCl3): δ 8.66 (1H, s, Ar-H, H-2), 2.87-2.83 (2H, m, CH2), 2.75-2.70 (2H, m, CH2), 
1.87-1.82 (4H, m, 2 × CH2). 13C NMR (75 MHz, CDCl3): δ 168.0, 161.2, 155.2, 
129.3, 32.3, 25.6, 21.9, 21.8. LRMS [M+H+] 169.1. HRMS (ESI) m/z cald for 
C8H10ClN2 [M+H+]: 169.0527, found 169.0529. 
3-hydroxy-N-(4-((5,6,7,8-tetrahydroquinazolin-4-yl)amino)phenyl)benzamide 
(221) 
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4-Chloro-5,6,7,8-tetrahydroquinazoline 223 (37 mg, 0.22 mmol) was reacted with  
4-aminocarboxamide 197 (50 mg, 0.22 mmol) in isopropanol (8.5 mL) according to 
general procedure D for 4 h to obtain compound 221 (as TFA salt) as a white solid 
(55 mg, 70%) following reverse phase HPLC purification (0 to 100% MeCN over 40 
min).  
m.p. 234-237 oC (decomp.). IR (ATR): ν = 3248, 1684, 1675 cm-1. 1H NMR (400 
MHz, DMSO-d6): δ 10.25 (1H, s, NH), 9.79 (1H, s, NH), 8.67 (1H, s, Ar-H, H-2), 
7.84-7.79 (2H, m, Ar-H, H-2’ + H-6’), 7.52-7.47 (2H, m, Ar-H, H-3’ + H-5’), 7.38 
(1H, dt, J 7.6, 1.4 Hz, Ar-H, H-6”), 7.37-7.26 (2H, m, Ar-H, H-2” + H-5”), 6.98 (1H, 
ddd, J 7.9, 2.5, 1.2 Hz, Ar-H, H-4”), 2.78-2.73 (2H, m), 2.59-2.56 (2H, m), 1.88-1.78 
(4H, m). 13C NMR (101 MHz, DMSO-d6): δ 166.0 (C=O), 160.5, 157.8, 153.5, 150.0, 
137.5, 136.7, 133.0, 129.9, 125.4, 120.8, 119.0, 118.6, 115.0, 114.6, 27.2, 22.3, 21.1, 
20.5. LRMS [M+H+] 361.3. HRMS (ESI) m/z cald for C21H21N4O2 [M+H+]: 
361.1659, found 361.1660.  
4-((6,7-dimethoxyquinazolin-4-yl)amino)benzoic acid (227) 
 
4-Chloro-6,7-dimethoxyquinazoline 174 (58 mg, 0.26 mmol), 4-aminobenzoic acid 
(36 mg, 0.26 mmol) in isopropanol (6 mL) were reacted for 5 h according to general 
procedure D to obtain 227 as a off-white solid (21 mg, 50%) which was used without 
further purification. 
m.p. 249-251oC (decomp.). IR (ATR): ν = 3272, 3086, 1676, 1641 cm-1. 1H NMR 
(400 MHz, DMSO-d6): δ 10.67 (1H, s, NH), 8.81 (1H, s, Ar-H, H-2), 8.05-8.02 (3H, 
m, Ar-H, H-2’ + H-6’ + H-8), 7.90 (2H, d, J 8.4 Hz, Ar-H, H-3’ + H-5’), 7.29 (1H, s, 
Ar-H, H-5), 4.00 (3H, s, OCH3), 3.99 (3H, s, OCH3). 13C NMR (101 MHz, DMSO-
d6): δ 167.3 (C=O), 157.9, 156.4, 150.6, 150.5, 142.4, 130.5 (× 2), 127.5, 123.4, 
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108.5, 103.3, 102.8, 57.0, 56.8. LRMS [M+H+] 326.0. HRMS (ESI) m/z cald for 
C17H16N3O4 [M+H+]: 326.1135, found 326.1135.  
4-((6,7-dimethoxyquinazolin-4-yl)amino)-N-(3-hydroxyphenyl)benzamide (226) 
 
To a solution of carboxylic acid 227 (8 mg, 0.024 mmol) in DMF (0.1 mL) was added 
HATU (9 mg, 0.024 mmol) and N,N-diisopropylethylamine (7 µL, 0.024 mmol). The 
reaction mixture was allowed to stir at room temperature for 16 h. The reaction 
mixture was diluted with ethyl acetate (20 mL), washed with water (5× 5 mL), brine 
(5 mL) and dried over anhydrous MgSO4. The solvent was subsequently removed in 
vacuo to give a crude a residue that was purified by reverse phase HPLC (0 to 100% 
MeCN over 40 min) to afford compound 226 (TFA salt) as a white solid (5 mg, 50%). 
m.p. 219-221oC (decomp.). IR (ATR): ν = 3307, 1684 cm-1. 1H NMR (400 MHz, 
DMSO-d6): δ 10.70 (1H, s, NH), 10.11 (1H, s, NH), 9.40 (1H, s, OH), 8.80 (1H, s, 
Ar-H, H-2), 8.06-8.04 (3H, m, Ar-H, H-2’ + H-6’ + H-8), 7.90 (2H, d, J 8.8 Hz, Ar-
H, H-3’ + H-5’), 7.38-7.36 (1H, m, Ar-H, H-2”), 7.30 (1H, s, Ar-H, H-5), 7.18 (1H, 
app. d, J 8.4 Hz, Ar-H, H-5”), 7.12-7.10 (1H, m, Ar-H), 6.51 (1H, app. d, J 8.0 Hz, 
Ar-H), 4.01 (3H, s, OCH3), 4.00 (3H, s, OCH3). 13C NMR (101 MHz, DMSO-d6): δ 
165.3 (C=O), 158.0, 157.9, 156.4, 150.7, 150.5, 141.1, 140.7, 131.9, 129.7, 128.8, 
127.4, 123.4, 111.6, 111.2, 108.4, 108.0, 103.3, 102.8, 57.0, 56.8. LRMS [M+H+] 
417.1. HRMS (ESI) m/z cald for C23H21N4O4 [M+H+]: 417.1557, found 417.1556. 
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7.6 Synthesis for compounds in chapter 6 
tert-butyl (3aS,4S,6R,6aR)-6-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylate (237) 
 
Anhydrous pyridine (4.6 mL, 56 mmol) was added dropwise to a solution of 
chromium trioxide (2.81 g, 28.1 mmol) in 4:1 v/v CH2Cl2: DMF (53 mL of CH2Cl2 
and 13 mL of DMF) and the mixture was allowed to stir at room temperature for 20 
min. Alcohol 127 (2.0 g, 6.8 mmol) was dissolved in DMF (3.3 mL) and the solution 
was diluted with CH2Cl2 (10 mL) and added dropwise to the above reaction mixture. 
Acetic anhydride (5.30 mL) and tert-butanol (dried over 4 Å molecular sieves 
overnight, 13.2 mL) were then added and the reaction was left to stir at room 
temperature for 24 h. The reaction was quenched with methanol (7 mL) and stirred for 
another 15 min before it was diluted with EtOAc (350 mL). The reaction was filtered 
through a plug of silica with a layer of MgSO4 on top before it was concentrated in 
vacuo. The resulting residue was re-dissolved in EtOAc (250 mL) and washed with  
1 M HCl (2× 75 mL), water (75 mL) and brine (75 mL). The organic layer was dried 
over anhydrous MgSO4 and the solvent was removed in vacuo to give a crude residue 
that was purified by column chromatography (2:1 v/v Hexane: EtOAc → 2:1 EtOAc: 
Hexane) to afford tert-butyl ester 237 as a white foam (1.2 g, 50%).  
IR (ATR): ν = 2981, 1694 cm-1. 1H NMR (400 MHz, CDCl3): δ 9.27 (1H, s, NH), 
7.41 (1H, d, J 8.1 Hz, H-6), 5.73 (1H, d, J 8.0 Hz, H-5), 5.58 (1H, app. s, H-1’), 5.25 
(1H, dd, J 6.0, 1.8 Hz, H-2’), 5.17 (1H, app. d, J 6.0 Hz, H-3’), 4.59 (1H, d, J 1.9 Hz, 
H-4’), 1.53 (3H, s, CH3), 1.46 (9H, s, CO2tBu), 1.36 (3H, s, CH3). LRMS [M+H+] 
355.0. [α]!!". = +10o (c = 0.21 in CH2Cl2). These data are in agreement with those 
previously reported by Boojamra et al.[145b]  
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tert-butyl (4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
((triisopropylsilyl)oxy)-4,5-dihydrofuran-2-carboxylate (241) 
 
To a solution of tert-butyl ester 237 (3.29 g, 9.28 mmol) in tert-butanol (67 mL) was 
added with rapid stirring potassium tert-butoxide (2.08 g, 18.2 mmol) and the reaction 
was stirred at room temperature for 15 min. Glacial acetic acid was added dropwise to 
adjust the pH of the reaction (pH = 7). The resulting gelatinous mixture was 
concentrated in vacuo to yield a yellow solid that was purified by column 
chromatography (95:5 v/v CH2Cl2: MeOH → 9:1 v/v CH2Cl2: MeOH) to afford ester 
240 as a white foam (3.64 g). 
To a solution of ester 240 (3.64 g, 12.3 mmol) and N,N-diisopropylethylamine (2.1 
mL, 12.3 mmol) in DMF (37 mL) was added triisopropylsilyl 
trifluoromethanesulfonate (4.9 mL, 17.6 mmol) and the reaction was stirred at room 
temperature for 2.5 h. The reaction was quenched with saturated aqueous Na2CO3 (40 
mL) and partitioned between Et2O (200 mL) and H2O (40 mL). The organic layer was 
washed with 0.2 M HCl (50 mL), H2O (5× 50 mL), brine (50 mL) and dried over 
anhydrous Na2SO4. The organic layer was concentrated in vacuo to give a crude 
residue that was purified by column chromatography (2:1 v/v Hexane: EtOAc) to 
afford ester 241 as a white foam (4.57 g, 71% over 2 steps).  
IR (ATR): ν = 2944, 2868, 1725, 1698 cm-1. 1H NMR (500 MHz, CDCl3): δ 8.70 
(1H, s, NH), 7.03 (1H, d, J 8.1 Hz, H-6), 6.27 (1H, d, J 3.2 Hz, H-3’), 5.96 (1H, d, J 
2.6 Hz, H-1’), 5.77 (1H, d, J 8.1 Hz, H-5), 5.23 (1H, dd, J 3.3, 2.6 Hz, H-2’), 1.54 
(9H, s, CO2tBu), 1.12-1.07 (3H, m, [CH(CH3)2]3Si) 1.06-1.02 (18H, m, 
[CH(CH3)2]3Si). 13C NMR (126 MHz, CDCl3): δ 162.5 (C=O), 158.2, 151.3, 149.3, 
140.0, 111.2, 103.7, 95.1, 83.5, 79.7, 28.0, 17.8, 17.8, 12.0. LRMS [M+H+] 453.0. 
HRMS (ESI) cald for C22H36N2O6SiNa [M+Na+]: 475.2240 found 475.2238. 
 [α]!!" = -182o (c = 0.27 in CH2Cl2). 
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tert-butyl (2R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
((triisopropylsilyl)oxy)tetrahydrofuran-2-carboxylate (242) 
 
To a solution of ester 241 (568 mg, 1.25 mmol) in methanol (21 mL) was added 10% 
Pd/C (86 mg) and the reaction was degassed by passing through 3 cycles of 
alternating high vacuum and nitrogen. The reaction mixture was allowed to stir under 
an atmosphere of hydrogen for 30 min. At this point, the reaction was filtered over 
Celite, and the filter cake was washed thoroughly with methanol (100 mL). The 
solvent was removed in vacuo to give a crude residue that was purified by column 
chromatography (1:1 v/v Hexane: EtOAc) to afford ester 242 as a viscous colourless 
oil (480 mg, 84%).  
IR (ATR): ν = 2943, 2867, 1688 cm-1. 1H NMR (500 MHz, CDCl3): δ 7.18 (1H d, J 
8.1 Hz, H-6), 5.72-5.68 (2H, m, H-1’ + H-5), 4.78-4.74 (2H, m, H-2’ + H-4’), 2.57 
(1H, ddd, J 13.2, 8.7, 6.2 Hz, H-3’), 2.24 (1H, ddd, J 13.3, 5.2, 3.8 Hz, H-3’), 1.49 
(9H, s, CO2tBu), 1.15-1.05 (3H, m, [CH(CH3)2]3Si), 1.05-1.01 (18H, m, 
[CH(CH3)2]3Si). 13C NMR (126 MHz, CDCl3): δ 170.0 (C=O), 163.0, 149.7, 141.4, 
102.2, 97.2, 82.2, 78.3, 75.1, 37.8, 28.0, 17.8, 17.8, 11.9. LRMS [M+H+] 455.3. 
HRMS (ESI) cald for C22H38N2O6SiNa [M+Na+]: 477.2397 found 477.2400. ![α]!!" = -14o (c = 0.41 in CH2Cl2). 
1-((2R,3R,5R)-5-(hydroxymethyl)-3-((triisopropylsilyl)oxy)tetrahydrofuran-2-
yl)pyrimidine-2,4(1H,3H)-dione (243) 
 
Ester 242 (456 mg, 1.0 mmol) was dissolved in 9:1 v/v TFA: CH2Cl2 (2.2 mL) and 
the reaction was stirred at room temperature for 15 min. The solvent was removed in 
vacuo to give a residue that was subsequently dissolved in THF (13 mL) and cooled 
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to 0 oC prior to the addition of isobutyl chloroformate (390 µL, 3 mmol) and  
N,N-diisopropylethylamine (260 µL, 1.5 mmol). The reaction mixture was allowed to 
warm up to room temperature and was stirred for a further 1.5 h before being cooled 
to 0 oC. Sodium borohydride (265 mg, 7 mmol) was added, followed by dropwise 
addition of water (2.3 mL) over 20 min to dissolve the sodium borohydride. The 
reaction was allowed to stir at 0 oC for 1 h before being concentrated in vacuo. The 
residue was partitioned between EtOAc (40 mL) and water (10 mL). The organic 
phase was separated, washed with 1 M HCl (10 mL), brine (10 mL), dried over 
anhydrous MgSO4. The solvent was removed in vacuo to give a crude residue that 
was purified by column chromatography (4:1 v/v EtOAc: Hexane → EtOAc) to 
afford alcohol 243 as a white foam (265 mg, 69%).  
IR (ATR): ν = 2943, 2866, 1686 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.25 (1H, d, J 
8.1 Hz, H-6), 5.72 (1H, d, J 8.1 Hz, H-5), 5.69 (1H, d, J 2.1 Hz, H-1’), 4.73 (1H, ddd, 
J 5.7, 3.5, 2.1 Hz, H-2’), 4.61 (1H, app. dq, J 9.0, 4.7 Hz, H-4’), 3.80-3.72 (2H, m, H-
5’), 2.60 (1H, s, OH), 2.27 (1H, ddd, J 13.9, 8.3, 5.8 Hz, H-3’), 1.96 (1H, ddd, J 13.6, 
5.0, 3.4 Hz, H-3’), 1.20-1.08 (3H, m, [CH(CH3)2]3Si), 1.06 (18H, d, J 7.0, 
[CH(CH3)2]3Si). 13C NMR (101 MHz, CDCl3): δ 163.2, 150.0, 140.2, 102.1, 95.3, 
82.4, 76.1, 65.1, 34.8, 17.9, 17.8, 12.0. LRMS [M+Na+] 407.0. HRMS (ESI) cald for 
C18H32N2O5SiNa [M+Na+]: 407.1978 found 407.1973. [α]!!"  = -11o (c = 0.44 in 
CH2Cl2). 
((2R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
((triisopropylsilyl)oxy)tetrahydrofuran-2-yl)methyl 4-methylbenzenesulfonate 
(244) 
 
Alcohol 243 (1.53 g, 3.97 mmol) and p-toluenesufonyl chloride (3.70 g, 19.3 mmol) 
were dissolved in pyridine (33 mL) and the reaction was allowed to stir at room 
temperature for 18 h. At this point, the reaction was concentrated in vacuo to afford a 
residue that was dissolved in EtOAc (200 mL) which was washed with water  
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(50 mL), 1 M HCl (50 mL), brine (50 mL) and dried over anhydrous MgSO4. The 
solvent was removed in vacuo to give a crude residue that was purified by column 
chromatography (1:1 v/v Hexane: EtOAc) to afford tosylate 244 as a colourless oil 
(1.73 g, 82%). 
IR (ATR): ν = 2944, 2866, 1686 cm-1. 1H NMR (500 MHz, CDCl3): δ 8.86 (1H, s, 
NH), 7.80 (2H, app. d, J 8.0 Hz, Ar-H), 7.34 (2H, d, J 8.0 Hz, Ar-H), 7.13 (1H, d, J 
8.1 Hz, H-6), 5.70 (1H, d, J 8.1 Hz, H-5), 5.54 (1H, d, J 2.0 Hz, H-1’), 4.75-4.67 (1H, 
m, H-4’), 4.65 (1H, app. dt, J 5.1, 2.0 Hz, H-2’), 4.21 (1H, dd, J 10.4, 7.0 Hz, H-5’), 
4.12 (1H, dd, J 10.4, 4.5 Hz, H-5’), 2.45 (3H, s, CH3), 2.22 (1H, ddd, J 13.7, 8.3, 5.4 
Hz, H-3’), 1.88 (1H, app. dt, J 13.7, 3.6 Hz, H-3’), 1.15-1.02 (3H, m, [CH(CH3)2]3Si), 
1.00 (18H, d, J 6.7 Hz, [CH(CH3)2]3Si). 13C NMR (126 MHz, CDCl3): δ 163.0, 149.8, 
145.0, 140.0, 132.7, 129.9, 128.0, 102.1, 95.7, 79.0, 75.8, 71.5, 35.2, 21.7, 17.9, 17.8, 
11.9. LRMS [M+Na+] 561.0. HRMS (ESI) cald for C25H38N2O7SSiNa [M+Na+]: 
561.2067 found 561.2061. [α]!!" = -7.3o (c = 0.31 in CH2Cl2). 
1-((2R,3R,5R)-5-(azidomethyl)-3-((triisopropylsilyl)oxy)tetrahydrofuran-2-
yl)pyrimidine-2,4(1H,3H)-dione (245) 
 
Tosylate 244 (1.65 g, 3.07 mmol) was dissolved in DMF (34 mL). Sodium azide (2.0 
g, 30.7 mmol) was added and the reaction was heated at 75 oC for 4 h. The reaction 
was diluted with ethyl acetate (200 mL), washed with water (5× 40 mL), brine (40 
mL) and dried over anhydrous MgSO4. The solvent was removed in vacuo to give a 
crude residue that was purified by column chromatography (1:1 v/v EtOAc: Hexane) 
to afford azide 245 as a colourless oil (1.09 g, 87%).  
IR (ATR): ν = 2944, 2867, 2102, 1686 cm-1. 1H NMR (400 MHz, CDCl3): δ 9.01 
(1H, s, NH), 7.21 (1H, d, J 8.1 Hz, H-6), 5.72 (1H, d, J 8.1 Hz, H-5), 5.66 (1H, d, J 
2.1 Hz, H-1’), 4.75 (1H, ddd, J 5.7, 3.6, 2.1 Hz, H-2’), 4.62 (1H, tt, J 7.4, 4.7 Hz,  
H-4’), 3.60 (1H, dd, J 12.7, 7.1 Hz, H-5’), 3.39 (1H, dd, J 12.7, 4.6 Hz, H-5’), 2.28 
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(1H, ddd, J 13.5, 7.9, 5.7 Hz, H-3’), 1.93 (1H, ddd, J 13.5, 4.9, 3.5 Hz, H-3’), 1.19-
1.08 (3H, m, [CH(CH3)2]3Si), 1.06 (18H, J 6.7 Hz, [CH(CH3)2]3Si). 13C NMR (101 
MHz, CDCl3): δ 163.2 (C=O), 149.9 (C=O), 140.4, 102.1, 96.1, 80.6, 76.1, 55.1, 36.3, 
17.9, 17.9, 12.0. LRMS [M+H+] 410.0. HRMS (APCI) cald for C18H31N5O4SiNa 
[M+Na+]: 432.2043 found 432.2038. [α]!!" = -20o (c = 0.32 in CH2Cl2). 
(9H-fluoren-9-yl)methyl (((2R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)-4-((triisopropylsilyl)oxy)tetrahydrofuran-2-yl)methyl)carbamate (247) 
 
To a solution of azide 245 (567 mg, 1.38 mmol) in methanol (49 mL) was added 10% 
Pd/C (240 mg) and the reaction was degassed by passing through 3 cycles of 
alternating high vacuum and nitrogen. The reaction mixture was allowed to stir under 
an atmosphere of hydrogen for 1.5 h. At this point, the reaction was filtered over 
Celite, and the filter cake was washed thoroughly with methanol (200 mL). The 
solvent was removed in vacuo to afford amine 246 as a colourless oil (529 mg, quant.) 
that was used in the next step without further purification. 
To a solution of amine 246 (529 mg, 1.38 mmol) in dioxane (19 mL) was added 10% 
aqueous Na2CO3 solution (37 mL) and the resulting solution was allowed to cool to  
0 oC. Fmoc chloride (535 mg, 2.07 mmol) in dioxane (3.8 mL) was subsequently 
added to the above reaction mixture and the reaction was allowed to stir at 0 oC for  
2 h before being warmed up to room temperature for 1 h. At this point, the reaction 
was poured onto water (50 mL) and extracted with diethyl ether (2× 100 mL). The 
combined organic layers were washed with brine (50 mL), dried over anhydrous 
MgSO4. The solvent was removed in vacuo to give a crude residue that was purified 
by column chromatography (1:1 v/v Hexane: EtOAc) to afford Fmoc-carbamate 247 
as a colourless oil (733 mg, 88% over 2 steps).  
IR (ATR): ν = 2947, 2867, 1775, 1688 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.49 
(1H, s, NH), 7.77 (2H, app. d, J 7.6 Hz, Ar-H), 7.60 (2H, d, J 7.5 Hz, 2H), 7.40 (2H, 
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app. t, J 7.5 Hz, Ar-H), 7.31 (2H, td, J 7.4, 1.2 Hz), 7.20 (1H, d, J 8.1 Hz, Ar-H, H-6), 
5.86-5.56 (2H, m, H-1’ + H-5), 5.37-5.19 (1H, m, NH), 4.75-4.64 (1H, m, H-3’), 
4.63-4.53 (1H, m, H-4’), 4.43 (2H, app. d, J 7.1 Hz, Fmoc-CH2), 4.22 (1H, app. t, J 
6.9 Hz, Fmoc-CH), 3.56 (1H, ddd, 1H, J 14.6, 7.3, 3.2 Hz, H-5’), 3.40 (1H, ddd, 1H, J 
14.0, 8.1, 4.8 Hz, H-5’), 2.40-2.20 (1H, m, H-3’), 1.85 (1H, app. dt, J 13.8, 4.3 Hz,  
H-3’), 1.12 (3H, m, [CH(CH3)2]3Si), 1.07 (18H, d, J 6.0 Hz, [CH(CH3)2]3Si).  
13C NMR (101 MHz, CDCl3): δ 162.6 (C=O), 156.5 (C=O), 149.7 (C=O), 143.9, 
141.3, 140.0, 127.7, 127.0, 125.0, 120.0, 102.1, 95.2, 80.7, 76.2, 66.8, 45.8, 36.0, 
29.6, 17.9, 17.8, 11.9. LRMS [M+H+] 606.3. HRMS cald for C33H43N3O6SiNa 
[M+Na+]: 628.2813, found 628.2811. [α]!!" = -26o (c = 0.22 in CH2Cl2). 
(9H-fluoren-9-yl)methyl (((2R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)-4-hydroxytetrahydrofuran-2-yl)methyl)carbamate (236) 
 
Amine 247 (230 mg, 0.38 mmol) was suspended in a 9:1 v/v TFA: H2O mixture (19 
mL) and the reaction was allowed to stir at room temperature for 4.5 h. At this point, 
solid NaHCO3 (1.0 g) was added to neutralise the reaction mixture and the aqueous 
layer was subsequently extracted with a mixture of ethyl acetate and isopropanol (9:1 
v/v EtOAc: isopropanol, 4× 50 mL). The combined organic layers were washed with 
water (50 mL), brine (50 mL) and dried over anhydrous MgSO4. The solvent was 
removed in vacuo to give a crude residue that was purified by column 
chromatography (98:2 v/v CH2Cl2: MeOH → 9:1 v/v CH2Cl2: MeOH) to afford 
amine 236 as a colourless oil (130 mg, 73%).  
IR (ATR): ν = 3325, 2928, 1669 cm-1. 1H NMR (400 MHz, Acetone-d6): δ 7.88 (2H, 
d, J 7.6 Hz, Ar-H), 7.73 (2H, d, J 7.5 Hz, Ar-H), 7.57 (1H, d, J 8.1 Hz, H-6), 7.43 
(2H, app. t, J 7.5 Hz, Ar-H), 7.34 (2H, app. t, J 7.5 Hz, Ar-H), 5.81 (1H, d, J 3.0 Hz, 
H-1’), 5.70-5.51 (1H, m, H-5), 4.68-4.56 (2H, dt, m, H-2’ + H-4’), 4.40-4.31 (2H, m, 
Fmoc-CH2), 4.25 (1H, app. t, J 7.2 Hz, Fmoc-CH), 3.49-3.40 (2H, m, H-5’), 2.39 
(1H, app. dt, J 13.7, 6.9 Hz, H-3’), 2.00-1.85 (1H, m, H-3’). 13C NMR (101 MHz, 
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CD3OD): δ 164.9 (C=O), 157.6 (C=O), 150.9 (C=O), 143.9, 141.2, 141.0, 127.4, 
126.7, 124.8, 124.8, 119.5, 101.1, 93.6, 80.0, 75.0, 66.4, 45.0, 34.8. !
LRMS [M+H+] 450.3. HRMS (ESI) m/z cald for C24H23N3O6Na [M+Na+]: 472.1479, 
found 472.1474. [!]!!" = -9.4o (c = 0.56 in CH2Cl2). 
tert-butyl (S)-3-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(tert-butoxy)-
3-oxopropyl)-1H-indole-1-carboxylate (266) 
 
A solution of copper(I) chloride (33 mg, 0.33 mmol), tert-butanol (5.1 mL, 54 mmol) 
and DIC (8.1 mL, 51 mmol) were heated to 40 oC for 48 h. The reaction was 
subsequently diluted with CH2Cl2 (120 mL) and the solution was added dropwise to a 
solution of Fmoc-L-Trp(Boc)-OH (9.0 g, 17.1 mmol) in CH2Cl2 (90 mL). The 
reaction was stirred at room temperature for 18 h. The reaction was subsequently 
washed with saturated aqueous Na2CO3 solution (40 mL), brine (40 mL) and dried 
over anhydrous MgSO4. The solvent was removed in vacuo to give a crude a residue 
that was purified by column chromatography (4:1 v/v Hexane: EtOAc) to afford tert-
butyl ester 266 as a white foam (4.69 g, 47%).  
IR (ATR): ν = 2977, 1729 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.14 (1H, d, J 8.3 Hz, 
Ar-H), 7.81-7.64 (2H, m, Ar-H), 7.61-7.47 (3H, m, Ar-H), 7.46-7.35 (3H, m, Ar-H), 
7.35-7.27 (3H, m, Ar-H), 7.22 (ddd, J = 8.1, 7.3, 1.1 Hz, 1H), 5.40 (1H, d, J 8.1 Hz, 
NH), 4.65 (1H, app. dt, J 8.4, 5.8 Hz, α-CH), 4.40 (1H, dd, J 10.5, 7.4 Hz, Fmoc-
CH2), 4.33 (1H, dd, J 10.6, 7.1 Hz, Fmoc-CH2), 4.21 (1H, app. t, J 7.1 Hz, Fmoc-
CH), 3.24 (1H, t, J 5.1 Hz, β-CH2), 1.64 (9H, s, 3× CH3), 1.42 (9H, s, 3× CH3). ![!]!!"  = +162o (c = 0.34 in CH2Cl2). These data are in agreement with those 
previously reported by Conroy.[152] 
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tert-butyl (S)-3-(3-(tert-butoxy)-2-(((4-nitrophenoxy)carbonyl)amino)-3-
oxopropyl)-1H-indole-1-carboxylate (255) 
 
Tert-Butyl ester 266 (2.76 g, 4.74 mmol) were treated with 20 vol.% piperidine in 
acetonitrile (20 mL) and the reaction was allowed to stir at room temperature for  
20 min. The solvent was removed in vacuo to give a crude residue that was purified 
by column chromatography (3:1 v/v Hexane: EtOAc, 0.1 vol.% Et2NH) to afford 
protected tryptophan 267 as a yellow oil (1.28 g, 75%). 
To a solution protected tryptophan 267 (1.28 g, 3.56 mmol) and  
N,N-diisopropylethylamine (620 µL, 3.56 mmol) in CH2Cl2 (26 mL) was added  
p-nitrophenyl chloroformate (860 mg, 4.27 mmol) and the reaction was allowed to stir 
at room temperature for 19 h. The solvent was removed in vacuo to give a crude 
residue that was purified by column chromatography (7:1 v/v Hexane: EtOAc → 5:1 
v/v Hexane: EtOAc) to afford carbamate 255 as a white foam (1.49 g, 80%).  
IR (ATR): ν = 2988, 2973, 1724 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.23 (2H, d, J 
9.1 Hz, Ar-H, H-3 + H-5), 7.57 (1H, app. dt, J 7.9, 1.0 Hz, Ar-H), 7.46 (1H, s, Ar-H), 
7.34 (1H, ddd, J 8.4, 7.2, 1.3 Hz, Ar-H), 7.29-7.21 (3H, m, Ar-H, Trp-H + H-2 +  
H-4), 5.74 (1H, d, J 7.8 Hz, NH), 4.70-4.58 (1H, m, α-CH), 3.35 (1H, dd, J 14.8, 5.8, 
β-CH2), 3.25 (1H, dd, J 14.9, 5.5 Hz, β-CH2), 1.66 (9H, s, 3× CH3), 1.46 (9H, s, 3× 
CH3). 13C NMR (101 MHz, CDCl3): δ 170.0 (C=O), 155.7 (C=O), 152.5 (C=O), 
144.9, 130.7, 125.5, 125.1, 124.7, 124.2, 122.7, 122.0, 121.6, 118.9, 115.4, 114.8, 
83.8, 83.1, 54.9, 28.2, 28.0, 27.5. [!]!!" = +75o (c = 0.36 in CH2Cl2). These data are in 
agreement with those previously reported by Conroy.[152] 
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tert-butyl ((2S,3R)-1-((benzyloxy)amino)-3-hydroxy-1-oxobutan-2-yl)carbamate 
(264) 
 
To a solution of Boc-L-Thr-OH 268 (12 g, 55 mmol) in acetonitrile (600 mL) at room 
temperature was added HBTU (21.8 g, 57 mmol) followed by O-benzyl-
hydroxylamine hydrochloride (9.6 g, 60 mmol). After 5 min,  
N,N-diisopropylethylamine (29 mL, 165 mmol) was added over 2 min and the 
reaction was allowed to stir at room temperature for 2 h. The solvent was removed in 
vacuo and subsequently dissolved in ethyl acetate (400 mL), washed with 10 vol.% 
citric acid (2× 100 mL), water (200 mL), saturated aqueous NaHCO3 (200 mL), brine 
(200 mL) and dried over anhydrous Na2SO4. The solvent was concentrated in vacuo 
to give a residue that was purified by column chromatography (4:1 v/v Hexane: 
EtOAc) to give hydroxamic acid 264 as a white foam (11.8 g, 80%).  
IR (ATR): ν = 3320, 2976, 2972, 1666 cm-1. 1H NMR (400 MHz, CDCl3): δ 10.01 
(1H, s, NH), 7.39-7.20 (2H, m, Ar-H), 7.21-7.10 (3H, m, Ar-H), 5.76 (1H, d, J 8.5 
Hz, α-CH), 4.74 (2H, s, CH2Ph), 4.05-3.99 (1H, m, β-CH), 1.28 (9H, s, 3× CH3, 
Boc), 1.00 (3H, d, J 6.2 Hz, γ-CH3). LRMS [M+Na+] 347.0. [!]!!" = -66o (c = 0.48 in 
CH2Cl2). These data are in agreement with those previously reported by Miller et 
al.[157]  
(2S,3S)-3-((benzyloxy)amino)-2-((tert-butoxycarbonyl)amino)butanoic acid (270) 
 
A solution of triphenylphosphine (9.2 g, 35 mmol) and hydroxamic acid 264 (11.4 g, 
35 mmol) in THF (350 mL) at 0 oC was added DIAD (6.9 mL, 35 mmol). The 
reaction was allowed to warm up to room temperature and stirred for 24 h. The 
solvent was removed in vacuo to give a crude residue that was purified by column 
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chromatography (3:2 v/v Hexane: EtOAc) to afford lactam 269 (1:1.1 mol/mol lactam 
269: reduced DIAD) as a white solid (12.2 g, 23 mmol of lactam 269) which was used 
without further purification.  
To a solution of lactam 269 (23 mmol) in a mixture of THF and water (1:1 v/v, 42 
mL) was added 1 M NaOH solution (25 mL, 25.3 mmol) over 1 h and the reaction 
was stirred for another 1 h at room temperature. THF was removed in vacuo and the 
aqueous layer was washed with diethyl ether (3× 40 mL), acidified to pH 3-4 and 
extracted with ethyl acetate (3× 80 mL). The combined organic layers were dried over 
anhydrous Na2SO4 and the solvent was removed in vacuo to afford acid 270 as a 
white foam (6.5 g, 56% over two steps) which was used without further purification.  
IR (ATR): ν = 2978, 2928, 1711 cm-1. 1H NMR (500 MHz, CDCl3): δ 7.93 (2H, s), 
7.62-6.64 (5H, m, Ar-H), 5.40 (1H, s, NH), 4.73 (2H, m, CH2Ph), 4.64-4.57 (1H, m, 
α-CH), 3.53 (1H, qd, J 6.8, 3.9 Hz, β-CH), 1.45 (9H, s, 3× CH3, Boc), 1.08 (1H, d, J 
6.8 Hz, γ-CH3). LRMS [M+H+] 325.0. [!]!!" = +0.4o (c = 1.0 in CHCl3). These data 
are in agreement with Boojamra et al.[145b]  
(2S,3S)-3-((benzyloxy)(methyl)amino)-2-((tert-butoxycarbonyl)amino)butanoic 
acid (271) 
 
Sodium cyanoborohydride (1.82 g, 28 mmol) was added to a solution of acid 270 (6.0 
g, 19 mmol) in methanol (33 mL) at 0 oC. Formaldehyde (1.7 mL, 20 mmol) was 
subsequently added over 1 h. The reaction was allowed to warm up to room 
temperature and stirred for 16 h. The reaction mixture was concentrated in vacuo, 
diluted with saturated aqueous potassium carbonate solution (40 mL), washed with 
diethyl ether (2× 20 mL) and acidified to pH 2 with 1 M HCl. The aqueous layer was 
extracted with ethyl acetate (2× 80 mL), washed with brine and dried over anhydrous 
MgSO4. The solvent was removed in vacuo to afford acid 271 as a white foam (6.1 g, 
97%) which was used without further purification.  
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IR (ATR): ν = 2978, 2927, 1715 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.50-7.30 (5H, 
m, Ar-H), 5.32 (1H, d, J 7.9 Hz, NH), 4.74 (2H, s, CH2Ph), 4.38 (1H, app. t, J 8.0 Hz, 
α-CH), 3.27-3.03 (1H, m, β-CH), 2.66 (3H, s, NCH3), 1.45 (9H, s, 3× CH3, Boc), 
1.21 (1H, d, J 6.6 Hz, γ-CH3). LRMS [M+H+] 339.1. [!]!!" = +5.0o (c = 0.38 in 
CH2Cl2). These data are in agreement with Boojamra et al.[145b]  
 (2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
((benzyloxy)(methyl)amino)butanoic acid (272) 
 
Acid 271 (4.42 g, 13 mmol) in a mixture of TFA and CH2Cl2 (1:1 v/v) was stirred at 
room temperature for 30 min. The solvent was removed in vacuo to give a residue 
that was dissolved in THF (70 mL). Saturated aqueous NaHCO3 solution as well as 
solid NaHCO3 (approx. 10 g) were added (until the reaction mixture was basic), 
followed by Fmoc-succinimide (4.62 g, 14 mmol). The reaction was allowed to stir at 
room temperature for 16 h. At this point, water (100 mL) was added and the reaction 
mixture was washed with diethyl ether (3× 50 mL). The aqueous layer was acidified 
to pH 2 with 1 M HCl and extracted with ethyl acetate (3× 250 mL). The combined 
organic layers were dried over anhydrous MgSO4 and the solvent was removed in 
vacuo to give a crude residue that was purified by column chromatography (3:1 v/v 
Hexane: EtOAc → 1:1 v/v Hexane: EtOAc) to afford Fmoc-protected acid 272 as a 
colourless oil (4.19 g, 70%).  
IR (ATR): ν = 2955, 1720 cm-1. 1H NMR (500 MHz, CDCl3): δ 7.96-7.69 (2H, m, 
Ar-H), 7.59 (2H, dd, J 7.7, 3.4 Hz, Ar-H), 7.41-7.27 (9H, m, Ar-H), 5.60 (1H, d, J 8.3 
Hz, NH), 4.75 (2H, s, CH2Ph), 4.43 (3H, m, α-CH + Fmoc-CH2), 4.23 (1H, app. t, J 
7.2 Hz, Fmoc-CH), 3.30-3.05 (1H, m, β-CH), 2.68 (3H, s, NCH3), 1.22 (3H, d, J 6.9 
Hz, γ-CH3). 13C NMR (126 MHz, CDCl3): δ 173.5, 156.8, 143.8, 141.5, 136.0, 129.0, 
128.8, 128.6, 127.3, 127.2, 125.3, 120.1, 74.7, 67.4, 64.2, 55.3, 47.3, 41.2, 10.1. 
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LRMS [M+H+] 461.4. HRMS (ESI) m/z cald for C27H28N2O5Na [M+Na+]: 483.1896, 
found 483.1890. [!]!!" = +1.8o (c = 0.30 in CH2Cl2). 
(2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
(methylamino)butanoic acid (263) 
 
Nanoparticle zinc (2.15 g, 33 mmol) was added to a vigorously stirred solution of acid 
272 (3.04 g, 6.6 mmol) in methanol (34 mL). A solution of 2 M HCl (34 mL) was 
added dropwise and the reaction was allowed to stir at room temperature for 2 h. A 
further portion of nanoparticle zinc (0.31 g, 4.8 mmol) and 2 M HCl (11 mL) were 
then added and the reaction was allowed to stir at room temperature for 16 h. The 
reaction was concentrated in vacuo to half of its volume, subsequently diluted with 
H2O (400 mL) and washed with CH2Cl2 (80 mL). The aqueous layer was extracted 
with ethyl acetate (5× 150 mL) and ethyl acetate/methanol mixture (9:1 v/v EtOAc: 
MeOH, 2× 150 mL). The combined organic layers were dried over anhydrous 
MgSO4, the solvent was removed in vacuo to give acid 263 as a white solid (1.82 g, 
78%) that was used without further purification.  
m.p. 133-135 oC (decomp.). IR (ATR): ν = 3335, 3049, 1704 cm-1. 1H NMR (500 
MHz, CD3OD): δ 7.86-7.76 (2H, m, Ar-H), 7.70 (2H, app. t, J 7.4 Hz, Ar-H), 7.40 
(2H, dd, J 8.1, 6.7 Hz, Ar-H), 7.32 (2H, ddd, J 7.7, 6.8, 1.6 Hz, Ar-H), 4.72-4.67 (1H, 
m, DABA-α-CH), 4.55 (1H, dd, J 10.5, 6.7 Hz, Fmoc-CH2), 4.41-4.32 (1H, m, Fmoc-
CH2), 4.27 (1H, app. t, J 6.7 Hz, Fmoc-CH), 3.77-3.70 (1H, m, DABA-β-CH), 2.75 
(3H, s, NCH3), 1.26 (3H, d, J 6.5 Hz, DABA-γ-CH3). LRMS [M+H+] 355.1. [!]!!"  = +2.4o (c = 0.40 in MeOH). These data are in agreement with those previously 
reported by Conroy.[152] 
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(S)-2-((tert-butoxycarbonyl)amino)-3-(3-hydroxyphenyl)propanoic acid (274) 
 
To a solution of L-m-Tyr-OH 273 (354 mg, 1.95 mmol) in THF (2.8 mL) was added 
saturated aqueous NaHCO3 solution (5.7 mL), followed by di-tert-butyl dicarbonate 
(467 mg, 2.1 mmol) and the reaction was allowed to stir at room temperature for 16 h. 
The aqueous layer was acidified to pH 4-5 with 1 M HCl, extracted with ethyl acetate 
(4× 20 mL) and the solvent was removed in vacuo to afford acid 274 as a colourless 
oil (530 mg, 97%).  
IR (ATR): ν = 3330, 2968, 2928, 1686 cm-1. 1H NMR (500 MHz, Acetone-d6): δ 7.09 
(1H, app. t, J 7.8 Hz, Ar-H), 6.79-6.77 (1H, m, Ar-H), 6.74 (1H, d, J 7.6 Hz, Ar-H), 
6.69 (1H, dd, J 8.1, 2.4 Hz, Ar-H), 5.92 (1H, d, J 8.2 Hz, NH), 4.39 (1H, dt, J 8.1, 3.9 
Hz, α-CH), 3.12 (1H, dd, J 13.9, 5.1 Hz, β-CH2), 2.94 (1H, dd, J 13.8, 8.4 Hz, β-
CH2), 1.37 (9H, s, 3× CH3, Boc). LRMS [M+Na+] 304.2. [!]!!" = +9.0o (c = 0.42 in 
CH2Cl2). These data are in agreement with those previously reported by Conroy.[152]  
(S)-2-((tert-butoxycarbonyl)amino)-3-(3-((tert-
butyldimethylsilyl)oxy)phenyl)propanoic acid (275) 
 
To a solution of acid 274 (530 mg, 1.89 mmol) in CH2Cl2 (9.6 mL) at room 
temperature was added triethylamine (1 mL, 7.56 mmol), followed by tert-
butyldimethyl silyl chloride (855 mg, 5.67 mmol). The reaction was heated at 45 oC 
for 16 h. The reaction was poured onto H2O (20 mL), acidified to pH 2-3 and 
extracted with ethyl acetate (4× 50 mL). The solvent was removed in vacuo to give a 
crude residue that was purified by column chromatography (95:5 v/v CH2Cl2: MeOH, 
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0.1 vol.% CH3CO2H) to afford acid 275 as an off-white amorphous solid (373 mg, 
50%).  
IR (ATR): ν = 2957, 2929, 2858, 1718 cm-1. 1H NMR (400 MHz, Acetone-d6): δ 7.16 
(1H, app. t, J 7.8 Hz, Ar-H, H-5), 6.88 (1H, app. d, J 7.8 Hz, Ar-H, H-4), 6.83 (1H, 
app. t, J 2.1 Hz, Ar-H, H-2), 6.73 (1H, ddd, J 8.2, 2.5, 1.0 Hz, Ar-H, H-6), 5.62 (1H, 
s, NH), 4.39 (1H, dd, J 8.5, 4.9 Hz, α-CH), 3.15 (1H, dd, J 13.8, 4.9 Hz, β-CH2), 2.97 
(1H, dd, J 13.8, 8.5 Hz, β-CH2), 1.37 (9H, s, 3× CH3, Boc), 1.03-0.96 (9H, m, 
(CH3)3CSi), 0.24-0.17 (6H, m, 2× CH3Si). LRMS [M+Na+] 418.3. [!]!!" = +8.4o  
(c = 0.30 in CH2Cl2). These data are in agreement with those previously reported by 
Conroy.[152]  
General procedure G: synthesis of dipeptides 256-261 
To a solution of Boc-protected amino acids (1 eq.) in DMF (4-8 mL/mmol) was added 
HATU (1 eq.) and the solution was cooled to 0 oC after stirring at room temperature 
for 10 min. 263 (1 eq.) was added, followed by NMM or N,N-diisopropylethylamine 
(3 eq.) and the reaction was allowed to warm to room temperature and the reaction 
was stirred for 3-6 h. Upon completion, the reaction was diluted with ethyl acetate 
(60-100 mL) and washed successively with 0.2 M HCl (15-20 mL), water (5× 15 mL) 
and brine (15 mL). The solvent was removed in vacuo to give a crude residue that was 
purified by column chromatography or reverse phase HPLC to afford dipeptides 256-
261.  
(2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((S)-2-((tert-
butoxycarbonyl)amino)-3-(3-((tert-butyldimethylsilyl)oxy)phenyl)-N-
methylpropanamido)butanoic acid (256) 
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Boc-L-m-Tyr(OTBS)-OH 275 (470 mg, 1.19 mmol) was reacted with 263 (467 mg, 
1.19 mmol) in the presence of HATU (452 mg, 1.14 mmol) and NMM (392 µL, 3.56 
mmol) in DMF (4.8 mL) according to general procedure G for 3 h to obtain dipeptide 
256 after column chromatography (95:5 v/v CH2Cl2: MeOH) and reverse-phase 
HPLC purification (30 to 100% MeCN over 40 min, 10 min at 30% MeCN) as a 
white amorphous solid (195 mg, 22%).  
IR (ATR): 3321, 2930, 2838, 1713, 1639 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.76 
(2H, dd, J 7.6, 2.6 Hz, Ar-H), 7.64-7.54 (2H, m, Ar-H), 7.44-7.35 (2H, m, Ar-H), 
7.34-7.27 (2H, m, Ar-H), 7.12 (1H, app. t, J 7.9 Hz, Ar-H), 6.83 (1H, app. d, J 7.3 
Hz, Ar-H), 6.73-6.65 (2H, m, Ar-H), 5.75 (1H, s, NH), 5.48 (1H, d, J 8.8 Hz, NH), 
4.87-4.65 (2H, m, d, DABA1-β-CH + m-Tyr2-α-CH), 4.52-4.26 (3H, m, Fmoc-CH2 + 
DABA1-α-CH), 4.21 (1H, app. t, J 6.8 Hz, Fmoc-CH), 3.06-2.94 (1H, m, m-Tyr-β-
CH2), 2.91 (3H, s, NCH3), 2.86-2.76 (1H, m, m-Tyr2-β-CH2), 1.46-1.31 (9H, m, 3× 
CH3, Boc), 1.20 (3H, d, J 7.0 Hz, DABA1-γ-CH3), 1.00-0.92 (9H, m, 3× CH3, 
(CH3)3CSi), 0.20-0.13 (6H, m, 2× CH3Si). LRMS [M+H+] 732.4. [!]!!"  = -3.4o  
(c = 0.10 in CH2Cl2). These data are in agreement with those previously reported by 
Conroy.[152] 
(2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((S)-3-(4-(tert-
butoxy)phenyl)-2-((tert-butoxycarbonyl)amino)-N-methylpropanamido)butanoic 
acid (257) 
 
Boc-L-Tyr(OtBu)-OH (384 mg, 1.14 mmol) was reacted with 263 (406 mg, 1.14 
mmol) in the presence of HATU (433 mg, 1.14 mmol) and NMM (376 µL, 3.42 
mmol) in DMF (8.9 mL) according to general procedure G for 6 h to obtain dipeptide 
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257 after column chromatography (1:1 v/v EtOAc: Hexane → EtOAc) as a white 
amorphous solid (384 mg, 50%).  
IR (ATR): 3335, 3045, 1704 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.81-7.68 (2H, m, 
Ar-H), 7.64-7.53 (2H, m, Ar-H), 7.43-7.34 (2H, m, Ar-H), 7.33-7.27 (2H, m, Ar-H), 
7.08 (2H, d, J 7.8 Hz, Ar-H, H-2 + H-6), 6.94-6.83 (2H, m, Ar-H, H-3 + H-5), 5.91 
(1H, s, NH), 5.58 (1H, d, J 8.6 Hz, NH), 4.92-4.83 (1H, m, Tyr2-α-CH), 4.80-4.67 
(1H, m, DABA1-β-CH), 4.40-4.29 (3H, m, Fmoc-CH2 + DABA1-α-CH), 4.20 (1H, 
app. t, J 6.7 Hz, Fmoc-CH), 3.05-2.87 (4H, m, NCH3 + Tyr2-β-CH2), 2.81-2.68 (1H, 
m, Tyr2-β-CH2), 1.56-1.00 (21H, m, Boc + tBu + DABA1-γ-CH3). LRMS [M+H+] 
673.3. [!]!!" = -3.8o (c = 0.39 in CH2Cl2). These data are in agreement with those 
previously reported by Conroy.[152] 
(2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-((tert-
butoxycarbonyl)amino)-N-methylacetamido)butanoic acid (258) 
 
Boc-Gly-OH (100 mg, 0.56 mmol) was reacted with 263 (200 mg, 0.56 mmol) in the 
presence of HATU (214 mg, 0.56 mmol) and N,N-diisopropylethylamine (294 µL, 
1.69 mmol) in DMF (4 mL) according to general procedure G for 3 h to obtain 
dipeptide 258 after column chromatography (98:2 v/v CH2Cl2: MeOH → 95:5 v/v 
CH2Cl2: MeOH → 9:1 v/v CH2Cl2: MeOH, 0.1 vol.% CH3COOH) as a white foam 
(108 mg, 42%).  
IR (ATR): 3428, 3319, 2972, 1714, 1649 cm-1. 1H NMR (400 MHz, CDCl3, major 
rotamer): δ 7.83-7.69 (2H, m, Ar-H), 7.61-7.54 (2H, m, Ar-H), 7.38 (2H, ddd, J 8.2, 
5.4, 2.2 Hz, Ar-H), 7.29 (2H, app. t, J 7.2 Hz, Ar-H), 5.87 (1H, d, J 8.1 Hz, NH), 5.80 
(1H, s, NH), 4.99-4.77 (1H, m, DABA1-β-CH), 4.54-4.28 (3H, m, DABA1-α-CH + 
Fmoc-CH2), 4.20 (1H, app. t, J 6.8 Hz, Fmoc-CH), 4.12-3.88 (1H, m, Gly2-α-CH2), 
3.80 (1H, d, J 17.1 Hz, Gly2-α-CH2), 2.80 (3H, s, NCH3), 1.47-1.34 (9H, m, 3× CH3, 
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Boc), 1.22 (3H, d, J 6.8 Hz, DABA1-γ-CH3). 13C NMR (101 MHz, CDCl3, major 
rotamer): δ 172.2 (C=O), 170.6 (C=O), 156.1 (C=O), 156.0 (C=O), 143.8, 141.2, 
127.7, 127.1, 125.0, 119.9, 79.7, 67.1, 56.4, 51.6, 47.2, 42.7, 38.6, 28.3, 14.0. LRMS 
[M+H+] 512.3. HRMS (ESI) m/z cald for C27H33N3O7Na [M+Na+]: 534.2210, found 
534.2212. [!]!!" = -20.7o (c = 0.58 in CH2Cl2). 
(2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((S)-2,5-bis((tert-
butoxycarbonyl)amino)-N-methylpentanamido)butanoic acid (259) 
 
Boc-L-ornithine(NHBoc)-OH (250 mg, 0.75 mmol) was reacted with 263 (267 mg, 
0.75 mmol) in the presence of HATU (287 mg, 0.75 mmol) and N,N-
diisopropylethylamine (390 µL, 2.25 mmol) in DMF (12 mL) according to general 
procedure G for 3 h to obtain dipeptide 259 after column chromatography (98:2 v/v 
CH2Cl2: MeOH → 95:5 v/v CH2Cl2: MeOH → 9:1 v/v CH2Cl2: MeOH, 0.1 vol.% 
CH3COOH) as a white foam (267 mg, 52%).  
IR (ATR): 3330, 2976, 2931, 1708, 1640 cm-1. 1H NMR (400 MHz, CDCl3, rotamers 
in 4:1 ratio, major rotamer): δ 7.87-7.73 (2H, m, Ar-H), 7.62 (2H, ddd, J 7.6, 4.2, 1.9 
Hz, Ar-H), 7.47-7.38 (2H, m, Ar-H), 7.36-7.30 (2H, m, Ar-H), 5.78-5.63 (2H, m, 2× 
NH), 5.11 (1H, s, NH), 5.03-4.91 (1H, m, DABA1-β-CH), 4.72-4.59 (1H, m, 
Ornithine2-α-CH), 4.54-4.34 (3H, m, DABA1-α-CH + Fmoc-CH2), 4.24 (1H, app. t, 
J 6.9 Hz, Fmoc-CH), 3.30-3.10 (1H, m, Ornithine2-δ-CH2), 2.94-2.86 (1H, m, 
Ornithine2-δ-CH2), 2.83 (3H, s, NCH3), 1.96-1.66 (1H, m, Ornithine2-β-CH2), 1.63-
1.32 (21H, m, 2× Boc + Ornithine2-β-CH2 + Ornithine2-γ-CH2), 1.26-1.16 (3H, m, 
DABA1-γ-CH3). 13C NMR (101 MHz, CDCl3, major rotamer): δ 174.8 (C=O), 171.9 
(C=O), 157.3 (C=O), 156.0 (C=O), 155.3 (C=O), 143.8, 141.3, 127.7, 127.1, 125.1, 
120.0, 80.5, 79.7, 79.6, 67.1, 56.4, 51.1, 50.4, 47.2, 40.7, 38.6, 28.6, 28.4, 24.8, 14.3. 
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LRMS [M+H+] 669.7. HRMS (ESI) m/z cald for C35H48N4O9Na [M+Na+]: 691.3313, 
found 691.3314. [!]!!"  = +15.1o (c = 0.45 in CH2Cl2). 
(2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((S)-2,6-bis((tert-
butoxycarbonyl)amino)-N-methylhexanamido)butanoic acid (260) 
 
Boc-L-Lysine(NHBoc)-OH (260 mg, 0.75 mmol) was reacted with 263 (267 mg, 0.75 
mmol) in the presence of HATU (287 mg, 0.75 mmol) and N,N-
diisopropylethylamine (390 µL, 2.25 mmol) in DMF (12 mL) according to general 
procedure G for 3 h to obtain dipeptide 260 after column chromatography (98:2 v/v 
CH2Cl2: MeOH → 95:5 v/v CH2Cl2: MeOH → 9:1 v/v CH2Cl2: MeOH, 0.1 vol.% 
CH3COOH) as a white foam (279 mg, 55%).  
IR (ATR): 3318, 2975, 2933, 1708, 1650 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.79-
7.70 (2H, m, Ar-H), 7.59 (2H, dd, J 7.5, 4.3 Hz, Ar-H), 7.43-7.35 (2H, m, Ar-H), 7.31 
(2H, app. t, J 7.3 Hz, Ar-H), 5.87 (1H, s, NH), 5.62 (1H, s, NH), 5.53 (1H, d, J 8.2 
Hz, NH), 5.00-4.86 (1H, m, DABA1-β-CH), 4.72-4.52 (1H, m, Lys2-α-CH), 4.50-
4.31 (3H, m, DABA1-α-CH + Fmoc-CH2), 4.22 (1H, app. t, J 6.9 Hz, Fmoc-CH), 
3.25-3.06 (2H, m, Lys2-ε-CH2), 2.80 (3H, s, NCH3), 1.83-1.66 (1H, m, Lys2-β-CH2), 
1.64-1.27 (23H, m, 2× Boc + Lys2-β-CH2 + Lys2-γ-CH2 + Lys2-δ-CH2), 1.21 (3H, d, 
J 6.8 Hz, DABA1-γ-CH3). LRMS [M+H+] 683.5. HRMS (ESI) m/z cald for 
C36H50N4O9Na [M+Na+]: 705.3470, found 705.3477. [!]!!"  = -4.8o (c = 0.31 in 
CH2Cl2). 
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(2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((S)-4-(tert-butoxy)-2-
((tert-butoxycarbonyl)amino)-N-methyl-4-oxobutanamido)butanoic acid (261) 
 
Boc-L-Asp(OtBu)-OH (162 mg, 0.56 mmol) was reacted with 263 (200 mg, 0.56 
mmol) in the presence of HATU (214 mg, 0.56 mmol) and N,N-
diisopropylethylamine (294 µL, 1.69 mmol) in DMF (8.9 mL) according to general 
procedure G for 3.5 h to obtain dipeptide 261 after column chromatography (98:2 v/v 
CH2Cl2: MeOH → 95:5 v/v CH2Cl2: MeOH → 9:1 v/v CH2Cl2: MeOH, 0.1 vol.% 
CH3COOH) as a white foam (156 mg, 45%).  
IR (ATR): 3307, 2976, 2929, 1710, 1641 cm-1. 1H NMR (400 MHz, CDCl3, rotamers 
in 1.5:1 ratio, major rotamer): δ 7.78-7.70 (2H, m, Ar-H), 7.59 (2H, app. t, J 7.5 Hz, 
Ar-H), 7.42-7.35 (2H, m, Ar-H), 7.33-7.27 (2H, m, Ar-H), 5.93 (1H, s, NH), 5.75 
(1H, d, J 9.2 Hz, NH), 4.99-4.98 (1H, m, Asp2-α-CH), 4.87-4.76 (1H, m, DABA1-β-
CH), 4.52-4.29 (3H, m, DABA1-α-CH + Fmoc-CH2), 4.24-4.17 (1H, m, Fmoc-CH), 
3.06 (3H, s, NCH3), 2.83-2.64 (1H, m, Asp2-β-CH2), 2.43 (1H, dd, J 15.3, 8.5 Hz, 
Asp2-β-CH2), 1.52-1.32 (18H, m, 6× CH3, Boc + CO2tBu), 1.32-1.18 (3H, m, 
DABA1-γ-CH3). 13C NMR (101 MHz, CDCl3, major rotamer): δ 172.9 (C=O), 172.2 
(C=O), 170.1 (C=O), 156.1 (C=O), 155.3 (C=O), 143.6, 141.3, 127.7, 127.1, 125.1, 
120.0, 81.8, 79.8, 67.1, 56.5, 54.5, 47.2 (× 2), 38.4, 30.5, 28.3, 28.1, 14.1.  
1H NMR (400 MHz, CDCl3, rotamers in 1.5:1 ratio, minor rotamer): δ 7.78-7.70 (2H, 
m, Ar-H), 7.59 (2H, app. t, J 7.5 Hz, Ar-H), 7.42-7.35 (2H, m, Ar-H), 7.33-7.27 (2H, 
m, Ar-H), 6.21 (1H, d, J 10.0 Hz, NH), 5.55 (1H, d, J 10.2 Hz, NH), 4.99-4.98 (1H, 
m, Asp2-α-CH), 4.73-4.57 (1H, m, DABA1-β-CH), 4.52-4.29 (3H, m, DABA1-α-CH 
+ Fmoc-CH2), 4.24-4.17 (1H, m, Fmoc-CH), 3.18-3.08 (1H, m, Asp2-β-CH2), 2.92 
(3H, s, NCH3), 2.54 (1H, dd, J 16.5, 4.9 Hz, Asp2-β-CH2), 1.52-1.32 (21H, m,  
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2× Boc + DABA1-γ-CH3). 13C NMR (101 MHz, CDCl3, minor rotamer): δ 172.2 
(C=O), 171.9 (C=O), 169.9 (C=O), 156.1 (C=O), 155.3 (C=O), 143.8, 141.3, 129.0, 
128.2, 125.3, 120.0, 80.8, 80.6, 67.5, 57.6, 52.4, 48.6, 47.1, 39.0, 29.0, 28.4, 28.0, 
15.7. LRMS [M+H+] 626.3. HRMS (ESI) m/z cald for C33H43N3O9Na [M+Na+]: 
648.2891, found 648.2893. [!]!!" = -17.7o (c = 0.3 in CH2Cl2). 
 (2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((2S,3R)-2-((tert-
butoxycarbonyl)amino)-3-hydroxy-N-methylbutanamido)butanoic acid (262) 
 
To a solution of Boc-L-Thr-OH (95 mg, 0.43 mmol) in DMF (4.5 mL) was added 
HATU (163 mg, 0.43 mmol), HOAt (658 mg, 4.3 mmol) and N,N-
diisopropylethylamine (75 µL, 0.43 mmol) and the solution was cooled to 0 oC after 
stirring at room temperature for 5 min. 263 (152 mg, 0.43 mmol) was added, followed 
by N,N-diisopropylethylamine (150 µL, 0.86 mmol) and the reaction was warmed to 
room temperature. The reaction was allowed to stir at ambient temperature for 4 h. 
Upon completion, the reaction was diluted with ethyl acetate (60-100 mL) and 
washed successively with 0.2 M HCl (15-20 mL), water (5× 15 mL) and brine (15 
mL). The solvent was removed in vacuo to give a crude residue that was purified by 
column chromatography (98:2 v/v CH2Cl2: MeOH → 95:5 v/v CH2Cl2: MeOH → 9:1 
v/v CH2Cl2: MeOH, 0.1 vol.% CH3COOH) to afford dipeptide 262 as a white foam 
(160 mg, 37%).  
IR (ATR): 3307, 2976, 1710, 1635 cm-1. 1H NMR (400 MHz, DMSO-d6, rotamers in 
3:1 ratio, major rotamer): δ 7.89 (2H, app. d, J 7.6 Hz, Ar-H), 7.73 (2H, app. t, J 6.1 
Hz, Ar-H), 7.42 (2H, td, J 7.6, 1.4 Hz, Ar-H), 7.37-7.29 (2H, m, Ar-H), 6.49 (1H, d, J 
8.1 Hz, NH), 5.86 (1H, d, J 8.2 Hz, NH), 4.94-4.81 (1H, m, DABA1-β-CH), 4.74 
(1H, s), 4.47-4.13 (5H, m, DABA1-α-CH + Thr2-α-CH + Fmoc-CH + Fmoc-CH2), 
3.92-3.63 (1H, m, Thr2-β-CH), 2.69 (3H, s, NCH3), 1.37 (9H, s, 3× CH3, Boc), 1.10 
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(3H, d, J 6.9 Hz, DABA1-γ-CH3), 1.00 (3H, d, J 6.3 Hz, Thr2-γ-CH3). 13C NMR (100 
MHz, DMSO-d6, major rotamer): δ 172.6 (C=O), 171.7 (C=O), 156.7 (C=O), 155.8 
(C=O), 144.2, 141.2, 128.1, 127.5, 125.8, 120.6, 78.6, 67.0, 66.4, 58.2, 57.0, 49.5, 
47.1, 38.7, 28.6, 20.2, 14.2. LRMS [M+H+] 556.4. HRMS (ESI) m/z cald for 
C29H37N3O8Na [M+Na+]: 578.2472, found 578.2478. [!]!!"  = -16.3o (c = 0.46 in 
CH2Cl2). 
General procedure H: loading amino acids onto 2-chlorotrityl chloride resin 
2-Chlorotrityl chloride resin (100-200 mesh) with 1% DVB (1.22 mmol/g, 50-160 
µmol, 1 eq.) was allowed to swell in anhydrous CH2Cl2 (3-5 mL) for 30 min. 
Dipeptides 256-262 (100-320 µmol, 2 eq.) were dissolved in anhydrous CH2Cl2 (2-2.6 
mL/100 µmol). N,N-diisopropylethylamine (200-640 µmol, 2-8 eq.) was added and 
the resin was shaken for 16 h. The resin was subsequently washed with DMF (5× 5 
mL), CH2Cl2 (5× 5 mL) and DMF (5× 5 mL). The resin was capped by treatment with 
17:2:1 v/v/v CH2Cl2: MeOH: iPr2NEt (3-6 mL) for 40 min. The resin was then 
washed with DMF (5× 5 mL), CH2Cl2 (5× 5 mL) and DMF (5× 5 mL). The resin was 
subsequently treated with 10 vol.% piperidine in DMF (3-5 mL) for 4 min (× 2) and 
the efficiency of amino acid loading was determined by spectroscopic measurement 
of the resulting fulvene piperidine adduct at λ = 301 nm.  
General procedure I: Fmoc-strategy solid phase peptide synthesis 
Fmoc deprotection: A solution of 10 vol.% piperidine/DMF (5 mL) was added to the 
resin and shaken for 4 min (×!2). The resin was subsequently washed with DMF (5×!3 
mL), CH2Cl2 (5×! 3 mL) and DMF (5×! 3 mL). Efficiency of previous amino acid 
coupling was determined by spectroscopic measurement of the resulting fulvene 
piperidine adduct at λ = 301 nm. 
Amino Acid Coupling: A solution of protected amino acid (200-640 µmol, 4 eq.), 
PyBOP (200-640 µmol, 4 eq.) and NMM (0.4-1.28 mmol, 8 eq.) in DMF (0.1 M) was 
added to the resin (1 eq.) and shaken for 1 h at room temperature. The resin was then 
washed with DMF (5× 5 mL), CH2Cl2 (5× 5 mL) and DMF (5× 5 mL). 
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Capping: A solution of 10 vol.% acetic anhydride/pyridine (5 mL) was added to the 
resin and shaken for 3 min. The resin was subsequently washed with DMF (5× 5 mL), 
CH2Cl2 (5× 5 mL) and DMF (5× 5 mL). 
General procedure J: Solid-phase urea formation  
A solution of carbamate 255 (100-320 µmol, 2 eq.) and N,N-diisopropylethylamine 
(200-640 µmol, 4 eq.) in DMF (17 µL/µmol) was added to the resin (50-160 µmol, 1 
eq.). The resin was shaken at room temperature for 6 h. The resin was subsequently 
washed with DMF (5× 5 mL), CH2Cl2 (5× 5 mL) and DMF (5× 5 mL). 
General procedure K: Cleavage from 2-chlorotrityl chloride resin and work-up 
A solution of 30 vol.% hexafluoroisopropanol (HFIP) in CH2Cl2 (5-10 mL) was 
added to the resin and shaken for 30 min. The resin was subsequently washed with 
CH2Cl2 (6× 10 mL) and the combined cleavage and washing solutions were removed 
in vacuo. The resulting residue was dissolved in 9:1 v/v MeCN: H2O and purified by 
reverse phase HPLC. 
General procedure L: synthesis of dihydrosansanmycin analogues 229, 231,  
250-254 via fragment condensation strategy 
To a solution of amine 294 (15-25 µmol, 1.2 eq.) in CH2Cl2 and DMF (1:1 v/v 
CH2Cl2: DMF, 0.1 M) was added depsipeptide 286 and 289-293 (13-21 µmol, 1 eq.). 
HOAt (5-5.5 eq.), immediately followed by DIC (1 eq.). The reaction was allowed to 
stir at room temperature for 1.5 h. At this point, the solvent was removed by placing 
the reaction flask under a stream of nitrogen. The reaction was then suspended in a 
mixture of TFA and iPr3SiH in CH2Cl2 (1:1 v/v TFA: CH2Cl2, 2.5 vol.% iPr3SiH, 
0.15 mL/µmol) and the reaction was stirred at room temperature for 1.5-2 h. At this 
point, the solvent was removed in vacuo and azeotroped with toluene to afford a crude 
residue that was dissolved in water and purified by reverse phase HPLC purification. 
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(2S,5S,9S)-9-((1-(tert-butoxycarbonyl)-1H-indol-3-yl)methyl)-2-((S)-1-((S)-2-
((tert-butoxycarbonyl)amino)-3-(3-((tert-butyldimethylsilyl)oxy)phenyl)-N-
methylpropanamido)ethyl)-12,12-dimethyl-5-(2-(methylsulfinyl)ethyl)-4,7,10-
trioxo-11-oxa-3,6,8-triazatridecanoic acid (286) 
 
Dipeptide 256 (146 mg, 200 µmol) was loaded onto 2-chlorotrityl chloride resin (83 
mg, 100 µmol) in CH2Cl2 (2 mL) using N,N-diisopropylethylamine (40 µL, 220 
µmol) and Fmoc-deprotected according to general procedure H. Fmoc-L-Met(O)-OH 
(387 mg, 400 µmol) was subsequently coupled with PyBOP (208 mg, 400 µmol) and 
NMM (82 µL, 800 µmol) in DMF (1 mL) (general procedure I). Carbamate 255 (106 
mg, 200 µmol) was subsequently coupled according to general procedure J. 
Following cleavage from the resin (general procedure K), the peptide was purified by 
reverse phase HPLC (50-100% MeCN over 40 min, 10 min at 50% MeCN) to afford 
depsipeptide 286 as a fluffy white solid (26.2 mg, 26%).  
IR (ATR): 3300, 2923, 2853, 1733, 1638 cm-1. 1H NMR (400 MHz, CDCl3, major 
rotamer): δ 8.26 (1H, br. s), 8.21 (1H, br. s), 8.15-8.00 (1H, m, Ar-H), 7.55 (1H, dd, J 
8.0, 3.1 Hz, Ar-H), 7.39 (1H, s, Ar-H), 7.29-7.23 (1H, m, Ar-H), 7.17 (1H, app. q, J 
7.0 Hz, Ar-H), 7.09 (1H, app. td, J 7.8, 3.1 Hz, Ar-H), 6.88 (1H, app. t, J 9.8 Hz, Ar-
H), 6.80 (1H, dd, J 6.4, 4.4 Hz, Ar-H), 6.68 (1H, dt, J 8.4, 2.6 Hz, Ar-H), 6.11 (1H, s, 
NH), 5.85 (1H, s, NH), 5.60 (1H, s, NH), 5.36 (1H, s, NH), 5.13-4.97 (1H, m, 
DABA1-β-CH), 4.73-4.59 (2H, m, m-Tyr2-α-CH, Trp4-α-CH), 4.50 (1H, app. t, J 
8.8 Hz, DABA1-α-CH), 3.35-3.03 (5H, m, Trp4-β-CH2 + NCH3), 3.02-2.92  (1H, m, 
m-Tyr2-β-CH2),  2.93-2.70 (4H, m, m-Tyr2-β-CH2, Met(O)3-α-CH + Met(O)3-γ-
CH2), 2.51 (3H, s, S(O)CH3), 2.40-2.25 (1H, m, Met(O)3-β-CH2), 2.09-1.91 (1H, m, 
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Met(O)3-β-CH2), 1.62 (9H, s, 3× CH3),  1.36-1.19 (21H, m, 2× Boc + CO2tBu + 
DABA1-γ-CH3), 0.97 (9H, s, (CH3)3CSi), 0.19 (6H, s, 2× CH3Si). 13C NMR (101 
MHz, CDCl3): δ 173.9 (C=O), 171.9 (C=O), 171.7 (C=O), 171.6 (C=O), 156.9, 155.9, 
155.6, 149.6, 139.1, 135.3, 130.7, 129.2, 124.5, 124.0, 122.7, 122.5, 120.8, 119.4, 
118.2, 115.8, 115.1, 83.5, 82.0, 78.9, 55.4, 54.1, 53.1, 52.6, 51.7, 50.2, 37.6, 37.5, 
29.8, 29.7, 28.3, 28.0, 27.9, 25.7, 18.1, 14.9, -4.4, -4.3. LRMS [M+H+] 1043.6. 
HRMS (ESI) m/z cald for C51H78N6O13SSiNa [M+Na+]: 1065.5009, found 1065.5005. [!]!!" = +6.2o (c = 0.16 in CH2Cl2). 
(2S,5S,9S)-9-((1-(tert-butoxycarbonyl)-1H-indol-3-yl)methyl)-2-((S)-1-((S)-2-
((tert-butoxycarbonyl)amino)-3-(3-((tert-butyldimethylsilyl)oxy)phenyl)-N-
methylpropanamido)ethyl)-5-isobutyl-12,12-dimethyl-4,7,10-trioxo-11-oxa-3,6,8-
triazatridecanoic acid (287) 
 
Dipeptide 256 (73 mg, 100 µmol) was loaded onto 2-chlorotrityl chloride resin (41 
mg, 50 µmol) in CH2Cl2 (1 mL) using N,N-diisopropylethylamine (20 µL, 110 µmol) 
and Fmoc-deprotected according to general procedure H. Fmoc-L-Leu-OH (71 mg, 
200 µmol) was subsequently coupled with PyBOP (104 mg, 200 µmol) and NMM (41 
µL, 400 µmol) in DMF (0.5 mL) (general procedure I). Carbamate 255 (53 mg, 100 
µmol) was subsequently coupled according to general procedure J. Following 
cleavage from the resin (general procedure K), the peptide was purified by reverse 
phase HPLC (50-100% MeCN over 40 min, 10 min at 50% MeCN) to afford 
depsipeptide 287 as a fluffy white solid (17.6 mg, 35%).  
IR (ATR): 3300, 2923, 2853, 1733, 1625 cm-1. 1H NMR (400 MHz, CDCl3, major 
rotamer): δ 8.04 (1H, app. d, J 8.0 Hz, Ar-H), 7.64 (1H, d, J 5.2 Hz, Ar-H), 7.54 (1H, 
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app. d, J 7.7 Hz, Ar-H), 7.41 (1H, s, Ar-H), 7.30-7.24 (1H, m, Ar-H), 7.24-7.18 (1H, 
m, Ar-H), 7.04 (1H, app. t, J 7.7 Hz, Ar-H), 6.69-6.62 (3H, m, Ar-H), 5.73 (1H, s, 
NH), 5.47 (1H, s, NH), 4.91-4.53 (4H, m, DABA1-α-CH, DABA1-β-CH, m-Tyr2-α-
CH, Trp4-α-CH), 4.33-4.15 (1H, m, Leu3-α-CH), 3.22-3.07 (2H, m, Trp4-β-CH2), 
3.03-2.90 (4H, m, NCH3, m-Tyr2-β-CH2), 2.72-2.54 (1H, m, m-Tyr2-β-CH2), 1.72-
1.45 (12H, m, 3× CH3, Leu3-β-CH2, Leu3-γ-CH), 1.44-1.25 (18H, m, 6× CH3), 1.23 
(3H, d, J 6.9 Hz, DABA1-γ-CH3), 0.96 (9H, m, (CH3)3CSi), 0.94-0.81 (6H, m, 2× 
Leu3-δ-CH3), 0.17 (6H, s, 2× CH3Si). 13C NMR (101 MHz, CDCl3, major rotamer): δ 
174.2 (C=O), 174.0 (C=O), 173.5 (C=O), 171.5 (C=O), 157.5, 155.4, 155.2, 149.8, 
138.0, 135.2, 130.8, 129.2, 124.4, 124.0, 122.6, 121.3, 121.0, 119.2, 118.3, 115.6, 
115.2, 83.8, 82.5, 81.8, 55.4, 54.1, 53.4, 52.2, 52.1, 41.3, 38.2, 30.5, 28.3, 28.2, 28.1, 
28.0, 27.9, 25.8, 24.6, 22.9, 21.9, 18.1, 14.1, -4.4, -4.4. LRMS [M+H+] 1009.7. ![!]!!" = +1.0o (c = 0.10 in CH2Cl2). These data are in agreement with those previously 
reported by Conroy.[152] 
(2S,5S,9S)-2-((S)-1-((S)-2,6-bis((tert-butoxycarbonyl)amino)-N-
methylhexanamido)ethyl)-9-((1-(tert-butoxycarbonyl)-1H-indol-3-yl)methyl)-5-
isobutyl-12,12-dimethyl-4,7,10-trioxo-11-oxa-3,6,8-triazatridecanoic acid (291) 
 
Dipeptide 260 (279 mg, 410 µmol) was loaded onto 2-chlorotrityl chloride resin (168 
mg, 205 µmol) in CH2Cl2 (2.8 mL) using N,N-diisopropylethylamine (142 µL, 820 
µmol) and Fmoc-deprotected according to general procedure H. Fmoc-L-Leu-OH 
(102 mg, 820 µmol) was subsequently coupled with PyBOP (426 mg, 820 µmol) and 
NMM (162 µL, 1.64 mmol) in DMF (2 mL) (general procedure I). Carbamate 255 
(218 mg, 410 µmol) was subsequently coupled according to general procedure J. 
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Following cleavage from the resin (general procedure K), the peptide was purified by 
reverse phase HPLC (50-100% MeCN over 40 min, 10 min at 50% MeCN) to afford 
depsipeptide 291 as a fluffy white solid (44.2 mg, 22%).  
IR (ATR): 3307, 2976, 1730, 1650 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.09 (1H, 
app. d, J 7.7 Hz, Ar-H), 7.78-7.50 (1H, m, Ar-H), 7.41 (1H, s, Ar-H), 7.33-7.22 (2H, 
m, Ar-H), 7.11 (1H, s), 6.65 (1H, s), 5.87-5.49 (3H, m, NH), 5.06-4.92 (1H, m, 
DABA1-β-CH), 4.87-4.42 (3H, m, DABA1-α-CH + Lys2-α-CH + Trp4-α-CH), 4.39-
4.29 (1H, m, Leu3-α-CH), 3.27-2.99 (4H, m, Lys2-ε-CH2 + Trp4-β-CH2), 2.94 (3H, 
s, NCH3), 1.91-1.24 (45H, m, 12× CH3 + Leu3-β-CH2 + Leu3-γ-CH + Lys2-β-CH2 + 
Lys2-γ-CH2 + Lys2-δ-CH2), 1.24-1.14 (3H, m, DABA1-γ-CH3), 0.97-0.85 (6H, m, 2× 
Leu3-δ-CH3). 13C NMR (101 MHz, CDCl3): δ 173.4 (C=O), 172.7 (C=O), 172.5 
(C=O), 171.4 (C=O), 158.8 (C=O), 158.5 (C=O), 157.2 (C=O), 149.7, 135.2, 130.7, 
124.5, 124.0, 122.7, 119.4, 115.8, 115.1, 83.7, 82.1, 80.9, 79.4, 54.8, 53.9, 52.8, 50.6, 
41.2, 40.3, 31.5, 29.5, 29.4, 28.4 (× 2), 28.2, 27.9, 27.0, 26.9, 24.6, 22.9, 14.3. LRMS 
[M+H+] 960.1. HRMS (ESI) m/z cald for C48H77N7O13Na [M+Na+]: 982.5472, found 
982.5479. [α]!!" = +13.6o (c = 0.41 in CH2Cl2). 
(2S,5S,9S)-2-((S)-1-((S)-4-(tert-butoxy)-2-((tert-butoxycarbonyl)amino)-N-methyl-
4-oxobutanamido)ethyl)-9-((1-(tert-butoxycarbonyl)-1H-indol-3-yl)methyl)-5-
isobutyl-12,12-dimethyl-4,7,10-trioxo-11-oxa-3,6,8-triazatridecanoic acid (292) 
 
Dipeptide 261 (90 mg, 144 µmol) was loaded onto 2-chlorotrityl chloride resin (59 
mg, 72 µmol) in CH2Cl2 (1 mL) using N,N-diisopropylethylamine (50 µL, 288 µmol) 
and Fmoc-deprotected according to general procedure H. Fmoc-Leu-OH (102 mg, 
288 µmol) was subsequently coupled with PyBOP (150 mg, 288 µmol) and NMM (59 
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µL, 576 µmol) in DMF (0.7 mL) (general procedure I). Carbamate 255 (76 mg, 144 
µmol) was subsequently coupled according to general procedure J. Following 
cleavage from the resin (general procedure K), the peptide was purified by reverse 
phase HPLC (50-100% MeCN over 40 min, 10 min at 50% MeCN) to afford 
depsipeptide 292 as a fluffy white solid (18.4 mg, 28%).  
IR (ATR): 3328, 2977, 2933, 1728, 1638 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.06 
(1H, app. d, J 8.1 Hz, Ar-H), 7.63 (1H, br. s), 7.53 (1H, app. d, J 7.7 Hz, Ar-H), 7.41 
(1H, s, Ar-H), 7.33-7.16 (2H, m, Ar-H), 5.77 (1H, s, NH), 5.62 (1H, s, NH), 4.93-4.76 
(2H, m, DABA1-α-CH + Asp2-α-CH), 4.69-4.48 (2H, m, DABA1-β-CH + Trp4-α-
CH), 4.26-4.14 (1H, m, Leu3-α-CH), 3.19-3.08 (2H, m, Trp4-β-CH2), 2.64 (1H, dd, J 
15.5, 5.0 Hz, Asp2-β-CH2), 2.36 (1H, dd, J 15.2, 7.9 Hz, Asp2-β-CH2), 1.69-1.45 
(12H, m, 3× CH3 + Leu3-β-CH2 + Leu3-γ-CH), 1.40 (9H, s, 3× CH3), 1.33 (9H, s, 3× 
CH3), 1.22 (3H, d, J 6.9 Hz, DABA1-γ-CH3), 0.93-0.79 (6H, m, 2× Leu3-δ-CH3). 
13C NMR (101 MHz, CDCl3): δ 173.9 (C=O), 172.9 (C=O), 172.2 (C=O), 171.4 
(C=O), 169.9 (C=O), 157.7, 155.2, 149.7, 135.2, 130.7, 124.4, 124.1, 122.6, 119.2, 
115.6, 115.2, 83.8, 82.6, 81.8, 80.0, 55.1, 54.2, 53.6, 51.8, 48.5, 41.2, 38.4, 28.3, 28.2, 
28.0, 27.9, 27.8, 24.7, 22.8, 21.8, 14.2. LRMS [M+H+] 903.6. HRMS (ESI) m/z cald 
for C45H70N6O13Na [M+Na+]: 925.4893, found 925.4898. [α]!!" = -1.7o (c = 0.11 in 
CH2Cl2). 
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 (2S,5S,9S)-9-((1-(tert-butoxycarbonyl)-1H-indol-3-yl)methyl)-2-((S)-1-((2S,3R)-2-
((tert-butoxycarbonyl)amino)-3-hydroxy-N-methylbutanamido)ethyl)-5-isobutyl-
12,12-dimethyl-4,7,10-trioxo-11-oxa-3,6,8-triazatridecanoic acid (293) 
 
Dipeptide 262 (89 mg, 160 µmol) was loaded onto 2-chlorotrityl chloride resin (66 
mg, 80 µmol) in CH2Cl2 (1.1 mL) using N,N-diisopropylethylamine (55 µL, 320 
µmol) and Fmoc-deprotected according to general procedure H. Fmoc-L-Leu-OH 
(114 mg, 320 µmol) was subsequently coupled with PyBOP (167 mg, 320 µmol) and 
NMM (65 µL, 640 µmol) in DMF (0.8 mL) (general procedure I). Carbamate 255 (85 
mg, 160 µmol) was subsequently coupled according to general procedure J. 
Following cleavage from the resin (general procedure K), the peptide was purified by 
reverse phase HPLC (50-100% MeCN over 40 min, 10 min at 50% MeCN) to afford 
depsipeptide 293 as a fluffy white solid (14 mg, 21%).  
IR (ATR): 3364, 2977, 1729, 1641 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.09 (1H, 
app. d, J 8.2 Hz, Ar-H), 7.69 (1H, app. d, J 8.8 Hz), 7.56 (1H, app. d, J 7.7 Hz, Ar-
H), 7.40 (1H, s, Ar-H), 7.32-7.17 (2H, m, Ar-H), 5.90 (1H, s, NH), 5.70 (1H, s, NH), 
5.61 (1H, s, NH), 5.20-4.91 (1H, m, DABA1-α-CH), 4.77-4.59 (2H, m, DABA1-β-
CH + Trp4-α-CH), 4.54 (1H, app. d, J 9.4 Hz, Thr2-α-CH), 4.19-4.10 (2H, m, Thr2-
β-CH + Leu3-α-CH), 3.21-3.12 (2H, m, Trp4-β-CH2), 2.99 (3H, s, NCH3), 1.71-1.46 
(12H, m, 3× CH3 + Leu3-β-CH2 + Leu3-γ-CH), 1.41 (9H, s, 3× CH3), 1.35 (9H, s, 3× 
CH3), 1.26-1.14 (6H, m, DABA1-γ-CH3 + Thr2-γ-CH3), 0.90 (3H, d, J 6.1 Hz, Leu3-
γ-CH3), 0.84 (3H, d, J 6.0 Hz, Leu3-δ-CH3).13C NMR (101 MHz, CDCl3): δ 173.4 
(C=O), 172.6 (C=O), 172.3 (C=O), 171.3 (C=O), 157.6 (C=O), 156.0 (C=O), 149.6, 
135.2, 130.8, 124.4, 124.1, 122.7, 119.3, 115.6, 115.1, 83.6, 82.5, 79.7, 66.7, 55.3, 
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54.2, 50.8, 41.4, 30.9, 29.9, 28.3, 28.2, 27.9, 24.7, 23.0, 21.8, 19.6, 14.0. LRMS 
[M+H+] 833.5. HRMS (ESI) m/z cald for C41H64N6O12Na [M+Na+]: 855.8474, found 
855.8470. [!]!!" = +2.7o (c = 0.15 in CH2Cl2). 
1-((2R,3R,5R)-5-(aminomethyl)-3-hydroxytetrahydrofuran-2-yl)pyrimidine-
2,4(1H,3H)-dione (294) 
 
Amine 236 (30 mg, 0.067 mmol) was treated with 20 vol.% piperidine in acetonitrile 
(0.8 mL) and the reaction was allowed to stir at room temperature for 30 min. The 
solvent was removed in vacuo and the resulting residue was dissolved in water (20 
mL) and washed with dichloromethane (4× 5 mL). The aqueous layer was lyophilised 
to give afford amine 294 as a foam (15 mg, quant.) which was used without further 
purification. 
IR (ATR): ν = 3375, 1684, 1629 cm-1. 1H NMR (500 MHz, CD3OD): δ 7.56 (1H, d, J 
8.0 Hz, H-6), 5.75 (1H, d, J 2.2 Hz, H-1’), 5.69 (1H, d, J 8.0 Hz, H-5), 4.68-4.48 (1H, 
m, H-4’), 4.42 (1H, ddd, J 6.1, 3.6, 2.2 Hz, H-2’), 2.91 (1H, dd, J 13.6, 3.7 Hz, H-5’), 
2.83 (1H, dd, J 13.5, 5.9 Hz, H-5’), 2.34 (1H, ddd, J 14.1, 8.1, 6.2 Hz, H-3’), 1.81 
(1H, ddd, J 13.7, 4.8, 3.6 Hz, H-3’). LRMS [M+H+] 228.0. [!]!!" = -1.6o (c = 0.25 in 
CH3OH). These data are in agreement with those previously reported by Boojamra et 
al.[145b]  
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(((S)-1-(((2S,3S)-3-((S)-2-amino-3-(4-hydroxyphenyl)-N-methylpropanamido)-1-
((((2R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
hydroxytetrahydrofuran-2-yl)methyl)amino)-1-oxobutan-2-yl)amino)-4-methyl-
1-oxopentan-2-yl)carbamoyl)-L-tryptophan (232) 
 
Dipeptide 257 (92 mg, 136 µmol) was loaded onto 2-chlorotrityl chloride resin (63 
mg, 76 µmol) in CH2Cl2 (2 mL) using N,N-diisopropylethylamine (95 µL, 544 µmol) 
and Fmoc-deprotected according to general procedure H. Fmoc-L-Leu-OH (107 mg, 
304 µmol) was double coupled with PyBOP (158 mg, 304 µmol) and NMM (63 µL, 
608 µmol) in DMF (1.5 mL) (general procedure I). Carbamate 255 (80 mg, 152 µmol) 
was subsequently coupled in the presence of N,N-diisopropylethylamine (53 µL, 304 
µmol) in DMF (2.5 mL) according to general procedure J. Following cleavage from 
the resin (general procedure K), the peptide was purified by reverse phase HPLC (50-
100% MeCN over 40 min, 10 min at 50% MeCN) to afford depsipeptide 288 as a 
fluffy white solid (30 mg, 41%).  
To a solution of depsipeptide 288 (9.2 mg, 9.7 µmol) and amine 294 (2.0 mg, 8.8 
µmol) in DMF (97 µL) was added HATU (7.4 mg, 19 µmol), HOAt (2.6 mg, 19 
µmol) and 2,4,6-trimethylpyridine (2.3 µL, 18 µmol). The reaction was allowed to stir 
at room temperature for 1 h. At this point, the reaction was diluted with ethyl acetate 
(20 mL) and washed with water (5× 5 mL), brine (5 mL) and dried over anhydrous 
MgSO4. The solvent was removed in vacuo and the resulting residue was suspended 
in a mixture of TFA and iPr3SiH in CH2Cl2 (1:1 v/v TFA: CH2Cl2, 2.5 vol.% iPr3SiH, 
1.5 mL) and the reaction was allowed to stir at room temperature for 1.5 h. At this 
point, the solvent was removed in vacuo to give a crude residue that was purified by 
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reverse phase HPLC (0 to 50% MeCN over 40 min) to afford dihydrosansanmycin 
232 as a fluffy white solid (3.3 mg, 35% over two steps).  
IR (ATR): 3365, 1673 cm-1. 1H NMR (400 MHz, CD3OD, rotamers in 2.2:1 ratio, 
major rotamer): δ 7.64 (1H, d, J 8.1 Hz, H-6), 7.59 (1H, app. d, J 7.9 Hz, Ar-H), 
7.39-7.25 (1H, m, Ar-H), 7.19-7.05 (4H, m, Ar-H), 7.00 (1H, ddd, J 8.0, 7.1, 1.2 Hz, 
Ar-H), 6.93-6.67 (2H, m, Ar-H, H-2” + H-6”), 5.85-5.66 (2H, m, H-1’ + H-5), 4.62-
4.38 (3H, m, DABA1-α-CH + Tyr2-α-CH + Trp4-α-CH), 4.20-4.04 (2H, m, 
DABA1-β-CH + Leu3-α-CH), 3.56-3.42 (2H, m, H-5’ + Trp4-β-CH2), 3.29-3.11 (3H, 
m, H-5’ + Trp4-β-CH2 + Tyr2-β-CH2), 3.09-2.87 (1H, m, Tyr2-β-CH2), 2.79 (3H, s, 
NCH3), 2.41-2.19 (1H, m, H-3’), 1.75 (1H, app. dt, J 13.4, 5.0 Hz, H-3’), 1.70-1.57 
(1H, m, Leu3-γ-CH), 1.55-1.41 (2H, m, Leu3-β-CH2), 0.96-0.88 (6H, m, 2× Leu3-δ-
CH3), 0.83 (3H, d, J 6.6 Hz, DABA1-γ-CH3).  
1H NMR (400 MHz, CD3OD, minor rotamer): δ 7.59 (1H, app. d, J 7.9 Hz, Ar-H), 
7.43 (1H, d, J 8.0 Hz, H-6), 7.39-7.25 (1H, m, Ar-H), 7.19-7.05 (4H, m, Ar-H), 7.00 
(1H, ddd, J 8.0, 7.1, 1.2 Hz, Ar-H), 6.93-6.67 (2H, m, Ar-H, H-2” + H-6”), 5.85-5.66 
(1H, m, H-1’), 5.62 (1H, d, J 8.0 Hz, H-5), 4.85-4.80 (1H, m, DABA1-β-CH), 4.62-
4.38 (3H, m, DABA1-α-CH + Tyr2-α-CH + Trp4-α-CH), 4.20-4.04 (1H, m, Leu3-α-
CH), 3.56-3.42 (2H, m, H-5’ + Trp4-β-CH2), 3.29-3.11 (3H, m, H-5’ + Trp4-β-CH2 + 
Tyr2-β-CH2), 3.09-2.87 (1H, m, Tyr2-β-CH2), 2.79 (3H, s, NCH3), 2.41-2.19 (1H, m, 
H-3’), 1.75 (1H, app. dt, J 13.4, 5.0 Hz, H-3’), 1.70-1.57 (1H, m, Leu3-γ-CH), 1.55-
1.41 (2H, m, Leu3-β-CH2), 1.32-1.24 (3H, m, DABA1-γ-CH3), 0.96-0.88 (6H, m, 2× 
Leu3-δ-CH3). LRMS [M+H+] 848.4. These data are in agreement with those 
previously reported by Conroy.[152]  
 
 
 
 
Chapter 7-Experimental 
 
281 
 
 
 
 
(((S)-1-(((2S,3S)-3-((S)-2-amino-3-(3-hydroxyphenyl)-N-methylpropanamido)-1-
((((2R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
hydroxytetrahydrofuran-2-yl)methyl)amino)-1-oxobutan-2-yl)amino)-4-methyl-
1-oxopentan-2-yl)carbamoyl)-L-tryptophan (230) 
 
To a solution of depsipeptide 287 (14 mg, 14 µmol) and amine 294 (3.4 mg, 15 µmol) 
in DMF (140 µL) was added HATU (11 mg, 30 µmol), HOAt (4.1 mg, 30 µmol) and 
2,4,6-trimethylpyridine (3.6 µL, 27 µmol). The reaction was allowed to stir at room 
temperature for 1 h. At this point, the reaction was diluted with ethyl acetate (20 mL) 
and washed with water (5× 5 mL), brine (5 mL) and dried over anhydrous MgSO4. 
The solvent was removed in vacuo and the resulting residue was dissolved in a 
mixture of acetonitrile and water (9:1 v/v MeCN: H2O) and purified by reverse phase 
HPLC (70-100% MeCN over 30 min, 10 min at 70% MeCN) to afford protected 
dihydrosansanmycin 297 as a fluffy white solid (9.2 mg, 55%). 
Protected dihydrosansanmycin 297 (9.2 mg, 7.6 µmol) was treated with a mixture of 
TFA and iPr3SiH in CH2Cl2 (1:1 v/v TFA: CH2Cl2, 2.5 vol.% iPr3SiH, 1.5 mL) and 
the reaction was allowed to stir at room temperature for 6 h. At this point, the solvent 
was removed in vacuo to give a crude residue that was purified by reverse phase 
HPLC (0 to 50% MeCN over 40 min) to afford dihydrosansanmycin 230 (as TFA 
salt) as a fluffy white solid (1.4 mg, 20% over two steps).  
IR (ATR): 3257, 3063, 2956, 1650, 1587 cm-1. 1H NMR (400 MHz, CD3OD, rotamers 
in 1.8:1, major rotamer): δ 7.67-7.56 (2H, m, Ar-H + H-6), 7.29 (1H, app. d, J 7.7 
Hz, Ar-H), 7.17-7.10 (2H, m, Ar-H), 7.07-7.01 (1H, m, Ar-H), 6.97 (1H, app. t, J 7.6 
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Hz, Ar-H), 6.74 (1H, d, J 6.9 Hz, Ar-H), 6.73-6.61 (2H, m, Ar-H), 5.73 (1H, d, J 2.7 
Hz, H-1’), 5.71 (1H, d, J 8.1 Hz, H-5), 4.63-4.50 (1H, m), 4.53-4.32 (4H, m), 4.22-
4.13 (1H, m), 4.07-3.99 (1H, m), 3.57-3.42 (1H, m), 3.24-3.07 (2H, m), 3.00-2.83 
(3H, m), 2.74 (3H, s, NCH3), 2.33-2.15 (1H, m, H-3’), 1.73 (1H, app. dt, J 13.5, 4.9 
Hz, H-3’), 1.64-1.53 (1H, m), 1.51-1.42 (1H, m), 1.34-1.28 (1H, m), 0.86 (6H, m, 2× 
Leu3-δ-CH3), 0.75 (3H, d, J 6.5 Hz, DABA1-γ-CH3).  
1H NMR (400 MHz, CD3OD, minor rotamer): δ 7.67-7.56 (2H, m, Ar-H), 7.39 (1H, 
d, J 8.1 Hz, H-6), 7.17-7.10 (2H, m, Ar-H), 7.07-7.01 (1H, m, Ar-H), 6.97 (1H, app. t, 
J 7.6 Hz, Ar-H), 6.74 (1H, d, J 6.9 Hz, Ar-H), 6.73-6.61 (2H, m, Ar-H), 5.73 (1H, d, J 
2.7 Hz, H-1’), 5.71 (1H, d, J 8.1 Hz, H-5), 4.63-4.50 (1H, m), 4.53-4.32 (4H, m), 
4.22-4.13 (1H, m), 4.07-3.99 (1H, m), 3.57-3.42 (1H, m), 3.24-3.07 (2H, m), 3.00-
2.83 (3H, m), 2.74 (3H, s, NCH3), 2.33-2.15 (1H, m, H-3’), 1.73 (1H, app. dt, J 13.5, 
4.9 Hz, H-3’), 1.64-1.53 (1H, m), 1.51-1.42 (1H, m), 1.34-1.28 (1H, m), 0.86 (6H, m, 
2× Leu3-δ-CH3), 0.75 (3H, d, J 6.5 Hz, DABA1-γ-CH3). LRMS [M+H+] 848.5. These 
data are in agreement with those previously reported by Conroy.[152]  
 (((2S)-1-(((2S,3S)-3-((S)-2-amino-3-(3-hydroxyphenyl)-N-methylpropanamido)-
1-((((2R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
hydroxytetrahydrofuran-2-yl)methyl)amino)-1-oxobutan-2-yl)amino)-4-
(methylsulfinyl)-1-oxobutan-2-yl)carbamoyl)-L-tryptophan (231) 
 
Depsipeptide 286 (7.8 mg, 7.5 µmol) was reacted with amine 294 (2.1 mg, 9 µmol) in 
CH2Cl2: DMF (1:1 v/v, 75 µL) in the presence of HOAt (5.4 mg, 39 µmol) and DIC 
(1.2 µL) for 1.5 h at room temperature according to general procedure L to obtain the 
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fully protected dihydrosansanmycin analogue 299. This compound was treated with a 
mixture of TFA and iPr3SiH in CH2Cl2 (1:1 v/v TFA: CH2Cl2, 2.5 vol.% iPr3SiH,  
1 mL) according to general procedure L to afford dihydrosansanmycin 231 (as a 
formate salt) after reverse phase HPLC purification (0 to 50% MeCN over 40 min, 10 
min at 100% H2O) as an amorphous white solid (3.1 mg, 44% over 2 steps).  
IR (ATR): 3344, 1675, 1591 cm-1. 1H NMR (400 MHz, CD3OD, major rotamer): δ 
7.66-7.62 (2H, m, Ar-H + H-6), 7.30 (1H, app. d, J 8.0 Hz, Ar-H), 7.19-7.09 (2H, m, 
Ar-H), 7.05 (1H, app. t, J 7.5 Hz, Ar-H), 6.98 (1H, app. q, J 7.0 Hz, Ar-H), 6.80-6.60 
(3H, m, Ar-H), 5.78-5.67 (2H, m, H-1’ + H-5), 4.62-4.50 (4H, m), 4.51-4.38 (2H, m), 
4.23-4.07 (1H, m), 3.53-3.39 (1H, m), 3.21-3.05 (3H, m), 3.01-2.82 (2H, m), 2.73 
(3H, s, NCH3), 2.59-2.53 (5H, m, Met(O)3-γ-CH2 + S(O)CH3), 2.34-2.10 (2H, m), 
2.03-1.86 (1H, m), 1.79-1.68 (1H, m), 0.76 (3H, d, J 6.4 Hz, DABA1-γ-CH3). !
These data are in agreement with those previously reported by Conroy.[152]  
(((S)-1-(((2S,3S)-3-((S)-2-amino-3-(3-hydroxyphenyl)-N-methylpropanamido)-1-
((((2R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
hydroxytetrahydrofuran-2-yl)methyl)amino)-1-oxobutan-2-yl)amino)-4-
(methylthio)-1-oxobutan-2-yl)carbamoyl)-L-tryptophan (229) 
 
Depsipeptide 286 (7.8 mg, 7.5 µmol) was reacted with amine 294 (2.1 mg, 9 µmol) in 
CH2Cl2: DMF (1:1 v/v, 75 µL) in the presence of HOAt (5.4 mg, 39 µmol) and DIC 
(1.2 µL) for 1.5 h at room temperature according to general procedure L to obtain the 
fully protected dihydrosansanmycin analogue 299.  This compound was suspended in 
a mixture of TFA and water (9:1 v/v TFA: H2O, 3 mL) and the reaction was cooled to  
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0 oC. Dimethyl sulfide (11 µL, 150 µmol) and ammonium iodide (22 mg, 150 µmol) 
were then added and the reaction was stirred at 0 oC for 30 min. At this point, the 
solvent was removed under a stream of nitrogen to give a crude residue that was 
purified by reverse phase HPLC (0 to 50% MeCN over 40 min, 10 min at 100% H2O) 
to afford dihydrosansanmycin 229 (as a formate salt) as an off-white amorphous solid 
(1.6 mg, 23% over two steps).  
IR (ATR): 3334, 2967, 1688, 1603 cm-1. 1H NMR (600 MHz, CD3OD, major 
rotamer): δ 7.65-7.62 (2H, m, Ar-H + H-6), 7.29 (1H, app. d, J 7.9 Hz, Ar-H), 7.17-
7.08 (2H, m), 7.04 (1H, app. t, J 7.5 Hz, Ar-H), 7.01-6.93 (1H, m), 6.76-6.62 (3H, m, 
Ar-H), 5.74 (1H, d, J 2.7 Hz, H-1’), 5.72 (1H, d, J 8.0 Hz, H-5), 4.65-4.52 (3H, m), 
4.51-4.32 (3H, m), 4.25-4.06 (1H, m), 3.51-3.46 (1H, m), 3.43-3.41 (1H, m), 3.25 
(1H, dd, J 14.0, 7.7 Hz), 3.20-3.15 (1H, m), 2.95-2.89 (1H, m), 2.88-2.81 (1H, m), 
2.73 (3H, s, NCH3), 2.50-2.35 (2H, m), 2.26-2.18 (1H, m, H-3’), 2.02 (3H, SCH3), 
1.98-1.90 (1H, m), 1.89-1.76 (1H, m), 1.73 (1H, app. dt, J 13.5, 4.9 Hz, H-3’), 0.73 
(3H, d, J 6.4 Hz, DABA1-γ-CH3). These data are in agreement with those previously 
reported by Conroy.[152]  
(((S)-1-(((2S,3S)-3-(2-amino-N-methylacetamido)-1-((((2R,4R,5R)-5-(2,4-dioxo-
3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxytetrahydrofuran-2-yl)methyl)amino)-
1-oxobutan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamoyl)-L-tryptophan 
(250) 
 
Dipeptide 258 (77 mg, 139 µmol) was loaded onto 2-chlorotrityl chloride resin (58 
mg, 70 µmol) in CH2Cl2 (1 mL) using N,N-diisopropylethylamine (49 µL, 280 µmol) 
and Fmoc-deprotected according to general procedure H. Fmoc-L-Leu-OH (98 mg, 
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280 µmol) was subsequently coupled using standard Fmoc-SPPS procedure with 
PyBOP (145 mg, 280 µmol) and NMM (57 µL, 560 µmol) in DMF (1.1 mL) (general 
procedure I). Carbamate 255 (74 mg, 140 µmol) was subsequently coupled according 
to general procedure J. Following cleavage from the resin (general procedure K), the 
peptide was purified by reverse phase HPLC (50-100% MeCN over 40 min, 10 min at 
50% MeCN) to afford depsipeptide 289 as a fluffy white solid (14.5 mg, 27%).  
Depsipeptide 289 (14.5 mg, 18 µmol) was reacted with amine 294 (5.0 mg, 22 µmol) 
in CH2Cl2: DMF (1:1 v/v, 180 µL) in the presence of HOAt (13 mg, 95 µmol) and 
DIC (2.8 µL) for 1.5 h at room temperature according to general procedure L to 
obtain fully protected dihydrosansanmycin analogue 296.  This compound was treated 
with a mixture of TFA and iPr3SiH in CH2Cl2 (1:1 v/v TFA: CH2Cl2, 2.5 vol.% 
iPr3SiH, 1.5 mL) according to general procedure L to afford dihydrosansanmycin 250 
(as formate salt) after reverse phase HPLC purification (0 to 50% MeCN over 40 min, 
10 min at 100% H2O) as a fluffy white solid (10 mg, 69% over 2 steps).  
IR (ATR): 3300, 2923, 1688, 1548 cm-1.  1H NMR (500 MHz, D2O: CD3OD, 2:1 v/v, 
rotamers in 1:1 ratio, rotamer 1): δ 7.68-7.60 (1H, m, Ar-H), 7.58 (1H, d, J 8.1 Hz, H-
6), 7.33 (1H, app. t, J 7.7 Hz), 7.16 (1H, s, Ar-H), 7.10-7.04 (1H, m, Ar-H), 7.02 (1H, 
dd, J 7.6, 4.1 Hz, Ar-H), 5.76 (1H, d, J 8.0 Hz, H-5), 5.72 (1H, d, J 2.8 Hz, H-1’), 
4.78-4.74 (1H, m, DABA1-β-CH), 4.58-4.53 (2H, m, H-4’ + DABA1-α-CH), 4.48-
4.26 (2H, m, H-2’ + Trp4-α-CH), 4.19-3.99 (2H, m, Gly2-α-CH2, Leu3-α-CH), 3.91 
(1H, d, J 16.2 Hz, Gly2-α-CH2), 3.45-3.33 (2H, m, H-5’), 3.33-3.28 (1H, m, Trp4-β-
CH2), 3.14 (1H, dd, J 14.5, 7.1 Hz, Trp4-β-CH2), 2.86 (3H, s, NCH3), 2.36-2.12 (1H, 
m, H-3’), 1.88-1.68 (1H, m, H-3’), 1.61-1.39 (3H, m, Leu3-β-CH2 + Leu3-γ-CH), 
1.30-1.07 (3H, m, DABA1-γ-CH3), 0.90-0.75 (6H, m, 2× Leu3-δ-CH3). 13C NMR 
(125 MHz, D2O: CD3OD, 2:1 v/v, mixture of rotamers with 1:1 ratio, rotamer 1): δ 
176.4 (C=O), 171.8 (C=O), 169.9 (C=O), 167.6 (C=O), 166.6 (C=O), 159.8 (C=O), 
152.4 (C=O), 142.9, 137.8, 129.1, 124.7, 122.3, 119.8, 119.7, 112.3, 111.9, 102.7, 
95.1, 80.9, 76.3, 57.2, 56.8, 54.3, 53.2, 44.9, 41.7, 41.3, 35.9, 29.6, 28.4, 25.7, 23.4, 
22.2, 15.1.  
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1H NMR (500 MHz, D2O: CD3OD, 2:1 v/v, rotamers in 1:1 ratio, rotamer 2): δ 7.68-
7.60 (1H, m, Ar-H), 7.49 (1H, d, J 8.0 Hz, H-6), 7.33 (1H, app. t, J 7.7 Hz), 7.12 (1H, 
s, Ar-H), 7.10-7.04 (1H, m, Ar-H), 7.02 (1H, dd, J 7.6, 4.1 Hz, Ar-H), 5.72 (1H, d, J 
2.8 Hz, H-1’), 5.70 (1H, d, J 8.1 Hz, H-5), 4.62-4.58 (1H, m, DABA1-α-CH), 4.48-
4.26 (3H, m, H-2’ + H-4’ + Trp4-α-CH), 4.19-3.99 (1H, m, DABA1-β-CH + Leu3-α-
CH), 3.84-3.70 (2H, m, Gly2-α-CH2), 3.57-3.41 (1H, m, H-5’), 3.33-3.28 (1H, m, 
Trp4-β-CH2), 3.28-3.19 (1H, m, H-5’), 3.14 (1H, dd, J 14.5, 7.1 Hz, Trp4-β-CH2), 
2.75 (3H, s, NCH3), 2.36-2.12 (1H, m, H-3’), 1.88-1.68 (1H, m, H-3’), 1.61-1.39 (3H, 
m, Leu3-β-CH2 + Leu3-γ-CH), 1.30-1.07 (3H, m, DABA1-γ-CH3), 0.90-0.75 (6H, m, 
2× Leu3-δ-CH3). 13C NMR (125 MHz, D2O: CD3OD, 2:1 v/v, mixture of rotamers 
with 1:1 ratio, rotamer 2): δ 176.0 (C=O), 171.8 (C=O), 169.9 (C=O), 167.6 (C=O), 
166.5 (C=O), 159.8 (C=O), 152.3 (C=O), 142.6, 137.8, 129.1, 124.7, 122.2, 119.7, 
119.6, 111.7, 112.2, 102.6, 95.0, 81.1, 76.2, 57.2, 56.8, 54.5, 54.0, 45.0, 42.7, 41.5, 
36.2, 30.6, 29.6, 25.7, 23.5, 23.3, 15.1. LRMS [M+H+] 742.5. HRMS (ESI) m/z cald 
for C34H48N9O10 [M+H+]: 742.3518, found 742.3519. 
(((2S)-1-(((2S,3S)-3-(2,5-diamino-N-methylpentanamido)-1-((((2R,4R,5R)-5-(2,4-
dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxytetrahydrofuran-2-
yl)methyl)amino)-1-oxobutan-2-yl)amino)-4-methyl-1-oxopentan-2-
yl)carbamoyl)-L-tryptophan (251) 
 
Dipeptide 259 (133 mg, 195 µmol) was loaded onto 2-chlorotrityl chloride resin (80 
mg, 98 µmol) in CH2Cl2 (3 mL) using N,N-diisopropylethylamine (68 µL, 390 µmol) 
and Fmoc-deprotected according to general procedure H. Fmoc-L-Leu-OH (137 mg, 
392 µmol) was subsequently coupled with PyBOP (203 mg, 392 µmol) and NMM (80 
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µL, 784 µmol) in DMF (0.95 mL) (general procedure I). Carbamate 255 (104 mg, 195 
µmol) was subsequently coupled in the presence of N,N-diisopropylethylamine (70 
µL, 390 µmol) in DMF (3.3 mL) according to general procedure J. Following 
cleavage from the resin (general procedure K), the peptide was purified by reverse 
phase HPLC (50-100% MeCN over 40 min, 10 min at 50% MeCN) to afford 
depsipeptide 290 as a fluffy white solid (15.2 mg, 17%).  
Depsipeptide 290 (15.2 mg, 16 µmol) was reacted with amine 294 (4.4 mg, 19 µmol) 
in CH2Cl2: DMF (1:1 v/v, 160 µL) in the presence of HOAt (12 mg, 88 µmol) and 
DIC (2.5 µL) for 1.5 h at room temperature according to general procedure L to 
obtain fully protected dihydrosansanmycin analogue 300. This compound was treated 
with a mixture of TFA and iPr3SiH in CH2Cl2 (1:1 v/v TFA: CH2Cl2, 2.5 vol.% 
iPr3SiH, 1.5 mL) according to general procedure L to afford dihydrosansanmycin 251 
(as a formate salt) after reverse phase HPLC purification (0 to 50% MeCN over 40 
min, 10 min at 100% H2O) as an amorphous white solid (9.2 mg, 65% over 2 steps).  
IR (ATR): 3292, 1572 cm-1. 1H NMR (400 MHz, D2O, rotamers in 1.5:1 ratio, 
rotamer 1): δ 7.71 (1H, dd, J 8.0, 4.5 Hz, Ar-H), 7.53-7.48 (2H, m, H-6 + Ar-H), 
7.29-7.23 (2H, m, Ar-H), 7.19 (1H, app. t, J 7.4 Hz, Ar-H), 5.79 (1H, d, J 8.0 Hz,  
H-5), 5.75 (1H, d, J 2.4 Hz, H-1’), 4.89-4.85 (1H, m, DABA1-β-CH), 4.66-4.60 (1H, 
m, DABA1-α-CH), 4.60-4.49 (2H, m, H-2’ + H-4’), 4.41-4.33 (2H, m, Ornithine2-α-
CH + Trp4-α-CH), 4.16-4.02 (1H, m, Leu3-α-CH), 3.49 (1H, dd, J 14.4, 6.7 Hz, H-
5’), 3.43-3.36 (1H, m, H-5’), 3.35-3.27 (1H, m, Trp4-β-CH2), 3.16-3.09 (1H, m, 
Trp4-β-CH2), 3.08-3.03 (1H, m, Ornithine2-δ-CH2), 2.98 (1H, app. t, J 7.0 Hz, 
Ornithine2-δ-CH2), 2.90 (3H, s, NCH3), 2.35 (1H, app. dt, J 13.8, 7.0 Hz, H-3’), 1.96-
1.68 (5H, m, H-3’ + Ornithine2-β-CH2 + Ornithine2-γ-CH2), 1.56-1.40 (3H, m, Leu3-
β-CH2 + Leu3-γ-CH), 1.23 (3H, d, J 6.8 Hz, DABA1-γ-CH3), 0.84 (6H, d, J 16.1 Hz, 
2× Leu3-δ-CH3). 13C NMR (101 MHz, D2O, rotamers in 1.5:1 ratio, rotamer 1): δ 
176.3 (C=O), 170.8 (C=O), 169.3 (C=O), 166.4 (C=O), 166.2 (C=O), 158.8 (C=O), 
151.3 (C=O), 141.6, 136.1, 127.2, 124.2, 121.7, 119.2, 118.7, 111.7, 110.4, 101.8, 
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93.0, 79.6, 74.8, 56.4, 55.6, 53.0, 51.3, 50.4, 43.2, 39.9, 38.7, 34.4, 28.2. 28.1, 26.6, 
21.9, 24.2, 20.7, 12.5.  
1H NMR (400 MHz, D2O, rotamers in 1.5:1 ratio, rotamer 2): δ 7.71 (1H, dd, J 8.0, 
4.5 Hz, Ar-H), 7.56 (1H, d, J 8.0 Hz, H-6), 7.29-7.53-7.48 (1H, m, Ar-H), 7.23 (2H, 
m, Ar-H), 7.19 (1H, app. t, J 7.4 Hz, Ar-H), 5.85 (1H, d, J 8.0 Hz, H-5), 5.75 (1H, d, 
J 2.4 Hz, H-1’), 4.68 (1H, m, Ornithine2-α-CH), 4.66-4.60 (1H, m, DABA1-α-CH), 
4.60-4.49 (2H, m, H-2’ + H-4’), 4.41-4.33 (1H, m, Trp4-α-CH), 4.31-4.22 (1H, m, 
DABA1-β-CH), 4.16-4.02 (1H, m, Leu3-α-CH), 3.49 (1H, dd, J 14.4, 6.7 Hz, H-5’), 
3.43-3.36 (1H, m, H-5’), 3.35-3.27 (1H, m, Trp4-β-CH2), 3.16-3.09 (1H, m, Trp4-β-
CH2), 3.08-3.03 (1H, m, Ornithine2-δ-CH2), 2.98 (1H, app. t, J 7.0 Hz, Ornithine2-δ-
CH2), 2.90 (3H, s, NCH3), 2.35 (1H, app. dt, J 13.8, 7.0 Hz, H-3’), 1.96-1.68 (5H, m, 
H-3’ + Ornithine2-β-CH2 + Ornithine2-γ-CH2), 1.56-1.40 (3H, m, Leu3-β-CH2 + 
Leu3-γ-CH), 1.23 (3H, d, J 6.8 Hz, DABA1-γ-CH3), 0.84 (6H, d, J 16.1 Hz, 2× Leu3-
δ-CH3). 13C NMR (101 MHz, D2O, rotamers in 1.5:1 ratio, rotamer 2): δ 175.9 
(C=O), 170.6 (C=O), 169.3 (C=O), 166.4 (C=O), 166.2 (C=O), 158.8 (C=O), 151.3 
(C=O), 141.6, 136.1, 127.2, 124.2, 121.7, 119.2, 118.7, 111.7, 110.4, 101.8, 93.3, 
79.8, 74.8, 56.4, 55.6, 53.0, 51.3, 50.6, 43.2, 39.9, 38.7, 34.4, 30.2, 28.1, 27.4, 24.2, 
21.9, 20.9, 14.1. LRMS [M+H+] 799.5. HRMS (ESI) m/z cald for C37H55N10O10 
[M+H+]: 799.4097, found 799.4102. 
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(((S)-1-(((2S,3S)-3-((S)-2,6-diamino-N-methylhexanamido)-1-((((2R,4R,5R)-5-
(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxytetrahydrofuran-2-
yl)methyl)amino)-1-oxobutan-2-yl)amino)-4-methyl-1-oxopentan-2-
yl)carbamoyl)-L-tryptophan (252) 
 
Depsipeptide 291 (18.6 mg, 19 µmol) was reacted with amine 294 (5.3 mg, 23 µmol) 
in CH2Cl2: DMF (1:1 v/v, 190 µL) in the presence of HOAt (14 mg, 100 µmol) and 
DIC (3.0 µL) for 1.5 h at room temperature according to general procedure L to 
obtain fully protected dihydrosansanmycin analogue 301. This compound was treated 
with a mixture of TFA and iPr3SiH in CH2Cl2 (1:1 v/v TFA: CH2Cl2, 2.5 vol.% 
iPr3SiH, 1.5 mL) according to general procedure L to afford dihydrosansanmycin 252 
(as a formate salt) after reverse phase HPLC purification (0 to 50% MeCN over 40 
min, 10 min at 100% H2O) as an amorphous white solid (6.8 mg, 39% over 2 steps).  
IR (ATR): 3325, 3063, 2961, 1673 cm-1. 1H NMR (500 MHz, D2O: CD3OD, 9:1 v/v, 
rotamers in 2:1 ratio, major rotamer): δ 7.70 (1H, app. t, J 5.9 Hz, Ar-H), 7.52-7.48 
(2H, m, H-6 + Ar-H), 7.31-7.20 (2H, m, Ar-H), 7.17 (1H, app. td, J 7.3, 1.5 Hz, Ar-
H), 5.78 (1H, d, J 8.1 Hz, H-5), 5.74 (1H, d, J 2.9 Hz, H-1’), 4.92-4.83 (1H, m, 
DABA1-β-CH), 4.75-4.67 (1H, m, Lys2-α-CH), 4.64-4.47 (3H, m, H-2’ + H-4’ + 
DABA1-α-CH), 4.37 (1H, app. t, J 6.8 Hz, Trp4-α-CH), 4.13-4.04 (1H, m, Leu3-α-
CH), 3.48 (1H, app. dt, J 13.8, 6.8 Hz, H-5’), 3.41-3.25 (2H, m, H-5’ + Trp4-β-CH2), 
3.10 (1H, dd, J 14.7, 7.8 Hz, Trp4-β-CH2), 3.02 (1H, app. t, J 7.7 Hz, Lys2-ε-CH2), 
2.95 (1H, app. t, J 7.8 Hz, Lys2-ε-CH2), 2.89 (3H, s, NCH3), 2.34 (1H, dd, J 13.8, 6.8 
Hz, H-3’), 1.90-1.56 (5H, m, H-3’ + Lys2-β-CH2 + Lys2-δ-CH2), 1.56-1.31 (5H, 
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Lys2-γ-CH2 + Leu3-β-CH2 + Leu3-γ-CH), 1.22 (3H, d, J 7.1 Hz, DABA1-γ-CH3), 
0.84 (6H, d, J 19.4 Hz, 2× Leu3-δ-CH3). 13C NMR (125 MHz, D2O, rotamers in 2:1 
ratio, major rotamer): δ 176.3 (C=O), 170.9 (C=O), 169.8 (C=O), 166.5 (C=O), 166.4 
(C=O), 158.9 (C=O), 151.5 (C=O), 141.7 (C-6), 136.2, 127.4, 124.2 (Trp-CH), 121.9 
(Trp-CH), 119.2, 118.9, 111.9, 110.6, 102.0, 93.2, 79.9, 74.9, 56.2, 55.7, 53.0, 51.2, 
51.1, 43.4, 39.9, 39.1, 34.5, 30.3, 29.9, 29.4, 26.6, 22.1, 21.1, 21.0, 12.6.  
1H NMR (500 MHz, D2O: CD3OD, 9:1 v/v, rotamers in 2:1 ratio, minor rotamer): δ 
7.70 (1H, app. t, J 5.9 Hz, Ar-H), 7.55 (1H, d, J 8.1 Hz, H-6), 7.52-7.48 (1H, m, Ar-
H), 7.31-7.20 (2H, m, Ar-H), 7.17 (1H, app. td, J 7.3, 1.5 Hz, Ar-H), 5.84 (1H, d, J 
8.2 Hz, H-5), 5.74 (1H, d, J 2.9 Hz, H-1’), 4.75-4.67 (1H, m, Lys2-α-CH), 4.64-4.47 
(3H, m, H-2’ + H-4’ + DABA1-α-CH), 4.37 (1H, app. t, J 6.8 Hz, Trp4-α-CH), 4.29-
4.21 (1H, m, DABA1-β-CH), 4.13-4.04 (1H, m, Leu3-α-CH), 3.48 (1H, app. dt, J 
13.8, 6.8 Hz, H-5’), 3.41-3.25 (2H, m, H-5’ + Trp4-β-CH2), 3.10 (1H, dd, J 14.7, 7.8 
Hz, Trp4-β-CH2), 3.02 (1H, app. t, J 7.7 Hz, Lys2-ε-CH2), 2.95 (1H, app. t, J 7.8 Hz, 
Lys2-ε-CH2), 2.87 (3H, s, NCH3), 2.34 (1H, dd, J 13.8, 6.8 Hz, H-3’), 1.90-1.56 (5H, 
m, H-3’ + Lys2-β-CH2 + Lys2-δ-CH2), 1.56-1.31 (5H, Lys2-γ-CH2 + Leu3-β-CH2 + 
Leu3-γ-CH), 1.17 (3H, d, J 6.6 Hz, DABA1-γ-CH3), 0.84 (6H, d, J 19.4 Hz, 2× Leu3-
δ-CH3). 13C NMR (125 MHz, D2O, rotamers in 2:1 ratio, minor rotamer): δ 176.3 
(C=O), 170.8 (C=O), 169.8 (C=O), 166.5 (C=O), 166.4 (C=O), 158.9 (C=O), 151.5 
(C=O), 141.9 (C-6), 136.2, 127.4, 124.2, 121.8, 119.3, 118.9, 111.9, 110.5, 101.9, 
93.5, 79.8, 74.9, 56.2, 55.7, 53.1, 51.1, 50.9, 43.3, 39.9, 39.1, 34.5, 29.9, 29.4, 28.2, 
26.5, 22.2, 21.1, 20.9, 14.1. LRMS [M+H+] 813.5. HRMS (ESI) m/z cald for 
C38H57N10O10 [M+H+]: 813.4254, found 813.4258. 
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(2S,6S,9S,10S,13S)-2-((1H-indol-3-yl)methyl)-13-amino-9-((((2R,4R,5R)-5-(2,4-
dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxytetrahydrofuran-2-
yl)methyl)carbamoyl)-6-isobutyl-10,11-dimethyl-4,7,12-trioxo-3,5,8,11-
tetraazapentadecanedioic acid (253) 
 
Depsipeptide 292 (19 mg, 21 µmol) was reacted with amine 294 (5.5 mg, 25 µmol) in 
CH2Cl2: DMF (1:1 v/v, 200 µL) in the presence of HOAt (15 mg, 110 µmol) and DIC 
(3.3 µL) for 1.5 h at room temperature according to general procedure L to obtain 
fully protected dihydrosansanmycin analogue 298.  This compound was treated with a 
mixture of TFA and iPr3SiH in CH2Cl2 (1:1 v/v TFA: CH2Cl2, 2.5 vol.% iPr3SiH, 1.8 
mL) according to general procedure L to afford dihydrosansanmycin 253 (as a 
formate salt) after reverse phase HPLC purification (0 to 50% MeCN over 40 min, 10 
min at 100% H2O) as a fluffy white solid (6.5 mg, 37% over 2 steps).  
IR (ATR): 3675, 2957, 1675, 1587 cm-1. 1H NMR (600 MHz, D2O, rotamers in 2:1 
ratio, major rotamer): δ 7.67 (1H, app. d, J 8.4 Hz, Ar-H), 7.57-7.38 (2H, m, H-6 + 
Ar-H), 7.29-7.19 (2H, m, Ar-H), 7.16 (1H, app. dt, J 8.1, 5.6 Hz, Ar-H), 5.76 (1H, d, 
J 8.6 Hz, H-5), 5.72-5.70 (1H, m, H-1’), 4.86-4.83 (1H, m, DABA1-β-CH), 4.59 (1H, 
d, J 9.0 Hz, DABA1-α-CH), 4.57-4.52 (1H, m, H-4’), 4.50-4.41 (3H, m, H-2’ + 
Asp2-α-CH + Trp4-α-CH), 4.15-4.05 (1H, m, Leu3-α-CH), 3.52 (1H, dd, J 14.7, 6.7 
Hz, H-5’), 3.38-3.35 (1H, m, H-5’), 3.31-3.28 (1H, m, Trp4-β-CH2), 3.15 (1H, td, J 
16.1, 7.5 Hz, Trp4-β-CH2), 2.81 (3H, s, NCH3), 2.60-2.57 (1H, m, Asp2-β-CH2), 2.51 
(1H, dd, J 17.6, 10.8 Hz, Asp2-β-CH2), 2.33-2.24 (1H, m, H-3’), 1.87-1.65 (1H, m, 
H-3’), 1.59-1.40 (3H, m, Leu3-β-CH2+ Leu3-γ-CH), 1.15 (3H, d, J 6.9 Hz, DABA1-
γ-CH3), 0.86 (6H, d, J 7.2 Hz, 2× Leu3-δ-CH3). 13C NMR (150 MHz, D2O, rotamers 
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in 2:1 ratio, major rotamer): δ 178.1 (C=O), 176.0 (C=O), 175.0 (C=O), 170.6 (C=O), 
169.1 (C=O), 166.0 (C=O), 158.7 (C=O), 151.2 (C=O), 141.6, 136.0, 126.8, 124.3, 
121.7, 118.9, 118.4, 111.6, 109.9, 101.9, 92.9, 79.8, 74.8, 55.5, 55.3, 55.2, 51.1, 43.0, 
40.0, 35.2, 34.3, 29.7, 27.8, 24.2, 22.0, 20.8, 12.6.  
1H NMR (600 MHz, D2O, rotamers in 2:1 ratio, minor rotamer): δ 7.67 (1H, app. d, J 
8.4 Hz, Ar-H), 7.57-7.38 (2H, m, H-6 + Ar-H), 7.29-7.19 (2H, m, Ar-H), 7.16 (1H, dt, 
J 8.1, 5.6 Hz, Ar-H), 5.80 (1H, d, J 8.7 Hz, H-5), 5.72-5.70 (1H, m, H-1’), 4.63 (1H, 
d, J 10.2 Hz, DABA1-α-CH), 4.57-4.52 (1H, m, H-4’), 4.50-4.41 (3H, m, H-2’ + 
Asp2-α-CH + Trp4-α-CH), 4.25 (1H, dt, J 10.1, 6.7 Hz, DABA1-β-CH), 4.15-4.05 
(1H, m, Leu3-α-CH), 3.44 (1H, dd, J 15.0, 6.6 Hz, H-5’), 3.35-3.33 (1H, m, H-5’), 
3.31-3.28 (1H, m, Trp4-β-CH2), 3.15 (1H, td, J 16.1, 15.2, 7.5 Hz, Trp4-β-CH2), 2.87 
(3H, s, NCH3), 2.73-2.67 (1H, m, Asp2-β-CH2), 2.66-2.60 (1H, m, Asp2-β-CH2), 
2.33-2.24 (1H, m, H-3’), 1.87-1.65 (1H, m, H-3’), 1.59-1.40 (3H, m, Leu3-β-CH2+ 
Leu3-γ-CH), 1.25 (3H, d, J 6.8 Hz, DABA1-γ-CH3), 0.84-0.80 (6H, m, 2× Leu3-δ-
CH3). 13C NMR (150 MHz, D2O, rotamers in 2:1 ratio, minor rotamer): δ 178.0 
(C=O), 176.0 (C=O), 175.0 (C=O), 170.6 (C=O), 169.1 (C=O), 166.0 (C=O), 158.7 
(C=O), 151.2 (C=O), 141.6, 136.0, 126.8, 124.1, 121.7, 118.9, 118.4, 111.6, 109.9, 
101.9, 92.9, 79.6, 74.8, 55.5, 55.3, 55.2, 52.7, 43.0, 40.0, 36.2, 34.3, 28.6, 27.8, 24.2, 
22.0, 20.8, 13.6. LRMS [M+H+] 800.5. HRMS (ESI) m/z cald for C36H49N9O12Na 
[M+Na+]: 822.3400, found 822.3402. 
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(((S)-1-(((2S,3S)-3-((2S,3R)-2-amino-3-hydroxy-N-methylbutanamido)-1-
((((2R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
hydroxytetrahydrofuran-2-yl)methyl)amino)-1-oxobutan-2-yl)amino)-4-methyl-
1-oxopentan-2-yl)carbamoyl)-L-tryptophan (254) 
 
Depsipeptide 293 (11 mg, 13 µmol) was reacted with amine 294 (3.6 mg, 15 µmol) in 
CH2Cl2: DMF (1:1 v/v, 120 µL) in the presence of HOAt (8.6 mg, 66 µmol) and DIC 
(2.0 µL) for 1.5 h at room temperature according to general procedure L to obtain 
fully protected dihydrosansanmycin analogue 302.  This compound was treated with a 
mixture of TFA and iPr3SiH in CH2Cl2 (1:1 v/v TFA: CH2Cl2, 2.5 vol.% iPr3SiH,  
2 mL) according to general procedure L to afford dihydrosansanmycin 254 (as a 
formate salt) after reverse phase HPLC purification (0 to 50% MeCN over 40 min, 10 
min at 100% H2O) as a fluffy white solid (5.5 mg, 52% over 2 steps).  
IR (ATR): 3296, 2954, 2928, 1679, 1589 cm-1. 1H NMR (400 MHz, D2O: CD3OD, 
4:1 v/v, rotamers in 1:1 ratio, rotamer 1): δ 7.64 (1H, app. d, J 7.9 Hz, Ar-H), 7.45-
7.43 (2H, m, H-6 + Ar-H), 7.23-7.15 (2H, m, Ar-H), 7.11 (1H, app. t, J 7.5 Hz, Ar-
H), 5.72 (1H, d, J 8.0 Hz, H-5), 5.68 (1H, d, J 3.0 Hz, H-1’), 4.84-4.81 (1H, m, 
DABA1-β-CH), 4.62-4.54 (1H, m, DABA1-α-CH), 4.52-4.40 (2H, m, H-2’ + H-4’), 
4.38-4.27 (1H, m, Trp4-α-CH), 4.20-4.16 (1H, m, Thr2-α-CH), 4.09-4.01 (2H, m, 
Thr2-β-CH + Leu3-α-CH), 3.45 (1H, dd, J 14.2, 6.7 Hz, H-5’), 3.36 (1H, m, H-5’), 
3.25-3.20 (1H, m, Trp4-β-CH2), 3.08 (1H, dd, J 14.7, 7.4 Hz, Trp4-β-CH2), 2.89 (3H, 
s, NCH3), 2.39-2.15 (1H, m, H-3’), 1.85-1.62 (1H, m, H-3’), 1.51-1.35 (2H, m, Leu3-
β-CH2), 1.29 (3H, d, J 7.2 Hz, Thr2-γ-CH3), 1.24-1.18 (4H, m, DABA1-γ-CH3 + 
Leu3-γ-CH), 0.86-0.73 (6H, m, 2× Leu3-δ-CH3). 13C NMR (101 MHz, D2O: CD3OD, 
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4:1 v/v, rotamers in 1:1 ratio, rotamer 1): δ 175.8 (C=O), 170.7 (C=O), 168.2 (C=O), 
166.2 (C=O), 166.1 (C=O), 158.6 (C=O), 153.9 (C=O), 141.7, 136.1, 127.2, 124.0, 
121.6, 119.0, 118.6, 111.6, 110.2, 101.7, 93.3, 79.7, 74.8, 65.6, 56.1, 55.8, 53.0, 52.9, 
51.3, 43.2, 40.0, 34.4, 28.0, 24.2, 21.9, 20.9, 18.6, 13.9.  
1H NMR (400 MHz, D2O: CD3OD, 4:1 v/v, rotamers in 1:1 ratio, rotamer 2): δ 7.64 
(1H, app. d, J 7.9 Hz, Ar-H), 7.51 (1H, d, J 8.0 Hz, H-6), 7.45-7.43 (1H, m, Ar-H), 
7.23-7.15 (2H, m, Ar-H), 7.11 (1H, t, J 7.5 Hz, Ar-H), 5.78 (1H, d, J 8.0 Hz, H-5), 
5.68 (1H, d, J 3.0 Hz, H-1’), 4.62-4.54 (1H, m, DABA1-α-CH), 4.52-4.40 (2H, m, H-
2’ + H-4’), 4.38-4.27 (2H, m, DABA1-β-CH + Trp4-α-CH), 4.20-4.16 (1H, m, Thr2-
α-CH), 4.09-4.01 (2H, m, Thr2-β-CH + Leu3-α-CH), 3.45 (1H, dd, J 14.2, 6.7 Hz, H-
5’), 3.36 (1H, m, H-5’), 3.25-3.20 (1H, m, Trp4-β-CH2), 3.08 (1H, dd, J 14.7, 7.4 Hz, 
Trp4-β-CH2), 2.84 (3H, s, NCH3), 2.39-2.15 (1H, m, H-3’), 1.85-1.62 (1H, m, H-3’), 
1.51-1.35 (2H, m, Leu3-β-CH2), 1.29 (3H, d, J 7.2 Hz, Thr2-γ-CH3), 1.24-1.18 (1H, 
m, Leu3-γ-CH), 1.15 (3H, d, J 7.0 Hz, DABA1-γ-CH3), 0.86-0.73 (6H, m, 2× Leu3-δ-
CH3). 13C NMR (101 MHz, D2O: CD3OD, 4:1 v/v, rotamers in 1:1 ratio, rotamer 1): δ 
175.8 (C=O), 170.5 (C=O), 168.2 (C=O), 166.2 (C=O), 166.1 (C=O), 158.6 (C=O), 
153.9 (C=O), 141.5, 136.1, 127.2, 124.0, 121.6, 119.0, 118.6, 111.6, 110.2, 101.7, 
93.0, 79.5, 74.8, 65.6, 56.1, 55.8, 53.0, 52.9, 51.3, 43.2, 40.0, 34.4, 28.0, 24.2, 21.9, 
20.7, 18.6, 12.6. LRMS [M+H+] 786.5. HRMS (ESI) m/z cald for C36H52N9O11 
[M+H+]: 786.3781, found 786.3782. 
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A1. Appendices for chapter 3  
A1.1 Purification of Type II DHQases 
      (Conducted by Dr. Adrian Lapthorn, University of Glasgow, UK) 
The H. pylori and S. coelicolor aroQ genes have been previously cloned into pET-15b 
vectors to facilitate purification and the M. tuberculosis aroD gene cloned into  
pET-28a was a gift from Prof. Chris Abell, University of Cambridge. Plasmids were 
transformed into BL21(DE3) competent cells and incubated overnight at 37° C on LB 
agar plates containing the appropriate concentration of the selection antibiotic 
(100µg/ml Ampicillin for pET-15b vectors and 30µg/ml kanamycin for the pET-28a 
vector). Single bacterial colonies were picked and inoculated into 500mL of 
autoinduction media[1] containing selection antibiotic and incubated at 37°C in a 
shaking incubator for a minimum of 24 hours.  The cells were harvested and purified 
using Ni2+ affinity as described previously.[2]  
A1.2 Whole cell inhibition assays M. tuberculosis 
     (Conducted by Ms. Elizabeth Randall or Ms. Angel Pang, Centenary Institute, 
      Sydney) 
M. tuberculosis H37Ra (ATCC 25177) or H37Rv (ATCC 27294) were grown in 
Middlebrook 7H9 broth medium supplemented with OADC (Difco Laboratories, 
Detroit, MI, USA), 0.5% glycerol, and 0.05% Tween-80. Freshly seeded cultures 
were grown at 37 oC, for approximately 14 days, to mid-exponential phase  
(OD600 0.4–0.8) for use in the inhibition assays.  
 
 
1 
                                                
[1] F. W. Studier, Protein Expr. Purif., 2005, 41, 207-234. 
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The effect of type II DHQase, GlmU uridyltransferase inhibitors and 
dihydrosansanmycin analogues against M. tuberculosis growth were measured by a 
resazurin reduction microplate assay, using the procedure previously described by 
Taneja and Tyagi.[3] M. tuberculosis grown to mid-exponential phase (OD600 0.4–0.8) 
was diluted to OD600 0.002 in 7H9S media (Middlebrook 7H9 with OADC, 0.5% 
glycerol, 0.02% tyloxapol, 1% tryptone) containing 0.5% DMSO; 96-well microtiter 
plates were set up with 100 µL inhibitors, serially diluted into 7H9S. Diluted  
M. tuberculosis (100 µL, representing ~2 ×104 CFU mL-1) was added to each well. 
Plates were incubated for 5 days at 37 oC in a humidified incubator prior to the 
addition of a 0.02% resazurin solution (30 µL) and 20% Tween-80 (12.5 µL) to each 
well. Sample fluorescence was measured after 48 h on a BMG Labtech Polarstar 
Omega instrument with an excitation wavelength of 530 nm and emission at 590 nm. 
Changes in fluorescence relative to positive control wells (H37Ra or H37Rv with no 
inhibitor) minus negative control wells (no H37Ra or H37Rv) were plotted for 
determination of MIC50 values. 
A1.3 Representative least square fitted curves to competitive inhibition 
model for type II DHQases 
 
                                                                                                                                      
[2] L. D. B. Evans, A. W. Roszak, L. J. Noble, D. A. Robinson, P. A. Chalk, J. L. 
Matthews, J. R. Coggins, N. C. Price, A. J. Lapthorn, FEBS Lett., 2002, 530, 
24-30. 
[3] N. K. Taneja, J. S. Tyagi, J. Antimicrob. Chemother., 2007, 60, 288-293. 
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A2. Appendices for chapter 5 
A2.1 Expression & purification of GlmU uridyltransferase 
      (Conducted by Mr. Daying Wen, University of Auckland, New Zealand) 
The glmU gene was amplified from M. tuberculosis genomic DNA by PCR using the 
primers 5’ GGCAGCGGCGCGATGACGTTTCCTGGTGACAC-3’ and  
5’ GAAAGCTGGGTGTCACGGTGTCTGATCAGC-3’. The construct was cloned 
into the pDEST17 N-terminal His6-tag vector (Invitrogen) using Gateway cloning. 
The GlmU protein was overexpressed in E. coli BL21(DE3) cell strain using an 
autoinduction protocol.[1] An overnight culture was prepared by inoculating 5 mL  
PA-0.5G medium supplemented with ampicillin (100 mg/mL) and incubating at 37 oC 
with shaking (180 rpm/min). Overnight cultures were transferred into 1 L ZYP-5052 
medium and incubated at 37 oC with shaking at 180 rpm/min. On reaching an OD600 
of 0.7 (approximately 4 h), the cell culture was cooled to 4 oC for 1 h. The culture was 
then incubated for approximately 18 h at 18 oC with shaking at 180rpm/min. Cells 
were harvested by centrifugation at 5000g for 10 min at 4 oC and resuspended in 
buffer A (25 mM NaH2PO4/Na2HPO4 pH 7.5, 100 mM NaCl, 14 mM  
β-mercaptoethanol, 20mM imidazole). Cells were lysed by cell disruption (Constant 
Cell Disruption System) and the lysate was centrifuged at 16000 rpm/ min for 40 min. 
The supernatant was applied onto an immobilized metal (Ni2+) affinity column 
HO CO2H
OH
OH
N
S
H. pylori type II DHQase
Ki = 94  ±  11 nM
51
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(IMAC) pre-equilibrated with buffer A. A linear imidazole gradient (0–1 M) was used 
to elute the fusion protein. The His6 tag was cleaved by incubation with recombinant 
tobacco etch virus (rTEV) protease (overnight at 4 oC), after which the rTEV protease 
and uncleaved protein were removed by a second IMAC step.  In a final purification 
step GlmU was applied onto a size-exclusion column (Hi Load 16/60 Superdex 200, 
GE Healthcare) equilibrated with buffer B (50mM HEPES, pH 7.5, 100mM NaCl,  
1mM DTT, 1mM EDTA). Purified GlmU protein was concentrated to 15mg/mL and 
stored in -80 oC freezer. Purity of the enzyme was confirmed by SDS-PAGE analysis 
to be >90%. Purified M. tuberculosis GlmU uridyltransferase possessed a specific 
activity of 2.0 units/mg of protein. The kinetic parameters, apparent KM and Vmax 
values of UTP were determined by measuring the initial rates at various 
concentrations of UTP (10-194 µM) at saturating concentration of GlcNAc-1-P  
(1 mM) and the data was fitted the Michelis-Menten model using GraphPad Prism 
(version 5.03 for Windows). The KM and Vmax values for GlcNAc-1-P were 
determined in a similar manner (21-200 µM of GlcNAc-1-P in the presence of 1 mM 
UTP). 
A2.2 IC50 curve for GlmU uridyltransferase inhibitor 213 
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A3. Representative NMR spectra from chapter 3, 5 and 6 
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Rapid assembly of potent type II dehydroquinase inhibitors via ‘‘Click’’
chemistry†
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The rapid synthesis of a library of potent type II dehydroquinase inhibitors is described. Inhibitors were
prepared via a key quinate-derived ene-yne intermediate using Cu(I)-catalysed azide-alkyne
cycloaddition (CuAAC) chemistry with a variety of aryl- and heteroaryl-azides.
Introduction
The shikimate pathway is responsible for the conversion of
erythrose-4-phosphate and phosphoenol pyruvate into cho-
rismate over seven enzyme-catalysed steps.1–3 The end product of
the pathway, chorismate, serves as the key branchpoint for the
biosynthesis of a host of aromatic secondary metabolites in
plants, bacteria, fungi and apicomplexan parasites in which the
pathway is known to operate.2,4 These include folate, the
aromatic amino acids tyrosine, tryptophan and phenylalanine,
and essential vitamins including the folate coenzymes, benzoid
and naphthenoid quinones. The absence of the shikimate
pathway in mammals, along with the essential role of this
pathway in the viability of plants, bacteria, fungi and apicom-
plexan parasites,5,6 makes the pathway an excellent target for the
development of broad spectrum herbicides, antibacterials, anti-
fungals and antimalarial agents.2,7
The third step of the shikimate pathway, the dehydration of 3-
dehydroquinate (1) to 3-dehydroshikimate (2), is catalysed by the
enzyme dehydroquinase (3-dehydroquinate dehydratase, EC
4.2.1.10). Interestingly, two structurally and mechanistically
different enzymes, type I and type II, have evolved to carry out
this transformation.8,9 Type I enzymes are dimeric proteins that
catalyse the syn-elimination of water via Schiff base formation
with a conserved active site lysine residue. In contrast, type II
dehydroquinases are dodecameric proteins which catalyse the
dehydration reaction via an E1CB mechanism (Scheme 1).
10,11 The
dehydration is initiated by abstraction of the pro-S hydrogen by
a conserved tyrosine (Tyr) residue to form an enol intermediate.
Anti-elimination of water then occurs, facilitated by a water
molecule and a conserved asparagine and histidine residue
(Scheme 1).
In the past decade there has been significant interest in the
design and synthesis of type II dehydroquinase inhibitors.12 This
is due, in major part, to the operation of this enzyme in a number
of pathogenic bacteria including Mycobacterium tuberculosis13
and Helicobacter pylori,14 the etiological agents of tuberculosis,
and gastric ulcers and gastric cancer, respectively. It is therefore
viewed as a potential target for the development of broad
Scheme 1 Proposed mechanism of the type II dehydroquinase-catalysed
dehydration of 3-dehydroquinate (1) to 3-dehydroshikimate (2).
Fig. 1 Schematic representation of potent type II dehydroquinase
inhibitors previously reported.15–21
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spectrum antibacterial agents.12 Previous work by Abell and
coworkers15–17 and Gonz!alez-Bello and coworkers18–21 has
revealed a number of key features deemed essential for selective
and potent inhibition of the type II dehydroquinases. Specifi-
cally, both groups have reported that compounds possessing an
anhydroquinate core with a terminal aromatic moiety extending
from C-3 (with or without a bridging linker) are potent inhibitors
of these enzymes (Fig. 1). Recent crystallographic evidence
suggests that potent inhibition of the enzyme by these
compounds is facilitated by a combination of the anhy-
droquinate core forming a number of hydrogen bonds with both
active site residues and a conserved water molecule, and secondly
the terminal aromatic moiety partaking in a p-stacking interac-
tion (face to face or edge to face) with the conserved active site
Tyr residue (which serves as the base in the proposed mechanism,
Scheme 1).16,21
In our present investigation, we envisioned the use of reliable
and robust chemistry to rapidly and efficiently assemble
a library of inhibitors, which contain these key inhibitory
features, from ene-yne intermediate 3 (Scheme 2). We initially
proposed an inhibitor library bearing a triazole functionality as
a rigid linker between the anhydroquinate core and a range of
terminal aryl or heteroaryl moieties at C-3, which we proposed
to install via a Cu(I)-catalysed alkyne-azide cycloaddition
(CuAAC) reaction.22,23 In order to maximise diversity in our
inhibitor library, we chose to incorporate terminal aryl rings
with a variety of electronic properties (4a–4f, Scheme 2).
Incorporation of a flexible methylene linker between the tri-
azole and the electron-rich thiophene and furan rings in
inhibitors 5a and 5b was also proposed to probe the effect of
conformational freedom on inhibition of the type II dehy-
droquinases (Scheme 2).
Results and discussion
Before embarking on the synthesis of the proposed inhibitor
library, triazole-based inhibitors 4a–4f, 5a and 5b were docked
into the active site of the type II dehydroquinases from S. coe-
licolor and H. pylori (PDB code: 1GU1 and 2WKS respectively)
using Glide! (Schr€odinger Inc.).24 The majority of the inhibitors
showed very similar binding modes (see ESI†). Representative
dockings of compound 4a into the active sites of S. coelicolor and
H. pylori type II dehydroquinases are shown in Fig. 2. The
typical docking mode involved the anhydroquinate core binding
into the active site where it forms a number of favourable
hydrogen bonding interactions with active site residues and
a conserved water molecule (see Fig. 2 and ESI†). In addition, the
terminal aryl and heteroaryl moieties were positioned in close
proximity to the essential Tyr residue (Tyr28 in S. coelicolor) in
the enzyme and, as such, were predicted to participate in a p-
stacking interaction with this conserved residue, consistent with
our design strategy.
Having established the suitability of the proposed inhibitors
via docking studies, we next embarked on the synthesis of key
ene-yne intermediate 3 (Scheme 3). The synthesis began with 3-
silylated lactone 6, obtained in 2 steps from commercially
available (!)-quinic acid using an established literature
Scheme 2 Retrosynthesis of triazole-based inhibitors 4a–4f, 5a and 5b.
Fig. 2 Docking of inhibitor 4a into the active site of (a) S. coelicolor type
II dehydroquinase and (b) H. pylori type II dehydroquinase.
272 | Med. Chem. Commun., 2010, 1, 271–275 This journal is ª The Royal Society of Chemistry 2010
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procedure.25 Treatment of 6 with excess dimethoxymethane and
phosphorus pentoxide gave the fully protected lactone 7 in 78%
yield. Desilylation at C-3 using tetrabutylammonium fluoride
(TBAF) furnished alcohol 8 in 87% yield and was followed by
oxidation with Dess–Martin periodinane (DMP) to afford the
corresponding ketone 9 in 90% yield. Ketone 9 was subsequently
converted to vinyl triflate 10 via deprotonation with potassium
hexamethyldisilazane, followed by reaction of the resulting
enolate with Comin’s triflating reagent to afford 10 in 67% yield.
Vinyl triflate 10 was next subjected to palladium-catalysed
Sonogashira cross-coupling conditions with TMS-acetylene to
afford protected ene-yne 11 in 75% yield. Subsequent silyl
deprotection with TBAF proceeded smoothly to afford 12, which
was treated with 90% trifluoroacetic acid (TFA) to give the key
ene-yne intermediate 3 in 64% yield over two steps.
With the key ene-yne intermediate 3 in hand, we next focussed
on the preparation of the proposed triazole-based inhibitors. To
this end, ene-yne 3 was reacted with a library of aryl- and het-
eroaryl-azides (see ESI†) using the robust CuAAC reaction
conditions22 (0.1 eq. CuSO4, 1 eq. sodium ascorbate, 1 : 1 v/v
water/tert-butanol) to furnish the corresponding triazole lactones
(Scheme 4). Saponification of the resulting lactones followed by
acidification afforded the desired triazole-based inhibitors 4a–4f,
5a and 5b in moderate to good yields (27–69%) over the two
steps.
The biological activity of triazole-based inhibitors 4a–4f, 5a
and 5b against type II dehydroquinase from three different
organisms, namely Streptomyces coelicolor, H. pylori and
M. tuberculosis, was determined using a UV spectrophotometric
assay (see ESI†).17 This entailed measuring the initial rate of
product (3-dehydroshikimate, 2) formation from 3-dehy-
droquinate (1)26 by detection of the enone-carboxylate chromo-
phore at l ¼ 234 nm. All the compounds proved to be
competitive, reversible inhibitors of the enzyme as shown by
a least squares fitting to a competitive model.
Gratifyingly, the majority of the triazole-based compounds
proved to be potent inhibitors of all three of the type II dey-
droquinases, with inhibition constants in the low- to mid-nano-
molar range (Table 1). Inhibitors 4a and 4f, bearing terminal
phenyl and 3-pyridyl rings respectively, proved to be particularly
potent against all three enzymes. Both compounds exhibited an
inhibition constant of 5.7 nM against S. coelicolor type II
dehydroquinase and, as such, represent two of the most potent
inhibitors of any type II dehydroquinase synthesised to date.
These two compounds also exhibited potent inhibition of H.
pylori type II dehydroquinase (4a: KI ¼ 225 nM, 4f: KI ¼ 375
nM) and of theM. tuberculosis enzyme (4a: KI¼ 39 nM, 4f: KI¼
136 nM). Inspection of the docking results reveals a number of
key features which are postulated to contribute to the potency of
these compounds. Firstly, the anhydroquinate core appeared to
bind to the active site of the enzymes in a very similar mode to
that observed in reported co-crystal structures of other
Scheme 3 Reagents and conditions: a) (OCH3)2CH2, P2O5, CH2Cl2, rt,
78%; b) TBAF, THF, 0 "C, 87%; c) DMP, CH2Cl2, rt, 90%; d) (i)
KHMDS, DMF, PhCH3, #78 "C, (ii) Comin’s reagent, #78 "C to rt,
67%; e) TMS-acetylene, [Pd(PPh3)4] (15 mol%), CuI (20 mol%), piperi-
dine, THF, 40 "C, 75%; f) Cat. TBAF, THF, rt.; g) 90% aq. TFA, rt, 64%
over 2 steps.
Scheme 4 Reagents and conditions: a) sodium ascorbate (1 eq.),
CuSO4$5H2O (0.1 eq.), R-N3, tert-butanol/water (1 : 1 v/v), rt; b) (i)
LiOH, THF, rt, (ii) Amberlite IR-120 (H+ form).
Table 1 Inhibition constants of triazole-based inhibitors 4a–4f and 5a
and 5b against S. coelicolor, H. pylori and M. tuberculosis type II dehy-
droquinase enzymes.a
Inhibitor
S. coelicolor
type II DHQase
KI/nM
H. pylori
type II DHQase
KI/nM
M. tuberculosis
type II DHQase
KI/nM
4a 5.7 $ 0.9 225 $ 51 39 $ 5
4b 29 $ 3 561 $ 75 154 $ 16
4c 78 $ 8 538 $ 83 230 $ 20
4d 1720 $ 120 5780 $ 540 3126 $ 315
4e 48 $ 4 157 $ 14 330 $ 24
4f 5.7 $ 0.8 375 $ 53 136 $ 12
5a 217 $ 17 2200 $ 300 2122 $ 193
5b 73 $ 10 925 $ 120 1579 $ 149
a Kinetic parameters of the type II dehydroquinase enzymes: S.
coelicolor: KM ¼ 679 $ 68 mM, kcat ¼ 84 s#1, 50 mM Tris.HCl, pH 7.0,
25 "C; H. pylori: KM ¼ 228 $ 33 mM, kcat ¼ 1.4 s#1, 50 mM
Tris$HOAc, pH 7.0, 25 "C; M. tuberculosis: KM ¼ 52 $ 8 mM, kcat ¼
6.3 s#1, 50 mM Tris.HCl, pH 7.0, 25 "C.
This journal is ª The Royal Society of Chemistry 2010 Med. Chem. Commun., 2010, 1, 271–275 | 273
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inhibitors.11,16,21 Specifically, the C-1 carboxylate is held in place
by two backbone amides of the protein chain, and the C-1
hydroxyl by the side chain imidazole of a conserved histidine
residue. There also appears to be a hydrogen bonding interaction
between the C-5 hydroxyl group and the side chain of another
histidine residue. The triazole-linked aryl rings appear to be
involved in a p-stacking interaction with the conserved Tyr
residue on the flexible loop and in the S. coelicolor type II
dehydroquinase dockings there is a potential cation-p interac-
tion with an arginine residue. A positive entropic effect resulting
from the displacement of water molecules from the region under
the flexible loop into the bulk solvent is also proposed to
contribute to the potency of these compounds. It is also impor-
tant to note that 4a, which has a terminal aromatic moiety
directly attached to the triazole linker, is significantly more
potent compared to an analogous compound bearing a flexible
methylene linker between the phenyl ring and the triazole
reported previously (KI ¼ 30 nM against S. coelicolor type II
dehydroquinase andKI¼ 3.75 mMagainstM. tuberculosis type II
dehydroquinase).19 This suggests that rigid positioning of the
terminal aromatic moiety may be an important feature for
a favourable p-stacking interaction with the conserved Tyr
residue, thus leading to more potent inhibition. This hypothesis
is supported by the significantly weaker inhibition exhibited by
5a and 5b, containing flexible methylene linked furan and thio-
phene groups respectively. Whilst these compounds still exhibi-
ted nanomolar inhibition constants against S. coelicolor type II
dehydroquinase, they were significantly less potent against the
H. pylori and M. tuberculosis enzymes.
Incorporation of a terminal p-fluorophenyl substituent in 4b
and an o-hydroxyphenyl moiety in 4e also led to potent inhibi-
tion of all three type II dehydroquinases (KI ¼ 29–330 nM).
However, these compounds were slightly less potent against all
three enzymes when compared to 4a, suggesting that small
changes in the electronics of the aryl moiety can modulate
potency of these compounds.
As part of our original design strategy we anticipated that the
electron-withdrawing m-nitro and m-carboxylate substituents, in
4c and 4d respectively, would result in more favourable p–p
interactions with the conserved active site Tyr residue of the type
II dehydroquinases, leading to more potent inhibitors. Unfor-
tunately this was not the case as 4c proved to be a less potent
inhibitor than compound 4a which bears only a phenyl substit-
uent. Furthermore, 4d exhibited the weakest inhibition of any
compound in this series, with inhibition constants in the low
micromolar range against all three enzymes. Inspection of the
S. coelicolor type II dehydroquinase docking results allows for
some speculative insight into the drop in potency of 4d. In
contrast to every other member of the triazole-based inhibitor
library, the anhydroquinate core in compound 4d docked into
the active site in a different binding mode (see ESI†). In this
mode 4d is no longer able to make a network of hydrogen
bonding interactions with the active site of the enzyme which
may explain the poor inhibitory properties of this compound.
Conclusions
In summary, we have designed and synthesised a novel series of
triazole-based type II dehydroquinase inhibitors using CuAAC
reactions between a key quinate-derived ene-yne and a variety of
aryl- and heteroaryl-azides. These were screened against
S. coelicolor, H. pylori and M. tuberculosis type II dehy-
droquinases. The majority of the compounds proved to be potent
inhibitors of all three type II dehydroquinases with inhibition
constants in the low to mid-nanomolar range. In particular, 4a
and 4f bearing terminal phenyl and 3-pyridyl rings directly linked
to the triazole moiety, represent some of the most potent inhib-
itors of the type II dehydroquinases from S.coelicolor, H.pylori
and M. tuberculosis ever synthesised. Future work in our labo-
ratories will involve co-crystallisation of the inhibitors in this
series with the type II dehydroquinases and evaluation
of their antibacterial activity against M. tuberculosis and
H. pylori in vitro.
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Synthesis and Evaluation of Potent Ene–yne Inhibitors of Type II
Dehydroquinases as Tuberculosis Drug Leads
Anh Thu Tran,[a] Katie M. Cergol,[a] Nicholas P. West,[b] Elizabeth J. Randall,[b] Warwick J. Britton,[b]
Syed Ali Imran Bokhari,[c] Musadiq Ibrahim,[c] Adrian J. Lapthorn,[c] and Richard J. Payne*[a]
The shikimate pathway is an essential biosynthetic route oper-
ating in plants, bacteria, fungi, and apicomplexan parasites.[1–4]
Consisting of seven enzyme-catalyzed steps, this pathway is re-
sponsible for the sequential conversion of erythrose-4-phos-
phate and phosphoenol pyruvate to chorismate, the precursor
for the biosynthesis of a range of aromatic amino acids, folates,
ubiquinone, and vitamins E and K.[1,5,6] The absence of this
pathway in mammals, alongside its essential role in the surviv-
al of plants, bacteria, fungi and apicomplexan parasites, makes
this an attractive target for the development of new herbicides
and antimicrobial agents.[1]
The enzyme dehydroquinase (3-dehydroquinate dehydra-
tase, EC 4.2.1.10) catalyzes the third step in the shikimate path-
way—the reversible dehydration of 3-dehydroquinate (1) to 3-
dehydroshikimate (2). Two structurally distinct dehydroquinase
(DHQase) enzymes are known (type I and II), which catalyze
the same dehydration reaction via two mechanistically distinct
pathways.[7,8] Type I dehydroquinases are functional dimers
that catalyze the syn-elimination of water via an imine inter-
mediate with a conserved lysine residue, which enables the ab-
straction of the pro-R hydrogen from the C-2 position (HR,
Scheme 1).[9, 10] In contrast, the type II dehydroquinases are do-
decamers that facilitate the anti-elimination of water via an
E1CB mechanism, whereby abstraction of the more acidic pro-S
hydrogen (HS, Scheme 1) is facilitated by a conserved tyrosine
residue, resulting in the formation of an enol intermediate 3
(Scheme 1).[7, 11,12]
Type II dehydroquinases are present in pathogenic bacteria
such as Mycobacterium tuberculosis,[13] the etiological agent of
tuberculosis (TB), and Helicobacter pylori,[14] a stomach patho-
gen that causes gastric ulcers and is linked to the development
of stomach cancer. Due to the increased resistance of these
and other microorganisms to current chemotherapies, antibac-
terial agents with novel mechanisms of action are required.
Since the 1990s, several new inhibitors of type II dehydroqui-
nases have been reported.[15] In particular, work by Gonz!lez-
Bello et al.[16–19] and Abell et al.[20–22] has highlighted several
specific features that contribute to the potent inhibition of this
enzyme. In particular, compounds possessing an anhydroqui-
nate core, mimicking the enol intermediate 3, attached either
directly to an aromatic moiety (e.g. , 4,[18] Figure 1), or via an in-
flexible linker, have proven successful. More recently, we have
reported potent inhibitors that support this design strategy, in-
corporating a rigid triazole linker between the anhydroquinate
core and a range of aromatic groups (e.g. , 5, Figure 1).[23] This
design of small molecules is supported by reported co-crystal
structures of inhibitors bound to the active site of type II dehy-
droquinases from H. pylori and Streptomyces coelicolor.[17,20]
More recently, Gonz!lez-Bello and co-workers reported the first
co-crystal structure of M. tuberculosis type II dehydroquinase
with a substrate-based inhibitor bound in the active site.[24]
This data further highlights the role of the quinate core, which
forms several hydrogen bonds with active site residues, and
terminal aromatic substituents, which participate in favourable
p-stacking interactions with a conserved tyrosine residue
within a flexible loop.
We have become interested in the development of type II
dehydroquinase inhibitors as potential tuberculosis drug leads,
which would operate via a mode of action that is different to
currently employed therapies. In this study, we report the de-
velopment of a range of ene–yne-based inhibitors 6–13 cen-
Scheme 1. Proposed mechanism for the dehydration of 3-dehydroquinate
(1) to 3-dehydroshikimate (2) by type II dehydroquinases.
Figure 1. Potent inhibitors of M. tuberculosis type II dehydroquinase.[17,22]
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tred on the key inhibitory features described above
(Scheme 2). We envisioned that these inhibitors could be pre-
pared in an efficient manner by employing a palladium-cata-
lyzed Sonogashira cross-coupling reaction[25,26] between a key
ene–yne intermediate 14 and several aromatic moieties en-
compassing a range of electronic and steric properties
(Scheme 2). In this case, the alkyne functionality serves as a
rigid, linear, hydrophobic linker between the anhydroquinate
core and the aromatic moieties, a strategy which has yet to be
exploited for type II dehydroquinase inhibition.
To support our inhibitor design, the proposed ene–yne com-
pounds 6–13 were initially docked into the active site of the
type II dehydroquinases from S. coelicolor (PDB code: 1GU1)
and H. pylori (PDB code: 2WKS) using Glide (Schrçdinger
Inc.).[27] Most inhibitors possess a common predicted binding
mode whereby the anhydroquinate core formed a number of
favourable hydrogen-bonding interactions with active site resi-
dues (as has been observed in previous crystal structures of
anhydroquinate-containing inhibitors, see Supporting Informa-
tion).[17,20] In addition, the rigid alkyne linker appeared to orient
the terminal aryl and heteroaryl moieties so as to achieve a fa-
vourable p-stacking interaction with the essential tyrosine resi-
due (Tyr28 in S. coelicolor and Tyr22 in H. pylori). Representative
docking poses of 9, bearing a terminal m-trifluoromethylphen-
yl substituent, depicting this common binding mode are
shown in Figure 2. Compounds 12 and 13, containing terminal
benzothiazole and quinoline groups, appeared to dock in a
modified mode against the S. coelicolor enzyme whereby the
anhydroquinate core was oriented 180 degrees from the
normal pose (see Supporting Information). It is assumed that
this is due to the steric nature of the terminal bicyclic rings,
which, in order to partake in a favourable p-stacking interac-
tion with the conserved tyrosine residue, must present the an-
hydroquinate core in a different orientation.
Having established that the proposed inhibitors provided fa-
vourable binding modes in silico, we next undertook the syn-
thesis of key ene–yne 14, and the subsequent elaboration to
inhibitors 6–13. To this end, ene–yne 14 was first prepared
from commercially available (!)-quinic acid (15) in nine steps
(Scheme 3).[23,28] With the key ene–yne 14 in hand, we directed
our attention towards the synthesis of the proposed ene–yne
inhibitors 6–13 (Scheme 3). Subjecting ene–yne 14 to palladi-
um-catalyzed Sonogashira cross-coupling reaction conditions
with a variety of aryl halides or triflates afforded the precursor
lactones that, upon saponification, resulted in the desired in-
Scheme 2. Retrosynthesis of ene–yne inhibitors 6–13.
Scheme 3. Synthesis of ene–yne inhibitors 6–13 from (!)-quinic acid. Re-
agents and Conditions : a) R-X (X=Br, I, or OTf), Pd(PPh3)4, CuI, piperidine,
THF, 40 8C; b) LiOH, THF/H2O, RT, 30–85% (two steps).
Figure 2. Molecular docking of 9 into the active site of a) S. coelicolor type II
dehydroquinase (PDB code: 1GU1) and b) H. pylori type II dehydroquinase
(PDB code: 2WKS).
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hibitors 6–13 in moderate to good yields over the two steps
(30–85%).
Compounds 6–13 were next screened against type II dehy-
droquinases from three organisms, namely S. coelicolor,
H. pylori and M. tuberculosis. The inhibitors were tested using a
UV spectrophotometric assay, detecting the enone carboxylate
chromophore of the enzymatic product 3-dehydroshikimate (2)
at l=234 nm.[21] Gratifyingly, the majority of the compounds
prepared in this study proved to be potent inhibitors of all
three of the type II dehydroquinases studied, with inhibition
constants in the nanomolar range. Introduction of terminal
phenyl or 4-fluorophenyl substituents, in 6 and 7 respectively,
led to potent inhibition of all three of the type II dehydroqui-
nases (Table 1). Both compounds were low nanomolar inhibi-
tors of the S. coelicolor enzyme (Ki=12–28 nm) ; however, they
were less potent against the M. tuberculosis enzyme with inhib-
ition constants of 356 nm and 548 nm for 6 and 7, respectively.
This phenomenon has been reported for previously prepared
anhydroquinate-based inhibitors, suggesting subtle differences
in the active site structures of these two enzymes.[19,20, 22] Com-
pounds 8 and 9 bearing electron withdrawing m-trifluorome-
thylphenyl and m-nitrophenyl substituents, respectively, exhib-
ited the most potent inhibition of all three of the enzymes. No-
tably, compounds 8 and 9 exhibited inhibition constants of
133 nm and 108 nm, respectively, against M. tuberculosis type II
dehydroquinase and, as such, represent two of the most
potent inhibitors ever tested against this enzyme. It is impor-
tant to note that compounds 8 and 9 were also potent inhibi-
tors of H. pylori type II dehydroquinase with inhibition con-
stants of 98 nm and 103 nm, respectively. To our knowledge,
these are the most potent inhibitors ever reported against this
enzyme. Introduction of a 3-pyridyl and 3-quinoline moiety in
10 and 13, respectively, led to a significant drop in potency
against all three enzymes, suggesting that introduction of ni-
trogen heterocycles is detrimental to inhibition of the type II
dehydroquinases. Interestingly, compounds 11 and 12 bearing
terminal thiophene and benzothiazole rings also led to potent
inhibition of all three enzymes including M. tuberculosis type II
dehydroquinase.
Having prepared a library of type II dehydroquinase inhibi-
tors with nanomolar affinity, we were interested in assessing
the antibacterial activity of these compounds. Specifically, we
chose to test the activity of 6–13 against virulent M. tubercu-
losis (strain H37Rv) to assess the potential of these compounds
as TB drug leads. The activity against replicating M. tuberculosis
was measured using the well-established microplate-based
assay with Alamar blue (resazurin) readout (MABA) for determi-
nation of bacterial growth (see Supporting Information).[29–32]
Although the inhibitors demonstrated activity, the majority of
the compounds exhibited low millimolar IC50 values against
the growth of M. tuberculosis, significantly less potent than the
in vitro activity against type II dehydroquinase from M. tubercu-
losis (see Supporting Information). The most potent inhibitor
of M. tuberculosis growth was compound 8 bearing an m-nitro-
phenyl moiety, which exhibited an IC50 value of 450 mm and a
minimal inhibition concentration (MIC) of 1.2 mm (see Support-
ing Information). A possible explanation for the reduced activi-
ty of these compounds against M. tuberculosis may be due to
the type II dehydroquinase in the shikimate pathway of M. tu-
berculosis being non-rate limiting. As such, high levels of
enzyme inhibition would be required to show significant inhib-
ition of bacterial growth. An alternative rationale for the poor
activity of these compounds is correlated with their hydrophilic
nature, which may make it difficult for the compounds to tra-
verse the waxy mycobacterial cell wall. Future work in our lab-
oratories will therefore focus on the preparation of prodrug
analogues of 6–13. It is anticipated that this will enable greater
concentrations of the inhibitors to enter the M. tuberculosis cell
for inhibition of type II dehydroquinase.
In summary, we have successfully designed and synthesized
a small library of ene–yne inhibitors guided by in silico docking
studies. The compounds were synthesized in an efficient
manner using a Sonogashira cross-coupling reaction between
an alkyne-derivatized anhydroquinate core and a range of aro-
matic and heteroaromatic coupling partners. The vast majority
of the inhibitors prepared in this study exhibited nanomolar in-
hibition of type II dehydroquinases from S. coelicolor and the
medically relevant H. pylori and M. tuberculosis. The most
potent inhibitors were those possessing meta-substituted ter-
minal phenyl moieties bearing electron-withdrawing nitro- or
trifluoromethyl-substituents. The compounds proved to exhibit
only moderate antibacterial activity when screened against
M. tuberculosis, ascribed to the hydrophilic nature of the inhibi-
tors. Future work in our laboratories will involve increasing the
lipophilicity of 6–13 by utilising a prodrug approach and the
design of a second generation series of type II dehydroquinase
inhibitors with improved cell penetrating properties.
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Elucidation of Mycobacterium tuberculosis Type II
Dehydroquinase Inhibitors using a Fragment Elaboration
Strategy
Anh Thu Tran,[a] Nicholas P. West,[b] Warwick J. Britton,[b] and Richard J. Payne*[a]
Introduction
Since its initial identification in 1882, Mycobacterium tuberculo-
sis, the causative agent of tuberculosis (TB), has remained
a major global health risk.[1] According to the World Health Or-
ganization, there were 9.4 million new cases of TB in 2009 and
1.7 million deaths, with these figures expected to rise consider-
ably over the next decade.[1] The current situation has been at-
tributed to poor public health management, particularly in de-
veloping countries, where there is a high TB burden and rapid
spread of TB infection.[1] A further challenge for TB treatment is
the ability of M. tuberculosis to remain dormant in macrophag-
es in very low numbers for decades after initial infection, re-
sulting in a lifelong risk of disease reactivation, especially in
immune-compromised individuals such as those with human
immunodeficiency virus (HIV) co-infection.[1,2]
In recent years, the emergence of multidrug-resistant (MDR)
and extensively drug-resistant (XDR) strains of M. tuberculosis
has threatened global control of TB. MDR M. tuberculosis strains
are defined as being resistant to the major first-line antituber-
cular agents isoniazid and rifampicin and, as such, require the
use of second-line treatments such as fluoroquinolones and in-
jectable agents (e.g. , aminoglycosides and polypeptides).[3] The
use of second-line drugs inevitably increases the exposure of
M. tuberculosis to a wider range of antibacterials which has led
to the emergence of XDR M. tuberculosis strains, defined as
those resistant to isoniazid, rifampicin, and any fluoroquino-
lone and one of the three injectable drugs.[4] The treatment of
individuals infected with XDR M. tuberculosis is confined to
a small number of highly toxic and less effective antibiotics ; as
a result, XDR-TB is often untreatable, highlighted by a 98%
mortality rate in a recent outbreak in South Africa.[5]
Given the alarming rise in the number of MDR and XDR
M. tuberculosis infections combined with the high rate of HIV
co-infection, there is an urgent need for new TB drugs that op-
erate via novel modes of action to combat dwindling treat-
ment options.[6] Among some of the promising drug targets
identified by the complete analysis of the M. tuberculosis
genome are enzymes in the shikimate pathway.[7] This biosyn-
thetic pathway operates in plants, bacteria, fungi and apicom-
plexan parasites, but is absent in mammals and is therefore an
attractive target for the development of small-molecule inhibi-
tors to serve as herbicides, antibacterials, fungicides, and anti-
parasitic agents.[8] The shikimate pathway consists of seven
enzyme-catalyzed steps and is responsible for the conversion
of erythrose-4-phosphate 1 and phosphoenol pyruvate 2 into
chorismate 3 and is essential for M. tuberculosis growth in vitro
(Scheme 1).[9] Chorismate serves as a precursor for the biosyn-
thesis of a range of aromatic amino acids, folate, ubiquinone,
and vitamins E and K.[10] The presence of the shikimate path-
way in M. tuberculosis has led to significant interest in the de-
velopment of inhibitors of enzymes in this pathway to serve as
TB drug leads.[11]
The third step of the shikimate pathway, the reversible dehy-
dration of 3-dehydroquinate 4 to 3-dehydroshikimate 5, is cat-
alyzed by the enzyme dehydroquinase (DHQase, 3-dehydroqui-
nate dehydratase, EC 4.2.1.10; Scheme 1). Interestingly, two
structurally and mechanistically distinct enzymes (type I and
type II DHQases) have evolved to catalyze the same dehydra-
tion reaction.[12] Type I DHQases are homodimeric proteins that
catalyze the syn elimination of water via formation of a Schiff
base with a conserved lysine residue, which enables abstrac-
tion of the pro-R hydrogen atom from the C2 position.[13] In
contrast, type II enzymes are homododecamers that catalyze
A library of novel Mycobacterium tuberculosis type II dehydro-
quinase (DHQase) inhibitors were discovered through the use
of a fragment elaboration approach. Putative active site bind-
ing fragments were initially assessed in silico which led to the
selection of two small aromatic fragments for further investiga-
tion. Synthetic elaboration of the fragments provided a library
of 34 inhibitors that exhibited low-micromolar inhibition of
type II DHQase. A number of these inhibitors also showed anti-
bacterial activity in the low-micromolar range in screens
against M. tuberculosis in vitro; these now serve as lead com-
pounds for further development of therapeutics for the treat-
ment of tuberculosis.
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the dehydration reaction via an E1CB mechanism.
[14] The reac-
tion is initiated by abstraction of the more acidic pro-S hydro-
gen atom by a conserved tyrosine residue, resulting in the for-
mation of an enol intermediate (Scheme 2). Anti elimination of
water then occurs, facilitated by a conserved water molecule
and asparagine and histidine residues (Scheme 2).[15]
The essentiality of type II DHQase in M. tuberculosis and
other pathogenic bacteria such as Helicobacter pylori (the etio-
logical agent of gastric ulcers) has fueled research efforts into
the design and synthesis of type II DHQase inhibitors as anti-
bacterial leads. Since the 1990s, several inhibitors of this
enzyme have been reported based on the substrate and
enzyme-bound intermediate. In particular, work by Abell and
co-workers,[16] Gonz!lez-Bello and colleagues,[17] as well as from
our research group[18] has identified several key features that
contribute to the potent inhibition of type II DHQases from
a variety of organisms.
In particular, compounds that
possess an anhydroquinate core
as a mimic of the enol enzyme
intermediate of type II DHQase,
either attached directly or by
a rigid linker to a terminal aro-
matic moiety, have provided
compounds with inhibition con-
stants in the nanomolar range
against a range of type II DHQas-
es, including the M. tuberculosis
enzyme (compounds 6–9,
Figure 1). The binding modes of
these inhibitors have been pre-
dicted by molecular modeling
and confirmed by enzyme–inhib-
itor co-crystal structures.[16c,19]
These studies have established
the importance of the anhydro-
quinate core, which forms a hy-
drogen bonding network with active site residues, and the ter-
minal aromatic moieties, which participate in a p–p stacking
interaction with the essential Tyr residue present on a flexible
loop (Figure 2).
Scheme 1. The shikimate pathway.
Scheme 2. Proposed mechanism for the dehydration of 3-dehydroquinate
(4) to 3-dehydroshikimate (5) by type II DHQase.
Figure 1. Previously synthesized inhibitors and inhibition constants against
M. tuberculosis type II DHQase.[16c,17a,18]
Figure 2. Crystal structure of S. coelicolor type II DHQase (PDB code: 2CJF)
with thioether 8 bound.[16c]
1032 www.chemmedchem.org " 2012 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2012, 7, 1031 – 1043
MED R. J. Payne et al.
Results and Discussion
We recently reported a number of potent type II DHQase in-
hibitors that support the aforementioned design strategy
through the incorporation of a rigid triazole or alkyne linker
between the anhydroquinate core and a range of aromatic
moieties (e.g. , 7 and 9, Figure 1).[18] Despite potent inhibition
(in the nanomolar range) against M. tuberculosis type II
DHQase, these compounds exhibited poor antibacterial activity
when tested against the virulent H37Rv strain of M. tuberculosis
in vitro.[18b] The poor antibacterial activity was attributed to the
hydrophilic nature of the triol carboxylate motif present in the
anhydroquinate core of these compounds. Indeed, improved in
vitro antibacterial activity of anhydroquinate-based inhibitors
has recently been observed by the use of a prodrug strategy,
whereby the carboxylic acid of a similar class of inhibitors was
derivatized as the corresponding n-propyl esters.[17c] Continu-
ing our efforts to develop type II DHQase inhibitors as TB drug
leads, in this study we sought to identify alternate, simplified
scaffolds to replace the highly polar anhydroquinate core tradi-
tionally employed in type II DHQase inhibition studies.
In silico fragment selection
We used an in silico screening approach to identify small, func-
tionally simple molecules capable of establishing favorable in-
teractions with the active site of M. tuberculosis type II DHQase.
Specifically, we selected a total of 13 putative active site bind-
ing fragments that were present as part of a 42-compound li-
brary of proposed type II DHQase inhibitors recently reported
by Kumar et al. in a virtual screening campaign (see Support-
ing Information).[20] The 13 aryl-based fragments with ClogP
values ranging from !0.3 to 2.4 were docked into the active
site of M. tuberculosis type II DHQase using Glide (Schrçdinger
Inc.)[21] to evaluate the suitability of these compounds as more
hydrophobic replacements of the anhydroquinate core (see
Supporting Information). Two fragments, namely 3,4-dihydrox-
yacetophenone 11 and the corresponding acetonide analogue
12, were subsequently selected for synthetic elaboration.
These two fragments were chosen based on favorable ClogP
values and Glide XP scores, and because these scaffolds are
amenable to synthetic elaboration to generate inhibitors.
The results of molecular docking studies of the two frag-
ments are shown in Figure 3 along with the predicted binding
mode of 2,3-dehydroquinate 10. The carbonyl moiety of 3,4-di-
hydroxyacetophenone 11 was predicted to make hydrogen
bonding interactions with the amide backbone between
His101 and Ile102 as well as the side chain of Asn75 in a simi-
lar manner to the C1 carboxylate and C1 hydroxy group of 2,3-
anhydroquinate 10. Importantly, 2,3-anhydroquinic acid is pre-
dicted to form other hydrogen bonding interactions that are
absent in the molecular docking of 11. These include hydrogen
bonding interactions between the C1 carboxylate of 10 with
the amide backbone between Ile102 and Ser103 and the hy-
droxy side chain of Ser103. Furthermore, the C1 hydroxy group
of 10 was predicted to form a hydrogen bond with the side
chain of His101. Acetonide-derived acetophenone 12 was pre-
dicted to bind to M. tuberculosis type II DHQase in exclusively
one binding mode, different from that predicted for 11. Specif-
ically, only the carbonyl group of the acetophenone moiety
was predicted to form a hydrogen bonding interaction with
the amide backbone between His101 and Ile102, whereas the
acetonide moiety is oriented into a subsidiary binding pocket.
Extra binding affinity in this pose can be attributed to a p-
stacking interaction with Tyr24. We chose to pursue inhibitors
based on 12 irrespective of this altered binding mode, as in-
corporation of aryl groups onto the acetophenone moiety of
12 was predicted to reorient the acetonide core and provide
a similar binding pose to 11 (see below). In addition, inhibitors
based on this acetonide core would be synthetic intermediates
en route to inhibitors based on 11.
Figure 3. Molecular docking of A) 2,3-dehydroquinate 10, B) 3,4-dihydroxya-
cetophenone 11, and C) acetonide analogue 12 into the active site of M. tu-
berculosis type II DHQase (PDB code: 2XB8).[19a]
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The suitability of these two fragments as mimics of the an-
hydroquinate core and as inhibitors of type II DHQase was fur-
ther verified by screening for their inhibitory activity against
M. tuberculosis type II DHQase using a continuous kinetic UV
spectrophotometric assay[18a] that detects the formation of the
enone–carboxylate chromophore of 3-dehydroshikimate 5 at
l=234 nm (Table 1). We were pleased to find that compounds
11 and 12 exhibited micromolar inhibition against the enzyme
(Ki : 173 and 120 mm, respectively). Importantly, these small mol-
ecules showed inhibition constants similar to that of 2,3-dehy-
droquinate 10 (Ki=200 mm),
[22] yet possessed significantly more
favorable ClogP values (Table 1). Both fragments were also
tested against replicating M. tuberculosis (H37Ra strain) using
an Alamar blue (resazurin) bacterial growth assay.[23] Both 11
and 12 exhibited significant antibacterial activity (MIC50: 275
and 330 mm, respectively) and, as such, were further confirmed
as suitable fragments for chemical elaboration to generate
a novel library of type II DHQase inhibitors with antitubercular
activity.
Fragment elaboration
Having demonstrated the suitability of 11 and 12 as small scaf-
folds with considerable inhibitory activity against M. tuberculo-
sis type II DHQase, we next focused on elaborating these frag-
ments to provide more potent inhibitors. Specifically, we chose
to investigate conjugates of 11 and 12 in which a range of aryl
and heteroaryl moieties were appended. These groups were
designed to occupy the subsidiary binding pocket to form a fa-
vorable p–p stacking interaction with the conserved tyrosine
residue (Tyr24) present on the flexible loop, which was predict-
ed to enhance potency. Ether and thioether linkages to 11 and
12 were proposed by implementing a broad range of aryl and
heteroaryl alcohols and thiols to provide a series of inhibitors
with variation in the steric and electronic nature of the termi-
nal aryl and heteroaryl moieties (e.g. , general structures 13
and 14, Figure 4).
A number of proposed inhibitors were assessed for suitabili-
ty by the use of in silico molecular docking into the active site
of M. tuberculosis type II DHQase studies using Glide (Support-
ing Information). These docking studies suggested that the
majority of the inhibitors are capable of binding with the cate-
chol and aryl acetonide moieties that occupy the active site of
the enzyme, thus enabling the formation of hydrogen bonding
interactions with key active site residues. Notably, the elaborat-
ed inhibitors of the aryl acetonide core (see general structure
13, Figure 4) led to a reorientation in binding mode relative to
that predicted for fragment 12 alone, such that the pose was
similar to that observed for 11 and the elaborated inhibitors of
this fragment. The docking studies also suggested that the ter-
minal aromatic moieties of all inhibitors are capable of occupy-
ing the subsidiary binding site to interact with Tyr24 (located
on the flexible loop) via an offset face-to-face or edge-to-face
p-stacking interaction (see the Supporting Information for
binding poses).
Synthesis
Having designed a library of target inhibitors in silico, we next
undertook the synthesis of the proposed O- and S-linked inhib-
itors 15a–q (containing the acetonide core of 12) from cate-
chol 17 (Scheme 3). Friedel–Crafts acylation using acetyl chlo-
ride in the presence of excess aluminum chloride provided 3,4-
dihydroxyacetophenone 11 in 95% yield. Subsequent protec-
tion of the diol by treatment with acetone in the presence of
excess phosphorus pentoxide furnished the acetonide-protect-
ed 3,4-dihydroxyacetophenone 12 in 40% yield. From here,
bromination of 12 using copper(II) bromide in ethyl acetate
and dichloromethane at reflux afforded the acetonide-protect-
ed a-bromoketone 18 in 57% yield which served as a key in-
termediate for the preparation of the proposed inhibitor li-
brary. Reaction of 18 with a range of aryl- and heteroaryl-de-
rived alcohols and thiols facilitated nucleophilic substitution of
the bromide and provided the 17 acetonide-based O- and S-
linked inhibitors 15a–q in moderate to excellent yields (59–
91%). These compounds were subsequently deprotected using
Table 1. ClogP values and activity of compounds 10–12 against M. tuber-
culosis type II DHQase (Ki) and M. tuberculosis strain H37Ra (MIC50).
Compound Ki [mm] MIC50 [mm]
[c] ClogP
10 200!20[a] >1000 "2.7
11 173!34[b] 275!49 1.0
12 120!23[b] 330!14 2.4
[a] Inhibition constant for 10 was determined by Frederickson et al.[22] Ki-
netic constants for this study: KM=64!6 mm ; 50 mm Tris·HCl, pH 7.0,
25 8C. [b] Kinetic constants: KM=25!3 mm, kcat=4.5 s"1; 50 mm Tris·HCl,
pH 7.0, 25 8C. [c] Isoniazid MIC50=176!14 nm ; rifampicin MIC50=1.7!
0.4 nm ; Glide XP scores: 10 "10, 11 "7.7, 12 "7.2. Data represent the
mean !SD from two replicate assays for M. tuberculosis type II DHQase
and three replicate assays for M. tuberculosis H37Ra.
Figure 4. Generalized inhibitor structures bearing an acetonide (compound
13) or catechol (compound 14) core linked to aryl or heteroaryl rings. X=O
or S; R=variety of aryl and heteroaryl groups.
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90% aqueous trifluoroacetic acid to afford 17 catechol-based
O- and S-linked inhibitors 16a–q (Scheme 3).
Enzyme inhibition assays
Having successfully prepared a library of 34 inhibitors, we next
evaluated these compounds for their enzyme inhibitory activi-
ty. To this end, compounds 15a–q and 16a–q were screened
against M. tuberculosis type II DHQase using a previously de-
scribed kinetic assay.[18a] The majority of the catechol-based in-
hibitors 16a–q possessed considerably enhanced inhibitory ac-
tivities (Ki : 5–39 mm) against M. tuberculosis type II DHQase over
compounds 11 and 12 alone (Ki : 173 and 120 mm, respectively;
Table 2). Although the majority of the compounds clearly fitted
a competitive, reversible model of inhibition, compounds 16g,
16 i, 16 j, and 16p fitted a mixed inhibition model tending
toward a competitive mode of inhibition (alpha=1.3–2.2, see
Experimental Section and Supporting Information). This could
be explained by the presence of a bulky terminal aromatic
moiety in each of these compounds, which may bias interac-
tions with the subsidiary binding pocket and enable substrate
binding to the active site. Inhibitors 15a–q, containing the
acetonide core, exhibited similar inhibitory activity (Ki : 12–
48 mm), albeit slightly less potent than 16a–q against M. tuber-
culosis type II DHQase (Table 3). In a similar manner to the cate-
chol-based inhibitors, the incorporation of bulky aromatic moi-
eties generally resulted in better fitting to a mixed model of
enzyme inhibition (see Experimental Section and Supporting
Information). Notably, whereas fragments 11 and 12 are capa-
ble of inhibiting type II DHQase with effectiveness similar to
that of 2,3-anhydroquinate 10, the incorporation of aryl and
heteroaryl groups into the acetophenone moiety resulted in—
on average—a tenfold increase in inhibitory potency com-
pared with an increase of three orders of magnitude for similar
aromatic moieties appended to C3 of the anhydroquinate core
in prior inhibitor studies.[16c,18a] Inspection of docking results of
the inhibitors and comparison with the fragments suggests
weaker hydrogen bonding interactions between the carbonyl
moiety of the acetophenone core and the amide backbone be-
tween Ile102 and Ser103 in the inhibitors as a result of the
newly formed p-stacking interaction. In contrast, the hydrogen
bonding interactions in the active site of the anhydroquinate-
based inhibitors are not reorganized if a terminal aromatic
moiety is appended to facilitate a p-stacking interaction,
owing to the pre-organized nature of the hydrogen bonding
functionalities. This may reflect a limitation of using planar
scaffolds in place of the chiral anhydroquinate core for potent
inhibition of type II dehydroquinases.
For both series of compounds (15a–q and 16a–q) altering
the electronic or steric properties of the aromatic moieties did
not result in dramatic differences in the inhibition of the
enzyme (see Tables 2 and 3). The flat structure–activity data
from this study suggest that the subsidiary binding pocket of
the M. tuberculosis enzyme is capable of accommodating a di-
verse range of aryl and heteroaryl rings for favorable p-stack-
ing interactions.[16c,18a] While large variations in inhibition activi-
ty were not observed between the compounds, inhibitors 16 f,
16g, and 16m, bearing 2-naphthyl, 1-naphthyl, and 4-chloro-
phenyl moieties, respectively, exhibited the most potent inhibi-
tion of type II DHQase, with respective inhibition constants of
5, 8, and 6 mm.
Inhibition of Mycobacterium tuberculosis
Having demonstrated that the fragment-derived inhibitors are
capable of exhibiting low-micromolar inhibition of M. tubercu-
losis type II DHQase in vitro, we were next interested in evalu-
ating the in vitro activity against M. tuberculosis to evaluate the
potential of these compounds to serve as new TB drug leads.
We were pleased to observe that most inhibitors exhibited sig-
Scheme 3. Synthesis of O- and S-linked inhibitors 15a–q and 16a–q. Reagents and conditions: a) 1. AcCl, DCE, AlCl3, 10 8C!RT, 2. HCl(aq), 10 8C, 95%;
b) (CH3)2CO, P2O5, PhCH3, 75 8C, 40%; c) CuBr2, EtOAc/CH2Cl2 (1:1 v/v), reflux, 57%; d) Ar-OH or Ar-SH, K2CO3, acetone, reflux, 4–5 h, 59–91%; e) 90% TFA, RT,
1.5 h, 57–100%.
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Table 2. Activity of acetophenone-based inhibitors 16a–q against M. tu-
berculosis type II DHQase (Ki) and M. tuberculosis strain H37Ra (MIC50).
Compd R X Ki [mm]
[a] MIC50 [mm]
[b]
16a O 18!2 330!14
16b S 12!2 370!84
16c O 20!3 505!134
16d O 14!2 375!35
16e O 13!3 360!14
16 f O 5!1 370!14
16g O 8!2[c] 455!7
16h O 12!2 570!42
16 i O 39!9[c] 195!49
16 j O 8!3[c] 350!14
16k S 36!5 >1000
16 l S 14!3 485!134
16m S 6!1 295!106
16n S 14!2 270!1
16o S 17!2 >1000
16p S 10!2[c] 350!28
16q S 13!2 690!70
[a] Kinetic constants: KM=25!3 mm, kcat=4.5 s"1; 50 mm Tris·HCl, pH 7.0,
25 8C. [b] Isoniazid MIC50=176!14 nm ; rifampicin MIC50=1.7!0.4 nm.
[c] Mixed model inhibition. Data represent the mean !SD from two repli-
cate assays for M. tuberculosis type II DHQase and three replicate assays
for M. tuberculosis H37Ra.
Table 3. Activity of acetonide-based inhibitors 15a–q against M. tubercu-
losis type II DHQase (Ki) and M. tuberculosis strain H37Ra (MIC50).
Compd R X Ki [mm]
[a] MIC50 [mm]
[b]
15a O 29!5 115!28
15b S 42!16[c] 90!7
15c O 22!5[c] 690!56
15d O 41!5 140!1
15e O 15!2 690!14
15 f O 13!3 40!7
15g O 18!3 55!7
15h O 28!3 835!35
15 i O 48!16[c] >1000
15 j O 30!6[c] 363!10
15k S 27!10[c] >1000
15 l S 35!7[c] 73!18
15m S 19!2 70!7
15n S 12!5[c] 33!4
15o S 18!2 10!1
15p S 19!4[c] 575!120
15q S 19!2 850!14
[a] Kinetic constants: KM=22!3 mm, kcat=4.4 s"1; 50 mm Tris·HCl, pH 7.0,
25 8C. [b] Isoniazid MIC50=176!14 nm ; rifampicin MIC50=1.7!0.4 nm.
[c] Mixed model inhibition. Data represent the mean !SD from two repli-
cate assays for M. tuberculosis type II DHQase and three replicate assays
for M. tuberculosis H37Ra.
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nificant inhibition of M. tuberculosis growth in vitro (MIC50: 10–
835 mm). Although there was no clear correlation between the
inhibition of M. tuberculosis type II DHQase and the MIC50
values against M. tuberculosis growth, some interesting SAR
trends emerged. Firstly, the majority of acetonide-based com-
pounds were at least twofold more potent than the corre-
sponding catechol-based inhibitors against M. tuberculosis
growth in vitro. This finding may reflect the increased hydro-
phobicity of the acetonide-based compounds, a factor that has
been shown to be important in the penetration of the waxy
cell wall of M. tuberculosis.[24] It is feasible that the acetonide
moiety of these compounds is hydrolyzed after entry into the
mycobacterial cell. However, it is entirely possible, given the
variation in activity against M. tuberculosis, that the compounds
prepared in this study inhibit alternate or multiple pathways in
vitro. Nonetheless, the incorporation of bicyclic moieties such
as benzothiazole and 2-naphthalene groups in 15o and 15n
resulted in the most potent inhibitors of M. tuberculosis
growth, with MIC50 values of 10 and 33 mm, respectively. Com-
pound 15o was also shown to possess significant activity
against the virulent H37Rv strain of M. tuberculosis (MIC50=
33!5 mm) and, although significantly less potent than the
frontline TB drugs isoniazid and rifampicin, now serves as
a lead for further investigation.
Conclusions
In summary, we successfully employed an in silico fragment
screening approach to identify 3,4-dihydroxyacetophenone
and acetonide cores as replacements for the 2,3-anhydroqui-
nate core previously employed in type II DHQase inhibitors.
Elaboration of these fragments to incorporate a range of aryl
and heteroaryl moieties led to a library of inhibitors that pos-
sess low-micromolar inhibition of type II DHQase. Importantly,
this study has revealed compounds with promising activity
against M. tuberculosis growth in vitro. Future work in our re-
search groups will involve co-crystallization of acetophenone
and acetonide-based inhibitors with M. tuberculosis type II
DHQase; this will aid in the rational design of more potent
type II DHQase inhibitors. In addition, work is underway to
study the molecular mechanism of the antitubercular activity
exhibited by these compounds, the results of which will be re-
ported in due course.
Experimental Section
General synthesis procedures
1H NMR spectra were recorded at 300 K using Bruker Avance
DRX200, DRX300, DPX400, or III-600 NMR spectrometers at a fre-
quency of 200.1, 300.2, 400.2, and 600.0 MHz, respectively. 1H NMR
chemical shifts are reported in parts per million (ppm) and are ref-
erenced to solvent residual signals: CDCl3 (d=7.26 ppm), MeOD
(d=3.31 ppm), (CD3)2CO (d=2.05 ppm).
1H NMR data are reported
as chemical shift (dH), relative integral, multiplicity (s= singlet, d=
doublet, t= triplet, q=quartet, dd=doublet of doublets, ddd=
doublet of doublet of doublets), coupling constant (J in Hz), and
assignment where possible. Low-resolution mass spectra were re-
corded on a Finnigan LCQ Deca ion trap mass spectrometer (ESI).
High-resolution mass spectra were recorded on a Bruker 7T Fourier
Transform Ion Cyclotron Resonance (FTICR) mass spectrometer.
Melting points were recorded using a Stanford Research Systems
OptiMelt Automated Melting Point System. Infrared (IR) absorption
spectra were recorded on a Bruker Alpha Spectrometer with atte-
nuated total reflection (ATR) capability and were processed with
OPUS 6.5 software.
Analytical reversed-phase HPLC was performed on a Waters
System 2695 separations module with an Alliance series column
heater at 30 8C and 2996 photodiode array detector. Inhibitors 11
and 16a–q were analyzed using a Waters Sunfire BEH300 5 mm,
2.1!150 mm column (C18) at a flow rate of 0.2 mLmin
"1 using
a mobile phase of 0.1% TFA in H2O (Solvent A) and 0.1% TFA in
CH3CN (Solvent B) and a linear gradient of 0 to 100% B over
40 min. Inhibitors 19 and 15a–q were analyzed with a Waters Sun-
fire 300 5 mm, 2.1!150 mm column (C4) at a flow rate of
0.2 mLmin"1 using a mobile phase of 0.1% TFA in H2O (Solvent A)
and 0.1% TFA in CH3CN (Solvent B) and a linear gradient of 20 to
100% B over 40 min. Results were analyzed with Waters Empower
software. The purity of the final inhibitors was shown to be >97%
by analytical HPLC.
Materials : Analytical thin-layer chromatography (TLC) was per-
formed on commercially prepared silica plates (Merck Kieselgel 60
0.25 mm F254). Flash column chromatography was performed using
230–400 mesh Kieselgel 60 silica eluting with distilled solvents as
described. Ratios of solvents used for TLC and column chromatog-
raphy are expressed in v/v as specified. Compounds were visual-
ized by UV light at l 254 nm or by using vanillin or cerium molyb-
date stain. Commercial materials were used as received, unless oth-
erwise noted. Dichloromethane and methanol were distilled from
calcium hydride, and THF and diethyl ether were distilled over
sodium/benzophenone. Anhydrous DMF was purchased from
Sigma–Aldrich.
Molecular modeling
Protein preparation : The crystal structures of M. tuberculosis
type II DHQase were downloaded from the Research Collaboratory
for Structural Bioinformatics (RCSB) Protein Data Bank (PDB code:
2XB8).[19a] The structures were subjected to further modification to
ensure suitability for molecular docking using Glide (version 5.0).[21]
The ligand–protein co-crystal structures were imported into Accel-
rys DS visualizer 2.0 (Accelrys Software Inc.) where the dodecamers
were simplified into a dimer (Subunits A and B). (2R)-2-Methoxy-
benzyl-3-dehydroquinic acid was maintained in subunit A. Structur-
al water molecules were also removed. The simplified type II
DHQase protein structure was then imported into Maestro (ver-
sion 9.1) and prepared using the Protein Preparation Wizard tool, in
which bond orders were assigned to the ligands. Hydrogen atoms
were added to both ligands and the protein in a manner consis-
tent with physiological pH (pH 7.0) using an all-atom force field.
Restrained minimization of the protein structure was then conduct-
ed using impref using an OPLS-AA force field until the root mean
square deviation (RMSD) of non-hydrogen atoms reached 0.3.
Ligand preparation : Ligands were built in Maestro (version 9.1)
and used as maegz files. The ligands were then subjected to treat-
ment with Ligprep (version 2.3), which generates low-energy 3D
structures with tautomers and possible states at pH 7.
Glide docking : A receptor grid file was generated using the Recep-
tor Grid Generation utility in Glide (version 5.0). The ligand chosen
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was (2R)-2-methoxybenzyl-3-dehydroquinic acid as the center of
receptor grid generation; van der Waals radius scaling and partial
charge cutoff default values were used. Per-atom scale factors,
which soften receptor potential, were not used. After the receptor
grids were generated, ligands were docked into the active site
using extra precision (XP) mode.
Synthesis
1-(3,4-Dihydroxyphenyl)ethanone (11): Anhydrous AlCl3 (0.98 g,
7.4 mmol) was dissolved in 1,2-dichloroethane (DCE), and the reac-
tion was cooled to 10 8C for 30 min. Catechol 17 (0.32 g, 2.9 mmol)
was added in three portions over 5 min, and the reaction was
stirred at 10 8C for a further 30 min. Acetyl chloride (0.26 mL,
3.2 mmol) was added dropwise to the reaction mixture, which was
allowed to warm to room temperature and stirred for 20 h. The re-
action was subsequently cooled to 10 8C before quenching with
1m HCl (10 mL), and the reaction mixture was allowed to stir for
a further 2 h. The reaction mixture was diluted with CH2Cl2 (30 mL),
and the organic layer was separated. The aqueous layer was ex-
tracted with EtOAc (2!30 mL), and the combined organic layers
were washed with brine (40 mL) and dried over anhydrous Na2SO4.
The solvent was removed in vacuo to afford acetophenone 11 as
a red solid, which was used without further purification (0.43 g,
95%). Rf (8:1 v/v CH2Cl2/Et2O)=0.30; mp: 120–121 8C;
1H NMR
(400 MHz, CDCl3): d=7.47 (1H, dd, J=4.0, 8.0 Hz, Ar-H, C-6), 7.42
(1H, d, J=4.0 Hz, Ar-H, C-2), 6.88 ppm (1H, d, J=8.0 Hz, Ar-H, C-5);
13C NMR (100 MHz, [D6]acetone): d=195.9, 150.2, 145.3, 130.1,
122.2, 115.6, 114.8, 25.5 ppm; IR (ATR): n˜=3000, 1796 cm!1. These
data are in agreement with those previously reported by Xiao
et al.[25]
1-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)ethanone (12): A mixture
of 3,4-dihydroxyacetophenone 11 (3.87 g, 25 mmol) and P2O5
(220 mg) in toluene (13 mL) was heated at 75 8C. Acetone (7.4 mL,
100 mmol) was added dropwise to the suspension over 3 h. After
the addition, four portions of P2O5 (4!220 mg) were added to the
reaction mixture every 30 min. The reaction was allowed to stir at
75 8C for 5 h. The reaction was quenched with 25% NaOH(aq)
(15 mL), and the solvent was removed in vacuo to yield a crude
residue that was purified by column chromatography (2:1 v/v
CH2Cl2/hexane) to afford acetonide 12 as a pale-yellow oil (1.96 g,
40%). Rf (2:1 v/v CH2Cl2/hexane)=0.29;
1H NMR (400 MHz, CDCl3):
d=7.53 (1H, dd, J=1.6, 8.0 Hz, Ar-H, H-6), 7.35 (1H, s, Ar-H, H-2),
6.75 (1H, d, J=8.0 Hz, Ar-H, H-5), 2.52 (3H, s, CH3), 1.69 (6H, s, 2!
CH3);
13C NMR (100 MHz, CDCl3): d=196.5, 151.7, 147.9, 131.6,
124.4, 119.4, 107.9, 107.7, 26.5, 25.9 ppm; IR (ATR): n˜=1675 cm!1;
MS (ESI): m/z 193 [M+H]+ .
2-Bromo-1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)ethanone (18):
A solution of acetonide 12 (380 mg, 1.9 mmol) was added to a solu-
tion of CuBr2 (830 mg, 3.7 mmol) in EtOAc (2.5 mL) and CH2Cl2
(2.5 mL). The reaction mixture was held at reflux with vigorous stir-
ring for 9 h. The reaction mixture was then filtered, the solvent re-
moved in vacuo, and the crude residue purified by column chro-
matography (1:1 v/v CH2Cl2/hexane!2:1 v/v CH2Cl2/hexane) to
afford a-bromoketone 18 as a pale-yellow oil (290 mg, 57%). Rf
(1:1 v/v CH2Cl2/hexane)=0.26;
1H NMR (300 MHz, CDCl3): d=7.55
(1H, dd, J=1.8, 8.4 Hz, Ar-H, H-6), 7.36 (1H, d, J=1.8 Hz, Ar-H, H-2),
6.77 (1H, d, J=8.4 Hz, Ar-H, H-5), 4.36 (2H, s, CH2), 1.70 ppm (6H,
s, 2!CH3);
13C NMR (75 MHz, CDCl3): d=190.0, 152.9, 148.6, 128.5,
125.6, 120.2, 108.8, 108.3, 30.9, 26.3 ppm; IR (ATR): n˜=1668 cm!1.
General procedure for nucleophilic substitution of bromide 18 :
To a suspension of K2CO3 (0.18–0.23 mmol) in acetone (0.4 mL) was
added a suitable aryl or heteroaryl alcohol or thiol (0.22–
0.32 mmol), and the reaction mixture was stirred at room tempera-
ture for 15 min. Bromide 18 (0.16–0.21 mmol) in acetone (0.4 mL)
was added dropwise, and the reaction was stirred at reflux for 4–
5 h. The reaction was diluted with Et2O (10 mL) and washed with
H2O (2!10 mL). The organic layer was dried over anhydrous
MgSO4 and the solvent removed in vacuo to yield a crude residue
that was purified by column chromatography to afford the corre-
sponding ether or thioether.
1-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-2-phenoxyethanone
(15a): Phenol (21 mg, 0.22 mmol) was reacted with bromide 18
(57 mg, 0.21 mmol) using the general procedure described above
and purified by column chromatography (3:2 v/v CH2Cl2/hexane) to
afford 15a as a pale-yellow oil (40 mg, 67%). Rf (3:2 v/v CH2Cl2/
hexane)=0.45; 1H NMR (300 MHz, CDCl3): d=7.58 (1H, dd, J=1.5,
8.1 Hz, Ar-H), 7.40 (1H, d, J=1.5 Hz, Ar-H), 7.27 (2H, t, J=8.4 Hz,
2!Ar-H), 6.97–6.92 (3H, m, 3!Ar-H), 6.78 (1H, d, J=8.1 Hz, Ar-H),
5.17 (2H, s, CH2), 1.64 (6H, s, 2!CH3);
13C NMR (100 MHz, CDCl3):
d=192.7, 158.4, 152.9, 148.2, 129.8, 129.1, 124.4, 121.8, 120.1,
115.0, 108.4, 108.2, 70.6, 26.1 ppm; IR (ATR): n˜=1693 cm!1; HRMS
calcd for C17H16O4Na [M+Na]
+ 307.0941, found 307.0944.
1-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-2-(phenylthio)ethanone
(15b): Thiophenol (33 mL, 0.32 mmol) was reacted with bromide 18
(57 mg, 0.21 mmol) in acetone (0.4 mL) using the general proce-
dure described above and purified by column chromatography
(3:1 v/v hexane: CH2Cl2!3:2 v/v CH2Cl2/hexane) to afford 15b as
a pale-yellow oil (28 mg, 45%). Rf (3:2 v/v CH2Cl2/hexane)=0.43;
1H NMR (400 MHz, CDCl3): d=7.50 (1H, dd, J=1.5, 8.0 Hz, Ar-H),
7.39 (2H, dd, J=1.4, 7.7 Hz, 2!Ar-H), 7.34 (1H, d, J=1.5 Hz, Ar-H),
7.28 (2H, t, J=7.7 Hz, 2!Ar-H), 7.23–7.20 (1H, m, Ar-H), 6.74 (1H,
d, J=8.0 Hz, Ar-H), 4.20 (2H, s, CH2), 1.70 (6H, s, 2!CH3);
13C NMR
(100 MHz, CDCl3): d=192.5, 152.1, 148.3, 135.1, 131.7, 129.6, 129.1,
127.0, 124.8, 119.7, 108.3, 107.9, 41.9, 22.8 ppm; IR (ATR): n˜=
1671 cm!1; HRMS calcd for C17H16O3SNa [M+Na]
+ 323.0712, found
323.0708.
1-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-2-(3-(trifluoromethyl)-
phenoxy)ethanone (15c): 3-(Trifluoromethyl)phenol (39 mL,
0.32 mmol) was reacted with bromide 18 (57 mg, 0.21 mmol) using
the general procedure described above and purified by column
chromatography (3:2 v/v CH2Cl2/hexane) to afford 15c as a white
solid (67 mg, 90%). Rf (1:1 v/v CH2Cl2/hexane)=0.24; mp: 115–
116 8C; 1H NMR (282 MHz, CDCl3): d=7.54 (1H, dd, J=1.8, 8.1 Hz,
Ar-H), 7.42–7.33 (2H, m, 2!Ar-H), 7.26–7.20 (1H, m, Ar-H), 7.19–
7.14 (1H, m, Ar-H), 7.13–7.04 (1H, m, Ar-H), 6.79 (1H, d, J=8.1 Hz,
Ar-H), 5.23 (2H, s, CH2), 1.71 ppm (6H, s, 2!CH3);
13C NMR
(100 MHz, CDCl3): d=191.9, 158.2, 152.7, 148.3, 131.9 (q, J=33 Hz),
130.2, 128.4, 125.3 (q, J=270 Hz, CF3), 124.2, 119.9, 118.3 (q, J=
3.1 Hz), 118.1, 111.9 (q, J=3.2 Hz), 108.1, 107.8, 70.4, 26.0 ppm; IR
(ATR): n˜=1694 cm!1; HRMS calcd for C18H15F3O4Na [M+Na]
+
375.0815, found 375.0813.
1-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-2-(2-fluorophenoxy)-
ethanone (15d): 2-Fluorophenol (28 mL, 0.32 mmol) was reacted
with bromide 18 (57 mg, 0.21 mmol) using the general procedure
described above and purified by column chromatography (2:1 v/v
CH2Cl2/hexane) to afford 15d as a white solid (62 mg, 97%). Rf (2:1
v/v CH2Cl2/hexane)=0.43; mp: 113–114 8C;
1H NMR (282 MHz,
CDCl3): d=7.57 (1H, dd, J=1.8, 8.4 Hz, Ar-H), 7.38 (1H, d, J=
1.8 Hz, Ar-H), 7.08 (1H, dt, J=1.8, 8.1 Hz, Ar-H), 7.00 (1H, dd, J=
1.8, 8.1 Hz, Ar-H), 6.95–6.89 (2H, m, 2!Ar-H), 6.78 (1H, d, J=8.4 Hz,
Ar-H), 5.25 (2H, s, CH2), 1.70 ppm (6H, s, 2!CH3);
13C NMR
(100 MHz, CDCl3): d=192.2, 153.3 (d, J=258 Hz, ipso-C), 152.5,
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148.2, 146.1 (d, J=9.5 Hz, ortho-C), 128.5, 124.3 (d, J=4.8 Hz, para-
C), 124.2, 122.2 (d, J=7.9 Hz, meta-C), 119.8, 116.6 (d, J=19 Hz,
ortho-C), 116.0, 108.1, 107.8, 71.9, 26.0 ppm; IR (ATR): n˜=
1692 cm!1; HRMS calcd for C17H15FO4Na [M+Na]
+ 325.0845, found
325.0842.
1-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-2-(3-nitrophenoxy)etha-
none (15e): 3-Nitrophenol (32 mg, 0.23 mmol) was reacted with
bromide 18 (57 mg, 0.21 mmol) using the general procedure de-
scribed above and purified by column chromatography (3:1 v/v
CH2Cl2/hexane) to afford 15e as an off-white solid (41 mg, 59%). Rf
(3:2 v/v CH2Cl2/hexane)=0.28; mp: 171–172 8C;
1H NMR (300 MHz,
1:1 v/v CDCl3/[D6]acetone): d=7.87 (1H, dd, J=1.6, 8.1 Hz, Ar-H),
7.79 (1H, d, J=1.6 Hz, Ar-H), 7.64 (1H, dd, J=1.6, 8.1 Hz, Ar-H),
7.50 (1H, t, J=8.1 Hz, Ar-H), 7.36–7.33 (2H, m, 2!Ar-H), 6.85 (1H,
d, J=8.1 Hz, Ar-H), 5.46 (2H, s, CH2), 1.74 (6H, s, 2!CH3);
13C NMR
(100 MHz, 1:1 v/v CDCl3/[D6]acetone): d=196.5, 164.0, 157.7, 154.3,
153.4, 135.4, 133.5, 129.2, 127.0, 125.0, 121.4, 114.5, 113.3, 112.7,
75.6, 30.9 ppm; IR (ATR): n˜=1653 cm!1; HRMS calcd for
C17H15NO6Na [M+Na]
+ 352.0792, found 352.0793.
1-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-2-(naphthalen-2-yl-
oxy)ethanone (15 f): 2-Naphthol (31 mg, 0.22 mmol) was reacted
with bromide 18 (57 mg, 0.21 mmol) using the general procedure
described above and purified by column chromatography (3:2 v/v
CH2Cl2/hexane) to afford 15 f as a white solid (70 mg, 91%). Rf (3:2
v/v CH2Cl2/hexane)=0.45; mp: 129–130 8C (dec.) ;
1H NMR
(300 MHz, CDCl3): d=7.77–7.75 (2H, m, 2!Ar-H), 7.71 (1H, d, J=
8.4 Hz, Ar-H), 7.63 (1H, dd, J=1.6, 8.0 Hz, Ar-H), 7.45–7.43 (2H, m,
2!Ar-H), 7.34 (1H, t, J=7.2 Hz, Ar-H), 7.26 (1H, dd, J=2.4, 8.8 Hz,
Ar-H), 7.11 (1H, d, J=2.4 Hz, Ar-H), 6.80 (1H, d, J=8.0 Hz, Ar-H),
5.30 (2H, s, CH2), 1.72 ppm (6H, s, 2!CH3);
13C NMR (75 MHz,
CDCl3): d=192.9, 156.5, 152.8, 148.6, 134.7, 130.1, 129.8, 129.3,
128.1, 127.3, 126.9, 124.6, 124.4, 120.0, 119.1, 108.4, 108.3, 107.7,
71.1, 26.3 ppm; IR (ATR): n˜=1689 cm!1; HRMS calcd for C21H18O4Na
[M+Na]+ 357.1097, found 357.1091.
1-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-2-(naphthalen-1-yl-
oxy)ethanone (15g): 1-Naphthol (31 mg, 0.22 mmol) was reacted
with bromide 18 (57 mg, 0.21 mmol) using the general procedure
described above and purified by column chromatography (3:2 v/v
CH2Cl2/hexane) to afford 15g as a colorless oil (54 mg, 77%). Rf
(3:2 v/v CH2Cl2/hexane)=0.51;
1H NMR (300 MHz, CDCl3): d=8.40–
8.37 (1H, m, Ar-H), 7.83–7.79 (1H, m, Ar-H), 7.65 (1H, dd, J=1.5,
8.1 Hz, Ar-H), 7.52–7.46 (4H, m, 4!Ar-H), 7.32 (1H, t, J=8.1 Hz, Ar-
H), 6.80–6.75 (2H, m, 2!Ar-H), 5.33 (2H, s, CH2), 1.71 (6H, s, 2!
CH3);
13C NMR (75 MHz, CDCl3): d=193.1, 154.3, 152.7, 148.6, 135.0,
129.3, 127.8, 126.9, 126.1, 126.0, 125.9, 124.8, 122.6, 121.6, 120.0,
108.3, 105.7, 71.6, 26.3 ppm; IR (ATR): n˜=1698 cm!1; HRMS calcd
for C21H19O4 [M+H]
+ 335.1278, found 335.1280.
1-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-2-(2-(isoxazol-5-yl)phe-
noxy)ethanone (15h): 2-(5-Isoxazolyl)phenol (38 mg, 0.23 mmol)
was reacted with bromide 18 (57 mg, 0.21 mmol) using the general
procedure described above and purified by column chromatogra-
phy (4:1 v/v CH2Cl2/hexane) to afford 15h as an off-white solid
(38 mg, 52%). Rf (4:1 v/v CH2Cl2/hexane)=0.32; mp: 138–139 8C
(dec.) ; 1H NMR (300 MHz, 1:1 v/v CDCl3/[D6]acetone): d=8.38 (1H,
s, Ar-H), 7.98 (1H, d, J=8.0 Hz, Ar-H), 7.68–7.65 (1H, m, Ar-H), 7.48
(1H, s, Ar-H), 7.42–7.38 (2H, m, 2!Ar-H), 7.15 (1H, d, J=8.0 Hz, Ar-
H), 7.10 (1H, t, J=8.0 Hz, Ar-H), 6.82 (1H, d, J=8.0 Hz, Ar-H), 5.52
(2H, s, CH2), 1.71 (6H, s, 2!CH3);
13C NMR (100 MHz, 1:1 v/v CDCl3/
[D6]acetone): d=192.0, 154.6, 152.3, 151.2, 148.2, 131.1, 128.6,
127.4, 123.9, 121.4, 119.7, 116.7, 112.6, 108.0, 107.3, 103.9, 70.4,
25.6 ppm; IR (ATR): n˜=1697 cm!1; HRMS calcd for C20H17NO5Na
[M+Na]+ 374.0998, found 374.1002.
1-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-2-(4-(naphthalen-2-yl)-
phenoxy)ethanone (15 i): 4-(Naphthalen-2-yl)phenol (40 mg,
0.18 mmol) was reacted with bromide 18 (45 mg, 0.16 mmol) using
the general procedure described above and purified by column
chromatography (3:2 v/v CH2Cl2/hexane) to afford 15 i as a white
solid (40 mg, 62%). Rf (2:1 v/v CH2Cl2/hexane)=0.40; mp: 119–
120 8C (dec.) 1H NMR (400 MHz, CDCl3): d=7.99 (1H, s, Ar-H), 7.90–
7.84 (3H, m, 3!Ar-H), 7.70 (1H, d, J=8.3 Hz, Ar-H), 7.66–7.61 (3H,
m, 3!Ar-H), 7.51–7.44 (3H, m, 3!Ar-H), 7.05 (2H, d, J=8.4 Hz, 2!
Ar-H), 6.81 (1H, d, J=8.1 Hz, Ar-H), 5.24 (2H, s, CH2), 1.72 ppm (6H,
s, 2!CH3);
13C NMR (100 MHz, CDCl3): d=192.5, 157.8, 152.3, 148.2,
138.0, 134.4, 132.5, 128.8, 128.5, 128.4, 128.0, 127.6, 126.2, 125.7,
125.4, 125.1, 124.2, 119.7, 115.2, 108.0, 107.9, 70.6, 25.7 ppm; IR
(ATR): n˜=1691 cm!1; HRMS calcd for C27H23O4 [M+H]
+ 411.1596,
found 411.1591.
1-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-2-(3-(naphthalen-2-yl)-
phenoxy)ethanone (15 j): 3-(Naphthalen-2-yl)phenol (40 mg,
0.18 mmol) was reacted with bromide 18 (45 mg, 0.16 mmol) using
the general procedure described above and purified by column
chromatography (3:2 v/v CH2Cl2/hexane) to afford 15 j as a foam
(38 mg, 58%). Rf (2:1 v/v CH2Cl2/hexane)=0.50;
1H NMR (400 MHz,
CDCl3): d=8.02 (1H, d, J=1.4 Hz, Ar-H), 7.92–7.85 (3H, m, 3!Ar-H),
7.72 (1H, dd, J=1.8, 8.5 Hz, Ar-H), 7.62 (1H, dd, J=1.8, 8.2 Hz, Ar-
H), 7.51–7.48 (2H, m, 2!Ar-H), 7.44 (1H, d, J=1.8 Hz, Ar-H), 7.40
(1H, app. t, J=7.8 Hz, Ar-H), 7.36 (1H, app. t, J=1.4 Hz, Ar-H), 7.34–
7.32 (1H, m, Ar-H), 6.94 (1H, ddd, J=1.4, 2.6, 7.8 Hz, Ar-H), 6.80
(1H, d, J=8.2 Hz, Ar-H), 5.26 (2H, s, CH2), 1.73 ppm (6H, s, 2!CH3);
13C NMR (100 MHz, CDCl3): d=192.6, 158.9, 152.2, 147.9, 142.7,
137.9, 133.6, 132.7, 129.9, 128.8, 128.4, 128.2, 127.6, 126.3, 126.0,
125.9, 125.6, 124.7, 120.8, 119.7, 114.3, 113.3, 108.0, 107.9, 70.7,
26.3 ppm; IR (ATR): n˜=1706 cm!1; HRMS calcd for C27H23O4 [M+
H]+ 411.1596, found 411.1591.
1-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-2-(2-(trifluoromethyl)-
phenylthio)ethanone (15k): 2-Trifluoromethyl benzenethiol (43 mL,
0.32 mmol) was reacted with bromide 18 (57 mg, 0.21 mmol) using
the general procedure described above and purified by column
chromatography (3:2 v/v CH2Cl2/hexane) to afford 15k as a pale-
yellow oil (38 mg, 49%). Rf (3:2 v/v CH2Cl2/hexane)=0.79;
1H NMR
(400 MHz, CDCl3): d=7.65 (1H, m, Ar-H), 7.59–7.50 (2H, m, 2!Ar-
H), 7.46 (1H, t, J=7.6 Hz, Ar-H), 7.35–7.31 (2H, m, 2!Ar-H), 6.76
(1H, d, J=8.0 Hz, Ar-H), 4.24 (2H, s, CH2), 1.07 (6H, s, 2!CH3);
13C NMR (100 MHz, CDCl3): d=192.2, 152.6, 148.4, 134.7, 133.4,
132.6, 130.8 (q, J=30 Hz), 129.8, 127.4, 127.2 (q, J=5.5 Hz), 125.4
(q, J=272 Hz, CF3), 125.2, 120.0, 108.6, 108.2, 41.4, 26.0 ppm; IR
(ATR): n˜=1672 cm!1; HRMS calcd for C18H15F3O3SNa [M+Na]
+
391.0586, found 391.0588.
1-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-2-((4-fluorophenyl)-
thio)ethanone (15 l): 4-Fluorothiophenol (34 mL, 0.32 mmol) was
reacted with bromide 18 (57 mg, 0.21 mmol) using the general
procedure described above and purified by column chromatogra-
phy (3:2 v/v CH2Cl2/hexane) to afford 15 l as a pale-yellow oil
(42 mg, 63%). Rf (3:2 v/v CH2Cl2/hexane)=0.28;
1H NMR (300 MHz,
CDCl3): d=7.47 (1H, dd, J=1.8, 8.1 Hz, Ar-H), 7.45–7.36 (2H, m, 2!
Ar-H), 7.31 (1H, d, J=1.8 Hz, Ar-H), 7.00–6.94 (2H, m, 2!Ar-H), 6.75
(1H, d, J=8.1 Hz, Ar-H), 4.08 (2H, s, CH2), 1.72 ppm (6H, s, 2!CH3);
13C NMR (100 MHz, CDCl3): d=192.6, 162.0 (d, J=210 Hz, ipso-C),
152.4, 148.6, 134.1 (d, J=8.1 Hz, meta-C), 130.0 (d, J=3.1 Hz, para-
C), 129.8, 125.1, 120.0, 116.5 (d, J=22 Hz, ortho-C), 108.6, 108.2,
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42.0, 26.0 ppm; IR (ATR): n˜=1649 cm!1; HRMS calcd for
C17H15FO3SNa [M+Na]
+ 341.0618, found 341.0615.
2-((4-Chlorophenyl)thio)-1-(2,2-dimethylbenzo[d][1,3]dioxol-5-
yl)ethanone (15m): 4-Chlorothiophenol (45 mg, 0.32 mmol) was
reacted with bromide 18 (57 mg, 0.21 mmol) using the general
procedure described above and purified by column chromatogra-
phy (3:2 v/v CH2Cl2/hexane) to afford 15m as a pale-yellow oil
(31 mg, 44%). Rf (3:2 v/v CH2Cl2/hexane)=0.59;
1H NMR (300 MHz,
CDCl3): d=7.50 (1H, dd, J=1.5, 8.1 Hz, Ar-H), 7.33 (2H, d, J=
8.8 Hz, 2!Ar-H), 7.26–7.23 (3H, m, 3!Ar-H), 6.75 (1H, d, J=8.1 Hz,
Ar-H), 4.17 (2H, s, CH2), 1.70 ppm (6H, s, 2!CH3);
13C NMR
(100 MHz, CDCl3): d=192.4, 152.6, 148.5, 133.9, 133.5, 132.2, 129.9,
129.6, 125.1, 120.0, 108.6, 108.2, 41.4, 26.3 ppm; IR (ATR): n˜=
1672 cm!1; HRMS calcd for C17H16ClO3S [M+H]
+ 335.0503, found
335.0502.
1-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-2-(naphthalen-2-yl-
thio)ethanone (15n): 2-Naphthalenethiol (51 mg, 0.31 mmol) was
reacted with bromide 18 (57 mg, 0.21 mmol) using the general
procedure described above and purified by column chromatogra-
phy (3:2 v/v CH2Cl2/hexane) to afford 15n as a pale-yellow oil
(39 mg, 53%). Rf (2:1 v/v CH2Cl2/hexane)=0.53;
1H NMR (300 MHz,
CDCl3): d=7.83–7.73 (4H, m, 4!Ar-H), 7.55 (1H, dd, J=1.8, 8.1 Hz,
Ar-H), 7.48 (1H, d, J=1.8 Hz, Ar-H), 7.47–7.43 (2H, m, 2!Ar-H), 7.36
(1H, d, J=1.5 Hz, Ar-H), 6.75 (1H, d, J=8.1 Hz, Ar-H), 4.30 (2H, s,
CH2), 1.69 ppm (6H, s, 2!CH3);
13C NMR (75 MHz, CDCl3): d=192.7,
152.5, 148.5, 134.1, 132.9, 132.6, 130.1, 129.0, 128.3, 128.1, 127.7,
126.9, 126.4, 125.1, 119.9, 108.7, 108.2, 41.3, 26.3 ppm; IR (ATR): n˜=
1668 cm!1; HRMS calcd for C21H18O3SNa [M+Na]
+ 373.0869, found
373.0863.
2-(Benzo[d]thiazol-2-ylthio)-1-(2,2-dimethylbenzo[d][1,3]dioxol-
5-yl)ethanone (15o): 2-Mercaptobenzothiazole (66 mg, 0.36 mmol)
was reacted with bromide 18 (50 mg, 0.18 mmol) using the general
procedure described above and purified by column chromatogra-
phy (49:1 v/v CH2Cl2 : acetone) to afford 15o as a pale-yellow oil
(39 mg, 61%). Rf (2:1 v/v CH2Cl2/hexane)=0.20;
1H NMR (400 MHz,
CDCl3): d=7.83 (1H, app.d, J=8.0 Hz, Ar-H), 7.74 (1H, app.d, J=
7.8 Hz, Ar-H), 7.67 (1H, app.d, J=7.5 Hz, Ar-H), 7.44–7.38 (2H, m,
2!Ar-H), 7.31–7.26 (1H, m, Ar-H), 6.80 (1H, d, J=8.0 Hz, Ar-H), 4.87
(2H, s, CH2), 1.71 ppm (6H, s, 2!CH3);
13C NMR (100 MHz, CDCl3):
d=190.7, 164.8, 152.5, 151.9, 147.4, 135.0, 129.2, 125.6, 124.8,
123.8, 121.1, 120.8, 119.2, 107.7, 107.4, 40.3, 25.5 ppm; IR (ATR): n˜=
1673 cm!1; HRMS calcd for C18H16NO3S2 [M+H]
+ 358.0566, found
358.0569.
1-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-2-((4,5-diphenyloxazol-
2-yl)thio)ethanone (15p): 4,5-Diphenyloxazole-2-thiol (61 mg,
0.24 mmol) was reacted with bromide 18 (50 mg, 0.18 mmol) using
the general procedure described above and purified by column
chromatography (2:1 v/v CH2Cl2/hexane) to afford 15p as a color-
less oil (52 mg, 65%). Rf (2:1 v/v CH2Cl2/hexane)=0.29;
1H NMR
(400 MHz, CDCl3): d=7.65 (1H, dd, J=1.6, 8.0 Hz, Ar-H), 7.62 (2H,
dd, J=1.6, 8.0 Hz, 2!Ar-H), 7.54 (2H, dd, J=1.6, 8.0 Hz, 2!Ar-H),
7.44 (1H, d, J=1.6 Hz, Ar-H), 7.39–7.31 (6H, m, Ar-H), 6.79 (1H, d,
J=8.0 Hz, Ar-H), 4.77 (2H, s, CH2), 1.71 ppm (6H, s, 2!CH3);
13C NMR (100 MHz, CDCl3): d=191.1, 158.3, 152.5, 148.2, 147.4,
136.4, 129.6, 128.7, 128.6, 128.5, 126.4, 124.8, 119.7, 108.1, 107.8,
40.6, 25.6 ppm; IR (ATR): n˜=1675 cm!1; HRMS calcd for C26H22NO4S
[M+H]+ 444.1264, found 444.1264.
2-((2-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-2-oxoethyl)thio)qui-
nazolin-4(3H)-one (15q): 2-Mercaptoquinazolin-4(3H)-one (56 mg,
0.31 mmol) was reacted with bromide 18 (57 mg, 0.21 mmol) using
the general procedure described above to yield 15q as a white
solid which was used without further purification (55 mg, 71%). Rf
(9:1 v/v CH2Cl2/acetone)=0.54; mp: 219–220 8C (dec.) ;
1H NMR
(400 MHz, [D6]DMSO): d=8.04 (1H, dd, J=1.2, 7.9 Hz, Ar-H), 7.76
(1H, dd, J=1.7, 8.2 Hz, Ar-H), 7.72 (1H, dt, J=1.5, 8.5 Hz, Ar-H),
7.50 (1H, d, J=1.7 Hz, Ar-H), 7.42 (1H, dt, J=1.2, 7.9 Hz), 7.27 (1H,
app.d, J=8.5 Hz, Ar-H), 7.05 (1H, d, J=8.2 Hz, Ar-H), 4.82 (2H, s,
CH2), 1.73 ppm (6H, s, 2!CH3);
13C NMR (100 MHz, [D6]DMSO): d=
192.0, 161.6, 155.6, 151.9, 148.4, 147.4, 134.9, 130.7, 126.6, 126.1,
125.0, 120.3, 120.1, 108.5, 108.1, 37.8, 26.0 ppm; IR (ATR): n˜=
1661 cm!1; HRMS calcd for C19H17N2O4S [M+H]
+ 369.0904, found
369.0903.
General procedure for the deprotection of 15a–q : Aqueous tri-
fluoroacetic acid (90%, 0.3–0.4 mL) was added dropwise to aceto-
nide-based inhibitor 15a–q (0.017–0.12 mmol), and the reaction
was stirred at room temperature or at 50 8C for 1.5–5 h. At this
point, the solvent was removed in vacuo to yield a crude residue
that was purified by column chromatography.
1-(3,4-Dihydroxyphenyl)-2-phenoxyethanone (16a): Acetonide-
based inhibitor 15a (27 mg, 0.095 mmol) was deprotected using
the general procedure described above at room temperature for
1.5 h and purified by column chromatography (95:5 v/v CH2Cl2/
CH3OH) to afford inhibitor 16a as an off-white solid (20 mg, 87%).
Rf (95:5 v/v CH2Cl2/CH3OH)=0.26; mp: 157–158 8C (dec.) ;
1H NMR
(400 MHz, [D6]acetone): d=7.55–7.57 (2H, m, 2!Ar-H), 7.25–7.29
(2H, m, 2!Ar-H), 6.91–6.96 (4H, m, 4!Ar-H), 5.38 ppm (2H, s, CH2);
13C NMR (100 MHz, [D6]acetone): d=192.7, 159.0, 150.9, 145.5,
129.7, 128.0, 122.0, 121.2, 115.3, 115.1, 115.0, 70.4 ppm; IR (ATR):
n˜=3404 (br. OH str.), 3367 (br. OH str.), 1676 cm!1; HRMS calcd for
C14H12O4Na [M+Na]
+ 267.0628, found 267.0624.
1-(3,4-Dihydroxyphenyl)-2-(phenylthio)ethanone (16b): Aceto-
nide-based inhibitor 15b (25 mg, 0.083 mmol) was deprotected
using the general procedure described above at room temperature
for 1.5 h and purified by column chromatography (98:2 v/v CH2Cl2/
CH3OH) to afford inhibitor 16b as a pale-yellow oil (23 mg, 93%).
Rf (9:1 v/v CH2Cl2/CH3OH)=0.43;
1H NMR (300 MHz, [D6]acetone):
d=7.53–7.50 (2H, m, 2!Ar-H), 7.41–7.39 (2H, dd, J=1.2, 7.5 Hz,
2!Ar-H), 7.29 (2H, t, J=7.5 Hz, 2!Ar-H), 7.19 (1H, t, J=7.5 Hz, Ar-
H), 6.92 (1H, d, J=8.4 Hz, Ar-H), 4.41 ppm (2H, s, CH2);
13C NMR
(100 MHz, [D6]acetone): d=192.5, 150.9, 145.4, 136.6, 129.4, 129.3,
128.7, 126.5, 122.8, 115.7, 115.2, 40.3 ppm; IR (ATR): n˜=3474 (br.
OH str.), 3270 (br. OH str.), 1657 cm!1; HRMS calcd for C14H12SO3Na
[M+Na]+ 283.0399, found 283.0395.
1-(3,4-Dihydroxyphenyl)-2-(3-(trifluoromethyl)phenoxy)ethanone
(16c): Acetonide-based inhibitor 15c (20 mg, 0.057 mmol) was de-
protected using the general procedure described above at room
temperature for 1.5 h and purified by column chromatography
(95:5 v/v CH2Cl2/CH3OH) to afford inhibitor 16c as a white solid
(14 mg, 78%). Rf (95:5 v/v CH2Cl2/CH3OH)=0.32; mp: 192–193 8C
(dec.) ; 1H NMR (282 MHz, [D6]acetone): d=7.56–7.49 (3H, m, Ar-H),
7.29–7.24 (3H, m, Ar-H), 6.95 (2H, d, J=8.0 Hz, 2!Ar-H), 5.56 ppm
(2H, s, CH2);
13C NMR (100 MHz, [D6]acetone): d=191.1, 158.6,
150.4, 144.6, 130.6 (q, J=32 Hz), 129.9, 126.9, 122.4 (q, J=262 Hz,
CF3), 121.1, 118.1, 117.5 (app.d, J=3.7 Hz), 114.5, 114.2, 111.0
(app.d, J=3.4 Hz), 69.6 ppm; IR (ATR): n˜=3508 (br. OH str.), 3349
(br. OH str.), 1678 cm!1; HRMS calcd for C15H11F3O4Na [M+Na]
+
335.0502, found 335.0501.
1-(3,4-Dihydroxyphenyl)-2-(2-fluorophenoxy)ethanone (16d):
Acetonide-based inhibitor 15d (17 mg, 0.056 mmol) was depro-
tected using the general procedure described above at room tem-
perature for 1.5 h and purified by column chromatography (98:2 v/
v CH2Cl2/CH3OH) to afford inhibitor 16d as a white solid (14 mg,
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98%). Rf (98:2 v/v CH2Cl2/CH3OH)=0.20; mp: 190–191 8C (dec.) ;
1H NMR (282 MHz, [D6]acetone): d=7.54–7.51 (2H, m, Ar-H), 7.13
(1H, t, J=7.8 Hz, Ar-H), 7.06–7.03 (2H, m, 2!Ar-H), 6.94–6.92 (2H,
m, 2!Ar-H), 5.46 ppm (2H, s, CH2);
13C NMR (75 Hz, [D6]acetone):
d=193.1, 153.7 (d, J=244 Hz, ipso-C), 152.1, 147.9 (d, J=11 Hz,
ortho-C), 146.4, 128.6, 125.6 (d, J=3.8 Hz, para-C), 122.9, 122.6 (d,
J=6.8 Hz, meta-C), 117.2 (d, J=18 Hz, ortho-C), 116.5, 116.2, 115.7,
71.9 ppm; IR (ATR): n˜=3320 (br. OH str.), 1691 cm!1; HRMS calcd
for C14H11FO4Na [M+Na]
+ 285.0534, found 285.0537.
1-(3,4-Dihydroxyphenyl)-2-(3-nitrophenoxy)ethanone (16e): Ace-
tonide-based inhibitor 15e (22 mg, 0.067 mmol) was deprotected
using the general procedure described above at room temperature
for 1.5 h and purified by column chromatography (95:5 v/v CH2Cl2/
CH3OH) to afford inhibitor 16e as an off-white solid (16 mg, 85%).
Rf (95:5 v/v CH2Cl2/CH3OH)=0.21; mp: 206–207 8C (dec.) ;
1H NMR
(300 MHz, [D6]acetone): d=7.83 (1H, dd, J=1.2, 8.1 Hz, Ar-H), 7.81
(1H, d, J=2.7 Hz, Ar-H), 7.60–7.54 (3H, m, 3!Ar-H), 7.41 (1H, dd,
J=1.6, 8.0 Hz, Ar-H), 6.95 (1H, d, J=8.0 Hz, Ar-H), 5.62 ppm (2H, s,
CH2);
13C NMR (75 MHz, [D6]acetone): d=192.6, 160.6, 152.2, 150.5,
146.5, 131.6, 128.5, 123.0, 122.9, 116.9, 116.3, 115.9, 110.5,
71.6 ppm; IR (ATR): n˜=3491 (br. OH str.), 3398 (br. OH str.),
1679 cm!1; HRMS calcd for C14H11NO6Na [M+Na]
+ 312.0479, found
312.0476.
1-(3,4-Dihydroxyphenyl)-2-(naphthalen-2-yloxy)ethanone (16 f):
Acetonide-based inhibitor 15 f (39 mg, 0.12 mmol) was deprotect-
ed using the general procedure described above at room tempera-
ture for 1.5 h and purified by column chromatography (95:5 v/v
CH2Cl2/CH3OH) to afford inhibitor 16 f as an off-white solid (31 mg,
88%). Rf (95:5 v/v CH2Cl2/CH3OH)=0.36; mp: 174–175 8C (dec.) ;
1H NMR (300 MHz, [D6]acetone): d=7.86–7.84 (2H, m, 2!Ar-H),
7.75 (1H, d, Ar-H, J=8.1 Hz), 7.62–7.60 (2H, m, 2!Ar-H), 7.43 (1H,
dt, J=1.5, 8.1 Hz, Ar-H), 7.36–7.32 (2H, m, 2!Ar-H), 7.25 (1H, dd,
J=2.4, 9.0 Hz, Ar-H), 6.98 (1H, d, J=8.7 Hz, Ar-H), 5.51 (2H, s, CH2);
13C NMR (100 MHz, [D6]acetone): d=191.6, 156.1, 150.2, 144.6,
134.2, 128.9, 128.8, 127.2, 127.1, 126.3, 125.8, 123.2, 121.2, 118.2,
114.5, 114.4, 106.8, 69.7 ppm); IR (ATR): n˜=3423 (br. OH str.), 3283
(br. OH str.), 1682 cm!1; HRMS calcd for C18H14O4Na [M+Na]
+
317.0784, found 317.0787.
1-(3,4-Dihydroxyphenyl)-2-(naphthalen-1-yloxy)ethanone (16g):
Acetonide-based inhibitor 15g (39 mg, 0.12 mmol) was deprotect-
ed using the general procedure described above at room tempera-
ture for 1.5 h and purified by column chromatography (98:2 v/v
CH2Cl2/CH3OH) to afford inhibitor 16g as a colorless oil (31 mg,
88%). Rf (9:1 v/v CH2Cl2/CH3OH)=0.51;
1H NMR (300 MHz,
[D6]acetone): d=8.40–8.37 (1H, m, Ar-H), 7.88–7.85 (1H, m, Ar-H),
7.63–7.61 (2H, m, 2!Ar-H), 7.55–7.47 (3H, m, 3!Ar-H), 7.38 (1H, t,
J=7.8 Hz, Ar-H), 6.99–6.94 (2H, m, 2!Ar-H), 5.57 ppm (2H, s, CH2);
13C NMR (75 MHz, [D6]acetone): d=192.4, 154.5, 151.2, 145.6, 135.1,
127.9, 127.8, 126.7, 126.2, 126.1, 125.5, 122.6, 122.5, 120.8, 115.5,
115.3, 105.8, 70.8 ppm; IR (ATR): n˜=3518 (br. OH str.), 3430 (br. OH
str.), 1705 cm!1; HRMS calcd for C18H14O4Na [M+Na]
+ 317.0784,
found 317.0787.
1-(3,4-Dihydroxyphenyl)-2-(2-(isoxazol-5-yl)phenoxy)ethanone
(16h): Acetonide-based inhibitor 15h (29 mg, 0.082 mmol) was de-
protected using the general procedure described above at room
temperature for 1.5 h and purified by column chromatography (9:1
v/v CH2Cl2/CH3OH) to afford inhibitor 16h as an off-white solid
(23 mg, 92%). Rf (9:1 CH2Cl2/CH3OH)=0.50; mp: 198–199 8C (dec.) ;
1H NMR (300 MHz, [D6]acetone): d=8.53 (1H, d, J=1.8 Hz, Ar-H),
8.03 (1H, dd, J=1.5, 7.8 Hz, Ar-H), 7.66–7.64 (2H, m, 2!Ar-H), 7.56
(1H, d, J=1.8 Hz, Ar-H), 7.50 (1H, t, J=8.4 Hz, Ar-H), 7.33 (1H, d,
J=8.4 Hz, Ar-H), 7.19 (1H, t, J=7.8 Hz), 7.00 (1H, d, J=8.7 Hz, Ar-
H), 5.69 ppm (2H, s, CH2);
13C NMR (100 MHz, [D6]acetone): d=
191.3, 164.8, 154.9, 151.2, 150.9, 145.3, 131.2, 127.2, 127.1, 121.6,
121.2, 116.5, 115.1, 114.6, 112.9, 104.3, 70.4 ppm; IR (ATR): n˜=3352
(br. OH str.), 3234 (br. OH str.), 1683 cm!1; HRMS calcd for
C17H13NO5Na [M+Na]
+ 334.0686, found 334.0689.
1-(3,4-Dihydroxyphenyl)-2-(4-(naphthalen-2-yl)phenoxy)etha-
none (16 i): Acetonide-based inhibitor 15 i (10 mg, 0.024 mmol)
was deprotected using the general procedure described above at
room temperature for 1.5 h and purified by column chromatogra-
phy (9:1 v/v CH2Cl2/CH3OH) to afford inhibitor 16 i as a foam
(7.5 mg, 84%). Rf (9:1 v/v CH2Cl2/CH3OH)=0.56;
1H NMR (400 MHz,
[D6]acetone): d=8.13 (1H, s, Ar-H), 7.98–7.96 (2H, m, 2!Ar-H), 7.91
(1H, d, J=8.4 Hz, Ar-H), 7.81 (1H, dd, J=1.8, 8.6 Hz, Ar-H), 7.75
(2H, d, J=8.8 Hz, 2!Ar-H), 7.60–7.58 (2H, m, 2!Ar-H), 7.54–7.47
(2H, m, 2!Ar-H), 7.11 (2H, d, J=8.8 Hz, 2!Ar-H), 6.97 (1H, d, J=
8.0 Hz, Ar-H), 5.46 ppm (2H, s, CH2);
13C NMR (100 MHz,
[D6]acetone): d=192.2, 158.3, 150.9, 145.2, 137.9, 133.9, 133.4,
132.4, 128.3, 128.1, 128.0, 127.5, 126.2, 125.6, 125.1, 124.7, 121.6,
115.1, 114.9, 114.7, 70.0 ppm; IR (ATR): n˜=3300 (br. OH str.),
1726 cm!1; HRMS calcd for C24H19O4 [M+H]
+ 371.1278, found
371.1278.
1-(3,4-Dihydroxyphenyl)-2-(3-(naphthalen-2-yl)phenoxy)etha-
none (16 j): Acetonide-based inhibitor 15 j (21 mg, 0.051 mmol)
was deprotected using the general procedure described above at
room temperature for 1.5 h and purified by column chromatogra-
phy (9:1 v/v CH2Cl2/CH3OH) to afford inhibitor 16 j as a white foam
(16 mg, 84%). Rf (9:1 v/v CH2Cl2/CH3OH)=0.50;
1H NMR (400 MHz,
[D6]acetone): d=8.17 (1H, s, Ar-H), 7.99–7.96 (2H, m, 2!Ar-H), 7.92
(1H, dd, J=2.1 Hz, 8.8 Hz, Ar-H), 7.81 (1H, dd, J=1.8, 8.5 Hz, Ar-H),
7.66–7.56 (2H, m, 2!Ar-H), 7.54–7.50 (2H, m, 2!Ar-H), 7.41–7.39
(3H, m, 3!Ar-H), 7.00 (1H, ddd, J=1.7, 2.4, 7.6 Hz, Ar-H), 6.95 (1H,
d, J=8.2 Hz), 5.49 ppm (2H, s, 2!CH2);
13C NMR (100 MHz,
[D6]acetone): d=192.0, 159.2, 150.9, 145.1, 142.1, 138.0, 133.7,
132.9, 129.9, 128.4, 128.2, 127.5 (!2) 126.2, 126.0, 125.6, 125.2,
121.7, 119.9, 114.9, 114.7, 113.7, 113.5, 69.8 ppm; IR (ATR): n˜=3339
(br. OH), 1689 cm!1; HRMS calcd for C24H19O4 [M+H]
+ 371.1278,
found 371.1273.
1-(3,4-Dihydroxyphenyl)-2-((2-(trifluoromethyl)phenyl)thio)etha-
none (16k): Acetonide-based inhibitor 15k (18 mg, 0.049 mmol)
was deprotected using the general procedure described above at
room temperature for 1.5 h and purified by column chromatogra-
phy (98:2 v/v CH2Cl2/CH3OH) to afford inhibitor 16k as an off-white
solid (13 mg, 86%). Rf (9:1 v/v CH2Cl2/CH3OH)=0.45; mp: 169–
170 8C (dec.) ; 1H NMR (300 MHz, CD3OD): d=7.68 (1H, dd, J=1.2,
7.8 Hz, Ar-H), 7.62 (1H, dd, J=1.2, 7.8 Hz, Ar-H), 7.53 (1H, dt, J=
1.5, 7.8 Hz, Ar-H), 7.48–7.43 (2H, m, 2!Ar-H), 7.35 (1H, dt, J=1.2,
7.5 Hz, Ar-H), 6.82 (1H, d, J=8.5 Hz, Ar-H), 4.87 ppm (2H, s, CH2);
13C NMR (100 MHz, [D6]acetone): d=191.9, 151.1, 145.4, 136.4,
132.9, 131.2, 128.9, 128.6, 127.0 (q, J=28 Hz), 126.3, 125.9 (q, J=
271 Hz, CF3), 122.9, 115.6, 115.3, 40.7 ppm; IR (ATR): n˜=3485 (br.
OH str.), 3367 (br. OH str.), 1657 cm!1; HRMS calcd for C15H12F3O3S
[M+H]+ 329.0454, found 329.0454.
1-(3,4-Dihydroxyphenyl)-2-((4-fluorophenyl)thio)ethanone (16 l):
Acetonide-based inhibitor 15 l (29 mg, 0.091 mmol) was deprotect-
ed using the general procedure described above at room tempera-
ture for 1.5 h and purified by column chromatography (98:2 v/v
CH2Cl2/CH3OH) to afford inhibitor 16 l as a pale-yellow oil (18 mg,
73%). Rf (9:1 v/v CH2Cl2/CH3OH)=0.42;
1H NMR (300 MHz,
[D6]acetone): d=7.58–7.42 (4H, m, 4!Ar-H), 7.09–7.04 (2H, m, 2!
Ar-H), 6.78 (1H, d, J=7.8 Hz, Ar-H), 4.35 ppm (2H, s, CH2);
13C NMR
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(100 MHz, [D6]acetone): d=192.1, 162.0 (d, J=240 Hz, ipso-C),
150.6, 145.0, 132.4 (d, J=8.0 Hz, meta-C), 131.3 (d, J=3.1 Hz, para-
C), 128.2, 122.5, 116.0 (d, J=20 Hz, ortho-C), 115.3, 114.7, 40.9 ppm;
IR (ATR): n˜=3527 (br. OH str.), 3329 (br. OH str.), 1654 cm!1; HRMS
calcd for C14H11FO3SNa [M+Na]
+ 301.0305, found 301.0301.
2-((4-Chlorophenyl)thio)-1-(3,4-dihydroxyphenyl)ethanone
(16m): Acetonide-based inhibitor 15m (20 mg, 0.060 mmol) was
deprotected using the general procedure described above at room
temperature for 1.5 h and purified by column chromatography
(98:2 v/v CH2Cl2/CH3OH) to afford inhibitor 16m as a pale-yellow
oil (17 mg, 98%). Rf (9:1 v/v CH2Cl2/CH3OH)=0.45;
1H NMR
(300 MHz, [D6]acetone): d=7.52–7.49 (2H, m, 2!Ar-H), 7.38 (2H, d,
J=8.7 Hz, 2!Ar-H), 7.30 (2H, d, J=8.7 Hz, 2!Ar-H), 6.92 (1H, d,
J=8.8 Hz, Ar-H), 4.45 ppm (2H, s, CH2);
13C NMR (75 MHz,
[D6]acetone): d=193.1, 151.9, 146.3, 136.5, 132.8, 131.9, 130.1,
129.5, 123.8, 116.6, 116.1, 41.2 ppm; IR (ATR): n˜=3545 (br. OH str.),
3442 (br. OH str.), 1709 cm!1; HRMS calcd for C14H11ClO3SNa [M+
Na]+ 317.0010, found 317.0015.
1-(3,4-Dihydroxyphenyl)-2-(naphthalen-2-ylthio)ethanone (16n):
Acetonide-based inhibitor 15n (30 mg, 0.086 mmol) was depro-
tected using the general procedure described above at room tem-
perature for 1.5 h and purified by column chromatography (98:2 v/
v CH2Cl2/CH3OH) to afford inhibitor 16n as a white solid (20 mg,
75%). Rf (9:1 v/v CH2Cl2/CH3OH)=0.71; mp: 125–126 8C (dec.) ;
1H NMR (400 MHz, [D6]acetone): d=7.95–7.84 (4H, m, 4!Ar-H),
7.63–7.60 (2H, m, 2!Ar-H), 7.57–7.48 (3H, m, 3!Ar-H), 6.98 (1H, d,
J=8.0 Hz, Ar-H), 4.62 ppm (2H, s, CH2);
13C NMR (100 MHz,
[D6]acetone): d=192.1, 150.7, 145.1, 134.0, 133.9, 131.9, 128.4,
128.3, 127.7, 127.1, 127.0, 126.7, 126.5, 125.8, 122.6, 115.3, 114.9,
39.8 ppm; IR (ATR): n˜=3470 (br. OH str.), 3384 (br. OH str.),
1667 cm!1; HRMS calcd for C18H14O3SNa [M+Na]
+ 333.0556, found
333.0554.
2-(Benzo[d]thiazol-2-ylthio)-1-(3,4-dihydroxyphenyl)ethanone
(16o): Acetonide-based inhibitor 15o (6 mg, 0.017 mmol) was de-
protected using the general procedure described above at room
temperature for 1.5 h and purified by column chromatography
(98:2 v/v CH2Cl2/CH3OH) to afford inhibitor 16o as a yellow oil
(4.4 mg, 83%). Rf (9:1 v/v CH2Cl2/CH3OH)=0.37;
1H NMR (400 MHz,
[D6]acetone): d=7.95 (1H, d, J=8.0 Hz, Ar-H), 7.81 (1H, d, J=
8.0 Hz, Ar-H), 7.63 (1H, dd, J=1.8, 8.0 Hz, Ar-H), 7.60 (1H, d, J=
1.8 Hz, Ar-H), 7.46 (1H, app. t, J=8.0 Hz, Ar-H), 7.36 (1H, app. t, J=
8.0 Hz, Ar-H), 6.99 (1H, d, J=8.0 Hz, Ar-H), 5.03 ppm (2H, s, CH2);
13C NMR (100 MHz, [D6]acetone): d=190.5, 167.0, 153.2, 151.0,
145.2, 135.3, 128.2, 126.2, 124.4, 122.4, 121.4, 121.3, 115.2, 115.0,
40.3 ppm; IR (ATR): n˜=3287 (br. OH str.), 1671 cm!1; MS (ESI): m/z
318 [M+H]+ .
1-(3,4-Dihydroxyphenyl)-2-((4,5-diphenyloxazol-2-yl)thio)etha-
none (16p): Acetonide-based inhibitor 15p (40 mg, 0.090 mmol)
was deprotected using the general procedure described above at
room temperature for 1.5 h and purified by column chromatogra-
phy (9:1 v/v CH2Cl2/CH3OH) to afford inhibitor 16p as a white solid
(30 mg, 83%). Rf (95:5 v/v CH2Cl2/CH3OH)=0.35; mp: 190–191 8C
(dec.) ; 1H NMR (400 MHz, [D6]DMSO): d=7.51–7.38 (12H, m, 12!
Ar-H), 6.85 (1H, d, J=8.5 Hz, Ar-H), 4.96 ppm (2H, s, CH2);
13C NMR
(100 MHz, [D6]DMSO): d=191.4, 158.8, 151.5, 146.7, 145.8, 136.2,
132.1, 129.4, 129.2, 127.9, 126.6, 122.6, 115.7, 115.6, 40.2 ppm; IR
(ATR): n˜=3257 (br. OH str.), 1659 cm!1; HRMS calcd for C23H18NO4S
[M+H]+ 404.0951, found 404.0951.
2-((2-(3,4-Dihydroxyphenyl)-2-oxoethyl)thio)quinazolin-4(3H)-
one (16q): Acetonide-based inhibitor 15q (18 mg, 0.049 mmol)
was deprotected using the general procedure described above at
50 8C for 5 h and purified by column chromatography (9:1 v/v
CH2Cl2/CH3OH) to afford inhibitor 16q as a white solid (16 mg,
83%). Rf (9:1 v/v CH2Cl2/CH3OH)=0.48; mp: 214–215 8C;
1H NMR
(400 MHz, [D6]DMSO): d=9.99 (1H, s, OH), 9.43 (1H, s, OH), 8.01
(1H, d, J=8.2 Hz, Ar-H), 7.70 (1H, dt, J=1.1, 8.0 Hz, Ar-H), 7.53 (1H,
dd, J=1.7, 8.5 Hz, Ar-H), 7.43 (1H, d, J=1.7 Hz, Ar-H), 7.39 (1H,
app. t, J=8.0 Hz, Ar-H), 7.27 (1H, app.d, J=8.2 Hz, Ar-H), 6.88 (1H,
d, J=8.2 Hz, Ar-H), 4.76 ppm (2H, s, CH2);
13C NMR (100 MHz,
[D6]DMSO): d=191.7, 161.5, 155.5, 151.5, 148.7, 145.6, 135.1, 128.2,
126.5, 126.2, 126.1, 122.3, 120.3, 115.6 (!2), 37.5 ppm; IR (ATR): n˜=
3164 (br. OH str.), 1667 cm!1; HRMS calcd for C16H13N2O4S [M+H]
+
329.0591, found 329.0590.
Biological assays
M. tuberculosis type II DHQase assay : Enzyme assays for type II
DHQase from M. tuberculosis (overexpressed and purified as de-
scribed previously)[15,23,24] were carried out using a Shimadzu UV/
Vis 1800 spectrometer with a 6!6 Peltier cell holder using 1 cm
path length quartz cuvettes at l 234 nm to monitor the formation
of the product, 3-dehydroshikimate. Initial reaction rates were mea-
sured by the increase in absorbance at 234 nm from formation of
the enone–carboxylate chromophore of 3-dehydroshikimate (e=
1.2!104m!1 cm!1). The assays were performed at 25 8C in Tris·HCl
buffer (0.05m, pH 7.0) for M. tuberculosis type II DHQase. The
assays contained 3.80 nm enzyme, and were performed in dupli-
cate. The assay mixtures were prepared in 1 mL quartz cuvettes,
and the assays were initiated by the addition of the substrate (3-
dehydroquinate, synthesized by a published procedure)[26] to the
mixture after incubating the buffer, inhibitor in 0.5% DMSO, and
enzyme at 25 8C for 3 min. The kinetic data for inhibition studies
were obtained by measuring the initial rates of reaction over
a range of inhibitor concentrations (3–4 different concentrations)
at five different substrate concentrations (0.9KM–4KM). The inhibi-
tion constants (Ki) and the standard deviations were determined
using nonlinear regression fitting to the competitive model by
GraphPad Prism (version 5.03 for Windows). Kinetic data that were
poorly fitted to a competitive model (R2<0.95) were fitted to
a mixed inhibition model in GraphPad Prism using nonlinear re-
gression to derive the inhibition constants (Ki) and the standard de-
viations.
Microplate-based assay with Alamar blue (resazurin) readout
for M. tuberculosis
M. tuberculosis H37Ra (ATCC 25177) was grown in Middlebrook
7H9 broth medium supplemented with OADC (Difco Laboratories,
Detroit, MI, USA), 0.5% glycerol, and 0.05% Tween-80. Freshly
seeded cultures were grown at 37 8C, for approximately 14 days, to
mid-exponential phase (OD600 0.4–0.8) for use in the inhibition
assays. The effect of the type II DHQase inhibitors against M. tuber-
culosis growth were measured by a resazurin reduction microplate
assay, using the procedure previously described by Taneja and
Tyagi.[23a] M. tuberculosis grown to mid-exponential phase
(OD600 0.4–0.8) was diluted to OD600 0.002 in 7H9S media (Middle-
brook 7H9 with OADC, 0.5% glycerol, 0.02% tyloxapol, 1% tryp-
tone) containing 0.5% DMSO; 96-well microtiter plates were set up
with 100 mL inhibitors, serially diluted into 7H9S. Diluted M. tuber-
culosis (100 mL, representing ~2!104 CFUmL!1) was added to each
well. Plates were incubated for 5 days at 37 8C in a humidified incu-
bator prior to the addition of a 0.02% resazurin solution (30 mL)
and 20% Tween-80 (12.5 mL) to each well. Sample fluorescence
was measured after 48 h on a BMG Labtech Polarstar Omega in-
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strument with an excitation wavelength of 530 nm and emission at
590 nm. Changes in fluorescence relative to positive control wells
(H37Ra with no inhibitor) minus negative control wells (no H37Ra)
were plotted for determination of MIC50 values.
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Inhibition studies onMycobacterium tuberculosis
N-acetylglucosamine-1-phosphate uridyltransferase
(GlmU)†
Anh Thu Tran,a Daying Wen,b Nicholas P. West,c,d Edward N. Baker,b
Warwick J. Brittonc,d and Richard J. Payne*a
Peptidoglycan is an essential component of the cell wall of bacteria, including Mycobacterium tuberculo-
sis, that provides structural strength and rigidity to enable internal osmotic pressure to be withstood. The
ﬁrst committed step in the biosynthesis of peptidoglycan involves the formation of uridine diphosphate-
N-acetylglucosamine (UDP-GlcNAc) from uridine triphosphate (UTP) and GlcNAc-1-phosphate. This reac-
tion is catalysed by N-acetylglucosamine-1-phosphate uridyltransferase (GlmU), a bifunctional enzyme
with two independent active sites that possess acetyltransferase and uridyltransferase activities. Herein,
we report the ﬁrst inhibition study targeted against the uridyltransferase activity of M. tuberculosis GlmU.
A number of potential inhibitors were initially prepared leading to the discovery of active aminoquin-
azoline-based compounds. The most potent inhibitor in this series exhibited an IC50 of 74 μM against GlmU
uridyltransferase activity and serves as a promising starting point for the discovery of more potent
inhibitors.
Introduction
Tuberculosis (TB), caused by infection with the bacterium
Mycobacterium tuberculosis has remained a major global health
risk since the first identification of the disease in 1882.1
According to the World Health Organization, in 2011 there
were 8.3 million new reported cases of TB and 1.4 million
deaths as a result of the disease.2 A major challenge for TB
treatment is the persistent nature of M. tuberculosis where the
bacterium is capable of residing in a dormant state in very low
numbers for decades after the initial infection.1 This results in
a lifelong risk of disease reactivation especially in immune
compromised patients such as those co-infected with human
immunodeficiency virus (HIV).1 To eﬀectively combat the per-
sistency of M. tuberculosis, a combination therapy comprising
of four frontline antibiotics (rifampicin, isoniazid, ethambutol
and pyrazinamide) for a period of 6–9 months is employed.3,4
However, poor adherence to this treatment regimen has con-
tributed to the emergence of multi-drug resistant (MDR) TB,
which requires the use of second line therapies, and exten-
sively drug resistant (XDR) TB, for which there is no eﬀective
treatment in many resource limited countries.
Given the increased incidence of drug resistant TB cases
worldwide, there is a desperate need for the development of
new anti-tubercular agents that operate via novel modes of
action to the currently employed drugs. A very successful
avenue for anti-tubercular development has involved the devel-
opment of compounds that target enzymes responsible for the
biosynthesis and assembly of the mycobacterial cell wall.
Examples include currently employed first and second-line TB
drugs such as isoniazid, ethambutol and ethionamide.5 These
agents act by disrupting the biosynthesis or the incorporation
of mycolic acid, a key lipid which constitutes a major com-
ponent of the mycobacterial cell wall (Fig. 1).5
Another essential component of the mycobacterial cell wall
is the peptidoglycan layer which provides structural strength
and rigidity to the bacterium to withstand internal osmotic
pressure. Structurally, peptidoglycan consists of a repeating
unit of N-acetylglucosamine (NAG) and N-acetylmuramic acid
(NAM) bearing crosslinked peptide bridges (Fig. 1).7 Whilst
interference of peptidoglycan biosynthesis has been an extremely
†Electronic supplementary information (ESI) available: Experimental procedures
for compounds 1–4 and 36–38, 1H and 13C NMR spectra of all novel compounds
and results for GlmU assay optimisation studies. See DOI: 10.1039/c3ob41896k
aSchool of Chemistry, Building F11, The University of Sydney, Camperdown,
NSW 2006, Australia. E-mail: richard.payne@sydney.edu.au; Fax: +61 29351 3329;
Tel: +61 29351 5877
bMaurice Wilkins Centre for Molecular Biodiscovery and Laboratory of Structural
Biology, School of Biological Sciences, University of Auckland, Auckland, 1010,
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cCentenary Institute, Newtown, NSW 2042, Australia
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successful avenue for the development of antibacterial agents
against gram-positive and gram-negative bacteria, enzymes
responsible for the construction of this structure in myco-
bacteria have not been extensively investigated as drug targets.
This is in part due to the well-established broad-spec-
trum β-lactamase (BlaC) activity of M. tuberculosis that inacti-
vates traditional β-lactam antibiotics.4,8,9 However, other
enzymes responsible for the biosynthesis of peptidoglycan
remain viable TB drug targets. Indeed, following the publi-
cation of the M. tuberculosis genome in 1998,10 a number of
enzymes responsible for the biosynthesis of peptidoglycan
have been elucidated thereby providing new targets for the
development of anti-tubercular lead compounds that operate
via novel modes of action. One such target is N-acetylglucos-
amine-1-phosphate uridyltransferase (GlmU).11,12 This bi-func-
tional enzyme, found exclusively in bacteria, is responsible for
catalysing the formation of UDP-GlcNAc, an important inter-
mediate in the biosynthesis of peptidoglycan in M. tuberculo-
sis.11 Importantly, a crystal structure of M. tuberculosis GlmU
has recently been solved which has provided important
insights into the two active sites of the enzyme.11
The bifunctional role of GlmU arises from two independent
domains of the enzyme which possess acetyltransferase and
uridyltransferase activities.11 The acetyltransferase domain,
found in the C-terminus of the protein is responsible for the
first step of the reaction, in which an acetyl group is trans-
ferred from AcCoA to GlcN-1-P forming GlcNAc-1-P.11 GlcNAc-
1-P then serves as a substrate for the uridyltransferase active
site in the N-terminus of the enzyme which forms UDP-GlcNAc
(Scheme 1).11 Structurally, the C-terminus of the protein
adopts a regular left-hand β-helix while the N-terminus exhi-
bits a Rossmann fold topology (Scheme 1B).11 It has been pro-
posed that the mechanism of M. tuberculosis GlmU catalysis
first involves UTP and Mg2+ binding to the uridyltransferase
active site prior to GlcNAc-1-P binding in the adjacent
pocket.11,13 Upon GlcNAc-1-P binding, the enzyme undergoes
major conformational changes to facilitate uridylation which
begins with nucleophilic attack by the phosphate group of
GlcNAc-1-P at the α-phosphate of UTP thus forming a penta-
coordinate intermediate stabilised by the Mg2+ cation
(Scheme 1A).11,13 The final steps involve inversion of stereo-
chemistry at the α-phosphate and the release of pyrophosphate
(Scheme 1A).11,13
Inhibitors of the Haemophilus influenzae and Trypanosoma
brucei GlmU isozymes were recently identified by high-
throughput screening with some compounds exhibiting IC50
values in the low to mid-micromolar range.14–16 To date,
however, no inhibitors have been reported for the M. tuberculo-
sis enzyme. Herein we report the first inhibition study against
M. tuberculosis GlmU. Since the uridyltransferase activity is
proposed to be the rate-limiting step of the two catalytic pro-
cesses (as hypothesised through kinetic modeling studies) we
chose to target the uridyltransferase activity of the enzyme in
this work.17
Results and discussion
GlmU uridyltransferase kinetic assay
Prior to the design of GlmU uridyltransferase inhibitors, we
first embarked on the development of a continuous kinetic
assay for M. tuberculosis GlmU uridyltransferase. To this end, a
double-enzyme-coupled continuous assay was developed based
on an assay originally reported by Webb and co-workers which
monitors the formation of inorganic pyrophosphate.18,19
Specifically, this assay used excess amounts of two coupling
enzymes, namely inorganic pyrophosphatase (IPP) (EC 3.6.1.1)
and purine nucleoside phosphorylase (PNPase) (EC 2.4.2.1) in the
Scheme 1 (A) Mechanism of uridylation by GlmU. (B) Structure of M. tubercu-
losis GlmU showing the C- and N-terminal catalytic domains.11
Fig. 1 A schematic of the M. tuberculosis cell envelope showing the arrange-
ment of key components; mycolic acids, arabinogalactan, peptidoglycan
and porins. The peptidoglycan layer is enlarged (below) depicting classical
4 → 3 and non-classical 3 → 3 interpeptide bonds. NAM: N-acetylmuramic acid;
NAG: N-acetylglucosamine; A2pm: meso-diaminopimelate; Ala: alanine and Glu:
glutamic acid.6
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presence of 2-amino-6-mercapto-7-methylpurine ribonucleo-
side (MESG).18,19 In this double coupled enzyme assay, the
pyrophosphate produced by GlmU uridyltransferase is sub-
sequently hydrolysed to inorganic phosphate by IPP. The in-
organic phosphate then serves as a substrate for PNPase which
catalyses the phosphorolytic cleavage of the glycosidic bond in
MESG (λmax = 330 nm), resulting in the formation of 2-amino-6-
mercapto-7-methylpurine (λmax = 360 nm) that can be detected
spectroscopically (Scheme 2).18,19
During the development of the GlmU uridyltransferase
kinetic assay, a number of variables including the concen-
trations of M. tuberculosis GlmU and MESG and assay tempera-
ture were modified to identify the optimal assay conditions. In
addition, experiments to confirm that the coupling enzymes,
inorganic pyrophosphatase and purine nucleoside phosphoryl-
ase, were not rate-limiting and that the assay was directly
measuring the activity of GlmU uridyltransferase were per-
formed (see ESI†). These studies were further supported by a
linear dependence of reaction rate on GlmU uridyltransferase
concentration (see ESI†).
The optimized assay was subsequently used for the deter-
mination of kinetic parameters for both UTP and GlcNAc-1-P
as substrates for GlmU activity whereby the apparent KM and
Vmax values for one substrate were determined at a saturating
concentration (1 mM) of the other substrate (Fig. 2 and 3).
Design of bisubstrate and transition-state based inhibitors of
GlmU uridyltransferase
Following the development of the coupled continuous kinetic
assay for M. tuberculosis GlmU uridyltransferase, we next
embarked on the design and synthesis of inhibitors of this
enzyme. The substrates and putative transition state of the
GlmU uridyltransferase reaction were used as starting points
for inhibitor design. To begin with, two transition-state
mimics were designed and synthesised (compounds 1 and 2,
Fig. 4A). Compound 1 featured a di-carboxylate moiety capable
of co-ordinating to the catalytic Mg2+ in a similar manner to
the phosphate motif in the transition state. In contrast, com-
pound 2 possessed a 2,3-dihydroxybenzamide moiety which
was designed to serve as a surrogate for the leaving pyrophos-
phate group (Fig. 4A). Unfortunately, despite the incorpor-
ation of characteristic transition state features of the proposed
GlmU uridyltransferase reaction, these compounds only
exhibited weak inhibition against the enzyme (10% and 60%
inhibition at 2 mM, Fig. 4A).
Fig. 4 First generation M. tuberculosis GlmU uridyltransferase inhibitors.
Scheme 2 Double-enzyme-coupled M. tuberculosis GlmU uridyltransferase
assay.
Fig. 3 Least square ﬁtted curve to the Michaelis–Menten model for M. tuber-
culosis GlmU uridyltransferase (KM GlcNAc-1-P = 22 ± 1 μM, Vmax = 0.076 ±
0.001 μM s−1, [UTP] = 1 mM).
Fig. 2 Least square ﬁtted curve to the Michaelis–Menten model for M. tuber-
culosis GlmU uridyltransferase (KM UTP = 34 ± 3 μM, Vmax = 0.082 ± 0.002 μM s−1,
[GlcNAc-1-P] = 1 mM).
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2013 Org. Biomol. Chem., 2013, 11, 8113–8126 | 8115
Pu
bli
sh
ed
 on
 15
 O
cto
be
r 2
01
3. 
Do
wn
loa
de
d b
y U
niv
ers
ity
 of
 Sy
dn
ey
 on
 30
/01
/20
14
 23
:12
:48
. 
View Article Online
In addition to the above transition-state mimics, we also
designed bisubstrate inhibitors containing structural features
of both GlcNAc-1-P and UTP. Compound 3 possessed an
α-linked GlcNAc moiety while 4 contained a GlcNAc mimicking
catechol unit. Each of these compounds also featured a
uridine motif with a sulfonamide or aminothiazole bridge.
The sulfonamide linker was chosen as this functionality has
been successfully used as a phosphate bioisostere20 while the
aminothiazole moiety was successfully employed by Kiessling
and co-workers21 as a pyrophosphate shape mimic in the
development of UDP-galactopyranose mutase inhibitors.
Unfortunately, both sulfonamide and aminothiazole-based
compounds demonstrated weak inhibition of M. tuberculosis
GlmU uridyltransferase activity (3: 55% inhibition at 2 mM, 4:
37% inhibition at 2 mM, Fig. 4B).
In parallel with our transition-state and bisubstrate inhibi-
tor design strategy, we also synthesised aminoquinazoline-
based inhibitors 5 and 6 (Fig. 4C) which were identified in a
recent high-throughput screen against H. influenzae GlmU uridyl-
transferase by Doig and co-workers from AstraZeneca (see
ESI† for synthesis).14 These compounds exhibited promising
activity when screened against M. tuberculosis GlmU uridyl-
transferase. Specifically, compound 5 exhibited 44% inhibition
of the uridyltransferase activity at 50 μM while compound 6
was slightly less potent with 36% inhibition at the same con-
centration (Fig. 4C). It should be noted that while this rep-
resents a significant drop in activity compared to that
observed against H. influenzae GlmU uridyltransferase, the
M. tuberculosis GlmU N-terminal domain only possesses 41%
sequence identity to the H. influenzae isozyme. It is also impor-
tant to note that strong absorption of the aminoquinazoline
compounds at λ = 360 nm meant that the assays could not be
conducted with inhibitor concentrations above 50 μM.
Encouraged by the activity of analogues 5 and 6, we
embarked on the design and synthesis of an aminoquin-
azoline-based inhibitor library using the more potent 6,7-
dimethoxyquinazoline inhibitor 5 as a starting point to explore
structure–activity relationships against M. tuberculosis GlmU
uridyltransferase. The general strategy for structural modifi-
cations of compound 5 is summarised in Fig. 5. Our SAR
exploration was focused on the sequential evaluation of the
role and relative importance of the central 1,4-phenylenedi-
amine linker, the terminal phenyl group and the bicyclic
dimethoxyquinazoline scaﬀold.
Our initial investigation focused on the evaluation of the
importance of the terminal phenyl group and the central 1,4-
phenylenediamine linker in 5. To this end, we proposed to
replace the phenyl moiety of aminoquinazoline-based inhibi-
tor 5 with cyclohexane, pyrrolidine and 4-hydroxypyrrolidine,
while piperazine and 1,2-diaminocyclohexane linkers were
employed to substitute the 1,4-phenylenediamine moiety in 5.
These groups were introduced to evaluate the eﬀect of incor-
porating hydrogen bond donors and acceptors as well as con-
formational flexibility into the terminal group and the central
linker on GlmU uridyltransferase inhibitory activity. Com-
pounds lacking the terminal phenyl group were also syn-
thesised to assess the contribution of this functionality on
inhibitory activity.
Synthesis of aminoquinazoline GlmU uridyltransferase
inhibitors
Synthesis of a series of aminoquinazoline GlmU inhibitors
began with 2-amino-4,5-dimethoxybenzoic acid 7. Conden-
sation of 7 with ammonium acetate and trimethyl ortho-
formate aﬀorded quinazolinone intermediate 8 in 85% yield
(Scheme 3). Reaction of 8 with phosphorus(V) oxychloride then
provided the corresponding chloroquinazoline 9 which was
subsequently subjected to SNAr reactions with 1,4-phenylene-
diamine, piperazine and racemic trans-1,2-diaminocyclo-
hexane respectively to aﬀord amines 10–12 in good yields
(Scheme 3).
Amines 10–12 were subsequently coupled with a variety of
carboxylic acids using either N,N′-diisopropylcarbodiimide
(DIC) or O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyl-
uronium hexafluorophosphate (HATU) as coupling reagents to
aﬀord inhibitors 13–17 in 37–50% yield (Scheme 4A–4C). The
tert-butyl carbamate of 18 was removed by treatment with 4 M
HCl in dioxane to provide inhibitor 19 (Scheme 4D).
As a result of solubility problems in the coupling reaction, a
modified procedure was required for the preparation of the
Fig. 5 Proposed structural modiﬁcations of inhibitor 5.
Scheme 3 Synthesis of amines 10–12. Reagents and conditions: (a) CH(OMe)3,
NH4OAc, MeOH, 120 °C, 3 h, 85%; (b) POCl3, 110 °C, 5 h, 70%; (c) (±)-trans-1,2-
diaminocyclohexane, 2-propanol, 110 °C, 3 h, 60%; (d) piperazine hydrochloride
hydrate, 2-propanol, 110 °C, 3 h, 70%; (e) 1,4-phenylenediamine, 2-propanol,
110 °C, 3 h, 85%.
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proposed inhibitor bearing an unsubstituted pyrrolidine term-
inal group. An SNAr reaction between (S)-N-(4-aminophenyl)-
pyrrolidine-2-carboxamide fragment 20 (see ESI† for synthesis)
and chloroquinazoline 9 initially provided Fmoc-protected
aminoquinazoline 21 (Scheme 4E). Deprotection of the Fmoc-
carbamate using 25% piperidine (v/v) in a mixture of
methanol and dichloromethane (1 : 1 v/v) aﬀorded inhibitor 22
in moderate yield over two steps.
GlmU uridyltransferase inhibition studies
With the first series of 11 inhibitors in hand, we next evaluated
these compounds for their inhibitory activity. To this end,
compounds 13–17, 19 and 22 were screened against M. tubercu-
losis GlmU uridyltransferase using the double-coupled con-
tinuous kinetic assay described above. The inhibition assays
were carried out at fixed concentrations of UTP and GlcNAc-1-
P ([UTP] = 35 μM and [GlcNAc-1-P] = 35 μM) in the presence
of the inhibitors at 50 μM. Unfortunately, as with parent com-
pounds, we were unable to obtain IC50 values for the majority
of compounds owing to the combination of low solubility at
high concentrations (>200 μM) and high absorbance (at λ =
360 nm) at concentrations that were required for determining
an accurate IC50 value.
After screening the 1,4-phenylenediamine-linked series of
inhibitors (5, 12, 13, 19 and 22), it was clear that the terminal
phenyl group is essential for inhibition of GlmU uridyltransfer-
ase activity (Table 1). This is emphasised by the substitution of
the phenyl group in 5 with a cyclohexane moiety in 13 which
resulted in a two-fold decrease in inhibition (5: 44% inhibition
at 50 μM and 13: 22% inhibition at 50 μM, Table 1). Similarly,
removal of this group in 12 led to a three-fold drop in potency
(12: 14% inhibition at 50 μM, Table 1). Replacement of the
terminal phenyl group in 5 with pyrrolidine and hydroxypyrrol-
idine in 19 and 22 respectively, also resulted in reduced
inhibition of GlmU uridyltransferase activity (8% inhibition
at 50 μM for 19 and 22). Replacement of the rigid 1,4-
Scheme 4 Synthesis of inhibitors 13–17, 19, 22. Reagents and conditions: (A)
(a) 13: cyclohexane carboxylic acid, DIC (2 eq.), DMAP (2 eq.), DMF, rt, 20 h,
56%; (B) (b) 14: benzoic acid, HATU (1.5 eq.), iPr2NEt (1.5 eq.), DMF, rt, 4 h,
47%; 15: cyclohexane carboxylic acid, HATU (1.5 eq.), iPr2NEt (1.5 eq.), DMF, rt,
20 h, 50%; (C) (c) 16: benzoic acid, HATU (1.5 eq.), iPr2NEt (1.5 eq.), DMF, rt, 4 h,
30%; 17: cyclohexane carboxylic acid, HATU (1.5 eq.), iPr2NEt (1.5 eq.), DMF, rt,
24 h, 31%; (D) (d) 18: Boc-L-Hyp-OH, HATU (1.5 eq.), iPr2NEt (1.5 eq.), DMF, rt,
20 h; (e) 19: 4 M HCl in dioxane, rt, 16 h, 30% over 2 steps. (E) (f ) 21: chloroquin-
azoline 9, 2-propanol, 110 °C, 3 h; (g) 22: 25 vol.% piperidine, CH2Cl2–MeOH
(1 : 1, v/v), rt, 30 min, 25% over 2 steps.
Table 1 Inhibition of uridyltransferase activity ofM. tuberculosis GlmU by amino-
quinazoline inhibitors with variation in linker and terminal groups
Compound Linker (L) R % Inhibition at 50 μM
5 44%
13 22%
12 H 14%
19 8%
22 8%
11 H No inhibition
14 14%
15 No inhibition
10 H No inhibition
16 No inhibition
17 No inhibition
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phenylenediamine linker in 5 and 13 with piperazine (14 and
15) and 1,2-diaminocyclohexane linkers (16 and 17) also
resulted in a substantial decrease in activity, suggesting that
precise positioning of terminal groups is necessary for optimal
interactions with GlmU uridyltransferase active site residues.
Piperazine-linked inhibitor 14 bearing a terminal phenyl ring
only exhibited 14% inhibition at 50 μM compared to 44% inhi-
bition at 50 μM for 5 (Table 1). Similar to the observation in
the 1,4-phenylenediamine series, replacement of the phenyl
moiety in 14 with cyclohexane in 15 led to a further decrease
in enzyme inhibition. This decrease was even more pro-
nounced in the 1,2-diaminocyclohexane-linked compounds 16
and 17 in which no inhibition of GlmU uridyltransferase
activity was observed at 50 μM (Table 1). This result suggests
an important role for the 1,4-substitution of the linker unit for
optimal activity.
Given the superiority of the rigid 1,4-phenylenediamine
linker over more flexible linkers, we decided to retain this
linker in a second-generation series of GlmU uridyltransferase
inhibitors. In order to identify the optimal terminal group for
the 1,4-phenylenediamine linked inhibitors, a large range of
aryl moieties with varied electronic and steric properties were
incorporated via the previously established synthetic route
(Scheme 5).
We were first interested in investigating the eﬀect of the
terminal group on inhibition of GlmU uridyltransferase
activity. In a co-crystal structure of H. influenzae GlmU, the
terminal benzamide group of 5 clearly occupies a lipophilic
pocket adjacent to the GlcNAc binding subsite. However, the
homologous residues in the predicted lipophilic pocket of the
M. tuberculosis enzyme (V229-V235, V139-T143 and V180-A182)
do not exhibit high sequence homology to those in H. influen-
zae GlmU (A217-V223, L129-133 and V168-T170). As such, we
decided to probe the interactions made with the lipophilic
pocket of M. tuberculosis GlmU by incorporating a range of
substituents of varied steric bulk and electronics as the term-
inal moiety. Initial studies incorporating hydrophobic moieties
resulted in compounds with low solubility under our enzyme
assay conditions (not shown). However, 4-fluorophenylisox-
azole-based inhibitor 23 could be solubilised to a concentration
of 50 μM, however this modification resulted in a two-fold
decrease in potency compared to 5. This suggests that exten-
sion of the terminal aryl moiety is not well accommodated in
the lipophilic pocket of M. tuberculosis GlmU. Substitution of
the terminal phenyl ring in 5 with pyrazine in 24 resulted in
reduced potency against GlmU uridyltransferase (24: 19% at
50 μM and 5: 44% at 50 μM) as did the introduction of a range
of both electron-donating and electron-withdrawing ortho and
para substituents into the terminal phenyl ring in 25–29
(13–21% at 50 μM). However, substitution at the meta position
of the terminal phenyl ring was well-tolerated with inhibitors
bearing m-hydroxyphenyl 30 and m-methoxyphenyl 31moieties
similarly potent to lead compound 5 with 38% and 35% inhi-
bition at 50 μM, respectively. In contrast to the vast majority of
inhibitors synthesised in this study, for compound 30, we were
able to determine an IC50 value due to the solubility at high
concentrations in the assay conditions (1% DMSO in water,
IC50 = 74 ± 1 μM). Introduction of other meta substituents
such as nitro and amino groups (compounds 32 and 33
respectively) into the terminal phenyl ring of 5 led to dimin-
ished inhibitory activity.
Given that m-hydroxy substituted compound 30 was equi-
potent to lead compound 5, we were next interested in probing
whether larger substituents could be accommodated in this
region. To this end, cyanomethyl and carboxymethyl groups
were appended to the m-hydroxyl of 30, to investigate the
possibility of hydrogen bonding and ionic interactions in this
region (Scheme 6). Surprisingly, compound 34 with a cyano-
methyl group did not exhibit any inhibition at 50 μM while
compound 35, containing a carboxymethyl extension was equi-
potent to the unfunctionalised inhibitor 30. In the absence of
an enzyme-inhibitor co-crystal structure it is diﬃcult to ration-
alize the diﬀering activity of these two compounds. Future
work in our laboratories will therefore target the co-crystalli-
sation of inhibitors described in Table 2 with M. tuberculosis
GlmU to quantify the binding mode in the uridyltransferase
active site to facilitate structure-based inhibitor design.
Having established m-hydroxylphenyl as a suitable terminal
group (on the basis of potency and solubility profile), we next
turned our attention to the two methoxy substituents on the
quinazoline ring. To this end, inhibitors 36 and 37, in which
the dimethoxyphenyl moiety in 30 was replaced by thiophenyl
(36) and cyclohexanyl (37) moieties, were synthesised (see ESI†
Scheme 5 Synthesis of inhibitors 23–33 via a SNAr route.
Scheme 6 Synthesis of cyanomethyl and carboxymethyl compounds 43 and
44. Reagents and conditions: (a) 34: bromoacetonitrile (1.1 eq.), Cs2CO3 (2.5
eq.), MeCN, 80 °C, 1 h, 55%; 35: tert-butyl bromoacetate (1.3 eq.), Cs2CO3 (2.6
eq.), MeCN, 50 °C, 3 h followed by TFA–CH2Cl2 (1 : 1 v/v), 16 h, rt, 14% over 2
steps.
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for synthesis). Compound 36 exhibited comparable inhibitory
activity against GlmU uridyltransferase activity as 30 (36: 38%
compared to 30: 35% inhibition at 50 μM, Table 3). Inhibitor
37, bearing a cyclohexyl ring was slightly less potent (37: 29%
inhibition at 50 μM, Table 3). While preliminary, the above
results indicate that although the methoxy groups were not
essential for inhibition of GlmU uridyltransferase, the planar-
ity of the quinazoline ring may contribute to the binding of
inhibitors to the active site of GlmU uridyltransferase. These
results are in stark contrast with those obtained for the
H. influenzae (Hi) enzyme by Doig and co-workers.14 Specifically,
the co-crystal structure of the aminoquinazoline-based inhibitor 6
bound to HiGlmU uridyltransferase revealed an important
hydrogen bonding interaction between the C-7 hydroxyl of the
quinazoline ring with the amide backbone of an alanine
residue (A13 in HiGlmU uridyltransferase). It was proposed
that this hydrogen bonding interaction mimicks the inter-
action made by the C-2 carbonyl of the uridine moiety in the
substrate (UTP). In light of the above results, it is therefore
possible that the aminoquinazoline inhibitors synthesised
here exhibit diﬀerent binding modes to M. tuberculosis GlmU
compared to the HiGlmU homologue. These results also oﬀer
the possibility of further structural modifications in future
inhibition studies.
At this point, we were also interested in the arrangement of
hydrogen bond donor and acceptor moieties in the amide
linker that bridges the central motif with the terminal groups.
To this end, we prepared compound 38 with a reverse amide
linker (see ESI† for synthesis) and surprisingly, this compound
showed a remarkable decrease in inhibition of GlmU (38: 7%
at 50 μM, 30: 35% at 50 μM), suggesting that the alignment of
hydrogen bond donors and acceptors in the amide linker
region may be important for inhibition of the enzyme.
The aminoquinazoline-based inhibitor library was also
screened for activity against the virulent H37Rv M. tuberculosis
strain to assess the anti-tubercular activity of these com-
pounds. The compounds were screened using a microplate-
based assay with Alamar blue (resazurin) readout (MABA).22–24
Unfortunately, most compounds did not possess significant
anti-tubercular activity (MIC50s > 250 μM) with the exception
of compound 6 and 17 which exhibited MIC50s of 200 μM
against the growth of M. tuberculosis.
Conclusions
In summary, we have developed a continuous double coupled
kinetic assay for M. tuberculosis GlmU uridyltransferase and
successfully synthesised the first micromolar inhibitors
Table 2 Inhibition of uridyltransferase activity ofM. tuberculosis GlmU by amino-
quinazoline inhibitors with varied terminal aryl groups
Compound R R1 % Inhibition at 50 μM
23 Me 19%
24 Me 19%
25 Me 14%
26 Me 13%
27 Me 16%
28 Me 18%
29 Me 21%
30 Me 35% (IC50 = 74 ± 1 μM)
31 Me 38%
32 Me No inhibition
33 Me 17%
34 Me No inhibition
35 Me 34%
Table 3 Inhibition of uridyltransferase activity of M. tuberculosis GlmU by
inhibitors with variation in the aminoquinazoline core or central amide linker
Compound R L % Inhibition at 50 μM
36 38%
37 30%
38 7%
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against this enzyme. These inhibitors will serve as useful tools
for enzyme co-crystallisation studies which will provide impor-
tant information on the interactions necessary for potent inhi-
bition of M. tuberculosis GlmU uridyltransferase. Experiments
towards this goal are currently underway in our laboratories
and will be reported in due course.
Experimental
Biological experimental
Expression and purification of M. tuberculosis GlmU
uridyltransferase. The glmU gene was amplified from
M. tuberculosis genomic DNA by PCR using the primers
5′ GGCAGCGGCGCGATGACGTTTCCTGGTGACAC-3′ and
5′ GAAAGCTGGGTGTCACGGTGTCTGATCAGC-3′. The construct
was cloned into the pDEST17 N-terminal His6-tag vector
(Invitrogen) using Gateway cloning. The GlmU protein was
overexpressed in E. coli BL21(DE3) cell strain using an auto-
induction protocol.25 An overnight culture was prepared by
inoculating 5 mL PA-0.5G medium supplemented with ampi-
cillin (100 mg mL−1) and incubating at 37 °C with shaking
(180 rpm). Overnight cultures were transferred into 1 L
ZYP-5052 medium and incubated at 37 °C with shaking at
180 rpm. On reaching an OD600 of 0.7 (approximately 4 h), the
cell culture was cooled to 4 °C for 1 h. The culture was then
incubated for approximately 18 h at 18 °C with shaking at
180 rpm. Cells were harvested by centrifugation at 5000g for
10 min at 4 °C and resuspended in buﬀer A (25 mM NaH2PO4–
Na2HPO4 pH 7.5, 100 mM NaCl, 14 mM β-mercaptoethanol,
20 mM imidazole). Cells were lysed by cell disruption
(Constant Cell Disruption System) and the lysate was centri-
fuged at 16 000 rpm for 40 min. The supernatant was applied
onto an immobilized metal (Ni2+) aﬃnity column (IMAC) pre-
equilibrated with buﬀer A. A linear imidazole gradient (0–1 M)
was used to elute the fusion protein. The His6 tag was cleaved
by incubation with recombinant tobacco etch virus (rTEV)
protease (overnight at 4 °C), after which the rTEV protease and
uncleaved protein were removed by a second IMAC step. In a
final purification step GlmU was applied onto a size-exclusion
column (Hi Load 16/60 Superdex 200, GE Healthcare) equili-
brated with buﬀer B (50 mM HEPES, pH 7.5, 100 mM NaCl,
1 mM DTT, 1 mM EDTA). Purified GlmU protein was concen-
trated to 15 mg mL−1 and stored in −80 °C freezer. Purity of
the enzyme was confirmed by SDS-PAGE analysis to be >90%.
Purified M. tuberculosis GlmU uridyltransferase possessed a
specific activity of 2.0 units per mg of protein.
M. tuberculosis GlmU uridyltransferase assays. In 96-well
plate format, the standard inhibition assay of 200 μL contained
the following (50 mM Tris·HCl (pH 7.6), 5 mM MgCl2, 1 mM
DTT, 0.2 mM 7-methyl-6-thioguanosine (MESG), 1 U mL−1
purine nucleoside phosphorylase (PNPase), 2.4 U mL−1
inorganic pyrophosphatase, 94 nM M. tuberculosis GlmU uridyl-
transferase, 35 μM GlcNAc-1-P and 50 μM of a given inhibi-
tor (dissolved in DMSO and water mixture with a final
concentration of 1% DMSO in assay) with the exception of
inhibitor 30 for which a range of concentrations were used
(0–400 μM). The assay mix was incubated, in duplicate at 25 °C
for 10 minutes prior to initiation by the addition of 35 μM UTP
and monitored for 6 minutes at 360 nm on a Polarstar-Omega
(BMG LabTech) microplate reader. The IC50 value for 30 was
determined by non-linear regression fitting to the sigmoidal
Hill equation (below) using GraphPad Prism (version 5.03 for
Windows), where vi/vo is the initial fractional velocity, A and B
represent top and bottom of curve, l is the logarithm of inhibi-
tor concentration and h is Hill slope.
vi
vo
¼ Bþ A # B
1þ 10ðlog IC50#lÞ&h
Microplate-based assay with Alamar blue (resazurin) readout
for virulent M. tuberculosis H37Rv. M. tuberculosis H37Rv
(ATCC 27294) was grown in Middlebrook 7H9 broth medium
supplemented with OADC (Difco Laboratories, Detroit, MI,
USA), 0.5% glycerol, and 0.05% Tween-80. Freshly seeded cul-
tures were grown at 37 °C, for approximately 14 days, to mid-
exponential phase (OD600 0.4–0.8) for use in the inhibition
assays. The eﬀect of the GlmU uridyltransferase inhibitors
against M. tuberculosis growth were measured by a resazurin
reduction microplate assay, using the procedure previously
described by Taneja and Tyagi.22 M. tuberculosis grown to mid-
exponential phase (OD600 0.4–0.8) was diluted to OD600 0.002
in 7H9S media (Middlebrook 7H9 with OADC, 0.5% glycerol,
0.02% tyloxapol, 1% tryptone) containing 0.5% DMSO; 96-well
microtiter plates were set up with 100 μL inhibitors, serially
diluted into 7H9S. Diluted M. tuberculosis (100 μL, represent-
ing ∼2 × 104 CFU mL−1) was added to each well. Plates were
incubated for 5 days at 37 °C in a humidified incubator prior
to the addition of a 0.02% resazurin solution (30 μL) and 20%
Tween-80 (12.5 μL) to each well. Sample fluorescence was
measured after 48 h on a BMG Labtech Polarstar Omega
instrument with an excitation wavelength of 530 nm and emis-
sion at 590 nm. Changes in fluorescence relative to positive
control wells (H37Rv with no inhibitor) minus negative control
wells (no H37Rv) were plotted for determination of MIC50
values.
General synthetic experimental
1H NMR spectra were recorded at 300 K unless otherwise speci-
fied using a Bruker Avance DPX 300, DPX 400 and DPX 500
NMR spectrometer at a frequency of 400.2 and 500.2 MHz
respectively. 1H NMR chemical shifts are reported in parts per
million (ppm) and are referenced to solvent residual signals:
CDCl3 δ 7.26, MeOD δ 3.31, (CD3)2CO δ 2.05, DMSO δ 2.50.
1H NMR data is reported as chemical shift (δH), relative inte-
gral, multiplicity (s = singlet, d = doublet, t = triplet, q =
quartet, dd = doublet of doublets, ddd = doublet of doublet of
doublets, tt = triplet of triplets, qd = quartet of doublets), coup-
ling constant ( J Hz) and assignment where possible. Number-
ing of carbons and protons is shown in Fig. S1 (ESI†). Low
resolution mass spectra were recorded on a Finnigan LCQ
Deca ion trap mass spectrometer (ESI). High resolution mass
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spectra were recorded on a Bruker 7 T Fourier Transform Ion
Cyclotron Resonance Mass Spectrometer (FTICR).
Melting points were recorded using a Stanford Research
Systems OptiMelt Automated Melting Point System. Infrared
(IR) absorption spectra were recorded on a Bruker ALPHA
Spectrometer with Attenuated Total Reflection (ATR) capa-
bility, using OPUS 6.5 software. Optical rotations were
measured using a POLAAR 2001 polarimeter and [α]25D values
are reported in 10−1 deg cm2 g−1.
Preparative reverse phase HPLC was performed using a
Waters 600 Multisolvent Delivery System and Waters 500 pump
with a Waters 2996 photodiode array detector or Waters 490E
programmable wavelength detector operating at 254 and
280 nm. A Waters Sunfire 5 μm, 19 × 150 mm column was
used at a flow rate of 7 mL min−1. Preparative HPLC was per-
formed at a flow rate of 7 mL min−1. Compounds were eluted
with 0.1% TFA in water (solvent A), and 0.1% TFA in CH3CN
(solvent B) using a linear gradient of 0–100% B over 40 min.
LC-MS was performed on a Shimadzu LC-MS 2020 instru-
ment consisting of a LC-M20A pump and a SPD-20A UV/Vis
detector coupled to a Shimadzu 2020 mass spectrometer (ESI)
operating in positive mode. Separations were performed on a
Waters Sunfire 5 µm, 2.1 × 150 mm column (C18), operating at
a flow rate of 0.2 mL min−1. Separations were performed using
a mobile phase of 0.1% formic acid in water (solvent A) and
0.1% formic acid in acetonitrile (solvent B) and a linear gradi-
ent of 0–100% B over 30 min or 0–50% B over 30 min.
Materials
Analytical thin layer chromatography (TLC) was performed on
commercially prepared silica plates (Merck Kieselgel 60
0.25 mm F254). Flash column chromatography was performed
using 230–400 mesh Kieselgel 60 silica eluting with distilled
solvents as described. Ratios of solvents used for TLC and
column chromatography are expressed in v/v as specified.
Compounds were visualised by UV light at 254 nm or using
vanillin or cerium molybdate stain. Commercial materials
were used as received unless otherwise noted. DCM and
methanol were distilled from calcium hydride, and THF and
diethyl ether were distilled over sodium/benzophenone. Anhy-
drous DMF was purchased from Sigma-Aldrich.
2-(3,4-Dimethoxyphenyl)-6-morpholino-4H-chromen-4-one
(8). To a solution of 4,5-dimethoxyanthranilic acid 7 (1.0 g,
5.1 mmol) in methanol (4 mL) was added trimethyl ortho-
formate (2.20 mL, 20.3 mmol) and ammonium acetate (1.56 g,
20.3 mmol). The reaction was heated at 120 °C for 3 h. The
reaction was allowed to cool to room temperature, water
(40 mL) was added and the suspension was stirred for an
additional 1 h. The solution was subsequently filtered to
aﬀord 8 as a white solid (900 mg, 86%). M.p. 283–284 °C
(decomp.). IR (ATR): ν = 2837, 1645, 1606 cm−1. 1H NMR
(400 MHz, DMSO-d6): δ 7.96 (1H, s, Ar–H, H-2), 7.43 (1H, s,
Ar–H, H-5), 7.08 (1H, s, Ar–H, H-8), 3.90 (3H, s, OCH3), 3.85
(3H, s, OCH3). 13C NMR (75 MHz, DMSO-d6): δ 160.3, 154.4,
148.5, 144.8, 143.8, 115.6, 107.9, 104.9, 55.9, 55.7. LRMS
[M + H+] 207.0. These data are in agreement with those
previously reported by VanBrocklin et al.26
4-Chloro-6,7-dimethoxyquinazoline (9). A mixture of quin-
azoline 8 (0.44 g, 2.0 mmol) and phosphorus(V) oxychloride
(4.4 mL, 43 mmol) was refluxed for 5 h. Solvent was removed
in vacuo and the residue was dissolved in dichloromethane
(200 mL) and washed with saturated aqueous NaHCO3 solu-
tion (3 × 50 mL) and brine (50 mL). The organic layer was
dried over anhydrous MgSO4 and the solvent was removed
in vacuo to aﬀord a crude residue that was purified by column
chromatography (95 : 5 v/v CH2Cl2–MeOH) to aﬀord 9 as a
white solid (310 mg, 70%). M.p. 186–188 °C. IR (ATR):
ν = 1683 cm−1. 1H NMR (400 MHz, CDCl3): δ 8.87 (1H, s, Ar–H,
H-2), 7.39 (1H, s, Ar–H, H-5), 7.33 (1H, s, Ar–H, H-8), 4.07 (6H,
s, 2 × OCH3). 13C NMR (101 MHz, CDCl3): δ 159.1, 156.8, 152.5,
151.5, 149.1, 119.6, 106.9, 102.7, 56.6, 56.4. LRMS [M + H+]
225.0. These data are in agreement with those previously
reported by VanBrocklin et al.26
General procedure 1: synthesis of aminoquinazoline-based
inhibitors 10–12, 22, 32–42. To a solution of 4-chloro-6,7-
dimethoxyquinazoline 9 (0.07–1.33 mmol) in isopropanol
(11.2–25.7 mL mmol−1) was added 1,2-diaminocyclohexane,
piperazine hydrochloride hydrate, 1,4-phenylenediamine or
the corresponding 4-aminocarboxamides (0.07–5.63 mmol,
1–12 eq.) and the reaction mixture was heated at 120 °C for
3–5 h. The reaction was subsequently filtered and washed with
diethyl ether (2 × 10 mL) to obtain compounds 10–12, 22–33
which were purified by column chromatography, reverse phase
HPLC or used without further purification as specified.
General procedure 2: synthesis of aminoquinazoline-based
inhibitors 14–19. To a stirring solution of amine 10–12
(0.26–0.31 mmol) in DMF (58 mL mmol−1) was added benzoic
acid, cyclohexanecarboxylic acid or Boc-L-hydroxyproline
(1.1 eq.), N,N-diisopropylethylamine (1–1.6 eq.) and HATU
(1.6 eq.). The reaction mixture was allowed to stir at room
temperature for 4–20 h at which point it was diluted with ethyl
acetate (30 mL), washed with water (4 × 10 mL), brine (10 mL)
and dried over anhydrous MgSO4. The solvent was removed
in vacuo to give a crude residue that was purified by column
chromatography or reverse phase HPLC to aﬀord compound
14–19.
N1-(6,7-Dimethoxyquinazolin-4-yl)cyclohexane-1,2-diamine
(10). 4-Chloro-6,7-dimethoxyquinazoline 9 (300 mg, 1.33 mmol)
was added to a solution of 1,2-diaminocyclohexane (0.65 mL,
5.33 mmol) in isopropanol (15 mL) according to general pro-
cedure 1. Following column chromatography (9 : 1 v/v CH2Cl2–
MeOH) compound 10 was aﬀorded as a yellow solid (234 mg,
60%). M.p. 123–126 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.37
(1H, d, J 8.2 Hz, NH), 8.75 (1H, s, Ar–H, H-2), 8.07 (2H, br. s,
NH2), 7.88 (1H, s, Ar–H, H-8), 7.35 (1H, s, Ar–H, H-5),
4.59–4.54 (1H, m, H-1′), 3.98 (6H, s, OCH3), 3.40 (1H, t,
J 11.4 Hz, H-2′), 2.16 (1H, app. dd, J 13.3, 4.1 Hz, H-3′), 2.01
(1H, app. d, J 12.8 Hz, H-6′), 1.83–1.79 (2H, m, H-5′), 1.65–1.54
(2H, m, H-3′ + H-6′), 1.38–1.32 (2H, m, H-4′). 13C NMR
(101 MHz, DMSO-d6): δ 158.8, 154.3, 153.5, 148.6, 146.3, 109.4,
107.1, 103.9, 57.0, 56.1, 52.9, 52.5, 31.5, 30.3, 24.7, 24.3. LRMS
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[M + H+] 303.2. HRMS (ESI) m/z cald for C16H23N4O2 [M + H+]:
303.1816, found 303.1817.
6,7-Dimethoxy-4-(piperazin-1-yl)quinazoline (11). 4-Chloro-
6,7-dimethoxyquinazoline 9 (300 mg, 1.33 mmol) was added to
a solution of piperazine hexahydrate (1.03 g, 5.32 mmol) in
isopropanol (15 mL) according to general procedure 1 for 3 h.
The reaction was subsequently diluted with dichloromethane
(100 mL), washed with brine (2 × 40 mL) and dried over anhy-
drous Na2SO4. The solvent was removed in vacuo to give a
residue that was purified by column chromatography (9 : 1 v/v
CH2Cl2–CH3OH → 4 : 1 v/v CH2Cl2–CH3OH) to aﬀord com-
pound 11 as a white solid (255 mg, 70%). M.p. 153–154 °C. IR
(ATR): ν = 3235, 2827, 1616 cm−1. 1H NMR (500 MHz, CD3OD):
δ 8.48 (1H, s, Ar–H, H-2), 7.13 (2H, s, Ar–H, H-5 + H-8),
3.97 (3H, s, OCH3), 3.95 (3H, s, OCH3), 3.66 (4H, t, J = 5 Hz,
H-2′ + H-6′), 3.04 (4H, t, J = 5 Hz, H-3′ + H-5′). 13C NMR
(125 MHz, CD3OD): δ 163.8, 155.2, 152.0, 148.9, 148.1, 110.9,
105.7, 103.2, 55.2, 55.1, 50.1, 44.9. LRMS [M + H+] 275.1.
HRMS (ESI) m/z cald for C14H19N4O2 [M + H+]: 275.1503, found
275.1502.
N1-(6,7-Dimethoxyquinazolin-4-yl)benzene-1,4-diamine (12).
4-Chloro-6,7-dimethoxyquinazoline 9 (103 mg, 0.46 mmol) was
added to a solution of 1,4-phenylenediamine (609 mg,
5.63 mmol) in isopropanol (7.5 mL) according to general pro-
cedure 1 to obtain 12 as a yellow solid (120 mg, 89%).
M.p. 137–140 °C (decomp.). IR (ATR): ν = 3333, 1631 cm−1.
1H NMR (400 MHz, DMSO-d6): δ 8.32 (1H, s, Ar–H, H-2), 7.81
(1H, s, Ar–H, H-8), 7.29 (2H, d, J 8.8 Hz, Ar–H, H-2′ + H-6′),
7.13 (1H, s, Ar–H, H-5), 6.60 (2H, d, J 8.8 Hz, Ar–H, H-3′ +
H-5′), 3.94 (3H, s, OCH3), 3.93 (3H, s, OCH3). 13C NMR
(75 MHz, DMSO-d6): δ 157.0, 154.2, 152.2, 148.8, 145.6, 127.4,
124.9, 118.3, 113.7, 108.3, 105.6, 102.4, 56.2, 55.8. LRMS
[M + H+] 297.1. These data are in agreement with those
previously reported by Garske et al.27
N-(4-((6,7-Dimethoxyquinazolin-4-yl)amino)phenyl)cyclohexane
carboxamide (13). To a mixture of cyclohexane carboxylic acid
(29 mg, 0.22 mmol) in DMF (1.6 mL) was added N,N′-diisopropyl-
carbodiimide (55 μL, 0.35 mmol) and 4-dimethylaminopyri-
dine (43 mg, 0.35 mmol). The solution was allowed to stir at
room temperature for 15 min. Amine 12 (60 mg, 0.20 mmol)
was then added to the above reaction mixture which was
allowed to stir at room temperature for 20 h. The reaction
mixture was diluted with ethyl acetate (50 mL), washed with
water (5 × 15 mL), brine (15 mL) and dried over anhydrous
MgSO4. The solvent was removed in vacuo to give a crude
residue that was purified by reverse phase HPLC (0 to 100%
MeCN over 40 min) to aﬀord compound 13 as a yellow solid
(50 mg, 56%). M.p. 222–225 °C (decomp.). IR (ATR): ν = 2937,
1676 cm−1. 1H NMR (400 MHz, DMSO-d6): δ 10.85 (1H, s, NH),
9.97 (1H, s, NH), 8.76 (1H, s, Ar–H, H-2), 8.05 (1H, s, Ar–H,
H-8), 7.72 (2H, d, J 8.9 Hz, Ar–H, H-2′ + H-6′), 7.56 (2H, d,
J 8.9 Hz, Ar–H, H-3′ + H-5′), 7.28 (1H, s, Ar–H, H-5), 4.00 (3H, s,
OCH3), 3.99 (3H, s, OCH3), 2.35 (1H, tt, J 11.6, 3.5 Hz, H-1″),
1.86–1.73 (4H, m), 1.67 (1H, d, J 11.7 Hz), 1.43 (2H, qd, J 11.4,
9.9, 2.0 Hz), 1.35–1.17 (3H, m). 13C NMR (101 MHz, DMSO-d6):
δ 174.8 (CvO), 158.6, 158.3, 156.5, 150.5, 149.9, 138.0, 132.2,
125.3, 119.6, 107.7, 103.6, 101.4, 57.0, 56.9, 45.3, 29.6, 25.9,
25.7. LRMS [M + H+] 407.2. HRMS (ESI) m/z cald for
C23H27N4O3 [M + H+]: 407.2077, found 407.2078.
(4-(6,7-Dimethoxyquinazolin-4-yl)piperazin-1-yl)(phenyl)-
methanone (14). Amine 11 (71 mg, 0.26 mmol) was reacted
with benzoic acid (35 mg, 0.29 mmol) in DMF (15 mL) in the
presence of N,N-diisopropylethylamine (70 μL, 0.26 mmol) and
HATU (156 mg, 0.40 mmol) for 4 h according to general pro-
cedure 2. Purification by column chromatography (9 : 1 v/v
CH2Cl2–CH3OH) provided compound 14 as a white solid
(45 mg, 47%). M.p. 221–223 °C (decomp.). IR (ATR): ν = 2800,
1641 cm−1. 1H NMR (400 MHz, DMSO-d6): δ 8.57 (1H, s, Ar–H,
H-2), 7.49–7.44 (4H, m, Ar–H), 7.24 (1H, s, Ar–H, H-8), 7.16
(1H, s, Ar–H, H-5), 3.94 (3H, s, OCH3), 3.92 (3H, s, OCH3),
3.75–3.56 (8H, m, 4 × CH2). 13C NMR (101 MHz, DMSO-d6): δ
169.9 (CvO), 163.3, 155.0, 152.8, 149.2, 148.9, 136.4, 130.0,
128.9, 127.4, 111.1, 107.9, 104.1, 56.4, 56.3, 49.5 (×2). LRMS
[M + H+] 379.4. HRMS (ESI) m/z cald for C21H23N4O3 [M + H+]:
379.1765, found 379.1764.
Cyclohexyl(4-(6,7-dimethoxyquinazolin-4-yl)piperazin-1-yl)-
methanone (15). Amine 11 (71 mg, 0.26 mmol) was reacted
with cyclohexane carboxylic acid (38 mg, 0.29 mmol) in DMF
(15 mL) in the presence of N,N-diisopropylethylamine (70 μL,
0.26 mmol) and HATU (156 mg, 0.40 mmol) for 20 h according
to general procedure 2. Purification by reverse phase HPLC
(0 to 100% MeCN over 40 min) provided compound 15 as
a white solid (50 mg, 50%). M.p. 165–166 °C (decomp.).
IR (ATR): ν = 2936, 2855, 1792, 1772, 1678 cm−1. 1H NMR
(400 MHz, CD3OD): δ 8.66 (1H, s, Ar–H, H-2), 7.47 (1H, s, Ar–
H, H-8), 7.24 (1H, s, Ar–H, H-5), 4.35 (4H, dt, J = 10.4, 5.2 Hz,
H-3′ + H-5′), 4.08 (3H, s, OCH3), 4.03 (3H, s, OCH3), 3.88–3.84
(4H, m, H-2′ + H-6′), 2.72 (1H, ddd, J 11.3, 8.1, 3.2 Hz, H-1″),
1.86–1.77 (5H, m), 1.56–1.27 (5H, m). 1H NMR (100 MHz,
CD3OD): δ 176.1 (CvO), 161.9, 157.3, 149.6, 146.2, 137.4,
106.6, 105.8, 98.8, 55.9, 55.6, 44.0, 40.9, 40.2, 29.0, 25.6, 25.3.
LRMS [M + H+] 385.1. HRMS (ESI) m/z cald for C21H29N4O3
[M + H+]: 385.2234, found 385.2232.
N-(2-((6,7-Dimethoxyquinazolin-4-yl)amino)cyclohexyl)benz-
amide (16). Amine 10 (65 mg, 0.21 mmol) was reacted with
benzoic acid (28 mg, 0.23 mmol) in DMF (12 mL) in the pres-
ence of N,N-diisopropylethylamine (58 μL, 0.20 mmol) and
HATU (126 mg, 0.32 mmol) for 4 h according to general pro-
cedure 2. Purification by column chromatography (95 : 5 v/v
CH2Cl2–CH3OH) provided compound 16 as a pale yellow oil
(41 mg, 48%). IR (ATR): ν = 2923, 1707 cm−1. 1H NMR
(400 MHz, DMSO-d6): δ 8.40 (1H, d, J 11.0 Hz, NH), 8.38 (1H, s,
Ar–H, H-2), 7.76 (1H, s, NH), 7.59 (2H, dd, J 7.3, 1.4 Hz, Ar–H,
H-2″ + H-6″), 7.48 (1H, s, Ar–H, H-8), 7.45–7.38 (1H, m, Ar–H,
H-4″), 7.37–7.28 (2H, m, Ar–H, H-3″ + H-5″), 7.01 (1H, s, Ar–H,
H-5), 4.30 (1H, app. dd, J 13.6, 7.9 Hz, H-2′), 4.04 (1H, app. dd,
J 12.1, 9.8 Hz, H-1′), 3.89 (3H, s, OCH3), 3.87 (3H, s, OCH3),
2.11 (1H, t, J 11.4 Hz), 2.02 (1H, app. d, J 12.7 Hz), 1.78 (2H,
app. d, J 8.7 Hz, CH2), 1.70–1.42 (2H, m, CH2), 1.36 (2H, app. t,
J 10.3 Hz, CH2). 13C NMR (101 MHz, DMSO-d6): δ 167.1 (CvO),
158.8, 154.3, 153.6, 148.8, 145.8, 134.9, 131.5, 128.6, 127.4,
108.5, 107.1, 102.4, 56.5, 56.1, 54.8, 54.1, 32.2 (×2), 25.2, 25.1.
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LRMS [M + H+] 407.2. HRMS (ESI) m/z cald for C23H27N4O3
[M + H+]: 407.2078, found 407.2076.
N-(2-((6,7-Dimethoxyquinazolin-4-yl)amino)cyclohexyl)cyclo-
hexane carboxamide (17). Amine 10 (93 mg, 0.31 mmol) was
reacted with cyclohexane carboxylic acid (84 μL, 0.48 mmol) in
DMF (18 mL) in the presence of N,N-diisopropylethylamine
(58 μL, 0.20 mmol) and HATU (181 mg, 0.48 mmol) for 24 h
according to general procedure 2. Purification by column
chromatography (98 : 2 v/v CH2Cl2–CH3OH → 95 : 5 v/v
CH2Cl2–CH3OH) provided compound 17 as a white solid
(40 mg, 31%). M.p. 98–100 °C (decomp.). IR (ATR): ν = 3266,
2934, 2859, 1675, 1636 cm−1. 1H NMR (400 MHz, CD3OD):
δ 8.60 (1H, s, Ar–H, H-2), 7.86 (1H, d, J 6.0 Hz, NH), 7.67 (1H,
s, Ar–H, H-8), 7.12 (1H, s, Ar–H, H-5), 4.43 (1H, dt, J 11.6,
4.8 Hz, H-2′), 4.05 (3H, s, OCH3), 4.02 (3H, s, OCH3), 4.01–3.93
(1H, m, H-1′), 2.20–2.12 (1H, m, H-3′), 2.02–1.93 (2H, m),
1.92–1.83 (2H, m), 1.70–1.40 (8H, m), 1.33–1.15 (2H, m),
1.11–1.01 (3H, m), 0.95 (1H, app. dt, J 12.0, 3.6 Hz, H-5′).
13C NMR (101 MHz, CD3OD): δ 178.0 (CvO), 159.5, 157.2,
151.0, 148.3, 134.3, 106.5, 102.7, 98.8, 57.1, 55.8, 55.8, 51.8,
44.8, 31.3, 30.7, 29.2, 28.9, 25.3, 25.2, 25.1, 24.6, 24.3. LRMS
[M + H+] 413.2. HRMS (ESI) m/z cald for C23H33N4O3 [M + H+]:
413.2547, found 413.2546.
(2S,4R)-N-(4-((6,7-Dimethoxyquinazolin-4-yl)amino)phenyl)-
4-hydroxypyrrolidine-2-carboxamide (19). Amine 12 (74 mg,
0.26 mmol) was reacted with Boc-L-hydroxyproline (97 mg,
0.29 mmol) in DMF (15 mL) in the presence of N,N-diisopropyl-
ethylamine (70 μL, 0.26 mmol) and HATU (156 mg,
0.40 mmol) for 20 h according to general procedure 2 to
obtain Boc-carbamate 18 which was used without further puri-
fication. To a solution of Boc-carbamate 18 (52 mg,
0.10 mmol) in THF (3 mL) was added 4 M HCl in dioxane
(408 μL). The reaction was stirred at room temperature for 16 h
at which point the reaction was quenched with saturated
aqueous NaHCO3 (10 mL). The mixture was then extracted into
ethyl acetate (3 × 50 mL), washed with water, brine and dried
over anhydrous MgSO4. The solvent was removed in vacuo to
give a crude residue that was purified by reverse phase HPLC
(0 to 100% MeCN over 40 min) to aﬀord compound 19 (32 mg,
30%) as a yellow amorphous solid. IR (ATR): ν = 3581, 1739,
1724 cm−1. 1H NMR (400 MHz, CD3OD): δ 8.67 (1H, s, Ar–H,
H-2), 7.98 (1H, s, Ar–H, H-8), 7.77–7.72 (4H, m, Ar–H, H-2′ +
H-6′ + H-3′ + H-5′), 7.25 (1H, s, Ar–H, H-5), 4.74–4.57 (2H, m,
H-2″ + H-4″), 4.09 (3H, s, OCH3), 4.08 (3H, s, OCH3), 3.51 (1H,
dd, J 12.1, 3.5 Hz, H-5″ax), 3.39 (1H, dd, J 12.5, 1.8 Hz, H-5″eq),
2.61 (1H, dd, J 13.6, 7.5 Hz, H-3″eq), 2.22 (1H, ddd, J 14.0, 10.3,
4.0 Hz, H-3″ax). 13C NMR (101 MHz, CD3OD): δ 166.5 (CvO),
158.5, 157.5, 151.4, 148.3, 136.1, 136.0, 133.3, 124.7, 120.0,
107.5, 102.4, 99.4, 69.9, 59.3, 55.9, 55.8, 53.9, 38.7. LRMS
[M + H+] 410.0. HRMS (ESI) m/z cald for C21H24N5O4 [M + H+]:
410.1820, found 410.1823. [α]25D = +28° (c = 0.1 in CH3OH).
(S)-N-(4-((6,7-Dimethoxyquinazolin-4-yl)amino)phenyl)pyrrol-
idine-2-carboxamide (22). 4-Chloro-6,7-dimethoxyquinazoline
9 (100 mg, 0.44 mmol) was reacted with amine 20 (191 mg,
0.44 mmol) in isopropanol (9.6 mL) according to general pro-
cedure 1 to obtain Fmoc-carbamate 21 as a yellow solid which
was submitted to the next step without purification. A solution
of Fmoc-carbamate 21 was treated with 25% piperidine (5 mL)
in a mixture of dichloromethane and methanol (1 : 1, v/v) for
1 h. The solvent was removed in vacuo to aﬀord a crude residue
that was purified by column chromatography (95 : 4 : 1 v/v/v
CH2Cl2–MeOH–Et3N → 90 : 9 : 1 v/v/v CH2Cl2–MeOH–Et3N) to
aﬀord compound 22 as an amorphous solid (59 mg, 34% over
2 steps). IR (ATR): ν = 3066, 2986, 1673, 1639 cm−1. 1H NMR
(400 MHz, DMSO-d6, 330 K): δ 10.59 (1H, s, NH), 8.67 (1H, s,
Ar–H, H-2), 8.01 (1H, s, Ar–H, H-8), 7.74–7.66 (4H, m, Ar–H,
H-2′ + H-6′ + H-3′ + H-5′), 7.30 (1H, s, Ar–H, H-5), 4.40 (1H, m,
H-2″), 3.99 (6H, s, 2 × OCH3), 3.33 (2H, m, H-5″), 2.43 (1H, m,
H-3″eq), 2.03 (3H, m, H-3″ax + H-4″). 13C NMR (100 MHz,
DMSO-d6, 330 K): δ 167.2 (CvO), 158.7, 156.3, 150.7, 150.4,
140.0, 135.8, 134.4, 124.9, 120.4, 108.3, 103.7, 103.2, 60.4, 57.1,
56.8, 46.4, 30.0, 24.0. LRMS [M + H+] 394.0. HRMS (ESI) m/z
cald for C21H24N5O3 [M + H+]: 394.1874, found 394.1872.
[α]25D = −26° (c = 0.15 in CH3OH).
N-(4-((6,7-Dimethoxyquinazolin-4-yl )amino)phenyl )-3-
(4-fluoro-phenyl)-5-methylisoxazole-4-carboxamide (23). 4-Chloro-
6,7-dimethoxyquinazoline 9 (90 mg, 0.39 mmol) was reacted
with the corresponding 4-aminocarboxamide (124 mg,
0.39 mmol) in isopropanol (8.8 mL) according to general pro-
cedure 1 to obtain compound 23 as an oﬀ-white solid (140 mg,
72%). M.p. 253–256 °C (decomp.). IR (ATR): ν = 1659,
1631 cm−1. 1H NMR (400 MHz, DMSO-d6): δ 11.45 (1H, s, NH),
10.64 (1H, s, NH), 8.76 (1H, s, Ar–H, H-2), 8.34 (1H, s, Ar–H,
H-8), 7.81–7.72 (4H, m, Ar–H, H-2′ + H-6′ + H-2″ + H-6″), 7.66
(2H, d, J 8.5 Hz, Ar–H, H-3′ + H-5′), 7.42–7.30 (3H, m, Ar–H,
H-5, H-3″ + H-5″), 4.02 (3H, s, CH3), 3.99 (3H, s, OCH3), 2.62
(3H, s, OCH3); 13C NMR (100 MHz, DMSO-d6): δ 170.7, 164.8
(CvO), 161.4 (d, J 199 Hz, ipso-C), 159.9, 158.5, 156.7, 150.6,
149.1, 137.1, 135.9, 133.2, 130.5 (d, J 8.7 Hz, meta-C), 125.8,
125.0 (d, J 3.1 Hz, para-C), 120.4, 116.4 (d, J 21.8 Hz, ortho-C),
113.6, 107.7, 104.5, 100.3, 57.4, 56.9, 12.5. LRMS [M + H+]
500.3. HRMS (ESI) m/z cald for C27H23FN5O4 [M + H+]:
500.1729, found 500.1728.
N-(4-((6,7-Dimethoxyquinazolin-4-yl)amino)phenyl)pyrazine-
2-carboxamide (24). 4-Chloro-6,7-dimethoxyquinazoline 9
(50 mg, 0.22 mmol) was reacted with the corresponding
4-aminocarboxamide (109 mg, 0.22 mmol) in isopropanol
(3.1 mL) according to general procedure 1 to obtain a crude
solid that was purified by reverse-phase HPLC (gradient:
0–100% MeCN over 40 min) to aﬀord compound 24 (TFA salt)
as a yellow solid (80 mg, 90%). M.p. 220–224 °C (decomp.).
IR (ATR): ν = 3340, 1686 cm−1. 1H NMR (500 MHz, DMSO-d6):
δ 10.89 (1H, s, NH), 10.86 (1H, s, NH), 9.30 (1H. d, J 1.5 Hz,
Ar–H, H-3″), 8.94 (1H, d, J 2.5 Hz, Ar–H, H-5″), 8.89–8.82 (1H,
m, Ar–H, H-6″), 8.77 (1H, s, Ar–H, H-2), 8.04 (1H, s, Ar–H, H-8),
8.00 (2H, d, J 8.9 Hz, Ar–H, H-2′ + H-6′), 7.65 (2H, d, J 8.9 Hz,
Ar–H, H-3′ + H-5′), 7.27 (1H, s, Ar–H, H-5), 3.99 (6H, s,
2 × OCH3); 13C NMR (100 MHz, DMSO-d6): δ 162.3 (CvO),
158.5, 156.7, 150.7, 150.0, 148.4, 145.6, 144.7, 143.9, 137.4,
136.8, 133.6, 125.5, 121.4, 107.9, 103.8, 101.4, 57.2, 57.1. LRMS
[M + H+] 403.3. HRMS (ESI) m/z cald for C21H19N6O3 [M + H+]:
403.1513, found 403.1514.
Organic & Biomolecular Chemistry Paper
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N-(4-((6,7-Dimethoxyquinazolin-4-yl)amino)phenyl)-2-hydroxy
benzamide (25). 4-Chloro-6,7-dimethoxyquinazoline 9 (16 mg,
0.072 mmol) was reacted with the corresponding 4-aminocarb-
oxamide (16 mg, 0.072 mmol) in isopropanol (1.6 mL)
according to general procedure 1 to obtain a crude solid that
was purified by reverse-phase HPLC (gradient: 0–100% MeCN
over 40 min) to aﬀord compound 25 as a yellow solid (9 mg,
30%). M.p. = 213–214 °C. IR (ATR): ν = 3385, 1703 cm−1.
1H NMR (400 MHz, Acetone-d6): δ 9.94 (1H, s, NH), 8.71 (1H, s,
Ar–H, H-2), 8.04 (1H, dd, J = 8.0, 1.6 Hz, Ar–H, H-6″), 7.96 (1H,
s, Ar–H, H-8), 7.87–7.75 (4H, m, Ar–H, H-2′ + H-3′ + H-5′ +
H-6′), 7.68 (1H, s, Ar–H, H-5), 7.47 (1H, ddd, J = 8.6, 7.1, 1.6
Hz, Ar–H, H-4″), 7.00 (1H, app. d, J 8.6 Hz, Ar–H, H-3″), 6.93
(1H, dd, J 7.6, 7.1 Hz, Ar–H, H-5″), 4.01 (3H, s, OCH3), 3.96
(3H, s, OCH3). 13C NMR (100 MHz, DMSO): δ 166.9 (CvO),
158.8, 158.5, 158.1, 156.4, 150.4, 150.3, 136.3, 134.1, 133.7,
129.5, 125.1, 121.6, 119.5, 118.1, 117.7, 107.9, 103.6, 102.0,
57.0, 56.8. LRMS [M + H+] 417.3. HRMS (ESI) m/z cald for
C23H21N4O4 [M + H+]: 417.1557, found 417.1560.
N-(4-((6,7-Dimethoxyquinazolin-4-yl)amino)phenyl)-2-nitro-
benzamide (26). 4-Chloro-6,7-dimethoxyquinazoline 9 (200 mg,
0.86 mmol) was reacted with the corresponding 4-amino-
carboxamide (221 mg, 0.86 mmol) in isopropanol (20 mL)
according to general procedure 1 to obtain compound 26 as a
yellow solid (200 mg, 52%) after filtration and washing
with diethyl ether (2 × 10 mL). M.p. 263–265 °C (decomp.).
IR (ATR): ν = 2756, 1679, 1530 cm−1. 1H NMR (500 MHz,
DMSO-d6): δ 11.37 (1H, s, NH), 10.85 (1H, s, NH), 8.80 (1H, s,
Ar–H, H-2), 8.30 (1H, s, Ar–H, H-8), 8.17 (1H, app. d, J 8.0 Hz,
Ar–H, H-3″), 7.90 (1H, dd, J 8.0, 7.5 Hz, Ar–H, H-5″), 7.82–7.77
(4H, m, Ar–H, H-2′ + H-6′ + H-3′ + H-5′), 7.68 (2H, m, Ar–H,
H-4″ + H-6″), 7.36 (1H, s, Ar–H, H-5), 4.02 (3H, s, OCH3), 3.99
(3H, s, OCH3). 13C NMR (125 MHz, DMSO-d6): δ 164.6 (CvO),
158.6, 156.7, 150.6, 149.2, 146.9, 137.4, 136.0, 134.6, 133.0 (×2),
131.5, 129.8, 125.8, 124.8, 120.2, 107.7, 104.3, 100.4, 57.4, 56.9.
LRMS [M + H+] 446.2. HRMS (ESI) m/z cald for C23H20N5O5
[M + H+]: 446.1459, found 446.1459.
2-Amino-N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)-
benzamide (27). Compound 26 (45 mg, 0.10 mmol) in ethyl
acetate (1.5 mL) was hydrogenated (1 atm) over 10% Pd/C
(15 mg) for 16 h. The reaction mixture was subsequently fil-
tered over Celite® and the filtrate concentrated in vacuo. Puri-
fication by reverse phase HPLC (gradient: 0–100% MeCN over
40 min) provided compound 27 as a yellow solid (12 mg, 29%).
M.p. 127–128 °C (decomp.). IR (ATR): ν = 3452, 1677,
1639 cm−1. 1H NMR (400 MHz, CD3OD): δ 8.67 (1H, s, Ar–H,
H-2), 7.99 (1H, s, Ar–H, H-8), 7.88–7.77 (2H, m, Ar–H, H-2′ +
H-6′), 7.71 (2H, d, J 8.9 Hz, Ar–H, H-3′ + H-5′), 7.67 (1H, dd, J =
7.9, 1.5 Hz, Ar–H, H-6″), 7.30 (1H, ddd, J 8.5, 7.5, 1.5 Hz, Ar–H,
H-4″), 7.22 (1H, s, Ar–H, H-5), 6.93–6.84 (1H, m, Ar–H, H-3″),
6.80 (1H, app. t, J = 7.5 Hz, Ar–H, H-5″), 4.08 (6H, s, 2 × OCH3).
13C NMR (101 MHz, CD3OD): δ 168.7 (CvO), 158.5, 157.6,
151.4, 148.0, 147.8, 137.4, 135.3, 132.5, 132.2, 128.0, 124.5,
121.0, 117.5, 117.2, 117.0, 107.3, 102.5, 99.0, 55.9, 55.8. LRMS
[M + H+] 416.0. HRMS (ESI) m/z cald for C23H22N5O3 [M + H+]:
416.1717, found 416.1714.
N-(4-((6,7-Dimethoxyquinazolin-4-yl)amino)phenyl)-4-hydroxy
benzamide (28). 4-Chloro-6,7-dimethoxyquinazoline 9 (21 mg,
0.09 mmol) was reacted with the corresponding 4-aminocarb-
oxamide (32 mg, 0.094 mmol) in isopropanol (2.0 mL)
according to general procedure 1 to obtain TBS-protected inter-
mediate as a yellow solid which was used in the next step
without purification (50 mg, quant.). To a solution of the TBS-
protected intermediate (50 mg, 0.094 mmol) in anhydrous
tetrahydrofuran (1 mL) was added tetrabutylammonium fluor-
ide (1 M solution in THF, 0.11 mL, 0.11 mmol) and the reac-
tion was allowed to stir at room temperature for 1 h.
The reaction mixture was then diluted with ethyl acetate
(60 mL) and washed with saturated aqueous NH4Cl solution
(2 × 30 mL) and brine (30 mL). The organic layer was then
dried over anhydrous MgSO4. The solvent was removed
in vacuo to give a crude residue that purified by reverse-phase
HPLC (gradient: 0–100% MeCN over 40 min) to aﬀord com-
pound 28 (TFA salt) as a yellow solid (20 mg, 51% over
2 steps). M.p. 164–165 °C. IR (ATR): ν = 3009, 1709 cm−1;
1H NMR (400 MHz, DMSO-d6): δ 10.91 (1H, s, NH), 10.13 (1H,
s, NH), 8.77 (1H, s, Ar–H, H-2), 8.08 (1H, s, Ar–H, H-8),
7.93–7.83 (4H, m, Ar–H), 7.62 (2H, d, J 8.5 Hz, Ar–H, H-3′ +
H-5′), 7.30 (1H, s, Ar–H, H-5), 6.88 (2H, d, J 8.2 Hz, Ar–H, H-4″ +
H-5″), 3.99 (6H, s, 2 × OCH3). 13C NMR (100 MHz, DMSO-d6):
δ 165.6 (CvO), 161.1, 158.3, 156.5, 150.5, 149.9, 138.0, 137.3,
132.6, 130.2, 125.7, 125.2, 120.8, 115.4, 107.7, 103.7, 101.3,
57.1, 56.9. LRMS [M + H+] 417.1. HRMS (ESI) m/z cald for
C23H21N4O4 [M + H+]: 417.1557, found 417.1557.
N-(4-((6,7-Dimethoxyquinazolin-4-yl)amino)phenyl)-4-fluoro-
benzamide (29). 4-Chloro-6,7-dimethoxyquinazoline 9 (100 mg,
0.44 mmol) was reacted with the corresponding 4-amino-
carboxamide (102 mg, 0.44 mmol) in isopropanol (9.6 mL)
according to general procedure 1. Purification by reverse phase
HPLC (gradient: 0–100% MeCN over 40 min) provided com-
pound 29 as a yellow solid (12 mg, 29%). M.p. 257–260 °C
(decomp.). IR (ATR): ν = 1636 cm−1. 1H NMR (400 MHz,
DMSO-d6): δ 10.89 (1H, s, NH), 10.41 (1H, s, NH), 8.77 (1H, s,
Ar–H, H-2), 8.09–8.03 (3H, m, Ar–H, H-8, H-2″ + H-6″), 7.87
(2H, d, J 8.6 Hz, Ar–H, H-2′ + H-6′), 7.65 (2H, d, J 8.6 Hz, Ar–H,
H-3′ + H-5′), 7.39 (2H, app. t, J 8.6 Hz, Ar–H, H-3″ + H-5″), 7.27
(1H, s, Ar–H, H-2), 3.99 (6H, s, 2 × OCH3). 13C NMR (100 MHz,
DMSO-d6): δ 165.8 (CvO), 165.0 (d, J 161 Hz, ipso-C), 158.7,
158.3, 156.5, 150.5, 149.9, 137.5, 133.0, 131.7 (d, J 3.4 Hz, para-C),
130.8 (d, J 9.2 Hz, meta-C), 125.3, 121.1, 115.8 (d, J 22 Hz,
ortho-C), 107.7, 103.6, 101.3, 57.0, 56.9. LRMS [M + H+] 419.4.
HRMS (ESI) m/z cald for C23H20FN4O3 [M + H+]: 419.1514,
found 419.1513.
N-(4-((6,7-Dimethoxyquinazolin-4-yl)amino)phenyl)-3-hydroxy
benzamide (30). 4-Chloro-6,7-dimethoxyquinazoline 9 (54 mg,
0.24 mmol) was reacted with the corresponding 4-amino-
carboxamide (54 mg, 0.24 mmol) in isopropanol (5.6 mL) accord-
ing to general procedure 1. Purification by reverse phase HPLC
(gradient: 0–100% MeCN over 40 min) provided compound 30
as a yellow solid (39 mg, 39%). M.p. 181–182 °C (decomp.).
IR (ATR): ν = 3474, 1675 cm−1. 1H NMR (500 MHz, DMSO-d6):
δ 10.71 (1H, br. s), 10.28 (1H, s, NH), 9.78 (1H, br. s), 8.74 (1H,
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s, Ar–H, H-2), 8.04 (1H, s, Ar–H, H-8), 7.87 (2H, d, J 8.7 Hz,
Ar–H, H-2′ + H-6′), 7.64 (2H, d, J 8.7 Hz, Ar–H, H-3′ + H-5′),
7.40 (1H, d, J 7.7 Hz, Ar–H, H-6″), 7.35–7.33 (2H, m, Ar–H, H-2″
+ H-5″), 7.26 (1H, s, Ar–H, H-5), 6.99 (1H, dd, J = 8.0, 2.5 Hz,
Ar–H, H-4″), 3.99 (6H, s, 2 × OCH3). 13C NMR (125 MHz,
DMSO-d6): δ 166.0 (CvO), 158.5, 158.2, 157.8, 156.3, 150.4,
150.3, 137.4, 136.8, 133.2, 129.9, 125.0, 120.9, 119.0, 118.6,
115.0, 107.9, 103.5, 102.1, 57.0, 56.8. LRMS [M + H+] 417.3.
HRMS (ESI) m/z cald for C23H21N4O4 [M + H+]: 417.1557, found
417.1558.
N-(4-((6,7-Dimethoxyquinazolin-4-yl)amino)phenyl)-3-methoxy
benzamide (31). 4-Chloro-6,7-dimethoxyquinazoline 9 (72 mg,
0.32 mmol) was reacted with the corresponding 4-amino-
carboxamide (78 mg, 0.32 mmol) in isopropanol (7.4 mL) accord-
ing to general procedure 1 to obtain compound 31 (90 mg,
65%) as a yellow solid after filtration and washing with diethyl
ether (2 × 10 mL). M.p. 187–190 °C (decomp.). IR (ATR):
ν = 2952, 1674 cm−1. 1H NMR (400 MHz, DMSO-d6): δ 11.11
(1H, s, NH), 10.36 (1H, s, NH), 8.78 (1H, s, Ar–H, H-2), 8.24
(1H, s, Ar–H, H-8), 7.89 (2H, d, J = 8.4 Hz, Ar–H, H-2′ + H-6′),
7.67 (2H, d, J 8.4 Hz, Ar–H, H-3′ + H-5′), 7.57 (1H, app. d,
J 7.7 Hz, 1H, Ar–H, H-6″), 7.52 (1H, s, Ar–H, H-2″), 7.46 (1H,
app. t, J 7.9 Hz, Ar–H, H-5″), 7.32 (1H, s, Ar–H, H-5), 7.17 (1H,
dd, J = 8.0, 2.5 Hz, Ar–H, H-4″), 4.01 (3H, s, OCH3), 3.99 (3H, s,
OCH3), 3.85 (3H, s, OCH3). 13C NMR (101 MHz, DMSO-d6):
δ 165.7 (CvO), 159.7, 158.4 (×2), 156.6, 150.6, 149.5, 137.6,
136.7, 133.0, 130.1, 125.4, 121.0, 120.4, 117.8, 113.5, 107.8,
104.2, 100.9, 57.3, 56.9, 55.9. LRMS [M + H+] 417.3. HRMS
(ESI) m/z cald for C23H21N4O4 [M + H+]: 417.1557, found
417.1560.
N-(4-((6,7-Dimethoxyquinazolin-4-yl)amino)phenyl)-3-nitro-
benzamide (32). 4-Chloro-6,7-dimethoxyquinazoline 9 (160 mg,
0.69 mmol) was reacted with the corresponding 4-amino-
carboxamide (177 mg, 0.69 mmol) in isopropanol (16 mL) accord-
ing to general procedure 1 to obtain compound 32 (TFA salt)
as a yellow solid (300 mg, 98%) after filtration and washing
with diethyl ether (2 × 10 mL). M.p. 140–144 °C (decomp.). IR
(ATR): ν = 1673, 1640 cm−1. 1H NMR (500 MHz, DMSO-d6):
δ 10.69 (1H, s, NH), 8.79 (1H, t, J 2.0 Hz, Ar–H, H-2″), 8.71 (1H,
s, Ar–H, H-2), 8.44 (1H, dd, J 8.2, 2.0 Hz, Ar–H, H-4″), 8.43 (1H,
dd, J 8.0, 1.5 Hz, Ar–H, H-6″), 8.04 (1H, s, Ar–H, H-8), 7.88–7.84
(3H, m, Ar–H, H-2′ + H-6′ + H-5″), 7.68 (2H, d, J 9.0 Hz, Ar–H,
H-3′ + H-5′), 7.25 (1H, s, Ar–H, H-5), 3.98 (3H, s, OCH3), 3.97
(3H, s, OCH3). 13C NMR (126 MHz, DMSO-d6): δ 164.1 (CvO),
158.4, 156.6, 150.6, 150.3, 148.4, 138.0, 136.9, 136.7, 134.7,
133.8, 130.9, 126.9, 125.3, 122.9, 121.5, 108.0, 103.6, 101.9,
57.1, 57.0. LRMS [M + H+] 446.2. HRMS (ESI) m/z cald for
C23H20N5O5 [M + H+]: 446.1459, found 446.1459.
3-Amino-N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)-
benzamide (33). Compound 32 (61 mg, 0.13 mmol) in metha-
nol (10 mL) was hydrogenated (1 atm) over 10% Pd/C (13 mg)
for 24 h. The reaction mixture was subsequently filtered over
Celite® and the filtrate concentrated in vacuo to aﬀord a crude
solid that was purified by reverse phase HPLC (gradient:
0–100% MeCN over 40 min) to aﬀord compound 33 as a yellow
solid (16 mg, 30%). M.p. 121–123 °C (decomp.). IR (ATR):
ν = 1735, 1697 cm−1. 1H NMR (400 MHz, DMSO-d6): δ 11.06
(1H, s, NH), 10.24 (1H, s, NH), 8.80 (1H, s, Ar–H, H-2),
8.08 (1H, s, Ar–H, H-8), 7.87 (2H, d, J 8.5 Hz, Ar–H,
H-2′ + H-6′), 7.61 (2H, d, J 8.5 Hz, Ar–H, H-3′ + H-5′), 7.28 (1H,
s, Ar–H, H-5), 7.20–7.15 (3H, m, Ar–H), 6.81 (1H, app. d,
J 8.0 Hz, Ar–H, H-4″), 4.00 (6H, s, 2 × OCH3). 13C NMR
(101 MHz, DMSO-d6): δ 166.8 (CvO), 158.5, 156.7, 150.6,
149.6, 148.3, 138.1, 136.3, 132.5, 129.3, 125.5, 120.8, 118.0,
116.0, 115.7, 114.0, 107.6, 103.8, 100.8, 57.1, 57.0. LRMS
[M + H+] 416.3. HRMS (ESI) m/z cald for C23H22N5O3 [M + H+]:
416.1717, found 416.1717.
3-(Cyanomethoxy)-N-(4-((6,7-dimethoxyquinazolin-4-yl)amino)-
phenyl)benzamide (34). Compound 30 (20 mg, 0.048 mmol),
bromoacetonitrile (3.7 μL, 0.053 mmol) and cesium carbonate
(39 mg, 0.12 mmol) in anhydrous acetonitrile (1 mL) was
heated at 80 °C for 1 h. The reaction was subsequently filtered
and the solvent was removed in vacuo to aﬀord a crude residue
that was purified by reverse phase HPLC (0 to 100% MeCN
over 40 min) to aﬀord compound 34 (TFA salt) as a yellow solid
(12 mg, 55%). M.p. 141–144 °C. IR (ATR): ν = 2954, 2365,
1672 cm−1. 1H NMR (500 MHz, DMSO-d6): δ 10.39 (1H, s, NH),
8.76 (1H, s, Ar–H, H-2), 8.04 (1H, s, Ar–H, H-8), 7.89–7.87 (2H,
m, Ar–H, H-2′ + H-6′), 7.71–7.63 (4H, m, Ar–H, H-3′ + H-5′, H-2″
+ H-6″), 7.56 (1H, t, J = 8.0 Hz, Ar–H, H-5″), 7.33 (1H, dd,
J = 8.2, 2.7 Hz, Ar–H, H-4″), 7.27 (1H, s, Ar–H, H-5), 5.28 (2H, s,
CH2), 3.99 (6H, 2 × OCH3). 13C NMR (126 MHz, DMSO-d6):
δ 165.2 (CvO), 158.5, 158.2, 156.8, 156.4, 150.4, 150.2, 137.3,
137.0, 133.3, 130.4, 125.1, 122.2, 121.0, 118.45, 116.9, 114.7,
107.9, 103.6, 101.8, 57.0, 56.8, 54.2. LRMS [M + H+] 456.3.
HRMS (ESI) m/z cald for C25H22N5O4 [M + H+]: 456.1666, found
456.1666.
2-(3-((4-((6,7-Dimethoxyquinazolin-4-yl)amino)phenyl)carb-
amoyl)phenoxy)acetic acid (35). Compound 30 (60 mg,
0.14 mmol), tert-butyl bromoacetate (28 μL, 0.19 mmol) and
cesium carbonate (118 mg, 0.36 mmol) in anhydrous aceto-
nitrile (3 mL) was heated at 50 °C for 3 h. The reaction was
subsequently filtered and the solvent was removed in vacuo to
aﬀord a crude residue that was dissolved in a mixture of tri-
fluoroacetic acid in dichloromethane (300 μL, 1 : 1 v/v). The
reaction was stirred at room temperature for 16 h. The solvent
was removed in vacuo to give a crude residue that was purified
by reverse phase HPLC (0 to 100% MeCN over 40 min) to
aﬀord compound 35 as a yellow solid (10 mg, 14% over 2
steps). M.p. 236–239 °C (decomp.). IR (ATR): ν = 3365, 1679,
1631 cm−1. 1H NMR (500 MHz, DMSO-d6): δ 10.32 (1H, s, NH),
8.61 (1H, s, Ar–H, H-2), 7.98 (1H, s, Ar–H, H-8). 7.83 (1H, d,
J 8.5 Hz, Ar–H, H-3′ + H-5′), 7.70 (2H, d, J 8.5 Hz, H-2′ + H-6′),
7.59 (1H, app. d, J 8.0 Hz, Ar–H, H-6″), 7.51–7.50 (1H, m, Ar–H,
H-2″), 7.46–7.43 (1H, m, Ar–H, H-5″), 7.27 (1H, s, Ar–H, H-5),
7.14 (1H, dd, J 8.5, 2.5 Hz, Ar–H, H-4″), 4.78 (2H, s, CH2), 3.97
(3H, s, OCH3), 3.95 (3H, s, OCH3). 13C NMR (126 MHz, DMSO-
d6): δ 170.5 (CvO), 165.4 (CvO), 158.8, 158.2, 157.7, 155.6,
151.4, 149.9, 136.6, 136.4, 134.3, 130.0, 124.3, 121.1, 120.8,
118.2, 114.1, 108.5, 104.2, 103.1, 65.1, 56.8, 56.6. LRMS
[M + Na+] 496.9. HRMS (ESI) m/z cald for C25H23N4O6 [M + H+]:
475.1612, found 475.1612.
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